PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SERDULA, MK; COLLINS, ME; WILLIAMSON, DF; ANDA, RF; PAMUK, E; BYERS, TE				SERDULA, MK; COLLINS, ME; WILLIAMSON, DF; ANDA, RF; PAMUK, E; BYERS, TE			WEIGHT CONTROL PRACTICES OF UNITED-STATES ADOLESCENTS AND ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							PREVALENCE; POPULATION; OVERWEIGHT	Objective: To estimate the prevalence of various weight-loss practices in U.S. adolescents and adults. Design: The Youth Risk Behavior Survey, a self-administered survey of a random sample of high school students in 1990 and the Behavioral Risk Factor Surveillance System, a random-digit dial survey in 1989. Setting: Thirty-eight states and the District of Columbia. Participants: High school students (n = 11 467) and adults 18 years and older (n = 60 861). Results: Among high school students, 44% of female students and 15% of male students reported that they were trying to lose weight. An additional 26% of female students and 15% of male students reported that they were trying to keep from gaining more weight. Students reported that they had used the following weight control methods in the 7 days preceding the survey: exercise (51% of female students and 30% of male students); skipping meals (49% and 18%, respectively); taking diet pills (4% and 2%, respectively); and vomiting (3% and 1%, respectively). Among adults, 38% of women and 24% of men reported that they were trying to lose weight, whereas 28% of each sex reported that they were trying to maintain their weight. Conclusions: Attempts to lose or maintain weight are very prevalent among both adolescents and adults, especially among females.			SERDULA, MK (corresponding author), CTR DIS CONTROL & PREVENT, 4770 BUFORD HIGHWAY NE, MAILSTOP K26, ATLANTA, GA 30341 USA.							DAWSON DA, 1988, AM J PUBLIC HEALTH, V78, P1326, DOI 10.2105/AJPH.78.10.1326; DESMOND SM, 1989, J SCHOOL HEALTH, V59, P353, DOI 10.1111/j.1746-1561.1989.tb04743.x; DREWNOWSKI A, 1988, AM J PUBLIC HEALTH, V78, P1322, DOI 10.2105/AJPH.78.10.1322; HERZOG DB, 1985, NEW ENGL J MED, V313, P295, DOI 10.1056/NEJM198508013130505; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; KOLBE LJ, 1990, HLTH ED, V21, P44; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; STEPHENSON MG, 1987, PUBLIC HEALTH REP, V102, P61; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1989, NATIONAL ADOLESCENT; [No title captured]; 1991, MMWR, V40, P747	13	212	214	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				667	671		10.7326/0003-4819-119-7_Part_2-199310011-00008	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363194				2022-12-24	WOS:A1993MA33000008
J	KUO, CC; BEAN, BP				KUO, CC; BEAN, BP			G-PROTEIN MODULATION OF ION PERMEATION THROUGH N-TYPE CALCIUM CHANNELS	NATURE			English	Article							CHICK SENSORY NEURONS; GTP-BINDING PROTEIN; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; INHIBITION; CURRENTS; RECEPTOR; CONDUCTANCE; MECHANISM	N-TYPE calcium channels in cell membranes are inhibited by neurotransmitters such as noradrenaline1-4, luteinizing hormone-releasing (LHRH)5-7, gamma-aminobutyric acid (GABA)8,9 and glutamate10,11. Although GTP-binding proteins (G proteins) are probably the common mediators of such inhibition6,11-14, it is unclear exactly bow G proteins alter the operation of the channel. Various experiments have shown changes in channel gating2-6,15,16. Here we show that inward current carried by Na+ through N-type channels was far less inhibited by LHRH or by internal GTP-gammaS than was current carried by Ba2+. With external Ba2+ and internal Cs+, LHRH inhibited the Ba2+-carried inward limb of the instantaneous current-voltage curve much more than the Cs+-carried outward limb. Noise analysis showed that LHRH or GTP-gammaS decrease single-channel current carried by Ba2+. These results suggest that alteration of the ion permeation pathway contributes significantly to G-protein inhibition of N-type Ca2+ channels.			KUO, CC (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Kuo, Chung-Chin/0000-0001-8208-6829				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BLEY KR, 1990, NEURON, V2, P379; BOLAND LM, 1993, J NEUROSCI, V13, P516; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DOLPHIN AC, 1986, BRIT J PHARMACOL, V88, P213, DOI 10.1111/j.1476-5381.1986.tb09489.x; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES S, 1992, NEUROSCI LETT, V145, P153, DOI 10.1016/0304-3940(92)90009-V; KASAI H, 1992, J PHYSIOL-LONDON, V448, P189, DOI 10.1113/jphysiol.1992.sp019036; KUO CC, 1993, J PHYSIOL-LONDON, V466, P683; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; POLLO A, 1992, PFLUG ARCH EUR J PHY, V422, P75; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V444, P669, DOI 10.1113/jphysiol.1991.sp018900; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SIGWORTH FJ, 1980, NATURE, V283, P293, DOI 10.1038/283293a0; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358	26	68	68	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					258	262		10.1038/365258a0	http://dx.doi.org/10.1038/365258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396731				2022-12-24	WOS:A1993LX47100056
J	BARBET, NC; CARR, AM				BARBET, NC; CARR, AM			FISSION YEAST WEE1 PROTEIN-KINASE IS NOT REQUIRED FOR DNA DAMAGE-DEPENDENT MITOTIC ARREST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; M-PHASE; MITOSIS; REPLICATION; DIVISION; MUTANTS	CHECKPOINTS maintain the dependency relationships between discrete events in the cell cycle (for example, ensuring mitosis does not occur before DNA replication is complete)1,2. In Schizosaccharomyces pombe, mitotic checkpoints monitor DNA synthesis3 and the presence of DNA damage4,5. The replication-dependent mitotic checkpoint prevents mitosis by inactivating p34cdc2 kinase3. The mechanism by which the DNA damage checkpoint interacts with the mitotic machinery is distinct from that used by the replication checkpoint4,5. The activity of p34cdc is controlled, in part, by the wee 1 protein kinase6, which inactivates cdc2 through phosphorylation at tyrosine-15 (ref. 7). Here we report normal mitotic arrest after DNA damage in S. pombe cells in which the wee 1 gene is defective or missing. We suggest why these findings contradict a recent report8 which suggested that the wee1 gene product was required for DNA damage-dependent mitotic arrest.	SUSSEX UNIV,MRC,CELL MUTAT UNIT,FALMER,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HAGAN IM, 1988, THESIS U LONDON; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Mitchison J M, 1975, Methods Cell Biol, V11, P201, DOI 10.1016/S0091-679X(08)60324-6; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2	14	89	97	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					824	827		10.1038/364824a0	http://dx.doi.org/10.1038/364824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355807				2022-12-24	WOS:A1993LU58100062
J	NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C				NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C			RISK-FACTORS FOR HIV-INFECTION AMONG YOUNG-ADULT MEN IN NORTHERN THAILAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; TRANSMISSION; WOMEN	Objective.-To determine the sociodemographic and behavioral risk factors associated with human immunodeficiency virus (HIV) infection in two cohorts of young men selected for military service in northern Thailand. Design.-Military conscripts were studied cross-sectionally after conscription in May 1991 and November 1991. Risk factors were assessed by interview with trained nonmilitary interviewers. Setting.-Two military training bases in Chiang Mai, Thailand. Participants.-A total of 2417 young men aged 19 to 23 years (mean age, 21 years) conscripted by lottery into military service in the Royal Thai Army or Royal Thai Air Force from six provinces in northern Thailand. Main Outcome Measures.-Human immunodeficiency virus seroprevalence by enzyme-linked immunosorbent assay confirmed by Western blot and univariate and multivariate analyses of sociodemographic and behavioral risk factors associated with HIV seroprevalence. Results.-Overall, 289 (12.0%) of 2417 men were HIV-seropositive at baseline. The strongest associations with being HIV positive were heterosexual activities. History of sex with a female commercial sex worker (CSW) was frequent (96.5% of men who were HIV-positive and 79.0% of men who were HIV-negative) and strongly associated with HIV infection on univariate and multivariate analyses (adjusted odds ratio, 1.60 to 2.07, depending on the frequency of CSW contact). Also, sexually transmitted diseases were common and associated with HIV infection in both univariate and multivariate analyses (adjusted odds ratio, 3.36). Sex with other males and injection drug use were uncommon and not associated with HIV infection. Condom use was reported in 61.5% of men at last sex with a CSW but was not shown to be protective of prevalent HIV infection. Conclusion.-The epidemic of HIV infection has spread widely among young men in northern Thailand, despite reported frequent and recent use of condoms during sex with female CSWs. Control of HIV infection in this population will probably require more regular and effective use of condoms, prevention and treatment of sexually transmitted diseases, and reduction in the frequency of CSW contact.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; CHIANG MAI UNIV,DEPT FAMILY MED,CHIANG MAI,THAILAND; CHIANG MAI UNIV,DEPT PATHOL,CHIANG MAI,THAILAND; MINIST PUBL HLTH,CHIANG MAI,THAILAND; ROYAL THAI ARMY,CHIANG MAI,THAILAND; ROYAL THAI AF,CHIANG MAI,THAILAND; ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ; ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University; Ministry of Public Health - Thailand; Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BAGASRA O, 1993, J INFECT DIS, V167, P789, DOI 10.1093/infdis/167.4.789; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HALSEY NA, 1992, JAMA-J AM MED ASSOC, V267, P2062, DOI 10.1001/jama.267.15.2062; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; MUECKE MA, 1992, SOC SCI MED, V35, P891, DOI 10.1016/0277-9536(92)90103-W; PADIAN NS, 1987, REV INFECT DIS, V9, P947; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO, P71; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; SIRISOPANA N, 1992, 8 INT C AIDS AMST; TAWEESAK N, 1992, 8TH INT C AIDS AMST; THONGCHAROEN P, 1989, HUMAN IMMUNODEFICIEN; UNGACHASAK K, 1990, 6TH INT C AIDS SAN F; UNGCHUSAK K, 1991, 7 INT C AIDS FLOR; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	20	132	134	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					955	960		10.1001/jama.270.8.955	http://dx.doi.org/10.1001/jama.270.8.955			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345647				2022-12-24	WOS:A1993LT56700026
J	DAY, S; WARD, H; PERROTTA, L				DAY, S; WARD, H; PERROTTA, L			PROSTITUTION AND RISK OF HIV - MALE PARTNERS OF FEMALE PROSTITUTES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe risk behaviours for infection with HIV in male sexual partners of female prostitutes. Design-A cross sectional study. Setting-Genitourinary medicine clinic, St Mary's Hospital, London. Subjects-112 self identified male sexual partners of female prostitutes: 101 who reported commerical sexual relationships only, five who reported noncommercial relationships only, and six who reported both commercial and non-commercial relationships. Main outcome measures-Reported risk behaviours for infection with HIV. Results-Of the 40 men who had had previous HIV tests or were tested during the study, two (5%) were infected with HIV. Of the men who would answer the questions, 34/94 reported having sex with other men, 2/105 reported using injected drugs, 8/105 had a history of blood transfusion, 14/108 reported a past history of gonorrhoea, 44/102 reported paying for sex abroad, and 8/92 said that they had also been paid for sex. Of the 55 men who reported paying for vaginal intercourse in the past year, 45 (82%) said that they had always used a condom. In contrast, of the 11 non-paying partners of prostitutes, only two (18%) reported ever using a condom with their partners. Conclusions-Men who have sex with female prostitutes cannot be assumed to be at risk of infection with HIV only by this route: homosexual contact may place them at greater risk. Despite the heterogeneity among male sexual partners of prostitutes, patterns of use of condoms were uniform when they were considered as a reflection of the type of relationship a man had with a female prostitute rather than a consequence of an individual's level of risk.			DAY, S (corresponding author), ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.		Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036; Day, Sophie/0000-0002-9822-9094				ALEXANDER P, 1990, SEX WORK WRITINGS WO, P15; CHIASSON NA, 1988, 4 P INT C AIDS STOCK, P273; DAY S, 1990, ANTE PUBLIQUE MALADI, P88; KINNELL H, 1989, PROSTITUES THEIR CLI; MCLEOD E, 1982, WOMEN WORKING PROSTI; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; PLUMMER FA, 1991, AIDS, V5, pS169; WALLACE J, 1988, 4 P INT C AIDS STOCH, P273; WARD H, 1993, BRIT MED J, V307, P356, DOI 10.1136/bmj.307.6900.356; WARD H, 1990, RECENT ADV STD AIDS, V4, P183	10	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					359	361		10.1136/bmj.307.6900.359	http://dx.doi.org/10.1136/bmj.307.6900.359			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374418	Green Published, Bronze			2022-12-24	WOS:A1993LR76800019
J	LLEDO, PM; VERNIER, P; VINCENT, JD; MASON, WT; ZOREC, R				LLEDO, PM; VERNIER, P; VINCENT, JD; MASON, WT; ZOREC, R			INHIBITION OF RAB3B EXPRESSION ATTENUATES CA2+-DEPENDENT EXOCYTOSIS IN RAT ANTERIOR-PITUITARY-CELLS	NATURE			English	Article							GTP-BINDING PROTEIN; MEMBRANE CAPACITANCE; BOVINE LACTOTROPHS; SYNTHETIC PEPTIDES; ENDOCYTIC PATHWAY; CHROMAFFIN CELLS; SECRETION; BRAIN; DOMAIN; MELANOTROPHS	LOW-MOLECULAR-WEIGHT GTP-binding proteins (small G proteins) of the Rab family have been proposed to act as central regulators of vesicular traffic1,2, and proteins of the Rab3 subfamily (Rab3A, B, C and D)3-6 are thought to be,associated with membrane vesicles or granules undergoing exocytotic fusion with the plasma membrane7-10. Rab3A is highly expressed in brain11, whereas Rab3B is the major form found in rat anterior pituitary gland. We report here that antisense oligonucleotides against Rab3B, introduced into pituitary cells using the whole-cell patch clamp technique, specifically and reversibly block expression of Rab3B. We find that calcium-dependent exocytosis is inhibited without affecting endocytosis. Antisense oligonucleotides directed against Rab3A have no effect. Our results indicate that Rab3B is likely to be a key intracellular signalling molecule which can control exocytosis downstream of other calcium-dependent processes in anterior pituitary cells.	INST A FESSARD,CNRS,F-91198 GIF SUR YVETTE,FRANCE; UNIV LJUBLJANA FAC MED,INST PATHOPHYSIOL,61105 LJUBLJANA,SLOVENIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Ljubljana	LLEDO, PM (corresponding author), AFRC,BABRAHAM INST,DEPT NEUROBIOL,CAMBRIDGE CB2 4AT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AYALA J, 1989, J NEUROSCI RES, V22, P241, DOI 10.1002/jnr.490220303; BAERTSCHI AJ, 1992, MOL ENDOCRINOL, V6, P2257, DOI 10.1210/me.6.12.2257; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Marty A., 1983, SINGLE CHANNEL RECOR, P107; Mason W T, 1986, Methods Enzymol, V124, P207; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PUSH M, 1988, PFLUGERS ARCH, V411, P204; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; RUPNIK M, 1992, FEBS LETT, V303, P221, DOI 10.1016/0014-5793(92)80524-K; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; SIKDAR SK, 1989, FEBS LETT, V253, P88, DOI 10.1016/0014-5793(89)80936-6; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TARASKEVICH PS, 1984, FED PROC, V43, P2373; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VONGRAFENSTEIN H, 1986, J CELL BIOL, V103, P2343, DOI 10.1083/jcb.103.6.2343; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473; ZOREC R, 1991, METHODS NEUROSCI, V4, P194, DOI DOI 10.1016/B978-0-12-185257-3.50018-5	36	185	186	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					540	544		10.1038/364540a0	http://dx.doi.org/10.1038/364540a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393147				2022-12-24	WOS:A1993LQ66700059
J	SHINTON, R; SAGAR, G				SHINTON, R; SAGAR, G			LIFELONG EXERCISE AND STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY; RISK-FACTORS; BLOOD-PRESSURE; HEART-DISEASE; DEATH; WOMEN; HYPERTENSION; HEALTH	Objectives-To examine the potential of lifelong patterns of increased physical activity to prevent stroke. Design-Case-control study. Setting-11 general practices in west Birmingham. Subjects-125 men and women who had just had their first stroke and were aged 35-74 and 198 controls frequency matched for age and sex recruited over 24 months during 1988-90. Exclusion criteria were a previous history of stroke, mitral valvular heart disease combined with atrial fibrillation, primary or metastatic cerebral neoplasm, or coagulation disorder or myeloproliferative disease. Main outcome measures-Odds ratios for stroke related to lifetime history of exercise after 15 years of age. Results-A history of vigorous exercise during the ages 15-25 appeared to protect from stroke: odds ratio adjusted for age and sex 0.33 (95% confidence interval 0.2 to 0.6). This effect was independent of other potential risk factors. Increasing years of participation in vigorous exercise between the ages of 15 and 55 produced an increasing protection from stroke (p<0.001). In the 65 cases and 169 controls who were free of cardiac ischaemia, peripheral vascular disease, and poor health recent vigorous exercise and walking were protective against stroke: odds ratios of 0.41 (0.2 to 1.0) for recent vigorous exercise and 0.30 (0.1 to 0.7) for recent walking. Conclusions-Appreciable protection from stroke in later life is conferred by vigorous exercise in early adulthood. This increased level of physical activity should, if possible, be continued lifelong.	UNIV BIRMINGHAM, DUDLEY RD HOSP, DEPT MED, BIRMINGHAM B18 7QH, ENGLAND; DUDLEY RD GEN HOSP, DEPT RADIOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND	University of Birmingham					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR SN, 1991, AM J EPIDEMIOL, V133, P266, DOI 10.1093/oxfordjournals.aje.a115871; Breslow N, 1980, STATISTICAL METHODS, V32; DYKEN ML, 1984, STROKE, V15, P1105; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBA.RS, 1967, LANCET, V1, P753, DOI 10.1016/S0140-6736(67)91367-0; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; SHINTON RA, 1992, LIFESTYLE RISK STROK; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Weiner J. S., 1969, IBP HDB, V9; 1989, STROKE BETTER MANAGE; 1990, REFERENCE MANUAL; 1971, WHO TECHNICAL REPORT, V469; 1992, LANCET, V340, P19; 1991, MED ASPECTS EXERCISE	27	84	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					231	234		10.1136/bmj.307.6898.231	http://dx.doi.org/10.1136/bmj.307.6898.231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369683	Bronze, Green Published			2022-12-24	WOS:A1993LP31400021
J	BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM				BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM			INSULIN-RESISTANCE IN OFFSPRING OF HYPERTENSIVE PARENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; PIMA-INDIANS; GLUCOSE-INTOLERANCE; FAMILY HISTORY; BLOOD-PRESSURE; METABOLISM; SENSITIVITY; RECEPTOR; OBESITY; GENE	Objective-To determine if insulin resistance is present in normotensive adults at increased risk of developing hypertension. Design-Normotensive subjects with at least one hypertensive parent were paired with offspring of normotensive parents (controls), being matched for age, sex, social class, and physical activity. Setting-Outpatient clinic. Subjects-30 paired subjects (16 men and 14 women) with and without a family history of hypertension, aged 18-32, with a body mass index <25 kg/m2, with blood pressure < 130/85 mm Hg, and not taking drugs. Interventions-Euglycaemic glucose clamp (two hour infusion of insulin 1 mU/kg/min) and intravenous glucose tolerance test (injection of 100 ml 20% glucose). Main outcome measures-Insulin mediated glucose disposal and insulin secretion. Results-The offspring of hypertensive parents had slightly higher blood pressure than did the controls (mean 117 (SD 6) v 108 (5) mm Hg systolic, p=0.013; 76 (7) v 67 (6) mm Hg diastolic, p=0.017). Their insulin mediated glucose disposal was lower than that of controls (29.5 (6.5) v 40.1 (8.6) mumol/kg/min, p=0.002), but, after adjustment for blood pressure, the difference was not significant (difference 6.9 (95% confidence interval -1.5 to 15.3), p=0.10). Insulin secretion in the first hour after injection of glucose was slightly but not significantly higher in the offspring of hypertensive patients (9320 (5484) v 6723 (3751) pmol.min/l). The two groups had similar concentrations of plasma glucose (5.2 (0.3) v 5.1 (0.4) mmol/l), serum cholesterol (4.4 (0.8) v 4.6 (0.8) mmol/l), serum triglyceride (0.89 (0.52) v 0.68 (0.27) mmol/l), and serum low density lipoprotein cholesterol (2.81 (0.65) v 2.79 (0.61) mmol/l). The offspring of hypertensive parents, however, had lower serum concentrations of high density lipoprotein cholesterol (1.24 (0.31) v 1.56 (0.35) mmol/l, p=0.002) and higher serum concentrations of non-esterified fatty acids (0.7 (0.4) v 0.4 (0.4) mmol/l, p=0.039). Conclusions-Young normotensive subjects who are at increased risk of developing hypertension are insulin resistant.	ROYAL VICTORIA HOSP, SIR GEORGE E CLARK METAB UNIT, BELFAST BT12 6BA, NORTH IRELAND; ROYAL VICTORIA HOSP, REG ENDOCRINE LAB, BELFAST BT12 6BA, NORTH IRELAND									BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; DEFRONZO RA, 1982, INT J OBESITY, V6, P73; DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KUSARI J, 1991, J CLIN INVEST, V88, P1323, DOI 10.1172/JCI115437; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LAAKSO M, 1991, DIABETES S1, V40, pA100; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; MUNGER RG, 1988, J HYPERTENS, V6, P647, DOI 10.1097/00004872-198808000-00008; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; OELBAUM RS, 1991, DIABETOLOGIA, V34, P260, DOI 10.1007/BF00405085; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RABEN N, 1991, DIABETES, V40, P118, DOI 10.2337/diabetes.40.1.118; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN G, 1968, DIABETES, V17, P560, DOI 10.2337/diab.17.9.560; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIZZA RA, 1981, DIABETES, V30, P990, DOI 10.2337/diabetes.30.12.990; ROONEY DP, 1991, EUR J CLIN INVEST, V21, P430, DOI 10.1111/j.1365-2362.1991.tb01391.x; ROONEY DP, 1992, METABOLISM, V41, P317, DOI 10.1016/0026-0495(92)90278-I; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SALTIN B, 1968, CIRCULATION, V38, P1104, DOI 10.1161/01.CIR.38.6.1104; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; STAMLER R, 1979, JAMA-J AM MED ASSOC, V241, P43, DOI 10.1001/jama.241.1.43; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, J HYPERTENS       S6, V7, P8; 1990, CHALLENGE 90S CHANGE	41	102	105	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					92	96		10.1136/bmj.307.6896.92	http://dx.doi.org/10.1136/bmj.307.6896.92			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343735	Green Published, Bronze			2022-12-24	WOS:A1993LM58500022
J	MICHALEK, MT; GRANT, EP; GRAMM, C; GOLDBERG, AL; ROCK, KL				MICHALEK, MT; GRANT, EP; GRAMM, C; GOLDBERG, AL; ROCK, KL			A ROLE FOR THE UBIQUITIN-DEPENDENT PROTEOLYTIC PATHWAY IN MHC CLASS I-RESTRICTED ANTIGEN PRESENTATION	NATURE			English	Article							TOXIC LYMPHOCYTES-T; ACTIVATING ENZYME; MOLECULES; EXPRESSION; DEGRADATION; PROTEIN; ICAM-1; CELLS; GENE; E1	THE degradation of most cellular proteins starts with their covalent conjugation with ubiquitin1,2. This labels the proteins for rapid hydrolysis to oligopeptides by a (26S) proteolytic complex containing a (20S) degradative particle called the proteasome3,4. Some system in the cytosol also generates antigenic peptides from endogenously synthesized cellular and viral proteins5-10. These peptides bind to newly synthesized class I major histocompatibility complex molecules in the endoplasmic reticulum and peptide/class I complexes are then transported to the cell surface for presentation to cytotoxic T cells11,12. How these peptides are produced is unknown, although a modification that promotes ubiquitin-dependent degradation of a viral protein enhances its presentation with class I13 and indirect evidence suggests a role for proteolytic particles closely resembling and perhaps identical to the proteasome4,12,14,15. Using cells that exhibit a temperature-sensitive defect in ubiquitin conjugation, we report here that nonpermissive temperature inhibited class I-restricted presentation of ovalbumin introduced into the cytosol, but did not affect presentation of an ovalbumin peptide synthesized from a minigene. These results implicate the ubiquitin-dependent proteolytic pathway in the production of antigenic peptides.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	MICHALEK, MT (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA.							ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DANG LH, 1990, J IMMUNOL, V144, P4082; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MICHALEK MT, 1991, J IMMUNOL, V146, P449; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; Moss B, 1991, CURRENT PROTOCOLS MO; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1992, P NATL ACAD SCI USA, V89, P8918, DOI 10.1073/pnas.89.19.8918; SIU G, 1989, J IMMUNOL, V143, P3813; SMITH MH, 1990, MOL IMMUNOL, V27, P169, DOI 10.1016/0161-5890(90)90112-D; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; WILEY HS, 1987, METHOD ENZYMOL, V146, P402; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	37	310	324	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					552	554		10.1038/363552a0	http://dx.doi.org/10.1038/363552a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8389422				2022-12-24	WOS:A1993LF93900053
J	BIESECKER, BB; BOEHNKE, M; CALZONE, K; MARKEL, DS; GARBER, JE; COLLINS, FS; WEBER, BL				BIESECKER, BB; BOEHNKE, M; CALZONE, K; MARKEL, DS; GARBER, JE; COLLINS, FS; WEBER, BL			GENETIC-COUNSELING FOR FAMILIES WITH INHERITED SUSCEPTIBILITY TO BREAST AND OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTON DISEASE; LINKAGE	Efforts are under way to isolate a gene (BRCA1) on chromosome 17q12-21. Mutations in this gene predispose women to breast and ovarian cancer. Women with germline mutations in BRCA1 are estimated to have an 85% lifetime risk of developing breast cancer and an increased but as yet undetermined risk of ovarian cancer. It is estimated that one in 200 to 400 American women may be carriers of BRCA1 mutations. We have identified several families that show linkage between breast and/or ovarian cancer and genetic markers that flank BRCA1. It is now possible, within these linked families, to prospectively identify family members likely to be carrying BRCA1 mutations. Because of profound and immediate clinical ramifications, we offered to provide this information to one such extended family. To provide information to this family, we developed a protocol to address the many issues that arise in the delivery of these services. Although testing for BRCA1 mutation carriers is currently limited to very rare families being analyzed for research purposes, this experience presages the complexities of the much larger scale availability of population screening for BRCA1 mutations, which is likely to become a reality in the next few years.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ROOM 5510,MSRB 1,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR HUMAN GENOME,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; HOWARD HUGHES MED INST,ANN ARBOR,MI; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Biesecker, Barbara/0000-0001-9665-8963; Markel, Dorene/0000-0002-3382-6779; Calzone, Kathleen/0000-0002-2354-6810	NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER; NCI NIH HHS [CA57601] Funding Source: Medline; NHGRI NIH HHS [HG00209] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARASON A, IN PRESS AM J HUM GE; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLOCH M, 1990, AM J HUM GENET, V46, P1; CHAMBERLAIN JS, IN PRESS AM J HUM GE; CHAPMAN MA, 1990, AM J HUM GENET, V47, P1; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins F S, 1991, J Clin Ethics, V2, P260; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; EASTON DF, IN PRESS AM J HUM GE; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HANNIG VL, 1991, AM J MED GENET, V40, P425, DOI 10.1002/ajmg.1320400409; HUGGINS M, 1990, AM J HUM GENET, V47, P4; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LEONE A, 1991, CANCER RES, V51, P2490; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LI FP, 1992, J CLIN ONCOL, V10, P1203, DOI 10.1200/JCO.1992.10.8.1203; LYNCH HT, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90787-4; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MORTON NE, 1955, AM J HUM GENET, V7, P277; NAROD SA, 1991, LANCET, V338, P82; Quaid K A, 1992, J Genet Couns, V1, P277, DOI 10.1007/BF00962825; ROSEN P, 1992, FEB INT C RISK AD AD; SATO T, 1991, CANCER RES, V51, P5794; WHITE R, 1992, 17 CHROM WORKSH PARK; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; 1989, AM J KIDNEY DIS, V13, P85; 1989, GUIDELINES PREDICTIV	28	256	258	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1970	1974		10.1001/jama.269.15.1970	http://dx.doi.org/10.1001/jama.269.15.1970			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8352830				2022-12-24	WOS:A1993KX21500028
J	GARFIN, SR; COHEN, MS				GARFIN, SR; COHEN, MS			SCAPULOTHORACIC PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									INDIANA HAND CTR,INDIANAPOLIS,IN		GARFIN, SR (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							EMERY RJH, 1991, J BONE JOINT SURG AM, V73A, P1526, DOI 10.2106/00004623-199173100-00010; MILCH H, 1961, Clin Orthop, V20, P139; RICHARDS RR, 1989, CLIN ORTHOPAEDICS, V247, P111	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1867	1867						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411532				2022-12-24	WOS:A1993MB46400034
J	LARSSON, LG; BAUM, J; MUDHOLKAR, GS; KOLLIA, GD				LARSSON, LG; BAUM, J; MUDHOLKAR, GS; KOLLIA, GD			BENEFITS AND DISADVANTAGES OF JOINT HYPERMOBILITY AMONG MUSICIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOBILITY; STUDENTS; PAIN	Background. Joint hypermobility is considered to be both an advantage and a disadvantage. However, the degree of hypermobility in members of particular occupations requiring intense physical activity and the nature of the association between symptoms referable to specific joints and their hypermobility are unknown. Methods. We interviewed 660 musicians (300 women and 360 men) about work-related symptoms such as joint pain and swelling and examined them for joint hypermobility according to a standard protocol. We then determined the relation between the mobility of their fingers, thumbs, elbows, knees, and spine and any symptoms referable to these regions. Results. Five of the 96 musicians (5 percent) with hypermobility of the wrists, mostly instrumentalists who played the flute, violin, or piano, had pain and stiffness in this region, whereas 100 of the 564 musicians (18 percent) Hypermobility of the elbow was associated with symptoms in only 1 of 208 musicians (<1 percent), whereas 7 of 452 (2 percent) without this hypermobility had symptoms (P = 0.45). Among the 132 musicians who had hypermobile knees, 6 (5 percent) had symptoms, whereas only 1 of 528 (<1 percent) with normal knees had symptoms (P<0.001). Of the 462 musicians who had normal mobility of the spine, 50 (11 percent) had symptoms involving the back, as compared with 46 of the 198 musicians (23 percent) who had hypermobility of the spine (P<0.001). Conclusions. Among musicians who play instruments requiring repetitive motion, hypermobility of joints such as the wrists and elbows may be an asset, whereas hypermobility of less frequently moved joints such as the knees and spine may be a liability.	UNIV ROCHESTER, MONROE COMMUNITY HOSP, SCH MED & DENT, ARTHRIT & CLIN IMMUNOL UNIT, ROCHESTER, NY 14620 USA; HOSP RHEUMAT DIS, OSTERSUND, SWEDEN; UNIV ROCHESTER, DEPT STAT, DIV BIOSTAT, ROCHESTER, NY 14627 USA	University of Rochester; University of Rochester								Adams F, 1849, HIPPOCRATES GENUINE; ALRAWI ZS, 1985, BRIT J RHEUMATOL, V24, P326; BEIGHTON P, 1973, ANN RHEUM DIS, V32, P413, DOI 10.1136/ard.32.5.413; BENNATI F, 1831, REV PARIS, V11, P52; BIRO F, 1983, PEDIATRICS, V72, P701; BROOKS P, 1989, BRIT J RHEUMATOL, V28, P180; CARTER C, 1964, J BONE JOINT SURG BR, V46, P40, DOI 10.1302/0301-620X.46B1.40; DAWSON WJ, 1988, MED PROBL PERFORM AR, V3, P19; FRY HJH, 1986, MED J AUSTRALIA, V145, P620, DOI 10.5694/j.1326-5377.1986.tb139514.x; FRY HJH, 1989, ANN RHEUM DIS, V48, P998, DOI 10.1136/ard.48.12.998; GEDALIA A, 1985, J PEDIATR-US, V107, P873, DOI 10.1016/S0022-3476(85)80178-5; GRAHAME R, 1972, ANN RHEUM DIS, V31, P109, DOI 10.1136/ard.31.2.109; HOCHBERG F H, 1983, Journal of the American Medical Association, V249, P1869, DOI 10.1001/jama.249.14.1869; HORAN F T, 1973, Rheumatology and Rehabilitation, V12, P47, DOI 10.1093/rheumatology/12.1.47; LARSSON LG, 1993, BRIT J RHEUMATOL, V32, P116; LARSSON LG, 1987, ARTHRITIS RHEUM, V30, P1426, DOI 10.1002/art.1780301216; Lichtor J, 1972, J Sports Med, V1, P22; MANCHESTER RA, 1988, MED PROBL PERFORM AR, V3, P15; RISHER RA, 1934, STATISTICAL METHODS; SMITH RD, 1967, J AMER MED ASSOC, V199, P820, DOI 10.1001/jama.199.11.820; SUTRO CJ, 1947, SURGERY, V21, P67; WYNNEDAVIES R, 1971, P ROY SOC MED, V64, P689, DOI 10.1177/003591577106400649; Zelen M, 1972, 6 BERK S MATH STAT P, P737	23	98	101	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1079	1082		10.1056/NEJM199310073291504	http://dx.doi.org/10.1056/NEJM199310073291504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371729				2022-12-24	WOS:A1993LZ64000004
J	KUMPF, RA; DOUGHERTY, DA				KUMPF, RA; DOUGHERTY, DA			A MECHANISM FOR ION SELECTIVITY IN POTASSIUM CHANNELS - COMPUTATIONAL STUDIES OF CATION-PI INTERACTIONS	SCIENCE			English	Article							ENERGY PERTURBATION SIMULATIONS; ACETYLCHOLINE-RECEPTOR; AROMATIC INTERACTIONS; TEA BLOCKADE; K+ CHANNEL; BINDING; WATER; PERMEATION; RESIDUES; PROTEINS	A combination of computational methods has been used to evaluate the interaction between the pi face of a benzene molecule and the monovalent cations of lithium, sodium, potassium, and rubidium. In the gas phase, the ions are strongly bound, and the affinity for benzene follows the expected electrostatic trend (lithium, largest; rubidium, smallest). However, in an aqueous environment, a reordering occurs such that the potassium ion is preferred over all the other ions for 2:1 benzene:ion complexes. The selectivity sequence parallels that seen in voltage-gated potassium channels. Given that several conserved aromatic residues are present in the pore region of such channels, these results suggest that the cation-pi interaction may be responsible for the ion selectivity in potassium channels.	CALTECH,DIV CHEM & CHEM ENGN,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125	California Institute of Technology								AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BOGUSZ S, 1992, PROTEIN ENG, V5, P285, DOI 10.1093/protein/5.4.285; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHANGEUX JP, 1992, TRENDS PHARMACOL SCI, V13, P299, DOI 10.1016/0165-6147(92)90094-M; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; EISENMAN G, 1990, PROG CELL R, V1, P195; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1992, J INCLUS PHENOM MOL, V12, P23, DOI 10.1007/BF01053854; EISENMAN G, 1975, BIOCH SERIES, V2, P27; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; Frisch M. J, 1992, GAUSSIAN 92; FRISCH MJ, 1990, GAUSSIAN 90; Hehre W.J., 1986, AB INITIO MOL ORBITA; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; JORGENSEN WL, 1989, J AM CHEM SOC, V111, P3770, DOI 10.1021/ja00192a057; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; JORGENSEN WL, 1989, BOSS VERSION 27; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LENTZ TL, 1991, BIOCHEMISTRY-US, V30, P10949, DOI 10.1021/bi00109a020; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1982, BIOPHYS J, V38, P227, DOI 10.1016/S0006-3495(82)84552-9; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PETTI MA, 1988, J AM CHEM SOC, V110, P682; SUNNER J, 1981, J PHYS CHEM-US, V85, P1814, DOI 10.1021/j150613a011; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAFT RW, 1990, PURE APPL CHEM, V62, P17, DOI 10.1351/pac199062010017; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WU J, 1991, BIOPHYS J, V60, P238, DOI 10.1016/S0006-3495(91)82046-X; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409	43	597	602	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1708	1710		10.1126/science.8378771	http://dx.doi.org/10.1126/science.8378771			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378771				2022-12-24	WOS:A1993LY58400018
J	GASTER, B				GASTER, B			THE LEARNING-CURVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1280	1280		10.1001/jama.270.11.1280	http://dx.doi.org/10.1001/jama.270.11.1280			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360952				2022-12-24	WOS:A1993LW34500001
J	SUELING, HM; JOHNSTON, D; MARTIN, IG; DIXON, MF; LANSDOWN, MRJ; MCMAHON, MJ; AXON, ATR				SUELING, HM; JOHNSTON, D; MARTIN, IG; DIXON, MF; LANSDOWN, MRJ; MCMAHON, MJ; AXON, ATR			GASTRIC-CANCER - A CURABLE DISEASE IN BRITAIN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; ADJUVANT CHEMOTHERAPY; MULTIVARIATE-ANALYSIS; SURGICAL-MANAGEMENT; PROGNOSTIC FACTORS; STOMACH; CARCINOMA; ADENOCARCINOMA; SURVIVAL; EXPERIENCE	Objective-To determine whether more vigorous efforts aimed at earlier diagnosis allied to radical surgical resection lead to improved survival of patients with gastric cancer. Design-Prospective audit of all cases of gastric cancer treated during 1970-89. Setting-Department of surgery, general hospital. Subjects-493 consecutive patients with gastric adenocarcinoma. Main outcome measures-Operative mortality, postoperative morbidity, and five year survival after radical potentially curative resection. Results-207 (42%) patients underwent potentially curative resection. The proportion of all patients in whom this was possible increased significantly (p < 0.01) from 31% in the first five year period to 53% in the last five year period. The proportion of patients who had early gastric cancer rose from 1% to 15% (p < 0.01) and stage I disease rose from 4% to 26% (p < 0.001). After potentially curative resection, mortality 30 days after operation was 6%. Operative mortality decreased from 9% in the 1970s to 5% in the 1980s. Likewise, the incidence of serious postoperative complications decreased from 33% in the 1970s to 17% in the 1980s (p < 0.01). Five year survival was 60% in patients who underwent curative resection, 98% in patients with early gastric cancer, and 93%, 69%, and 28% in stage I, II, and III disease respectively. By the late 1980s five year survival after operation was about 70%. Conclusions-These findings suggest that an increasing proportion of patients with gastric cancer could be diagnosed at a relatively early pathological stage when about two thirds are curable by means of radical surgery.	GEN INFIRM, CTR DIGEST DIS, ACAD UNIT PATHOL, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; GEN INFIRM, CTR DIGEST DIS, DEPT GASTROENTEROL, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds	SUELING, HM (corresponding author), GEN INFIRM, CTR DIGEST DIS, ACAD UNIT SURG, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND.							ADASHEK K, 1979, ANN SURG, V189, P6, DOI 10.1097/00000658-197901000-00002; AKOH JA, 1991, BRIT J SURG, V78, P349, DOI 10.1002/bjs.1800780325; ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; BUCHHOLTZ TW, 1978, ANN SURG, V188, P711, DOI 10.1097/00000658-197812000-00001; CASSELL P, 1976, BRIT J SURG, V63, P603, DOI 10.1002/bjs.1800630811; COSTELLO CB, 1977, BRIT J SURG, V64, P47, DOI 10.1002/bjs.1800640112; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM D, 1987, BRIT J SURG, V74, P715, DOI 10.1002/bjs.1800740822; CUSCHIERI A, 1986, BRIT J SURG, V73, P513; DAY NE, 1989, WORLD J SURG, V13, P3, DOI 10.1007/BF01671147; DESMOND AM, 1976, P ROY SOC MED, V69, P257; ESTAPE J, 1991, ANN SURG, V213, P219, DOI 10.1097/00000658-199103000-00006; Gear M W, 1980, Br Med J, V280, P1135; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HARTLEY LC, 1987, AUST NZ J SURG, V57, P5, DOI 10.1111/j.1445-2197.1987.tb01230.x; HAWLEY PR, 1970, BRIT J SURG, V57, P862; HISAMICHI S, 1984, JPN J CLIN ONCOL, V14, P211; INBERG MV, 1972, ACTA CHIR SCAND, V138, P195; INOKUCHI K, 1984, JPN J SURG, V14, P351, DOI 10.1007/BF02469540; IRVIN TT, 1988, BRIT J SURG, V75, P106, DOI 10.1002/bjs.1800750205; ITOH H, 1989, AM J SURG, V158, P14, DOI 10.1016/0002-9610(89)90305-X; KAIBARA N, 1990, AM J SURG, V159, P218, DOI 10.1016/S0002-9610(05)80265-X; KAJITANI T, 1981, JPN J SURG, V11, P127; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; KIM JP, 1987, WORLD J SURG, V11, P465, DOI 10.1007/BF01655811; Kodama Y, 1981, World J Surg, V5, P241; LINDAHL AK, 1988, EUR J SURG ONCOL, V14, P55; MARUYAMA K, 1987, SCAND J GASTROENTERO, V22, P63, DOI 10.3109/00365528709091021; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MEYERS WC, 1987, ANN SURG, V205, P1, DOI 10.1097/00000658-198701000-00001; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MSIKA S, 1989, WORLD J SURG, V13, P118, DOI 10.1007/BF01671171; Murakami T, 1979, World J Surg, V3, P685; NAKAJIMA T, 1978, INT J CLIN PHARM BI, V16, P209; NAKAJIMA T, 1989, HEPATO-GASTROENTEROL, V36, P79; Nielsen S A, 1974, Acta Chir Scand, V140, P313; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SHIU MH, 1980, ANN SURG, V192, P730, DOI 10.1097/00000658-198012000-00007; SHIU MH, 1989, HEPATO-GASTROENTEROL, V36, P7; SIEWERT JR, 1993, BRIT J SURG, V80, P1015, DOI 10.1002/bjs.1800800829; SJOSTEDT S, 1986, ACTA CHIR SCAND, P25; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; SUELING HM, 1993, GUT               S1, V34, pS15; SVENNEVIG JL, 1976, ACTA CHIR SCAND, V142, P78; YAN CJ, 1985, AM J SURG, V149, P771, DOI 10.1016/S0002-9610(85)80183-5; 1989, MORTALITY STATISTICS	48	204	211	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	1993	307	6904					591	596		10.1136/bmj.307.6904.591	http://dx.doi.org/10.1136/bmj.307.6904.591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401015	Bronze, Green Published			2022-12-24	WOS:A1993LW14900015
J	WOOD, SA; ALLEN, ND; ROSSANT, J; AUERBACH, A; NAGY, A				WOOD, SA; ALLEN, ND; ROSSANT, J; AUERBACH, A; NAGY, A			NON-INJECTION METHODS FOR THE PRODUCTION OF EMBRYONIC STEM CELL-EMBRYO CHIMERAS	NATURE			English	Article							MOUSE EMBRYO		MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; AFRC, BABRAHAM INST, CAMBRIDGE CB2 4AT, ENGLAND	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	WOOD, SA (corresponding author), MAX PLANCK INST IMMUNBIOL, DEPT MOLEC EMBRYOL, W-7800 FREIBURG, GERMANY.		allen, nick d/A-4336-2010; Nagy, Andras/G-6465-2013; Wood, Stephen A/E-8357-2011	Nagy, Andras/0000-0003-4311-0413; Wood, Stephen A/0000-0002-2576-7457; Allen, Nicholas/0000-0003-4009-186X				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FRIEDRICH G, 1991, GENE DEV, V6, P1; FUJII JT, 1983, J EMBRYOL EXP MORPH, V74, P79; FUJII JT, 1980, DEV BIOL, V74, P239, DOI 10.1016/0012-1606(80)90066-4; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9605; LALLEMAND Y, 1990, DEVELOPMENT, V110, P1241; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, PRACTICAL APPROACH S; NAGY A, IN PRESS P NATN ACAD; PASCOE WS, 1992, BIOCHIM BIOPHYS ACTA, V114, P209; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; STEWART C, 1980, J EMBRYOL EXP MORPH, V58, P289; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582	16	194	210	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					87	89		10.1038/365087a0	http://dx.doi.org/10.1038/365087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361547				2022-12-24	WOS:A1993LV64600062
J	RICHARDSON, GE; TUCKER, MA; VENZON, DJ; LINNOILA, RI; PHELPS, R; PHARES, JC; EDISON, M; IHDE, DC; JOHNSON, BE				RICHARDSON, GE; TUCKER, MA; VENZON, DJ; LINNOILA, RI; PHELPS, R; PHARES, JC; EDISON, M; IHDE, DC; JOHNSON, BE			SMOKING CESSATION AFTER SUCCESSFUL TREATMENT OF SMALL-CELL LUNG-CANCER IS ASSOCIATED WITH FEWER SMOKING-RELATED 2ND PRIMARY CANCERS	ANNALS OF INTERNAL MEDICINE			English	Article						SMOKING CESSATION; CARCINOMA, OAT CELL; LUNG NEOPLASMS; NEOPLASMS, 2ND PRIMARY; SMOKING	ACUTE NONLYMPHOCYTIC LEUKEMIA; COMBINED MODALITY THERAPY; LONG-TERM SURVIVORS; HODGKINS-DISEASE; COMBINATION CHEMOTHERAPY; BRONCHOGENIC-CARCINOMA; PROGNOSTIC FACTORS; NECK-CANCER; FOLLOW-UP; 10-YEAR EXPERIENCE	Objective: To determine the incidence of second primary cancers developing in patients surviving free of cancer for 2 or more years after treatment for small-cell lung cancer and to assess the potential effect of smoking cessation. Design: Retrospective review of 540 patients from a single institution with a median follow-up of 6.1 years. Setting. A single government institution (the National Cancer Institute). Patients: Consecutive sample of 540 patients with histologically confirmed small-cell lung cancer treated from 1973 through 1989 on therapeutic clinical trials. Measurements: The relative risk for second primary cancers and death were calculated in patients who remained free of cancer for 2 years after initiation of therapy. The relation of these end points to smoking history was also determined. Results: Fifty-five patients (10%) were free of cancer 2 years after initiation of therapy. Eighteen of these patients developed one or more second primary cancers, including 13 who developed second primary non-small-cell lung cancer. The risk for any second primary cancer compared with that in the general population was increased four times (relative risk, 4.4; 95% CI, 2.5-7.2), with a relative risk of a second primary non-small-cell lung cancer of 16 (CI, 8.4-27). Forty-three patients discontinued smoking within 6 months of starting treatment for small-cell lung cancer, and 12 continued to smoke. In those who stopped smoking at time of diagnosis, the relative risk of a second lung cancer was 11 (CI, 4.4 to 23), whereas, in those who continued to smoke, it was 32 (CI, 12 to 69). Conclusions: Patients with small-cell lung cancer who survive cancer-free for more than 2 years have a significantly increased risk for development of a second primary smoking-related cancer. Cigarette smoking cessation after successful therapy is associated with a decrease in risk for a second smoking-related primary cancer.	NATL NAVAL MED CTR, NCI, NAVY MED ONCOL BRANCH, BLDG 8, ROOM 4101, BETHESDA, MD 20899 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA			Richardson, Gary/AAB-1728-2019; Venzon, David J/B-3078-2008; Tucker, Margaret A/B-4297-2015					BOICE JD, 1991, NIH913180 PUBL; BOIVIN JF, 1988, CANCER, V61, P2541, DOI 10.1002/1097-0142(19880615)61:12<2541::AID-CNCR2820611225>3.0.CO;2-G; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BROWER M, 1983, AM J MED, V75, P993, DOI 10.1016/0002-9343(83)90880-X; CASTIGLIANO SG, 1968, J AM DENT ASSOC, V77, P580, DOI 10.14219/jada.archive.1968.0275; CHAK LY, 1984, J CLIN ONCOL, V2, P385, DOI 10.1200/JCO.1984.2.5.385; CIMINO G, 1991, J CLIN ONCOL, V9, P432, DOI 10.1200/JCO.1991.9.3.432; COHEN MH, 1977, CANCER TREAT REP, V61, P349; COHEN MH, 1979, CANCER TREAT REP, V63, P163; COOPER JS, 1989, INT J RADIAT ONCOL, V17, P449, DOI 10.1016/0360-3016(89)90094-1; CORTESE DA, 1983, J THORAC CARDIOV SUR, V86, P373; CULLEN JW, 1989, CANCER PRINCIPLES PR, P181; DAVIS S, 1985, J CLIN ONCOL, V3, P80, DOI 10.1200/JCO.1985.3.1.80; DEARING MP, 1990, J CLIN ONCOL, V8, P1042, DOI 10.1200/JCO.1990.8.6.1042; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; GARFINKEL L, 1991, CA-CANCER J CLIN, V41, P137, DOI 10.3322/canjclin.41.3.137; GILLIS TM, 1983, AM J SURG, V146, P512, DOI 10.1016/0002-9610(83)90243-X; GLUCKMAN JL, 1983, LARYNGOSCOPE, V93, P71; GOULD VE, 1983, LAB INVEST, V49, P519; HELLQUIST H, 1982, CLIN OTOLARYNGOL, V7, P11, DOI 10.1111/j.1365-2273.1982.tb01557.x; HEYNE KH, 1992, J CLIN ONCOL, V10, P1519, DOI 10.1200/JCO.1992.10.10.1519; HONG WK, 1985, CANCER-AM CANCER SOC, V56, P1242, DOI 10.1002/1097-0142(19850915)56:6<1242::AID-CNCR2820560603>3.0.CO;2-Z; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONG WK, 1983, NEW ENGL J MED, V308, P75, DOI 10.1056/NEJM198301133080204; IHDE DC, 1986, J CLIN ONCOL, V4, P1443, DOI 10.1200/JCO.1986.4.10.1443; IHDE DC, 1991, P AN M AM SOC CLIN, V10, P240; JACOBS RH, 1986, CANCER, V58, P2177, DOI 10.1002/1097-0142(19861115)58:10<2177::AID-CNCR2820581003>3.0.CO;2-O; JESSE RH, 1976, AM J SURG, V132, P435, DOI 10.1016/0002-9610(76)90314-7; JOHNSON BE, 1986, AM J MED, V80, P1103, DOI 10.1016/0002-9343(86)90672-8; JOHNSON BE, 1990, J CLIN ONCOL, V8, P396, DOI 10.1200/JCO.1990.8.3.396; JOHNSON BE, 1988, AM J MED, V85, P194; JOHNSON BE, 1985, ANN INTERN MED, V103, P430, DOI 10.7326/0003-4819-103-3-430; JOHNSON DH, 1986, AM J MED, V81, P962, DOI 10.1016/0002-9343(86)90388-8; LEQUAGLIE C, 1991, CHEST, V100, P1053, DOI 10.1378/chest.100.4.1053; LICCIARDELLO JTW, 1989, INT J RADIAT ONCOL, V17, P467, DOI 10.1016/0360-3016(89)90096-5; LIPPMAN SM, 1989, INT J RADIAT ONCOL, V17, P691, DOI 10.1016/0360-3016(89)90126-0; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LIVINGSTON RB, 1984, AM J MED, V77, P415, DOI 10.1016/0002-9343(84)90095-0; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; MASON MK, 1982, THORAX, V37, P453, DOI 10.1136/thx.37.6.453; MATTHEWS MJ, 1988, LUNG CANCER COMPREHE, P5; MCDONALD S, 1989, INT J RADIAT ONCOL, V17, P457, DOI 10.1016/0360-3016(89)90095-3; MEMOLI VA, 1986, LUNG CANCER, V2, P56; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MOORE C, 1971, J AMER MED ASSOC, V218, P553, DOI 10.1001/jama.218.4.553; OSHITA F, 1991, EUR J CANCER, V27, P427, DOI 10.1016/0277-5379(91)90378-Q; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1044, DOI 10.1200/JCO.1986.4.7.1044; OSTERLIND K, 1986, CANCER RES, V46, P4189; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1307, DOI 10.1200/JCO.1986.4.9.1307; PASTORINO U, 1991, LUNG CANCER, V7, P133; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PEREZSTABLE EJ, 1992, AM REV RESPIR DIS, V145, P53, DOI 10.1164/ajrccm/145.1.53; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; RATAIN MJ, 1987, BLOOD, V70, P1412; REYNOLDS RD, 1978, CANCER, V42, P2887, DOI 10.1002/1097-0142(197812)42:6<2887::AID-CNCR2820420651>3.0.CO;2-9; ROSTI G, 1991, P AN M AM SOC CLIN, V10, P268; SAGMAN U, 1992, J CLIN ONCOL, V10, P1525, DOI 10.1200/JCO.1992.10.10.1525; SHIELDS TW, 1978, J THORAC CARDIOV SUR, V76, P439; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Smith R A, 1976, Thorax, V31, P507, DOI 10.1136/thx.31.5.507; SOUHAMI RL, 1990, BRIT J CANCER, V61, P584, DOI 10.1038/bjc.1990.131; SOUHAMI RL, 1985, CANCER RES, V45, P2878; SPIEGELMAN D, 1989, J CLIN ONCOL, V7, P344, DOI 10.1200/JCO.1989.7.3.344; THOMAS P, 1990, ANN THORAC SURG, V49, P242, DOI 10.1016/0003-4975(90)90145-V; THOMPSON SG, 1990, THORAX, V45, P356, DOI 10.1136/thx.45.5.356; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1980, BRIT MED J, V280, P216, DOI 10.1136/bmj.280.6209.216; VANBODEGOM PC, 1989, THORAX, V44, P788, DOI 10.1136/thx.44.10.788; VANLEEUWEN FE, 1989, J CLIN ONCOL, V7, P1046, DOI 10.1200/JCO.1989.7.8.1046; VINCENT MD, 1987, EUR J CANCER CLIN ON, V23, P1589, DOI 10.1016/0277-5379(87)90436-6; VOGELSANG GB, 1985, AM J MED, V79, P49, DOI 10.1016/0002-9343(85)90545-5; WARREN WH, 1990, CANCER, V65, P1003, DOI 10.1002/1097-0142(19900215)65:4<1003::AID-CNCR2820650427>3.0.CO;2-Y; WILLERS S, 1992, ARCH ENVIRON HEALTH, V47, P357, DOI 10.1080/00039896.1992.9938375; WYNDER EL, 1977, CANCER, V40, P1872, DOI 10.1002/1097-0142(197710)40:4+<1872::AID-CNCR2820400817>3.0.CO;2-#; WYNDER EL, 1969, CANCER, V24, P730, DOI 10.1002/1097-0142(196910)24:4<730::AID-CNCR2820240411>3.0.CO;2-L	77	176	177	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					383	390		10.7326/0003-4819-119-5-199309010-00006	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8393311				2022-12-24	WOS:A1993LZ47600006
J	CLARK, MM; KARPIUK, P; GALEF, BG				CLARK, MM; KARPIUK, P; GALEF, BG			HORMONALLY MEDIATED INHERITANCE OF ACQUIRED CHARACTERISTICS IN MONGOLIAN GERBILS	NATURE			English	Article							ADULT FEMALE MICE; INTRAUTERINE POSITION; UTERINE POSITION; SEXUAL-BEHAVIOR; FETUSES; RATS; MORPHOLOGY; CONTIGUITY; ANDROGEN; UTERUS	THE intrauterine position relative to members of the same or opposite sex that a rodent fetus occupies affects both its morphology and behaviour when adult1-14. Female fetuses that mature between males are androgenized by testosterone crossing fetal membranes15,16, and their phenotypes as adults differ significantly from those of sisters that received less intrauterine exposure to exogenous testosterone17-20. We report here that adult female Mongolian gerbils that gestated between male fetuses produce litters containing a significantly greater proportion of sons than the litters produced by those that gestated between female fetuses. Consequently, daughters delivered by dams that gestated between male fetuses are more likely to have gestated between male fetuses and be androgenized in utero than are daughters of dams that gestated between female fetuses. Female gerbils thus tend to inherit the phenotype (either androgenized or not androgenized) of their respective mothers.			CLARK, MM (corresponding author), MCMASTER UNIV,DEPT PSYCHOL,HAMILTON L8S 4K1,ONTARIO,CANADA.		Galef, Bennett G/A-5678-2008					BROWN MJ, 1984, ENDOCRINOLOGY, V115, P2318, DOI 10.1210/endo-115-6-2318; CLARK MM, 1991, PHYSIOL BEHAV, V49, P239, DOI 10.1016/0031-9384(91)90038-P; CLARK MM, 1993, DEV PSYCHOBIOL, V26, P185, DOI 10.1002/dev.420260402; CLARK MM, 1990, DEV PSYCHOBIOL, V23, P29, DOI 10.1002/dev.420230104; CLARK MM, 1991, DEV PSYCHOBIOL, V24, P81, DOI 10.1002/dev.420240202; CLARK MM, 1986, ANIM BEHAV, V34, P551, DOI 10.1016/S0003-3472(86)80124-5; CLARK MM, 1988, PHYSIOL BEHAV, V42, P15, DOI 10.1016/0031-9384(88)90253-3; CLARK MM, 1990, PHYSIOL BEHAV, V47, P301, DOI 10.1016/0031-9384(90)90146-U; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; CLEMENS LG, 1974, REPRODUCTIVE BEHAVIO, P25; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; KINSLEY C, 1986, HORM BEHAV, V20, P7, DOI 10.1016/0018-506X(86)90025-5; KINSLEY C, 1986, HORM BEHAV, V20, P201, DOI 10.1016/0018-506X(86)90018-8; KINSLEY CH, 1986, PHYSIOL BEHAV, V36, P793, DOI 10.1016/0031-9384(86)90434-8; MEISEL RL, 1981, SCIENCE, V213, P239, DOI 10.1126/science.7244634; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; SAAL FSV, 1992, PHYSIOL BEHAV, V52, P163, DOI 10.1016/0031-9384(92)90447-A; SAAL FSV, 1983, SCIENCE, V220, P1306, DOI 10.1126/science.6857252; SAAL FSV, 1978, BIOL REPROD, V19, P842; TOBET SA, 1982, HORM BEHAV, V16, P251, DOI 10.1016/0018-506X(82)90025-3; VOMACHKA AJ, 1986, HORM BEHAV, V20, P181, DOI 10.1016/0018-506X(86)90016-4; VONSAAL FS, 1991, J ANIM SCI, V67, P1824; WECHMAN R, 1985, BIOL REPROD, V33, P803, DOI 10.1095/biolreprod33.4.803; ZIELINSKI WJ, 1992, BEHAV ECOL SOCIOBIOL, V30, P185, DOI 10.1007/BF00166702	25	99	102	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					712	712		10.1038/364712a0	http://dx.doi.org/10.1038/364712a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355782	Bronze			2022-12-24	WOS:A1993LT67700055
J	REINER, O; CARROZZO, R; SHEN, Y; WEHNERT, M; FAUSTINELLA, F; DOBYNS, WB; CASKEY, CT; LEDBETTER, DH				REINER, O; CARROZZO, R; SHEN, Y; WEHNERT, M; FAUSTINELLA, F; DOBYNS, WB; CASKEY, CT; LEDBETTER, DH			ISOLATION OF A MILLER-DIEKER LISSENCEPHALY GENE CONTAINING G-PROTEIN BETA-SUBUNIT-LIKE REPEATS	NATURE			English	Article							MOLECULAR DISSECTION; SEQUENCE; YEAST; DELETIONS; CLONING; REGION	LISSENCEPHALY (agyria-pachygyria) is a human brain malformation manifested by a smooth cerebral surface and abnormal neuronal migration1,2. Identification of the gene(s) involved in this disorder would facilitate molecular dissection of normal events in brain development3. Type 1 lissencephaly occurs either as an isolated abnormality or in association with dysmorphic facial appearance in patients with Miller-Dieker syndrome4,5. About 15% of patients with isolated lissencephaly and more than 90% of patients with Miller-Dieker syndrome have microdeletions in a critical 350-kilobase region in chromosome 17p13.3 (ref. 6). These deletions are hemizygous, so haplo-insufficiency for a gene in this interval is implicated. Here we report the cloning of a gene (LIS-1, lissencephaly-1) in 17p13.3 that is deleted in Miller-Dieker patients. Non-overlapping deletions involving either the 5' or 3' end of the gene were found in two patients, identifying LIS-1 as the disease gene. The deduced amino-acid sequence shows significant homology to beta-subunits of heterotrimeric G proteins, suggesting that it could possibly be involved in a signal transduction pathway crucial for cerebral development.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV MINNESOTA,SCH MED,DEPT NEUROL,DIV PEDIAT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Dobyns, William/AAI-2768-2020; Dobyns, William Brian/ABC-6525-2021; Reiner, Orly/E-9455-2010	Dobyns, William/0000-0002-7681-2844; Reiner, Orly/0000-0001-7560-9599				AICARDI J, 1989, INT PEDIATR, V4, P118; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; DIEKER H, 1969, CLIN DELINEATION BIR, V2, P1; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; DOBYNS WB, 1989, NEUROL CLIN, V7, P89, DOI 10.1016/S0733-8619(18)30830-2; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KUWANO A, 1991, AM J HUM GENET, V49, P707; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MILLER JQ, 1963, NEUROLOGY, V13, P841, DOI 10.1212/WNL.13.10.841; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ORIKIN SH, 1976, NEW ENGL J MED, V295, P710; SAMBROOK S, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5	29	867	888	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					717	721		10.1038/364717a0	http://dx.doi.org/10.1038/364717a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355785				2022-12-24	WOS:A1993LT67700058
J	ROEHL, H; KIMBLE, J				ROEHL, H; KIMBLE, J			CONTROL OF CELL FATE IN C-ELEGANS BY A GLP-1 PEPTIDE CONSISTING PRIMARILY OF ANKYRIN REPEATS	NATURE			English	Article							OF-FUNCTION MUTATIONS; CAENORHABDITIS-ELEGANS; NOTCH-GENE; LIN-12; DROSOPHILA; SEQUENCES; LINEAGES; LOCUS	THE homologous proteins GLP-1 and LIN-12 are required for cell interactions during nematode development1-5. glp-1 and lin-12 are members of a gene family that includes Drosophila Notch and several vertebrate homologues6. The members of this family have a single transmembrane domain and a similar arrangement of repeated amino-acid motifs (see Fig. 1). The mechanism by which proteins in this family function is not understood. One hypothesis is that these proteins are receptors, each with an extracellular domain that binds a ligand and an intracellular domain that influences the activity of downstream cell fate regulators. Here we report that a region of the GLP-1 intracellular domain, consisting primarily of six ankyrin repeats, is sufficient to direct cell fate. The cell fate transformations seen are similar to transformations caused by gain-of-function mutations in either glp-1 or lin-12 and do not rely on endogenous lin-12 or glp-1 activity. We propose that the ankyrin repeat region of GLP-1 is responsible for controlling downstream regulators of cell fate.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	ROEHL, H (corresponding author), UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706, USA.							ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BRENNER S, 1974, GENETICS, V77, P71; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LISSEMORE J, IN PRESS GENETICS; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PRIESS JR, 1987, CELL, V51, P610; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	26	101	112	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					632	635		10.1038/364632a0	http://dx.doi.org/10.1038/364632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350921				2022-12-24	WOS:A1993LR77100054
J	TZOURIO, C; IGLESIAS, S; HUBERT, JB; VISY, JM; ALPEROVITCH, A; TEHINDRAZANARIVELO, A; BIOUSSE, V; WOIMANT, F; BOUSSER, MG				TZOURIO, C; IGLESIAS, S; HUBERT, JB; VISY, JM; ALPEROVITCH, A; TEHINDRAZANARIVELO, A; BIOUSSE, V; WOIMANT, F; BOUSSER, MG			MIGRAINE AND RISK OF ISCHEMIC STROKE - A CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET AGGREGABILITY; BLOOD-PRESSURE; HEADACHE; SYMPTOMS; SMOKING; WOMEN	Objectives-To determine whether migraine is a risk factor for ischaemic stroke. Design-A case-control study. Setting-Two hospitals in Paris. Subjects-212 patients with stroke (137 men and 75 women) and 212 controls matched for sex, age (to within five years), and history of hypertension. Main outcome measures-Ischaemic stroke, confirmed by brain computed tomography or magnetic resonance imaging, and history of headache, recorded with structured questionnaire during interview. Results-Prevalence of migraine did not differ between patients with stroke and controls: 18/137 v 17/137 for men (odds ratio 1.1 (95% confidence interval 0.5 to 2.2), p=0.86); 23/75 v 17/75 for women (odds ratio 1.6 (0.7 to 3.5), p=0.24); and 41/212 v 34/212 for both sexes (odds ratio 1.3 (0.8 to 2.3), p=0.33). When subjects were split into two age groups, however, prevalence of migraine was significantly higher among younger women (aged <45) with stroke compared with their controls (13/20 v 6/20, odds ratio 4.3 (1.2 to 16.3), p=0.03). Furthermore, the risk of ischaemic stroke was higher among younger women who smoked (7/20 v 1/20, odds ratio 10.2 (1.1 to 93.3)). Conclusions-Prevalence of migraine was not different between patients with stroke and matched controls except among women aged <45, when migraine and stroke were significantly associated.	HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS 12, FRANCE; HOP LARIBOISIERE, SERV NEUROL, F-75475 PARIS 10, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	TZOURIO, C (corresponding author), INSERM, U360, 16 AV PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; [Anonymous], 1989, STROKE, V20, P1407; Breslow N, 1980, STATISTICAL METHODS, V32; CHEN TC, 1987, ARCH NEUROL-CHICAGO, V44, P1024, DOI 10.1001/archneur.1987.00520220030011; COUCH JR, 1977, NEUROLOGY, V27, P843, DOI 10.1212/WNL.27.9.843; DIXON WJ, 1983, BMDP STATISTICAL SOF; GILL JS, 1989, ARCH INTERN MED, V149, P2053, DOI 10.1001/archinte.149.9.2053; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; KALENDOVSKY Z, 1975, ARCH NEUROL-CHICAGO, V32, P13, DOI 10.1001/archneur.1975.00490430035004; MARKUSH RE, 1975, NEUROLOGY, V25, P430, DOI 10.1212/WNL.25.5.430; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TATEMICHI TK, 1986, STROKE PATHOPHYSIOLO, V2, P845; WATERS WE, 1971, BMJ-BRIT MED J, V1, P142, DOI 10.1136/bmj.1.5741.142; WEISS NS, 1972, NEW ENGL J MED, V287, P631, DOI 10.1056/NEJM197209282871303; ZIEGLER DK, 1977, NEUROLOGY, V27, P265, DOI 10.1212/WNL.27.3.265; 1990, SAS USERS GUIDE STAT, V1	17	177	178	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	1993	307	6899					289	292		10.1136/bmj.307.6899.289	http://dx.doi.org/10.1136/bmj.307.6899.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374374	Bronze, Green Published			2022-12-24	WOS:A1993LQ51600016
J	BASHIR, ZI; BORTOLOTTO, ZA; DAVIES, CH; BERRETTA, N; IRVING, AJ; SEAL, AJ; HENLEY, JM; JANE, DE; WATKINS, JC; COLLINGRIDGE, GL				BASHIR, ZI; BORTOLOTTO, ZA; DAVIES, CH; BERRETTA, N; IRVING, AJ; SEAL, AJ; HENLEY, JM; JANE, DE; WATKINS, JC; COLLINGRIDGE, GL			INDUCTION OF LTP IN THE HIPPOCAMPUS NEEDS SYNAPTIC ACTIVATION OF GLUTAMATE METABOTROPIC RECEPTORS	NATURE			English	Article							LONG-TERM POTENTIATION; PROTEIN KINASE-C; RAT HIPPOCAMPUS; BLOCKS INDUCTION; STRIATAL NEURONS; AREA CA1; ACID; TRANSMISSION; MAINTENANCE; STIMULATION	UNDERSTANDING the mechanisms of long-term potentiation (LTP) should provide insights into the molecular basis of learning and memory in vertebrates. Ionotropic glutamate receptors play a central role in LTP; AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate) receptors and NMDA (N-methyl-D-aspartate) receptors mediate synaptic responses that are enhanced in LTP and, in addition, NMDA receptors are necessary for the induction of LTP in most pathways1. There is also circumstantial evidence that metabotropic glutamate receptors (mGluRs) may be involved in LTP because the specific mGluR agonist aminocyclopentane dicarboxylate can augment tetanus-induced LTP2 and, under certain circumstances, can itself induce a slow-onset potentiation3,4. But the absence of any effective mGluR antagonist has prevented the determination of whether mGluRs are involved in the induction of tetanus-induced LTP. We report here that (RS)-alpha-methyl-4-carboxyphenylglycine is a specific mGluR antagonist in the hippocampus and have used this compound to examine the nature of the involvement of mGluRs in LTP. We show that synaptic activation of mGluRs is necessary for the induction of both NMDA receptor-dependent and NMDA receptor-independent forms of LTP in the hippocampus.	UNIV BRISTOL,SCH MED SCI,DEPT PHARMACOL,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	BASHIR, ZI (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PHARMACOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Berretta, Nicola/K-5667-2016; collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Seal, Andrew/C-8550-2014; Henley, Jeremy M/A-2776-2009	Berretta, Nicola/0000-0001-8097-6238; Collingridge, Graham L/0000-0002-9572-5359; Seal, Andrew/0000-0003-3656-4054; Bashir, Zafar/0000-0003-3650-2136; Henley, Jeremy/0000-0003-3589-8335	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BEHNISCH T, 1991, NEUROREPORT, V2, P386, DOI 10.1097/00001756-199107000-00008; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; BRAMHAM CR, 1992, NEUROCHEM INT, V20, P441, DOI 10.1016/0197-0186(92)90021-I; CHARPAK S, 1991, P ROY SOC B-BIOL SCI, V243, P221, DOI 10.1098/rspb.1991.0035; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; DERRICK BE, 1992, J PHARMACOL EXP THER, V263, P725; DESAI MA, 1992, SYNAPSE, V12, P206, DOI 10.1002/syn.890120305; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARVEY J, 1991, BRIT J PHARMACOL, V104, pC79; HU GY, 1992, ACTA PHYSIOL SCAND, V145, P187, DOI 10.1111/j.1748-1716.1992.tb09354.x; IRVING AJ, 1992, CELL CALCIUM, V13, P293, DOI 10.1016/0143-4160(92)90064-Y; IRVING AJ, 1990, EUR J PHARMACOL, V186, P363, DOI 10.1016/0014-2999(90)90462-F; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; IZUMI Y, 1991, NEUROSCI LETT, V122, P187, DOI 10.1016/0304-3940(91)90854-M; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTIN MR, 1983, NEUROPEPTIDES, V4, P45, DOI 10.1016/0143-4179(83)90007-0; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; REYMANN KG, 1989, NEUROSCI LETT, V98, P166, DOI 10.1016/0304-3940(89)90504-1; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; STANTON PK, 1991, NEUROSCI LETT, V127, P61, DOI 10.1016/0304-3940(91)90895-Z; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; STRATTON KR, 1989, EUR J PHARMACOL, V173, P235, DOI 10.1016/0014-2999(89)90529-3; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2	36	660	683	2	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					347	350		10.1038/363347a0	http://dx.doi.org/10.1038/363347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	8388549				2022-12-24	WOS:A1993LD91700052
J	GYORKE, S; FILL, M				GYORKE, S; FILL, M			RYANODINE RECEPTOR ADAPTATION - CONTROL MECHANISM OF CA2+-INDUCED CA2+ RELEASE IN HEART	SCIENCE			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; SKELETAL-MUSCLE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; CHANNEL; ACTIVATION; CELLS; INACTIVATION; CONTRACTION	Adaptation of single cardiac ryanodine receptor (RyR) channels was demonstrated by application of the caged calcium ion (Ca2+) methodology. In contrast to conventional desensitization found in surface membrane ligand-gated channels, single cardiac RyR channels adapted to maintained Ca2+ stimuli, preserving their ability to respond to a second (larger) Ca2+ stimulus. RyR adaptation may represent a molecular control mechanism for smoothly graded Ca2+-induced Ca2+ release in heart and may be a fundamental feature of channels, including the inositol trisphosphate receptor, that are involved in intracellular Ca2+ signaling in many cell types.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029640] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29-AR41197] Funding Source: Medline; NINDS NIH HHS [R01-NS29640] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHU A, 1991, Biophysical Journal, V59, p102A; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FILL M, 1990, BIOPHYS J, V50, P471; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GYORKE S, 1992, J PHYSIOL-LONDON, V456, P443; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; SWILLENS S, 1992, MOL PHARMACOL, V41, P110; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TATE CA, 1985, J BIOL CHEM, V260, P9618; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189	34	292	295	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					807	809		10.1126/science.8387229	http://dx.doi.org/10.1126/science.8387229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8387229				2022-12-24	WOS:A1993LA74400030
J	ZAHLER, AM; NEUGEBAUER, KM; LANE, WS; ROTH, MB				ZAHLER, AM; NEUGEBAUER, KM; LANE, WS; ROTH, MB			DISTINCT FUNCTIONS OF SR PROTEINS IN ALTERNATIVE PREMESSENGER RNA SPLICING	SCIENCE			English	Article							BINDING PROTEINS; POLYMERASE-II; INVITRO; REGULATORS; TRANSCRIPTION; EXPRESSION; SITES; ASF	Alternative splicing of precursor messenger RNAs (pre-mRNAs) is a common mechanism of regulating gene expression. SR proteins are a family of pre-mRNA splicing factors that are structurally related and evolutionarily conserved. Any member of the SR family can complement a splicing-deficient extract that lacks the entire family of SR proteins. Here it is demonstrated that particular SR proteins have distinct functions in alternative pre-mRNA splicing in vitro. In addition, SR proteins are differentially expressed in a variety of tissues. These results suggest a fundamental role for SR proteins in the regulation of alternative splicing.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	Fred Hutchinson Cancer Center; Harvard University				Zahler, Alan/0000-0003-0027-1647	PHS HHS [42786-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARDY CT, 1990, J CLIN MICROBIOL, V28, P2534, DOI 10.1128/JCM.28.11.2534-2538.1990; HARPER JE, 1991, MOL CELL BIOL, V11, P5945, DOI 10.1128/MCB.11.12.5945; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, UNPUB	20	360	364	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					219	222		10.1126/science.8385799	http://dx.doi.org/10.1126/science.8385799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385799				2022-12-24	WOS:A1993KW45200040
J	TSE, A; TSE, FW; ALMERS, W; HILLE, B				TSE, A; TSE, FW; ALMERS, W; HILLE, B			RHYTHMIC EXOCYTOSIS STIMULATED BY GNRH-INDUCED CALCIUM OSCILLATIONS IN RAT GONADOTROPES	SCIENCE			English	Article							LUTEINIZING-HORMONE SECRETION; MEMBRANE CAPACITANCE; CELLS; PITUITARY; CA-2+; RELEASE	In pituitary gonadotropes, gonadotropin-releasing hormone (GnRH) induces the rhythmic release of Ca2+ from an inositol 1,4,5-trisphosphate (IP3)-sensitive store. Simultaneous measurement of the concentration of cytosolic free Ca2+ ([Ca2+]i) and exocytosis in single identified gonadotropes showed that each elevation of [Ca2+]i induced a burst of exocytosis. These phenomena were largely suppressed by buffering of [Ca2+]i but persisted in the absence of extracellular Ca2+. Activation of voltage-gated Ca2+ channels by brief depolarizations seldom supplied enough Ca2+ for exocytosis, but [Ca2+]i elevations induced by photolysis of caged IP3 did trigger exocytosis, confirming that GnRH-stimulated gonadotropic hormone secretion is closely coupled to intracellular Ca2+ release. Agonist-induced oscillations of [Ca2+]i in secretory cells may be a mechanism to optimize the secretory output while avoiding the toxic effects of sustained elevation of [Ca2+]i.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SJ-40,SEATTLE,WA 98195; MAX PLANCK INST MED RES,W-6900 HEIDELBERG 1,GERMANY	University of Washington; University of Washington Seattle; Max Planck Society			Tse, Frederick/C-3449-2013; Tse, Amy/C-3142-2013	Tse, Amy/0000-0002-0847-7466				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLINKS JR, 1982, PROG BIOPHYS MOL BIO, V40, P1, DOI 10.1016/0079-6107(82)90011-6; CHANG JP, 1988, ENDOCRINOLOGY, V123, P87, DOI 10.1210/endo-123-1-87; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, CELL CALCIUM, V12, P229, DOI 10.1016/0143-4160(91)90023-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEONG DA, 1991, CELL CALCIUM, V12, P255, DOI 10.1016/0143-4160(91)90025-A; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MOENTER SM, 1992, ENDOCRINOLOGY, V130, P503, DOI 10.1210/en.130.1.503; MORIARTY GC, 1975, ENDOCRINOLOGY, V97, P1215, DOI 10.1210/endo-97-5-1215; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PENNER R, 1989, TRENDS NEUROSCI, V12, P159, DOI 10.1016/0166-2236(89)90059-3; SMITH PF, 1984, ENDOCRINOLOGY, V115, P2484, DOI 10.1210/endo-115-6-2484; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSE A, IN PRESS ENDOCRINOLO; TSE A, IN PRESS PULSATILITY; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZOREC R, 1991, J GEN PHYSIOL, V97, P473, DOI 10.1085/jgp.97.3.473	32	225	227	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					82	84		10.1126/science.8385366	http://dx.doi.org/10.1126/science.8385366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	8385366				2022-12-24	WOS:A1993KV42300032
J	THOMAS, HE; STUNNENBERG, HG; STEWART, AF				THOMAS, HE; STUNNENBERG, HG; STEWART, AF			HETERODIMERIZATION OF THE DROSOPHILA ECDYSONE RECEPTOR WITH RETINOID-X RECEPTOR AND ULTRASPIRACLE	NATURE			English	Article							RESPONSE ELEMENT; MAMMALIAN-CELLS; ACID; SUPERFAMILY; EXPRESSION; PROTEINS; PRODUCT; MEMBER; FAMILY; GENES	ECDYSONE in Drosophila has been a paradigm for steroid hormones since its ability to induce gene activity directly was demonstrated by its effects on moulting and polytene chromosome puffing1-3. The ecdysone receptor (EcR) was recently confirmed as a member of the nuclear receptor superfamily by cloning and characterization in a Drosophila cell line4. Here we show that EcR needs to heterodimerize with either the retinoid X receptor (RXR)5 or its Drosophila homologue, ultraspiracle (USP)6, for DNA binding and transactivation. These results place the ecdysone receptor in the heterodimerizing class of the nuclear receptor superfamily and demonstrate that the role of RXR/USP as a central and promiscuous partner in mediating the activity of these receptors7-12 is highly conserved. Whereas EcR-USP DNA-binding activity is unaffected by hormone, EcR-RXR DNA-binding activity is stimulated by either ecdysteroid or 9-cis-retinoic acid, demonstrating that hormone can play a role in heterodimer stabilization.	EMBL,GENE EXPRESS PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Stunnenberg, Hendrik G./D-6875-2012; Stewart, A. Francis/E-7789-2010	Stunnenberg, Hendrik G./0000-0002-0066-1576; 				AMIN J, 1991, MOL CELL BIOL, V11, P5937, DOI 10.1128/MCB.11.12.5937; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; PERRIMON N, 1985, GENETICS, V111, P23; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	29	441	454	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					471	475		10.1038/362471a0	http://dx.doi.org/10.1038/362471a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385270				2022-12-24	WOS:A1993KV42400091
J	GRESSENS, P; HILL, JM; GOZES, I; FRIDKIN, M; BRENNEMAN, DE				GRESSENS, P; HILL, JM; GOZES, I; FRIDKIN, M; BRENNEMAN, DE			GROWTH-FACTOR FUNCTION OF VASOACTIVE-INTESTINAL-PEPTIDE IN WHOLE CULTURED MOUSE EMBRYOS	NATURE			English	Article							SYMPATHETIC NEUROBLASTS; NEUROTROPHIC ACTION; REGULATES MITOSIS; RAT-BRAIN; POLYPEPTIDE; ANTAGONIST; SURVIVAL; VIP; DIFFERENTIATION; QUANTITATION	FACTORS controlling central nervous system (CNS) growth immediately after neurulation are mostly unknown. Vasoactive intestinal peptide (VIP) receptors are widely distributed in the embryonic nervous system1,2, and VIP has trophic and mitogenic properties3,4 on embryonic neural tissues but inhibits growth5 and mitosis in certain tumours6. To address the potential effects of VIP on embryonic growth, we used whole postimplantation embryo cultures7,8. After a 4-h incubation, VIP stimulated growth, increasing somite number, embryonic volume, DNA and protein content, and number of cells in S-phase. A VIP antagonist9,10 substantially inhibited these VIP-mediated increments in growth. The VIP antagonist completely suppressed VIP-stimulated mitosis in the CNS while decreasing the same. in non-neuronal tissues by 38%. In vitro autoradiography revealed GTP-sensitive and GTP-insensitive VIP receptors which were differentially regulated in VIP antagonist-treated embryos. The present study suggests that VIP acts as a growth factor on early postimplantation embryos through multiple VIP receptors that exhibit tissue-specific responses.	NICHHD, DEV NEUROBIOL LAB, BETHESDA, MD 20892 USA; TEL AVIV UNIV, DEPT CHEM PATHOL, IL-69978 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Weizmann Institute of Science	GRESSENS, P (corresponding author), NINCDS, EXPTL NEUROPATHOL LAB, BETHESDA, MD 20892 USA.		gressens, pierre/M-7557-2017	gressens, pierre/0000-0002-0909-4221				ALLEN JM, 1985, J NEURO-ONCOL, V3, P197, DOI 10.1007/BF00165179; AUDIGIER S, 1986, BRAIN RES, V376, P363, DOI 10.1016/0006-8993(86)90200-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; BRENNEMAN DE, 1985, PEPTIDES, V6, P35, DOI 10.1016/0196-9781(85)90132-9; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; BRENNEMAN DE, 1987, J CELL BIOL, V104, P1603, DOI 10.1083/jcb.104.6.1603; BROWN NA, 1981, TERATOLOGY, V24, P65, DOI 10.1002/tera.1420240108; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; EMSON PC, 1979, BRAIN RES, V177, P437, DOI 10.1016/0006-8993(79)90462-1; GOZES I, 1988, NEUROENDOCRINOLOGY, V47, P27, DOI 10.1159/000124886; GOZES I, 1989, ENDOCRINOLOGY, V125, P2945, DOI 10.1210/endo-125-6-2945; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; GOZES Y, 1991, BRAIN RES, V540, P319, DOI 10.1016/0006-8993(91)90528-4; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GRESSENS P, 1992, J NEUROPATH EXP NEUR, V51, P206, DOI 10.1097/00005072-199203000-00010; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; Heyner S., 1990, Current Topics in Developmental Biology, V24, P137, DOI 10.1016/S0070-2153(08)60086-1; Hill J. M., 1992, Society for Neuroscience Abstracts, V18, P1294; HILL J M, 1991, Society for Neuroscience Abstracts, V17, P1126; HILL JM, 1992, NEUROSCIENCE, V48, P925, DOI 10.1016/0306-4522(92)90280-F; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; MCGREGOR GP, 1982, NEUROSCI LETT, V28, P21, DOI 10.1016/0304-3940(82)90202-6; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; New D.A., 1971, METHODS MAMMALIAN EM, P305; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; POSTON GJ, 1988, PANCREAS, V3, P439, DOI 10.1097/00006676-198808000-00012; RUSSELL JT, 1990, SOC NEUR ABSTR, V16, P194; SCHOLAR EM, 1991, CANCER, V67, P1561, DOI 10.1002/1097-0142(19910315)67:6<1561::AID-CNCR2820670617>3.0.CO;2-Z; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; THEILER K, 1975, HOUSE MOUSE; TSUTSUI Y, 1987, AM J PATHOL, V127, P262; VANMAELEFABRY G, 1988, ARCH BIOL, V99, P431	33	263	278	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	1993	362	6416					155	158		10.1038/362155a0	http://dx.doi.org/10.1038/362155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383805				2022-12-24	WOS:A1993KR02800059
J	PEARCE, D; YAMAMOTO, KR				PEARCE, D; YAMAMOTO, KR			MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ACTIVITIES DISTINGUISHED BY NONRECEPTOR FACTORS AT A COMPOSITE RESPONSE ELEMENT	SCIENCE			English	Article							C-JUN; DNA-BINDING; FOS-JUN; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; NEGATIVE REGULATOR; COMPLEMENTARY-DNA; GENE-EXPRESSION; RETINOIC ACID; HORMONE	Mineralocorticoid and glucocorticoid hormones elicit distinct physiologic responses, yet the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) bind to and activate transcription similarly from a consensus simple hormone response element (HRE). The activities of GR and MR at plfG, a 25-base pair composite response element to which both the steroid receptors and transcription factor AP1 can bind, are analyzed here. Under conditions in which GR represses AP1-stimulated transcription from plfG, MR was inactive. With the use of MR-GR chimeras, a segment of the NH2-terminal region of GR (amino acids 105 to 440) was shown to be required for this repression. Thus, the distinct physiologic effects mediated by MR and GR may be determined by differential interactions of nonreceptor factors with specific receptor domains at composite response elements.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV NEPHROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADLER AA, IN PRESS P NATL ACAD; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BASTL CP, 1989, AM J PHYSIOL, V257, pF1027, DOI 10.1152/ajprenal.1989.257.6.F1027; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1990, ONCOGENE, V5, P929; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOBSEN MD, 1991, THESIS U CALIFORNIA; JOELS M, 1990, P NATL ACAD SCI USA, V87, P4495, DOI 10.1073/pnas.87.12.4495; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LAPLACE JR, 1992, J CLIN INVEST, V90, P1370, DOI 10.1172/JCI116003; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PATEL PD, 1989, MOL ENDOCRINOL, V3, P1877, DOI 10.1210/mend-3-11-1877; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TURNAMIAN SG, 1989, J CLIN INVEST, V84, P1924, DOI 10.1172/JCI114380; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	42	406	408	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1993	259	5098					1161	1165		10.1126/science.8382376	http://dx.doi.org/10.1126/science.8382376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8382376				2022-12-24	WOS:A1993KM91700039
J	SMITH, TJ				SMITH, TJ			WHICH HAT DO I WEAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BONE-MARROW TRANSPLANTATION; METASTATIC BREAST-CANCER; PATIENT-RELATIONSHIP; COST-EFFECTIVENESS											Coates Alan S., 1992, INTRO NEW TREATMENTS, P447; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOLDER AM, 1978, MED MALPRACTICE; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; Percy Walker, 1971, LOVE RUINS; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; SMITH TJ, 1992, HIGH DOSE CANCER THE; SMITH TJ, 1993, P AM SOC CLIN ONCOL, V12, pA63; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; WEISEMAN T, 1991, ONCOL ISSUES, V6, P7	14	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1657	1659		10.1001/jama.270.14.1657	http://dx.doi.org/10.1001/jama.270.14.1657			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411481				2022-12-24	WOS:A1993MA29400001
J	BENNETT, HJ				BENNETT, HJ			THE INS AND OUTS OF OUTIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1508	1508		10.1001/jama.270.13.1508	http://dx.doi.org/10.1001/jama.270.13.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371451				2022-12-24	WOS:A1993LZ33400001
J	BROWN, WT; HOUCK, GE; JEZIOROWSKA, A; LEVINSON, FN; DING, XH; DOBKIN, C; ZHONG, N; HENDERSON, J; BROOKS, SS; JENKINS, EC				BROWN, WT; HOUCK, GE; JEZIOROWSKA, A; LEVINSON, FN; DING, XH; DOBKIN, C; ZHONG, N; HENDERSON, J; BROOKS, SS; JENKINS, EC			RAPID FRAGILE-X CARRIER SCREENING AND PRENATAL-DIAGNOSIS USING A NONRADIOACTIVE PCR TEST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; DNA-SEQUENCE; GENE; MUTATION; REPEAT; AMPLIFICATION; REGION; FREQUENCY; PROGRAM	Objective.-To develop a rapid, nonradioactive test using the polymerase chain reaction (PCR) capable of detecting full fragile X mutations, premutations, and resolving normal alleles and to apply this to prenatal diagnosis and carrier screening of pregnant women at risk for fragile X carrier status. Design.-Prenatal and blood sample PCR analysis with confirmation by direct Southern blotting and cytogenetic techniques. Setting.-Samples sent to a DNA diagnostic research laboratory at a tertiary referral center. Participants.-Pregnant women with a family history of undiagnosed mental retardation or known fragile X syndrome and controls. Results.-A rapid, nonradioactive PCR screening protocol for the fragile X mental retardation-1 gene for both normal and mutant alleles was developed. Analysis of 570 control X chromosomes showed a modal number of 30 CGG repeats (range, 12 to 52 repeats) and a calculated heterozygosity of approximately 80%. No excess of homozygosity was found, indicating the test was accurate for normal allele resolution. In addition, 150 unrelated pregnant women were screened. Within known fragile X families, five of 20 pregnant women were diagnosed as carriers. Two new fragile X families were diagnosed among relatives of 130 females with family histories of undiagnosed mental retardation, although no carriers were identified. Prenatal PCR testing of 28 carriers accurately detected nine fetuses with full mutations. Conclusions.-This rapid, nonradioactive PCR protocol allows accurate resolution of normal alleles as well as simultaneous detection of carrier alleles and full mutations. With this approach, efficient screening of pregnant women at risk for fragile X carrier status, subsequent genetic counseling of identified carriers, and reliable prenatal diagnosis can be offered.			BROWN, WT (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT HUMAN GENET, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.		Brown, William/GXN-2777-2022		PHS HHS [MCJ360587] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL DA, 1991, NUCLEIC ACIDS RES, V19, P5079, DOI 10.1093/nar/19.18.5079; BLOMQUIST HK, 1983, CLIN GENET, V24, P393; Brown W T, 1992, Mol Genet Med, V2, P39; BROWN WT, 1992, AM J MED GENET, V43, P96, DOI 10.1002/ajmg.1320430114; BROWN WT, 1991, AM J MED GENET, V38, P292, DOI 10.1002/ajmg.1320380226; BROWN WT, 1988, NUCLEIC ACID PROBES, P11; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAQUILA RT, 1991, NUCLEIC ACIDS RES, V19, P3749, DOI 10.1093/nar/19.13.3749; DEKA R, 1992, AM J HUM GENET, V51, P1325; DOBKIN CS, 1991, LANCET, V338, P957; ERSTER SH, 1992, HUM GENET, V90, P55; FORNAGE M, 1992, GENOMICS, V12, P63, DOI 10.1016/0888-7543(92)90407-J; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HAGERMAN RJ, 1991, FRAGILE X SYNDROME; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST M, 1991, LANCET, V338, P956, DOI 10.1016/0140-6736(91)91831-E; INNIS MA, 1990, PCR PROTOCOLS, P54; JENKINS EC, 1992, 1992 INTERNATIONAL FRAGILE X CONFERENCE PROCEEDINGS, P349; JENKINS EC, 1992, GENETIC DISORDERS FE, P241; KRAWCZUN MS, 1992, AM J MED GENET, V43, P149, DOI 10.1002/ajmg.1320430123; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACPHERSON JN, 1992, J MED GENET, V29, P802, DOI 10.1136/jmg.29.11.802; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MANDEL JL, 1992, AM J MED GENET, V43, P5, DOI 10.1002/ajmg.1320430104; MARKHAM AF, 1993, BMJ-BRIT MED J, V306, P441, DOI 10.1136/bmj.306.6875.441; McCabe E R, 1991, PCR Methods Appl, V1, P99; MOSER HW, 1989, PRINCIPLES PRACTICE, V1, P495; NOLIN SL, 1991, AM J MED GENET, V38, P251, DOI 10.1002/ajmg.1320380218; OOSTRA BA, 1993, J MED GENET, V30, P410, DOI 10.1136/jmg.30.5.410; OUDET C, 1993, AM J HUM GENET, V52, P297; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PERGOLIZZI RG, 1992, LANCET, V339, P271, DOI 10.1016/0140-6736(92)91334-5; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P353, DOI 10.1016/0003-2697(90)90307-U; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHELBOURNE P, 1993, NEW ENGL J MED, V328, P471, DOI 10.1056/NEJM199302183280704; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; STRAUSS WM, 1988, CURRENT PROTOCOLS MO; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1991, NEW ENGL J MED, V325, P1720, DOI 10.1056/NEJM199112123252407; TRNOVSKY J, 1992, BIOTECHNIQUES, V13, P800; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Walsh P S, 1992, PCR Methods Appl, V1, P241, DOI 10.1101/gr.1.4.241; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WITT M, 1989, HUM GENET, V82, P271, DOI 10.1007/BF00291168; YAMAGATA H, 1992, LANCET, V339, P692, DOI 10.1016/0140-6736(92)90862-W; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	55	234	239	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1569	1575		10.1001/jama.270.13.1569	http://dx.doi.org/10.1001/jama.270.13.1569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371467				2022-12-24	WOS:A1993LZ33400030
J	RADANOV, BP; STURZENEGGER, M; DISTEFANO, G; SCHNIDRIG, A; ALJINOVIC, M				RADANOV, BP; STURZENEGGER, M; DISTEFANO, G; SCHNIDRIG, A; ALJINOVIC, M			FACTORS INFLUENCING RECOVERY FROM HEADACHE AFTER COMMON WHIPLASH	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL-SPINE; INJURIES; NECK; SPRAIN	Objective-To assess the relation between pretraumatic and trauma related headache in patients suffering from whiplash. Design-Follow up study of patients examined a mean (SD) of 7.4 (4.2) days after trauma and again at three and six months. Setting-Patients referred from primary care. Subjects-117 patients (mean age 30.8 (9.5) years. Main outcome measures-Prevalence of trauma related headache and the predictive relation by multiple logistic regression between different somatic and psychological variables and trauma related headache at each examination. Results-Prevalence of trauma related headache decreased from 57% to 27%. History of pretraumatic headache proved a significant risk factor for presenting with trauma related headache. A significant relation between trauma related headache and the following variables was found: at seven days the initial wellbeing score, early onset of neck pain, depression scale from the personality inventory, and the initial intensity of neck pain; at three months, intensity of neck pain, and history of pretraumatic headache; and at six months neck pain, pain intensity, and history of pretraumatic headache. Conclusions-History of pretraumatic headache significantly increases the likelihood of presenting with trauma related headache but only in combination with findings indicative of clinically important injury to the cervical spine.	UNIV BERN,INSELSPITAL,DEPT NEUROL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern	RADANOV, BP (corresponding author), UNIV BERN,DEPT PSYCHIAT,CONSULTAT SERV MURTENSTR 21,CH-3010 BERN,SWITZERLAND.							ARENA JG, 1984, J PSYCHOSOM RES, V28, P79, DOI 10.1016/0022-3999(84)90043-6; BALLA J, 1988, HEADACHE PROBLEMS DI, P241; BELLAVANCE A, 1989, NEUROLOGY, V39, P1269, DOI 10.1212/WNL.39.9.1269; BOQUET J, 1989, CEPHALALGIA, V9, P15, DOI 10.1046/j.1468-2982.1989.0901015.x; DEANS GT, 1987, INJURY, V18, P10, DOI 10.1016/0020-1383(87)90375-5; DVORAK J, 1987, ORTHOPADE, V16, P2; EDMEADS J, 1988, NEUROLOGY, V38, P1874, DOI 10.1212/WNL.38.12.1874; Fahrenberg J, 1984, FREIBURGER PERSONLIC; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; KELLY R, 1988, HEADACHE PROBLEMS DI, P217; LANCE JW, 1988, AUST NZ J MED, V18, P311, DOI 10.1111/j.1445-5994.1988.tb02043.x; MAIMARIS C, 1988, INJURY, V19, P393, DOI 10.1016/0020-1383(88)90131-3; MARTIN PR, 1988, BEHAV RES THER, V26, P353, DOI 10.1016/0005-7967(88)90090-3; MARTIN PR, 1992, J PSYCHOSOM RES, V36, P137, DOI 10.1016/0022-3999(92)90022-T; MERSKEY H, 1984, CAN MED ASSOC J, V130, P1119; NORRIS SH, 1983, J BONE JOINT SURG BR, V65, P608, DOI 10.1302/0301-620X.65B5.6643566; NORUSIS MJ, 1990, SPSS ADV STATISTICS, P44; PEARCE JMS, 1989, J NEUROL NEUROSUR PS, V52, P1329, DOI 10.1136/jnnp.52.12.1329; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; VONZERSSEN D, 1983, METHODOLOGY EVALUATI, P183; WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234; 1988, CEPHALALGIA S, V7, P8	22	55	58	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					652	655		10.1136/bmj.307.6905.652	http://dx.doi.org/10.1136/bmj.307.6905.652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LX470	8401050	Bronze, Green Published			2022-12-24	WOS:A1993LX47000016
J	LAMANTIA, ML; LENNARZ, WJ				LAMANTIA, ML; LENNARZ, WJ			THE ESSENTIAL FUNCTION OF YEAST PROTEIN DISULFIDE-ISOMERASE DOES NOT RESIDE IN ITS ISOMERASE ACTIVITY	CELL			English	Article							ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; BOND FORMATION; GENE; GLUTATHIONE; CELL; PURIFICATION; PROCOLLAGEN	Protein disulfide isomerase (PDI) is believed to function in vivo by catalyzing the isomerization of disulfide bonds in proteins and thereby facilitating their folding. In S. cerevisiae PDI is encoded by an essential gene. Deletion of nearly one-third of the C-terminal residues of PDI altered PDI's cellular localization but not cell viability. Further deletions resulted in lethality, but these truncated proteins still exhibited PDI activity in vitro. Cells carrying a variant PDI in which both -CGHC-active sites were disrupted were viable. However, these cells exhibited a delay in the disulfide bond formation and transport of carboxypeptidase Y. In vitro enzyme assays revealed that disruption of both sites abolished catalytic activity. These results indicate that PDI catalyzes disulfide bond formation both in vivo and in vitro and that the integrity of the active sites is required for catalysis. However, this catalytic activity is not essential for yeast viability.	SUNY, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NIGMS NIH HHS [GM33184, GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184, R37GM033185, R01GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; Gurd F R, 1972, Methods Enzymol, V25, P424, DOI 10.1016/S0076-6879(72)25038-8; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAMBERT N, 1984, BIOCHEM SOC T, V12, P1024; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1993, IN PRESS J BIOL CHEM, V268; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; VUORI K, 1992, J BIOL CHEM, V267, P7211; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; WICKERHAM LJ, 1946, J BACTERIOL, V142, P414	50	194	204	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					899	908		10.1016/0092-8674(93)90469-7	http://dx.doi.org/10.1016/0092-8674(93)90469-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374956				2022-12-24	WOS:A1993LX29200015
J	KNAUS, WA; HARRELL, FE; FISHER, CJ; WAGNER, DP; OPAL, SM; SADOFF, JC; DRAPER, EA; WALAWANDER, CA; CONBOY, K; GRASELA, TH				KNAUS, WA; HARRELL, FE; FISHER, CJ; WAGNER, DP; OPAL, SM; SADOFF, JC; DRAPER, EA; WALAWANDER, CA; CONBOY, K; GRASELA, TH			THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ILL HOSPITALIZED ADULTS; ORGAN-SYSTEM FAILURE; GRAM-NEGATIVE SEPSIS; REGRESSION-MODELS; SEPTIC SHOCK; PROPORTIONAL HAZARDS; MONOCLONAL-ANTIBODY; MORTALITY; TRIAL; DEFINITIONS	Objective.- To develop a survival model and severity assessment method to estimate the 28-day mortality risk for patients with sepsis syndrome entering phase 2 and 3 drug evaluations. Design.- Retrospective analysis of intensive care unit admissions with sepsis syndrome by means of log-normal regression to identify risk factors for 28-day mortality. Prospective application of the model to patients with gram-negative infection meeting sepsis syndrome criteria from separate data collection (validation group). Patients.- A total of 58 737 intensive care unit admissions at 107 hospitals in the United States and Western Europe screened to yield 1195 patients meeting entry criteria for the sepsis syndrome study for the original model; 295 hospitalized patients with gram-negative infection meeting criteria for sepsis syndrome for validation. Main Outcome Measures.- Survival time and mortality at 28 days after fulfillment of the sepsis syndrome criteria. Results.- Acute physiologic abnormalities were the most important prognostic factors influencing outcome (82% of total chi2). Specific disease resulting in intensive care unit admission and the time the patient was in the hospital and intensive care unit before qualification were also independent risks, as were age and a clinical history of cirrhosis. The model's overall classification accuracy was a Somers' Dyx of .52 (rank correlation between predicted risk and 28-day mortality) (receiver operating characteristic area, 0.76), with equal accuracy (Dyx=.59; receiver operating characteristic area, 0.80) in the independent group of patients. Conclusions.- We created an accurate independent estimate for 28-day mortality risk for patients with sepsis syndrome (severe sepsis). This estimate could improve the evaluation of new drugs by investigating whether the drug's benefit varies by patient risk and then determining the amount of benefit for individual patients.	DUKE UNIV, MED CTR, DIV BIOMETRY, DURHAM, NC 27710 USA; CLEVELAND CLIN EDUC FDN, CRIT CARE RES UNIT, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA; WALTER REED ARMY INST RES, WASHINGTON, DC 20307 USA; APACHE MED SYST INC, WASHINGTON, DC USA; SUNY Buffalo, CTR PHARMACOEPIDEMIOL RES, BUFFALO, NY 14260 USA	Duke University; Cleveland Clinic Foundation; Brown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	KNAUS, WA (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, ICU, RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA.		Knaus, William/AAX-2138-2020		AHRQ HHS [HSO 7137] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; DAMIANO AM, 1992, J CLIN EPIDEMIOL, V45, P93, DOI 10.1016/0895-4356(92)90001-4; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; Goodman LA, 1979, MEASURES ASS CROSS C; GORE SM, 1984, APPL STAT-J ROY ST C, V33, P176; GRASELA TH, 1987, DRUG INTEL CLIN PHAR, V21, P902, DOI 10.1177/106002808702101112; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HULSEBOS RG, 1992, 6TH EUR C INT CAR ME; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; KNAUS WA, 1992, S COMPUTER APPLICATI, P987; LAWLESS JF, 1982, STATISTICAL MODELS M; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Meinert CL, 1986, CLIN TRIALS DESIGN C; PARILLO JE, 1989, TXB CRITICAL CARE ME, P111; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; SIRIO CA, 1993, CLIN RES, V14, pA152; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; WARRE HS, 1992, NEW ENGL J MED, V236, P1153; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	36	158	160	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1233	1241		10.1001/jama.270.10.1233	http://dx.doi.org/10.1001/jama.270.10.1233			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355388				2022-12-24	WOS:A1993LV64900031
J	WACHTEL, TJ; STEIN, MD				WACHTEL, TJ; STEIN, MD			FEE-FOR-TIME SYSTEM - A CONCEPTUAL-FRAMEWORK FOR AN INCENTIVE-NEUTRAL METHOD OF PHYSICIAN-PAYMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RELATIVE-VALUE SCALE; FINANCIAL INCENTIVES; CARE; MEDICINE; SPECIALTIES; OBJECTIONS; MALONEY; REFORM; RBRVS		RHODE ISL HOSP, DIV GERIATR, 593 EDDY ST, PROVIDENCE, RI 02903 USA; BROWN UNIV, DEPT COMMUNITY HLTH, PROVIDENCE, RI 02912 USA; BROWN UNIV, DEPT MED, PROVIDENCE, RI 02912 USA; RHODE ISL HOSP, DIV GEN INTERNAL MED, PROVIDENCE, RI 02902 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								BOCK RS, 1983, NEW ENGL J MED, V319, P785; BRAHAM RL, 1990, J GEN INTERN MED, V5, P95, DOI 10.1007/BF02600506; DELOZIER JE, 1991, VITAL HLTH STAT, V203, P7; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GERETY MB, 1992, J AM GERIATR SOC, V40, P1272, DOI 10.1111/j.1532-5415.1992.tb03655.x; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; HADLEY J, 1986, MED PHYSICIAN PAYMEN, P29; HADLEY J, 1986, MED PHYSICIAN PAYMEN, P47; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; HSIAO W, 1992, JAMA-J AM MED ASSOC, V267, P1822, DOI 10.1001/jama.267.13.1822; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; HSIAO WC, 1987, JAMA-J AM MED ASSOC, V258, P799, DOI 10.1001/jama.258.6.799; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1991, NEW ENGL J MED, V325, P1820, DOI 10.1056/NEJM199112193252523; JENCKS SF, 1985, NEW ENGL J MED, V312, P1492, DOI 10.1056/NEJM198506063122306; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; KIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441; LEAF A, 1984, NEW ENGL J MED, V310, P718, DOI 10.1056/NEJM198403153101111; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MALONEY JV, 1992, JAMA-J AM MED ASSOC, V268, P3363, DOI 10.1001/jama.268.23.3363; MALONEY JV, 1992, JAMA-J AM MED ASSOC, V267, P2896; MALONEY JV, 1991, JAMA-J AM MED ASSOC, V266, P3453; MECHANIC D, 1985, NEW ENGL J MED, V312, P181, DOI 10.1056/NEJM198501173120312; MENDENHALL RC, 1978, JAMA-J AM MED ASSOC, V240, P1160, DOI 10.1001/jama.240.11.1160; Pauly MV, 1980, DOCTORS THEIR WORKSH, P57; RADECKI SE, 1992, JAMA-J AM MED ASSOC, V267, P1824, DOI 10.1001/jama.267.13.1824; REAGAN MD, 1987, NEW ENGL J MED, V317, P1729; RELMAN AS, 1992, NEW ENGL J MED, V327, P1522, DOI 10.1056/NEJM199211193272112; RELMAN AS, 1987, NEW ENGL J MED, V316, P1150, DOI 10.1056/NEJM198704303161810; ROE BB, 1982, NEW ENGL J MED, V307, P551, DOI 10.1056/NEJM198208263070910; ROPER WL, 1988, NEW ENGL J MED, V319, P865, DOI 10.1056/NEJM198809293191311; SCHWARTZ H, 1978, NEW ENGL J MED, V299, P1071, DOI 10.1056/NEJM197811092991913; SCOVERN H, 1988, NEW ENGL J MED, V319, P787, DOI 10.1056/NEJM198809223191211; Somers A R, 1977, Inquiry, V14, P115; SOMERS AR, 1984, NEW ENGL J MED, V311, P853, DOI 10.1056/NEJM198409273111312; STARR P, 1992, LOGIC HLTH CARE REFO, P65; 1987, ANN INTERN MED, V106, P151	43	7	7	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1226	1229		10.1001/jama.270.10.1226	http://dx.doi.org/10.1001/jama.270.10.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355386				2022-12-24	WOS:A1993LV64900029
J	MOMBAERTS, P; ARNOLDI, J; RUSS, F; TONEGAWA, S; KAUFMANN, SHE				MOMBAERTS, P; ARNOLDI, J; RUSS, F; TONEGAWA, S; KAUFMANN, SHE			DIFFERENT ROLES OF ALPHA-BETA AND GAMMA-DELTA T-CELLS IN IMMUNITY AGAINST AN INTRACELLULAR BACTERIAL PATHOGEN	NATURE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; LISTERIA-MONOCYTOGENES; MEDIATED-IMMUNITY; INFECTION; MICE; PROTECTION; INTERFERON; LYMPHOCYTES; EXPRESSION; RESOLUTION	SEVERAL bacterial pathogens of medical importance are able to persist and replicate inside host mononuclear phagocytes. Protective immunity depends on specific T lymphocytes that induce granulomatous lesions at the sites of bacterial multiplication1,2. Listeria monocytogenes is an intracellular pathogen that replicates inside mononuclear phagocytes and hepatocytes of mice1-4. Invasion from the phagosomal compartment into the cytoplasmic compartment is the principal mechanism of intracellular survival5. Early in infection, resistance against L. monocytogenes is mediated by polymorphonuclear phagocytes which destroy infected liver cells, followed by natural killer cells which activate macrophages by means of interferon-gamma (refs 6, 7). A specific immune response by T cells then develops which leads to sterile eradication of the microbes1,2,8. T cells are also responsible for the highly effective protection in vaccinated mice against secondary infections1,2. Although the role of alphabeta T cells has been demonstrated in these immune responses, that of gammadelta T cells is unclear2,9,10. Here we use mice that selectively lack either alphabeta or gammadelta T cells as a result of targeted germ-line mutations in their T-cell receptor genes11,12 to investigate the relative roles of these T-cell populations during experimental infection with L. monocytogenes. We find that in primary listeriosis, either alphabeta or gammadelta T cells are sufficient for early protection. Resistance to secondary infection is mediated mainly by alphabeta T cells but also involves gammadelta T cells. Thus alphabeta T-cell-deficient mice can be rendered partially resistant by vaccination, and gammadelta T cells are shown to be responsible for this protective effect. In infected gammadelta T-cell-deficient mice we noticed the appearance of unusual liver lesions, indicating that gammadelta T cells have a unique regulatory role in this bacterial infection.	UNIV ULM,DEPT IMMUNOL,ALBERT EINSTEIN ALLEE 11,D-89070 ULM,GERMANY; MIT,DEPT BIOL,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Ulm University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268				BALDRIDGE JR, 1990, INFECT IMMUN, V58, P654, DOI 10.1128/IAI.58.3.654-658.1990; BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CONLAN JW, 1991, J EXP MED, V174, P741, DOI 10.1084/jem.174.3.741; DUNN PL, 1991, J INFECT DIS, V164, P869, DOI 10.1093/infdis/164.5.869; EMMERLING P, 1974, J INFECT IMMUN, V12, P437; EMMERLING P, 1974, INFECT IMMUN, V12, P437; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GREGORY SH, 1993, J IMMUNOL, V150, P2901; HAAS W, 1993, REV IMMUNOL, V11, P637; HAHN H, 1981, REV INFECT DIS, V3, P1221; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KAUFMANN SHE, 1986, MICROB PATHOGENESIS, V1, P249, DOI 10.1016/0882-4010(86)90049-5; KAUFMANN SHE, 1982, J EXP MED, V155, P1754, DOI 10.1084/jem.155.6.1754; KAUFMANN SHE, 1985, INFECT IMMUN, V48, P263, DOI 10.1128/IAI.48.1.263-266.1985; KAUFMANN SHE, 1993, REV IMMUNOL, V11, P129; KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NORTH RJ, 1970, J EXP MED, V132, P521, DOI 10.1084/jem.132.3.521; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; ROBERTS AD, 1993, INFECT IMMUN, V61, P1113, DOI 10.1128/IAI.61.3.1113-1116.1993; SINGH IG, 1992, INFECT IMMUN, V60, P257, DOI 10.1128/IAI.60.1.257-263.1992	25	410	410	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					53	56		10.1038/365053a0	http://dx.doi.org/10.1038/365053a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361537				2022-12-24	WOS:A1993LV64600052
J	BARGMANN, CI; HARTWIEG, E; HORVITZ, HR				BARGMANN, CI; HARTWIEG, E; HORVITZ, HR			ODORANT-SELECTIVE GENES AND NEURONS MEDIATE OLFACTION IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; UDP-GLUCURONOSYL TRANSFERASE; CHEMOSENSORY NEURONS; DEFECTIVE-MUTANTS; NERVOUS-SYSTEM; DROSOPHILA; CELL; CHEMOTAXIS; IDENTIFICATION; TRANSDUCTION	Olfaction is a versatile and sensitive mechanism for detecting volatile odorants. We show that the nematode C. elegans detects many volatile chemicals, which can be attractants, repellents, or attractants at low concentrations and repellents at high concentrations. Through laser ablation, we have identified chemosensory neurons that detect volatile odorants. Chemotaxis to volatile odorants requires different sensory neurons from chemotaxis to water-soluble attractants, indicating that C. elegans might have senses that correspond to smell and taste, respectively. Single neurons have complex sensory properties, since six distinguishable volatile odorants are sensed by only two types of sensory neurons. Chemotaxis to subsets of volatile odorants is disrupted by mutations in the odr genes, which might be involved in odorant sensation or signal transduction.	UNIV CALIF SAN FRANCISCO, DEPT ANAT, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BARGMANN, CI (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.			Bargmann, Cornelia/0000-0002-8484-0618	NIDCD NIH HHS [DC01393] Funding Source: Medline; NIGMS NIH HHS [GM24663] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ache B.W., 1987, NEUROBIOLOGY TASTE S, P39; ALBERT PS, 1981, J COMP NEUROL, V198, P435, DOI 10.1002/cne.901980305; ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AMOORE JE, 1977, CHEM SENS FLAV, V2, P267, DOI 10.1093/chemse/2.3.267; ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1990, COLD SH Q B, V55, P529; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRENNER S, 1974, GENETICS, V77, P71; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; CULOTTI JG, 1978, GENETICS, V90, P243; DAINTY RH, 1985, J APPL BACTERIOL, V59, P303, DOI 10.1111/j.1365-2672.1985.tb03324.x; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; DUSENBERY DB, 1975, GENETICS, V80, P297; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; GYORGYI TK, 1988, P NATL ACAD SCI USA, V85, P9851, DOI 10.1073/pnas.85.24.9851; HELFAND SL, 1989, P NATL ACAD SCI USA, V86, P2908, DOI 10.1073/pnas.86.8.2908; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1988, NEMATODE CAENORHABDI, P491; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LEWIS JA, 1977, J COMP NEUROL, V172, P489, DOI 10.1002/cne.901720306; LILLY M, 1990, GENETICS, V124, P293; MCKENNA M, 1989, P NATL ACAD SCI USA, V86, P8118, DOI 10.1073/pnas.86.20.8118; NOTTEBOHM E, 1992, NATURE, V359, P829, DOI 10.1038/359829a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; PEVSNER J, 1985, P NATL ACAD SCI USA, V82, P3050, DOI 10.1073/pnas.82.9.3050; REED RR, 1990, CELL, V60, P1, DOI 10.1016/0092-8674(90)90706-K; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; ROYER SM, 1991, J COMP NEUROL, V306, P49, DOI 10.1002/cne.903060105; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SIDDIQI O, 1987, TRENDS GENET, V3, P137, DOI 10.1016/0168-9525(87)90204-6; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STOCKER RF, 1988, DEV BIOL, V127, P12, DOI 10.1016/0012-1606(88)90184-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wood WB, 1988, NEMATODE CAENORHABDI; WOODARD C, 1992, J NEUROGENET, V8, P17, DOI 10.3109/01677069209167269; WOODARD C, 1989, GENETICS, V123, P315; ZECHMAN JM, 1985, CAN J MICROBIOL, V31, P232, DOI 10.1139/m85-045; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	55	826	869	5	260	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					515	527		10.1016/0092-8674(93)80053-H	http://dx.doi.org/10.1016/0092-8674(93)80053-H			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348618				2022-12-24	WOS:A1993LT73900013
J	SHEPHERD, JC; SCHUMACHER, TNM; ASHTONRICKARDT, PG; IMAEDA, S; PLOEGH, HL; JANEWAY, CA; TONEGAWA, S				SHEPHERD, JC; SCHUMACHER, TNM; ASHTONRICKARDT, PG; IMAEDA, S; PLOEGH, HL; JANEWAY, CA; TONEGAWA, S			TAP1-DEPENDENT PEPTIDE TRANSLOCATION IN-VITRO IS ATP-DEPENDENT AND PEPTIDE SELECTIVE	CELL			English	Article							CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEASOME-RELATED GENE; MHC-LINKED TRANSPORTER; MULTIDRUG RESISTANCE; MICROSOMAL-MEMBRANES; ANTIGEN PRESENTATION; BACTERIAL TRANSPORT; CYSTIC-FIBROSIS; P-GLYCOPROTEIN	T cells detect infection of cells by recognizing peptide fragments of foreign proteins bound to class I molecules of the major histocompatibility complex (MHC) on the surface of the infected cell. MHC class I molecules bind peptide in the endoplasmic reticulum, and analysis of mutant cells has demonstrated that an adequate supply of peptides requires the presence of two genes in the MHC class II locus that encode proteins called transporters associated with antigen processing (TAP) 1 and 2. TAP1 and TAP2 are members of the ATP-binding cassette family of membrane translocators. In this study, we demonstrate in a cell-free system that TAP1 is part of an ATP-dependent, sequence-specific, peptide translocator.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	SHEPHERD, JC (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DIV IMMUNOBIOL FMB402,NEW HAVEN,CT 06510, USA.		Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804				Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BIJLMAKERS MKE, 1993, IN PRESS EUR J IMMUN; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P2676, DOI 10.1073/pnas.90.7.2676; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YEWDELL JW, 1993, J EXP MED, V177, P1785, DOI 10.1084/jem.177.6.1785; ZWEERINK HJ, 1993, J IMMUNOL, V150, P1763	49	329	331	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					577	584		10.1016/0092-8674(93)80058-M	http://dx.doi.org/10.1016/0092-8674(93)80058-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348620				2022-12-24	WOS:A1993LT73900018
J	THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ				THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ			THERAPEUTIC AEROSOLS IN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL VENTILATOR CIRCUITS; DELIVERY; LUNG; NEBULIZERS; DEPOSITION; INSULIN	The use and variety of drugs administered to children as inhaled aerosols is increasing, but little is known about how much drug reaches the lung and how it is distributed there in different age groups. In this article the reasons for measuring aerosol deposition in children are discussed and the potential methods for doing this described. Of the methods available, only the use of radiolabelled aerosols gives accurate information on total lung deposition and distribution. The potential risk of the radiation exposure required for these measurements varies with the age of the child but seems to be small. Properly designed studies are expected to clarify the factors affecting lung deposition in children and identify methods of inhalation associated with efficient and predictable delivery of the drug. Measurements of radioaerosol deposition may therefore be justified in children when this information is expected to lead to improvements in the effectiveness or safety of their treatment.	ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, MED PHYS DIRECTORATE, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, DEPT NUCL MED, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	THOMAS, SHL (corresponding author), NEWCASTLE UNIV, WOLFSON DEPT CLIN PHARMACOL, NEWCASTLE UPON TYNE NE1 4LP, ENGLAND.							AHRENS RC, 1986, PEDIATR PULM, V2, P19, DOI 10.1002/ppul.1950020108; ALDERSON PO, 1974, J PEDIATR-US, V84, P479, DOI 10.1016/S0022-3476(74)80664-5; [Anonymous], 1991, Ann ICRP, V21, P1; BLACKHALL MI, 1987, EUR J RESPIR DIS, V71, P96; BORGSTROM L, 1990, PHARMACEUT RES, V7, P1068, DOI 10.1023/A:1015951402799; CAMERON D, 1990, CRIT CARE MED, V18, P866, DOI 10.1097/00003246-199008000-00015; CAMERON D, 1990, PAEDIATRIC PULMONOLO, V10, P208; CHUA HL, 1991, AM REV RESPIR DIS, V43, pA706; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; DAHLBACK M, 1989, J AEROSOL MED, V2, P339; DAVIES DS, 1984, EUR J RESPIR DIS, V65, P141; ELLIOTT RB, 1987, AUST PAEDIATR J, V23, P293; EVERARD ML, 1992, ARCH DIS CHILD, V67, P586, DOI 10.1136/adc.67.5.586; EVERARD ML, 1992, ARCH DIS CHILD-FETAL, V67, P826, DOI 10.1136/adc.67.7_Spec_No.826; HINDLE M, 1992, BRIT J CLIN PHARMACO, V34, P311, DOI 10.1111/j.1365-2125.1992.tb05921.x; HUNG OR, 1993, CLIN PHARMACOL THER, V53, P207; LESOUEF PN, 1992, LANCET, V339, P1282, DOI 10.1016/0140-6736(92)91602-5; ODOHERTY MJ, 1993, THORAX, V48, P220, DOI 10.1136/thx.48.3.220; SALMON B, 1990, ARCH DIS CHILD, V65, P401, DOI 10.1136/adc.65.4.401; SILVERMAN M, 1990, ARCH DIS CHILD, V65, P906, DOI 10.1136/adc.65.8.906; THOMAS SHL, 1991, CLIN SCI, V81, P767, DOI 10.1042/cs0810767; WILKIE RA, 1987, J PEDIATR-US, V111, P278, DOI 10.1016/S0022-3476(87)80087-2; WOLFSDORF J, 1969, PEDIATRICS, V43, P799; 1988, SERIES MBI, V16; 1987, ANN ICRP, V18, P219; 1989, SERIES DH2, V14	27	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					245	247		10.1136/bmj.307.6898.245	http://dx.doi.org/10.1136/bmj.307.6898.245			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369692	Bronze, Green Published			2022-12-24	WOS:A1993LP31400031
J	SULLIVAN, KMC; BUSA, WB; WILSON, KL				SULLIVAN, KMC; BUSA, WB; WILSON, KL			CALCIUM MOBILIZATION IS REQUIRED FOR NUCLEAR VESICLE FUSION IN-VITRO - IMPLICATIONS FOR MEMBRANE TRAFFIC AND IP(3) RECEPTOR FUNCTION	CELL			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RAT-LIVER NUCLEI; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; GOLGI-APPARATUS; XENOPUS OOCYTES; RELEASE; CA-2+; CELL; TRISPHOSPHATE	We studied the fusion of nuclear vesicles bound to chromatin in Xenopus egg extracts. Fusion was inhibited by 5 mM BAPTA, a Ca2+ buffer that suppresses cytosolic [Ca2+] gradients. The BAPTA-inhibited step in fusion was biochemically distinct from, and occurred later than, the GTPgammaS-sensitive step mediated by the monomeric GTPase, ADP-ribosylation factor. Exogenous inositol 1,4,5-trisphosphate (IP3), which triggers Ca2+ release from lumenal stores via IP3 receptors, stimulated fusion in the presence of BAPTA. This rescue was specific, because inositol 1,3,4-trisphosphate had no effect. Heparin, a potent antagonist of IP3 receptors, independently blocked fusion in an IP3-reversible manner. We suggest that phosphoinositide signaling may regulate nuclear vesicle fusion.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University	SULLIVAN, KMC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.							ALBRITTON NL, 1992, SCIENCE, V258, P1812; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1992, CELL CALCIUM, V13, P313, DOI 10.1016/0143-4160(92)90066-2; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; Ferris Christopher D., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P95; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILLESPIE JI, 1983, J PHYSIOL-LONDON, V344, P359, DOI 10.1113/jphysiol.1983.sp014945; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; IVORRA I, 1991, BIOCHEM J, V273, P317, DOI 10.1042/bj2730317; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Lino Masamitsu, 1992, Nature (London), V360, P76; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1988, CELL BIOL INT REP, V12, P833, DOI 10.1016/0309-1651(88)90091-4; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MATTER N, 1993, J BIOL CHEM, V268, P732; Meldolesi Jacopo, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P187; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, J PHYSIOL-LONDON, V433, P207, DOI 10.1113/jphysiol.1991.sp018422; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RANDAZZO PA, 1993, IN PRESS J BIOL CHEM; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WIESE C, 1993, IN PRESS CURR OPIN C, V5; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	80	130	131	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1411	1422		10.1016/0092-8674(93)90366-X	http://dx.doi.org/10.1016/0092-8674(93)90366-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391933	Bronze			2022-12-24	WOS:A1993LL20900015
J	YALCINKAYA, TM; SIITERI, PK; VIGNE, JL; LICHT, P; PAVGI, S; FRANK, LG; GLICKMAN, SE				YALCINKAYA, TM; SIITERI, PK; VIGNE, JL; LICHT, P; PAVGI, S; FRANK, LG; GLICKMAN, SE			A MECHANISM FOR VIRILIZATION OF FEMALE SPOTTED HYENAS INUTERO	SCIENCE			English	Article							CROCUTA-CROCUTA; SEX-DIFFERENCES; TESTOSTERONE; DEFICIENCY	Female spotted hyenas exhibit male-like genitalia and dominance over males. Hyena ovarian tissues incubated in vitro produced large quantities of the steroid hormone precursor androstenedione. The activity of aromatase, which converts androstenedione to estrogen, was one-twentieth as great in hyena versus human placental homogenates. In comparison, the activity of 17beta-hydroxysteroid dehydrogenase, which converts androstenedione to testosterone, was equal in the two homogenates. The limited aromatase activity may allow the hyena placenta to convert high circulating concentrations of androstenedione to testosterone, which results in virilization of the fetal external genitalia and possibly destruction of fetal ovarian follicles. Androstenedione production by residual ovarian stromal cells during reproductive life accounts for the epigenetic transmission of virilization in female spotted hyenas.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA 94143 USA; UNIV CALIF BERKELEY, DEPT ZOOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT PSYCHOL, BERKELEY, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-39825] Funding Source: Medline; NIMH NIH HHS [MH-39917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARISTOTLE, 1965, HIST ANIMAIUM; BEATTY WW, 1979, HORM BEHAV, V12, P112, DOI 10.1016/0018-506X(79)90017-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS D. DWIGHT, 1949, FIELDIANA ZOOL, V31, P277; FRANK LG, 1989, SYM ZOOL S, V61, P127; GIVENS J, 1992, CURRENT ISSUES ENDOC, P3; GLICKMAN SE, 1987, P NATL ACAD SCI USA, V84, P3444, DOI 10.1073/pnas.84.10.3444; GLICKMAN SE, 1992, J REPROD FERTIL, V95, P451; HARADA N, 1992, J BIOL CHEM, V267, P4781; HILLIER SG, 1979, BIOL REPROD, V20, P261, DOI 10.1095/biolreprod20.2.261; HORIE K, 1992, HUM REPROD, V7, P184, DOI 10.1093/oxfordjournals.humrep.a137614; JOST A, 1985, HDB BEHAVIORAL NEURO, V7, P3; KRUUK H, 1972, SPOTTED HYENA; LICHT P, 1992, J REPROD FERTIL, V95, P463; LINDEQUE M, 1982, J REPROD FERTIL, V65, P405; MATTHEWS L. HARRISON, 1939, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V230, P1; MIYAIRI S, 1985, J BIOL CHEM, V260, P320; NEAVES WB, 1980, J REPROD FERTIL, V59, P509; NEW MI, 1986, ENDOCR REV, V7, P331, DOI 10.1210/edrv-7-3-331; PANG S, 1985, J CLIN ENDOCR METAB, V60, P428, DOI 10.1210/jcem-60-3-428; PAYNE RW, 1956, ENDOCRINOLOGY, V59, P306, DOI 10.1210/endo-59-3-306; PEDERSEN JM, 1990, HORM BEHAV, V24, P403, DOI 10.1016/0018-506X(90)90018-S; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369, DOI 10.1210/endo-65-3-369; SCHREIBER JR, 1976, ENDOCRINOLOGY, V99, P590, DOI 10.1210/endo-99-2-590; SHOZU M, 1991, J CLIN ENDOCR METAB, V72, P560, DOI 10.1210/jcem-72-3-560; SIEGEL S, 1956, NONPARAMETRIC STAT, P108; SIITERI PK, 1966, J CLIN ENDOCR METAB, V26, P751, DOI 10.1210/jcem-26-7-751; SIITERI PK, 1974, J CLIN ENDOCR METAB, V38, P113, DOI 10.1210/jcem-38-1-113; SIMPSON JL, 1992, CURRENT ISSUES ENDOC, P59; THOMSON ML, 1992, J ENDOCRINOL, V132, P148; WYNN RM, 1964, AM J ANAT, V115, P327, DOI 10.1002/aja.1001150208	31	91	92	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1929	1931		10.1126/science.8391165	http://dx.doi.org/10.1126/science.8391165			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8391165				2022-12-24	WOS:A1993LJ34900039
J	LANGECARTER, CA; PLEIMAN, CM; GARDNER, AM; BLUMER, KJ; JOHNSON, GL				LANGECARTER, CA; PLEIMAN, CM; GARDNER, AM; BLUMER, KJ; JOHNSON, GL			A DIVERGENCE IN THE MAP KINASE REGULATORY NETWORK DEFINED BY MEK KINASE AND RAF	SCIENCE			English	Article							PROTEIN-KINASE; SIGNAL TRANSDUCTION; GENE; TYROSINE; INSULIN; DOMAINS; FAMILY; YEAST; ERKS	Mitogen-activated protein kinases (MAPKs) are rapidly phosphorylated and activated in response to various extracellular stimuli in many different cell types. Such regulation of MAPK results from sequential activation of a series of protein kinases. The kinases that phosphorylate MAPKs, the MAP kinase kinases (MEKs) are also activated by phosphorylation. MEKs are related in sequence to the yeast protein kinases Byr1 (from Schizosaccharomyces pombe) and Ste7 (from Saccharomyces cerevisiae), which function in the pheromone-induced signaling pathway that results in mating. Byr1 and Ste7 are in turn regulated by the protein kinases Byr2 and Ste11. The amino acid sequence of the mouse homolog of Byr2 and Ste11, denoted MEKK (MEK kinase), was elucidated from a complementary DNA sequence encoding a protein of 672 amino acid residues (73 kilodaltons). MEKK was expressed in all mouse tissues tested, and it phosphorylated and activated MEK. Phosphorylation and activation of MEK by MEKK was independent of Raf, a growth factor-regulated protein kinase that also phosphorylates MEK. Thus, MEKK and Raf converge at MEK in the protein kinase network mediating the activation of MAPKs by hormones, growth factors, and neurotransmitters.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LANGECARTER, CA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.		Blumer, Kendall J/C-5268-2012	Gardner, Anne/0000-0001-7095-772X; Lange, Carol/0000-0003-2751-3976	NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK 37871] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER C, UNPUB; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; QIAN NX, IN PRESS P NATL ACAD; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SEGER R, 1992, J BIOL CHEM, V267, P25628; SETH A, 1991, J BIOL CHEM, V266, P23521; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173	36	1041	1074	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					315	319		10.1126/science.8385802	http://dx.doi.org/10.1126/science.8385802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385802				2022-12-24	WOS:A1993KX80000026
J	KOPF, M; LEGROS, G; BACHMANN, M; LAMERS, MC; BLUETHMANN, H; KOHLER, G				KOPF, M; LEGROS, G; BACHMANN, M; LAMERS, MC; BLUETHMANN, H; KOHLER, G			DISRUPTION OF THE MURINE IL-4 GENE BLOCKS TH2 CYTOKINE RESPONSES	NATURE			English	Article							STIMULATORY FACTOR-I; CD4+ T-CELLS; MONOCLONAL-ANTIBODY; IGE RESPONSES; GROWTH-FACTOR; LYMPHOCYTE-T; STEM-CELLS; INVIVO; CLONES; MICE	MURINE T-helper clones are classified into two distinct subsets (Th1 and Th2) on the basis of their patterns of lymphokine secretion. Th1 clones secrete interleukin-2 (IL-2), tumour necrosis factor-beta (TNF-beta) and interferon-gamma (IFN-gamma), whereas Th2 clones secrete IL-4, IL-5 and IL-10 (ref. 1). These subsets are reciprocally regulated by IL-4, IL-10 and IFN-gamma and differentially promote antibody or delayed-type hypersensitivity responses2,3. To evaluate whether IL-4 is required for mounting Th2 responses, we generated IL-4-mutant mice (IL4-/-)4,5 and assessed the cytokine secretion pattern of T cells both from naive and Nippostrongylus brasiliensis infected mice. CD4+ T cells from naive IL-4-/- mice failed to produce Th2-derived cytokines after in vitro stimulation. The levels of Th2 cytokines IL-5, IL-9 and IL-10 from CD4+ T cells obtained after nematode infection were significantly reduced. The reduced IL-5 production in IL-4-/- mice correlated with reduced helminth-induced eosinophilia, which has been shown to be dependent on IL-5 in vivo6. We conclude that IL4 is required for the generation of the Th2-derived cytokines and that immune responses dependent on these cytokines are impaired.	CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8006 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	Novartis; University of Zurich; Roche Holding	KOPF, M (corresponding author), MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY.		Le Gros, Graham/C-6725-2011; Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Le Gros, Graham/0000-0002-5721-0442				BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DEKRUYFF RH, 1990, EUR J IMMUNOL, V20, P2219, DOI 10.1002/eji.1830201010; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOETSCHMANN T, 1987, NATURE, V330, P376; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; JENNINGS FW, 1963, EXP PARASITOL, V13, P367, DOI 10.1016/0014-4894(63)90087-0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130; SEDER RA, 1991, EUR J IMMUNOL, V21, P1241, DOI 10.1002/eji.1830210522; STREET NE, 1990, J IMMUNOL, V144, P1629; SVETIC A, 1991, J IMMUNOL, V147, P2391; SWAIN SL, 1990, J IMMUNOL, V145, P3796; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	30	1113	1147	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					245	248		10.1038/362245a0	http://dx.doi.org/10.1038/362245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384701				2022-12-24	WOS:A1993KT02600056
J	ONYANGO, FE; STEINHOFF, MC; WAFULA, EM; WARIUA, S; MUSIA, J; KITONYI, J				ONYANGO, FE; STEINHOFF, MC; WAFULA, EM; WARIUA, S; MUSIA, J; KITONYI, J			HYPOXEMIA IN YOUNG KENYAN CHILDREN WITH ACUTE LOWER RESPIRATORY-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTIONS; SYNCYTIAL VIRUS; CLINICAL SIGNS; PULSE OXIMETRY; PNEUMONIA; BRONCHIOLITIS; INFANTS; BACTEREMIA; CRITERIA; DEATH	Objectives-To determine the prevalence, clinical correlates, and outcome of hypoxaemia in acutely ill children with respiratory symptoms. Design-Prospective observational study. Setting-Paediatric casualty ward of a referral hospital at 1670 m altitude in Nairobi, Kenya. Subjects-256 Infants and children under 3 years of age with symptoms of respiratory infection. Main outcome measures-Prevalence of hypoxaemia, defined as arterial oxygen saturation <90% determined by pulse oximetry, and condition of patient on the fifth day after admission. Results-Over half (151) of the children were hypoxaemic, and short term mortality was 4.3 times greater in these children. In contrast, the relative risk of a fatal outcome in children with radiographic pneumonia was only 1.03 times that of children without radiographic pneumonia. A logistic regression model showed that in 3-11 month old infants a respiratory rate greater-than-or-equal-to 70/min, grunting, and retractions were the best independent clinical signs for the prediction of hypoxaemia. In the older children a respiratory rate of greater-than-or-equal-to 60/min was the single best clinical predictor of hypoxaemia. The presence of hypoxaemia predicted radiographic pneumonia with a sensitivity of 71% and specificity of 55%. Conclusions-Over half the children presenting to this referral hospital with respiratory symptoms were hypoxaemic. A group of specific clinical signs seem useful in predicting hypoxaemia. The clear association of hypoxaemia with mortality suggests that the detection and effective treatment of hypoxaemia are important aspects of the clinical management of acute infections of the lower respiratory tract in children in hospital in developing regions.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; UNIV NAIROBI,COLL HLTH SCI,DEPT PAEDIAT & CHILD HLTH,NAIROBI,KENYA	Johns Hopkins University; Johns Hopkins University; University of Nairobi								BANKS RA, 1984, BRIT J DIS CHEST, V78, P352; BERMAN S, 1990, Pediatric Emergency Care, V6, P179, DOI 10.1097/00006565-199009000-00003; CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CHERIAN T, 1988, LANCET, V2, P125; CHRETIEN J, 1984, NEW ENGL J MED, V310, P382; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; HALL CB, 1979, AM J DIS CHILD, V133, P798, DOI 10.1001/archpedi.1979.02130080038006; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; LEMESHOW S., 1989, APPL LOGISTIC REGRES, P10; MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; NORUSIS MJ, 1990, SPSSPC PLUS ADV STAT; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; REYNOLDS EO, 1963, J PEDIATR-US, V63, P1135, DOI 10.1016/S0022-3476(63)80196-1; ROSEN LM, 1989, AM J EMERG MED, V7, P567, DOI 10.1016/0735-6757(89)90275-1; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P81; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHAW KN, 1991, AM J DIS CHILD, V145, P151, DOI 10.1001/archpedi.1991.02160020041012; Swischuk LE, 1986, EMERGENCY RADIOLOGY; THILO EH, 1991, AM J DIS CHILD, V145, P1137, DOI 10.1001/archpedi.1991.02160100069025; 1990, WHOARI905; 1987, Q J MED, V239, P195	25	119	122	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					612	615		10.1136/bmj.306.6878.612	http://dx.doi.org/10.1136/bmj.306.6878.612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8369033	Bronze, Green Published			2022-12-24	WOS:A1993KQ85900018
J	THIEL, DJ; LIVINS, P; STERN, EA; LEWIS, A				THIEL, DJ; LIVINS, P; STERN, EA; LEWIS, A			MICROSECOND-RESOLVED XAFS OF THE TRIPLET EXCITED-STATE OF PT2(P2O5H2)4(4-)	NATURE			English	Article							BINUCLEAR PLATINUM(II); ELECTRONIC SPECTROSCOPY; DIPHOSPHITE COMPLEXES; SPECTRA; RAMAN; ABSORPTION	LITTLE is known about the excited-state structures of most inorganic compounds. Time-resolved resonance Raman and time-resolved infrared spectroscopies can provide only indirect structural information for short-lived excited species in solution at room temperature. Time-resolved X-ray diffraction' has the potential to give more direct information, but no excited-state structures have yet been reported; picosecond gas-phase electron diffraction has been proposed recently2, but not yet demonstrated. Here we report a technique that combines the X-ray absorption fine-structure (XAFS) method3 With rapid-flow laser spectroscopy4 to measure structural changes in a solution-phase excited-state transition-metal complex with microsecond resolution. We find that the triplet excited state of Pt2(P2O5H2)44-, with a lifetime of about 4 mus, undergoes a contraction in the Pt-Pt distance of 0.52 +/- 0.13 angstrom relative to the ground state. We anticipate that time-resolved XAFS will have broad applications in chemistry and biology.	UNIV WASHINGTON,DEPT PHYS,SEATTLE,WA 98195; HEBREW UNIV JERUSALEM,DIV APPL PHYS,JERUSALEM,ISRAEL	University of Washington; University of Washington Seattle; Hebrew University of Jerusalem	THIEL, DJ (corresponding author), CORNELL UNIV,DEPT APPL PHYS,ITHACA,NY 14853, USA.							BOUDREAUX EA, 1986, INT J QUANTUM CHEM Q, V20, P239; CHE CM, 1983, J AM CHEM SOC, V105, P5492, DOI 10.1021/ja00354a059; CHE CM, 1983, J AM CHEM SOC, V105, P4604, DOI 10.1021/ja00352a015; COWMAN CD, 1973, J AM CHEM SOC, V95, P7873, DOI 10.1021/ja00804a057; FORDYCE WA, 1981, J AM CHEM SOC, V103, P7061, DOI 10.1021/ja00414a006; HARVEY EL, 1987, J AM CHEM SOC, V109, P5233, DOI 10.1021/ja00251a031; HIRAGA T, 1989, J AM CHEM SOC, V111, P7466, DOI 10.1021/ja00201a029; MARCUS MA, 1977, SCIENCE, V195, P1328, DOI 10.1126/science.841330; NEWVILLE M, IN PRESS PHYS REV B; PETERSON JR, 1985, J PHYS CHEM-US, V89, P2486, DOI 10.1021/j100258a013; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RICE SF, 1983, J AM CHEM SOC, V105, P4571, DOI 10.1021/ja00352a011; ROUNDHILL DM, 1989, ACCOUNTS CHEM RES, V22, P55, DOI 10.1021/ar00158a002; ROUNDHILL DM, 1987, J AM CHEM SOC, V109, P6076, DOI 10.1021/ja00254a028; STEIN P, 1983, J AM CHEM SOC, V105, P3489, DOI 10.1021/ja00349a020; Stern E. A., 1983, Handbook on synchrotron radiation, P955; STIEGMAN AE, 1987, INORG CHEM, V26, P1112, DOI 10.1021/ic00254a029; SZEBENYI DME, 1988, T AM CRYSTALLOGR ASS, V24, P167; WILLIAMSON JC, 1991, P NATL ACAD SCI USA, V88, P5021, DOI 10.1073/pnas.88.11.5021; ZIPP AP, 1988, COORDIN CHEM REV, V84, P47, DOI 10.1016/0010-8545(88)80031-6	20	69	69	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					40	43		10.1038/362040a0	http://dx.doi.org/10.1038/362040a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383295				2022-12-24	WOS:A1993KP97600052
J	PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ				PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ			TEMPORAL CHANGES IN THE CARE AND OUTCOMES OF ELDERLY PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, 1987 THROUGH 1990	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; THROMBOLYTIC THERAPY; GENDER BIAS; SELECTION	Objective.-To investigate changes between 1987 and 1990 in the care and outcomes associated with acute myocardial infarction (AMI) in elderly patients. Design.-Retrospective cohort study using a longitudinal database created from Medicare administrative files. Patients.-Cohorts comprising a total of 856 847 AMI patients insured by Medicare between 1987 and 1990. Main Outcome Measures.-Annual rates of mortality at 30 days and 1 year following AMI, and the use of coronary angiography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty during the first 90 days after a new AMI. Results.-Between 1987 and 1990, mortality rates decreased 10% overall from 26% to 23% at 30 days (P<.001) and from 40% to 36% at 1 year following AMI (P<.001). Declines in mortality and adjusted risks of 1-year mortality were similar in men and women and in blacks and whites, but mortality declines were more evident in those younger than 85 years. Meanwhile, the proportion of elderly AMI patients having angiography within the first 90 days after their index admission increased from 24% to 33% (P<.001); proportions increased for both genders and all races. The proportion of patients undergoing revascularization procedures increased from 13% to 21 %; while rates of bypass surgery increased from 8% to 11%, rates of angioplasty doubled from 5% to 10% (all P<.001). Conclusions.-Between 1987 and 1990, survival of elderly patients following AMI improved significantly. While changes in patient treatment may be responsible, the increased use of thrombolytic therapy appears to be only a partial explanation. Also, while the use of coronary angiography and revascularization procedures increased dramatically, the degree to which it caused the improvement in survival could not be determined.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, JOHN F KENNEDY SCH GOVT, CAMBRIDGE, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	PASHOS, CL (corresponding author), HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, 25 SHATTUCK ST, PARCEL B, BOSTON, MA 02115 USA.		Newhouse, Joseph/AGJ-5632-2022		AHRQ HHS [HS-06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1988, LANCET, V2, P349; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WILCOX RG, 1988, LANCET, V2, P525; 1993, MONTHLY VITAL STATIS, V41, P18; 1989, INT CLASSIFICATION D; 1991, PHYSICIANS CURRENT P; 1990, 1990 HCFA STATISTICS	22	93	96	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1832	1836		10.1001/jama.270.15.1832	http://dx.doi.org/10.1001/jama.270.15.1832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411527				2022-12-24	WOS:A1993MB46400026
J	LAOR, A; COHEN, L; DANON, YL				LAOR, A; COHEN, L; DANON, YL			EFFECTS OF TIME, SEX, ETHNIC-ORIGIN, AND AREA OF RESIDENCE ON PREVALENCE OF ASTHMA IN ISRAELI ADOLESCENTS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; NATURAL-HISTORY; UNITED-STATES; CHILDREN; SYMPTOMS; SCHOOLCHILDREN; CHILDHOOD; HEALTH; SAMPLE	Objectives-To study effects of time, sex, ethnic origin, and area of residence on prevalence of asthma in Israeli adolescents. Design-Retrospective survey of asthma from computerised medical draft records of conscripts examined up to the end of 1989. Setting-Five regional centres in Israel. Subjects-443186 conscripts (262836 males and 180350 females) aged 17-18 who were born over a nine year period. Main outcome measures-Asthma determined by medical history, physical examination, and lung function tests at rest and after exercise. Results-Asthma was more prevalent in males than females (26.5/1000 v 21.4/1000, relative risk 1.25 (95% confidence interval 1.19 to 1.32)). Subjects were split into three groups according to year of birth, and prevalence of asthma increased over time from 18/1000 to 24/1000 to 36/1000 (risk of asthma 0.56 (0.54 to 0.59) for first birth group relative to last birth group and 0.69 (0.66 to 0.72) for second group relative to last group). Risk of asthma was also affected by ethnic origin (highest for Western origin and lowest for north African origin, relative risk 1.63 (1.56 to 1.71)) and area of residence (highest in the central coastal region-risk of 1.24 (1.19 to 1.30) relative to the north coastal region-and lowest in inland areas-risk of 0.67 (0.64 to 0.70) relative to north coastal region). Conclusions-Prevalence of asthma in Israel is increasing and is higher in males, in people of Western origin, and in those living in the most industrialised coastal region.	CHILDRENS MED CTR ISRAEL,KIPPER INST CHILD IMMUNOL,IL-42600 PETAH TIQWA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,HAIFA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	LAOR, A (corresponding author), LADY DAVIES CARMEL HOSP,DEPT INTERNAL MED B,IL-34362 HAIFA,ISRAEL.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; AURBACH I, 1993, THORAX, V48, P139; BROOK U, 1991, Harefuah, V120, P539; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; CHARPIN D, 1988, ALLERGY, V43, P481, DOI 10.1111/j.1398-9995.1988.tb01624.x; DIPEDE C, 1991, CHEST, V99, P916, DOI 10.1378/chest.99.4.916; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GERSTMAN BB, 1989, J ALLERGY CLIN IMMUN, V83, P1032, DOI 10.1016/0091-6749(89)90444-2; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HORNE SL, 1989, CHEST, V95, P992, DOI 10.1378/chest.95.5.992; HORNE SL, 1990, CLIN INVEST MED, V13, P333; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; KAPLAN BA, 1988, J ASTHMA, V25, P125, DOI 10.3109/02770908809073199; KARK JD, 1986, ISRAEL J MED SCI, V22, P318; MCCULLAGH P, 1985, GENERALIZED LINEAR M; MCFADDEN ER, 1991, HARRISONS PRINCIPLES, P1047; MITCHELL EA, 1991, SOC SCI MED, V32, P831, DOI 10.1016/0277-9536(91)90309-Z; PATTEMORE PK, 1989, THORAX, V44, P168, DOI 10.1136/thx.44.3.168; PEDERSEN PA, 1987, CHEST, V91, pS107, DOI 10.1378/chest.91.6.107S; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SCHWARTZ YA, 1990, ANN ALLERGY, V65, P105; WITZMAN M, 1990, AM J DIS CHILD, V144, P1189; 1990, P200 SAS I TECHN REP	32	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					841	844		10.1136/bmj.307.6908.841	http://dx.doi.org/10.1136/bmj.307.6908.841			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401126	Green Published, Bronze			2022-12-24	WOS:A1993MA29300021
J	ALLISON, DB; HESHKA, S; SEPULVEDA, D; HEYMSFIELD, SB				ALLISON, DB; HESHKA, S; SEPULVEDA, D; HEYMSFIELD, SB			COUNTING CALORIES - CAVEAT-EMPTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WEIGHT	Objective.-To determine the accuracy of caloric labeling of ''diet'' and ''health'' foods and whether the accuracy differs for certain categories of food suppliers. Design.-Survey; ''diet'' and ''health'' foods were analyzed via bomb calorimetry and categorized as regionally distributed, nationally advertised, or locally prepared. Setting.-Foods were sampled from retail merchants throughout the borough of Manhattan, New York, NY. Sample.-A convenience sample of 40 food items including regionally distributed (n=12), nationally advertised (n=20), and locally prepared items (n=8). Main Outcome Measures.-Number of kilocalories per item and number of kilocalories per gram. Results.-All locally prepared foods had more actual than labeled kilocalories. The mean percentage of actual kilocalories greater than the labeled kilocalories (mean percentage over label) per item was 85.42% (SD=77.88%; P=.01). Regionally distributed foods had significantly more kilocalories than were reported (P=.001 for kilocalories per item, P=.02 for kilocalories per gram) and mean percentage over label per item was 25.22% (SD=15.58%) and per gram was 14.97% (SD=17.95%). Nationally advertised foods did not have significantly more actual than reported kilocalories (P=.37 for per item, P=.78 for per gram). Mean percentage over label per gram was -0.01% (SD=9.13%) and per item was 2.18% (SD=13.93%). Conclusion.-These findings suggest that food labels may be inadequate sources for caloric monitoring. Health care professionals should consider the accuracy of caloric labeling when advising patients to use food labels to help monitor their caloric intake.			ALLISON, DB (corresponding author), COLUMBIA UNIV,COLL PHYSICIANS & SURGEONS,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10025, USA.		Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425; Allison, David/0000-0003-3566-9399	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER; NIDDK NIH HHS [DKNY2618, DK26687] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON RG, 1983, PERSPECTIVE APPLICAT, P11; BANDINI LG, 1990, PEDIATR RES, V27, P198, DOI 10.1203/00006450-199002000-00022; BURROS M, 1989, NY TIMES        0809, pC1; EDGINGTON ES, 1987, J COUNS PSYCHOL, V34, P437, DOI 10.1037/0022-0167.34.4.437; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KLASSEN ML, 1991, J ADVERTISING RES, V30, P32; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; MILLER DS, 1959, BRIT J NUTR, V13, P501, DOI 10.1079/BJN19590064; STUNKARD AJ, 1992, TREATMENT SERIOUSLY, P33; WADDEN TA, 1992, TREATMENT SERIOUSLY, P44; 1992, CONSUM REP, V59, P483; 1993, FED REGISTER, V58, P2302; 1991, U CALIF BERKELEY NEW, V8, P1	14	15	15	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1454	1456		10.1001/jama.270.12.1454	http://dx.doi.org/10.1001/jama.270.12.1454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371446				2022-12-24	WOS:A1993LX17300030
J	CHAN, IT; LIMMER, A; LOUIE, MC; BULLOCK, ED; FUNGLEUNG, WP; MAK, TW; LOH, DY				CHAN, IT; LIMMER, A; LOUIE, MC; BULLOCK, ED; FUNGLEUNG, WP; MAK, TW; LOH, DY			THYMIC SELECTION OF CYTOTOXIC T-CELLS INDEPENDENT OF CD8-ALPHA-LCK ASSOCIATION	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; I ALPHA-3 DOMAIN; TRANSGENIC MICE; LYMPHOCYTES-T; CYTOPLASMIC DOMAINS; POSITIVE SELECTION; NEGATIVE SELECTION; ANTIGEN RECEPTOR; CD4 RECEPTOR; P56LCK	The CD8alpha cytoplasmic domain associates with p56lck, a nonreceptor protein-tyrosine kinase. The biological relevance of CD8alpha-Lck association in T cell development was tested with transgenic mice generated to express a CD8alpha molecule with two amino acid substitutions in its cytoplasmic domain, which abolishes the association of CD8alpha with Lck. The CD8alpha mutant was analyzed in a CD8-/- background and in the context of the transgenic 2C T cell receptor. The development and function of CD8+ T cells in these mice were apparently normal. Thus, CD8alpha-Lck association is not necessary for positive selection, negative selection, or CD8-dependent cytotoxic function.	WASHINGTON UNIV,SCH MED,DEPT MED GENET & MOLEC MICROBIOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA	Howard Hughes Medical Institute; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto				Fung-Leung, Wai-Ping/0000-0001-7013-8855	NIAID NIH HHS [AI 155322-13] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN IY, UNPUB; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GORMAN SD, 1988, J IMMUNOL, V140, P3646; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAUCHI H, 1987, NUCLEIC ACIDS RES, V15, P4337, DOI 10.1093/nar/15.10.4337; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	35	66	66	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1581	1584		10.1126/science.8372352	http://dx.doi.org/10.1126/science.8372352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372352				2022-12-24	WOS:A1993LX47400031
J	KIM, H; JACOBSON, EL; JACOBSON, MK				KIM, H; JACOBSON, EL; JACOBSON, MK			SYNTHESIS AND DEGRADATION OF CYCLIC ADP RIBOSE BY NAD GLYCOHYDROLASES	SCIENCE			English	Article							EGG-SPECIFIC NADASE; 2ND-MESSENGER ENZYME; CALCIUM RELEASE; CA-2+ RELEASE; MECHANISM; METABOLITE; MICROSOMES; MODULATION; TISSUES; ADENINE	Cyclic adenosine diphosphoribose (cADPR), a recently discovered metabolite of nicotinamide adenine dinucleotide (NAD), is a potent calcium-releasing agent postulated to be a new second messenger. An enzyme that catalyzes the synthesis of cADPR from NAD and the hydrolysis of cADPR to ADP-ribose (ADPR) was purified to homogeneity from canine spleen microsomes. The net conversion of NAD to ADPR categorizes this enzyme as an NAD glycohydrolase. NAD glycohydrolases are ubiquitous membrane-bound enzymes that have been known for many years but whose function has not been identified. The results presented here suggest that these enzymes may function in the regulation of calcium homeostasis by the ability to synthesize and degrade cADPR.	UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,LEXINGTON,KY 40536; UNIV N TEXAS,HLTH SCI CTR,DEPT MED,FT WORTH,TX 76107; UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,FT WORTH,TX 76107; UNIV KENTUCKY,LUCILLE PARKER MARKEY CANC CTR,LEXINGTON,KY 40536; UNIV KENTUCKY,COLL ALLIED HLTH PROFESS,DEPT CLIN SCI,LEXINGTON,KY 40536	University of Kentucky; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of Kentucky; University of Kentucky					NCI NIH HHS [CA43894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZGONZALEZ R, 1983, ANAL BIOCHEM, V135, P69, DOI 10.1016/0003-2697(83)90732-7; BERRIDGE MJ, 1989, NATURE, V341, P167; BULL HG, 1978, J BIOL CHEM, V253, P5186; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; Handler P, 1942, J BIOL CHEM, V143, P49; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KAPLAN NO, 1956, J BIOL CHEM, V221, P823; Kim H.-J., UNPUB; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MULERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; PASCAL M, 1976, FEBS LETT, V66, P107, DOI 10.1016/0014-5793(76)80596-0; PRICE SR, 1987, PYRIDINE NUCLEOTIDE, P513; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TARNUS C, 1979, BIOORG CHEM, V16, P38; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WILLIAMSON KC, 1989, ADP RIBOSYLATING TOX, P493; YOST DA, 1981, J BIOL CHEM, V256, P3647	31	238	239	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1330	1333		10.1126/science.8395705	http://dx.doi.org/10.1126/science.8395705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8395705				2022-12-24	WOS:A1993LV65600031
J	KERANEN, T; RIEKKINEN, PJ				KERANEN, T; RIEKKINEN, PJ			REMISSION OF SEIZURES IN UNTREATED EPILEPSY	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE		UNIV HOSP KUOPIO,DEPT NEUROL,SF-70210 KUOPIO,FINLAND	Kuopio University Hospital; University of Eastern Finland								BERAN R G, 1982, Neuroepidemiology, V1, P201, DOI 10.1159/000110703; Gowers WR, 1881, EPILEPSY OTHER CHRON; HAERER AF, 1986, EPILEPSIA, V27, P66, DOI 10.1111/j.1528-1157.1986.tb03503.x; KERANEN T, 1989, EPILEPSIA, V30, P413, DOI 10.1111/j.1528-1157.1989.tb05320.x; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P203, DOI 10.1111/j.1528-1157.1974.tb04942.x	5	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					483	483		10.1136/bmj.307.6902.483	http://dx.doi.org/10.1136/bmj.307.6902.483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400934	Green Published, Bronze			2022-12-24	WOS:A1993LU59000024
J	MUELLER, MW; HETZER, M; SCHWEYEN, RJ				MUELLER, MW; HETZER, M; SCHWEYEN, RJ			GROUP-II INTRON RNA CATALYSIS OF PROGRESSIVE NUCLEOTIDE INSERTION - A MODEL FOR RNA EDITING	SCIENCE			English	Article							MESSENGER-RNA; LARIAT FORMATION; INVITRO; TETRAHYMENA; SITES	The self-splicing bl1 intron lariat from mitochondria of Saccharomyces cerevisiae catalyzed the insertion of nucleotidyl monomers derived from the 3' end of a donor RNA into an acceptor RNA in a 3' to 5' direction in vitro. In this catalyzed reaction, the site specificity provided by intermolecular base pair interactions, the formation of chimeric intermediates, the polarity of the nucleotidyl insertion, and its reversibility all resemble such properties in previously proposed models of RNA editing in kinetoplastid mitochondria. These results suggest that RNA editing occurs by way of a concerted, two-step transesterification mechanism and that RNA splicing and RNA editing might be prebiotically related mechanisms; possibly, both evolved from a primordial demand for self-replication.			MUELLER, MW (corresponding author), UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,DR BOHR GASSE 9,A-1030 VIENNA,AUSTRIA.							ATKINSON RJ, 1989, NATURE, V340, P290, DOI 10.1038/340290a0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MULLER MW, 1991, J MOL BIOL, V222, P145, DOI 10.1016/0022-2836(91)90201-G; SCHMEIZER C, 1987, CELL, V51, P753, DOI 10.1016/0092-8674(87)90098-5; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; Sollner-Webb B, 1991, CURR OPIN CELL BIOL, V3, P1056, DOI 10.1016/0955-0674(91)90129-M; SOLLNERWEBB B, 1992, NATURE, V356, P743, DOI 10.1038/356743a0; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; WEINER AM, 1990, CELL, V61, P917, DOI 10.1016/0092-8674(90)90053-H; WEISSMANN C, 1990, NATURE, V343, P697, DOI 10.1038/343697a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	28	14	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1035	1038		10.1126/science.8351516	http://dx.doi.org/10.1126/science.8351516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351516				2022-12-24	WOS:A1993LT74700031
J	KILLEEN, N; LITTMAN, DR				KILLEEN, N; LITTMAN, DR			HELPER T-CELL DEVELOPMENT IN THE ABSENCE OF CD4-P56(LCK) ASSOCIATION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; TRANSGENIC MICE; PHYSICAL ASSOCIATION; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; POSITIVE SELECTION; ALPHA-3 DOMAIN; LYMPHOCYTES-T	THE CD4 and CD8 glycoproteins are expressed on helper and cytoxic T lymphocytes, respectively, and have important functions in the differentiation and activation of these cells1-8. These molecules are thought to participate in signal transduction by binding to the same class II or class I major histocompatibility complex molecules that are engaged by the T-cell antigen receptor9-13. The cytoplasmic domains of both CD4 and CD8 interact with the protein tyrosine kinase p56lck (refs 14-17), an essential participant in thymocyte maturation18 and T-cell activation19. This interaction is required for effective in vitro responses to antigen5-8, suggesting that signalling through p56lck is a major function of CD4 and CD8. Here we investigate the role of the CD4-p56lck interaction during T-lymphocyte development by expressing wild-type and truncated products of CD4 transgenes in mice that lack endogenous CD4 and hence have defective helper-cell development3,4. We find that transgenic CD4, which cannot associate with p56lck, can nevertheless rescue the helper-cell lineage when overexpressed. This result indicates that the contribution of CD4 to lineage development need not involve signalling through p56lck, and provides insight into the general function of CD4 and CD8.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KILLEEN, N (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COLLINS TL, 1992, J IMMUNOL, V148, P2159; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; Hogan B., 1986, MANIPULATING MOUSE E; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KIYOSHI M, 1993, SCIENCE, V254, P1788; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LOCKSLEY R, IN PRESS SCIENCE; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROBEY E, 1991, P NATL ACAD SCI USA, V88, P608, DOI 10.1073/pnas.88.2.608; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; XU H, IN PRESS CELL; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	37	123	123	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					729	732		10.1038/364729a0	http://dx.doi.org/10.1038/364729a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355789				2022-12-24	WOS:A1993LT67700062
J	HASTY, P; BRADLEY, A; MORRIS, JH; EDMONDSON, DG; VENUTI, JM; OLSON, EN; KLEIN, WH				HASTY, P; BRADLEY, A; MORRIS, JH; EDMONDSON, DG; VENUTI, JM; OLSON, EN; KLEIN, WH			MUSCLE DEFICIENCY AND NEONATAL DEATH IN MICE WITH A TARGETED MUTATION IN THE MYOGENIN GENE	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; REGULATORY GENE; MESSENGER-RNA; MOUSE EMBRYO; EXPRESSION; REGION; CDNA; SUBUNIT; MYOD; DIFFERENTIATION	Myogenin is a muscle-specific transcription factor that can induce myogenesis in a variety of cell types in tissue culture. To test myogenin's role in vivo, mice homozygous for a targeted mutation in the myogenin gene were generated. These mice survive fetal development but die immediately after birth and show a severe reduction of all skeletal muscle. Myogenin-mutant mice differ from mice carrying mutations in genes for the related myogenic factors Myf5 and MyoD, which have no muscle defects. Myogenin is therefore essential for the development of functional skeletal muscle.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; UTMD Anderson Cancer Center	HASTY, P (corresponding author), BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030, USA.			Hasty, Paul/0000-0003-3046-0131; Bradley, Allan/0000-0002-2349-8839; Edmondson, Diane/0000-0003-3702-9715				BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRUNETTI A, 1990, MOL ENDOCRINOL, V4, P880, DOI 10.1210/mend-4-6-880; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHEN JM, 1953, J ANAT, V87, P130; CHEN JM, 1952, J ANAT, V86, P373; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEDFORD RM, 1980, P NATL ACAD SCI-BIOL, V77, P5749, DOI 10.1073/pnas.77.10.5749; OLSON E, 1990, GENOMICS, V8, P427, DOI 10.1016/0888-7543(90)90028-S; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUCNICKI MA, 1992, CELL, V71, P383; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	36	1041	1098	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					501	506		10.1038/364501a0	http://dx.doi.org/10.1038/364501a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393145				2022-12-24	WOS:A1993LQ66700044
J	PEUNOVA, N; ENIKOLOPOV, G				PEUNOVA, N; ENIKOLOPOV, G			AMPLIFICATION OF CALCIUM-INDUCED GENE-TRANSCRIPTION BY NITRIC-OXIDE IN NEURONAL CELLS	NATURE			English	Article							LONG-TERM POTENTIATION; CYCLIC-AMP; C-FOS; NERVOUS-SYSTEM; FACTOR CREB; BINDING-PROTEIN; PHOSPHORYLATION; MESSENGER; SEQUENCE; KINASES	NITRIC oxide (NO) is a short-lived, highly reactive gas, which has been identified as a mediator in vasodilation, an active agent in macrophage cytotoxicity and neurotoxicity, and a neurotransmitter in the central and peripheral nervous systems1-5. Production of NO by neurons is critical for facilitated synaptic transmission in models of synaptic plasticity such as long-term potentiation and long-term depression, suggesting a role for NO as a retrograde messenger that could complete a hypothetical feed-back loop by strengthening the connection between postsynaptic and presynaptic cells6-10. We report here that although alone NO has no evident effect on transcription, it can act as an amplifier of calcium signals in neuronal cells. NO and Ca2+ action have to coincide in time for amplification to occur. Experiments with a series of simplified reporter genes in combination with specific recombinant protein kinase inhibitors suggest that induction of gene activity following NO-amplified calcium action involves protein kinase A-dependent activation of the transcription factor CREB.	COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory			Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1990, COLD SH Q B, V55, P137; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Curran T, 1988, ONCOGENE HDB, P307; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; Schulman H, 1991, Curr Opin Neurobiol, V1, P43, DOI 10.1016/0959-4388(91)90009-V; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; WALSH DA, 1991, METHOD ENZYMOL, V201, P304	29	282	297	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					450	453		10.1038/364450a0	http://dx.doi.org/10.1038/364450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8392663				2022-12-24	WOS:A1993LP64000057
J	HAWORTH, EA; BOOY, R; STIRZAKER, L; WILKES, S; BATTERSBY, A				HAWORTH, EA; BOOY, R; STIRZAKER, L; WILKES, S; BATTERSBY, A			IS THE COLD CHAIN FOR VACCINES MAINTAINED IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							STORAGE	Objective-To investigate the cold chain for vaccines and compliance with the local code of practice for storage. Design-In a random sample of general practices orders for live vaccines (oral polio and measles, mumps, and rubella) were accompanied by a cold chain monitor which was activated on leaving the supplying pharmacy. The monitors were read at specified intervals and when all vaccines in the order had been used. Structured interview was used to check compliance with the local code of practice on storage. Setting-West Berkshire and Aylesbury Vale district health authorities. Subjects-16 (25%) general practices in West Berkshire, and 13 (50%) in Aylesbury Vale. Main outcome measures-Compliance with code of practice. Changes in the cold chain monitor. Results-For six key requirements within the code of practice compliance varied from 70% to 0%. Only 16 of 29 practices had a named person responsible for vaccine storage and only four were aware of the local code of practice. Vaccine was stored for longer and more breaks in the cold chain occurred in West Berkshire than in Aylesbury Vale. The potency of some vaccines in 10 of 26 orders became suspect before use. Conclusions-Knowledge of appropriate management of the cold chain in two districts was poor. Breaks in the chain were more frequent and compromised potency more likely when vaccine had been stored for more than eight weeks. Problems in maintaining the cold chain indicate the need for continuing audit, which should become a prerequisite for payments to general practitioners for immunisation.	JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; AYLESBURY VALE HLTH AUTHOR,AYLESBURY HP19 3DX,ENGLAND; WHO,OPERAT MANAGEMENT,BATH BA3 6RL,ENGLAND	University of Oxford; World Health Organization	HAWORTH, EA (corresponding author), PROSPECT PK HOSP,W BERKSHIRE HLTH AUTHOR,READING RG3 4EJ,ENGLAND.		Booy, Robert/D-4188-2011					BISHAI DM, 1992, PEDIATRICS, V89, P193; HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; KRUGMAN RD, 1974, J PEDIATR-US, V85, P512, DOI 10.1016/S0022-3476(74)80455-5; LERMAN SJ, 1971, J AMER MED ASSOC, V216, P1311, DOI 10.1001/jama.216.8.1311; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; NOKES DJ, 1991, LANCET, V338, P1309, DOI 10.1016/0140-6736(91)92601-W; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756; 1987, WHO EPICCIS83REV1; 1985, WHO EPICCIS851; 1989, MMWR, V38, P863; 1990, GUIDELINES STORAGE V; 1989, GUIDELINES STORAGE V; 1990, IMMUNISATION INFECTI	13	29	29	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					242	244		10.1136/bmj.307.6898.242	http://dx.doi.org/10.1136/bmj.307.6898.242			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369691	Bronze, Green Published			2022-12-24	WOS:A1993LP31400029
J	VONKROSIGK, M; BAL, T; MCCORMICK, DA				VONKROSIGK, M; BAL, T; MCCORMICK, DA			CELLULAR MECHANISMS OF A SYNCHRONIZED OSCILLATION IN THE THALAMUS	SCIENCE			English	Article							NUCLEUS RETICULARIS THALAMI; LATERAL GENICULATE-NUCLEUS; NEURONS; CAT; RAT; INVITRO	Spindle waves are a prototypical example of synchronized oscillations, a common feature of neuronal activity in thalamic and cortical systems in sleeping and waking animals. Spontaneous spindle waves recorded from slices of the ferret lateral geniculate nucleus were generated by rebound burst firing in relay cells. This rebound burst firing resulted from inhibitory postsynaptic potentials arriving from the perigeniculate nucleus, the cells of which were activated by burst firing in relay neurons. Reduction of gamma-aminobutyric acid(A) (GABA(A)) receptor-mediated inhibition markedly enhanced GABA(B) inhibitory postsynaptic potentials in relay cells and subsequently generated a slowed and rhythmic population activity resembling that which occurs during an absence seizure. Pharmacological block of GABA(B) receptors abolished this seizure-like activity but not normal spindle waves, suggesting that GABA(B) antagonists may be useful in the treatment of absence seizures.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University			McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011	McCormick, David A/0000-0002-9803-8335; 				[Anonymous], [No title captured]; AVANZINI G, 1989, J PHYSIOL-LONDON, V416, P111, DOI 10.1113/jphysiol.1989.sp017752; AVOLI M., 1990, GENERALIZED EPILEPSY; BAL T, IN PRESS J PHYSL LON; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; BUZSAKI G, 1988, J NEUROSCI, V8, P4007; CUCCHIARO J, 1991, J COMP NEUROL, V31, P316; DOSSI RC, 1992, J PHYSIOL-LONDON, V447, P215, DOI 10.1113/jphysiol.1992.sp018999; FITZPATRICK D, 1984, J NEUROSCI, V4, P1809; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HOUSER CR, 1980, BRAIN RES, V200, P341, DOI 10.1016/0006-8993(80)90925-7; HUGUENARD JR, 1992, J NEUROPHYSIOL, V68, P373; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; KING GA, 1979, NEUROPHARMACOLOGY, V18, P47, DOI 10.1016/0028-3908(79)90008-X; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; MCCORMICK DA, 1988, NATURE, V334, P246, DOI 10.1038/334246a0; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; Steriade M., 1990, THALAMIC OSCILLATION	23	613	621	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					361	364		10.1126/science.8392750	http://dx.doi.org/10.1126/science.8392750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392750				2022-12-24	WOS:A1993LM67800039
J	EBNER, R; CHEN, RH; SHUM, L; LAWLER, S; ZIONCHECK, TF; LEE, A; LOPEZ, AR; DERYNCK, R				EBNER, R; CHEN, RH; SHUM, L; LAWLER, S; ZIONCHECK, TF; LEE, A; LOPEZ, AR; DERYNCK, R			CLONING OF A TYPE-I TGF-BETA RECEPTOR AND ITS EFFECT OF TGF-BETA BINDING TO THE TYPE-II RECEPTOR	SCIENCE			English	Article							GROWTH-FACTOR-BETA; EXPRESSION CLONING; PROTEIN-KINASE; PURIFICATION	Transforming growth factor-beta (TGF-beta) affects cellular proliferation, differentiation, and interaction with the extracellular matrix primarily through interaction with the type I and type II TGF-beta receptors. The type II receptors for TGF-beta and activin contain putative serine-threonine kinase domains. A murine serine-threonine kinase receptor, Tsk 7L, was cloned that shared a conserved extracellular domain with the type II TGF-beta receptor. Overexpression of Tsk 7L alone did not increase cell surface binding of TGF-beta, but coexpression with the type II TGF-beta receptor caused TGF-beta to bind to Tsk 7L, which had the size of the type I TGF-beta receptor. Overexpression of Tsk 7L inhibited binding of TGF-beta to the type II receptor in a dominant negative fashion. Combinatorial interactions and stoichiometric ratios between the type I and II receptors may therefore determine the extent of TGF-beta binding and the resulting biological activities.	UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, HEMATOL ONCOL SECT 111H, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT GROWTH & DEV, PROGRAM DEV BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT IMMUNOL, STANFORD, CA 94305 USA	University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University			Chen, Ruey-Hwa/G-6121-2019; Lopez, Andrea/GQQ-3059-2022	Chen, Ruey-Hwa/0000-0001-8124-5832; 				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAIRACH A, 1991, PROSITE DICT PROTEIN; BOYD FT, 1990, J CELL SCI, P131; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; EBNER R, UNPUB; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, UNPUB; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70, P1068; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOPEZ A, UNPUB; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Scott J D, 1992, Curr Opin Neurobiol, V2, P289, DOI 10.1016/0959-4388(92)90117-4; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Smith A J, 1980, Methods Enzymol, V65, P560; ULLRICH A, 1990, CELL, V61, P243; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	35	413	453	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1344	1348		10.1126/science.8388127	http://dx.doi.org/10.1126/science.8388127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8388127				2022-12-24	WOS:A1993LE02500048
J	SWEDLOW, JR; SEDAT, JW; AGARD, DA				SWEDLOW, JR; SEDAT, JW; AGARD, DA			MULTIPLE CHROMOSOMAL POPULATIONS OF TOPOISOMERASE-II DETECTED INVIVO BY TIME-LAPSE, 3-DIMENSIONAL WIDE-FIELD MICROSCOPY	CELL			English	Article							DNA TOPOISOMERASE; DROSOPHILA-MELANOGASTER; NUCLEAR-ENVELOPE; MITOTIC CHROMOSOMES; SCAFFOLD ATTACHMENT; CONDENSATION; CHROMATIN; INVITRO; EMBRYOS; ORGANIZATION	The localization of topoisomerase II (topo II) in vivo was studied by recording time-lapse, three-dimensional data sets of living Drosophila melanogaster embryos injected with rhodamine-labeled topo II. These images show that topo II is concentrated at specific sites within the interphase nucleus and that this localization is temporally regulated. The enzyme is not restricted to a central chromosome axis, but is distributed uniformly throughout the chromosome. During mitosis, the enzyme present in the early prophase chromosome is lost in two stages, following prophase and following anaphase. Overall, 70% of the enzyme leaves the nucleus and diffuses into the cytoplasm. The localization of the enzyme thus correlates with its role in chromosome condensation and segregation. Rather than being solely a structural protein, topo II appears to localize at the sites on the chromosome where it is required.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	SWEDLOW, JR (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Swedlow, Jason/0000-0002-2198-1958	NIGMS NIH HHS [GM-25101, GM-31627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031627, R01GM025101] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Castleman KR., 1979, DIGITAL IMAGE PROCES; CHEN H, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P141; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1983, J CELL SCI, V61, P31; FUCHS JP, 1983, J CELL SCI, V64, P331; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRAOKA Y, 1989, NATURE, V342, P293, DOI 10.1038/342293a0; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIEH TS, 1983, METHOD ENZYMOL, V100, P161; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MOENS PB, 1989, CHROMOSOMA, V98, P317, DOI 10.1007/BF00292383; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PARHAM P, 1986, HDB EXPT IMMUNOLOGY; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; UDVARDY A, 1991, MOL CELL BIOL, V11, P4973, DOI 10.1128/MCB.11.10.4973; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WHALEN AM, 1991, J CELL BIOL, V112, P203, DOI 10.1083/jcb.112.2.203; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	59	158	163	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					97	108		10.1016/0092-8674(93)90163-K	http://dx.doi.org/10.1016/0092-8674(93)90163-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8384932				2022-12-24	WOS:A1993KW75300011
J	IKEDA, RM; KONDRACKI, SF; DRABKIN, PD; BIRKHEAD, GS; MORSE, DL				IKEDA, RM; KONDRACKI, SF; DRABKIN, PD; BIRKHEAD, GS; MORSE, DL			PLEURODYNIA AMONG FOOTBALL PLAYERS AT A HIGH-SCHOOL - AN OUTBREAK ASSOCIATED WITH COXSACKIEVIRUS-B1	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ASEPTIC-MENINGITIS	Objective.-Enteroviral outbreaks involving athletic teams have been described, although the mode of transmission has been unclear. In September 1991, an out-break of pleurodynia among high school football players provided an opportunity to identify possible modes of transmission. Design.-Retrospective cohort outbreak investigation. Setting.-Public high school in upstate New York. Results.-Illness was reported by 17 (20%) of the football players. Behaviors involving contact with common water containers were associated with illness, including eating ice cubes from the team ice chest (relative risk [RR], 9.2; 95% confidence interval [CI], 1.3 to 65.5) and drinking water f rom the team cooler (RR, 6.3; 95% CI, 1.5 to 25.7). Coxsackievirus B1 was isolated in four (50%) of the eight stool specimens collected. Conclusions.-Contamination of common water containers by an infected player may have contributed to or initiated the outbreak. In addition to discouraging direct oral contact with common drinking containers, use of individual water containers and ice packs for injuries was recommended.	NEW YORK STATE DEPT HLTH,BUR COMMUNICABLE DIS CONTROL,ALBANY,NY 12201	State University of New York (SUNY) System	IKEDA, RM (corresponding author), CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,4770 BUFORD HWY NE,ATLANTA,GA 30341, USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560				ALEXANDER JP, 1993, J INFECT DIS, V167, P1201, DOI 10.1093/infdis/167.5.1201; BARON RC, 1982, JAMA-J AM MED ASSOC, V248, P1724, DOI 10.1001/jama.248.14.1724; CHONG AYH, 1975, TROP GEOGR MED, V27, P151; EVANS AS, 1931, VIRAL INFECTIONS HUM; HORSTMANN DM, 1950, JAMA-J AM MED ASSOC, V142, P236, DOI 10.1001/jama.1950.02910220016004; MOORE M, 1983, JAMA-J AM MED ASSOC, V249, P2039, DOI 10.1001/jama.249.15.2039; RUSSELL W R, 1949, Br Med J, V1, P465; RUSSELL WR, 1947, BRIT MED J, V2, P1023, DOI 10.1136/bmj.2.4538.1023; SCHOUB BD, 1985, J HYG-CAMBRIDGE, V95, P447, DOI 10.1017/S0022172400062872; Sylvesr E, 1934, EPIDEMIC MYALGIA BOR; THOMAS JC, 1990, J SCHOOL HEALTH, V60, P395	11	16	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2205	2206		10.1001/jama.270.18.2205	http://dx.doi.org/10.1001/jama.270.18.2205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411604				2022-12-24	WOS:A1993ME81600032
J	SCHEJTER, ED; WIESCHAUS, E				SCHEJTER, ED; WIESCHAUS, E			BOTTLENECK ACTS AS A REGULATOR OF THE MICROFILAMENT NETWORK GOVERNING CELLULARIZATION OF THE DROSOPHILA EMBRYO	CELL			English	Article							SEQUENCE-ANALYSIS; GENE ACTIVITY; MELANOGASTER; EMBRYOGENESIS; BLASTODERM; MYOSIN; CYTOKINESIS; TAILLESS; SET; EXPRESSION	A dynamic network of cortical microfilaments is associated with the cleavage furrow membranes during cellularization of the Drosophila embryo. A specific set of structural rearrangements in this network is required for orchestration and execution of its mechanistic roles. We describe the characterization of the gene bottleneck (bnk), mutations in which disturb the proper sequence of rearrangements of the microfilament network, leading to a variety of morphological defects during cellularization. bnk, whose expression is restricted to the blastoderm stages of Drosophila embryogenesis, encodes a novel, exceptionally basic protein that specifically colocalizes with the microfilament network. The expression pattern and mutant phenotype of bnk suggest a direct role for this element in regulation of the dynamic restructuring of the actin-based cytoskeleton of cellularizing Drosophila embryos.			SCHEJTER, ED (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.				NICHD NIH HHS [5R01HD15587] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015587] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CAVANER DR, 1987, NUCLEIC ACIDS RES, V15, P1353; CROZATIER M, 1992, GENETICS, V131, P905; DELOZANNE A, 1987, SCIENCE, V236, P1081; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FOE VE, 1983, J CELL SCI, V61, P31; FOE VE, 1993, IN PRESS DEV DROSOPH; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; FRASCH M, 1987, GENE DEV, V1, P981, DOI 10.1101/gad.1.9.981; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KATOH K, 1989, PROTOPLASMA, V150, P83, DOI 10.1007/BF01403663; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P663; KIEHART DP, 1991, CURR TOP MEMBR, V38, P79; LEVY LS, 1982, DEV BIOL, V94, P451, DOI 10.1016/0012-1606(82)90362-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MAHONEY PA, 1987, DEV BIOL, V122, P464, DOI 10.1016/0012-1606(87)90310-1; MAHOWALD AP, 1963, EXP CELL RES, V32, P457, DOI 10.1016/0014-4827(63)90186-1; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIGNONI F, 1992, DEVELOPMENT, V115, P239; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PLANQUES V, 1991, EXP CELL RES, V192, P557, DOI 10.1016/0014-4827(91)90076-7; POLLARD TD, 1990, ANN NY ACAD SCI, V582, P120; Poodry C.A., 1992, P143; RICKOLL WL, 1976, DEV BIOL, V49, P304, DOI 10.1016/0012-1606(76)90278-5; ROSE LS, 1992, GENE DEV, V6, P1255, DOI 10.1101/gad.6.7.1255; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHEJTER ED, 1992, COLD SPRING HARB SYM, V57, P653, DOI 10.1101/SQB.1992.057.01.071; SCHEJTER ED, 1993, ANNU REV CELL BIOL, V9, P67, DOI 10.1146/annurev.cellbio.9.1.67; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; SCHWALM FE, 1988, INSECT MORPHOGENESIS, P136; SCHWEISGUTH F, 1990, GENE DEV, V4, P922, DOI 10.1101/gad.4.6.922; SIMPSON L, 1990, DEVELOPMENT, V110, P851; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TURNER FR, 1976, DEV BIOL, V50, P95, DOI 10.1016/0012-1606(76)90070-1; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; VINCENT A, 1985, J MOL BIOL, V186, P149, DOI 10.1016/0022-2836(85)90265-7; WARN RM, 1986, EXP CELL RES, V163, P201, DOI 10.1016/0014-4827(86)90573-2; WARN RM, 1990, J CELL SCI, V96, P35; WARN RM, 1980, J EMBRYOL EXP MORPH, V57, P167; WARN RM, 1986, J CELL SCI, P311; WARN RM, 1983, EXP CELL RES, V143, P103, DOI 10.1016/0014-4827(83)90113-1; WIESCHAUS E, 1988, DEVELOPMENT, V104, P483; Wieschaus E., 1986, P199; WOLF N, 1988, DEVELOPMENT, V102, P311; WONG YC, 1981, NUCLEIC ACIDS RES, V9, P6749, DOI 10.1093/nar/9.24.6749; YONEMURA S, 1991, J CELL SCI, V100, P73; YOUNG PE, 1991, DEVELOPMENT, V111, P1; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97; ZIPURSKY SL, 1985, P NATL ACAD SCI USA, V82, P1855, DOI 10.1073/pnas.82.6.1855	67	74	75	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					373	385		10.1016/0092-8674(93)80078-S	http://dx.doi.org/10.1016/0092-8674(93)80078-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402919				2022-12-24	WOS:A1993MD88500018
J	HERMAN, J				HERMAN, J			MOTKE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									BEN GURION UNIV NEGEV, IL-84105 BEER SHEVA, ISRAEL	Ben Gurion University									0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					851	852		10.7326/0003-4819-119-8-199310150-00012	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379606				2022-12-24	WOS:A1993MB49600012
J	BITTNER V; WEINER, DH; YUSUF, S; ROGERS, WJ; MCINTYRE, KM; BANGDIWALA, SI; KRONENBERG, MW; KOSTIS, JB; KOHN, RM; GUILLOTTE, M; GREENBERG, B; WOODS, PA; BOURASSA, MG				BITTNER, V; WEINER, DH; YUSUF, S; ROGERS, WJ; MCINTYRE, KM; BANGDIWALA, SI; KRONENBERG, MW; KOSTIS, JB; KOHN, RM; GUILLOTTE, M; GREENBERG, B; WOODS, PA; BOURASSA, MG			PREDICTION OF MORTALITY AND MORBIDITY WITH A 6-MINUTE WALK TEST IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE-HEART-FAILURE; EXERCISE CAPACITY; ISOSORBIDE DINITRATE; FUNCTIONAL-CAPACITY; PROGNOSTIC VALUE; PERFORMANCE; DISEASE; DETERMINANTS; HYDRALAZINE; VARIABLES	Objective.-To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricular dysfunction. Design.-Data were collected during a prospective cohort study, the Studies of Left Ventricular Dysfunction (SOLVD) Registry Substudy. Setting.-Twenty tertiary care hospitals in the United States, Canada, and Belgium. Participants.-A stratified random sample of 898 patients from the SOLVD Registry who had either radiological evidence of congestive heart failure and/or an ejection fraction of 0.45 or less were enrolled in the substudy and underwent a detailed clinical evaluation including a 6-minute walk test. Patients were followed up for a mean of 242 days. Outcome Measures.-Mortality and hospitalization. Results.-During follow-up, 52 walk-test participants (6.2%) died and 252 (30.3%) were hospitalized. Hospitalization for congestive heart failure occurred in 78 participants (9.4%), and the combined endpoint of death or hospitalization for congestive heart failure occurred in 114 walk-test participants (13.7%). Compared with the highest performance level, patients in the lowest performance level had a significantly greater chance of dying (10.23% vs 2.99%; P=.01), of being hospitalized (40.91% vs 19.90%; P=.002), and of being hospitalized for heart failure (22.16% vs 1.990/o; P<.0001). In a logistic regression model, ejection fraction and distance walked were equally strong and independent predictors of mortality and heart failure hospitalization rates during follow-up. Conclusion.-The 6-minute walk test is a safe and simple clinical tool that strongly and independently predicts morbidity and mortality in patients with left ventricular dysfunction.	OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA; UNIV N CAROLINA, DEPT BIOSTAT, COLLABORAT STUDIES COORDINATING CTR, CHAPEL HILL, NC 27514 USA; VET AFFAIRS MED CTR, BOSTON, MA USA; UNIV MED & DENT NEW JERSEY, DEPT MED & PHARMACOL, NEW BRUNSWICK, NJ USA; SUNY Buffalo, DEPT MED, BUFFALO, NY 14260 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; MONTREAL HEART INST, RES CTR, MONTREAL H1T 1C8, QUEBEC, CANADA; SUNY Buffalo, DEPT RES, BUFFALO, NY 14260 USA; VET AFFAIRS MED CTR, MANCHESTER, NH USA; NIH, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RES, BOSTON, MA 02115 USA	Oregon Health & Science University; University of North Carolina; University of North Carolina Chapel Hill; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard Medical School; Vanderbilt University; Universite de Montreal; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Institutes of Health (NIH) - USA; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	BITTNER V (corresponding author), UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, THT 328 UAB STN, BIRMINGHAM, AL 35294 USA.			Bourassa, Martial G./0000-0002-4439-8650; Yusuf, Salim/0000-0003-4776-5601	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055001] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC55001] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER BJ, 1986, AM HEART J, V111, P697, DOI 10.1016/0002-8703(86)90102-X; BANGDIWALA SI, 1992, AM J CARDIOL, V70, P347, DOI 10.1016/0002-9149(92)90617-8; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, P11; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COHN JN, 1987, CIRCULATION, V75, P49; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; COHN JN, 1990, CIRCULATION, V81, P48; DUNSELMAN PHJM, 1988, AM HEART J, V116, P1475, DOI 10.1016/0002-8703(88)90731-4; FRANCIOSA JA, 1987, CIRCULATION, V75, P20; FRANCIOSA JA, 1979, AM J MED, V67, P460, DOI 10.1016/0002-9343(79)90794-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; GIBBS JSR, 1990, J AM COLL CARDIOL, V15, P52, DOI 10.1016/0735-1097(90)90174-N; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; GRIFFIN BP, 1991, AM J CARDIOL, V67, P848, DOI 10.1016/0002-9149(91)90618-U; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; GUYATT GH, 1985, J CHRON DIS, V38, P517, DOI 10.1016/0021-9681(85)90035-9; GUYATT GH, 1984, THORAX, V39, P818, DOI 10.1136/thx.39.11.818; JAFRI SM, 1986, AM HEART J, V112, P194, DOI 10.1016/0002-8703(86)90706-4; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; KNOX AJ, 1988, THORAX, V43, P388, DOI 10.1136/thx.43.5.388; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; MEILER SEL, 1987, AM HEART J, V113, P1207, DOI 10.1016/0002-8703(87)90935-5; ROZKOVEC A, 1989, EUR HEART J, V10, P63, DOI 10.1093/oxfordjournals.eurheartj.a059382; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; WILLENS HJ, 1987, AM HEART J, V114, P377, DOI 10.1016/0002-8703(87)90506-0; 1990, AM J CARDIOL, V66, P315; 1991, NEW ENGL J MED, V325, P293	28	629	689	3	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1702	1707		10.1001/jama.270.14.1702	http://dx.doi.org/10.1001/jama.270.14.1702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411500				2022-12-24	WOS:A1993MA29400026
J	BRECHNER, RJ; COWIE, CC; HOWIE, LJ; HERMAN, WH; WILL, JC; HARRIS, MI				BRECHNER, RJ; COWIE, CC; HOWIE, LJ; HERMAN, WH; WILL, JC; HARRIS, MI			OPHTHALMIC EXAMINATION AMONG ADULTS WITH DIAGNOSED DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETINOPATHY; PREVALENCE; RISK; CARE; AGE; YR	Objective.-To assess whether adults with diagnosed diabetes in the United States are receiving recommended eye examinations for detection of diabetic retinopathy and what factors are associated with receiving them. Design, Setting, and Participants.-The design was a cross-sectional survey of the civilian, noninstitutionalized US population 18 years of age or older, based on the 1989 National Health Interview Survey. A multistage probability sampling strategy was used to identify a representative sample of 84 572 persons. A questionnaire on diabetes was administered to all subjects with diagnosed diabetes (n=2405). Main Outcome Measure.-A dilated eye examination in the past year. Main Results.-Of all adults with diagnosed diabetes in the United States, only 49% had a dilated eye examination in the past year. This included 57% of people with insulin-dependent diabetes mellitus (IDDM), 55% with insulin-treated noninsulin-dependent diabetes mellitus (NIDDM), and 44% with NIDDM not treated with insulin. Even among diabetics at high risk of vision loss because of retinopathy or long duration of diabetes, the proportion with a dilated eye examination was only 61% and 57%, respectively. By logistic regression, the probability of a dilated eye examination among persons with NIDDM increased with older age, higher socioeconomic status, and having attended a diabetes education class. The probability of a dilated eye examination was not independently related to race, duration of diabetes, frequency of physician visits for diabetes, or health insurance. Conclusions.-About half of adults with diabetes in the United States are not receiving timely and recommended eye care to detect and treat retinopathy. Wide-spread interventions, including patient and professional education, are needed to ensure that diabetic patients who are not receiving appropriate eye care have an annual dilated eye examination to detect retinopathy and prevent vision loss.	NIDDKD, NATL DIABET DATA GRP, WESTWOOD BLDG, ROOM 620, BETHESDA, MD 20892 USA; CTR DIS CONTROL & PREVENT, NATL CTR CHRON DIS PREVENT & HLTH PROMOT, DIV DIABET TRANSLAT, ATLANTA, GA USA; SCI SYST INC, BETHESDA, MD USA; NATL CTR HLTH STAT, DIV HLTH INTERVIEW STAT, HYATTSVILLE, MD 20782 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								[Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1976, Am J Ophthalmol, V81, P383; AWH CC, 1991, ARCH INTERN MED, V151, P1405, DOI 10.1001/archinte.151.7.1405; BERGER W, 1986, DIABETOLOGIA, V29, pA517; BUSH TL, 1989, AM J PUBLIC HEALTH, V79, P1554, DOI 10.2105/AJPH.79.11.1554; Cochran WG, 1977, SAMPLING TECHNIQUES, P319; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1985, OPHTHALMOLOGY, V92, P485; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1985, NIH851468 PUBL, pCH13; KLEIN R, 1985, DIABETES MELLITUS MA, P101; KOONS DA, 1973, VITAL HLTH STAT   54, V2; KOVAR MG, 1985, VITAL HLTH STAT   18, V1; LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1; MASSEY JT, 1989, VITAL HLTH STAT  110, V2; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, SURVEY DATA ANAL SOF; SINGER DE, 1992, ANN INTERN MED, V116, P683; SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660; SPRAFKA JM, 1990, ARCH INTERN MED, V150, P857, DOI 10.1001/archinte.150.4.857; WITKIN SR, 1984, JAMA-J AM MED ASSOC, V251, P2534, DOI 10.1001/jama.251.19.2534; 1992, DIABETES CARE S2, V15, P16; 1988, PHYSICIANS GUIDE INS, P109; 1980, VISION PROBLEMS US, P1; 1988, DIABETES CARE, V11, P745; 1990, VITAL HLTH STAT 176, V10; 1991, PREVENTION TREATMENT, P5; 1988, PHYSICIANS GUIDE NON, P69; 1989, DIABETIC RETINOPATHY	38	210	215	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1714	1718		10.1001/jama.270.14.1714	http://dx.doi.org/10.1001/jama.270.14.1714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411502				2022-12-24	WOS:A1993MA29400028
J	SLATTERY, ML; KERBER, RA				SLATTERY, ML; KERBER, RA			A COMPREHENSIVE EVALUATION OF FAMILY HISTORY AND BREAST-CANCER RISK - THE UTAH POPULATION DATABASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPRODUCTIVE FACTORS; ATTRIBUTABLE RISK; AGE; DISEASE; ONSET; EPIDEMIOLOGY; ASSOCIATION; INDICATOR; WOMEN	Objective.-The purpose of this study is to assess the impact of family history on the risk of developing breast cancer. Design.-A case-control study design was used. Setting.-To provide a comprehensive assessment of family history risk, we used the Utah Population Database, a linked database compiled of genealogy data of the descendants of Mormon pioneer families, cancer data from the Utah Cancer Registry, and mortality data from the Utah Department of Vital Statistics. Patients.-All women diagnosed with breast cancer who were in the genealogy database and the Utah Cancer Registry were included. Controls were women selected from the genealogy, who like cases had no record of previous cancer. They were matched to the cases by age and place of birth. Outcome.-Several definitions of family history were used. The total familial risk variable, developed to work effectively in the Utah Genealogy Database, accounts for all family members, their degree of relatedness to the case, and the amount of time they were observed for possible cancer diagnosis. Results.-A threefold increase in risk, estimated by the odds ratio (OR), of breast cancer among those with the highest family history score (6% of cases) was observed when compared with those with the lowest family history score. The OR for women with a first-degree relative with breast cancer was 2.45 (95% confidence interval [CI], 1.84 to 3.06). If the nearest relative was a second-degree relative, the OR was 1.82 (95% CI, 1.39 to 2.24); if the nearest relative was a third-degree relative, the OR was 1.35 (95% CI, 1.07 to 1.64). A slightly greater risk was observed if the first-degree relative was a woman's mother (OR, 2.44; 95% CI, 1.77 to 3.42) rather than a sister (OR, 2.01; 95% CI, 1.66 to 2.43). Among subjects diagnosed before the age of 50 years, the disease experience of relatives prior to age 50 was most important, while for older subjects the experience of relatives of all ages was of roughly equal importance. Women who developed contralateral breast cancer within 3 years of initial diagnosis were nearly 10 times as likely as women without breast cancer to have a first-degree relative with breast cancer. Based on the risk estimates in this study, we have estimated that approximately 17% to 19% of breast cancer in the population could be attributed to family history. Women who had a first-degree relative with colon cancer had a 30% increased risk of breast cancer. Conclusions.-In this study population, women with a family history of breast cancer, even if the nearest relative with breast cancer is a third-degree relative, are at increased risk of the disease.			SLATTERY, ML (corresponding author), UNIV UTAH,SCH MED,DEPT FAMILY & PREVENT MED,50 N MED DR,ROOM C26,SALT LAKE CITY,UT 84132, USA.		Kerber, Richard/B-8038-2009		NCI NIH HHS [5-R01-CA48998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1989, CANCER, V63, P349, DOI 10.1002/1097-0142(19890115)63:2<349::AID-CNCR2820630225>3.0.CO;2-R; ANDERSON DE, 1971, CANCER, V28, P1500, DOI 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D; [Anonymous], 1976, INT CLASSIFICATION D; [Anonymous], 1990, FERTILITY CHANGE AM; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Byrne C, 1991, Epidemiology, V2, P276, DOI 10.1097/00001648-199107000-00007; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HORN PL, 1988, AM J EPIDEMIOL, V128, P309, DOI 10.1093/oxfordjournals.aje.a114971; JANERICH DT, 1980, MED HYPOTHESES, V6, P1149, DOI 10.1016/0306-9877(80)90137-1; JORDE LB, 1982, HUM BIOL, V54, P583; JORDE LB, 1984, MIGRATION MOBILITY, P83; JORDE LB, 1990, ENCY HUMAN BIOL; KELSEY JL, 1988, CANCER RES, V48, P5615; KING MC, 1990, CANCER SURV, V9, P417; LYNCH HT, 1988, BREAST CANCER RES TR, V12, P275, DOI 10.1007/BF01811240; LYNCH HT, 1988, BREAST CANCER RES TR, V11, P263, DOI 10.1007/BF01807285; Malecot G., 1969, MATH HEREDITY; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MURRAY PP, 1989, OBSTET GYNECOL, V73, P977; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PARAZZINI F, 1992, INT J CANCER, V51, P677, DOI 10.1002/ijc.2910510502; PRESTON DL, 1990, EPICURE GENERALIZED; ROSEMAN DL, 1990, ARCH INTERN MED, V150, P191, DOI 10.1001/archinte.150.1.191; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SKOLNICK M, 1980, CANCER INCIDENCE DEF	33	236	244	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1563	1568		10.1001/jama.270.13.1563	http://dx.doi.org/10.1001/jama.270.13.1563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371466				2022-12-24	WOS:A1993LZ33400029
J	JOHNSON, DG; SCHWARZ, JK; CRESS, WD; NEVINS, JR				JOHNSON, DG; SCHWARZ, JK; CRESS, WD; NEVINS, JR			EXPRESSION OF TRANSCRIPTION FACTOR E2F1 INDUCES QUIESCENT CELLS TO ENTER S-PHASE	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELLULAR DNA-SYNTHESIS; BINDING PROTEIN; ADENOVIRUS-E1A PREVENTS; CYCLE REGULATION; E1A PROTEINS; DOMAINS; RB; IDENTIFICATION; SUPPRESSOR	SEVERAL lines of evidence implicate the E2F transcription factor as an important component of cell proliferation control. First, E2F binding sites are found in the promoters of genes responsive to proliferation signals and the level of E2F binding activity increases at a time when many of these genes are activated1-3. Second, the tumour suppressor protein Rb, as well as the related p107 protein, complexes with E2F2-7, resulting in an inhibition of E2F transcriptional activity3,8-12. Third, oncogenic products of the DNA tumour viruses can dissociate these E2F complexes4,13. We provide here direct evidence that E2F is involved in cellular proliferation control. Specifically, we demonstrate that overexpression of the E2F1 complementary DNA14,15 can activate DNA synthesis in cells that would otherwise growth-arrest, with an efficiency that is similar to that achieved by the expression of the adenovirus E1A gene. Moreover, microinjection of the E2F1 cDNA into quiescent cells can induce S-phase entry, whereas two E2F1 mutants, which are unable to transactivate the DHFR and TK promoters, are unable to induce S phase. We conclude that the E2F transcription factor plays an important role in progression into S phase and that this probably coincides with its capacity to stimulate transcription.			JOHNSON, DG (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,POB 3054,DURHAM,NC 27710, USA.			Johnson, David/0000-0002-6223-1790				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHALLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CROSS WD, IN PRESS MOL CELL BI; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	31	762	785	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					349	352		10.1038/365349a0	http://dx.doi.org/10.1038/365349a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377827				2022-12-24	WOS:A1993LY49600055
J	GORDON, NLM; DAWSON, AA; BENNETT, B; INNES, G; EREMIN, O; JONES, PF				GORDON, NLM; DAWSON, AA; BENNETT, B; INNES, G; EREMIN, O; JONES, PF			OUTCOME IN COLORECTAL ADENOCARCINOMA - 2 7-YEAR STUDIES OF A POPULATION	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; HEPATIC METASTASES; CANCER; CARCINOMA; PERFUSION; SURGERY	Objective-To record every patient with proved colorectal adenocarcinoma presenting from a defined population over two years in 1968-9 and during 1980-2, and to compare treatment and outcome over seven years. Design-Retrospective in 1968-9 and prospective in 1980-2. Setting-Aberdeen general hospitals. Subjects-Every patient presenting to the four general surgical units with histological proof of colorectal adenocarcinoma. Main findings-On average, one new patient presented each week per 100000 population. The proportion of patients aged 65 and over rose from 67% to 71%. An operation was performed on 385 patients in 1968-9 and on 399 during 1980-2. At laparotomy the proportion of patients who seemed to be curable and had a radical operation rose slightly, from 56% to 61%, and operative mortality fell from 9% to 5%. In all there were 421 survivors of curative surgery, and seven years later three quarters were either alive (51%) or had died without recurrence (25%). In both studies some 40% of patients were considered incurable when they presented, but the number who had a palliative resection rose from 59% to 85%. Conclusions-The contribution of radical surgery to the treatment of colorectal adenocarcinoma is substantial, with three quarters of patients so treated showing no evidence of recurrence after seven years. Operative mortality in an elderly population is now low, and improvement in late outcome is more likely to come from developments in adjuvant therapy than in operative technique. A continuing problem is that 40% of patients are not curable when they present, although palliative resection can now be offered to over 80%.	UNIV ABERDEEN,DEPT MED,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 1FX,SCOTLAND; UNIV ABERDEEN,DEPT SURG,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen; University of Aberdeen; University of Aberdeen								ARCHER SG, 1989, BRIT J SURG, V76, P545, DOI 10.1002/bjs.1800760607; BEART RW, 1983, DIS COLON RECTUM, V26, P393, DOI 10.1007/BF02553382; BROWN SCW, 1988, BRIT J SURG, V75, P645, DOI 10.1002/bjs.1800750708; CALLAGHAN J, 1990, AM J SURG, V159, P277, DOI 10.1016/S0002-9610(05)81216-4; CLARKE DN, 1980, BMJ-BRIT MED J, V280, P431, DOI 10.1136/bmj.280.6212.431; COLLINS REC, 1993, ANN R COLL SURG ENGL, V75, pS33; DARBY CR, 1992, BRIT J SURG, V79, P206, DOI 10.1002/bjs.1800790305; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; FIELDING LP, 1993, LANCET, V341, P471, DOI 10.1016/0140-6736(93)90217-5; FIELDING LP, 1992, LANCET, V340, P502, DOI 10.1016/0140-6736(92)91708-G; FINLAY IG, 1988, BRIT J SURG, V75, P641, DOI 10.1002/bjs.1800750707; FINLAY IG, 1986, BRIT J SURG, V73, P732, DOI 10.1002/bjs.1800730918; GRAY R, 1991, BRIT J CANCER, V63, P841, DOI 10.1038/bjc.1991.187; HARDCASTLE JD, 1989, LANCET, V1, P1160; JACKSON BT, 1992, ANN R COLL SURG ENGL, V74, pS63; KEE F, 1992, BRIT MED J, V305, P158, DOI 10.1136/bmj.305.6846.158; MCARDLE CS, 1990, BRIT J SURG, V77, P280, DOI 10.1002/bjs.1800770314; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; TAYLOR I, 1985, BRIT J SURG, V72, P359, DOI 10.1002/bjs.1800720509; 1990, BRIT J SURG, V77, P1063; 1993, ORG GENERAL SURGICAL; 1983, 1982 REG GEN SCOTL A	22	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					707	710		10.1136/bmj.307.6906.707	http://dx.doi.org/10.1136/bmj.307.6906.707			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401092	Green Published, Bronze			2022-12-24	WOS:A1993LY29200019
J	BRITT, AB; CHEN, JJ; WYKOFF, D; MITCHELL, D				BRITT, AB; CHEN, JJ; WYKOFF, D; MITCHELL, D			A UV-SENSITIVE MUTANT OF ARABIDOPSIS DEFECTIVE IN THE REPAIR OF PYRIMIDINE-PYRIMIDINONE(6-4) DIMERS	SCIENCE			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; ESCHERICHIA-COLI; DNA DAMAGE; ULTRAVIOLET-RADIATION; CELLS; GENE; THALIANA; REMOVAL	Plants are continually subjected to ultraviolet-B (UV-B) irradiation (290 to 320 nanometers) as a component of sunlight, which induces a variety of types of damage to the plant DNA. Repair of the two major DNA photoproducts was analyzed in wild-type Arabidopsis thaliana and in a mutant derivative whose growth was sensitive to UV-B radiation. In wild-type seedlings, repair of cyclobutane pyrimidine dimers occurred more slowly in the dark than in the light; repair of this photoproduct was not affected in the mutant. Repair, in the dark, of pyrimidine-pyrimidinone(6-4) dimers was defective in the UV-sensitive mutant.	UNIV TEXAS,MD ANDERSON CANC RES CTR,DEPT CARCINOGENESIS,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center	BRITT, AB (corresponding author), UNIV CALIF DAVIS,BOT SECT,DAVIS,CA 95616, USA.							ALLARD R. W., 1956, HILGARDIA, V24, P235; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1985, J BIOL CHEM, V260, P1438; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; Fisher RA, 1928, J GENET, V20, P79, DOI 10.1007/BF02983317; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; FRANKLIN WA, 1984, P NATL ACAD SCI-BIOL, V81, P3821, DOI 10.1073/pnas.81.12.3821; FREDERICK JE, 1988, PHOTOCHEM PHOTOBIOL, V47, P571, DOI 10.1111/j.1751-1097.1988.tb08846.x; GANESAN AK, 1981, DNA REPAIR LABORAT A, V1, P89; KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x; Klekowski E, 1988, MUTATION DEV SELECTI; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KRANZ AR, 1987, GENETIC RESOURCES AR, V24, P421; MCLENNAN AG, 1987, MUTAT RES, V181, P1, DOI 10.1016/0027-5107(87)90281-8; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PANG QS, 1991, PLANT PHYSIOL, V95, P536, DOI 10.1104/pp.95.2.536; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SMALL GD, 1987, MUTAT RES, V181, P31, DOI 10.1016/0027-5107(87)90284-3; STAPLETON AE, 1992, PLANT CELL, V4, P1353, DOI 10.1105/tpc.4.11.1353; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; VELEMINSKY J, 1990, MUTATION ENV, V340, P195; WALBOT V, 1985, TRENDS GENET, V1, P65; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4; 1970, ISCO TABLES	30	147	163	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1571	1574		10.1126/science.8372351	http://dx.doi.org/10.1126/science.8372351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372351				2022-12-24	WOS:A1993LX47400028
J	CHULAGRAFF, Q; DOE, CQ				CHULAGRAFF, Q; DOE, CQ			NEUROBLAST SPECIFICATION AND FORMATION REGULATED BY WINGLESS IN THE DROSOPHILA CNS	SCIENCE			English	Article							ACHAETE-SCUTE COMPLEX; NEUROGENESIS; MELANOGASTER; EXPRESSION; EPIDERMIS; PRODUCT; PROTEIN; GENES	The Drosophila central nervous system (CNS) develops from a heterogeneous population of neural stem cells (neuroblasts), yet the genes regulating neuroblast determination remain unknown. The segmentation gene wingless is regionally expressed in the neuroectoderm from which neuroblasts develop. A conditional wingless mutation is used to inactivate CNS function without affecting segmentation. The stripe of wingless-expressing neuroectoderm generates apparently normal neuroblasts after wingless inactivation; however, adjacent anterior and posterior neuroectoderm requires wingless nonautonomously for subsequent neuroblast determination and formation. Loss of wingless results in the absence or duplication of identified neuroblasts, highlighting its role in generating neuroblast diversity in the CNS.	UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1990, ANNU REV GENET, V24, P387; CHULAGRAFF Q, UNPUB; Cui X, UNPUB; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1992, DEVELOPMENT, V116, P855; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOODMAN CS, 1993, DEV DROSOPHILA; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; SKAER H, 1992, DEVELOPMENT, V116, P745; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; YANG XH, 1993, GENE DEV, V7, P504, DOI 10.1101/gad.7.3.504	21	149	150	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1594	1597		10.1126/science.8372355	http://dx.doi.org/10.1126/science.8372355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372355				2022-12-24	WOS:A1993LX47400035
J	ARRUDA, S; BOMFIM, G; KNIGHTS, R; HUIMABYRON, T; RILEY, LW				ARRUDA, S; BOMFIM, G; KNIGHTS, R; HUIMABYRON, T; RILEY, LW			CLONING OF AN MYCOBACTERIUM-TUBERCULOSIS DNA FRAGMENT ASSOCIATED WITH ENTRY AND SURVIVAL INSIDE CELLS	SCIENCE			English	Article							TUBERCLE-BACILLI; MYCOBACTERIA; ANTIGEN; PROTEIN	Mycobacterium tuberculosis infects one-third of the world's human population. This widespread infection depends on the organism's ability to escape host defenses by gaining entry and surviving inside the macrophage. DNA sequences of M. tuberculosis have been cloned; these confer on a nonpathogenic Escherichia coli strain an ability to invade HeLa cells, augment macrophage phagocytosis, and survive for at least 24 hours inside the human macrophage. This capacity to gain entry into mammalian cells and survive inside the macrophage was localized to two distinct loci on the cloned M. tuberculosis DNA fragment.	CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,NEW YORK,NY 10021; NEW YORK BLOOD CTR,NEW YORK,NY 10021	Cornell University; New York Blood Center			Arruda, Sergio/AAO-3987-2021		FIC NIH HHS [TW00018] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANDERSON BE, 1990, INFECT IMMUN, V58, P2760, DOI 10.1128/IAI.58.9.2760-2769.1990; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; DRAPER P, 1970, NATURE, V228, P860, DOI 10.1038/228860a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARTMAN AB, 1990, J BACTERIOL, V172, P1905, DOI 10.1128/jb.172.4.1905-1915.1990; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LOWRIE DB, 1983, J MED MICROBIOL, V16, P1, DOI 10.1099/00222615-16-1-1; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RASTOGI N, 1990, RES MICROBIOL, V141, P217, DOI 10.1016/0923-2508(90)90034-N; SHEPARD CC, 1957, J EXP MED, V105, P39, DOI 10.1084/jem.105.1.39; YAMAMOTO T, 1958, Int J Lepr, V26, P111	12	301	332	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1454	1457		10.1126/science.8367727	http://dx.doi.org/10.1126/science.8367727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367727				2022-12-24	WOS:A1993LW54900035
J	DEVARY, Y; ROSETTE, C; DIDONATO, JA; KARIN, M				DEVARY, Y; ROSETTE, C; DIDONATO, JA; KARIN, M			NF-KAPPA-B ACTIVATION BY ULTRAVIOLET-LIGHT NOT DEPENDENT ON A NUCLEAR SIGNAL	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; C-JUN; CELL-PROLIFERATION; GENE ACTIVATION; PROTEIN-KINASE; 65-KD SUBUNIT; REL; TRANSDUCTION	Exposure of mammalian cells to radiation triggers the ultraviolet (UV) response, which includes activation of activator protein-1 (AP-1) and nuclear factor kappa B (NF-kappaB). This was postulated to occur by induction of a nuclear signaling cascade by damaged DNA. Recently, induction of AP-1 by UV was shown to be mediated by a pathway involving Src tyrosine kinases and the Ha-Ras small guanosine triphosphate-binding protein, proteins located at the plasma membrane. It is demonstrated here that the same pathway mediates induction of NF-kappaB by UV. Because inactive NF-kappaB is stored in the cytosol, analysis of its activation directly tests the involvement of a nuclear-initiated signaling cascade. Enucleated cells are fully responsive to UV both in NF-kappaB induction and in activation of another key signaling event. Therefore, the UV response does not require a signal generated in the nucleus and is likely to be initiated at or near the plasma membrane.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER; NCI NIH HHS [CA50528] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIDONATO JA, UNPUB; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORRUM F, 1969, BIOCHEM J, V115, P465; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, IN PRESS GENES DEV; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; POSTE G, 1972, EXP CELL RES, V73, P273, DOI 10.1016/0014-4827(72)90049-3; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROSETTE C, UNPUB; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WALLACE BM, 1992, SCIENCE, V257, P1211, DOI 10.1126/science.1519057; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	46	595	619	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1442	1445		10.1126/science.8367725	http://dx.doi.org/10.1126/science.8367725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367725				2022-12-24	WOS:A1993LW54900031
J	LOCKSLEY, RM; REINER, SL; HATAM, F; LITTMAN, DR; KILLEEN, N				LOCKSLEY, RM; REINER, SL; HATAM, F; LITTMAN, DR; KILLEEN, N			HELPER T-CELLS WITHOUT CD4 - CONTROL OF LEISHMANIASIS IN CD4-DEFICIENT MICE	SCIENCE			English	Article							MURINE CUTANEOUS LEISHMANIASIS; CLASS-II MOLECULES; IFN-GAMMA; MONOCLONAL-ANTIBODY; SUSCEPTIBLE BALB/C; INTERFERON-GAMMA; INVOLVEMENT; RESISTANCE; INVIVO; IL-4	Expression of either the CD4 or CD8 glycoproteins discriminates two functionally distinct lineages of T lymphocytes. A null mutation in the gene encoding CD4 impairs the development of the helper cell lineage that is normally defined by CD4 expression. Infection of CD4-null mice with Leishmania has revealed a population of functional helper T cells that develops despite the absence of CD4. These CD8- alphabetaT cell receptor+ T cells are major histocompatibility complex class II-restricted and produce interferon-gamma when challenged with parasite antigens. These results indicate that T lymphocyte lineage commitment and peripheral function need not depend on the function of CD4.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	LOCKSLEY, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [AI30663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FONG TAT, 1989, J IMMUNOL, V143, P2887; HATAM F, UNPUB; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLADAY BJ, 1991, J IMMUNOL, V147, P1653; HUANG L, 1992, J EXP MED, V176, P699, DOI 10.1084/jem.176.3.699; JANEWAY CA, 1993, CURR BIOL, V3, P282, DOI 10.1016/0960-9822(93)90179-R; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, UNPUB; KUBOTA H, 1992, J IMMUNOL, V149, P1143; MILON G, 1986, J IMMUNOL, V136, P1467; MITCHELL GF, 1983, J IMMUNOGENET, V10, P395; MORRIS L, 1992, J IMMUNOL, V149, P2715; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; REINER SL, UNPUB; REINER SL, IN PRESS J IMMUNOL M; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; TITUS RG, 1987, EUR J IMMUNOL, V17, P1429, DOI 10.1002/eji.1830171007; TITUS RG, 1985, J IMMUNOL, V135, P2108; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	28	243	247	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1448	1451		10.1126/science.8367726	http://dx.doi.org/10.1126/science.8367726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367726				2022-12-24	WOS:A1993LW54900033
J	SOMMER, T; JENTSCH, S				SOMMER, T; JENTSCH, S			A PROTEIN TRANSLOCATION DEFECT LINKED TO UBIQUITIN CONJUGATION AT THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							YEAST; DEGRADATION; MEMBRANE; ENZYME; ENCODES; GENE; POLYPEPTIDES; INSERTION; PATHWAY; COMPLEX	UBIQUITIN-Conjugating enzymes function in selective proteolysis pathways and catalyse the covalent attachment of ubiquitin to proteolytic substrates1-4. Here we report the identification of an integral membrane ubiquitin-conjugating enzyme. This enzyme, UBC6, localizes to the endoplasmic reticulum (ER), with the catalytic domain facing the cytosol. ubc6 loss-of-function mutants suppress the protein translocation defect caused by a mutation in SEC61, which encodes a key component of a multisubunit protein translocation apparatus of the ER5-11. The expression of the sec61 mutant phenotype requires both the activity of UBC6 and its localization at the ER membrane. This suggests that UBC6 may mediate selective degradation of ER membrane proteins and that the protein translocation defect of sec61 may be caused by proteolysis of components of a structurally distorted mutant translocation apparatus.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1986, REV CELL BIOL, V7, P25; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, GUIDE YEAST GENETICS; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TIERNEY DJ, 1992, ARCH BIOCHEM BIOPHYS, V293, P9, DOI 10.1016/0003-9861(92)90358-4; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	30	271	276	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					176	179		10.1038/365176a0	http://dx.doi.org/10.1038/365176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396728				2022-12-24	WOS:A1993LW44200052
J	COOK, M; FERNER, RE				COOK, M; FERNER, RE			ADVERSE DRUG-REACTIONS - WHO IS TO KNOW	BRITISH MEDICAL JOURNAL			English	Article									DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND					Ferner, Robin/0000-0003-3769-1346				DAVIES DM, 1991, TXB ADVERSE DRUG REA; HASLMAN R, 1988, ADVERSE DRUG REACT, V3, P133; KARCH FE, 1976, CLIN PHARMACOL THER, V19, P489; 1992, BRIT NATIONAL FORMUL	4	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					480	481		10.1136/bmj.307.6902.480	http://dx.doi.org/10.1136/bmj.307.6902.480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400931	Bronze, Green Published			2022-12-24	WOS:A1993LU59000021
J	MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F				MANNHEIMER, C; ELIASSON, T; ANDERSSON, B; BERGH, CH; AUGUSTINSSON, LE; EMANUELSSON, H; WAAGSTEIN, F			EFFECTS OF SPINAL-CORD STIMULATION IN ANGINA-PECTORIS INDUCED BY PACING AND POSSIBLE MECHANISMS OF ACTION	BRITISH MEDICAL JOURNAL			English	Article							ELECTRICAL NERVE-STIMULATION; CORONARY BLOOD-FLOW; OXYGEN-CONSUMPTION; BETA-BLOCKADE; METABOLISM; LACTATE; DISEASE; REPRODUCIBILITY; IMPROVEMENT; ADENOSINE	Objective-To investigate the effects of spinal cord stimulation on myocardial ischaemia, coronary blood flow, and myocardial oxygen consumption in angina pectoris induced by atrial pacing. Design-The heart was paced to angina during a control phase and treatment with spinal cord stimulation. Blood samples were drawn from a peripheral artery and the coronary sinus. Setting-Multidisciplinary pain centre, department of medicine, Ostra Hospital, and Wallenberg Research Laboratory, Sahlgrenska Hospital, Gothenburg, Sweden. Subjects-Twenty patients with intractable angina pectoris, all with a spinal cord stimulator implanted before the study. Results-Spinal cord stimulation increased patients' tolerance to pacing (p<0.001). At the pacing rate comparable to that producing angina during the control recording, myocardial lactate production during control session turned into extraction (p=0.003) and, on the electrocardiogram, ST segment depression decreased, time to ST depression increased, and time to recovery from ST depression decreased (p=0.01; p<0.05, and p <0.05, respectively). Spinal cord stimulation also reduced coronary sinus blood flow (p=0.01) and myocardial oxygen consumption (p=0.02). At the maximum pacing rate during treatment, all patients experienced anginal pain. Myocardial lactate extraction reverted to production (p<0.01) and the magnitude and duration of ST segment depression increased to the same values as during control pacing, indicating that myocardial ischaemia during treatment with spinal cord stimulation gives rise to anginal pain. Conclusions-Spinal cord stimulation has an antianginal and anti-ischaemic effect in severe coronary artery disease. These effects seem to be secondary to a decrease in myocardial oxygen consumption. Furthermore, myocardial ischaemia during treatment gives rise to anginal pain. Thus, spinal cord stimulation does not deprive the patient of a warning signal.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT NEUROSURG,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	MANNHEIMER, C (corresponding author), OSTRA HOSP,CTR MULTIDISCIPLINARY PAIN,DEPT MED,S-41685 GOTHENBURG,SWEDEN.							AUGUSTINSSON LE, 1985, ANN SURG, V202, P104, DOI 10.1097/00000658-198507000-00017; BLOMBERG S, 1989, EUR HEART J, V10, P437, DOI 10.1093/oxfordjournals.eurheartj.a059507; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; CHANDLER MJ, 1993, EUR HEART J, V14, P96, DOI 10.1093/eurheartj/14.1.96; COHEN LS, 1966, AM J CARDIOL, V17, P153, DOI 10.1016/0002-9149(66)90347-X; COOK AW, 1976, NEW YORK STATE J MED, V76, P366; DELANDSHEERE C, 1992, AM J CARDIOL, V69, P1143, DOI 10.1016/0002-9149(92)90926-P; EMANUELSSON H, 1987, AM HEART J, V114, P1360, DOI 10.1016/0002-8703(87)90537-0; FEIGL EO, 1983, PHYSIOL REV, V63, P1, DOI 10.1152/physrev.1983.63.1.1; FORRESTE.JS, 1971, AM J CARDIOL, V27, P237, DOI 10.1016/0002-9149(71)90296-7; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GERTZ EW, 1980, CIRCULATION, V61, P256, DOI 10.1161/01.CIR.61.2.256; Gybels J, 1987, Acta Neurochir Suppl (Wien), V38, P64; HOSOBUCHI Y, 1985, APPL NEUROPHYSIOL, V48, P372, DOI 10.1159/000101161; IHLEN H, 1983, CARDIOLOGY, V70, P177, DOI 10.1159/000173591; JACKSON G, 1977, BRIT HEART J, V39, P829; JACOBS MJHM, 1990, J VASC SURG, V12, P354, DOI 10.1067/mva.1990.22787; KNABB RM, 1983, CIRC RES, V53, P33, DOI 10.1161/01.RES.53.1.33; KROGER K, 1989, EUR HEART J, V10, P179, DOI 10.1093/eurheartj/10.suppl_F.179; LEHMANN EL, 1986, TESTING STATISTICAL, P233; LUNDEBERG T, 1988, LANCET, V2, P712; MANNHEIMER C, 1989, BRIT HEART J, V62, P36; MANNHEIMER C, 1988, BRIT HEART J, V59, P56; MANNHEIMER C, 1985, CIRCULATION, V71, P308, DOI 10.1161/01.CIR.71.2.308; MILLER WL, 1979, CIRC RES, V45, P708, DOI 10.1161/01.RES.45.6.708; MOSHER P, 1964, CIRC RES, V14, P250, DOI 10.1161/01.RES.14.3.250; NEILL WA, 1974, J LAB CLIN MED, V83, P428; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; REMME WJ, 1992, EUR HEART J S, V13, pP1963; ROBERTSON RM, 1983, AM HEART J, V105, P901, DOI 10.1016/0002-8703(83)90387-3; SANDERSON JE, 1992, EUR HEART J, V13, P628, DOI 10.1093/oxfordjournals.eurheartj.a060226; SIEGFRIED J, 1982, APPL NEUROPHYSIOL, V45, P201; SOWTON G. E., 1967, CARDIOVASC RES, V1, P301, DOI 10.1093/cvr/1.4.301; THADANI U, 1979, CIRCULATION, V60, P1036, DOI 10.1161/01.CIR.60.5.1036	34	149	156	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					477	480		10.1136/bmj.307.6902.477	http://dx.doi.org/10.1136/bmj.307.6902.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400930	Green Published, Bronze			2022-12-24	WOS:A1993LU59000020
J	MULKEY, RM; HERRON, CE; MALENKA, RC				MULKEY, RM; HERRON, CE; MALENKA, RC			AN ESSENTIAL ROLE FOR PROTEIN PHOSPHATASES IN HIPPOCAMPAL LONG-TERM DEPRESSION	SCIENCE			English	Article							POTENTIATED SYNAPTIC RESPONSES; OKADAIC ACID; AREA CA1; KINASE ACTIVITY; MICROCYSTIN-LR; CALYCULIN-A; MOUSE SKIN; STIMULATION; CALMODULIN; INDUCTION	The effectiveness of long-term potentiation (LTP) as a mechanism for information storage would be severely limited if processes that decrease synaptic strength did not also exist. In area CA1 of the rat hippocampus, prolonged periods of low-frequency afferent stimulation elicit a long-term depression (LTD) that is specific to the stimulated input. The induction of LTD was blocked by the extracellular application of okadaic acid or calyculin A, two inhibitors of protein phosphatases 1 and 2A. The loading of CA1 cells with microcystin LR, a membrane-impermeable protein phosphatase inhibitor, or calmodulin antagonists also blocked or attenuated LTD. The application of calyculin A after the induction of LTD reversed the synaptic depression, suggesting that phosphatase activity is required for the maintenance of LTD. These findings indicate that the synaptic activation of protein phosphatases plays an important role in the regulation of synaptic transmission.	UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH045334, F32MH010306] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10306, MH00942, MH45334] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARTOLA A, IN PRESS TRENDS NEUR; BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLINO A, 1992, J NEUROSCI, V12, P180; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HERRON CE, UNPUB; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KLANN E, 1991, J BIOL CHEM, V266, P24253; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPHO, V23, P1; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; SUGANUMA M, 1990, CANCER RES, V50, P3521; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	37	530	541	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1051	1055		10.1126/science.8394601	http://dx.doi.org/10.1126/science.8394601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8394601				2022-12-24	WOS:A1993LT74700036
J	KENDRICK, AH; HIGGS, CMB; WHITFIELD, MJ; LASZLO, G				KENDRICK, AH; HIGGS, CMB; WHITFIELD, MJ; LASZLO, G			ACCURACY OF PERCEPTION OF SEVERITY OF ASTHMA - PATIENTS TREATED IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PEAK-FLOW; MORTALITY	Objective-To determine the frequency of poor perception of severity of asthma in general practice. Design-Asthmatic patients recorded their perceived severity of asthma, with a visual analogue score, and a coded measurement of their peak expiratory flow up to four times daily for 14 consecutive days. Settings-11 general practices in and around Bristol. Subjects-255 asthmatic patients (139 men and 116 women) aged 17-76 who were recruited by random selection from the general practices' disease registers or when they requested prescriptions for inhaled bronchodilators. Main outcome measures-Correlation between visual analogue scores and peak expiratory flow (as a percentage of predicted peak flow). Results-152 (60%) of the patients showed no significant correlation between visual analogue asthma scores and simultaneous peak flow measurements (p>0.05) and were termed poor discriminators. The distribution of good and poor discriminators within each general practice was similar (chi2=6.11, df=10). The two groups were not characterised by differences in the maximum, minimum, or standard deviation of peak expiratory flow or visual analogue score; in age; or in the proportion of men and women in each group. Conclusion-In general practice a high proportion of asthmatic patients do not reliably detect changes in their lung function. This reinforces the need for careful objective assessment of lung function in the management of asthma.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH,GEN PRACTICE UNIT,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	KENDRICK, AH (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT RESP,BRISTOL BS2 8HW,AVON,ENGLAND.							BARNES PJ, 1992, THORAX, V47, P408, DOI 10.1136/thx.47.6.408; BATES DV, 1952, CLIN SCI, V11, P203; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; FRITZ GK, 1990, J DEV BEHAV PEDIATR, V11, P69; HETZEL MR, 1979, LANCET, V1, P597; HIGGS CMB, 1986, THORAX, V41, P671, DOI 10.1136/thx.41.9.671; HIGGS CMB, 1987, THESIS U CAMBRIDGE C; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PEIFFER C, 1989, CLIN SCI, V77, P237, DOI 10.1042/cs0770237; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; RICHARDSON RB, 1984, CLIN PHYS PHYSIOL M, V5, P201, DOI 10.1088/0143-0815/5/3/004; RUBINFELD AR, 1976, LANCET, V1, P882; RUBINFELD AR, 1977, CHEST, V72, P154, DOI 10.1378/chest.72.2.154; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; STEINER H, 1987, PSYCHOSOM MED, V49, P35, DOI 10.1097/00006842-198701000-00003	20	169	171	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					422	424		10.1136/bmj.307.6901.422	http://dx.doi.org/10.1136/bmj.307.6901.422			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374455	Green Published, Bronze			2022-12-24	WOS:A1993LR89500019
J	NAKATSU, Y; TYNDALE, RF; DELOREY, TM; DURHAMPIERRE, D; GARDNER, JM; MCDANEL, HJ; NGUYEN, Q; WAGSTAFF, J; LALANDE, M; SIKELA, JM; OLSEN, RW; TOBIN, AJ; BRILLIANT, MH				NAKATSU, Y; TYNDALE, RF; DELOREY, TM; DURHAMPIERRE, D; GARDNER, JM; MCDANEL, HJ; NGUYEN, Q; WAGSTAFF, J; LALANDE, M; SIKELA, JM; OLSEN, RW; TOBIN, AJ; BRILLIANT, MH			A CLUSTER OF 3 GABA(A) RECEPTOR SUBUNIT GENES IS DELETED IN A NEUROLOGICAL MUTANT OF THE MOUSE P-LOCUS	NATURE			English	Article							PRADER-WILLI SYNDROME; ANGELMAN SYNDROMES; REGION; LOCALIZATION; BENZODIAZEPINE; CHROMOSOME-7; EXPRESSION; BETA-3; ALPHA; MODEL	THE mouse pink-eyed cleft-palate (p(cp)) mutation is characterized by hypopigmentation associated with cleft palate, neurological disorders and runting1,2. Most p(cp) homozygotes are born with cleft palate and die shortly after birth, presumably as a result of feeding problems3. A few exceptional p(cp) mutants live beyond this stage but display tremor and jerky gait2. We report here that the genes encoding the gamma-aminobutyric acid type A (GABA(A)) receptor subunits alpha5 (originally described as alpha4; ref. 4), beta3 and gamma3 are disrupted by a deletion in p(cp) mice. We also show that the alpha5 and gamma3 genes are located between the p and beta3 genes on mouse chromosome 7. The p(cp) deletion leads to alterations of binding properties of the GABA(A) receptors in the brain, providing an in vivo model system for studying GABA(A) receptor function. The human homologue of the region deleted in p(cp) mice is associated with Angelman syndrome5-9. Thus, p(cp) mice may be useful in defining the region containing the gene(s) for this syndrome.	FOX CHASE CANC CTR,INST CANC RES,7701 BURHOLME AVE,PHILADELPHIA,PA 19111; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	Fox Chase Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Nakatsu, Yoshimichi/0000-0001-7408-7071; Tyndale, Rachel/0000-0003-1297-2053				ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; BRILLIANT MH, 1992, MAMM GENOME, V3, P187, DOI 10.1007/BF00355717; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; CHAILLET JR, 1991, GENOMICS, V11, P773, DOI 10.1016/0888-7543(91)90090-2; CULIAT CT, 1993, P NATL ACAD SCI USA, V90, P5105, DOI 10.1073/pnas.90.11.5105; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; HAMABE J, 1991, AM J MED GENET, V41, P54, DOI 10.1002/ajmg.1320410116; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KNOLL JHM, 1993, HUM MOL GENET, V2, P183, DOI 10.1093/hmg/2.2.183; KORPI ER, 1993, NATURE, V361, P356, DOI 10.1038/361356a0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LYON MF, 1992, P NATL ACAD SCI USA, V89, P6968, DOI 10.1073/pnas.89.15.6968; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; OLSEN RW, 1990, J CHEM NEUROANAT, V3, P59; PHILLIPS RJS, 1977, MOUSE NEWSLETTER, V56, P18; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REIS A, 1993, LANCET, V341, P122, DOI 10.1016/0140-6736(93)92606-T; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SILVERS WK, 1979, COAT COLORS MICE, P90; SINNETT D, 1993, AM J HUM GENET, V52, P1216; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; WAGSTAFF J, 1991, GENOMICS, V11, P1071, DOI 10.1016/0888-7543(91)90034-C; WILCOX AS, 1992, P NATL ACAD SCI USA, V89, P5857, DOI 10.1073/pnas.89.13.5857; WILSONSHAW D, 1991, FEBS LETT, V284, P211, DOI 10.1016/0014-5793(91)80687-X; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x; ZHANG JH, 1991, J COMP NEUROL, V308, P586, DOI 10.1002/cne.903080407	32	94	95	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					448	450		10.1038/364448a0	http://dx.doi.org/10.1038/364448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8392662				2022-12-24	WOS:A1993LP64000056
J	MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD				MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD			EFFECT OF SPINAL OSTEOPHYTOSIS ON BONE-MINERAL DENSITY-MEASUREMENTS IN VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									WHIPPS CROSS HOSP & CHEST CLIN,DEPT RHEUMATOL,LONDON E11 1NR,ENGLAND	University of London; Queen Mary University London	MASUD, T (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Langley-Evans, Simon C/F-3564-2012; Spector, Tim D/F-6533-2012	Langley-Evans, Simon C/0000-0002-1969-8416; 	Arthritis Research UK [17489] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		DAWSONHUGHES B, 1990, CALCIFIED TISSUE INT, V46, P280, DOI 10.1007/BF02555008; DEQUEKER J, 1985, CLIN RHEUM DIS, V11, P271; LAWRENCE JS, 1969, ANN RHEUM DIS, V28, P6121; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; REID IR, 1991, J CLIN ENDOCR METAB, V72, P1372, DOI 10.1210/jcem-72-6-1372	5	164	171	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					172	173		10.1136/bmj.307.6897.172	http://dx.doi.org/10.1136/bmj.307.6897.172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343746	Green Published, Bronze			2022-12-24	WOS:A1993LN18400021
J	STEINE, S				STEINE, S			WILL IT HURT, DOCTOR - FACTORS PREDICTING PATIENTS EXPERIENCE OF PAIN DURING DOUBLE-CONTRAST EXAMINATION OF THE COLON	BRITISH MEDICAL JOURNAL			English	Article											STEINE, S (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							FORK FT, 1982, DIAGNOSTIC VALUE LAR; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; MORIARTY KJ, 1992, BRIT MED J, V304, P1166, DOI 10.1136/bmj.304.6835.1166; STEINE S, 1992, Scandinavian Journal of Primary Health Care, V10, P134, DOI 10.3109/02813439209014050; 1990, INCIDENCE CANCER NOR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					100	100		10.1136/bmj.307.6896.100	http://dx.doi.org/10.1136/bmj.307.6896.100			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343703	Green Published, Bronze			2022-12-24	WOS:A1993LM58500025
J	BEKKERS, JM				BEKKERS, JM			ENHANCEMENT BY HISTAMINE OF NMDA-MEDIATED SYNAPTIC TRANSMISSION IN THE HIPPOCAMPUS	SCIENCE			English	Article							RAT HIPPOCAMPUS; PYRAMIDAL CELLS; BRAIN; CURRENTS; NEURONS; MECHANISMS; IMPAIRMENT; RECEPTORS; FIBERS	Histamine is a neuromodulator in the brain, and the hippocampus is one of the regions of the brain that is innervated by histaminergic neurons. When applied to cultured hippocampal neurons, histamine selectively increased by up to tenfold the amplitude of the component of synaptic transmission that was mediated by N-methyl-D-aspartate (NMDA) receptors. Spontaneous miniature synaptic currents and the current elicited by applied NMDA also were enhanced, indicating that the histamine effect was expressed primarily postsynaptically. These results suggest that histamine may modulate processes involving NMDA receptors, such as the induction of long-term potentiation.			BEKKERS, JM (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV NEUROSCI, CANBERRA, ACT 2601, AUSTRALIA.			Bekkers, John/0000-0001-8619-5512				BARBIN G, 1976, J NEUROCHEM, V26, P259, DOI 10.1111/j.1471-4159.1976.tb04474.x; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DEALMEIDA MAMR, 1986, ARCH INT PHARMACOD T, V283, P193; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; HAAS HL, 1983, NATURE, V302, P432, DOI 10.1038/302432a0; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; INAGAKI N, 1988, J COMP NEUROL, V273, P283, DOI 10.1002/cne.902730302; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCCORMICK DA, 1991, J NEUROSCI, V11, P3188; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; PELLMAR TC, 1986, J NEUROPHYSIOL, V55, P727, DOI 10.1152/jn.1986.55.4.727; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SCHWARTZ JC, 1986, TRENDS PHARMACOL SCI, V7, P24, DOI 10.1016/0165-6147(86)90236-1; SCHWARTZ JC, 1991, PHYSIOL REV, V71, P1, DOI 10.1152/physrev.1991.71.1.1; SEGAL M, 1981, BRAIN RES, V213, P443, DOI 10.1016/0006-8993(81)90251-1; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; SPRINGFIELD SA, 1988, CELL MOL NEUROBIOL, V8, P431, DOI 10.1007/BF00711227; TONKISS J, 1992, EXP BRAIN RES, V90, P572; WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	31	133	143	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					104	106		10.1126/science.8391168	http://dx.doi.org/10.1126/science.8391168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8391168				2022-12-24	WOS:A1993LK43400043
J	DUFFNER, PK; HOROWITZ, ME; KRISCHER, JP; FRIEDMAN, HS; BURGER, PC; COHEN, ME; SANFORD, RA; MULHERN, RK; JAMES, HE; FREEMAN, CR; SEIDEL, FG; KUN, LE				DUFFNER, PK; HOROWITZ, ME; KRISCHER, JP; FRIEDMAN, HS; BURGER, PC; COHEN, ME; SANFORD, RA; MULHERN, RK; JAMES, HE; FREEMAN, CR; SEIDEL, FG; KUN, LE			POSTOPERATIVE CHEMOTHERAPY AND DELAYED RADIATION IN CHILDREN LESS-THAN 3 YEARS OF AGE WITH MALIGNANT BRAIN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; PHASE-II; IRRADIATION; SURVIVAL; VINCRISTINE; THERAPY; GROWTH	Background. Among patients with malignant brain tumors, infants and very young children have the worst prognosis and the most severe treatment-related neurotoxic effects. Therefore, in 1986, the Pediatric Oncology Group began a study in which postoperative chemotherapy was given in order to permit a delay in the delivery of radiation to the developing brain. Methods. Children under 36 months of age with biopsy-proved malignant brain tumors were treated postoperatively with two 28-day cycles of cyclophosphamide plus vincristine, followed by one 28-day cycle of cisplatin plus etoposide. This sequence was repeated until the disease progressed or for two years in 132 children under 24 months of age at diagnosis and for one year in 66 children 24 to 36 months of age at diagnosis. After this, the patients received radiation therapy. The response to the first two cycles of chemotherapy was measured in 102 patients with residual postoperative disease. Results. The first two cycles of cyclophosphamide and vincristine produced complete or partial responses in 39 percent of the 102 patients who could be evaluated. The response rates were highest among patients with medulloblastomas, malignant gliomas, or ependymomas. Patients with brain-stem gliomas or embryonal tumors (primitive neuroectodermal tumors) had little or no response. The progression-free survival rate was 41 percent at one year for children who were 24 to 36 months old at diagnosis and 39 percent at two years for those under 24 months of age at diagnosis. Multivariate analysis identified embryonal tumors as a significant adverse prognostic feature (relative risk, 2.2; 95 percent confidence interval, 1.4 to 3.4) and complete resection as a favorable feature (relative risk, 0.33; 95 percent confidence interval, 0.20 to 0.54). Complete responses to chemotherapy were associated with a progression-free survival rate approaching that achieved with gross total resection. A comparison of cognitive evaluations obtained at base line and after one year of chemotherapy revealed no evidence of deterioration in cognitive function. Conclusions. Chemotherapy appears to be an effective primary postoperative treatment for many malignant brain tumors in young children. Disease control for one or two years in a large minority of patients permitted a delay in the delivery of radiation and, on the basis of preliminary results, a reduction in neurotoxicity. For patients who had undergone total surgical resection or who had a complete response to chemotherapy, the results are sufficiently encouraging to suggest that radiation therapy may not be needed in this subgroup of children after at least one year of chemotherapy.	SUNY Buffalo, SCH MED & BIOMED SCI, BUFFALO, NY 14260 USA; ROSWELL PK CANC INST, BUFFALO, NY USA; UNIV FLORIDA, PEDIAT ONCOL GRP STAT OFF, GAINESVILLE, FL 32611 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; CHILDRENS MERCY HOSP, KANSAS CITY, MO 64108 USA; UNIV CALIF SAN DIEGO, MED CTR, SAN DIEGO, CA 92103 USA; MONTREAL GEN HOSP, MONTREAL H3G 1A4, QUEBEC, CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; State University System of Florida; University of Florida; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital; Children's Mercy Hospital; University of California System; University of California San Diego; McGill University			Krischer, Jeffrey P/I-5004-2012					ALLEN JC, 1981, J NEUROSURG, V55, P749, DOI 10.3171/jns.1981.55.5.0749; ALLEN JC, 1983, CANCER, V52, P2001, DOI 10.1002/1097-0142(19831201)52:11<2001::AID-CNCR2820521105>3.0.CO;2-D; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BERTOLONE SJ, 1983, P AN M AM SOC CLIN, V2, P72; BLOOM HJG, 1990, INT J RADIAT ONCOL, V18, P723, DOI 10.1016/0360-3016(90)90392-W; BLOOM HJG, 1990, INT J RADIAT ONCOL, V19, P829; BURGER PC, 1991, SURGICAL PATHOLOGY N; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS PC, 1986, AM J ROENTGENOL, V147, P587, DOI 10.2214/ajr.147.3.587; DEUTSCH M, 1991, P AN M AM SOC CLIN, V10, P124; DUFFNER PK, 1986, NEUROLOGY, V36, P597, DOI 10.1212/WNL.36.5.597; DUFFNER PK, 1986, ANN NEUROL, V20, P424; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FINLAY J, 1991, P AN M AM SOC CLIN, V10, P308; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAN AB, 1982, CANCER TREAT REP, V66, P2013; LAMPKIN BC, 1967, PEDIATRICS, V39, P761; LEFKOWITZ I, 1989, P AN M AM SOC CLIN, V8, P87; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; McCarthy D, 1972, MANUAL MCCARTHY SCAL; ROSENSTOCK JG, 1976, J NEUROSURG, V45, P135, DOI 10.3171/jns.1976.45.2.0135; Russell D., 1989, PATHOLOGY TUMORS NER; SHALET SM, 1987, ARCH DIS CHILD, V62, P461, DOI 10.1136/adc.62.5.461; SHRIEVE DC, 1992, INT J RADIAT ONCOL, V24, P599, DOI 10.1016/0360-3016(92)90704-L; SHUSTER JJ, 1988, AM STAT, V42, P234; SKLANSKY BD, 1974, CANCER-AM CANCER SOC, V33, P460, DOI 10.1002/1097-0142(197402)33:2<460::AID-CNCR2820330222>3.0.CO;2-5; SNEDECOR GW, 1981, STATISTICAL METHODS, P228; SPOSTO R, 1989, J NEURO-ONCOL, V7, P165, DOI 10.1007/BF00165101; SPUNBERG JJ, 1981, INT J RADIAT ONCOL, V7, P727, DOI 10.1016/0360-3016(81)90465-X; SUC E, 1990, ACTA NEUROCHIR, V106, P93, DOI 10.1007/BF01809448; TIRELLI U, 1984, J CLIN ONCOL, V2, P432, DOI 10.1200/JCO.1984.2.5.432; WALKER RW, 1983, ANN NEUROL, V14, P371	34	575	582	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1725	1731		10.1056/NEJM199306173282401	http://dx.doi.org/10.1056/NEJM199306173282401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	8388548				2022-12-24	WOS:A1993LG03800001
J	ARNOLD, JMO; TEASELL, RW; MACLEOD, AP; BROWN, JE; CARRUTHERS, SG				ARNOLD, JMO; TEASELL, RW; MACLEOD, AP; BROWN, JE; CARRUTHERS, SG			INCREASED VENOUS ALPHA-ADRENOCEPTOR RESPONSIVENESS IN PATIENTS WITH REFLEX SYMPATHETIC DYSTROPHY	ANNALS OF INTERNAL MEDICINE			English	Note						REFLEX SYMPATHETIC DYSTROPHY; RECEPTORS, ADRENERGIC-ALPHA; NOREPINEPHRINE; HEMIPLEGIA; SYMPATHETIC NERVOUS SYSTEM		Reflex sympathetic dystrophy is a symptom complex characterized by vasomotor instability, hyperaesthesia, and pain. Hypothesizing that these symptoms could reflect diminished sympathetic innervation with resultant alpha-adrenoceptor hyper-responsiveness, we studied 11 patients who developed upper-limb reflex sympathetic dystrophy after hemiplegia or trauma and 11 normal controls who were similar in age to the study patients. The diameter of superficial hand veins was measured using a linear variable differential transformer during local infusion of saline and increasing concentrations of noradrenaline. The limbs affected with reflex sympathetic dystrophy showed marked alpha-adrenoceptor hyper-responsiveness, that is, less noradrenaline was required to cause 50% venoconstriction (1.5 compared with 6.8 ng/min, P = 0.001). The unaffected limb in patients with reflex sympathetic dystrophy also showed hyper-responsiveness to noradrenaline when compared with values in normal controls (6.8 compared with 27.4 ng/min P = 0.01), with such hyper-responsiveness being more marked in patients with hemiplegia. The findings provide the first direct evidence in humans of hyper-responsiveness of vascular alpha-adrenoceptors to noradrenaline in reflex sympathetic dystrophy.	VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; UNIV WESTERN ONTARIO, UNIV HOSP, LONDON N6A 5A5, ONTARIO, CANADA	Dalhousie University; University of Victoria; Western University (University of Western Ontario)	ARNOLD, JMO (corresponding author), VICTORIA HOSP, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA.		Arnold, Malcolm/G-2869-2011					ALRADI AO, 1985, CLIN PHARMACOL THER, V38, P495, DOI 10.1038/clpt.1985.214; BEJ MD, 1991, ARCH NEUROL-CHICAGO, V48, P912, DOI 10.1001/archneur.1991.00530210038020; Cannon WB, 1949, SUPERSENSITIVITY DEN; DRUMMOND PD, 1991, BRAIN, V114, P2025, DOI 10.1093/brain/114.5.2025; KOLTZENBURG M, 1991, TRENDS PHARMACOL SCI, V12, P399, DOI 10.1016/0165-6147(91)90615-Y; KOZIN F, 1979, ARTHRITIS ALLIED CON; ROSEN L, 1989, MICROVASC RES, V37, P289, DOI 10.1016/0026-2862(89)90047-2; SWEET WH, 1985, EVALUATION TREATMENT, P149; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WALLIN BG, 1976, SENSORY FUNCTIONS SK, V27, P489	10	138	140	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					619	621		10.7326/0003-4819-118-8-199304150-00008	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8383935				2022-12-24	WOS:A1993KW47000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNING ABOUT VIBRIO INFECTIONS AND RAW MOLLUSCAN SHELLFISH CONSUMPTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-24	WOS:A1993KQ85700005
J	JELINEK, LJ; LOK, S; ROSENBERG, GB; SMITH, RA; GRANT, FJ; BIGGS, S; BENSCH, PA; KUIJPER, JL; SHEPPARD, PO; SPRECHER, CA; OHARA, PJ; FOSTER, D; WALKER, KM; CHEN, LHJ; MCKERNAN, PA; KINDSVOGEL, W				JELINEK, LJ; LOK, S; ROSENBERG, GB; SMITH, RA; GRANT, FJ; BIGGS, S; BENSCH, PA; KUIJPER, JL; SHEPPARD, PO; SPRECHER, CA; OHARA, PJ; FOSTER, D; WALKER, KM; CHEN, LHJ; MCKERNAN, PA; KINDSVOGEL, W			EXPRESSION CLONING AND SIGNALING PROPERTIES OF THE RAT GLUCAGON RECEPTOR	SCIENCE			English	Article							ADENYL CYCLASE SYSTEM; PLASMA MEMBRANES; HEPATOCYTES; PROTEIN; TRANSDUCTION; BINDING; LIVER	Glucagon and the glucagon receptor are a primary source of control over blood glucose concentrations and are especially important to studies of diabetes in which the loss of control over blood glucose concentrations clinically defines the disease. A complementary DNA clone for the glucagon receptor was isolated by an expression cloning strategy, and the receptor protein was expressed in several kidney cell lines. The cloned receptor bound glucagon and caused an increase in the intracellular concentration of adenosine 3', 5'-monophosphate (cAMP). The cloned glucagon receptor also transduced a signal that led to an increased concentration of intracellular calcium. The glucagon receptor is similar to the calcitonin and parathyroid hormone receptors. It can transduce signals leading to the accumulation of two different second messengers, cAMP and calcium.	ZYMOGENET INC,4225 ROOSEVELT WAY NE,SEATTLE,WA 98105	Zymogenet Inc.								ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAREST R, 1983, J BIOL CHEM, V258, P8769; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK L, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGNYPOURMIR I, 1989, ENDOCRINOLOGY, V124, P2635, DOI 10.1210/endo-124-5-2635; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; POHL SL, 1971, J BIOL CHEM, V246, P1849; RODBELL M, 1971, J BIOL CHEM, V246, P1861; ROSENBERG G, UNPUB; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; SMITH RE, UNPUB, P54011; SONNE O, 1978, J BIOL CHEM, V253, P3203; SPRECHER C, UNPUB; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNGER RH, 1992, TXB ENDOCRINOLOGY, P1255; UNGER RH, 1990, DIABETES MELLITUS TH; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0	28	385	408	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1614	1616		10.1126/science.8384375	http://dx.doi.org/10.1126/science.8384375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8384375				2022-12-24	WOS:A1993KR54300040
J	WEIDMAN, P; ROTH, R; HEUSER, J				WEIDMAN, P; ROTH, R; HEUSER, J			GOLGI MEMBRANE DYNAMICS IMAGED BY FREEZE-ETCH ELECTRON-MICROSCOPY - VIEWS OF DIFFERENT MEMBRANE COATINGS INVOLVED IN TUBULATION VERSUS VESICULATION	CELL			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; TRANSPORT VESICLES; COATED VESICLES; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; BETA-COP; CLATHRIN; BINDING; STACK	We used high resolution three-dimensional electron microscopy to visualize Golgi cisternal structure and analyze morphological transitions induced by various in vitro incubations. Our images show that Golgi cisternae have two distinct surface coatings with different distributions and apparent functions. The first type, probably a coatomer coat, consists of tightly packed approximately 10 nm surface particles. These are localized exclusively to sites of membrane budding and are as intimately involved in bud formation as clathrin or caveolin coats. When this coating is exaggerated by GTPgammaS, the periphery of all cisternae is partitioned into coated vesicles that remain attached at their sites of formation. A second, much finer coating is evenly distributed over the periphery of cisternae, including tubules enclosing the fenestrae. It appears to stabilize the membrane curvature associated with tubules and edges. These different coatings must be considered in further attempts to unravel Golgi membrane trafficking mechanisms.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	WEIDMAN, P (corresponding author), ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104, USA.				NIGMS NIH HHS [5R01GM29647] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN V J, 1988, Journal of Cell Biology, V107, p759A; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; Beams H. W., 1968, International Review of Cytology, V23, P209, DOI 10.1016/S0074-7696(08)60273-9; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CLUETT EB, 1993, J CELL BIOL, V120, P709; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCMORROW I, 1990, J CELL BIOL, V110, P1513, DOI 10.1083/jcb.110.5.1513; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1991, CELL, V64, P1183; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P215; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1992, CELL, V2, P381; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	44	117	120	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					123	133		10.1016/S0092-8674(05)80089-3	http://dx.doi.org/10.1016/S0092-8674(05)80089-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402891				2022-12-24	WOS:A1993MB66700013
J	BARLOWE, C; SCHEKMAN, R				BARLOWE, C; SCHEKMAN, R			SEC12 ENCODES A GUANINE-NUCLEOTIDE-EXCHANGE FACTOR ESSENTIAL FOR TRANSPORT VESICLE BUDDING FROM THE ER	NATURE			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; BREFELDIN-A; YEAST; RAS; ARF	IN yeast a type II integral membrane glycoprotein that is essential for transport vesicle budding from the endoplasmic reticulum (ER) is encoded by SEC12 (refs 1-3). SAR1 was discovered as a multi-copy copy suppressor of the sec12-1ts strain and encodes a GTPase of M(r) 21,000 (21K) also essential for vesicle budding from the ER4,5. Sar1 is a peripherally associated membrane protein which shows enhanced membrane binding in cells containing elevated levels of Sec12 protein (refs 6, 7). We show here that a purified fragment of Sec12 promotes guanine-nucleotide dissociation from Sar1 whereas the purified mutant Sec12-1 has only 15% of the wild-type activity. GTP hydrolysis by Sar1 is not enhanced by Sec12, but is stimulated more than 50-fold by a mixture of Sec12 and Sec23, a GTPase-activating protein specific for Sar1 (ref. 8). We propose that Sec12 catalyses Sar1 guanine-nucleotide exchange in a process that recruits Sar1 to a vesicle formation site on the ER membrane.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								BARLOWE C, 1993, J BIOL CHEM, V268, P873; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SALAMA N, IN PRESS EMBO J; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIKORSKI RS, 1989, GENETICS, V122, P19; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; WUESTENHUBE LJ, 1992, METHOD ENZYMOL, V219, P212; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	28	370	377	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					347	349		10.1038/365347a0	http://dx.doi.org/10.1038/365347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377826				2022-12-24	WOS:A1993LY49600054
J	MAYNARD, N; BIHARI, D; BEALE, R; SMITHIES, M; BALDOCK, G; MASON, R; MCCOLL, I				MAYNARD, N; BIHARI, D; BEALE, R; SMITHIES, M; BALDOCK, G; MASON, R; MCCOLL, I			ASSESSMENT OF SPLANCHNIC OXYGENATION BY GASTRIC TONOMETRY IN PATIENTS WITH ACUTE CIRCULATORY FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; TUMOR NECROSIS FACTOR; INTRAMURAL PH; TISSUE OXYGENATION; PREDICTIVE VALUE; INTRAMUCOSAL PH; SEPSIS; INFECTION; ENDOTOXEMIA; CONSUMPTION	Objective.- To investigate the importance of splanchnic ischemia in patients with acute circulatory failure by comparing gastric intramucosal pH as measured by tonometry with conventional methods of assessing adequacy of tissue oxygenation. Design.- Prospective cohort of patients with acute circulatory failure in first 24 hours after admission to the intensive care unit. Setting.- Two general intensive care units in London, England. Patients.- Consecutive sample of 83 patients of varying diagnostic categories that required pulmonary artery catheterization. Main Outcome Measures.- Gastric intramucosal pH and hemodynamic, oxygen transport, and metabolic variables were measured on admission and at 12 hours and 24 hours after admission. Prediction of outcome (death or survival) by each measurement was assessed by sensitivity, specificity, and logistic regression analysis. Results.- Mean 24-hour Acute Physiology and Chronic Health Evaluation (APACHE II) score was 20.3. There were significant differences in mean gastric intramucosal pH between survivors and nonsurvivors on admission and at 24 hours, (7.40 vs 7.28, 7.40 vs 7.24, respectively; P<.001). Admission heart rate was higher (116 vs 101 beats per minute; P<.003) and mean arterial pressure lower (82 vs 97 mm Hg; P<.01) in nonsurvivors. There were no consistent differences in cardiac index, oxygen delivery, and oxygen uptake between survivors and nonsurvivors. Admission arterial pH was significantly lower (7.3 vs 7.36; P<.003), base excess more negative (-5.3 vs - 1.9; P<.001), and lactate concentration higher (3.14 vs 1.91 mmol/L; P<.03) in nonsurvivors. Gastric intramucosal pH had a sensitivity of 88% for predicting death and a likelihood ratio of 2.32, higher than for any other variable. Only gastric intramucosal pH at 24 hours independently predicted outcome. Conclusions.- Gastric intramucosal pH was the most reliable indicator of adequacy of tissue oxygenation in this group of patients. Inadequate regional blood flow as detected by a reduction in gastric intramucosal pH, but not by systemic measures, is an important contributor to morbidity and mortality in intensive care units.	GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND; LEWISHAM HOSP,DEPT INTENS CARE,LONDON SE13 6LH,ENGLAND; GUYS HOSP,DEPT SURG,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; ASTIZ M, 1988, CIRC SHOCK, V26, P311; BAILEY RW, 1982, SURG FORUM, V33, P194; BALDOCK G, 1991, SURV ANAESTHESIOL, V35, P178; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BERGOFSKY EH, 1964, J CLIN INVEST, V43, P193, DOI 10.1172/JCI104904; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BIHARI D, 1983, CARE CRITICALLY ILL, P189; BIHARI D, 1991, SURV ANAESTHESIOL, V35, P182; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOYD O, 1993, LANCET, V341, P142, DOI 10.1016/0140-6736(93)90005-2; CERRA FB, 1987, SURGERY, V101, P1; CERRA FB, 1988, PERSPECTIVES CRITICA, V1, P30; CUNNINGHAM J A, 1987, Current Surgery, V44, P229; DAHN MS, 1988, INTENS CARE MED, V14, P373, DOI 10.1007/BF00262891; DAHN MS, 1987, SURGERY, V101, P69; DANTZKER D, 1989, CRIT CARE CLIN, V5, P81; DAWSON AM, 1965, NATURE, V206, P943, DOI 10.1038/206943b0; DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1982, J SURG RES, V33, P39, DOI 10.1016/0022-4804(82)90007-5; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; FINK MP, 1991, CRIT CARE MED, V19, P627, DOI 10.1097/00003246-199105000-00009; GILMOUR DG, 1980, BRIT J SURG, V67, P82, DOI 10.1002/bjs.1800670204; GRUM CM, 1984, J APPL PHYSIOL, V56, P1065, DOI 10.1152/jappl.1984.56.4.1065; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; GYS T, 1988, CRIT CARE MED, V16, P1222, DOI 10.1097/00003246-198812000-00009; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; MAYNARD ND, 1991, BRIT MED J, V303, P1007, DOI 10.1136/bmj.303.6809.1007; McIver MA, 1926, AM J PHYSIOL, V76, P92, DOI 10.1152/ajplegacy.1926.76.1.92; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MEAKINS JL, 1980, SURG CLIN N AM, V60, P117; MEAKINS JL, 1989, SPLANCHNIC ISCHEMIA, P339; MICHIE HR, 1989, BRIT J SURG, V76, P670, DOI 10.1002/bjs.1800760706; MOVAT HZ, 1987, FASEB J, V46, P97; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; PAYNE CD, 1986, GLIM SYSTEM RELEASE; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1989, CLIN ASPECTS O2 TRAN, P102; TAKALA J, 1991, CLIN NUTR, V10, pS3; VINCENT JL, 1990, INTENS CARE MED, V16, pS145, DOI 10.1007/BF01785244; WARDLE EN, 1987, LIVER, V7, P63; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; Wright CI, 1934, J GEN PHYSIOL, V17, P657, DOI 10.1085/jgp.17.5.657	52	322	337	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1203	1210		10.1001/jama.270.10.1203	http://dx.doi.org/10.1001/jama.270.10.1203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355382				2022-12-24	WOS:A1993LV64900025
J	KOMORI, T; OKADA, A; STEWART, V; ALT, FW				KOMORI, T; OKADA, A; STEWART, V; ALT, FW			LACK OF N-REGIONS IN ANTIGEN RECEPTOR VARIABLE REGION GENES OF TDT-DEFICIENT LYMPHOCYTES	SCIENCE			English	Article							T-CELL RECEPTOR; GAMMA-DELTA; JUNCTIONAL DIVERSITY; B-CELL; V(D)J RECOMBINATION; CHAIN DIVERSITY; STEM-CELLS; EXPRESSION; INSERTION; SEGMENTS	During the assembly of immunoglobulin and T cell receptor variable region genes from variable (V), diversity (D), and joining (J) segments, the germline-encoded repertoire is further diversified by processes that include the template-independent addition of nucleotides (N regions) at gene segment junctions. Terminal deoxynucleotidyl transferase (TdT)-deficient lymphocytes had no N regions in their variable region genes, which shows that TdT is responsible for N region addition. In addition, certain variable region genes appeared at increased frequency in TdT-deficient thymocytes, which indicates that N region addition also influences repertoire development by alleviating sequence-specific constraints imposed on the joining of particular V, D, and J segments.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	KOMORI, T (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR LK, 1991, J IMMUNOL, V146, P1348; ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; BANGS LA, 1991, J IMMUNOL, V146, P1996; BOGUE M, 1991, EMBO J, V10, P3647, DOI 10.1002/j.1460-2075.1991.tb04931.x; BOLLUM JF, 1974, ENZYMES, V10, P145; CARLSSON L, 1990, INT IMMUNOL, V2, P639, DOI 10.1093/intimm/2.7.639; CARLSSON L, 1992, INT IMMUNOL, V4, P549, DOI 10.1093/intimm/4.5.549; CHANG LMS, 1971, BIOCHEM BIOPH RES CO, V44, P124, DOI 10.1016/S0006-291X(71)80167-5; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COLEMAN MS, 1974, P NATL ACAD SCI USA, V71, P4404, DOI 10.1073/pnas.71.11.4404; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; ELLIOT JF, 1968, NATURE, V331, P627; FEENEY AJ, 1991, J EXP MED, V174, P115, DOI 10.1084/jem.174.1.115; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; GEORGE JF, 1992, J IMMUNOL, V148, P1230; GILLFILLAN S, 1993, SCIENCE, V261, P1175; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KOMORI T, UNPUB; KUNG PC, 1976, J EXP MED, V141, P855; KYES S, 1991, P NATL ACAD SCI USA, V88, P7830, DOI 10.1073/pnas.88.17.7830; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCAFFREY R, 1973, P NATL ACAD SCI USA, V70, P36; MCCORMACK WT, 1991, P NATL ACAD SCI USA, V88, P7699, DOI 10.1073/pnas.88.17.7699; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; SCHWAGER J, 1991, EMBO J, V10, P2461, DOI 10.1002/j.1460-2075.1991.tb07785.x; SILVERSTONE AE, 1976, J EXP MED, V144, P544; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TONEGAWA S, 1983, NATURE, V302; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	50	382	387	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1171	1175		10.1126/science.8356451	http://dx.doi.org/10.1126/science.8356451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356451				2022-12-24	WOS:A1993LU58600033
J	WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN				WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN			JAK2 ASSOCIATES WITH THE ERYTHROPOIETIN RECEPTOR AND IS TYROSINE-PHOSPHORYLATED AND ACTIVATED FOLLOWING STIMULATION WITH ERYTHROPOIETIN	CELL			English	Article							SIGNAL TRANSDUCTION; CYTOPLASMIC REGION; PROTEIN-KINASE; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; IL-2 RECEPTOR; BETA-CHAIN; FAMILY; GROWTH	Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells through interaction with its receptor (EPOR). Although EPOR is a member of the cytokine receptor superfamily and lacks a kinase domain, EPO induces tyrosine phosphorylation, which is correlated with gene transcription and mitogenesis. Here we demonstrate that EPO induces tyrosine phosphorylation of JAK2 kinase and activates its in vitro autophosphorylation. Using EPOR mutants, phosphorylation and activation of kinase activity correlate with the induction of mitogenesis. Furthermore, JAK2 physically associates with a membrane-proximal region of the EPOR cytoplasmic domain that is required for biological activity. The results support the hypothesis that JAK2 is the kinase that couples EPO binding to tyrosine phosphorylation and mitogenesis.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; TOKYO MED & DENT UNIV, DEPT MED 1, TOKYO 113, JAPAN	New York University; Tokyo Medical & Dental University (TMDU)	WITTHUHN, BA (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA.		witthuhn, bruce/GSE-3193-2022	Miura, Osamu/0000-0002-0981-3054; Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1993, IN PRESS SEM IMMUNOL; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KRANTZ SB, 1991, BLOOD, V77, P419; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MANO H, 1993, ONCOGENE, V8, P417; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TORIGOE T, 1992, BLOOD, V80, P617; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	53	1092	1129	3	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					227	236		10.1016/0092-8674(93)90414-L	http://dx.doi.org/10.1016/0092-8674(93)90414-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343951				2022-12-24	WOS:A1993LP72600004
J	EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y				EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y			ADMINISTRATION OF VITAMIN-K TO NEWBORN-INFANTS AND CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							REGISTRY	Objectives-To investigate whether childhood cancer is associated with intramuscular administration of vitamin K to newborn infants. Design-Routines for administration of vitamin K to infants born after normal deliveries during 1973-89 were obtained from maternity hospitals. Occurrence of cancer up to the end of 1991 was identified by comparing these records with the national cancer registry. Adherence to the routine method of administering vitamin K was checked with the medical records of a sample of 396 infants (196 who had developed childhood cancer and 200 controls). Setting-All maternity hospitals in Sweden. Subjects-1 384 424 full term infants born after non-instrumental deliveries, 1 085 654 of whom were born in units where vitamin K was routinely given by intramuscular injection and 272 080 of whom were born where it was given orally. Main outcome measures-Odds ratios for cancer after intramuscular administration of vitamin K versus oral administration after stratification for year of birth. Results-Adherence to routine method of administering vitamin K was 92% in the 235 cases where individual information could be found. The risk of cancer after intramuscular administration of vitamim K was not elevated compared with that after oral administration: odds ratios of 1.01 (95% confidence interval 0.88 to 1.17) for all childhood cancers and 0.90 (0.70 to 1.16) for childhood leukaemia. Conclusions-The alleged association between intramuscular vitamin K prophylaxis to newborn infants and childhood cancer could not be verified in the present study of full term infants born after non-instrumental delivery.	LUND UNIV,DEPT EMBRYOL,BISKOPSGATAN 7,S-22362 LUND,SWEDEN; NATL BOARD HLTH,DEPT PUBL HLTH & EPIDEMIOL,S-10601 STOCKHOLM,SWEDEN; LINKOPING UNIV HOSP,DEPT PAEDIAT,S-58185 LINKOPING,SWEDEN	Lund University; National Board of Health & Welfare; Linkoping University								CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Ericson A, 1991, Acta Obstet Gynecol Scand, V70, P111, DOI 10.3109/00016349109006191; FORSBERG JG, 1990, APMIS, V98, P37, DOI 10.1111/j.1699-0463.1990.tb00999.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HULL D, 1992, BRIT MED J, V305, P326, DOI 10.1136/bmj.305.6849.326; HULL D, 1992, BMJ, V305, P709; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; ZACK M, 1991, CANCER RES, V51, P3696; 1989, CANCER REGISTRY CANC	10	82	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					89	91		10.1136/bmj.307.6896.89	http://dx.doi.org/10.1136/bmj.307.6896.89			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343734	Bronze, Green Published			2022-12-24	WOS:A1993LM58500020
J	JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T				JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T			MANAGEMENT OF RAISED BLOOD-PRESSURE IN NEW-ZEALAND - A DISCUSSION DOCUMENT	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STROKE	A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.	UNIV AUCKLAND,DEPT GEN PRACTICE,GOODFELLOW UNIT,AUCKLAND,NEW ZEALAND; ROTHERHAM MED CTR,CANTERBURY,NEW ZEALAND; HOKIANGA HLTH SERV,RAWENE,NEW ZEALAND; WAITANGIRUA HLTH CTR,WELLINGTON,NEW ZEALAND; UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV OTAGO,WELLINGTON SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND	University of Auckland; University of Auckland; University of Otago	JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Maling, Tim/0000-0002-5994-479X				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JM, 1987, LANCET, V1, P581; KAWACHI I, 1990, SOC SCI MED, V31, P1239, DOI 10.1016/0277-9536(90)90130-K; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RUSSEL D, 1991, LIFE NZ SURVEY COMMI; 1988, EUR HEART J, V9, P8; 1989, BMJ, V298, P694; 1988, ARCH INTERN MED, V148, P1023; 1989, J HYPERTENS, V7, P689	12	230	233	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					107	110		10.1136/bmj.307.6896.107	http://dx.doi.org/10.1136/bmj.307.6896.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343706	Green Published, Bronze			2022-12-24	WOS:A1993LM58500029
J	TORRES, BA; GRIGGS, ND; JOHNSON, HM				TORRES, BA; GRIGGS, ND; JOHNSON, HM			BACTERIAL AND RETROVIRAL SUPERANTIGENS SHARE A COMMON BINDING REGION ON CLASS-II MHC ANTIGENS	NATURE			English	Article							STAPHYLOCOCCAL ENTEROTOXIN-A; MAMMARY-TUMOR VIRUS; HLA-DR; MOLECULES; PEPTIDES; SURFACE; CELLS	STAPHYLOCOCCAL enterotoxin A (SEA), one of the most potent T-cell mitogens known, has been classified as a bacterial superantigen on the basis of ability to stimulate Vbeta-specific T-cell subsets1. SEA interacts with class II major histocompatibility complex (MHC) antigens on antigen-presenting cells and the T-cell antigen receptor (TCR) on T cells2-4, resulting in a ternary complex of MHC-SEA-TCR. Mls antigens are known to be products of mouse mammary tumour virus (MMTV)5,6, and it has been reported that two exogenous strains of MMTV encode retroviral superantigens in the open reading frames of the 3' long terminal repeat of the viral genome7,8; however, no binding of the putative MMTV superantigen to either MHC antigens or TCR has been demonstrated. Here we use synthetic peptides to identify a site on the MMTV-1 superantigen that binds to class II MHC antigens. The site is encompassed by amino-acid residues 76-119 of the MMTV-1 superantigen. Direct binding and competition experiments show that the MMTV superantigen and SEA bind to at least one common region on class II MHC antigens.			TORRES, BA (corresponding author), UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611, USA.							ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER H, 1989, J IMMUNOL, V142, P3151; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GRIGGS ND, 1992, J IMMUNOL, V148, P2516; JOHNSON HM, 1991, FASEB J, V5, P2706, DOI 10.1096/fasebj.5.12.1916093; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LEE JM, 1990, J IMMUNOL, V145, P3360; MAGAZINE HI, 1988, P NATL ACAD SCI USA, V85, P1237, DOI 10.1073/pnas.85.4.1237; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PONTZER CH, 1991, P NATL ACAD SCI USA, V88, P125, DOI 10.1073/pnas.88.1.125; PONTZER CH, 1992, P NATL ACAD SCI USA, V89, P7727, DOI 10.1073/pnas.89.16.7727; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; RUSSELL JK, 1990, BIOCHEM BIOPH RES CO, V168, P696, DOI 10.1016/0006-291X(90)92377-C; RUSSELL JK, 1991, P NATL ACAD SCI USA, V88, P7228, DOI 10.1073/pnas.88.16.7228; SETTE A, 1989, J IMMUNOL, V142, P35; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R	22	32	33	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					152	154		10.1038/364152a0	http://dx.doi.org/10.1038/364152a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8391645				2022-12-24	WOS:A1993LL36700051
J	PORTER, RK; BRAND, MD				PORTER, RK; BRAND, MD			BODY-MASS DEPENDENCE OF H+ LEAK IN MITOCHONDRIA AND ITS RELEVANCE TO METABOLIC-RATE	NATURE			English	Article							RELATIVE PROTON STOICHIOMETRIES; INNER MEMBRANE; LIVER-MITOCHONDRIA; PERMEABILITY; FORCE; CONDUCTANCE; PUMPS	THE standard metabolic rate of an animal is the rate of heat production under conditions that minimize known extra requirements for energy1,2. In tissues and cells from aerobic organisms, energy expenditure can conveniently be measured as oxygen consumption3,4. Measurements made using isolated rat hepatocytes have shown that a significant contribution to resting oxygen consumption (and hence heat production) is made by a futile cycle of proton pumping and proton leak across the mitochondrial inner membrane5. Two important factors affecting standard metabolic rate, thyroid status and phylogeny, also affect the proton permeability5-10. A third major factor affecting standard metabolic rate is body mass11,12. Here we show that proton leak decreases with increasing body mass in mammals. We suggest that differences in proton leak may partly explain the differences in standard metabolic rate between mammals of different mass.			PORTER, RK (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153; Porter, Richard/0000-0001-9854-5161				BLAXTER KL, 1989, ENERGY METABOLISM RU; BRAND MD, 1991, BIOCHEM J, V275, P81, DOI 10.1042/bj2750081; BRAND MD, 1990, J THEOR BIOL, V145, P267, DOI 10.1016/S0022-5193(05)80131-6; BRAND MD, 1992, EUR J BIOCHEM, V206, P775, DOI 10.1111/j.1432-1033.1992.tb16984.x; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; BRAND MD, 1992, EBEC SHORT REP, V7, P64; BRODY S, 1932, U MISSOURI AGR EXP S, V166, P89; BRODY S, 1951, BIOENERGETICS GROWTH; BROWN GC, 1989, J BIOL CHEM, V264, P14704; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1059, P55, DOI 10.1016/S0005-2728(05)80187-2; Calder WA., 1984, SIZE FUNCTION LIFE H; ELSE PL, 1985, AM J PHYSIOL, V248, pR415, DOI 10.1152/ajpregu.1985.248.4.R415; HAFNER RP, 1988, EUR J BIOCHEM, V178, P511, DOI 10.1111/j.1432-1033.1988.tb14477.x; HAFNER RP, 1989, FEBS LETT, V248, P175, DOI 10.1016/0014-5793(89)80455-7; HAFNER RP, 1991, BIOCHEM J, V275, P75, DOI 10.1042/bj2750075; HORRUM MA, 1990, MOL CELL ENDOCRINOL, V68, P137, DOI 10.1016/0303-7207(90)90186-C; Jansky L, 1965, ACTA U CAROL BIOL, V1, P1; Kleiber M, 1941, P SOC EXP BIOL MED, V48, P419, DOI 10.3181/00379727-48-13340; Kleiber M, 1961, FIRE LIFE; KLEIBER MAX, 1932, HILGARDIA, V6, P315; KREBS HA, 1950, BIOCHIM BIOPHYS ACTA, V4, P249, DOI 10.1016/0006-3002(50)90032-1; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; MITCHELL P, 1967, BIOCHEM J, V105, P1147, DOI 10.1042/bj1051147; NOBES CD, 1990, J BIOL CHEM, V265, P12903; SMITH RE, 1955, ANN NY ACAD SCI, V62, P403; [No title captured]	26	211	224	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					628	630		10.1038/362628a0	http://dx.doi.org/10.1038/362628a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8385274				2022-12-24	WOS:A1993KX43800046
J	ZHANG, SLJ; JACKSON, MB				ZHANG, SLJ; JACKSON, MB			GABA-ACTIVATED CHLORIDE CHANNELS IN SECRETORY NERVE-ENDINGS	SCIENCE			English	Article							GAMMA-AMINOBUTYRIC-ACID; SENSORY NEURONS; PATCH-CLAMP; SYNAPTIC TRANSMISSION; TRANSMITTER RELEASE; PYRAMIDAL CELLS; SPINAL NEURONS; TERMINALS; RAT; INHIBITION	Neurotransmitters acting on presynaptic terminals regulate synaptic transmission and plasticity. Because of the difficulty of direct electrophysiological recording from small presynaptic terminals, little is known about the ion channels that mediate these actions or about the mechanisms by which transmitter secretion is altered. The patch-clamp technique is used to show that the predominant inhibitory presynaptic neurotransmitter, gamma-aminobutyric acid (GABA), activates a GABA(A) receptor and gates a chloride channel in the membranes of peptidergic nerve terminals of the posterior pituitary. The opening of a chloride channel by GABA weakly depolarizes the nerve terminal membrane and blocks action potentials. In this way, GABA limits secretion by retarding the spread of excitation into the terminal arborization.	UNIV WISCONSIN,SCH MED,CTR NEUROSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	ZHANG, SLJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30016] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; BIELEFELDT K, 1992, J PHYSIOL-LONDON, V458, P41, DOI 10.1113/jphysiol.1992.sp019405; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BOWERY N, 1989, TRENDS PHARMACOL SCI, V10, P401, DOI 10.1016/0165-6147(89)90188-0; Davidoff RA, 1985, NEUROTRANSMITTER ACT, P3; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; GAINER H, 1986, NEUROENDOCRINOLOGY, V43, P557, DOI 10.1159/000124582; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JACKSON MB, 1982, J NEUROSCI, V2, P889; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; KUFFLER SW, 1984, NEURON BRAIN; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LIN JW, 1988, J NEUROSCI, V8, P1313; NEWBERRY NR, 1985, J PHYSIOL-LONDON, V360, P161, DOI 10.1113/jphysiol.1985.sp015610; NORDMANN JJ, 1977, J ANAT, V123, P213; OERTEL WH, 1982, P NATL ACAD SCI-BIOL, V79, P675, DOI 10.1073/pnas.79.2.675; RUDOMIN P, 1990, TRENDS NEUROSCI, V13, P499, DOI 10.1016/0166-2236(90)90084-N; SARIDAKI E, 1989, J ENDOCRINOL, V121, P343, DOI 10.1677/joe.0.1210343; TACHIBANA M, 1987, P NATL ACAD SCI USA, V84, P3501, DOI 10.1073/pnas.84.10.3501; TALEB O, 1987, PFLUG ARCH EUR J PHY, V409, P620, DOI 10.1007/BF00584663; THORN PJ, 1991, J PHYSIOL-LONDON, V432, P283; TOMIKO SA, 1983, NATURE, V301, P706, DOI 10.1038/301706a0; VINCENT SR, 1982, NEUROENDOCRINOLOGY, V34, P117, DOI 10.1159/000123288	34	145	151	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					531	534		10.1126/science.8380942	http://dx.doi.org/10.1126/science.8380942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8380942				2022-12-24	WOS:A1993KJ07900040
J	KLEIN, R; SMEYNE, RJ; WURST, W; LONG, LK; AUERBACH, BA; JOYNER, AL; BARBACID, M				KLEIN, R; SMEYNE, RJ; WURST, W; LONG, LK; AUERBACH, BA; JOYNER, AL; BARBACID, M			TARGETED DISRUPTION OF THE TRKB NEUROTROPHIN RECEPTOR GENE RESULTS IN NERVOUS-SYSTEM LESIONS AND NEONATAL DEATH	CELL			English	Article							TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; EMBRYONIC STEM-CELLS; GROWTH-FACTOR FAMILY; SENSORY NEURONS; PROLIFERATION; MOTONEURONS; EXPRESSION; SURVIVAL; MUTATION	We have generated mice carrying a germline mutation in the tyrosine kinase catalytic domain of the trkB gene. This mutation eliminates expression of gp145trkB, a protein-tyrosine kinase that serves as the signaling receptor for two members of the nerve growth factor family of neurotrophins, brain-derived neurotrophic factor and neurotrophin-4. Mice homozygous for this mutation, trkB(TK) (-/-), develop to birth. However, these animals do not display feeding activity, and most die by P1. Neuroanatomical examination of trkB(TK) (-/-) mice revealed neuronal deficiencies in the central (facial motor nucleus and spinal cord) and peripheral (trigeminal and dorsal root ganglia) nervous systems. These findings illustrate the role of the gp145trkB protein-tyrosine kinase receptor in the ontogeny of the mammalian nervous system.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X5, ON, CANADA	Bristol-Myers Squibb; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Wurst, Wolfgang/0000-0003-4422-7410; Smeyne, Richard/0000-0002-8459-5472				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BARBACID M, 1993, ONCOGENE, V8, P2033; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EASTER SS, 1993, J NEUROSCI, V13, P285; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEDREEN JC, 1985, J HISTOCHEM CYTOCHEM, V33, P134, DOI 10.1177/33.2.2578498; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAMBALLE F, 1993, IN PRESS J NEUROSCI; LAMBALLE F, 1993, IN PRESS EMBO J, V13; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TESSAROLLO L, 1993, DEVELOPMENT, V118, P463; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VOGEL KS, 1991, NEURON, V7, P819, DOI 10.1016/0896-6273(91)90284-7; WURST W, 1993, GENE TARGETING PRACT; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	50	579	585	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					113	122		10.1016/0092-8674(93)90683-H	http://dx.doi.org/10.1016/0092-8674(93)90683-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402890				2022-12-24	WOS:A1993MB66700012
J	MATSUYAMA, T; KIMURA, T; KITAGAWA, M; PFEFFER, K; KAWAKAMI, T; WATANABE, N; KUNDIG, TM; AMAKAWA, R; KISHIHARA, K; WAKEHAM, A; POTTER, J; FURLONGER, CL; NARENDRAN, A; SUZUKI, H; OHASHI, PS; PAIGE, CJ; TANIGUCHI, T; MAK, TW				MATSUYAMA, T; KIMURA, T; KITAGAWA, M; PFEFFER, K; KAWAKAMI, T; WATANABE, N; KUNDIG, TM; AMAKAWA, R; KISHIHARA, K; WAKEHAM, A; POTTER, J; FURLONGER, CL; NARENDRAN, A; SUZUKI, H; OHASHI, PS; PAIGE, CJ; TANIGUCHI, T; MAK, TW			TARGETED DISRUPTION OF IRF-1 OR IRF-2 RESULTS IN ABNORMAL TYPE-I IFN GENE INDUCTION AND ABERRANT LYMPHOCYTE DEVELOPMENT	CELL			English	Article							INTERFERON-BETA GENE; REGULATORY FACTOR-I; MEDIATE VIRUS INDUCIBILITY; T-CELLS; TRANSCRIPTIONAL ACTIVATOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; STEM-CELLS; EXPRESSION; MURINE	Interferon regulatory factor 1 (IRF-1), a transcriptional activator, and its antagonistic repressor, IRF-2, were originally identified as regulators of the type I interferon (IFN) system. We have generated mice deficient in either IRF-1 or IRF-2 by gene targeting in embryonic stem cells. IRF-1-deficient fibroblasts lacked the normally observed type I IFN induction by poly(I):poly(C), while they induced type I IFN to similar levels as the wild type following Newcastle disease virus (NDV) infection. In contrast, IRF-2-deficient fibroblasts showed up-regulated type I IFN induction by NDV infection. A profound reduction of TCRalphabeta+CD4-CD8+ T cells in IRF-1-deficient mice, with a thymocyte developmental defect, reveals a critical role for IRF-1 in T cell development. IRF-2-deficient mice exhibited bone marrow suppression of hematopoiesis and B lymphopoiesis and mortality following lymphocytic choriomeningitis virus infection.	UNIV TORONTO, DEPT IMMUNOL & MED BIOPHYS, ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Osaka University	MATSUYAMA, T (corresponding author), UNIV TORONTO, DEPT IMMUNOL & MED BIOPHYS, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA.		Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Ohashi, Pamela S./0000-0003-2915-9317; Kimura, Tohru/0000-0001-9227-0996; Pfeffer, Klaus/0000-0002-5652-6330				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AGUI T, 1991, EUR J IMMUNOL, V21, P2277, DOI 10.1002/eji.1830210942; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; Demaeyer E., 1988, INTERFERONS OTHER RE; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; EVERSON MP, 1990, CELL IMMUNOL, V127, P470, DOI 10.1016/0008-8749(90)90147-J; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUPTA SC, 1986, P NATL ACAD SCI USA, V83, P2604, DOI 10.1073/pnas.83.8.2604; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hogan B., 1986, MANIPULATING MOUSE E; IVANOV V, 1992, INT IMMUNOL, V4, P729, DOI 10.1093/intimm/4.7.729; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEHMANNGRUBE F, 1982, MOUSE BIOMEDICAL RES, V2, P231; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEVY D, 1990, NEW BIOL, V2, P383; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NARENDRAN A, 1992, EUR J IMMUNOL, V22, P1001, DOI 10.1002/eji.1830220419; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P649, DOI 10.1002/eji.1830190412; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; PAIGE CJ, 1983, NATURE, V302, P711, DOI 10.1038/302711a0; PAIGE CJ, 1982, J IMMUNOL METHODS, V52, P51, DOI 10.1016/0022-1759(82)90349-0; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCOLLAY R, 1984, IMMUNOL REV, V82, P79, DOI 10.1111/j.1600-065X.1984.tb01118.x; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STEWART WE, 1971, J VIROL, V7, P792, DOI 10.1128/JVI.7.6.792-801.1971; STEWART WE, 1979, INTERFERON SYSTEM, P233; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VILCEK J, 1990, HDB EXPT PHARM, P3; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; YOSHITAKE I, 1986, NUCLEIC ACIDS RES, V14, P10117; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1992, CURR OPIN IMMUNOL, V4, P408, DOI 10.1016/S0952-7915(06)80031-2	76	568	578	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					83	97		10.1016/S0092-8674(05)80086-8	http://dx.doi.org/10.1016/S0092-8674(05)80086-8			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402903				2022-12-24	WOS:A1993MB66700010
J	NAMBA, T; SUGIMOTO, Y; NEGISHI, M; IRIE, A; USHIKUBI, F; KAKIZUKA, A; ITO, S; ICHIKAWA, A; NARUMIYA, S				NAMBA, T; SUGIMOTO, Y; NEGISHI, M; IRIE, A; USHIKUBI, F; KAKIZUKA, A; ITO, S; ICHIKAWA, A; NARUMIYA, S			ALTERNATIVE SPLICING OF C-TERMINAL TAIL OF PROSTAGLANDIN-E RECEPTOR SUBTYPE-EP3 DETERMINES G-PROTEIN SPECIFICITY	NATURE			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BOVINE ADRENAL-MEDULLA; PERTUSSIS TOXIN; THROMBOXANE-A2 RECEPTOR; SIGNAL TRANSDUCTION; ADENYLYL CYCLASE; EXPRESSION; CLONING; REGIONS; CDNA	PEPTIDE hormones, neurotransmitters, and autacoids activate a family of seven-transmembrane-domain receptors1. Each of these receptors specifically couples to one of several G proteins, G(s), G(i), G(o) and G(p), to activate a specific second messenger system2. Cell surface receptors for prostanoids have been characterized pharmacologically3 and the complementary DNAs for thromboxane A2 receptor4,5 and the EP3 subtype of the prostaglandin (PG)E receptor6 reveal that they belong to the seven-transmembrane-domain receptor family. The EP3 receptor mediates the diverse physiological actions of PGE2 (ref. 3). Although most of them occur through coupling of the EP3 receptor to G(i) and inhibition of adenylyl cyclase, the EP3-mediated contraction of uterine muscle can only occur by activation of another second messenger pathway7. In chromaffin cells, two different second messenger pathways are activated by PGE2 binding to an apparently single EP3 receptor class8. Here we show that at least four isoforms of the EP3 receptor, which differ only at their C-terminal tails and are produced by alternative splicing, couple to different G proteins to activate different second messenger systems.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAESTHESIA,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Kyoto University; Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; FONG TM, 1992, MOL PHARMACOL, V41, P24; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GOUREAU O, 1992, AM J PHYSIOL, V263, pC257, DOI 10.1152/ajpcell.1992.263.1.C257; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NEGISHI M, 1989, J BIOL CHEM, V264, P3916; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	30	533	544	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					166	170		10.1038/365166a0	http://dx.doi.org/10.1038/365166a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396726				2022-12-24	WOS:A1993LW44200050
J	ARIEFF, AI; AYUS, JC				ARIEFF, AI; AYUS, JC			ENDOMETRIAL ABLATION COMPLICATED BY FATAL HYPONATREMIC ENCEPHALOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PERMANENT BRAIN-DAMAGE; MENORRHAGIA; VASOPRESSIN; SURGERY; WOMEN	Objectives.- To investigate the occurrence of hyponatremic encephalopathy and the effects of therapy for symptomatic hyponatremia on outcome in women undergoing endometrial ablation. Design and Setting.- Consultations from university-affiliated and community hospitals from June 1991 to June 1992. Patients.- Four generally healthy women who underwent elective endometrial ablation for dysfunctional bleeding and developed hyponatremic encephalopathy. Interventions.- Three patients were promptly treated with hypertonic (514 mmol/L) sodium chloride such that the serum sodium level increased from 102 to 123 mmol/L within 24 hours. The fourth patient was not treated until after suffering grand mal seizures followed by respiratory arrest. Main Outcome Measures.- Of the four patients who developed hyponatremic encephalopathy, the diagnosis was established before respiratory arrest occurred in three. The operative procedure was terminated and all three were aggressively treated with intravenous hypertonic sodium chloride. which raised the serum sodium level to modestly hyponatremic levels (120 to 130 mmol/L). All three completely recovered without sequelae. The fourth patient suffered respiratory arrest before therapy could be initiated. The patient remained comatose, and central diabetes mellitus and insipidus developed. She never regained consciousness and died after several days. Autopsy revealed cerebral edema and tonsillar herniation. Results.- The mean (+/-SD) preoperative serum sodium level was 138+/-1 mmol/L; at the time of diagnosis of hyponatremia, it was 107+/-13 mmol/L. In two patients, hyponatremic encephalopathy was diagnosed intraoperatively because of tremulousness and either hypothermia or hypoxemia. In the other two patients, the diagnosis was made postoperatively because of headache, nausea, emesis, and in one of these patients, respiratory arrest. Conclusions.- Women undergoing elective endometrial ablation can develop severe symptomatic hyponatremia, which can be fatal. The presence of symptoms suggesting hypo-osmolality should lead to immediate measurement of plasma sodium level. If hyponatremia with hypo-osmolality is present, early and appropriate therapy for the hyponatremia should be instituted before respiratory insufficiency occurs.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	University of California System; University of California San Francisco; Baylor College of Medicine	ARIEFF, AI (corresponding author), VET AFFAIRS MED CTR,DEPT MED,GERIATR SECT,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIA NIH HHS [R01 AG 08575] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; AYUS JC, IN PRESS ENDOCRINOL; BEAL JL, 1989, CAN J ANAESTH, V36, P278, DOI 10.1007/BF03010765; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; DEUTSCH S, 1966, ANESTHESIOLOGY, V27, P250, DOI 10.1097/00000542-196627030-00003; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; GARLSON KJ, 1993, NEW ENGL J MED, V328, P856; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; LEFLER HT, 1991, OBSTET GYNECOL, V77, P949; LOFFER FD, 1987, OBSTET GYNECOL, V69, P679; OSBORNE GA, 1991, ANAESTH INTENS CARE, V19, P217, DOI 10.1177/0310057X9101900211; PHIPPS JH, 1990, OBSTET GYNECOL, V76, P876, DOI 10.1097/00006250-199011000-00032; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; VANBOVEN MJ, 1989, ANESTHESIOLOGY, V71, P449, DOI 10.1097/00000542-198909000-00023	17	130	132	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1230	1232		10.1001/jama.270.10.1230	http://dx.doi.org/10.1001/jama.270.10.1230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355387				2022-12-24	WOS:A1993LV64900030
J	WILCOX, M; GARDOSI, J; MONGELLI, M; RAY, C; JOHNSON, I				WILCOX, M; GARDOSI, J; MONGELLI, M; RAY, C; JOHNSON, I			BIRTH-WEIGHT FROM PREGNANCIES DATED BY ULTRASONOGRAPHY IN A MULTICULTURAL BRITISH POPULATION	BRITISH MEDICAL JOURNAL			English	Article							LAST MENSTRUAL PERIOD; GESTATIONAL-AGE; BIPARIETAL DIAMETER; ULTRASOUND; GROWTH	Objective-To produce standard curves of birth weight according to gestational age validated by ultrasonography in the British population, with particular reference to the effects of ethnic origin. Design-Retrospective analysis of computerised obstetric database. Setting-Three large maternity units associated with Nottingham University with over 16 000 deliveries a year. Patients-41718 women with ultrasound dated singleton pregnancies and delivery between 168 and 300 days' gestation. Main outcome measures-Length of gestation, ethnic origin, parity, maternal height and weight at booking, smoking during pregnancy; the effect of these variables on birth weight. Results-Birth weights from ultrasound dated pregnancies have a higher population mean and show less flattening of the birthweight curve at term than those of pregnancies dated from menstrual history. Significant differences were observed in mean birth weights of babies of mothers of European origin (3357 g), of Afro-Carribean origin (3173 g), and from the Indian subcontinent (3096 g). There were also significant interethnic differences in length of gestation, parity, maternal height, booking weight, and smoking habit which affected birth weight. The ethnic differences in birth weight were even greater when the effect of smoking was excluded. Conclusions-Birthweight standards require precise dating of pregnancy and should describe the population from which they were derived. In a heterogeneous maternity population the accurate assessment of an individual baby's weight needs to take the factors which affect birthweight standards into consideration.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT OBSTET & GYNAECOL,PERINATAL RES & MONITORING UNIT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Gardosi, Jason/GXN-1375-2022	Gardosi, Jason/0000-0002-3230-1292				ANDERSON HR, 1990, P S EFFECTS SMOKING; CAMPBELL S, 1971, J OBSTET GYN BR COMM, V78, P513; CAMPBELL S, 1985, OBSTET GYNECOL, V65, P613; CAMPBELL S, 1984, REPORT RCOG WORKING; CARHILL R, 1985, DERIVATION EXPLOITAT; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1, P48; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GEIRSSON RT, 1991, ULTRASOUND OBST GYN, V1, P212, DOI 10.1046/j.1469-0705.1991.01030212.x; GEIRSSON RT, 1991, BRIT J OBSTET GYNAEC, V98, P108, DOI 10.1111/j.1471-0528.1991.tb10323.x; GRUNDY MFB, 1978, BRIT J OBSTET GYNAEC, V85, P481, DOI 10.1111/j.1471-0528.1978.tb15618.x; Hall M H, 1990, Paediatr Perinat Epidemiol, V4, P123, DOI 10.1111/j.1365-3016.1990.tb00625.x; HALL MH, 1985, BRIT J OBSTET GYNAEC, V92, P452, DOI 10.1111/j.1471-0528.1985.tb01348.x; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; PERSSON PH, 1983, AM J OBSTET GYNECOL, V146, P942, DOI 10.1016/0002-9378(83)90970-5; PERSSON PH, 1989, FETAL GROWTH, P13; ROBINSON HP, 1975, BRIT J OBSTET GYNAEC, V82, P702, DOI 10.1111/j.1471-0528.1975.tb00710.x; ROEMER VM, 1990, Z GEBURTSH PERINATOL, V194, P241; THOMSON A M, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P903; WALDENSTROM U, 1990, OBSTET GYNECOL, V76, P336; WEINER CP, 1985, OBSTET GYNECOL, V65, P323; WILCOX MA, 1993, BRIT J OBSTET GYNAEC, V100, P342, DOI 10.1111/j.1471-0528.1993.tb12977.x; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 1988, STATISTICAL PACKAGE	23	155	157	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					588	591		10.1136/bmj.307.6904.588	http://dx.doi.org/10.1136/bmj.307.6904.588			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401014	Bronze, Green Published			2022-12-24	WOS:A1993LW14900014
J	FLORESROMO, L; SHIELDS, J; HUMBERT, Y; GRABER, P; AUBRY, JP; GAUCHAT, JF; AYALA, G; ALLET, B; CHAVEZ, M; BAZIN, H; CAPRON, M; BONNEFOY, JY				FLORESROMO, L; SHIELDS, J; HUMBERT, Y; GRABER, P; AUBRY, JP; GAUCHAT, JF; AYALA, G; ALLET, B; CHAVEZ, M; BAZIN, H; CAPRON, M; BONNEFOY, JY			INHIBITION OF AN IN-VIVO ANTIGEN-SPECIFIC IGE RESPONSE BY ANTIBODIES TO CD23	SCIENCE			English	Article							NORMAL HUMAN-LYMPHOCYTES; LOW-AFFINITY RECEPTOR; FC-EPSILON RECEPTORS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; MOLECULAR-STRUCTURE; EXPRESSION; INTERLEUKIN-4; CDNA; INDUCTION	Immunoglobulin E (IgE) mediates many allergic responses. CD23 is a 45-kilodalton type II transmembrane glycoprotein expressed in many cell types. It is a low-affinity IgE receptor and interacts specifically with CD21, thereby modulating IgE production by B lymphocytes in vitro. In an in vivo model of an allergen-specific IgE response, administration of a rabbit polyclonal antibody to recombinant human truncated CD23 resulted in up to 90 percent inhibition of ovalbumin-specific IgE synthesis. Both Fabs and intact IgG inhibited IgE production in vitro and in vivo. Thus, CD23 participates in the regulation of IgE synthesis in vivo and so could be important in allergic disease.	GLAXO INST MOLEC BIOL,CP 674,CH-1228 GENEVA,SWITZERLAND; UNIV CATHOLIQUE LOUVAIN,FAC MED,EXPTL IMMUNOL UNIT,B-1200 BRUSSELS,BELGIUM; CTR IMMUNOL & BIOL PARASITAIRE,CNRS 624,INSERM,U167,F-59019 LILLE,FRANCE	GlaxoSmithKline; Universite Catholique Louvain; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille								ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AUBRY JP, 1993, J IMMUNOL METHODS, V159, P161, DOI 10.1016/0022-1759(93)90154-Y; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BAZIN H, UNPUB; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DELESPESSE G, 1992, IMMUNOL REV, V125, P76; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FISCHER E, 1991, J IMMUNOL, V146, P865; FLORESROMO L, UNPUB; GOLLNICK SO, 1990, J IMMUNOL, V144, P1974; GRABER P, UNPUB; HENCHOZ S, UNPUB; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; KAWABE T, 1988, J IMMUNOL, V141, P1376; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; KOLB JP, 1991, ADV PROSTAGLANDIN TH, P997; LUDIN C, 1987, EMBO J, V6, P109, DOI 10.1002/j.1460-2075.1987.tb04726.x; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MANOUVRIEZ P, 1984, J IMMUNOL, V133, P3274; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; PRINZ JC, 1990, EUR J IMMUNOL, V20, P1259, DOI 10.1002/eji.1830200610; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; YODOI J, 1979, J IMMUNOL, V123, P455; YUKAWA K, 1987, J IMMUNOL, V138, P2576	34	112	120	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1038	1041		10.1126/science.8351517	http://dx.doi.org/10.1126/science.8351517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351517				2022-12-24	WOS:A1993LT74700032
J	LIU, P; TARLE, SA; HAJRA, A; CLAXTON, DF; MARLTON, P; FREEDMAN, M; SICILIANO, MJ; COLLINS, FS				LIU, P; TARLE, SA; HAJRA, A; CLAXTON, DF; MARLTON, P; FREEDMAN, M; SICILIANO, MJ; COLLINS, FS			FUSION BETWEEN TRANSCRIPTION FACTOR CBF-BETA/PEBP2-BETA AND A MYOSIN HEAVY-CHAIN IN ACUTE MYELOID-LEUKEMIA	SCIENCE			English	Article							VIRUS ENHANCERS; NUCLEAR FACTOR; SHORT ARM; T-CELL; CHROMOSOME-16; PROTEIN; TRANSLOCATION; KINASE; GENE; CORE	The pericentric inversion of chromosome 16 [inv(16)(p13q22)] is a characteristic karyotypic abnormality associated with acute myeloid leukemia, most commonly of the M4Eo subtype. The 16p and 16q breakpoints were pinpointed by yeast artificial chromosome and cosmid cloning, and the two genes involved in this inversion were identified. On 16q the inversion occurred near the end of the coding region for CBFbeta, also known as PEBP2beta, a subunit of a heterodimeric transcription factor regulating genes expressed in T cells; on 16p a smooth muscle myosin heavy chain (SMMHC) gene (MYH11) was interrupted. In six of six inv(16) patient samples tested, an in-frame fusion messenger RNA was demonstrated that connected the first 165 amino acids of CBFbeta with the tail region of SMMHC. The repeated coiled coil of SMMHC may result in dimerization of the CBFbeta fusion protein, which in turn would lead to alterations in transcriptional regulation and contribute to leukemic transformation.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT HUMAN GENET,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Liu, Paul/A-7976-2012; Marlton, Paula/F-3026-2011	Liu, Paul/0000-0002-6779-025X; 	NCI NIH HHS [CA55164] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Callen D. F., 1992, American Journal of Human Genetics, V51, pA57; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DAUWERSE JG, 1992, BLOOD, V79, P1299; DENG Z, IN PRESS GENOMICS; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LIU P, 1992, SOMAT CELL MOLEC GEN, V18, P7, DOI 10.1007/BF01233445; LIU P, IN PRESS BLOOD; LIU PL, UNPUB; MARLTON P, UNPUB; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OGAWA E, IN PRESS P NATL ACAD; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SUGITA K, 1989, J VIROL, V63, P1715, DOI 10.1128/JVI.63.4.1715-1720.1989; SWAROOP A, IN PRESS CYTOGENET C; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WESSELS JW, 1991, BLOOD, V77, P1555; YANAGISAWA K, 1991, BLOOD, V78, P451; 1984, CANCER GENET CYTOGEN, V11, P275	40	654	676	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1041	1044		10.1126/science.8351518	http://dx.doi.org/10.1126/science.8351518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351518				2022-12-24	WOS:A1993LT74700033
J	VEEKEN, H				VEEKEN, H			MALARIA AND GOLD FEVER	BRITISH MEDICAL JOURNAL			English	Article								The mineral rich territory of the Yanomami Indians of northern Brazil has been invaded by miners-who have destroyed the environment and introduced disease. Medecins Sans Frontieres agreed to help combat the malaria epidemic. Conditions in the rainforest and villages and the health care facilities are described. Mere medical aid cannot prevent the Yanomami from being decimated.			VEEKEN, H (corresponding author), MEDECINS SANS FRONTIERES,POB 10014,1001 EA AMSTERDAM,NETHERLANDS.								0	6	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					433	434		10.1136/bmj.307.6901.433	http://dx.doi.org/10.1136/bmj.307.6901.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374458	Green Published, Bronze			2022-12-24	WOS:A1993LR89500023
J	LANG, RA; BISHOP, JM				LANG, RA; BISHOP, JM			MACROPHAGES ARE REQUIRED FOR CELL-DEATH AND TISSUE REMODELING IN THE DEVELOPING MOUSE EYE	CELL			English	Article							COLONY-STIMULATING FACTOR; SIGNAL RECOGNITION PARTICLE; CSF TRANSGENIC MICE; GENETIC ABLATION; DIPHTHERIA-TOXIN; IMMUNOHISTOCHEMICAL LOCALIZATION; EXPRESSION; DNA; DIFFERENTIATION; ANTIGEN	To identify and characterize tissue remodeling processes mediated by macrophages, we have generated transgenic mice in which diphtheria toxin is expressed from a macrophage-specific transgene. Expression of the transgene disrupts subsets of mature macrophages in both the eye and the peritoneal cavity and results in the persistence of two normally transient ocular tissues, the hyaloid vasculature and the pupillary membrane. Furthermore, the cells comprising the pupillary membrane appear alive up to 14 days after the structure is normally remodeled, suggesting that the macrophage actively elicits target cell death. Thus, these transgenic mice provide direct evidence for the active involvement of macrophages in developmentally programed tissue remodeling and identify the hyaloid vessels and the pupillary membrane in the eye as targets of macrophage-mediated remodeling.	UNIV CALIF SAN FRANCISCO,GW HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Lang, Richard/E-5578-2011	Lang, Richard/0000-0002-5212-254X				AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALAZS EA, 1980, A GRAEF ARCH KLIN EX, V213, P71, DOI 10.1007/BF00413534; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BLEIER R, 1982, J NEUROPATH EXP NEUR, V41, P315, DOI 10.1097/00005072-198205000-00006; BLOOM GUNNAR D., 1965, EXP EYE RES, V4, P249, DOI 10.1016/S0014-4835(65)80038-0; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CASSADY JR, 1957, ARCH OPHTHALMOL-CHIC, V58, P438; COHN P, 1982, J NEUROPATH EXP NEUR, V41, P330, DOI 10.1097/00005072-198205000-00007; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CUTHBERTSON RA, 1990, EXP EYE RES, V51, P335, DOI 10.1016/0014-4835(90)90030-X; CUTHBERTSON RA, 1989, DEV BIOL, V134, P119, DOI 10.1016/0012-1606(89)90083-3; DANNA KJ, 1982, J VIROL METHODS, V5, P335, DOI 10.1016/0166-0934(82)90025-8; DAVIDSON WF, 1984, J IMMUNOL, V133, P744; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVANS GA, 1989, GENE DEV, V3, P259, DOI 10.1101/gad.3.3.259; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRER I, 1990, NEUROSCIENCE, V39, P451, DOI 10.1016/0306-4522(90)90281-8; FUHRMAN LA, 1981, P NATL ACAD SCI USA, V78, P3418; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; Hogan B., 1986, MANIPULATING MOUSE E; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; HUME DA, 1983, J EXP MED, V157, P1704, DOI 10.1084/jem.157.5.1704; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOLLY DJ, 1983, NUCLEIC ACIDS RES, V11, P1855, DOI 10.1093/nar/11.6.1855; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LANG RA, 1991, IN VIVO, V5, P501; LANG RA, 1991, GROWTH FACTORS, V6, P131; LATKER CH, 1981, OPHTHALMOL VIS SCI, V21, P689; MANN I, 1928, DEV ABNORMALITIES; MARAUD R, 1979, BIOL CELL, V35, pA2; MATSUO N, 1971, INVEST OPHTH VISUAL, V10, P108; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; METCALF D, 1992, J EXP MED, V175, P877, DOI 10.1084/jem.175.4.877; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; REESE AB, 1949, ARCH OPHTHALMOL-CHIC, V41, P527; REESE AB, 1955, AM J OPHTHALMOL, V40, P317, DOI 10.1016/0002-9394(55)91866-3; RITCHINSKAYA EB, 1965, ARKH ANAT GISTOL EMB, V48, P91; SALU P, 1985, OPHTHALMIC RES, V17, P125, DOI 10.1159/000265363; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; SZIRMAI JA, 1958, ARCH OPHTHALMOL-CHIC, V59, P34, DOI 10.1001/archopht.1958.00940020058006; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; Torrey TW, 1965, ORGANOGENESIS, P559; UCHIDA T, 1982, MOL ACTION TOXINS VI, P1; UCKER DS, 1991, NEW BIOL, V3, P103; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEBER R, 1964, J CELL BIOL, V22, P481, DOI 10.1083/jcb.22.2.481; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307	60	292	299	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					453	462		10.1016/0092-8674(93)80047-I	http://dx.doi.org/10.1016/0092-8674(93)80047-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348612				2022-12-24	WOS:A1993LT73900007
J	PEPPELENBOSCH, MP; TERTOOLEN, LGJ; HAGE, WJ; DELAAT, SW				PEPPELENBOSCH, MP; TERTOOLEN, LGJ; HAGE, WJ; DELAAT, SW			EPIDERMAL GROWTH FACTOR-INDUCED ACTIN REMODELING IS REGULATED BY 5-LIPOXYGENASE AND CYCLOOXYGENASE PRODUCTS	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; ARACHIDONIC-ACID; SIGNAL TRANSDUCTION; MORPHOLOGICAL-CHANGES; A431 CELLS; CARCINOMA-CELLS; TYROSINE KINASE; EGF-RECEPTOR; 3T3 CELLS; BINDING	In a number of cell types, epidermal growth factor (EGF) evokes dramatic morphological changes, cortical actin polymerization, and stress fiber breakdown. The molecular processes by which increased EGF receptor tyrosine kinase activity results in actin reorganization and morphological changes are unresolved. Recently, we demonstrated that arachidonic acid metabolites function in EGF signal transduction. We now report that in A431 cells, HeLa cells, and rat-1 fibroblasts, the EGF-induced cortical actin polymerization is produced by lipoxygenase metabolism, whereas in these cells stress fiber breakdown is mediated by cyclooxygenase metabolites. Also, the EGF-provoked rounding up in A431 cells is dependent on arachidonic acid metabolism. We conclude that leukotrienes and prostaglandins act in concert, as second messengers, to produce morphological effects and actin reorganization, providing a novel mechanism for directing growth factor-induced cytoskeletal changes.			PEPPELENBOSCH, MP (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.			Peppelenbosch, Maikel/0000-0001-9112-6028				BERK BC, 1990, J BIOL CHEM, V265, P17334; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; FAULSTICH H, 1977, HOPPESEYLERS Z PHYSL, V385, P181; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MOLLENAAR WH, 1986, J BIOL CHEM, V251, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PACE J, 1991, J BIOL CHEM, V266, P19938; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Rainsford KD, 1988, PROSTAGLANDINS BIOL, P52; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIJKEN PJ, 1991, J CELL SCI, V100, P491; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WELSH JB, 1991, J CELL BIOL, V114, P533, DOI 10.1083/jcb.114.3.533; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	46	227	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					565	575		10.1016/0092-8674(93)80057-L	http://dx.doi.org/10.1016/0092-8674(93)80057-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348619				2022-12-24	WOS:A1993LT73900017
J	LI, R; BOTCHAN, MR				LI, R; BOTCHAN, MR			THE ACIDIC TRANSCRIPTIONAL ACTIVATION DOMAINS OF VP16 AND P53 BIND THE CELLULAR REPLICATION PROTEIN-A AND STIMULATE INVITRO BPV-1 DNA-REPLICATION	CELL			English	Article							HERPES-SIMPLEX VIRUS; EMBRYONAL CARCINOMA-CELLS; SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; SV40 ORIGIN; YEAST GAL4; T-ANTIGEN; WILD-TYPE; INITIATION	For papillomavirus DNA replication, the E2 enhancer protein cooperatively assists in binding of the E1 helicase to the origin. We report that, at limiting E1 and E2 levels, the enhancer proteins GAL4-VP16 and GAL4-p53(1-73) stimulate BPV in vitro DNA replication. This cell-free system was used to ascertain whether the acidic activation domains have a cellular target important for replication. Cellular extracts were depleted of replication activity by passage through a VP16 affinity column. The protein depleted was the cellular factor replication protein A. The direct interaction between replication protein A and VP16, as well as the activation of replication by VP16, is dependent upon the C-terminus of the VP16 activation domain. E2 and the activation domain of p53 also interact with replication protein A. We suggest that a link between transcription and replication involves factors that help convert a closed DNA complex to an open complex.			LI, R (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA 42414, CA 30490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030490, R01CA042414, R37CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHANG LS, 1990, J VIROL, V64, P2103, DOI 10.1128/JVI.64.5.2103-2109.1990; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANGMAN WL, 1992, CELL, V71, P3632; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FUJIMURA FK, 1982, P NATL ACAD SCI-BIOL, V79, P1479, DOI 10.1073/pnas.79.5.1479; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HANDA H, 1983, NATURE, V302, P545, DOI 10.1038/302545a0; HEINTZ N H, 1992, Current Opinion in Cell Biology, V4, P459, DOI 10.1016/0955-0674(92)90012-2; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATINKA M, 1981, NATURE, V290, P720, DOI 10.1038/290720a0; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KLESSIG DF, 1979, CELL, V17, P957, DOI 10.1016/0092-8674(79)90335-0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEBOWSKI J, 1985, NATURE, V317, P169; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MULLER WJ, 1988, MOL CELL BIOL, V8, P5000, DOI 10.1128/MCB.8.11.5000; NILSSON M, 1991, NUCLEIC ACIDS RES, V19, P7061, DOI 10.1093/nar/19.25.7061; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; RIO DC, 1983, CELL, V32, P1227, DOI 10.1016/0092-8674(83)90305-7; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SEKIKAWA K, 1981, P NATL ACAD SCI-BIOL, V78, P1100, DOI 10.1073/pnas.78.2.1100; SEO YS, 1993, P NATL ACAD SCI USA, V90, P2865, DOI 10.1073/pnas.90.7.2865; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SPALHOLZ BA, 1993, VIROLOGY, V193, P201, DOI 10.1006/viro.1993.1116; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINBERG D, 1991, P NATL ACAD SCI USA, V87, P8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG SW, 1991, J VIROL, V65, P2601, DOI 10.1128/JVI.65.5.2601-2611.1991; YANG L, 1991, COLD SPRING HARB SYM, V56, P335; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	95	322	322	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 18	1993	73	6					1207	1221		10.1016/0092-8674(93)90649-B	http://dx.doi.org/10.1016/0092-8674(93)90649-B			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	8390328				2022-12-24	WOS:A1993LH54800016
J	LANDWEBER, LF; GILBERT, W				LANDWEBER, LF; GILBERT, W			RNA EDITING AS A SOURCE OF GENETIC-VARIATION	NATURE			English	Article							POLYMERASE CHAIN-REACTION; OXIDASE SUBUNIT-III; SINGLE-STRANDED-DNA; TRYPANOSOMA-BRUCEI; MAXICIRCLE DNA; NUCLEOTIDE-SEQUENCE; NADH DEHYDROGENASE	KINETOPLASTID RNA editing alters mitochondrial RNA transcripts by addition and deletion of uridine residues1, producing open reading frames that may be twice as long as the original RNA2. Although the COIII gene encoding cytochrome c oxidase subunit III in Trypanosoma brucei is edited along its entire length2, the presumably homologous genes in two related trypanosomes, Leishmania tarentolae and Crithidia fasciculata, are only modestly edited at their 5' ends1. We used a comparative approach to investigate the evolution of an edited gene and to determine how well editing creates conserved protein sequences. As RNA editing probably involves the pairing of several guide RNA molecules with the messenger RNA3,4, We expected the edited proteins to be resistant to evolutionary change. Here we report that RNA editing is extensive in the mitochondria of four species of the insect parasite Herpetomonas, which is possibly an evolutionary precursor of T. brucei and L. tarentolae5, and the discovery that RNA editing is a novel source ot frameshift mutations over evolutionary time. The edited proteins accumulate mutations nearly twice as rapidly as the unedited versions.			LANDWEBER, LF (corresponding author), HARVARD UNIV,BIOL LABS,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; KREITMAN M, 1989, GENE ANAL TECH, V6, P84, DOI 10.1016/0735-0651(89)90021-6; LAKE JA, 1988, P NATL ACAD SCI USA, V85, P4779, DOI 10.1073/pnas.85.13.4779; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SLOOF P, 1987, NUCLEIC ACIDS RES, V15, P51, DOI 10.1093/nar/15.1.51; VOLLOCH V, 1991, P NATL ACAD SCI USA, V88, P10671, DOI 10.1073/pnas.88.23.10671; YOUNG IG, 1981, EUR J BIOCHEM, V116, P165, DOI 10.1111/j.1432-1033.1981.tb05314.x	16	51	53	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 13	1993	363	6425					179	182		10.1038/363179a0	http://dx.doi.org/10.1038/363179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	8387160				2022-12-24	WOS:A1993LB80100053
J	MARAIS, R; WYNNE, J; TREISMAN, R				MARAIS, R; WYNNE, J; TREISMAN, R			THE SRF ACCESSORY PROTEIN ELK-1 CONTAINS A GROWTH FACTOR-REGULATED TRANSCRIPTIONAL ACTIVATION DOMAIN	CELL			English	Article							SERUM-RESPONSE ELEMENT; C-FOS EXPRESSION; KINASE-C; TERNARY COMPLEX; RAS PROTEIN; CELLS; JUN; PHOSPHORYLATION; SEQUENCE; SIGNALS	The Elk-1 and SRF transcription factors form a ternary complex at the c-fos serum response element (SRE). Growth factor stimulation rapidly induces a reversible change in the electrophoretic mobility of the ternary complex, accompanied by increased phosphorylation of the Elk-1 C-terminal region and by the activation of a 42 kd cellular Elk-1 kinase. Phosphorylation of Elk-1 in vitro by partially purified p42/p44 MAP kinase induces a similar reduction in ternary complex mobility but has little effect on the efficiency of its formation. In vitro, MAP kinase phosphorylates the Elk-1 C-terminal region at multiple sites, which are also phosphorylated following growth factor stimulation in vivo. The Elk-1 C-terminal region functions as a regulated transcriptional activation domain whose activity in vivo is dependent on the integrity of the MAP kinase sites. These findings directly link transcriptional activation by the SRE to the growth factor-regulated phosphorylation of an SRE-binding protein.	IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Treisman, Richard/0000-0002-9658-0067; Marais, Richard/0000-0001-7484-4183				ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAURSEN RA, 1989, METHODS PROTEIN SEQU, P61; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PATEL G, 1992, NUCLEIC ACIDS RES, V20, P97, DOI 10.1093/nar/20.1.97; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	57	1189	1212	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 23	1993	73	2					381	393		10.1016/0092-8674(93)90237-K	http://dx.doi.org/10.1016/0092-8674(93)90237-K			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	8386592				2022-12-24	WOS:A1993KY50500018
J	CARLBERG, C; BENDIK, I; WYSS, A; MEIER, E; STURZENBECKER, LJ; GRIPPO, JF; HUNZIKER, W				CARLBERG, C; BENDIK, I; WYSS, A; MEIER, E; STURZENBECKER, LJ; GRIPPO, JF; HUNZIKER, W			2 NUCLEAR SIGNALING PATHWAYS FOR VITAMIN-D	NATURE			English	Article							HUMAN OSTEOCALCIN GENE; D RECEPTOR; THYROID-HORMONE; RETINOIC ACID; ELEMENTS; BINDING; 1,25-DIHYDROXYVITAMIN-D3; SUPERFAMILY; EXPRESSION; CELLS	THE dihydroxylated form of vitamin D3(1,25-dihydroxy-D3) mediates a biological response by binding to intracellular receptors1-4 which belong to the steroid receptor superfamily5. These receptors act as ligand-dependent transcription factors that bind to specific DNA sequences (reviewed in refs 6-9). We have identified two classes of vitamin D response elements that are activated either by the vitamin D receptor (VDR) alone or by heterodimers of VDR and the retinoid-X receptor-alpha (RXR-alpha)10. The motif GGGTGA arranged as a direct repeat with a spacing of six nucleotides or as a palindrome without spacing, or as an inverted palindrome with a 12-nucleotide spacing, confers vitamin D inducibility mediated by VDR alone. A second class of response elements, composed of directly repeated pairs of motifs (GGTCCA, AGGTCA, or GGGTGA) spaced by three nucleotides, is synergistically activated by RXR and VDR, but only in the presence of both ligands. Thus, the RXR ligand and the nature of the response element determine whether a nuclear receptor is co-regulated by RXR.	F HOFFMANN LA ROCHE & CO LTD, DEPT PHARMA RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DELUCA HF, 1990, KIDNEY INT, V38, pS2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIEWER SA, 1992, NATURE, V355, P446; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OZONO K, 1990, J BIOL CHEM, V265, P21881; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	32	530	534	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1993	361	6413					657	660		10.1038/361657a0	http://dx.doi.org/10.1038/361657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8382345				2022-12-24	WOS:A1993KM77600070
J	RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ				RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ			A PROSPECTIVE-STUDY OF LIPOPROTEIN(A) AND THE RISK OF MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; LP(A) LIPOPROTEIN; ARTERY DISEASE; SERUM LIPOPROTEIN(A); APOLIPOPROTEIN-B; PREDICTIVE VALUE; MEN; ASSOCIATION	Objective.-To assess prospectively the risk of myocardial infarction (MI) associated with elevated levels of lipoprotein(a) (Lp[a]). Design.-Nested case-control study using prospectively collected plasma samples. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 14 916 male physicians aged 40 to 84 years with no prior history of MI or stroke provided plasma samples at baseline and were followed up prospectively for an average period of 60.2 months. Samples from 296 physicians who subsequently developed MI were analyzed for Lp(a) level together with paired controls, matched for smoking status and age. Main Outcome Measure.-Fatal or nonfatal acute MI. Results.-The distribution of Lp(a) level among cases was virtually identical to that of controls (P=.88), and there was no significant difference between groups for median Lp(a) levels (103.0 mg/L vs 102.5 mg/L; P=.73). In analyses controlling for age and smoking status, we found no evidence of association between increasing level of Lp(a) and risk of MI (relative risks from lowest to highest quintiles of Lp(a): 1.00, 0.97, 0.83, 0.88, and 1.07; P for trend=.93) or a threshold effect at any pre-specified cutoff of Lp(a) level (relative risks associated with Lp[a] levels above the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution, respectively: 1.04, 1.00, 1.19, 1.00, and 1.07; all P values nonsignificant). Further adjustment for both lipid and nonlipid cardiovascular risk factors had no material impact. Conclusions.-In this prospective study of predominantly middle-aged white men, we found no evidence of association between Lp(a) level and risk of future MI. These data do not support the use of Lp(a) level as a screening tool to define cardiovascular risk among this population.	BRIGHAM & WOMENS HOSP,DEPT PEDIAT,DIV CARDIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PEDIAT,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DIV AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1977, J LIPID RES, V18, P331; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BERG K, 1974, CLIN GENET, V6, P230; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CRAIG WY, 1992, ATHEROSCLEROSIS, V93, P261, DOI 10.1016/0021-9150(92)90264-H; DAHLEN G, 1975, CLIN GENET, V7, P334; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DURRINGTON PN, 1988, LANCET, V1, P1070; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HAFFNER SM, 1992, METABOLISM, V41, P194, DOI 10.1016/0026-0495(92)90152-Z; HEARN JA, 1990, AM J CARDIOL, V66, P1176, DOI 10.1016/0002-9149(90)91094-M; HOEFLER G, 1988, ARTERIOSCLEROSIS, V8, P398, DOI 10.1161/01.ATV.8.4.398; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JAUHIAINEN M, 1990, 55TH M EUR ATH SOC B, P42; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOSTNER GM, 1992, CLIN CHIM ACTA, V211, P191, DOI 10.1016/0009-8981(92)90196-W; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P671; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MENSINK RP, 1992, J LIPID RES, V33, P1493; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; OLOFSSON BO, 1989, EUR HEART J, V10, P77; PARRA HJ, 1987, CLIN CHIM ACTA, V167, P27; PEARSON T, 1990, CIRCULATION, V82, pA475; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; SRINIVASAN SR, 1991, CIRCULATION, V84, P160, DOI 10.1161/01.CIR.84.1.160; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; [No title captured]; 1971, ISCHEMIC HEART DISEA	37	447	454	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2195	2199		10.1001/jama.270.18.2195	http://dx.doi.org/10.1001/jama.270.18.2195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411602				2022-12-24	WOS:A1993ME81600030
J	DORIG, RE; MARCIL, A; CHOPRA, A; RICHARDSON, CD				DORIG, RE; MARCIL, A; CHOPRA, A; RICHARDSON, CD			THE HUMAN CD46 MOLECULE IS A RECEPTOR FOR MEASLES-VIRUS (EDMONSTON STRAIN)	CELL			English	Article							MEMBRANE COFACTOR PROTEIN; MONOCLONAL-ANTIBODIES; COMPLEMENT ACTIVATION; FUSION; BINDING; LYMPHOCYTES; REPLICATION; SYSTEM; GENE; MCP	Measles virus normally causes disease in human beings, and the host range of this virus may be determined by a specific receptor on the surface of primate cells. Human-rodent somatic cell hybrids were tested for their ability to bind measles virus, and only cells that contained human chromosome 1 were capable of binding virus. A study of lymphocyte markers suggested that the complement regulator known either as membrane cofactor protein or CD46 was the measles virus receptor. We proved this hypothesis by demonstrating that hamster cell lines that expressed human CD46 could subsequently bind virus. Furthermore, infected CD46+ cells produced syncytia and viral proteins. Finally, polyclonal antisera against CD46 inhibited virus binding and infection. These results prove that human CD46 permits cells both to bind measles virus and to support infection.	MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3A 2B4,QUEBEC,CANADA	McGill University	DORIG, RE (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,6100 ROYALM AVE,MONTREAL H4P 2R2,PQ,CANADA.			Marcil, Anne/0000-0002-4111-1781				ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P268; ALBRECHT P, 1980, INFECT IMMUN, V25, P969; ALKHATIB G, 1986, VIROLOGY, V150, P479, DOI 10.1016/0042-6822(86)90312-0; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BELLINI WJ, 1979, J GEN VIROL, V43, P633, DOI 10.1099/0022-1317-43-3-633; BILLETER MA, 1991, PARAMYXOVIRUSES, P323; Blake FG, 1921, J EXP MED, V33, P385, DOI 10.1084/jem.33.3.385; BRINCKMANN UG, 1991, J GEN VIROL, V72, P2491, DOI 10.1099/0022-1317-72-10-2491; CARRIGAN DR, 1986, VIROLOGY, V148, P349, DOI 10.1016/0042-6822(86)90331-4; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; ENDERS JF, 1962, AM J DIS CHILD, V103, P335, DOI 10.1001/archpedi.1962.02080020347030; ENDERS JF, 1962, AM J DIS CHILD, V103, P473, DOI 10.1001/archpedi.1962.02080020485066; EY PL, 1986, METHOD ENZYMOL, V121, P497; FONG TM, 1993, NATURE, V362, P350; Fraser K. B., 1978, MEASLES VIRUS ITS BI; GASTEL B, 1973, Journal of the History of Medicine and Allied Sciences, V28, P34; GRAVES MC, 1978, VIROLOGY, V86, P254, DOI 10.1016/0042-6822(78)90025-9; HARROWE G, 1990, J CLIN INVEST, V85, P1324, DOI 10.1172/JCI114571; HARROWE G, 1992, CELL MOL NEUROBIOL, V12, P397, DOI 10.1007/BF00711541; HILLEMAN MR, 1968, J AMER MED ASSOC, V206, P587, DOI 10.1001/jama.206.3.587; HSI BL, 1988, AM J REPROD IMMUNOL, V18, P21; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JOSEPH BS, 1975, J VIROL, V16, P1638, DOI 10.1128/JVI.16.6.1638-1649.1975; KATZ SL, 1958, P SOC EXP BIOL MED, V97, P23, DOI 10.3181/00379727-97-23637; KNIGHT P, 1972, J VIROL, V10, P995, DOI 10.1128/JVI.10.5.995-1001.1972; KOHNO S, 1968, JPN J MED SCI BIOL, V21, P301, DOI 10.7883/yoken1952.21.301; KORENBERG JR, 1987, AM J HUM GENET, V41, P963; KRAH DL, 1989, VIROLOGY, V172, P386, DOI 10.1016/0042-6822(89)90147-5; KRAH DL, 1988, J VIROL, V62, P1565, DOI 10.1128/JVI.62.5.1565-1572.1988; LEVY JA, 1986, SCIENCE, V232, P998, DOI 10.1126/science.3010461; LIEBERT UG, 1987, J GEN VIROL, V68, P1715, DOI 10.1099/0022-1317-68-6-1715; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LISZEWSKI MK, 1992, CURR TOP MICROBIOL I, V178, P47; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAKINO S, 1970, JPN J MICROBIOL, V14, P501; MARKWELL MAK, 1990, PAROMYXOVIRUSES, P407; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; MORGAN EM, 1977, BACTERIOL REV, V41, P636, DOI 10.1128/MMBR.41.3.636-666.1977; MUSSER SJ, 1962, AM J DIS CHILD, V103, P476, DOI 10.1001/archpedi.1962.02080020488068; NANICHE D, 1993, J GEN VIROL, V74, P1073, DOI 10.1099/0022-1317-74-6-1073; NANICHE D, 1992, J GEN VIROL, V73, P2617, DOI 10.1099/0022-1317-73-10-2617; NEMEROW GR, 1985, J VIROL, V55, P347, DOI 10.1128/JVI.55.2.347-351.1985; NORRBY E, 1971, VIROLOGY, V44, P594; Norrby E., 1990, VIROLOGY, P1013; NORRBY ERLING, 1962, ARCH GES VIRUSFORSCH, V12, P164, DOI 10.1007/BF01258127; OHUCHI R, 1984, MICROBIOL IMMUNOL, V28, P757, DOI 10.1111/j.1348-0421.1984.tb00731.x; PERIES JR, 1960, CR HEBD ACAD SCI, V251, P820; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; PURCELL DFJ, 1991, IMMUNOGENETICS, V33, P335, DOI 10.1007/BF00216692; RICHARDSON C, 1986, VIROLOGY, V155, P508, DOI 10.1016/0042-6822(86)90212-6; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; ROTA JS, 1992, VIROLOGY, V188, P135, DOI 10.1016/0042-6822(92)90742-8; SCHUMACHER HP, 1972, ARCH GES VIRUSFORSCH, V36, P296, DOI 10.1007/BF01249860; SERGEL T, 1993, VIROLOGY, V193, P717, DOI 10.1006/viro.1993.1180; SEYA T, 1988, EUR J IMMUNOL, V18, P1289, DOI 10.1002/eji.1830180821; SHAVER DOROTHY N., 1964, ARCH GESAMTE VIRUSFORSCH, V14, P487, DOI 10.1007/BF01555080; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; VALDIMARSSON H, 1975, NATURE, V255, P554, DOI 10.1038/255554a0; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WEISS R, 1992, SCIENCE, V258, P546, DOI 10.1126/science.1329205; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILD TF, 1991, J GEN VIROL, V72, P435	63	844	878	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					295	305		10.1016/0092-8674(93)80071-L	http://dx.doi.org/10.1016/0092-8674(93)80071-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402913				2022-12-24	WOS:A1993MD88500011
J	NYGAARD, B; HEGEDUS, L; GERVIL, M; HJALGRIM, H; SOEJENSEN, P; HANSEN, JM				NYGAARD, B; HEGEDUS, L; GERVIL, M; HJALGRIM, H; SOEJENSEN, P; HANSEN, JM			RADIOIODINE TREATMENT OF MULTINODULAR NONTOXIC GOITER	BRITISH MEDICAL JOURNAL			English	Article							NONTOXIC GOITER; RADIOACTIVE IODINE; THYROID SIZE; THYROXINE TREATMENT; THERAPY; HYPERTHYROIDISM; NODULES; AGE; SEX	Objective-To investigate the long term effect of radioactive iodine on thyroid function and size in patients with non-toxic multinodular goitre. Design-Consecutive patients with multinodular non-toxic goitre selected for radioactive iodine treatment and followed for a minimum of 12 months (median 48 months) after an intended dose of 3.7 MBq/g thyroid tissue corrected to a 100% uptake of iodine-131 in 24 hours. Patients-69 patients with a growing multinodular non-toxic goitre causing local compression symptoms or cosmetic inconveniences. The treatment was chosen because of a high operative risk, previous thyroidectomy, or refusal to be operated on. Main outcome measurements-Standard thyroid function variables and ultrasonically determined thyroid volume before treatment as well as 1, 2, 3, 6, and 12 months after treatment and then once a year. Results-56 patients were treated with a single dose of I-131, 12 with two doses, and one with four doses. In 45 patients treated with one dose and remaining euthyroid the median thyroid volume was reduced from 73 (interquartile range 50-106) ml to 29 (23-48) ml at 24 months in the 39 patients in whom this was measured during follow up. The median reduction was 40 (22-48) ml (60% reduction, p<0.0001), half of which occurred within three months. Patients treated with two doses as well as those developing hypothyroidism and hyperthyroidism had a significant reduction in thyroid volume. Eleven patients developed hypothyroidism (cumulative five year risk 22%, 95% confidence interval 4.8% to 38.4%). Side effects were few: three cases of hyperthyroidism and two cases of radiation thyroiditis. Only one patient was dissatisfied with the result; she was referred for operation six months after treatment. Conclusions-A substantial reduction in thyroid volume accompanied by a low incidence of hypothyroidism and few side effects makes the use of radioactive iodine an attractive alternative to surgery in selected cases of non-toxic multinodular goitre.	ODENSE UNIV HOSP,DEPT INTERNAL MED & ENDOCRINOL M,DK-5000 ODENSE,DENMARK; HERLEV UNIV HOSP,DEPT INTERNAL MED & ENDOCRINOL,DK-2730 HERLEV,DENMARK; HERLEV UNIV HOSP,DEPT ULTRASOUND,DK-2730 HERLEV,DENMARK	University of Southern Denmark; Odense University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital			Hjalgrim, Henrik/AAG-4973-2021	Nygaard, Birte/0000-0002-9540-4950				AGERBAEK H, 1988, Ugeskrift for Laeger, V150, P533; BEAHRS OH, 1963, SURG GYNECOL OBSTET, V117, P535; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; FARRAR JJ, 1991, CLIN ENDOCRINOL, V35, P207, DOI 10.1111/j.1365-2265.1991.tb03523.x; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; HAAS V, 1988, ACTA ENDOCRINOL-COP, V119, P125, DOI 10.1530/acta.0.1190125; HALL P, 1992, LANCET, V340, P1; HANSEN JM, 1975, ACTA ENDOCRINOL-COP, V79, P60, DOI 10.1530/acta.0.0790060; HEGEDUS L, 1986, LANCET, V2, P339; HEGEDUS L, 1988, BRIT MED J, V297, P661, DOI 10.1136/bmj.297.6649.661; HEGEDUS L, 1986, ACTA ENDOCRINOL-COP, V113, P226, DOI 10.1530/acta.0.1130226; HEGEDUS L, 1987, BRIT MED J, V294, P801, DOI 10.1136/bmj.294.6575.801; HEGEDUS L, 1983, J CLIN ENDOCR METAB, V56, P260, DOI 10.1210/jcem-56-2-260; HEGEDUS L, 1986, AM J OBSTET GYNECOL, V155, P142, DOI 10.1016/0002-9378(86)90098-0; HEGEDUS L, 1986, LANCET, V2, P876; HEGEDUS L, 1991, THYROID S1, V1, P2; HOLLANDER M, 1973, NONPARAMETRIC STAT, P147; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; JARLOV AE, 1992, CLIN ENDOCRINOL, V37, P335, DOI 10.1111/j.1365-2265.1992.tb02334.x; KAY TWH, 1988, AM J MED, V84, P19, DOI 10.1016/0002-9343(88)90003-4; KEIDERLING W, 1964, DEUT MED WOCHENSCHR, V89, P453, DOI 10.1055/s-0028-1111038; KLEIN B, 1989, NUKLEARMED, V28, P129; PERRILD H, 1982, ACTA ENDOCRINOL-COP, V100, P382, DOI 10.1530/acta.0.1000382; VERELST J, 1990, ACTA ENDOCRINOL-COP, V122, P417, DOI 10.1530/acta.0.1220417	25	123	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					828	832		10.1136/bmj.307.6908.828	http://dx.doi.org/10.1136/bmj.307.6908.828			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401123	Green Published, Bronze			2022-12-24	WOS:A1993MA29300018
J	AGGER, WA				AGGER, WA			PREDATOR AND PREY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											AGGER, WA (corresponding author), GUNDERSON CLIN LTD, 1836 SOUTH AVE, LA CROSSE, WI 54601 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					526	526		10.7326/0003-4819-119-6-199309150-00014	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357121				2022-12-24	WOS:A1993LZ27500014
J	HILBERG, F; AGUZZI, A; HOWELLS, N; WAGNER, EF				HILBERG, F; AGUZZI, A; HOWELLS, N; WAGNER, EF			C-JUN IS ESSENTIAL FOR NORMAL MOUSE DEVELOPMENT AND HEPATOGENESIS	NATURE			English	Article							CELL-CYCLE PROGRESSION; FOS; DIFFERENTIATION; EXPRESSION; ONCOGENE; MUTATION; DEFECTS; GROWTH; RB	THE proto-oncogene c-jun is the cellular homologue of v-jun, the transforming oncogene of the avian sarcoma virus 17 (ref. 1). c-jun encodes one major component of the AP-1 transcription factor complex and is expressed in many organs during mouse development and in the adult2-4. Because of its rapid induction in cells following growth stimulation and the presence of AP-1 binding sites in the promoter regions of many genes, the c-Jun protein is thought to have important functions in cell proliferation and differentiation2,5-10. But embryonic stem (ES) cells lacking c-Jun are viable and have a normal in vitro differentiation capacity, although c-Jun appears to be important for growth of teratocarcinomas in vivo11. To define the function of c-jun better, targeted ES cells were used to generate mice lacking c-Jun. Here we report that heterozygous mutant mice appear normal, but embryos lacking c-Jun die at mid- to late-gestation and exhibit impaired hepatogenesis, altered fetal liver erythropoiesis and generalized oedema. Interestingly, c-jun-/- ES cells can participate efficiently in the development of all somatic cells in chimaeric mice except liver cells, further suggesting an essential function of c-Jun in hepatogenesis.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008	Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARTER R, 1991, ONCOGENE, V6, P229; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN DR, 1993, ONCOGENE, V8, P443; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HILBERG F, 1992, ONCOGENE, V7, P2371; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; ZATIOUKAL K, 1990, LAB INVEST, V62, P427	22	469	477	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					179	181		10.1038/365179a0	http://dx.doi.org/10.1038/365179a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371760				2022-12-24	WOS:A1993LW44200053
J	REECE, RJ; PTASHNE, M				REECE, RJ; PTASHNE, M			DETERMINANTS OF BINDING-SITE SPECIFICITY AMONG YEAST C6 ZINC CLUSTER PROTEINS	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; NUCLEOTIDE-SEQUENCE; GAL4; FINGER; ACTIVATOR; ADJACENT; INDUCTION; COMPLEX	Related DNA binding proteins often recognize similar DNA sites but can distinguish among them with the use of different protein-DNA contacts. Here, it is shown that members of the C6 zinc cluster family of yeast transcriptional activators distinguish related DNA sites by a different mechanism. The DNA binding site for each of these proteins contains identical nucleotide triplets (CGG ... CCG) but differs in the spacings between the triplets. It is shown that zinc clusters of these proteins work interchangeably to recognize the conserved triplets and that the region 19 amino acids to the carboxyl-terminal side of the zinc cluster, comprising the linker and the beginning of a dimerization element as inferred from the GAL4 crystal structure, directs the protein to its preferred site.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NIGMS NIH HHS [GM32308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DERIJCKE M, 1992, MOL CELL BIOL, V12, P68, DOI 10.1128/MCB.12.1.68; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; REECE RJ, UNPUB; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128	23	155	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					909	911		10.1126/science.8346441	http://dx.doi.org/10.1126/science.8346441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346441				2022-12-24	WOS:A1993LR89700037
J	HEYDUK, T; LEE, JC; EBRIGHT, YW; BLATTER, EE; ZHOU, YH; EBRIGHT, RH				HEYDUK, T; LEE, JC; EBRIGHT, YW; BLATTER, EE; ZHOU, YH; EBRIGHT, RH			CAP INTERACTS WITH RNA-POLYMERASE IN SOLUTION IN THE ABSENCE OF PROMOTER DNA	NATURE			English	Article							AMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; LAC PROMOTER; FLUORESCENCE POLARIZATION; RIBOSOMAL-SUBUNITS; BINDING; ACTIVATOR; MUTANTS; REGION	PROTEIN-PROTEIN interactions between transcription activator proteins and RNA polymerase or basal transcription factors have been suggested to be important for transcription activation1-8. Interactions between catabolite gene activator protein (CAP)9,10 and RNA polymerase have been proposed based on face-of-helix-dependent transcription activation by CAP11-13 and based on face-of-helix-dependent cooperative binding of CAP and RNA polymerase to promoter DNA14,15. Mutants of CAP specifically defective in transcription activation have been isolated (mutants defective in transcription activation, but not defective in DNA binding and DNA bending16-19). All such mutants contain amino-acid substitutions within a surface loop consisting of amino acids 152 to 166 of CAP16-19. Here we use the thermodynamically rigorous technique of fluorescence polarization20-23 to show that CAP interacts with RNA polymerase in solution in the absence of promoter DNA (K(D,app) = 2.8 x 10(-7) M), whereas [Ala158]CAP, a mutant of CAP specifically defective in transcription activation, does not.	RUTGERS UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Texas System; University of Texas Medical Branch Galveston			Ebright, Richard/O-3321-2019; Lee, James C/A-7849-2009	Ebright, Richard/0000-0001-8915-7140; 				BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BENTLEY K L, 1985, Biotechniques, V3, P356; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Ishihama A, 1990, Adv Biophys, V26, P19, DOI 10.1016/0065-227X(90)90005-E; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MANDECKI W, 1984, GENE, V31, P263, DOI 10.1016/0378-1119(84)90219-1; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; WEIEL J, 1982, J BIOL CHEM, V257, P1215; WEIEL J, 1981, BIOCHEMISTRY-US, V20, P5859, DOI 10.1021/bi00523a032; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	30	75	75	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					548	549		10.1038/364548a0	http://dx.doi.org/10.1038/364548a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393148				2022-12-24	WOS:A1993LQ66700061
J	HEDEGAARD, M; HENRIKSEN, TB; SABROE, S; SECHER, NJ				HEDEGAARD, M; HENRIKSEN, TB; SABROE, S; SECHER, NJ			PSYCHOLOGICAL DISTRESS IN PREGNANCY AND PRETERM DELIVERY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; PSYCHOSOCIAL STRESS; GESTATIONAL-AGE; SOCIAL SUPPORT; RISK-FACTORS; MORTALITY; DETERMINANTS; INFANTS	Objective-To investigate if psychological distress during pregnancy is associated with increased risk of preterm delivery. Design-Prospective, population based, follow up study with repeated measures of psychological distress (general health questionnaire), based on the use of questionnaires. Setting-Antenatal care clinic and delivery ward, Aarhus University Hospital, Denmark. Subjects-8719 women with singleton pregnancies attending antenatal care for the initial visit between 1 August 1989 and 30 September 1991; 5872 women (67%) completed all questionnaires. Main outcome measure-Preterm delivery. Estimation of gestational age at delivery was mainly based on early ultrasound measurements. Results-In 197 cases (3.6%) the woman delivered prematurely (less than 259 days). A dose-response relation between psychological distress in the 30th week of pregnancy and risk of preterm delivery was found, but distress measured in the 16th week was not related to preterm delivery. Control of confounding was secured by the use of multivariate logistic regression models. Relative risk for preterm delivery was 1.22 (95% confidence interval 0.84 to 1.79) for moderate distress and 1.75 (1.20 to 2.54) for high distress in comparison to low distress. Conclusions-Psychological distress later in pregnancy is associated with an increased risk of preterm delivery. Future interventional studies should focus on ways of lowering psychological distress in late pregnancy.	AARHUS UNIV, INST EPIDEMIOL & SOCIAL MED, DK-8000 AARHUS, DENMARK	Aarhus University	HEDEGAARD, M (corresponding author), AARHUS UNIV HOSP, DEPT OBSTET & GYNAECOL, PERINATAL EPIDEMIOL RES UNIT, DK-8000 AARHUS, DENMARK.							ARMITAGE P, 1987, STATISTICAL METHODS; BECH P, 1990, Ugeskrift for Laeger, V152, P383; BECH P, 1987, PSYCHOPATHOLOGY, V20, P169, DOI 10.1159/000284496; BECK NC, 1980, J PSYCHOSOM RES, V24, P343, DOI 10.1016/0022-3999(80)90026-4; BERKOWITZ GS, 1983, J PSYCHOSOM RES, V27, P283, DOI 10.1016/0022-3999(83)90050-8; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; Cronbach Lee J., 1990, ESSENTIALS PSYCHOL T, V5th; ERIKSEN PS, 1985, ACTA OBSTET GYN SCAN, V64, P65, DOI 10.3109/00016348509154690; Goldberg DP, 1972, DETECTION PSYCHIAT I; GREELAND S, 1978, AM J PUBLIC HEALTH, V79, P340; GRENNERT L, 1978, ACTA OBSTET GYN SCAN, P5; HADDERSALGRA M, 1988, DEV MED CHILD NEUROL, V30, P482; HAKULINEN A, 1988, ACTA PAEDIATR SCAND, V77, P340, DOI 10.1111/j.1651-2227.1988.tb10658.x; HEINONEN K, 1988, LANCET, V2, P204; HOFFMAN HJ, 1984, CLIN OBSTET GYNECOL, V27, P539, DOI 10.1097/00003081-198409000-00004; HOMER CJ, 1990, AM J PUBLIC HEALTH, V80, P173, DOI 10.2105/AJPH.80.2.173; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; I Chalmers, 1988, OXFORD DATABASE PERI; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANG RE, 1983, NEUROENDOCRINOLOGY, V37, P314, DOI 10.1159/000123566; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCDONALD RL, 1968, PSYCHOSOM MED, V30, P222, DOI 10.1097/00006842-196803000-00007; MCDOWELL J, 1987, MEASURING HLTH GUIDE; MUTALE T, 1991, BRIT J OBSTET GYNAEC, V98, P166, DOI 10.1111/j.1471-0528.1991.tb13363.x; NEWTON RW, 1984, BRIT MED J, V288, P1191, DOI 10.1136/bmj.288.6425.1191; NUCKOLLS KB, 1972, AM J EPIDEMIOL, V95, P431, DOI 10.1093/oxfordjournals.aje.a121410; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; OMER H, 1988, AM J PSYCHIAT, V145, P1507; SPENCER B, 1989, BRIT J OBSTET GYNAEC, V96, P281, DOI 10.1111/j.1471-0528.1989.tb02387.x; STEIN A, 1987, BRIT MED J, V295, P291, DOI 10.1136/bmj.295.6593.291; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VILLAR J, 1992, NEW ENGL J MED, V327, P1266, DOI 10.1056/NEJM199210293271803; WHO (WorldHealthOrganization), 1977, ACTA OBSTET GYNECOL, V56, P247; WILLIAMS CC, 1975, J PSYCHOSOM RES, V19, P123, DOI 10.1016/0022-3999(75)90059-8	35	315	322	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					234	239		10.1136/bmj.307.6898.234	http://dx.doi.org/10.1136/bmj.307.6898.234			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369684	Bronze, Green Published			2022-12-24	WOS:A1993LP31400022
J	GALE, NW; KAPLAN, S; LOWENSTEIN, EJ; SCHLESSINGER, J; BARSAGI, D				GALE, NW; KAPLAN, S; LOWENSTEIN, EJ; SCHLESSINGER, J; BARSAGI, D			GRB2 MEDIATES THE EGF-DEPENDENT ACTIVATION OF GUANINE-NUCLEOTIDE EXCHANGE ON RAS	NATURE			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR; INSULIN; P21RAS; GENE; STIMULATION; MUTATION; PRODUCTS; FAMILY; CELLS	ACTIVATION of receptor tyrosine kinases such as those for epidermal growth factor (EGF), platelet-derived growth factor, or nerve growth factor converts the inactive, GDP-bound form of Ras to the active, GTP-bound form1-4, and a dominant negative mutant of Ras interferes with signalling from such receptors5-8. The mechanisms by which receptor tyrosine kinases and Ras are coupled, however, are not well understood. Many cytoplasmic proteins regulated by such receptors contain Src-homology (SH) 2 and 3 domains, and the SH2- and SH3-containing protein Grb2, like its homologue from Caenorhabditis elegans, Sem-5, appears to play an important role in the control of Ras by receptor tyrosine kinases9-11. Here we show that overexpression of Grb2 potentiates the EGF-induced activation of Ras and mitogen-activated protein kinase by enhancing the rate of guanine nucleotide exchange on Ras. Cellular Grb2 appears to form a complex with a guanine-nucleotide-exchange factor for Ras, which binds to the ligand-activated EGF receptor, allowing the tyrosine kinase to modulate Ras activity.	COLD SPRING HARBOR LAB,1 BUNGTOWN RD,BOX 100,COLD SPRING HARBOR,NY 11724; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Cold Spring Harbor Laboratory; New York University				Bar-Sagi, Dafna/0000-0003-2597-8948				BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; POLAKIS P, 1992, CANCER SURV, V12, P25; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUZAKISADCOCK M, 1992, NATURE, V360, P689; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	30	561	583	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					88	92		10.1038/363088a0	http://dx.doi.org/10.1038/363088a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8386805				2022-12-24	WOS:A1993LA68200067
J	CAMACHO, P; LECHLEITER, JD				CAMACHO, P; LECHLEITER, JD			INCREASED FREQUENCY OF CALCIUM WAVES IN XENOPUS-LAEVIS OOCYTES THAT EXPRESS A CALCIUM-ATPASE	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; CA-2+ ATPASE; RELEASE; OSCILLATIONS; STORES; MUSCLE; PROPAGATION	When inositol 1,4,5-trisphosphate (IP3) receptors are activated, calcium is released from intracellular stores in excitatory propagating waves that annihilate each other upon collision. The annihilation phenomenon suggests the presence of an underlying refractory period that controls excitability. Enhanced calcium-adenosine triphosphatase (ATPase) activity might alter the refractory period of calcium release. Expression of messenger RNA encoding the avian calcium-ATPase (SERCA1) in Xenopus laevis oocytes increased the frequency of IP3-induced calcium waves and narrowed the width of individual calcium waves. The effect of SERCA1 expression on calcium wave frequency was dependent on the concentration of IP3 and was larger at higher (1 muM) than at lower (0.1 muM) concentrations of IP3. The results demonstrate that calcium pump activity can control IP3-mediated calcium signaling.			CAMACHO, P (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DEPT NEUROSCI, CHARLOTTESVILLE, VA 22908 USA.							ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DEVREOTES PN, 1983, DEV BIOL, V96, P405, DOI 10.1016/0012-1606(83)90178-1; DOCKERY JD, 1988, PHYSICA D, V30, P177, DOI 10.1016/0167-2789(88)90105-4; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1992, J BIOL CHEM, V267, P18776; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GORELOVA NA, 1983, J NEUROBIOL, V14, P353, DOI 10.1002/neu.480140503; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARKINS AB, 1991, BIOPHYS J, V59, P240; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILLER RN, 1981, BIOPHYS J, V34, P227, DOI 10.1016/S0006-3495(81)84847-3; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; RAPP PE, 1981, J EXP BIOL, V93, P119; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Winfree A.T., 1987, TIME BREAKS 3 DIMENS; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0	47	147	147	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1993	260	5105					226	229		10.1126/science.8385800	http://dx.doi.org/10.1126/science.8385800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385800				2022-12-24	WOS:A1993KW45200042
J	WHITBY, MC; RYDER, L; LLOYD, RG				WHITBY, MC; RYDER, L; LLOYD, RG			REVERSE BRANCH MIGRATION OF HOLLIDAY JUNCTIONS BY RECG PROTEIN - A NEW MECHANISM FOR RESOLUTION OF INTERMEDIATES IN RECOMBINATION AND DNA-REPAIR	CELL			English	Article							ESCHERICHIA-COLI RECA; RUVC GENE-PRODUCT; CONJUGATIONAL RECOMBINATION; HOMOLOGOUS RECOMBINATION; ATPASE ACTIVITY; RECBCD ENZYME; PURIFICATION; INHIBITION; REQUIRES; MUTANT	The RecG protein of E. coli is a junction-specific DNA helicase involved in recombination and DNA repair. The function of the protein was investigated using an in vitro recombination reaction catalyzed by RecA. We show that RecG counters RecA-driven strand exchange by catalyzing branch migration of the Holliday junction in the reverse direction. This activity represents a new mechanism for resolving recombination intermediates that is independent of junction cleavage. We discuss how reverse branch migration can facilitate DNA repair, promote recombination in conjugational crosses, and confine the distribution of Chi-stimulated cross-overs. We suggest that the RecG mechanism for resolution of junctions is universal and provides a simple system that allows gene conversion without associated crossing over.			WHITBY, MC (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GENET,NOTTINGHAM NG7 2UH,ENGLAND.			Whitby, Matthew/0000-0003-0951-3374	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FOGEL S, 1979, COLD SPRING HARB SYM, V43, P1325, DOI 10.1101/SQB.1979.043.01.152; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; HURST DD, 1972, P NATL ACAD SCI USA, V69, P101, DOI 10.1073/pnas.69.1.101; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JINGJER L, 1992, MOL MICROBIOL, V6, P2219; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KHIDHIR MA, 1985, MOL GEN GENET, V199, P133, DOI 10.1007/BF00327522; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; LAM ST, 1974, GENETICS, V77, P425; LLOYD RG, 1987, MOL GEN GENET, V209, P135, DOI 10.1007/BF00329848; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, 1984, MOL GEN GENET, V197, P328, DOI 10.1007/BF00330981; LU C, 1987, J MOL BIOL, V196, P497, DOI 10.1016/0022-2836(87)90027-1; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; MULLER B, 1993, IN PRESS J BIOL CHEM; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RINKEN R, 1992, J BACTERIOL, V174, P1172, DOI 10.1128/jb.174.4.1172-1178.1992; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1980, GENETICS, V94, P235; STORM PK, 1971, MUTAT RES, V13, P9, DOI 10.1016/0027-5107(71)90121-7; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI NK, 1992, P NATL ACAD SCI USA, V89, P5912, DOI 10.1073/pnas.89.13.5912; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	63	140	140	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					341	350		10.1016/0092-8674(93)80075-P	http://dx.doi.org/10.1016/0092-8674(93)80075-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402917				2022-12-24	WOS:A1993MD88500015
J	CURTIS, R; ADRYAN, KM; ZHU, Y; HARKNESS, PJ; LINDSAY, RM; DISTEFANO, PS				CURTIS, R; ADRYAN, KM; ZHU, Y; HARKNESS, PJ; LINDSAY, RM; DISTEFANO, PS			RETROGRADE AXONAL-TRANSPORT OF CILIARY NEUROTROPHIC FACTOR IS INCREASED BY PERIPHERAL-NERVE INJURY	NATURE			English	Article							FACTOR PREVENTS; SCIATIC-NERVE; MOTOR NEURONS; GROWTH-FACTOR; RAT; DEGENERATION; EXPRESSION; RECEPTOR; INVIVO; BDNF	CILIARY neurotrophic factor (CNTF) promotes the survival of several populations of neurons. including sensory and motor neurons1-4. Although CNTF is abundant in adult sciatic nerve, the mature protein lacks a signal sequence and is not secreted; therefore, it has been proposed to act as a lesion factor3. The identification of a functional CNTF receptor revealed ligand-specific phosphorylation cascades and gene induction5. However, it is not clear how these signal-transducing events are elicited in neuronal cell bodies that may be distant from the source of CNTF. We report here that CNTF can be retrogradely transported by adult sensory neurons. More importantly, sensory and motor neurons both show greatly increased transport of CnTF following peripheral nerve lesion. Axotomy-induced increases in retrograde transport of neurotrophic factors may be an important response of neuronal cell bodies during regeneration.			CURTIS, R (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FERGUSON IA, 1991, J COMP NEUROL, V313, P60; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANSSON HA, 1987, CELL TISSUE RES, V247, P241; HELGREN M, 1992, SOC NEUR ABSTR, V18, P619; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; HOLMLUND T H, 1992, Neurology, V42, P369; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENIUK N, 1992, BRAIN RES, V572, P300, DOI 10.1016/0006-8993(92)90489-V; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E	27	225	232	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					253	255		10.1038/365253a0	http://dx.doi.org/10.1038/365253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371780				2022-12-24	WOS:A1993LX47100054
J	KUNIN, CM; WHITE, LV; HUA, TH				KUNIN, CM; WHITE, LV; HUA, TH			A REASSESSMENT OF THE IMPORTANCE OF LOW-COUNT BACTERIURIA IN YOUNG-WOMEN WITH ACUTE URINARY SYMPTOMS	ANNALS OF INTERNAL MEDICINE			English	Article						BACTINURIA; URINARY TRACT INFECTIONS; COLONY COUNT, MICROBIAL; ESCHERICHIA-COLI; STAPHYLOCOCCUS	ACUTE URETHRAL SYNDROME; TRACT INFECTION; DYSURIA	Objective: To determine whether a statistical association exists between ''low-count'' bacteriuria (> 10(2) to 10(4) colony-forming units/mL) and acute urinary symptoms in young women. Design: Prospective, case-control study. Setting: Gynecology clinic at a student health center. Patients: Women with or without urinary or vaginal symptoms. Measurements: History of urinary infections and sexual activity. Quantitative determination of bacteriuria and pyuria and bacterial species; urine leukocyte esterase test; specific gravity; creatinine levels; vaginal leukocytes; and in-vitro culture of urine. Results: The frequency of recent sexual activity, pregnancies, and contraceptive practices was not statistically different between women with acute urinary symptoms and asymptomatic controls. Escherichia coli and Staphylococcus saprophyticus were the only microorganisms statistically associated with urinary symptoms and pyuria (P < 0.001). Low counts of these organisms were found in 10.2% of asymptomatic women. As the bacterial count increased, the association between these organisms and symptoms increased, and a step-wise increase occurred in the frequency and magnitude of pyuria, but the specific gravity and urine creatinine levels remained unchanged. Escherichia coli, even at low counts, grew well in the patients' own urine. Pyuria (>20 leukocytes/mm3) was present in 19.6% of asymptomatic women and was associated with vaginal leukorrhea. Conclusions: ''Low-count'' bacteriuria was statistically more frequent among young women with urinary symptoms than among asymptomatic controls. The low counts could not be explained by dilution of the urine or failure of the bacteria to grow well in the patients' urine. These findings suggest that the infection was not established in the bladder urine and that ''low-count'' bacteriuria might be an early phase of urinary tract infection.			KUNIN, CM (corresponding author), OHIO STATE UNIV, DEPT INTERNAL MED, ROOM M110, STARLING LOVING HALL, 320 W 10TH AVE, COLUMBUS, OH 43210 USA.							BROOKS D, 1972, LANCET, V2, P893; BRUMFITT W, 1981, LANCET, V2, P393; CATTELL WR, 1974, BRIT MED J, V4, P136, DOI 10.1136/bmj.4.5937.136; COX CE, 1968, J UROLOGY, V99, P632, DOI 10.1016/S0022-5347(17)62762-9; DANS PE, 1976, JOHNS HOPKINS MED J, V138, P13; FIHN SD, 1988, J INFECT DIS, V157, P196, DOI 10.1093/infdis/157.1.196; GALLAGHER DJ, 1965, BMJ-BRIT MED J, V1, P622, DOI 10.1136/bmj.1.5435.622; KASS EH, 1955, AM J MED, V18, P764, DOI 10.1016/0002-9343(55)90190-X; KOMAROFF AL, 1984, NEW ENGL J MED, V310, P368, DOI 10.1056/NEJM198402093100607; Kunin C., 1987, DETECTION PREVENTION; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; KUNIN CM, 1992, CLIN INFECT DIS, V15, P1041, DOI 10.1093/clind/15.6.1041; MASKELL R, 1979, LANCET, V1, P1058; MCDONALD MI, 1982, J UROLOGY, V128, P517, DOI 10.1016/S0022-5347(17)53025-6; MCGUCKIN MB, 1980, J UROLOGY, V124, P240, DOI 10.1016/S0022-5347(17)55385-9; MOND NC, 1965, LANCET, V1, P514; MOORE T, 1965, LANCET, V1, P626; NORDEN CW, 1968, J CLIN INVEST, V47, P2689, DOI 10.1172/JCI105952; O'Grady F, 1966, Br J Urol, V38, P156, DOI 10.1111/j.1464-410X.1966.tb09694.x; OGRADY FW, 1970, LANCET, V2, P1208; PAQUIN AJ, 1965, J CLIN INVEST, V44, P1084; PFAU A, 1977, J UROLOGY, V118, P292, DOI 10.1016/S0022-5347(17)57976-8; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; SANFORD JP, 1956, AM J MED, V20, P88, DOI 10.1016/0002-9343(56)90175-9; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; STAMEY TA, 1971, CALIF MED, V115, P1; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; STAMM WE, 1981, NEW ENGL J MED, V304, P956, DOI 10.1056/NEJM198104163041608; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STEENSBERG J, 1969, BMJ-BRIT MED J, V4, P390, DOI 10.1136/bmj.4.5680.390; TAPSALL JW, 1975, LANCET, V2, P637; WASHINGTON JA, 1990, ANN INTERN MED, V112, P387, DOI 10.7326/0003-4819-112-5-387; WONG ES, 1983, ANNU REV MED, V34, P337, DOI 10.1146/annurev.me.34.020183.002005	33	118	122	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					454	460		10.7326/0003-4819-119-6-199309150-00002	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357110				2022-12-24	WOS:A1993LZ27500002
J	PAREKH, AB; TERLAU, H; STUHMER, W				PAREKH, AB; TERLAU, H; STUHMER, W			DEPLETION OF INSP3 STORES ACTIVATES A CA2+ AND K+ CURRENT BY MEANS OF A PHOSPHATASE AND A DIFFUSIBLE MESSENGER	NATURE			English	Article							XENOPUS OOCYTES; INOSITOL PHOSPHATES; CALCIUM ENTRY; RECEPTOR; PHOSPHORYLATION; RESOLUTION; INJECTION; SEROTONIN; PROTEINS; CHANNEL	IN non-excitable cells, release of Ca2+ from the inositol 1,4,5-trisphosphate (InsP3)-sensitive store can activate Ca2+ entry1-3. Very little is known about the signal mechanism relating store emptying to plasma membrane Ca2+ influx. It has been suggested that the signal may be either a diffusible messenger like an inositol phosphate4, or the InsP3 receptor itself, which, by physically coupling to some component of Ca2+ entry in the plasma membrane, may link store release to Ca2+ entry5. The nature of the Ca2+ entry pathway is also unclear. Only in mast cells has a very selective Ca2+ current been observed after store emptying6. Activation of exogenous 5-hydroxytryptamine (5-HT) receptors expressed in Xenopus oocytes or direct injection of InsP3 evokes Ca2+ entry activated by InsP3 pool depletion7. Here we investigate the nature of this influx pathway and find a current activated by pool depletion. This has an unusual selectivity in that it is more permeable to Ca2+ ions than to other divalent cations (Ba2+, Sr2+ or Mn2+). Moreover, a K+ permeability is also stimulated after pool depletion. The activation of this store depletion current involves both a phosphatase and an unidentified diffusible messenger. Both the Ca2+ entry pathway and the activating factors found here may be relevant to pool-depleted Ca2+ entry in a variety of non-excitable cells.	MAX PLANCK INST EXPTL MED,DEPT MOLEC BIOL NEURONAL SIGNALS,D-37077 GOTTINGEN,GERMANY	Max Planck Society	PAREKH, AB (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MEMBRANE BIOPHYS,FASSBERG POB 2841,D-37077 GOTTINGEN,GERMANY.		Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOGH M, 1993, J PHYSL, V465, P359; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KRAMER RH, 1990, NEURON, V2, P335; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUBBERT H, 1987, J NEUROSCI, V7, P1159; LUPUMEIRI M, 1993, CELL CALCIUM, V14, P101, DOI 10.1016/0143-4160(93)90080-P; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; NOMURA Y, 1987, MOL BRAIN RES, V2, P113, DOI 10.1016/0169-328X(87)90004-0; PAREKH AB, IN PRESS J PHYSL; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WHITE MM, 1990, MOL PHARMACOL, V37, P720; YAO Y, 1992, P R SOC LOND B, V246, P269; ZODROW J, 1984, LIFE SCI, V34, P1967, DOI 10.1016/0024-3205(84)90128-0	28	379	381	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					814	818		10.1038/364814a0	http://dx.doi.org/10.1038/364814a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8395025				2022-12-24	WOS:A1993LU58100059
J	BIRD, AG; GORE, SM; BURNS, SM; DUGGIE, JG				BIRD, AG; GORE, SM; BURNS, SM; DUGGIE, JG			STUDY OF INFECTION WITH HIV AND RELATED RISK-FACTORS IN YOUNG OFFENDERS INSTITUTION	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To estimate the prevalence of infection with HIV in young offenders in Scotland and to obtain information about related risk factors and previous tests for HIV. Design-Voluntary anonymous study with subjects giving saliva samples for testing for HIV and completing questionnaires about risk factors. Setting-Polmont Young Offenders' Institution near Falkirk, Scotland. Subjects-421 of 424 available male prisoners in Polmont. The questionnaires of 17 of the prisoners were excluded because of inaccuracies. Main outcome measures-Prevalence of infection with HIV and related risk behaviour. Results-68 (17%) of prisoners admitted misuse of intravenous drugs, of whom 17 (25%) admitted having injected drugs while in prison. Three subjects admitted having anal intercourse while in prison. Prevalence of misuse of intravenous drugs varied geographically: 28% (33/120) of prisoners from Glasgow compared with 9% (7/81) of those from Edinburgh and Fife. A high level of heterosexual activity was reported, with 36% (142/397) of prisoners claiming to have had six or more female sexual partners in the year before they were imprisoned. Altogether 8% (32/389) of prisoners had previously taken a personal test for HIV: 50% (9/18) of those who had started misusing intravenous drugs before 1989, 18% (9/49) of those who started misuse later, and only 4% (14/322) of those who had not misused intravenous drugs. No saliva sample tested positive for antibodies to HIV, but 96 prisoners requested a confidential personal test for HIV as a result of heightened awareness generated by the study. Conclusions-Voluntary, anonymous HIV surveys can achieve excellent compliance in prisons, and the interest generated by the study suggests that prisons may be suitable sites for providing education and drug rehabilitation for a young male population at high risk of future infection with HIV.	INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND; CITY HOSP EDINBURGH,REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; HLTH CTR,GRP MED PRACTICE,GRANGEMOUTH FK3 9EL,SCOTLAND	MRC Biostatistics Unit; University of Cambridge	BIRD, AG (corresponding author), CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND.							BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, IN PRESS AIDS; GORE SM, 1992, LANCET, V340, P907, DOI 10.1016/0140-6736(92)93313-C; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; 1992, NATURE, V360, P407	5	41	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					228	231		10.1136/bmj.307.6898.228	http://dx.doi.org/10.1136/bmj.307.6898.228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369682	Bronze, Green Published			2022-12-24	WOS:A1993LP31400020
J	TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ				TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ			GENETIC SUSCEPTIBILITY TO NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GLUCOSE-INTOLERANCE ARE LOCATED IN HLA REGION	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY MEN; A ANTIGENS; FREQUENCY; FINLAND; RISK	Objectives-To test the hypothesis that the genetic susceptibility to non-insulin dependent diabetes mellitus is the same as that to insulin dependent disease and to see whether glucose intolerance is associated with specific HLA haplotypes. Design-Population based study of men in 1989 first tested for glucose tolerance in 1984. HLA haplotypes, including HLA-A, C, B, DR, and DQ, were defined serologically. HLA haplotype data from a population based Finnish study of childhood diabetes were used for predicting non-insulin dependent diabetes and impaired glucose tolerance. Setting-Two communities in Finland. Subjects-Representative cohort of Finnish men aged 70-89, comprising 98 men with non-insulin dependent diabetes mellitus and a randomly selected group of 74 men, who served as controls, who were tested for glucose tolerance twice within five years. Main outcome measures-Non-insulin dependent diabetes, impaired glucose tolerance, blood glucose concentration. Results-Diabetes associated HLA haplotypes were present in 94% (85/90) of diabetic subjects, 79% (27/34) of subjects with impaired glucose tolerance, and only 13% (3/23) of non-diabetic subjects. In this group of elderly men sensitivity of the diabetes associated HLA haplotypes for non-insulin dependent diabetes and impaired glucose tolerance was 90%, specificity 87%, and predictive power 97%. Mean fasting blood glucose concentration was only just significantly higher in men with diabetes associated haplotypes than in men with no such haplotypes, but there was a substantial difference in blood glucose values two hours after glucose loading (10.4 and 6.4 mmol/l in men with diabetes associated HLA haplotypes and men with no such haplotypes, respectively (p<0.0001)). Conclusions-These findings support the hypothesis that specific HLA haplotypes exhibit a common genetic determinant for insulin dependent and non-insulin dependent diabetes. Furthermore, HLA is a major genetic determinant of glucose intolerance in elderly Finnish men. The belief that the HLA predisposition to diabetes is specific for insulin dependent diabetes mellitus is largely incorrect.	ROYAL LONDON HOSP,MED UNIT,LONDON E1 1BB,ENGLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; LOIMAA DIST HOSP,LOIMAA,FINLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL,SF-00280 HELSINKI 28,FINLAND	Barts Health NHS Trust; Royal London Hospital; University of Eastern Finland; University of Turku; Finland National Institute for Health & Welfare					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037957] Funding Source: NIH RePORTER; NIA NIH HHS [AG087762] Funding Source: Medline; NIDDK NIH HHS [DK-37957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASMAL AC, 1981, S AFR MED J, V60, P3; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BAUR MP, 1984, HISTOCOMPATIBILITY; BENNETT AH, 1992, INT TXB DIABETES MEL, P147; BHATIA K, 1984, DIABETOLOGIA, V27, P370, DOI 10.1007/BF00304852; BRIGGS BR, 1980, DIABETES, V29, P68, DOI 10.2337/diabetes.29.1.68; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAHLQUIST G, 1989, DIABETOLOGIA, V32, P2; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GROOP L, 1983, ACTA ENDOCRINOL-COP, V104, P475, DOI 10.1530/acta.0.1040475; HARRIS H, 1950, ANN EUGENIC, V15, P95; KEYS A, 1970, CIRCULATION       S1, V41, P1; Neel J. V, 1976, GENETICS DIABETES ME, P1; NERUP J, 1974, LANCET, V2, P864; NISSINEN A, 1986, AGE AGEING, V15, P203, DOI 10.1093/ageing/15.4.203; OMAR MAK, 1988, DIABETES, V37, P796, DOI 10.2337/diabetes.37.6.796; PEKKANEN J, 1989, BRIT MED J, V299, P81, DOI 10.1136/bmj.299.6691.81; PYKE DA, 1977, CLIN ENDOCRINOL META, V6, P285, DOI 10.1016/S0300-595X(77)80039-X; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SERJEANTSOIN SW, 1981, MED J AUSTRALIA, V41, P462; SERJEANTSON SW, 1983, DIABETOLOGIA, V25, P13; SINGAL DP, 1973, DIABETES, V22, P429, DOI 10.2337/diab.22.6.429; SPEES EK, 1973, HISTOCOMPATIBILITY T, P345; TIENARI PJ, 1992, DIABETOLOGIA, V35, P254, DOI 10.1007/BF00400926; TIWARI JL, 1985, HLA DISEASE ASS, P210; TUOMILEHTO J, 1991, INT J EPIDEMIOL, V20, P1010, DOI 10.1093/ije/20.4.1010; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; TUOMILEHTO J, 1986, DIABETOLOGIA, V29, P611, DOI 10.1007/BF00869258; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; TUOMILEHTOWOLF E, 1992, ANN MED, V24, P533, DOI 10.3109/07853899209167007; VELLENA AA, 1980, NEW ENGL J MED, V303, P1065; WILLIAMS RC, 1981, DIABETOLOGIA, V21, P460; WOLF E, 1981, DIABETOLOGIA, V21, pA80; ZHAO TM, 1982, CHINESE MED J-PEKING, V95, P609; 1985, WHO TECH REP SER, V727	35	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					155	159		10.1136/bmj.307.6897.155	http://dx.doi.org/10.1136/bmj.307.6897.155			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343743	Bronze, Green Published			2022-12-24	WOS:A1993LN18400017
J	TAZI, J; KORNSTADT, U; ROSSI, F; JEANTEUR, P; CATHALA, G; BRUNEL, C; LUHRMANN, R				TAZI, J; KORNSTADT, U; ROSSI, F; JEANTEUR, P; CATHALA, G; BRUNEL, C; LUHRMANN, R			THIOPHOSPHORYLATION OF U1-70K PROTEIN INHIBITS PREMESSENGER RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; DROSOPHILA ENCODES; BINDING PROTEINS; SNRNP; SPLICEOSOME; POLYPEPTIDE; REGULATORS; YEAST; SITE; U1	THE U1 small nuclear ribonucleoprotein (snRNP) particle is one of the Sm class of snRNPs essential for splicing of precursor messenger RNA1-5. Mammalian U1 snRNP contains a 165-nucleotide long RNA molecule and at least 11 proteins: the U1-specific 70K proteins A and C, and the common U snRNP proteins (B', B, D1, D2, D3, E, F and G). One of the functions of U1 snRNP is recognition of the 5' splice site, an event that requires both U1 RNA and U1 proteins6-10. The 70K protein is the only heavily phosphorylated U1 protein in the cell11,12. Isolated U1 snRNPs are associated with a kinase activity that selectively phosphorylates the 70K protein in vitro in a reaction requiring ATP. Here we investigate the role of phosphorylation of the 70K protein in the splicing of pre-mRNA. The 70K protein on U1 snRNPs was phosphorylated in vitro with either ATP, or with ATP-gammaS, which gave a thiophosphorylated product that was resistant to dephosphorylation by phosphatases. When HeLa nuclear splicing extracts that had been depleted of endogenous U1 snRNPs were complemented with U1 snRNPs possessing normal phosphorylated 70K protein, mature spliceosomes were generated and the splicing activity of the extracts was fully restored. By contrast, if thiophosphorylated U1 snRNPs were used instead, splicing was completely inhibited, although formation of the mature spliceosome was unaffected. Our data show that the state of phosphorylation of the U1-specific 70K protein is critical for its participation in a pre-catalytic step of the splicing reaction.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,W-3550 MARBURG,GERMANY	Philipps University Marburg	TAZI, J (corresponding author), UNIV MONTPELLIER 2,CNRS,UNITE GENET MOLEC 1191,F-34095 MONTPELLIER 5,FRANCE.			Tazi, Jamal/0000-0002-1949-8748				AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BACH M, 1990, METHOD ENZYMOL, V181, P232; BIENCOWE BJ, 1989, CELL, V59, P531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LELAYTAHA MN, 1986, J MOL BIOL, V189, P519, DOI 10.1016/0022-2836(86)90321-9; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NELSON KK, 1988, GENE DEV, V2, P319, DOI 10.1101/gad.2.3.319; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1992, MOL CELL BIOL YEAST; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TAZI J, 1992, J BIOL CHEM, V267, P4322; TAZI J, IN PRESS MOL CELL BI; TETEI K, 1987, J BIOL CHEM, V262, P11667; WOOLEY JC, 1983, P NATL ACAD SCI-BIOL, V80, P5208, DOI 10.1073/pnas.80.17.5208; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	29	137	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					283	286		10.1038/363283a0	http://dx.doi.org/10.1038/363283a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387646				2022-12-24	WOS:A1993LC86600059
J	TROUCHE, D; GRIGORIEV, M; LENORMAND, JL; ROBIN, P; LEIBOVITCH, SA; SASSONECORSI, P; HARELBELLAN, A				TROUCHE, D; GRIGORIEV, M; LENORMAND, JL; ROBIN, P; LEIBOVITCH, SA; SASSONECORSI, P; HARELBELLAN, A			REPRESSION OF C-FOS PROMOTER BY MYOD ON MUSCLE-CELL DIFFERENTIATION	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; DNA-BINDING; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MYOGENIC DIFFERENTIATION; TRANSCRIPTION FACTOR; MYC HOMOLOGY; FIBROBLASTS; EXPRESSION; MYOBLASTS	TERMINAL differentiation and cell proliferation are in many cases, as in muscle cells1, mutually exclusive processes. While differentiating myoblasts are withdrawn from the cell cycle2, myogenesis is inhibited by some mitogens and overexpression of some oncogenes3,4, including proto-oncogene c-fos5 (which expresses a growth-associated protein constituting the regulatory factor AP-1 in conjunction with c-Jun6,7). MyoD, a muscle-specific transcription factor of the basic helix-loop-helix family8,9, acts at both levels because it triggers a muscle differentiation programme in non-muscle cells10-12, and induces a complete block of cell proliferation13,14. Antagonistic interaction between MyoD and c-Jun has been demonstrated15. We here show that c-fos expression greatly decreases upon muscle cell differentiation, concomitant with MyoD-induced activity. We have identified a MyoD-binding site overlapping with the serum-responsive element in the c-fos promoter. We demonstrate that MyoD can act as a negative regulator for c-fos transcription by blocking serum responsiveness through this binding site. These data suggest that the MyoD negative effect on cell growth could be partly mediated by transcriptional inactivation of growth-responsive genes.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Lenormand, Jean-Luc/M-6644-2014; Lenormand, Jean-Luc/ABF-3850-2021; Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015	Lenormand, Jean-Luc/0000-0002-2766-9180; Harel-Bellan, Annick/0000-0002-2339-153X; Trouche, Didier/0000-0003-1398-6481; Grigoriev, Michel/0000-0002-0252-2254				BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSI M, 1991, ONCOGENE, V6, P1767; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; METZ R, 1991, ONCOGENE, V6, P2165; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TROUCHE D, 1991, BLOOD, V77, P55; TROUCHE D, 1991, J IMMUNOL, V147, P2398	31	90	90	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					79	82		10.1038/363079a0	http://dx.doi.org/10.1038/363079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	8386804				2022-12-24	WOS:A1993LA68200064
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CHOLESTEROL TEST KIT TO BE AVAILABLE OVER-THE-COUNTER FOR HOME USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-24	WOS:A1993KW25000007
J	DIXON, DA; KOWALCZYKOWSKI, SC				DIXON, DA; KOWALCZYKOWSKI, SC			THE RECOMBINATION HOTSPOT-CHI IS A REGULATORY SEQUENCE THAT ACTS BY ATTENUATING THE NUCLEASE ACTIVITY OF THE ESCHERICHIA-COLI RECBCD ENZYME	CELL			English	Article							ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; BACTERIOPHAGE-LAMBDA; EXONUCLEASE-V; PHAGE-LAMBDA; RECD MUTANTS; DNA; ORIENTATION; DEOXYRIBONUCLEASE; SPECIFICITY	The RecBCD enzyme is a multifunctional enzyme that is essential for homologous recombination in E. coli. In vitro, the RecBCD enzyme degrades linear double-stranded DNA nonspecifically during the process of unwinding the double-stranded DNA. Here we demonstrate that this DNA degradation is asymmetric, with the strand that is 3' terminal at the entry site of RecBCD enzyme being degraded much more vigorously than the 5' terminal strand. Furthermore, interaction with the recombination hotspot chi causes an attenuation of the nuclease activity but not of the helicase activity and is accompanied by a pause of RecBCD enzyme at the chi site. These results demonstrate that chi is a unique regulatory element that acts by controlling the degradative function of RecBCD enzyme and, thereby, enhancing its recombination function.	UNIV CALIF DAVIS,MOLEC BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,CELL BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,BIOCHEM SECT,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University	DIXON, DA (corresponding author), UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CHENG KC, 1989, GENETICS, V123, P5; CLEAVER JE, 1972, BIOCHIM BIOPHYS ACTA, V262, P116, DOI 10.1016/0005-2787(72)90224-9; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DOWER NA, 1981, P NATL ACAD SCI-BIOL, V78, P7033, DOI 10.1073/pnas.78.11.7033; EGGLESTON AK, 1993, IN PRESS J MOL BIOL; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1967, J BACTERIOL, V93, P1729, DOI 10.1128/JB.93.5.1729-1731.1967; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; KOBAYASHI I, 1982, P NATL ACAD SCI-BIOL, V79, P5981, DOI 10.1073/pnas.79.19.5981; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LOVETT ST, 1988, GENETICS, V120, P37; MACKAY V, 1976, J BIOL CHEM, V251, P3716; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTZ DW, 1983, J BACTERIOL, V155, P664, DOI 10.1128/JB.155.2.664-680.1983; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SMITH JV, 1981, SCOT EDUC REV, V13, P25; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1990, GENETICS, V126, P519; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	46	203	206	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					87	96		10.1016/0092-8674(93)90162-J	http://dx.doi.org/10.1016/0092-8674(93)90162-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8384931				2022-12-24	WOS:A1993KW75300010
J	WANG, LY; TAVERNA, FA; HUANG, XP; MACDONALD, JF; HAMPSON, DR				WANG, LY; TAVERNA, FA; HUANG, XP; MACDONALD, JF; HAMPSON, DR			PHOSPHORYLATION AND MODULATION OF A KAINATE RECEPTOR (GLUR6) BY CAMP-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							RETINAL HORIZONTAL CELLS; PHOSPHATASES; ENHANCEMENT; NEURONS	Ligand-gated ion channels gated by glutamate constitute the major excitatory neurotransmitter system in the mammalian brain. The functional modulation of GluR6, a kainate-activated glutamate receptor, by adenosine 3',5'-monophosphate-dependent protein kinase A (PKA) was examined with receptors expressed in human embryonic kidney cells. Kainate-evoked currents underwent a rapid desensitization that was blocked by lectins. Kainate currents were potentiated by intracellular perfusion of PKA, and this potentiation was blocked by co-application of an inhibitory peptide. Site-directed mutagenesis was used to identify the site or sites of phosphorylation on GluR6. Although mutagenesis of two serine residues, Ser684 and Ser666, was required for complete abolition of the PKA-induced potentiation, Ser684 may be the preferred site of phosphorylation in native GluR6 receptor complexes. These results indicate that glutamate receptor function can be directly modulated by protein phosphorylation and suggest that a dynamic regulation of excitatory receptors could be associated with some forms of learning and memory in the mammalian brain.	UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,1 KINGS COLL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,FAC PHARM,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto								BARNES JM, 1992, PROG NEUROBIOL, V39, P113, DOI 10.1016/0301-0082(92)90007-2; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P391; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; DUNWIDDIE TV, 1992, J NEUROSCI, V12, P506; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kaczmarek L. K., 1987, NEUROMODULATION; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; LIMAN ER, 1989, BRAIN RES, V481, P399, DOI 10.1016/0006-8993(89)90822-6; LIN SS, 1991, TRENDS NEUROSCI, V14, P273, DOI 10.1016/0166-2236(91)90136-I; RAYMOND LA, IN PRESS NATURE; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; Wang L., UNPUB; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	26	185	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1173	1175		10.1126/science.8382377	http://dx.doi.org/10.1126/science.8382377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8382377				2022-12-24	WOS:A1993KM91700042
J	SWARTZ, KJ; MERRITT, A; BEAN, BP; LOVINGER, DM				SWARTZ, KJ; MERRITT, A; BEAN, BP; LOVINGER, DM			PROTEIN-KINASE-C MODULATES GLUTAMATE RECEPTOR INHIBITION OF CA2+ CHANNELS AND SYNAPTIC TRANSMISSION	NATURE			English	Article							OMEGA-CONOTOXIN; HIPPOCAMPAL-NEURONS; PERIPHERAL NEURONS; CALCIUM CHANNELS; PHORBOL ESTERS; RAT; DESENSITIZATION; PHOSPHORYLATES; TRANSMITTER; EXCITATION	FAST synaptic transmission in the central nervous system can be modulated by neurotransmitters and second-messenger pathways. For example, transmission at glutamatergic synapses can be depressed by the metabotropic glutamate receptor1,2, providing autoreceptor-mediated negative feedback. Metabotropic glutamate receptor inhibition of Ca2+ channels may contribute to this pathway3-6. In contrast, stimulation of protein kinase C can enhance excitatory synaptic transmission7, whereas both depression and enhancement of Ca2+ current have been reported8. Here we show that in hippocampal CA3 and cortical pyramidal neurons, activation of protein kinase C enhances current through N-type Ca2+ channels and, in addition, dramatically reduces G protein-dependent inhibition of these same channels by the metabotropic glutamate receptor. In parallel experiments on fast excitatory transmission at corticostriatal synapses, kinase C activators were similarly found to reduce the inhibitory effect produced by stimulation of the metabotropic glutamate receptor. The results show that second-to-second control of Ca2+ channels by the metabotropic glutamate receptor can itself be modulated on a slower timescale by protein kinase C. These mechanisms may be used in the control of fast excitatory synaptic transmission.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University	SWARTZ, KJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOSMA MM, 1989, P NATL ACAD SCI USA, V86, P2943, DOI 10.1073/pnas.86.8.2943; CORDINGLEY GE, 1986, BRIT J PHARMACOL, V88, P847, DOI 10.1111/j.1476-5381.1986.tb16258.x; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IRVING AJ, 1990, EUR J PHARMACOL, V186, P363, DOI 10.1016/0014-2999(90)90462-F; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LIPSCOMBE D, 1988, Society for Neuroscience Abstracts, V14, P153; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; MADISON D V, 1989, Society for Neuroscience Abstracts, V15, P16; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; POLLOCK WK, 1986, BIOCHEM J, V234, P67, DOI 10.1042/bj2340067; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SAHARA Y, 1991, Society for Neuroscience Abstracts, V17, P1168; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SCHOEPP DD, 1988, BIOCHEM PHARMACOL, V37, P4299, DOI 10.1016/0006-2952(88)90610-7; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P347, DOI 10.1113/jphysiol.1992.sp019168	35	194	196	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					165	168		10.1038/361165a0	http://dx.doi.org/10.1038/361165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8380626				2022-12-24	WOS:A1993KG46600063
J	WERNICK, RM; SMITH, DL; HOUGHTON, DC; PHILLIPS, DS; BOOTH, JL; RUNCKEL, DN; JOHNSON, DS; BROWN, KK; GABOURY, CL				WERNICK, RM; SMITH, DL; HOUGHTON, DC; PHILLIPS, DS; BOOTH, JL; RUNCKEL, DN; JOHNSON, DS; BROWN, KK; GABOURY, CL			RELIABILITY OF HISTOLOGIC SCORING FOR LUPUS NEPHRITIS - A COMMUNITY-BASED EVALUATION	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS NEPHRITIS; GLOMERULONEPHRITIS; HISTOLOGIC TECHNIQUES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); KIDNEY FAILURE, CHRONIC	TERM FOLLOW-UP; PROGNOSTIC FACTORS; INTEROBSERVER VARIABILITY; OBSERVER VARIATION; CLINICAL METHODS; GLOMERULONEPHRITIS; CLASSIFICATION; PREDNISONE; CYCLOPHOSPHAMIDE; ERYTHEMATOSUS	Objective: To determine the reliability of the National Institutes of Health (NIH)-modified semiquantitative histologic scoring system for lupus nephritis. Design: Cross-sectional study, repeated after 8 to 9 months. Setting: Four community hospitals and one university medical center. Participants: Five pathologists, all experienced in reading renal biopsy specimens, assessed 25 specimens that had been obtained from patients with a clinical diagnosis of systemic lupus erythematosus and showed diffuse proliferative glomerulonephritis. Measurements: Biopsy specimens were scored independently and blindly by pathologists for components of nephritis chronicity and activity. Reliability was measured by percentage agreement, intraclass correlation coefficient or kappa statistic, and individual reader effect on the group arithmetic mean. Results: As scored by the readers, the mean chronicity index score varied from 2.3 to 4.8 on a 12-point scale (P = 0.001) and the mean activity index score varied from 5.8 to 11.4 on a 24-point scale (P = 0.0001). Pairs of readers gave scores within 1 point for the chronicity index and within 2 points for the activity index in 50% of cases, and risk group assignments based on chronicity index (three strata) and activity index (two strata) were concordant in 59% and 76% of cases, respectively. Intraclass correlation coefficients for inter-reader agreement were 0.58 for the chronicity index (P < 0.01) and 0.52 for the activity index (P < 0.01). Intrareader agreement was uniformly higher than inter-reader agreement, but mean intraclass correlation coefficients exceeded 0.70 for only 1 of the 10 index components. Repeated readings yielded chronicity index scores that were more than 1 point discordant in 45% of cases and activity index scores that were more than 2 points discordant in 43% of cases. Risk group assignment changed on the basis of chronicity index and activity index in 36% and 21% of cases, respectively. Conclusions: In a nonreferral setting, the NIH-modified scoring system for lupus nephritis is only moderately reproducible and, if used to prognosticate renal outcome, may result in erroneous predictions of risk for renal failure and response to therapy.	OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEPHROL, PORTLAND, OR 97201 USA; VET AFFAIRS MED CTR, PORTLAND, OR 97207 USA; OREGON HLTH SCI UNIV, DEPT PUBL HLTH & PREVENT MED, PORTLAND, OR 97201 USA; ST VINCENT HOSP & MED CTR, DEPT PATHOL, PORTLAND, OR 97227 USA; GOOD SAMARITAN HOSP, PORTLAND, OR USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Saint Vincents Hospital Manhattan	WERNICK, RM (corresponding author), PROVIDENCE MED CTR, 4805 NE GLISAN ST, PORTLAND, OR 97213 USA.							ALEXOPOULOS E, 1990, KIDNEY INT, V37, P100, DOI 10.1038/ki.1990.14; APPEL GB, 1978, MEDICINE, V57, P371, DOI 10.1097/00005792-197809000-00001; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALDWIN DS, 1970, ANN INTERN MED, V73, P929, DOI 10.7326/0003-4819-73-6-929; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BALOW JE, 1988, HOSP PRACT, V23, P129; BANFI G, 1985, Q J MED, V55, P153; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; CARETTE S, 1983, ANN INTERN MED, V99, P1, DOI 10.7326/0003-4819-99-1-1; DONADIO JV, 1972, ANN INTERN MED, V77, P829, DOI 10.7326/0003-4819-77-6-829; ESDAILE JM, 1989, Q J MED, V72, P779; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; GAMBA G, 1991, NEPHRON, V57, P75, DOI 10.1159/000186220; KLINKHOFF AV, 1988, J RHEUMATOL, V15, P492; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; LAITMAN RS, 1989, AM J MED, V87, P132; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; MAGIL AB, 1988, KIDNEY INT, V34, P511, DOI 10.1038/ki.1988.211; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; NOSSENT HC, 1990, ARTHRITIS RHEUM, V33, P970, DOI 10.1002/art.1780330708; PILLEMER SR, 1988, J RHEUMATOL, V15, P284; PIRANI CL, 1964, NEPHRON, V1, P230, DOI 10.1159/000179336; PIRANI CL, 1968, PATHOL ANNU, V3, P249; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P424; RUSH PJ, 1986, KIDNEY INT, V29, P1066, DOI 10.1038/ki.1986.108; SACKETT DL, 1980, CAN MED ASSOC J, V123, P499; SCHWARTZ MM, 1992, KIDNEY INT, V42, P743, DOI 10.1038/ki.1992.342; SCHWARTZ MM, 1989, KIDNEY INT, V36, P891, DOI 10.1038/ki.1989.276; SHANES JG, 1987, CIRCULATION, V75, P401, DOI 10.1161/01.CIR.75.2.401; SILCOCKS PBS, 1983, J CLIN PATHOL, V36, P1269, DOI 10.1136/jcp.36.11.1269; SISSONS HA, 1975, POSTGRAD MED J, V51, P685, DOI 10.1136/pgmj.51.600.685; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; THOMAS GDH, 1983, J CLIN PATHOL, V36, P385, DOI 10.1136/jcp.36.4.385	40	52	53	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					805	811		10.7326/0003-4819-119-8-199310150-00006	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379602				2022-12-24	WOS:A1993MB49600006
J	BAKER, J; LIU, JP; ROBERTSON, EJ; EFSTRATIADIS, A				BAKER, J; LIU, JP; ROBERTSON, EJ; EFSTRATIADIS, A			ROLE OF INSULIN-LIKE GROWTH-FACTORS IN EMBRYONIC AND POSTNATAL-GROWTH	CELL			English	Article							FACTOR-II GENE; MESSENGER RIBONUCLEIC-ACIDS; GIANT TRANSGENIC MICE; IGF-II; BINDING-PROTEINS; PRENATAL GROWTH; DEVELOPING RAT; MOUSE EMBRYOS; DWARF MICE; ADULT-RAT	A developmental analysis of growth kinetics in mouse embryos carrying null mutations of the genes encoding insulin-like growth factor I (IGF-I), IGF-II, and the type 1 IGF receptor (IGF1R), alone or in combination, defined the onset of mutational effects leading to growth deficiency and indicated that between embryonic days 11.0 and 12.5, IGF1R serves only the in vivo mitogenic signaling of IGF-II. From E13.5 onward, IGF1R interacts with both IGF-I and IGF-II, while IGF-II recognizes an additional unknown receptor (XR). In contrast with the embryo proper, placental growth is served exclusively by an IGF-II-XR interaction. Additional genetic data suggested that the type 2 IGF/mannose 6-phosphate receptor is an unlikely candidate for XR. Postnatal growth curves indicated that surviving Igf-1(-/-) mutants, which are infertile and exhibit delayed bone development, continue to grow with a retarded rate after birth in comparison with wild-type littermates and become 30% of normal weight as adults.			BAKER, J (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							[Anonymous], 1991, INSULIN LIKE GROWTH; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BECK F, 1987, DEVELOPMENT, V101, P175; Boettiger E, 1938, ENDOCRINOLOGY, V22, P447, DOI 10.1210/endo-22-4-447; BURGOYNE PS, 1983, J REPROD FERTIL, V68, P387, DOI 10.1530/jrf.0.0680387; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CHARD T, 1989, J ENDOCRINOL, V123, P3, DOI 10.1677/joe.0.1230003; CHENG TC, 1983, ENDOCRINOLOGY, V113, P1669, DOI 10.1210/endo-113-5-1669; COCK AG, 1966, Q REV BIOL, V41, P131, DOI 10.1086/404940; DAUGHADAY WH, 1989, PERSPECT BIOL MED, V32, P194; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DERCOLE AJ, 1980, DEV BIOL, V79, P33, DOI 10.1016/0012-1606(80)90071-8; EICHER EM, 1980, J HERED, V71, P187, DOI 10.1093/oxfordjournals.jhered.a109344; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; ENESCO M, 1962, J EMBRYOL EXP MORPH, V10, P530; FILSON AJ, 1993, DEVELOPMENT, V118, P731; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GIRARD J, 1989, INTRAUTERINE GROWTH, P23; Gluckman P., 1992, HUMAN GROWTH BASIC C, P253; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; GOEDBLOED JF, 1972, ACTA ANAT, V82, P305; GREEN H, 1985, DIFFERENTIATION, V29, P195, DOI 10.1111/j.1432-0436.1985.tb00316.x; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; HOYT EC, 1988, MOL ENDOCRINOL, V2, P1077, DOI 10.1210/mend-2-11-1077; HUGGETT AS, 1951, J PHYSIOL-LONDON, V114, P306, DOI 10.1113/jphysiol.1951.sp004622; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; ISAKSSON OGP, 1991, PEDIATR NEPHROL, V5, P451, DOI 10.1007/BF01453680; JAMES DA, 1967, J REPROD FERTIL, V14, P265, DOI 10.1530/jrf.0.0140265; JOHNSON DR, 1974, GENETICS, V76, P795; JOHNSON DR, 1974, GENET RES, V24, P207, DOI 10.1017/S0016672300015226; JONAS HA, 1989, BIOCHEM J, V257, P101, DOI 10.1042/bj2570101; KIESS W, 1987, J BIOL CHEM, V262, P12745; KOHLER E, 1972, N-S ARCH PHARMAKOL, V272, P169, DOI 10.1007/BF00508767; LAIRD AK, 1965, GROWTH, V29, P233; LEE JE, 1990, DEVELOPMENT, V110, P151; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LINDAHL A, 1987, J ENDOCRINOL, V115, P263, DOI 10.1677/joe.0.1150263; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LUND PK, 1986, J BIOL CHEM, V261, P4539; MacDowell EC, 1927, J GEN PHYSIOL, V11, P57, DOI 10.1085/jgp.11.1.57; MACNEIL MD, 1983, GROWTH, V47, P371; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCLAREN A, 1965, J REPROD FERTIL, V9, P79, DOI 10.1530/jrf.0.0090079; MCLAREN A, 1965, J REPROD FERTIL, V9, P343; Medawar PB., 1945, ESSAYS GROWTH FORM, P157; MILNER RDG, 1987, EUR J PEDIATR, V146, P113, DOI 10.1007/BF02343214; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1806, DOI 10.1210/endo-120-5-1806; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; Needham J, 1931, CHEM EMBRYOLOGY; NILSSON A, 1986, SCIENCE, V233, P571, DOI 10.1126/science.3523759; NISSLEY SP, 1980, HORM METAB RES, V12, P158, DOI 10.1055/s-2007-996230; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKA Y, 1985, J BIOL CHEM, V260, P9435; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAYNE PR, 1967, NATURE, V215, P849, DOI 10.1038/215849a0; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; ROBERTS CT, 1986, J BIOL CHEM, V261, P25; ROTWEIN P, 1987, ENDOCRINOLOGY, V121, P2141, DOI 10.1210/endo-121-6-2141; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SENIOR PV, 1990, DEVELOPMENT, V109, P67; SHEA BT, 1987, ENDOCRINOLOGY, V121, P1924, DOI 10.1210/endo-121-6-1924; SHEA BT, 1990, GENET RES, V56, P21, DOI 10.1017/S0016672300028846; SIKOV MR, 1970, GROWTH, V34, P1; Snell GD, 1929, P NATL ACAD SCI USA, V15, P274, DOI 10.1073/pnas.15.3.274; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; VANBUULOFFERS S, 1983, ACTA ENDOCRINOL-COP, V103, P1; von Bertalanffy L., 1960, FUNDAMENTAL ASPECTS, P137, DOI 10.1016/b978-0-408-10638-2.50012-4; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WINICK M, 1965, DEV BIOL, V12, P451, DOI 10.1016/0012-1606(65)90009-6; ZHOU J, 1992, ENDOCRINOLOGY, V131, P1230, DOI 10.1210/en.131.3.1230	82	1963	2031	0	106	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					73	82		10.1016/0092-8674(93)90680-O	http://dx.doi.org/10.1016/0092-8674(93)90680-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402902				2022-12-24	WOS:A1993MB66700009
J	CHIK, CL; FRIEDMAN, A; MERRIAM, GR; GAHL, WA				CHIK, CL; FRIEDMAN, A; MERRIAM, GR; GAHL, WA			PITUITARY-TESTICULAR FUNCTION IN NEPHROPATHIC CYSTINOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYSTINOSIS; KIDNEY TRANSPLANTATION; TESTOSTERONE; KIDNEY FAILURE, CHRONIC; HYPOGONADISM	PLASMA TESTOSTERONE; HORMONE-SECRETION; LH; COMPLICATIONS; INSUFFICIENCY; HYPOGONADISM; CHILDREN; SUBUNITS; INVITRO; PATIENT	Objective: To evaluate reproductive function in patients with cystinosis and in renal transplant recipients without cystinosis. Design: Cross-sectional study. Setting: Clinical Center, National Institutes of Health. Patients: Ten male patients, 15 to 28 years old, with nephropathic cystinosis and renal allografts formed the study group; 11 renal transplant recipients who had a primary renal disorder other than cystinosis and were matched with study patients for age and renal function served as the control group. Measurements: Tanner staging, serum gonadotropin determinations, and testosterone and testosterone-binding globulin assessments. Selected patients also had a human chorionic gonadotropin (HCG) stimulation test, a gonadotropin-releasing hormone (GnRH) stimulation test, and serial sampling for luteinizing hormone (LH). Main Results: Although testosterone levels were within normal limits in 7 of 10 patients with cystinosis, the mean testosterone level in patients with cystinosis was 11.5 +/- 2.0 nmol/L compared with 24.2 +/- 3.0 nmol/L in control patients (P < 0.005). No patient with cystinosis reached Tanner stage 5 (full pubertal development), whereas 9 of 11 control patients did. Seven of 10 patients with cystinosis had elevations in LH or follicle-stimulating hormone (FSH) levels, suggesting testicular failure. These patients also had normal LH and FSH responses after GnRH stimulation, increased LH pulse frequency, and reduced testosterone response after HCG stimulation. In comparison, only 3 of 11 control patients had minimally elevated gonadotropin levels, and all 11 had normal testosterone levels. Microscopic testicular examination in one patient showed cystine crystals, germinal dysplasia, increased fibrosis, and Leydig cell hyperplasia. Conclusions: Abnormalities in the pituitary-testicular axis are common in male patients with cystinosis. These changes appear to be related to the disease cystinosis and not to treated renal failure per se.	NICHHD, HUMAN GENET BRANCH, BLDG 10, ROOM 95-242, BETHESDA, MD 20892 USA; UNIV WISCONSIN, MADISON, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Wisconsin System; University of Wisconsin Madison								ADAMSON MD, 1989, SEMIN NEPHROL, V9, P147; AMMENTI A, 1986, EUR J PEDIATR, V145, P548, DOI 10.1007/BF02429061; BLACKMAN MR, 1981, J CLIN ENDOCR METAB, V53, P39, DOI 10.1210/jcem-53-1-39; BLACKMAN MR, 1980, JNCI-J NATL CANCER I, V65, P81; CHAN AM, 1970, AM J MED, V48, P678, DOI 10.1016/S0002-9343(70)80002-X; DUFAU ML, 1972, CLIN CHIM ACTA, V37, P109, DOI 10.1016/0009-8981(72)90421-4; DUFAU ML, 1976, J CLIN ENDOCR METAB, V42, P958, DOI 10.1210/jcem-42-5-958; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; FRANCHIMONT P, 1974, CLIN ENDOCRINOL, V3, P27, DOI 10.1111/j.1365-2265.1974.tb03293.x; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1986, J PEDIATR-US, V109, P605, DOI 10.1016/S0022-3476(86)80221-9; GAHL WA, 1988, ANN INTERN MED, V109, P557, DOI 10.7326/0003-4819-109-7-557; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GROSS KM, 1985, J CLIN ENDOCR METAB, V60, P197, DOI 10.1210/jcem-60-1-197; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KOURIDES IA, 1974, ENDOCRINOLOGY, V94, P1411, DOI 10.1210/endo-94-5-1411; LUCKY AW, 1977, J PEDIATR-US, V91, P204, DOI 10.1016/S0022-3476(77)80813-5; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MATSUMOTO AM, 1984, J CLIN ENDOCR METAB, V58, P609, DOI 10.1210/jcem-58-4-609; MERRIAM GR, 1982, AM J PHYSIOL, V243, pE310, DOI 10.1152/ajpendo.1982.243.4.E310; ODELL WD, 1966, METABOLIS, V15, P287, DOI 10.1016/0026-0495(66)90142-9; ODELL WD, 1967, J LAB CLIN MED, V70, P973; REISS RE, 1988, NEW ENGL J MED, V319, P223, DOI 10.1056/NEJM198807283190406; ROTH JC, 1972, J CLIN ENDOCR METAB, V35, P926, DOI 10.1210/jcem-35-6-926; SAEZ JM, 1979, J CLIN ENDOCR METAB, V49, P278, DOI 10.1210/jcem-49-2-278; SMALS AGH, 1979, J CLIN ENDOCR METAB, V49, P12, DOI 10.1210/jcem-49-1-12; SMALS AGH, 1974, ACTA ENDOCRINOL-COP, V77, P753, DOI 10.1530/acta.0.0770753; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; SPRATT DI, 1987, J CLIN ENDOCR METAB, V64, P283, DOI 10.1210/jcem-64-2-283; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; WINTER JSD, 1972, J CLIN ENDOCR METAB, V34, P348, DOI 10.1210/jcem-34-2-348; WOLLENSEN F, 1976, METABOLISM, V8, P845	40	55	58	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				568	575		10.7326/0003-4819-119-7_Part_1-199310010-00004	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363167				2022-12-24	WOS:A1993MA29100004
J	KATZ, JD; WANG, B; HASKINS, K; BENOIST, C; MATHIS, D				KATZ, JD; WANG, B; HASKINS, K; BENOIST, C; MATHIS, D			FOLLOWING A DIABETOGENIC T-CELL FROM GENESIS THROUGH PATHOGENESIS	CELL			English	Article							NONOBESE DIABETIC MICE; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR TRANSGENIC MICE; ATHYMIC NUDE-MICE; NOD MICE; MONOCLONAL-ANTIBODY; CLONAL DELETION; LYMPHOCYTE-T; BETA-GENES; ANTIGEN	Nonobese diabetic (NOD) mice spontaneously develop a disease very similar to type 1 diabetes in humans. We have generated a transgenic mouse strain carrying the rearranged T cell receptor genes from a diabetogenic T cell clone derived from a NOD mouse. Self-reactive T cells expressing the transgene-encoded specificity are not tolerized in these animals, resulting in rampant insulitis and eventually diabetes. Features of the disease process emphasize two so-called check-points, recognized previously in the NOD and human diseases but easily misinterpreted. Although NOD mice are protected from insulitis and diabetes by expression of the E molecule encoded in the major histocompatibility complex, the transgenics are not, permitting us to exclude some possible mechanisms of protection.	UNIV COLORADO, HLTH SCI CTR, BARBARA DAVIS CTR DIABET, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	KATZ, JD (corresponding author), INST CHIM BIOL, GENET MOLEC EUCARYOTES LAB,CNRS,UNITE BIOL MOLEC, INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.			Katz, Jonathan/0000-0002-9864-2268				ACHAORBEA H, 1985, EUR J IMMUNOL, V15, P31, DOI 10.1002/eji.1830150107; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; Berg L J, 1989, Semin Immunol, V1, P105; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; BOHME J, 1990, SCIENCE, V249, P293, DOI 10.1126/science.2115690; BOITARD C, 1989, J EXP MED, V169, P1669, DOI 10.1084/jem.169.5.1669; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; BRADLEY BJ, 1992, DIABETES, V41, P1603, DOI 10.2337/diabetes.41.12.1603; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DARDENNE M, 1989, EUR J IMMUNOL, V19, P889, DOI 10.1002/eji.1830190516; DIAZGALLO C, 1992, P NATL ACAD SCI USA, V89, P8656, DOI 10.1073/pnas.89.18.8656; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; GARCHON HJ, 1992, CURR OPIN IMMUNOL, V4, P716, DOI 10.1016/0952-7915(92)90051-F; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HARADA M, 1986, EXP ANIM TOKYO, V35, P501, DOI 10.1538/expanim1978.35.4_501; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1989, P NATL ACAD SCI USA, V86, P8000, DOI 10.1073/pnas.86.20.8000; HASKINS K, 1988, DIABETES, V37, P1444, DOI 10.2337/diabetes.37.10.1444; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HAYAKAWA M, 1991, DIABETES, V40, P1210, DOI 10.2337/diabetes.40.9.1210; HAYWARD AR, 1989, J IMMUNOL, V143, P1555; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HUTCHINGS P, 1990, NATURE, V348, P639, DOI 10.1038/348639a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOIKE T, 1987, DIABETES, V36, P539, DOI 10.2337/diabetes.36.4.539; KOOP BF, 1992, GENOMICS, V13, P1209, DOI 10.1016/0888-7543(92)90039-U; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEE KU, 1988, DIABETES, V37, P989, DOI 10.2337/diabetes.37.7.989; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MAKINO S, 1980, Experimental Animals (Tokyo), V29, P1; MAKINO S, 1986, EXP ANIM TOKYO, V35, P495, DOI 10.1538/expanim1978.35.4_495; MALEK TR, 1983, P NATL ACAD SCI-BIOL, V80, P5694, DOI 10.1073/pnas.80.18.5694; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MILLER BJ, 1988, J IMMUNOL, V140, P52; MILLER JFAP, 1992, ANNU REV IMMUNOL, V10, P51, DOI 10.1146/annurev.iy.10.040192.000411; MIYAZAKI A, 1985, CLIN EXP IMMUNOL, V60, P622; MORI Y, 1986, DIABETOLOGIA, V29, P244, DOI 10.1007/BF00454884; NAGATA M, 1992, DIABETES, V41, P998, DOI 10.2337/diabetes.41.8.998; NAGATA M, 1989, J IMMUNOL, V143, P1155; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NISHIMOTO H, 1987, NATURE, V328, P432, DOI 10.1038/328432a0; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; Ohashi P S, 1989, Semin Immunol, V1, P95; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; PANKEWYCZ O, 1991, EUR J IMMUNOL, V21, P873, DOI 10.1002/eji.1830210403; PANKEWYCZ OG, 1992, EUR J IMMUNOL, V22, P2017, DOI 10.1002/eji.1830220810; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; POSSELT AM, 1992, SCIENCE, V256, P1321, DOI 10.1126/science.1598576; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; REICHERT RA, 1983, J EXP MED, V157, P813, DOI 10.1084/jem.157.3.813; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SEMPE P, 1991, EUR J IMMUNOL, V21, P1163, DOI 10.1002/eji.1830210511; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SIGNORELLI K, 1992, EUR J IMMUNOL, V22, P2487, DOI 10.1002/eji.1830221004; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; THIVOLET C, 1991, J IMMUNOL, V146, P85; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; UEHIRA M, 1989, INT IMMUNOL, V1, P210; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; UNO M, 1992, IMMUNOL LETT, V31, P47, DOI 10.1016/0165-2478(92)90009-D; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WICKER LS, 1992, J EXP MED, V176, P67, DOI 10.1084/jem.176.1.67; YAGI H, 1992, EUR J IMMUNOL, V22, P2387, DOI 10.1002/eji.1830220931; YASUNAMI R, 1988, EUR J IMMUNOL, V18, P481, DOI 10.1002/eji.1830180325	78	601	608	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1089	1100		10.1016/0092-8674(93)90730-E	http://dx.doi.org/10.1016/0092-8674(93)90730-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402882				2022-12-24	WOS:A1993LY49300015
J	BACK, NA; LINNEMANN, CC; PFALLER, MA; STANECK, JL; MORTHLAND, V				BACK, NA; LINNEMANN, CC; PFALLER, MA; STANECK, JL; MORTHLAND, V			RECURRENT EPIDEMICS CAUSED BY A SINGLE STRAIN OF ERYTHROMYCIN-RESISTANT STAPHYLOCOCCUS-AUREUS - THE IMPORTANCE OF MOLECULAR EPIDEMIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL INFECTIONS; GEL-ELECTROPHORESIS; NASAL CARRIER; PLASMID DNA; OUTBREAK; NURSERY	Objective.-To compare the accuracy of clinical epidemiologic findings with results of molecular epidemiologic analysis in identifying the source of recurrent epidemics of erythromycin-resistant Staphylococcus aureus (ERSA) infections in a well-baby nursery. Design.-Epidemic investigations with retrospective and prospective microbiological surveillance. Staphylococcus aureus isolates were evaluated by plasmid analysis and genotyping. Setting.-A well-baby nursery in a 700-bed university teaching hospital with approximately 250 deliveries per month. Patients.-Newborn, infants who developed ERSA infections during 1990 and 1991. Intervention.-Traditional infection control measures, including cohorting of infected infants and hand washing, were implemented. Personnel were cultured for nasal carriage of S aureus during both epidemics. Employees carrying ERSA were removed from the nursery and treated with mupirocin. Results.-In the first epidemic, 15 infants were infected with ERSA. A nursing assistant who cared for most of the infants was found to be a carrier of ERSA. She was removed from the nursery and the epidemic resolved. Fifteen months after the first epidemic ended, an epidemic that involved 11 infants began. The attending physician had a facial furuncle and was found to be a carrier of ERSA. The physician was treated and the epidemic resolved. Plasmid and genotyping showed the ERSA organisms from both epidemics were the same. The employee implicated in the first epidemic did not have the epidemic strain, but the physician who attended during both epidemics did. Conclusions.-Traditional epidemic investigations may lead to false conclusions that can only be recognized with molecular epidemiologic techniques. For these techniques to be useful in the control of outbreaks, plasmid analysis and/or genotyping must be readily available.	UNIV CINCINNATI,COLL MED,DEPT INFECT CONTROL,CINCINNATI,OH 45221; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; UNIV CINCINNATI,COLL MED,DEPT MED,CINCINNATI,OH 45221; UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45221	University System of Ohio; University of Cincinnati; Oregon Health & Science University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati								BELANI A, 1986, INFECT CONT HOSP EP, V7, P487, DOI 10.1017/S0195941700065097; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; HALL LMC, 1989, EPIDEMIOL INFECT, V103, P183, DOI 10.1017/S095026880003048X; HARTSTEIN AI, 1989, J CLIN MICROBIOL, V27, P1874, DOI 10.1128/JCM.27.8.1874-1879.1989; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; ICHIYAMA S, 1991, J CLIN MICROBIOL, V29, P2690, DOI 10.1128/JCM.29.12.2690-2695.1991; John J F Jr, 1989, Infect Dis Clin North Am, V3, P683; Kloos WE, 1991, MANUAL CLIN MICROBIO, P222; LIGHT IJ, 1972, PEDIATRICS, V49, P15; LINNEMANN CC, 1991, AM J MED, V91, pS238, DOI 10.1016/0002-9343(91)90375-8; NAKASHIMA AK, 1984, INFECT CONT HOSP EP, V5, P326, DOI 10.1017/S0195941700060513; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; RHINEHART E, 1987, ARCH INTERN MED, V147, P521, DOI 10.1001/archinte.147.3.521; ZUCCARELLI AJ, 1990, J CLIN MICROBIOL, V28, P97, DOI 10.1128/JCM.28.1.97-102.1990; 1984, MIA3 NAT COMM CLIN L	17	27	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1329	1333		10.1001/jama.270.11.1329	http://dx.doi.org/10.1001/jama.270.11.1329			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360968				2022-12-24	WOS:A1993LW34500030
J	HENKEL, T; MACHLEIDT, T; ALKALAY, I; KRONKE, M; BEN-NERIAH, Y; BAEUERLE, PA				HENKEL, T; MACHLEIDT, T; ALKALAY, I; KRONKE, M; BEN-NERIAH, Y; BAEUERLE, PA			RAPID PROTEOLYSIS OF I-KAPPA-B-ALPHA IS NECESSARY FOR ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B	NATURE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; DNA-BINDING; INHIBITOR; PHOSPHORYLATION; INTERLEUKIN-1; PRECURSOR; ENHANCER; INVITRO; CELLS	INDUCIBLE gene expression in eukaryotes is mainly controlled by the activity of transcriptional activator proteins, such as NF-kappaB (refs 1-3), a factor activated upon treatment of cells with phorbol esters, lipopolysaccharide4, interleukin-1 and tumour necrosis factor-alpha5. Activation of NF-kappaB involves release of the inhibitory subunit IkappaB from a cytoplasmic complex with the DNA-binding subunits Rel-A (formerly p65) and p50 (refs 6, 7). Cell-free experiments have suggested that protein kinase C and other kinases transfer phosphoryl groups onto IkappaB causing release of IkappaB and subsequent activation of NF-kappaB8-10. Here we report that IkappaB-alpha (formerly MAD-3)11 is degraded in cells after stimulation with phorbol ester, interleukin-1, lipopolysaccharide and tumour necrosis factor-alpha, an event coincident with the appearance of active NF-kappaB. Treatment of cells with various protease inhibitors or an antioxidant completely prevented the inducible decay of IkappaB-alpha as well as the activation of NF-kappaB. Our findings suggest that the activation of NF-kappaB relies on an inducible degradation of IkappaB-alpha through a cytoplasmic, chymotrypsin-like protease. In intact cells, phosphorylation of IkappaB-alpha is apparently not sufficient for activation of NF-kappaB.	GENE CTR, MOLEC BIOL LAB, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL; TECH UNIV MUNICH, INST MIKROBIOL & HYG, W-8000 MUNICH 2, GERMANY	Hebrew University of Jerusalem; Technical University of Munich			Ben-Neriah, Yinon/L-6285-2019					BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P786; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DEMARTIN R, IN PRESS EMBO J; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER M, IN PRESS EMBO J; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, IN PRESS METH ENZYM; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	29	1117	1134	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					182	185		10.1038/365182a0	http://dx.doi.org/10.1038/365182a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371761				2022-12-24	WOS:A1993LW44200054
J	YOUNGSON, C; NURSE, C; YEGER, H; CUTZ, E				YOUNGSON, C; NURSE, C; YEGER, H; CUTZ, E			OXYGEN SENSING IN AIRWAY CHEMORECEPTORS	NATURE			English	Article							NEURO-EPITHELIAL BODIES; RAT CAROTID-BODY; MEMBRANE PATCHES; CYTOCHROME-B; PO2 SENSOR; L-DOPA; CELLS; LUNG; HYPOXIA; LOCALIZATION	PULMONARY neuroepithelial bodies, composed of innervated clusters of amine- and peptide-containing cells, are widely distributed throughout the airway mucosa of human and animal lungs1-3. Structurally, neuroepithelial bodies resemble chemoreceptors (such as carotid body, taste buds) and are thought to function as hypoxia-sensitive airway sensors4. Evidence for this is indirect, however, and the mechanism of oxygen sensing by these cells is unknown. Here we culture neuroepithelial bodies isolated from rabbit fetal lungs and identify voltage-activated potassium, calcium and sodium currents using the whole-cell patch clamp technique. Upon exposure to hypoxia there is a reversible reduction (25-30%) in the outward potassium current, with no change in inward currents. In addition, we demonstrate the expression of an oxygen-binding protein (b-cytochrome, NADPH oxidase) on the plasma membrane of these cells. The identification of an oxygen-sensing mechanism (namely the presence of an O2-sensitive potassium channel coupled to an O2 sensor protein5) in the cells of pulmonary neuroepithelial bodies indicates that they are transducers of the hypoxia stimulus and hence may function as airway chemoreceptors in the regulation of respiration.	HOSP SICK CHILDREN, RES INST, DEPT PATHOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; University of Toronto								ACKER H, 1989, FEBS LETT, V256, P75, DOI 10.1016/0014-5793(89)81721-1; CHO T, 1989, CELL TISSUE RES, V255, P353; CUTZ E, 1990, ARTERIAL CHEMORECEPTION, P432; CUTZ E, 1985, LAB INVEST, V53, P672; CUTZ E, 1984, ENDOCRINE LUNG HLTH, P210; GAZDAR AF, 1988, CANCER RES, V48, P4078; GONZALEZ C, 1992, TRENDS NEUROSCI, V15, P146, DOI 10.1016/0166-2236(92)90357-E; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERTZBERG T, 1990, J PHYSIOL-LONDON, V425, P211, DOI 10.1113/jphysiol.1990.sp018099; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; LAUWERYNS JM, 1986, EXP LUNG RES, V11, P319, DOI 10.3109/01902148609062833; LAUWERYNS JM, 1973, Z ZELLFORSCH MIK ANA, V145, P521, DOI 10.1007/BF00306722; LAUWERYNS JM, 1977, CELL TISSUE RES, V182, P425; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PERRIN D G, 1991, Pediatric Pathology, V11, P431; POLAK JM, 1993, ANAT REC, V236, P169, DOI 10.1002/ar.1092360120; SCHULLER HM, 1991, EXP LUNG RES, V17, P837, DOI 10.3109/01902149109064321; STEA A, 1992, NEUROSCIENCE, V47, P727, DOI 10.1016/0306-4522(92)90180-A; Sternberger LA, 1979, IMMUNOCYTOCHEMISTRY, P104; STUART AE, 1974, CELL TISSUE RES, V153, P55, DOI 10.1007/BF00225445; ZACCONE G, 1992, ACTA ZOOL-STOCKHOLM, V73, P177, DOI 10.1111/j.1463-6395.1992.tb01185.x	27	384	391	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					153	155		10.1038/365153a0	http://dx.doi.org/10.1038/365153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371757				2022-12-24	WOS:A1993LW44200046
J	KIRSCHSTEIN, R				KIRSCHSTEIN, R			SLEEP RESEARCH HAS BROAD SWEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KIRSCHSTEIN, R (corresponding author), NIH,BETHESDA,MD 20892, USA.							KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1172	1172		10.1001/jama.270.10.1172	http://dx.doi.org/10.1001/jama.270.10.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355369				2022-12-24	WOS:A1993LV64900005
J	YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS				YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS			ANABOLIC-ANDROGENIC STEROID USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; DEPENDENCE; SCHOOL; SYMPTOMS; MEN	Objective.- To estimate the size of the anabolic-androgenic steroid (AAS) user population in the United States, to examine characteristics of AAS users, and to explore the association between AAS use and the use of other illicit drugs as well as self-reported aggressive behaviors. Design.- A cross-sectional study using data from the 1991 National Household Survey on Drug Abuse. Study Population.- The survey covered the population aged 12 years and older living in households in the United States. The results of the survey were based on personal interviews combined with self-administered questionnaires from 32 594 respondents. These respondents were randomly selected by means of a stratified multistage area sample of the household population. Results.- Estimates based on data from the National Household Survey on Drug Abuse indicated that there are more than 1 million current or former AAS users in this country, with more than half of the lifetime user population being 26 years of age or older. More than 300 000 individuals used AAS in the past year. Males had higher levels of AAS use during their lifetime than females (0.9% and 0.1%, respectively; P<.01). The median age of first use of AAS for the study population was 18 years; for 12- to 17-year-olds, the median age of initiation was 15 years. Among 12- to 34-year-olds, AAS use was significantly and positively associated with the use of other illicit drugs (P<.05), cigarettes (12- to 17-year-olds only; P<.01), and alcohol (P<.01). Furthermore, AAS use is highly correlated with self-reported aggressive behavior (P<.01) and crimes against property (P<.01). Conclusions.- These results indicate that AAS use impacts a large number of men and women from various racial and age groups across the nation. While causal inferences cannot be made regarding the associations between AAS use and use of other drugs as well as antisocial behavior, these findings should enhance our ability to profile the typical AAS user.	CTR SUBST ABUSE PREVENT, POLICY & PLANNING UNIT, ROCKVILLE, MD USA; NIDA, STAT & ANAL BRANCH, ROCKVILLE, MD USA; UNIV ILLINOIS, DEPT EPIDEMIOL & BIOSTAT, CHICAGO, IL 60680 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	YESALIS, CE (corresponding author), PENN STATE UNIV, DEPT HLTH POLICY & ADM, 115 HENDERSON BLDG, UNIV PK, PA 16802 USA.							ANDERSON W, 1991, PHYSICIAN SPORTSMED, V2, P91; ANNITTO WJ, 1980, J CLIN PSYCHIAT, V41, P143; [Anonymous], 1978, MAIL TELEPHONE SURVE; [Anonymous], 1990, LANCET, V336, P955; Bahrke M. S., 1993, ANABOLIC STEROIDS SP, P161; BAHRKE MS, 1990, NEW ENGL J MED, V323, P834; BAHRKE MS, 1992, AM J SPORT MED, V20, P717, DOI 10.1177/036354659202000613; Brower K. J., 1989, CLIN SPORTS MED, V1, P171; BROWER KJ, 1989, AM J PSYCHIAT, V146, P1075; BROWER KJ, 1989, J CLIN PSYCHIAT, V50, P31; BROWER KJ, 1990, AM J PSYCHIAT, V147, P510; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; CHOI P Y L, 1990, Human Psychopharmacology, V5, P349, DOI 10.1002/hup.470050407; Cochran W. G., 1977, SAMPLING TECHNIQUES; CONACHER GN, 1989, AM J PSYCHIAT, V146, P679; DALBY JT, 1992, AM J PSYCHIAT, V149, P271; DIMEFF R, 1991, Medicine and Science in Sports and Exercise, V23, pS18; Duchaine D, 1989, UNDERGROUND STEROID, V2; DURANT RH, 1993, NEW ENGL J MED, V328, P922, DOI 10.1056/NEJM199304013281304; ELOFSON G, 1990, PHYSICIAN SPORTSMED, V19, P15; FRIEDL KE, 1993, ANABOLIC STEROIDS SP, P107; FRIENHAR J, 1985, J CLIN PSYCHIAT, V46, P354; Goldman B, 1984, DEATH LOCKER ROOM ST; HANNAN CJ, 1991, PSYCHONEUROENDOCRINO, V16, P335, DOI 10.1016/0306-4530(91)90019-P; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HAYS L, 1992, J CLIN PSYCHIAT, V53, P130; HAYS LR, 1990, AM J PSYCHIAT, V147, P122; JOHNSTON LD, 1990, MONITORING FUTURE CO; JOHNSTON LD, 1991, MONITORING FUTURE CO; Kochakian C.D., 1993, ANABOLIC STEROIDS SP, P3; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; KROWCHUK DP, 1989, AM J DIS CHILD, V143, P486, DOI 10.1001/archpedi.1989.02150160116023; KRUSKEMPER HL, 1968, ANABOLIC STEROIDS; Lefavi R. G., 1990, J SPORT BEHAVIOR, V13, P157, DOI [10.1002/hup.470050407, DOI 10.1002/HUP.470050407]; LINDSTROM M, 1990, J INTERN MED, V227, P407, DOI 10.1111/j.1365-2796.1990.tb00179.x; MCCLARY SA, 1985, J DRUG EDUC, V15, P49, DOI 10.2190/0CE6-NDFE-BY7P-U6XJ; PERRY PJ, 1990, AM J SPORT MED, V18, P422, DOI 10.1177/036354659001800416; POPE HG, 1988, PHYSICIAN SPORTSMED, V16, P75, DOI 10.1080/00913847.1988.11709554; POPE HG, 1988, AM J PSYCHIAT, V145, P487; POPE HG, 1990, J CLIN PSYCHIAT, V51, P28; ROSS J, 1989, 1988 1989 SURVEY SUB; RYAN AJ, 1981, FED PROC, V40, P2682; SMART RG, 1978, DRUG ALCOHOL DEPEN, V3, P265, DOI 10.1016/0376-8716(78)90080-7; STRAUSS R H, 1985, Journal of the American Medical Association, V253, P2871, DOI 10.1001/jama.253.19.2871; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; TAYLOR W N, 1987, Chiropractic Sports Medicine, V1, P47; Taylor W. N., 1991, MACHO MED HIST ANABO; TAYLOR WN, 1987, PHYSICIAN SPORTSMED, V15, P140, DOI 10.1080/00913847.1987.11709356; TAYLOR WN, 1982, ANABOLIC STEROIDS AT; TRICKER R, 1989, J DRUG EDUC, V19, P313, DOI 10.2190/EGT5-4YWD-QX15-FLKK; UZYCH L, 1992, CAN J PSYCHIAT, V37, P23, DOI 10.1177/070674379203700106; Wadler G., 1989, DRUGS ATHLETE; WHITEHEAD R, 1992, J FAM PRACTICE, V35, P401; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; Wright J E, 1980, Exerc Sport Sci Rev, V8, P149, DOI 10.1249/00003677-198000080-00007; WRIGHT JE, 1982, ANABOLIC STEROIDS SP, V2; WRIGHT JE, 1978, ANABOLIC STEROIDS SP; Yesalis C. E., 1993, ANABOLIC STEROIDS SP, P49; YESALIS CE, 1989, SPORTS MED, V8, P129, DOI 10.2165/00007256-198908030-00001; 1977, MED SCI SPORTS EXERC, V9, P11; 1991, REPORT INTERAGENCY T; 1992, ADM921887 NAT I DRUG; 1984, MED SCI SPORTS EXERC, V19, P13; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P2923; 1990, ANABOLIC REFERENCE U, V22, P3	67	254	259	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1217	1221		10.1001/jama.270.10.1217	http://dx.doi.org/10.1001/jama.270.10.1217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355384				2022-12-24	WOS:A1993LV64900027
J	MASU, Y; WOLF, E; HOLTMANN, B; SENDTNER, M; BREM, G; THOENEN, H				MASU, Y; WOLF, E; HOLTMANN, B; SENDTNER, M; BREM, G; THOENEN, H			DISRUPTION OF THE CNTF GENE RESULTS IN MOTOR-NEURON DEGENERATION	NATURE			English	Article							CILIARY NEUROTROPHIC FACTOR; TYPE-2 ASTROCYTE DEVELOPMENT; CHOLINERGIC DIFFERENTIATION; NEURONOTROPHIC FACTOR; REGIONAL DISTRIBUTION; FACTOR PREVENTS; MESSENGER-RNA; GROWTH-FACTOR; SPINAL-CORD; RAT-BRAIN	CNTF is a cytosolic molecule expressed postnatally in myelinating Schwann cells and in a subpopulation of astrocytes. Although CNTF administration prevents lesion-mediated and genetically determined motor neuron degeneration, its physiological function remained elusive. Here it is reported that abolition of CNTF gene expression by homologous recombination results in a progressive atrophy and loss of motor neurons in adult mice, which is functionally reflected by a small but significant reduction in muscle strength.	LUDWIG MAXIMILIANS UNIV MUNCHEN, INST MOLEK TIERZUCHT, D-80539 MUNICH, GERMANY	University of Munich	MASU, Y (corresponding author), MAX PLANCK INST PSYCHIAT, NEUROCHEM ABT, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Sendtner, Michael/J-1542-2012; Wolf, Eckhard/AAT-7500-2021; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Wolf, Eckhard/0000-0002-0430-9510; Sendtner, Michael/0000-0002-4737-2974				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CORK LC, 1989, LAB INVEST, V61, P69; DOBREA GM, 1992, DEV BRAIN RES, V66, P209, DOI 10.1016/0165-3806(92)90082-8; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; IP NY, 1991, J NEUROSCI, V11, P3124; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MCNEIL PL, 1990, J CELL SCI, V96, P549; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUNSAT TL, 1988, NEUROLOGY, V38, P409, DOI 10.1212/WNL.38.3.409; OPPENHEIM RW, 1986, J COMP NEUROL, V246, P281, DOI 10.1002/cne.902460211; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAO MS, 1992, DEVELOPMENT, V116, P731; RAO MS, 1993, J NEUROBIOL, V24, P215, DOI 10.1002/neu.480240208; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SABATII DR, 1963, J CELL BIOL, V7, P19; SENDTNER M, 1991, J CELL SCI, P103; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WOLF E, 1993, THERIOGENOLOGY, V37, P341; 1989, SAS STATR USERS GUID, V2, P891	38	540	562	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					27	32		10.1038/365027a0	http://dx.doi.org/10.1038/365027a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361533	Green Submitted			2022-12-24	WOS:A1993LV64600043
J	MOLBAK, K; HOJLYNG, N; GOTTSCHAU, A; SA, JCC; INGHOLT, L; DASILVA, APJ; AABY, P				MOLBAK, K; HOJLYNG, N; GOTTSCHAU, A; SA, JCC; INGHOLT, L; DASILVA, APJ; AABY, P			CRYPTOSPORIDIOSIS IN INFANCY AND CHILDHOOD MORTALITY IN GUINEA-BISSAU, WEST-AFRICA	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; DIARRHEA	Objective-To investigate the epidemiology of and mortality from cryptosporidiosis in young children in Guinea Bissau, West Africa. Design-Three year community study of an open cohort followed up weekly. Setting-301 randomly selected houses in a semi-urban area in the capital, Bissau. Subjects-1315 children aged less than 4 years. Main outcome measures-Cryptosporidium infection detected by examination of stools during episode of diarrhoea and death of a child. Results-Cryptosporidium spp were found in 239 (7.4%) out of 3215 episodes of diarrhoea. The parasite was most common in younger children (median age 12 months) and at the beginning of the rainy seasons. The prevalence of cryptosporidiosis was 15% (77/513) in cases of persistent diarrhoea compared with 6.1% (148/2428) in diarrhoea lasting less than two weeks (p < 0-0001). Cryptosporidiosis was associated with excess mortality in children who had the infection in infancy, and this excess mortality persisted into the second year of life (relative mortality 2.9 (95% confidence interval 1.7 to 4.9)). The excess mortality could not be explained by malnutrition, or by socioeconomic factors, hygienic conditions, or breast feeding. Conclusions-Cryptosporidiosis is an important cause of death in otherwise healthy children in developing countries.	STATENS SERUM INST,PARASITOL LAB,DK-2300 COPENHAGEN,DENMARK; STATENS SERUM INST,DEPT STAT,DK-2300 COPENHAGEN,DENMARK; NATL PUBL HLTH LAB,BISSAU,GUINEA BISSAU	Statens Serum Institut; Statens Serum Institut	MOLBAK, K (corresponding author), STATENS SERUM INST,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Aaby, Peter/0000-0001-8331-1389; Molbak, Kare/0000-0002-3100-4990				ALLEN AVH, 1970, J CLIN PATHOL, V23, P545, DOI 10.1136/jcp.23.6.545; ARGENZIO RA, 1990, GASTROENTEROLOGY, V98, P1129, DOI 10.1016/0016-5085(90)90325-U; CROSS J H, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P257; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; FRIPP PJ, 1991, J INFECTION, V23, P93, DOI 10.1016/0163-4453(91)94239-G; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAXER MA, 1990, AM J TROP MED HYG, V42, P131, DOI 10.4269/ajtmh.1990.42.131; LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V; MATA L, 1984, AM J TROP MED HYG, V33, P24, DOI 10.4269/ajtmh.1984.33.24; MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566, DOI 10.1097/00006454-199008000-00008; PAL S, 1989, T ROY SOC TROP MED H, V83, P520, DOI 10.1016/0035-9203(89)90274-5; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; SALLON S, 1988, AM J DIS CHILD, V142, P312, DOI 10.1001/archpedi.1988.02150030086027; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SU SX, 1992, PARASITOL TODAY, V8, P24; 1988, B WORLD HEALTH ORGAN, V66, P709	18	99	101	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					417	420		10.1136/bmj.307.6901.417	http://dx.doi.org/10.1136/bmj.307.6901.417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374453	Bronze, Green Published			2022-12-24	WOS:A1993LR89500016
J	GRIGNANI, F; FERRUCCI, PF; TESTA, U; TALAMO, G; FAGIOLI, M; ALCALAY, M; MENCARELLI, A; GRIGNANI, F; PESCHLE, C; NICOLETTI, I; PELICCI, PG				GRIGNANI, F; FERRUCCI, PF; TESTA, U; TALAMO, G; FAGIOLI, M; ALCALAY, M; MENCARELLI, A; GRIGNANI, F; PESCHLE, C; NICOLETTI, I; PELICCI, PG			THE ACUTE PROMYELOCYTIC LEUKEMIA-SPECIFIC PML-RAR-ALPHA FUSION PROTEIN INHIBITS DIFFERENTIATION AND PROMOTES SURVIVAL OF MYELOID PRECURSOR CELLS	CELL			English	Article							RETINOIC ACID RECEPTOR; ADENOSINE 3'-5'-MONOPHOSPHATE-INDUCING AGENTS; GRANULOCYTIC DIFFERENTIATION; T(15-17) TRANSLOCATION; MOLECULAR EVALUATION; RESIDUAL DISEASE; GENE-EXPRESSION; FLOW-CYTOMETRY; C-MYC; APOPTOSIS	Acute promyelocytic leukemia is a clonal expansion of hematopoietic precursors blocked at the promyelocytic stage. The differentiation block can be reversed by retinoic acid, which induces blast maturation both in vitro and in vivo. Acute promyelocytic leukemia is characterized by a 15;17 chromosome translocation with breakpoints within the retinoic acid alpha receptor (RARalpha) gene on 17 and the PML gene, which encodes a putative transcription factor, on 15. A PML-RARalpha fusion protein is formed as a consequence of the translocation. We expressed the PML-RARalpha protein in U937 myeloid precursor cells and showed that they lost the capacity to differentiate under the action of different stimuli (vitamin D3 and transforming growth factor beta1), acquired enhanced sensitivity to retinoic acid, and exhibited a higher growth rate consequent to diminished apoptotic cell death. These results provide evidence of biological activity of PML-RARalpha and recapitulate critical features of the promyelocytic leukemia phenotype.	IST SUPER SANITA,DEPT HAEMATOL & ONCOL,I-00161 ROME,ITALY; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107	Istituto Superiore di Sanita (ISS); Jefferson University	GRIGNANI, F (corresponding author), UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY.		Alcalay, Myriam/B-3182-2016; Alcalay, Myriam/AAB-4300-2019; Ferrucci, Pier Francesco/AAQ-9002-2020; Testa, Ugo/J-6472-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Testa, Ugo/0000-0001-7900-8942; Ferrucci, Pier Francesco/0000-0001-6255-5851				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BIONDI A, 1991, BLOOD, V77, P1418; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DERMIME S, 1993, IN PRESS BLOOD; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIVERIO D, 1992, BLOOD, V79, P1; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LANOTTE M, 1991, BLOOD, V77, P1080; LOCOCO F, 1991, BLOOD, V77, P1657; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LONGO L, 1993, IN PRESS LEUK LYMPHO; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1991, BLOOD, V77, P909; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MITELMAN F, 1988, CATALOG CHROMOSOME A; MUINDI J, 1992, BLOOD, V79, P299; NERVI C, 1992, CANCER RES, V52, P3687; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLSSON IL, 1982, CANCER RES, V42, P3928; OLSSON IL, 1982, CANCER RES, V42, P3924; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAZA A, 1992, BLOOD, V79, P1037; RAZA A, 1987, BLOOD, V69, P1647; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; TESTA U, 1993, J IMMUNOL, V150, P2418; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	58	552	571	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					423	431		10.1016/0092-8674(93)80044-F	http://dx.doi.org/10.1016/0092-8674(93)80044-F			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394219				2022-12-24	WOS:A1993LT73900004
J	HEALD, R; MCLOUGHLIN, M; MCKEON, F				HEALD, R; MCLOUGHLIN, M; MCKEON, F			HUMAN WEE-1 MAINTAINS MITOTIC TIMING BY PROTECTING THE NUCLEUS FROM CYTOPLASMICALLY ACTIVATED CDC2 KINASE	CELL			English	Article							I-KAPPA-B; CELL-CYCLE; PROTEIN-KINASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; M-PHASE; MAMMALIAN-CELLS; HUMAN HOMOLOG	The wee1 tyrosine kinase and cdc25 tyrosine phosphatase of fission yeast play antagonistic roles in the induction of mitosis through cdc2 regulation. We show here that the human wee1-like tyrosine kinase is a nuclear protein that ensures the completion of DNA replication prior to mitosis in cells expressing otherwise catastrophic levels of cdc2 activators. Paradoxically, wee1-rescued cells display very high levels of mitotic cdc2 kinase activity. We account for this anomaly by our observation that the cdc2 activator, cdc25C, is a cytoplasmic protein that, like cyclin B1, enters the nucleus at the G2/M transition. Thus, cdc2 is likely to be activated in the cytoplasm and requires nuclear localization to initiate both cytoplasmic and nuclear mitotic transformations. The human wee1 kinase appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from this cytoplasmically activated cdc2 kinase.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Heald, Rebecca/0000-0001-6671-6528	NIGMS NIH HHS [GM37977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOFFMAN I, 1993, IN PESS EMBO J, V12; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAO PN, 1977, J CELL PHYSIOL, V91, P131, DOI 10.1002/jcp.1040910113; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	62	398	407	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					463	474		10.1016/0092-8674(93)80048-J	http://dx.doi.org/10.1016/0092-8674(93)80048-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348613				2022-12-24	WOS:A1993LT73900008
J	LI, J; TAYLOR, B				LI, J; TAYLOR, B			FACTORS AFFECTING UPTAKE OF MEASLES, MUMPS, AND RUBELLA IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION POLICY; CHILDREN; DISTRICT; RATES	Objective-To study factors affecting uptake of measles, mumps, and rubella immunisation. Design-Cohort study using data from computerised child health systems. Setting-10 health districts in North East Thames and North West Thames regions. Subjects-7841 children born in January to March 1990 and resident in the districts up till the end of October 1991. Main outcome measures-Overall uptake of measles, mumps, and rubella immunisation, variation of uptake among groups of children, and odds ratio of being vaccinated against measles, mumps, and rubella. Results-The overall uptake rate of measles, mumps, and rubella immunisation for the study cohort in the 10 districts was 82%. Wide variation was identified among children with different demographic characteristics. Lower uptake was associated with absent or incomplete primary immunisation, including omission of pertussis vaccine. Other factors affecting uptake included the type of resident district, birth order, where registered for immunisation (general practitioner or clinic), and one parent family status. Conclusions-Many districts have difficulties in meeting the 90% target for measles, mumps, and rubella immunisation, mainly because of the characteristics of their local population. To increase overall coverage, the health service should target families with adverse factors, especially those whose children have missed previous immunisations.			LI, J (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND.							BEGG NT, 1985, BRIT MED J, V291, P1370, DOI 10.1136/bmj.291.6506.1370; CAMPBELL AGM, 1983, ARCH DIS CHILD, V58, P3, DOI 10.1136/adc.58.1.3; HERTOGS D, 1989, PUBLIC HEALTH, V103, P421, DOI 10.1016/S0033-3506(89)80051-4; HODES DT, 1990, PUBLIC HEALTH, V104, P27, DOI 10.1016/S0033-3506(05)80342-7; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; JARMAN B, 1983, BRIT MED J, V286, P1704; JEFFERIES S, 1991, J PUBLIC HEALTH MED, V13, P312; JEFFERSON N, 1987, BRIT MED J, V294, P423, DOI 10.1136/bmj.294.6569.423; LI J, 1991, BRIT MED J, V303, P1035, DOI 10.1136/bmj.303.6809.1035; Li J, 1993, Health Trends, V25, P16; MARKS JS, 1979, PEDIATRICS, V64, P304; MILLER C, 1986, LANCET, V2, P732; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; PECKHAM C, 1989, PECKHAM REPORT NATIO; RILEY DJ, 1991, BRIT MED J, V302, P31, DOI 10.1136/bmj.302.6767.31; TCHIE LD, 1992, BMJ, V304, P816; WALKER D, 1986, BRIT MED J, V292, P1501, DOI 10.1136/bmj.292.6534.1501; White J M, 1992, Commun Dis Rep CDR Rev, V2, pR96; WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682; 1991, CM 1523; 1985, SAS USERS GUIDE STAT; 1990, IMMUNISATION INFECTI; 1986, LANCET, V2, P671; 1988, IMMUNISATION INFECTI	25	48	48	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					168	171		10.1136/bmj.307.6897.168	http://dx.doi.org/10.1136/bmj.307.6897.168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343745	Green Published, Bronze			2022-12-24	WOS:A1993LN18400020
J	WILSON, AC; LAMARCO, K; PETERSON, MG; HERR, W				WILSON, AC; LAMARCO, K; PETERSON, MG; HERR, W			THE VP16 ACCESSORY PROTEIN HCF IS A FAMILY OF POLYPEPTIDES PROCESSED FROM A LARGE PRECURSOR PROTEIN	CELL			English	Article							RNA POLYMERASE-II; TYPE-1 TRANSACTIVATOR VMW65; OCTAMER-BINDING-PROTEIN; HOMEO DOMAIN; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; CELLULAR FACTOR; DNA COMPLEX; OCT-1; PURIFICATION	Upon lytic infection of permissive cells, the herpes simplex virus (HSV) transactivator protein VP16 associates with an accessory protein termed host cell factor (HCF). Binding to HCF activates VP16 for association with the octamer motif-binding protein Oct-1, to form a multiprotein-DNA complex responsible for activating transcription of the HSV immediate early genes. We show that HCF comprises a series of related polypeptides that range from 110 to 300 kd, all of which are encoded by a single gene. Although there is no obvious sequence similarity between HCF and other known proteins, HCF contains eight repeats of a new 26 amino acid motif. cDNAs encoding HCF predict a large open reading frame of 2035 codons. When expressed in human cells, this large open reading frame encodes both the 300 kd and smaller HCF polypeptides, indicating that the smaller polypeptides arise by processing of the 300 kd protein.	TULARIK INC,S SAN FRANCISCO,CA 94080		WILSON, AC (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Wilson, Angus C/AAA-8153-2019; Herr, Winship/E-6491-2012	Wilson, Angus C/0000-0002-5016-4164; Herr, Winship/0000-0002-3606-4546	NCI NIH HHS [CA-13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODING CR, 1989, VIROLOGY, V173, P363; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MCLEAN C, 1982, J GEN VIROL, V63, P297, DOI 10.1099/0022-1317-63-2-297; NEVINS JR, 1992, SCIENCE, V258, P424; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; Sambrook J., 1989, MOL CLONING LAB MANU; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; WERSTUCK GH, 1993, J BIOL CHEM, V268, P1272; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	40	222	234	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					115	125		10.1016/0092-8674(93)90299-6	http://dx.doi.org/10.1016/0092-8674(93)90299-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8392914				2022-12-24	WOS:A1993LN62500012
J	HUANG, ZJ; EDERY, I; ROSBASH, M				HUANG, ZJ; EDERY, I; ROSBASH, M			PAS IS A DIMERIZATION DOMAIN COMMON TO DROSOPHILA PERIOD AND SEVERAL TRANSCRIPTION FACTORS	NATURE			English	Article							DNA-BINDING; GENE-PRODUCT; PROTEIN; CLOCK; MELANOGASTER; RECEPTOR; MYC	MUTATIONS in the period gene product (PER) can shorten or lengthen the circadian rhythms of Drosophila melanogaster1, but its biochemical activity has not been established. PER contains a motif of approximately 270 amino acids whose function is unknown (termed PAS2) and which is also present in three transcription factors of the basic-helix-loop-helix (bHLH) type, in the D. melanogaster single-minded gene product (SIM)2, and in both subunits of the mammalian dioxin receptor complex3,4,28. We show here that the PER PAS functions in vitro as a novel protein dimerization motif and that it can mediate associations between different members of the PAS protein family. The dimerization efficiency is decreased by several missense mutations in the PAS domain, including the original per(L) mutation, which lengthens circadian periods from 24 h to 29 h (ref. 1). The results indicate that the PAS domain may function as a dimerization domain in both SIM and the dioxin receptor complex, and that PER may regulate circadian gene transcription partly by interacting with the PAS domain of bHLH-PAS-containing transcription factors.	BRANDEIS UNIV, DEPT BIOL, HOWARD HUGHES MED INST, WALTHAM, MA 02254 USA	Brandeis University; Howard Hughes Medical Institute				Huang, Z. Josh/0000-0003-0592-028X				BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DUNLAP JC, 1988, P NATL ACAD SCI USA, V85, P1096, DOI 10.1073/pnas.85.4.1096; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SMITH RF, 1982, MOL GEN GENET, V185, P30, DOI 10.1007/BF00333786; VANDOREN M, 1991, DEVELOPMENT, V113, P245; ZERR DM, 1990, J NEUROSCI, V10, P2749; ZWIEBEL LJ, 1991, P NATL ACAD SCI USA, V88, P3882, DOI 10.1073/pnas.88.9.3882	27	443	453	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1993	364	6434					259	262		10.1038/364259a0	http://dx.doi.org/10.1038/364259a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391649				2022-12-24	WOS:A1993LM68300064
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DRONABINOL APPROVED FOR USE IN ANOREXIA ASSOCIATED WITH WEIGHT-LOSS IN PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1986, JAMA-J AM MED ASSOC, V256, P817	1	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-24	WOS:A1993KQ85700007
J	TSUDA, L; INOUE, YH; YOO, MA; MIZUNO, M; HATA, M; LIM, YM; ADACHIYAMADA, T; RYO, H; MASAMUNE, Y; NISHIDA, Y				TSUDA, L; INOUE, YH; YOO, MA; MIZUNO, M; HATA, M; LIM, YM; ADACHIYAMADA, T; RYO, H; MASAMUNE, Y; NISHIDA, Y			A PROTEIN-KINASE SIMILAR TO MAP KINASE ACTIVATOR ACTS DOWNSTREAM OF THE RAF KINASE IN DROSOPHILA	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; TYROSINE KINASE; EMBRYONIC-DEVELOPMENT; NUCLEOTIDE-SEQUENCE; TERMINAL ANLAGEN; GENE TORSO; PATTERN; LOCUS; MELANOGASTER	D-raf, a Drosophila homolog of Raf-1, plays key roles in multiple signal transduction pathways. Dsor1, a putative factor downstream of D-raf, was genetically identified by screening of dominant suppressors of D-raf. Dsor1Su1 mapped on X chromosome significantly suppressed the D-raf mutant phenotypes, and the loss-of-function mutations of Dsor1 showed phenotypes similar to those of the D-raf null mutations. Dsor1Su1 also significantly suppressed the mutations of other terminal class genes acting further upstream of D-raf. Molecular cloning of Dsor1 revealed its product with striking similarity to the microtubule-associated protein (MAP) kinase activator and yeast PBS2, STE7, and byr1. Our genetic results demonstrate the connection between raf and the highly conserved protein kinase cascade involving MAP kinase in vivo.	KANAZAWA UNIV,GRAD SCH NAT SCI & TECHNOL,KANAZAWA,ISHIKAWA 920,JAPAN; PUSAN NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,PUSAN 607,SOUTH KOREA; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Kanazawa University; Pusan National University; Nagoya University	TSUDA, L (corresponding author), AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BASLER K, 1988, CELL, V54, P299; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lawrence P.A., 1986, P229; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, P359; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAPP UR, 1991, ONCOGENE, V6, P495; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199	49	208	214	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					407	414		10.1016/0092-8674(93)90117-9	http://dx.doi.org/10.1016/0092-8674(93)90117-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381718				2022-12-24	WOS:A1993KM16200010
J	CLINTON, JJ				CLINTON, JJ			SICKLE-CELL DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AHCPR,ROCKVILLE,MD 20852										0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2158	2158		10.1001/jama.270.18.2158	http://dx.doi.org/10.1001/jama.270.18.2158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411588				2022-12-24	WOS:A1993ME81600008
J	GROETTRUP, M; UNGEWISS, K; AZOGUI, O; PALACIOS, R; OWEN, MJ; HAYDAY, AC; VONBOEHMER, H				GROETTRUP, M; UNGEWISS, K; AZOGUI, O; PALACIOS, R; OWEN, MJ; HAYDAY, AC; VONBOEHMER, H			A NOVEL DISULFIDE-LINKED HETERODIMER ON PRE-T-CELLS CONSISTS OF THE T-CELL RECEPTOR-BETA CHAIN AND A 33 KD GLYCOPROTEIN	CELL			English	Article							ANTIGEN RECEPTOR; TCR-BETA; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; ALPHA-CHAIN; SIGNAL TRANSDUCTION; SURFACE EXPRESSION; LYMPHOCYTES-B; LIGHT-CHAIN; GENE	We describe a novel signal-transducing protein complex, which consists of the T cell receptor (TCR) beta chain that is disulfide linked to a 33 kd glycoprotein and non-covalently associated with proteins of the CD3 complex on the surface of the pre-T cell line SCB.29. This 33 kd glycoprotein, provisionally designated gp33, represents neither of the known TCR chains and has escaped previous detection because it labels poorly by surface iodination. This glycoprotein is absent from the surface of mature T cell lines. A TCR beta complex with identical molecular masses before and after reduction can be immunoprecipitated from surface-iodinated large thymocytes of TCR alpha-deficient mice. The novel gp33-TCR beta complex may be entirely or partly responsible for control of early T cell development exerted by the TCR beta protein.	UNIV PARIS 05,INSERM,U373,F-75015 PARIS,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cancer Research UK; Yale University	GROETTRUP, M (corresponding author), BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND.							BENOIST C, 1992, CURR OPIN IMMUNOL, V4, P156, DOI 10.1016/0952-7915(92)90005-Y; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BROCKER T, 1993, EUR J IMMUNOL, V23, P1435, DOI 10.1002/eji.1830230705; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GROETTRUP M, 1993, EUR J IMMUNOL, V23, P1393, DOI 10.1002/eji.1830230633; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1993, THESIS U BASEL BASEL; HAARS R, 1986, J EXP MED, V164, P1, DOI 10.1084/jem.164.1.1; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONING F, 1988, J IMMUNOL, V140, P3126; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1989, EUR J IMMUNOL, V19, P2269, DOI 10.1002/eji.1830191214; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PEARSE M, 1988, P NATL ACAD SCI USA, V85, P6082, DOI 10.1073/pnas.85.16.6082; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROSLONIEC EF, 1989, J IMMUNOL, V142, P4176; SAITO T, 1987, J IMMUNOL, V139, P625; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAYLOR AH, 1990, J EXP MED, V172, P1643, DOI 10.1084/jem.172.6.1643; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1992, IMMUNOL TODAY, V13, P454, DOI 10.1016/0167-5699(92)90075-I; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VONBOEHMER H, 1993, CURR OPIN IMMUNOL, V5, P175, DOI 10.1016/0952-7915(93)90001-9; YAGUE J, 1985, CELL, V42, P81, DOI 10.1016/S0092-8674(85)80103-3	53	303	304	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					283	294		10.1016/0092-8674(93)80070-U	http://dx.doi.org/10.1016/0092-8674(93)80070-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402912				2022-12-24	WOS:A1993MD88500010
J	FACELLI, JC; GRANT, DM				FACELLI, JC; GRANT, DM			DETERMINATION OF MOLECULAR SYMMETRY IN CRYSTALLINE NAPHTHALENE USING SOLID-STATE NMR	NATURE			English	Article							CHEMICAL-SHIFT TENSORS; AROMATIC-COMPOUNDS; C-13	DIFFRACTION techniques have shown that the crystal structure of naphthalene has a unit cell with C(i) symmetry1-7. These studies were unable, however, to resolve any departure of the molecular structure from the D2h symmetry observed in the gaseous state. We found recently8 that the solid-state C-13-nuclear magnetic resonance (NMR) chemical shifts for naphthalene exhibit the C(i) symmetry of the unit cell. If these chemical-shift data reflect structural distortions of the molecule, rather than simply intermolecular effects on the shifts owing to the C(i) symmetry of the environment of each molecule, one could assert that the NMR data are able to reveal structural information beyond the limits of the diffraction methods. Here we show that this is the case by performing ab initio quantum-mechanical calculations of the C-13 chemical shifts for naphthalene, and their derivatives, with respect to structural parameters. We find that intermolecular shift terms (which of necessity exhibit C(i) symmetry) can account for only about 30% of the maximum deviations from D2h symmetry; the remainder must therefore result from structural distortions of the molecules below D2h symmetry. This sensitivity of NMR chemical shifts to very small changes in molecular structure opens up the possibility of using solid-state NMR along with quantum-chemical methods to refine structural parameters obtained from diffraction methods.	UNIV UTAH,UTAH SUPERCOMP INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	FACELLI, JC (corresponding author), UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112, USA.			facelli, julio/0000-0003-1449-477X				ABRAHAMS SC, 1949, ACTA CRYSTALLOGR, V2, P233, DOI 10.1107/S0365110X49000618; ALDERMAN DW, 1993, J MAGN RESON SER A, V101, P188, DOI 10.1006/jmra.1993.1029; Bragg W. H., 1921, P PHYS SOC LOND, V34, P33; BROCK CP, 1982, ACTA CRYSTALLOGR B, V38, P2218, DOI 10.1107/S0567740882008358; Chesnut D. B., 1989, ANN REP NMR SPECTROS, V21, P51, DOI DOI 10.1016/S0066-4103(08)60121-0; CRUICKSHANK DWJ, 1957, ACTA CRYSTALLOGR, V10, P504, DOI 10.1107/S0365110X57001826; DITCHFIELD R, 1974, MOL PHYS, V27, P789, DOI 10.1080/00268977400100711; Dunning Jr T. H., 1977, METHODS ELECT STRUCT; GRANT DM, 1993, NATO ADV SCI INST SE, V386, P367; JAMESON AK, 1987, CHEM PHYS LETT, V134, P461, DOI 10.1016/0009-2614(87)87173-7; ORENDT AM, 1992, J AM CHEM SOC, V114, P2832, DOI 10.1021/ja00034a012; PAWLEY GS, 1969, ACTA CRYSTALL B-STRU, VB 25, P2009, DOI 10.1107/S0567740869005073; Ponomarev V. I., 1976, Soviet Physics - Crystallography, V21, P215; Robertson J. M., 1933, P R SOC LONDON A, V142, P674; SHERWOOD MH, 1991, J AM CHEM SOC, V113, P750, DOI 10.1021/ja00003a003; WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005	16	90	90	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					325	327		10.1038/365325a0	http://dx.doi.org/10.1038/365325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377823				2022-12-24	WOS:A1993LY49600046
J	STEERE, AC				STEERE, AC			SERONEGATIVE LYME-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PENICILLIN; ARTHRITIS				STEERE, AC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853				DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; KALISH R A, 1991, Arthritis and Rheumatism, V34, pS43; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401	8	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1369	1369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360974				2022-12-24	WOS:A1993LW34500038
J	STOLLBERGER, C; SLANY, J; SCHUSTER, I; LEITNER, H; WINKLER, WB; KARNIK, R				STOLLBERGER, C; SLANY, J; SCHUSTER, I; LEITNER, H; WINKLER, WB; KARNIK, R			THE PREVALENCE OF DEEP VENOUS THROMBOSIS IN PATIENTS WITH SUSPECTED PARADOXICAL EMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Article						THROMBOPHLEBITIS; EMBOLISM; HEART SEPTAL DEFECTS, ATRIAL; ECHOCARDIOGRAPHY; PHLEBOGRAPHY	PATENT FORAMEN OVALE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; PULMONARY-EMBOLISM; VEIN THROMBOSIS; STROKE; ISCHEMIA; AUTOPSY	Objective: To determine the prevalence of venous thrombosis in patients with suspected paradoxical embolism. Design: Observational study. Patients: Two hundred sixty-four patients with clinically suspected embolic events underwent contrast transesophageal echocardiographic evaluation. Forty-nine patients (24 women, 25 men) had a patent foramen ovale. Forty-one patients had acute stroke, and 8 had acute limb ischemia. Setting. Echocardiography laboratory of a community hospital. Measurements: The presence of a patent foramen ovale was assessed by transesophageal contrast echocardiography. Forty-two patients had venographic evaluation of the lower-extremity venous system. Results: Venous thrombosis was clinically suspected in 6 patients and documented in 24 of the 42 patients with patent foramen ovale who underwent venographic study (57%; 95% CI, 41% to 72%). Venous thrombosis was confined to calf or popliteal veins in 15 cases. Fifteen of 17 patients who had venographic evaluation within 7 days of the index event had thrombosis compared with 9 of 25 patients who had later evaluations (P = 0.001). More patients with venous thrombosis than without venous thrombosis had a history of previous thromboembolism (13 of 24 compared with 1 of 8, respectively; P = 0.001). Conclusion: When a patent foramen ovale is detected in a patient with embolism, occult leg vein thrombosis is frequently present.			STOLLBERGER, C (corresponding author), KRANKENANSTALT RUDOLFSTIFTUNG WIEN, JUCHGASSE 25, A-1030 VIENNA, AUSTRIA.							ARCHER SL, 1991, CIRCULATION, V84, P693; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BILLER J, 1987, ARCH NEUROL-CHICAGO, V44, P740, DOI 10.1001/archneur.1987.00520190046016; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB114, DOI 10.1016/S0735-1097(86)80013-4; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M; KARNIK R, 1992, AM J CARDIOL, V69, P560, DOI 10.1016/0002-9149(92)91006-P; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEE RJ, 1991, STROKE, V22, P734, DOI 10.1161/01.STR.22.6.734; MCCARTHY ST, 1977, LANCET, V2, P800; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; STAHL JA, 1990, CIRCULATION, V82, P109; STOLLBERGER C, 1993, AM J CARDIOL, V71, P604, DOI 10.1016/0002-9149(93)90521-D; TURPIE AGG, 1987, LANCET, V1, P523; WEBSTER MWI, 1988, LANCET, V2, P11; WITTLICH N, 1988, CIRCULATION, V78, P441; 1968, DOCUMENTA GEIGY WISS	20	159	165	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					461	465		10.7326/0003-4819-119-6-199309150-00003	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357111				2022-12-24	WOS:A1993LZ27500003
J	KAI, J				KAI, J			PARENTS PERCEPTIONS OF TAKING BABIES RECTAL TEMPERATURE	BRITISH MEDICAL JOURNAL			English	Article							SCORING SYSTEM; BABY CHECK; AXILLARY; CHILDREN; ILLNESS; INFANTS	Objective-To explore the attitudes of parents to measuring their babies' rectal temperature. Design-Qualitative study using unstructured interviews of parents given ''Baby Check,'' a scoring system designed to assess severity of illness in babies that includes measurement of rectal temperature. Setting-One inner city general practice in Newcastle upon Tyne. Subjects--42 parents of 34 babies under 6 months old. Results-Parents were reluctant to measure rectal temperature in their babies; 37 parents spontaneously raised concerns. Fifteen did not undertake measurement, 16 did so once only, and 11 did so more than once. Parents' concerns included a fear of hurting their child, anxieties about sexual intimacy and abuse, difficulty in comforting their child, and concern for their child's feelings. Most (33) substituted axillary measurement. Conclusions--Parents' preference for the axillary method of measuring temperature and resistance to using a rectal method in their children was based on several concerns. If parents are to be encouraged to use the rectal method of measuring temperature in sick babies any benefits must be set against the generation of considerable parental anxiety and the resources that would be necessary to negotiate with parents and change their views.			KAI, J (corresponding author), MED SCH NEWCASTLE UPON TYNE,SCH HLTH CARE SCI,DEPT PRIMARY HLTH CARE,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND.			Kai, Joe/0000-0001-9040-9384				CAMPBELL B, 1988, CHILD SEXUAL ABUSE C; CLARKE S, 1992, BMJ, V304, P96; COLE TJ, 1991, J ROY STAT SOC A STA, V154, P287, DOI 10.2307/2983042; Glaser B. G., 1978, AWARENESS DYING; HOBBS CJ, 1986, LANCET, V2, P792; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; WEISSE ME, 1991, PEDIATR INFECT DIS J, V10, P541, DOI 10.1097/00006454-199107000-00013; WILKIN D, 1987, ANATOMY URBAN GENERA; 1989, BIRTH 5 GUIDE 1ST FI; 1988, REPORT INQUIRY CHILD	14	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					660	662		10.1136/bmj.307.6905.660	http://dx.doi.org/10.1136/bmj.307.6905.660			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401054	Bronze, Green Published			2022-12-24	WOS:A1993LX47000020
J	LI, M; WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA				LI, M; WEST, JW; NUMANN, R; MURPHY, BJ; SCHEUER, T; CATTERALL, WA			CONVERGENT REGULATION OF SODIUM-CHANNELS BY PROTEIN-KINASE-C AND CAMP-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							SOMATIC-CELL LINE; RAT-BRAIN; ALPHA-SUBUNIT; XENOPUS-OOCYTES; FUNCTIONAL EXPRESSION; CLONED CDNA; PHOSPHORYLATION; MODULATION; SITE; MEMBRANE	The function of voltage-gated sodium channels that are responsible for action potential generation in mammalian brain neurons is modulated by phosphorylation by adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (cA-PK) and by protein kinase C (PKC). Reduction of peak sodium currents by cA-PK in intact cells required concurrent activation of PKC and was prevented by blocking phosphorylation of serine 1506, a site in the inactivation gate of the channel that is phosphorylated by PKC but not by cA-PK. Replacement of serine 1506 with negatively charged amino acids mimicked the effect of phosphorylation. Conversion of the consensus sequence surrounding serine 1506 to one more favorable for cA-PK enhanced modulation of sodium currents by cA-PK. Convergent modulation of sodium channels required phosphorylation of serine 1506 by PKC accompanied by phosphorylation of additional sites by cA-PK. This regulatory mechanism may serve to integrate neuronal signals mediated through these parallel signaling pathways.			LI, M (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195, USA.				NIGMS NIH HHS [T32-GM07270] Funding Source: Medline; NINDS NIH HHS [R01-NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; GERSHON E, 1992, J NEUROSCI, V12, P3743; GINTY DD, 1992, J CELL BIOL, V116, P1465, DOI 10.1083/jcb.116.6.1465; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, UNPUB; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; Numann Randal, 1992, Society for Neuroscience Abstracts, V18, P1133; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; Samantha Murphy S, UNPUB; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SMITH RD, 1992, AM J PHYSIOL, V263, pC660, DOI 10.1152/ajpcell.1992.263.3.C660; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YANG XC, 1992, J NEUROSCI, V12, P268	33	245	247	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1439	1442		10.1126/science.8396273	http://dx.doi.org/10.1126/science.8396273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8396273				2022-12-24	WOS:A1993LW54900030
J	FU, XD				FU, XD			SPECIFIC COMMITMENT OF DIFFERENT PREMESSENGER RNAS TO SPLICING BY SINGLE SR PROTEINS	NATURE			English	Article							TRACT-BINDING PROTEIN; POLYPYRIMIDINE TRACT; CONSERVED FAMILY; FACTOR SC35; COMPLEXES; COMPONENTS; NUCLEUS; SITE; SF2; U1	HIGHER eukaryotic cells express a family of essential splicing factors with a characteristic RNA-binding domain and serine/arginine-rich (SR) motif. These SR proteins, which include SC35(2-6) and SF2/ASF7-12, are conserved from Drosophila to man, are required for early steps of spliceosome assembly, and can influence splice-site selections. To address their mechanisms of action, SR proteins were examined for their role in committing pre-messenger RNA to the splicing pathway. I report here that SC35 was sufficient on its own to form a committed complex with human beta-globin pre-mRNA. Examination of other SR proteins and pre-mRNA substrates revealed that single SR proteins committed different pre-mRNAs to splicing with pronounced substrate specificity. These results suggest that splicing of different pre-mRNAs may require distinct sets of SR proteins, and that the commitment by SR proteins may be a critical step at which alternative and tissue-specific splicing is regulated.			FU, XD (corresponding author), UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1992, MOL CELL BIOL, V12, P3156; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GE H, 1991, CELL, V66, P372; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MING T, 1993, CELL, V74, P105; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	25	253	264	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					82	85		10.1038/365082a0	http://dx.doi.org/10.1038/365082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361546				2022-12-24	WOS:A1993LV64600060
J	ALLEN, GC; DIXON, NE; KORNBERG, A				ALLEN, GC; DIXON, NE; KORNBERG, A			STRAND SWITCHING OF A REPLICATIVE DNA HELICASE PROMOTED BY THE ESCHERICHIA-COLI PRIMOSOME	CELL			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN ACTION; PHI-X174 DNA; PURIFIED ENZYMES; GENE-PRODUCT; VIRAL-DNA; FACTOR-Y; SEQUENCE; CONVERSION	The E. coli primosome assembles at an origin on a single-stranded DNA, like that of PHIX174, to promote replication of that template. Upon conversion to the duplex form, the primosome can generate a rolling circle product from this template. Rolling circle synthesis implies the transfer of the DnaB helicase from its initial loading site on the viral strand to a displaced complementary strand. Isolated primosomes promote only unit-length synthesis; supplementation with PriC, DnaC, and DnaT is necessary to reconstitute rolling circle synthesis. Rolling circle replication is sensitive to salts, whereas primosome assembly and unit-length synthesis are not. Thus, the primosome promotes two distinct reactions: assembly for first-round synthesis and strand switching for rolling circle synthesis.	AUSTRALIAN NATL UNIV,RES SCH CHEM,CTR MOLEC STRUCT & FUNCT,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	ALLEN, GC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305, USA.		Dixon, Nicholas E/A-1226-2008	Dixon, Nicholas E/0000-0002-5958-6945	NIGMS NIH HHS [GM07851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P11610; ALLEN GC, 1993, IN PRESS J BIOL CHEM, V268; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5267; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kornberg A., 1992, DNA REPLICATION; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LARK KG, 1978, CSHSQB, V43, P537; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MASAI H, 1990, J BIOL CHEM, V265, P15134; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SELZER G, 1982, P NATL ACAD SCI-BIOL, V79, P7082, DOI 10.1073/pnas.79.23.7082; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1981, J BIOL CHEM, V256, P5233; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZECHEL K, 1975, J BIOL CHEM, V250, P4684	37	18	18	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					713	722		10.1016/0092-8674(93)90518-U	http://dx.doi.org/10.1016/0092-8674(93)90518-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395352				2022-12-24	WOS:A1993LU59200014
J	VANDEURSEN, J; HEERSCHAP, A; OERLEMANS, F; RUITENBEEK, W; JAP, P; TERLAAK, H; WIERINGA, B				VANDEURSEN, J; HEERSCHAP, A; OERLEMANS, F; RUITENBEEK, W; JAP, P; TERLAAK, H; WIERINGA, B			SKELETAL-MUSCLES OF MICE DEFICIENT IN MUSCLE CREATINE-KINASE LACK BURST ACTIVITY	CELL			English	Article							NUCLEAR MAGNETIC-RESONANCE; BETA-GUANIDINOPROPIONIC ACID; EMBRYONIC STEM-CELLS; M-LINE; SATURATION-TRANSFER; ENERGY-TRANSPORT; RAT MUSCLE; PHOSPHOCREATINE; METABOLISM; SHUTTLE	To understand the physiological role of the creatine kinase-phosphocreatine (CK-PCr) system in muscle bioenergetics, a null mutation of the muscle CK (M-CK) gene was introduced into the germline of mice. Mutant mice show no alterations in absolute muscle force, but lack the ability to perform burst activity. Their fast-twitch fibers have an increased intermyofibrillar mitochondrial volume and an increased glycogenolytic/glycolytic potential. PCr and ATP levels are normal in resting M-CK-deficient muscles, but rates of high energy phosphate exchange between PCr and ATP are at least 20-fold reduced. Strikingly, PCr levels decline normally during muscle exercise, suggesting that M-CK-mediated conversion is not the only route for PCr utilization in active muscle.	CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT DIAGNOST RADIOL, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT PAEDIAT, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT NEUROL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	VANDEURSEN, J (corresponding author), CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT CELL BIOL & HISTOL, 6500 HB NIJMEGEN, NETHERLANDS.		Heerschap, Arend/G-5228-2010; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020				ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; Bergmeyer H. U., 1974, METHODS ENZYMATIC AN; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BLONDET P, 1987, J MAGN RESON, V71, P342, DOI 10.1016/0022-2364(87)90066-7; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROSNAN MJ, 1993, AM J PHYSIOL, V264, pC151, DOI 10.1152/ajpcell.1993.264.1.C151; BROWN TR, 1977, P NATL ACAD SCI USA, V74, P3627, DOI 10.1073/pnas.74.9.3627; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHEVLI R, 1979, BIOCHEM MED METAB B, V21, P162, DOI 10.1016/0006-2944(79)90068-1; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DANTZIG JA, 1991, J PHYSIOL-LONDON, V432, P639, DOI 10.1113/jphysiol.1991.sp018405; DAVULURI SP, 1981, COMP BIOCHEM PHYS B, V69, P329, DOI 10.1016/0305-0491(81)90322-9; DEGENS H, 1993, MECH AGEING DEV, V66, P299, DOI 10.1016/0047-6374(93)90016-K; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; DUNN JF, 1991, BIOCHIM BIOPHYS ACTA, V1096, P115, DOI 10.1016/0925-4439(91)90048-E; FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735; FITCH CD, 1974, J BIOL CHEM, V249, P1060; FITCH CD, 1980, METABOLISM, V29, P686, DOI 10.1016/0026-0495(80)90115-8; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GORI Z, 1988, BRIT J EXP PATHOL, V69, P639; Heerschap A, 1988, NMR Biomed, V1, P27, DOI 10.1002/nbm.1940010106; HSIEH PS, 1988, MAGNET RESON MED, V7, P56, DOI 10.1002/mrm.1910070107; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; KORETSKY AP, 1985, MAGNET RESON MED, V2, P586, DOI 10.1002/mrm.1910020610; KUSHMERICK MJ, 1985, AM J PHYSIOL, V248, pC542, DOI 10.1152/ajpcell.1985.248.5.C542; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Lillie RD, 1976, HISTOPATHOLOGIC TECH, V4th; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MATTHEWS PM, 1982, BIOCHIM BIOPHYS ACTA, V721, P312, DOI 10.1016/0167-4889(82)90084-2; Maughan D, 1989, Prog Clin Biol Res, V315, P137; MCGILVERY RW, 1974, J BIOL CHEM, V249, P5845; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MEYER RA, 1982, AM J PHYSIOL, V242, pC1, DOI 10.1152/ajpcell.1982.242.1.C1; MEYER RA, 1985, AM J PHYSIOL, V248, pC279, DOI 10.1152/ajpcell.1985.248.3.C279; MEYER RA, 1986, AM J PHYSIOL, V250, pC264, DOI 10.1152/ajpcell.1986.250.2.C264; REES D, 1989, MAGNET RESON MED, V9, P39, DOI 10.1002/mrm.1910090107; SAKS VA, 1976, FEBS LETT, V62, P293, DOI 10.1016/0014-5793(76)80078-6; Sambrook J., 1989, MOL CLONING LAB MANU; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P72, DOI 10.1016/0167-4889(84)90038-7; SHOUBRIDGE EA, 1987, AM J PHYSIOL, V252, pC532, DOI 10.1152/ajpcell.1987.252.5.C532; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SMEITINK J, 1992, ANN CLIN BIOCHEM, V29, P196, DOI 10.1177/000456329202900213; Srere PA., 1969, METHODS ENZYMOLOGY, P3, DOI DOI 10.1016/0076-6879(69)13005-0; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1992, GENOMICS, V12, P340, DOI 10.1016/0888-7543(92)90383-4; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WALLIMANN T, 1983, J MUSCLE RES CELL M, V4, P429, DOI 10.1007/BF00711948; WALLIMANN T, 1978, P NATL ACAD SCI USA, V75, P4296, DOI 10.1073/pnas.75.9.4296; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Wallimann T, 1989, Prog Clin Biol Res, V315, P159; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172; YOSHIZAKI K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P144, DOI 10.1016/0167-4889(90)90186-H; ZAHLER R, 1992, AM J PHYSIOL, V262, pH1022, DOI 10.1152/ajpheart.1992.262.4.H1022; ZWEIER JL, 1991, J BIOL CHEM, V266, P20296	64	278	285	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					621	631		10.1016/0092-8674(93)90510-W	http://dx.doi.org/10.1016/0092-8674(93)90510-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358791				2022-12-24	WOS:A1993LU59200006
J	COX, GA; COLE, NM; MATSUMURA, K; PHELPS, SF; HAUSCHKA, SD; CAMPBELL, KP; FAULKNER, JA; CHAMBERLAIN, JS				COX, GA; COLE, NM; MATSUMURA, K; PHELPS, SF; HAUSCHKA, SD; CAMPBELL, KP; FAULKNER, JA; CHAMBERLAIN, JS			OVEREXPRESSION OF DYSTROPHIN IN TRANSGENIC MDX MICE ELIMINATES DYSTROPHIC SYMPTOMS WITHOUT TOXICITY	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; EXPRESSION; MOUSE; GLYCOPROTEIN; PROTEIN; DEFICIENCY; MEMBRANE; COMPLEX	DUCHENNE and Becker muscular dystrophy (DMD and BMD) are X-linked recessive diseases caused by defective expression of dystrophin1,2. The mdx mouse, an animal model for DMD, has a mutation that eliminates expression of the 427K muscle and brain isoforms of dystrophin1,3,4. Although these animals do not display overt muscle weakness or impaired movement, the diaphragm muscle of the mdx mouse is severely affected and shows progressive myofibre degeneration and fibrosis which closely resembles the human disease5,6. Here we explore the feasibility of gene therapy for DMD by examining the potential of a full-length dystrophin transgene to correct dystrophic symptoms in mdx mice. We find that expression of dystrophin in muscles of transgenic mdx mice eliminates the morphological and immunohistological symptoms of muscular dystrophy. In addition, overexpression of dystrophin prevents the development of the abnormal mechanical properties associated with dystrophic muscle without causing deleterious side effects. Our results provide functional evidence for the feasibility of gene therapy for DMD.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,INST GERONTOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR HUMAN GENOME,ANN ARBOR,MI 48109; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Washington; University of Washington Seattle				Campbell, Kevin/0000-0003-2066-5889; Chamberlain, Jeffrey/0000-0001-5299-0059				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BROOKS SV, 1991, J PHYSIOL-LONDON, V436, P701, DOI 10.1113/jphysiol.1991.sp018574; CHAMBERLAIN JS, 1993, MOL CELL BIOL MUSCUL, P167; CHAPMAN VM, 1989, P NATL ACAD SCI USA, V86, P1292, DOI 10.1073/pnas.86.4.1292; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; EMERY AEH, 1987, OXFORD MONOG MED GEN, V15; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAULKNER JA, 1990, AM J PHYSIOL, V259, P259; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hogan B., 1986, MANIPULATING MOUSE E; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013; WELLS DJ, 1992, HUM MOL GENET, V1, P35	27	253	261	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					725	729		10.1038/364725a0	http://dx.doi.org/10.1038/364725a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355788	Green Published			2022-12-24	WOS:A1993LT67700061
J	SLESAREV, AI; STETTER, KO; LAKE, JA; GELLERT, M; KRAH, R; KOZYAVKIN, SA				SLESAREV, AI; STETTER, KO; LAKE, JA; GELLERT, M; KRAH, R; KOZYAVKIN, SA			DNA TOPOISOMERASE-V IS A RELATIVE OF EUKARYOTIC TOPOISOMERASE-I FROM A HYPERTHERMOPHILIC PROKARYOTE	NATURE			English	Article							DESULFUROCOCCUS-AMYLOLYTICUS; METHANOPYRUS-KANDLERI; ARCHAEBACTERIA; 110-DEGREES-C; METHANOGENS; ARCHAEA; GENE	THE DNA topoisomerases are ubiquitous enzymes that fulfil vital roles in the replication, transcription and recombination of DNA by carrying out DNA-strand passage reactions1-7. Here we characterize a prokaryotic counterpart to the eukaryotic topoisomerase I in the hyperthermophilic methanogen Methanopyrus kandleri8-10. The new enzyme, called topoisomerase V, has the following properties in common with eukaryotic topoisomerase I, which distinguish it from all other known prokaryotic topoisomerases: (1) its activity is Mg2+-independent; (2) it relaxes both negatively and positively supercoiled DNA; (3) it makes a covalent complex with the 3' end of the broken DNA strand; and (4) it is recognized by antibody raised against human topoisomerase I. Eukaryotic-like enzymes have been discovered in some hyperthermophilic prokaryotes, namely the eocytes11 and the extremely thermophilic archaebacteria12, and hyperthermophilic homologues of eukaryotic DNA polymerase-a, transcription factor IIB and DNA ligase13-15 have all been reported. Thus our findings support the idea that some essential parts of the eukaryotic transcription-translation and replication machineries were in place before the emergence of eukaryotes, and that the closest living relatives of eukaryotes may be hyperthermophiles.	RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; UKRAINIAN ACAD SCI,RE KAVETSKY INST ONCOL & RADIOBIOL,KIEV 252127,UKRAINE; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV REGENSBURG,LEHRSTUHL MIKROBIOL,W-8400 REGENSBURG,GERMANY; NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	Russian Academy of Sciences; National Academy of Sciences Ukraine; University of California System; University of California Los Angeles; University of Regensburg; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	SLESAREV, AI (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.			Kozyavkin, Sergei/0000-0001-5605-5113				BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BURGGRAF S, 1991, SYST APPL MICROBIOL, V14, P346, DOI 10.1016/S0723-2020(11)80308-5; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KORNBERG A, 1992, DNA REPLICATION, P379; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KURR M, 1991, ARCH MICROBIOL, V156, P239, DOI 10.1007/BF00262992; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P68; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SLESAREV AI, 1991, J BIOL CHEM, V266, P12321; SLESAREV AI, 1988, EUR J BIOCHEM, V173, P395, DOI 10.1111/j.1432-1033.1988.tb14012.x; TSE YC, 1980, J BIOL CHEM, V255, P5560; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	21	81	84	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					735	736		10.1038/364735a0	http://dx.doi.org/10.1038/364735a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8395022				2022-12-24	WOS:A1993LT67700064
J	TUCKER, PK; LUNDRIGAN, BL				TUCKER, PK; LUNDRIGAN, BL			RAPID EVOLUTION OF THE SEX-DETERMINING LOCUS IN OLD-WORLD MICE AND RATS	NATURE			English	Article							MYOTONIC-DYSTROPHY; DETERMINING REGION; Y-CHROMOSOME; CTG REPEAT; FRAGILE-X; GENE; SRY; INSTABILITY; EXPANSION; MUTATION	THE Y chromosome-linked sex determining locus (Sry) responsible for testis determination in mammals1-5 contains a DNA-binding motif (HMG box) that is conserved across species of marsupial and placental mammals (infraclasses Metatheria and Eutheria, respectively)1,4,6,7. But little to no sequence similarity is observed in flanking sequences between these two infraclasses, or among orders within each infraclass. We investigated the rate and pattern of evolution for the coding sequence of Sry in Old World mice and rats (subfamily Murinae). We found typical rates of synonymous substitution throughout the gene, but high rates of non-synonymous substitution, especially in the C-terminal (non-HMG box) region, when compared to other genes8. This region is also characterized by a frame-shift mutation and variation in a trinucleotide repeat motif. These data suggest that the non-box region is either functionally unconstrained or has undergone species-specific adaptive divergence.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	TUCKER, PK (corresponding author), UNIV MICHIGAN, MUSEUM ZOOL, ANN ARBOR, MI 48109 USA.							ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; Jukes TH., 1969, MAMMALIAN PROTEIN ME, P21, DOI [DOI 10.1093/BIOINFORMATICS/BTM404, 10.1016/B978-1-4832-3211-9.50009-7]; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NEI M, 1986, MOL BIOL EVOL, V3, P418; OHUIGIN C, 1992, J MOL EVOL, V35, P377, DOI 10.1007/BF00171816; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SU H, 1993, AM J HUM GENET, V52, P24; TUCKER PK, 1992, MAMM GENOME, V3, P254, DOI 10.1007/BF00292153; TUCKER PK, 1993, METHOD ENZYMOL, V224, P517, DOI 10.1016/0076-6879(93)24038-V; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; 1993, HUNTINGTONS DISEASE, V72, P971	27	214	220	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					715	717		10.1038/364715a0	http://dx.doi.org/10.1038/364715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355784	Green Published			2022-12-24	WOS:A1993LT67700057
J	GRUNDY, FJ; HENKIN, TM				GRUNDY, FJ; HENKIN, TM			TRANSFER-RNA AS A POSITIVE REGULATOR OF TRANSCRIPTION ANTITERMINATION IN BACILLUS-SUBTILIS	CELL			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SYNTHETASE GENES; PROTEIN; STEAROTHERMOPHILUS; CLONING; OPERON; TERMINATION; HOMOLOGY	Most Bacillus tRNA synthetase genes are regulated by a common transcription antitermination mechanism but respond individually to limitation for the cognate amino acid. The mRNA leader regions of these genes exhibit extensive structural conservation, with a single codon specific for the appropriate amino acid at the identical position in each structure. Alteration of this sequence in the tyrS gene from UAC (tyrosine) to UUC (phenylalanine) resulted in loss of induction by tyrosine limitation and a switch to induction by phenylalanine limitation. Insertion of an extra base immediately upstream of the codon did not alter regulation, indicating a nontranslational mechanism. A nonsense codon resulted in an uninducible phenotype that was suppressible in a lysyl-tRNA nonsense suppressor mutant, indicating that tRNA acts as an effector.			GRUNDY, FJ (corresponding author), ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,ALBANY,NY 12208, USA.				NIGMS NIH HHS [GM40650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BARSTOW DA, 1986, GENE, V46, P37, DOI 10.1016/0378-1119(86)90164-2; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P2480, DOI 10.1021/bi00383a012; BRAKHAGE AA, 1990, BIOCHIMIE, V72, P725, DOI 10.1016/0300-9084(90)90157-C; CHOW KC, 1988, GENE, V73, P537; DALE BA, 1971, J BACTERIOL, V108, P586, DOI 10.1128/JB.108.1.586-588.1971; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; FRIEDMAN DI, 1981, P NATL ACAD SCI-BIOL, V78, P1115, DOI 10.1073/pnas.78.2.1115; GHOSH B, 1984, P NATL ACAD SCI-BIOL, V81, P6305, DOI 10.1073/pnas.81.20.6305; GLASER P, 1990, DNA SEQUENCE, V1, P251; GRAFFE M, 1992, SCIENCE, V255, P994, DOI 10.1126/science.1372129; GRANDONI JA, 1992, J BACTERIOL, V174, P3212, DOI 10.1128/jb.174.10.3212-3219.1992; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GRUNBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, P1386; GRUNDY FJ, 1991, J BACTERIOL, V173, P4595, DOI 10.1128/jb.173.15.4595-4602.1991; HENKIN TM, 1984, MOL GEN GENET, V193, P364, DOI 10.1007/BF00330694; HENKIN TM, 1992, J BACTERIOL, V174, P1299, DOI 10.1128/jb.174.4.1299-1306.1992; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JIN DJ, 1988, J MOL BIOL, V204, P247, DOI 10.1016/0022-2836(88)90573-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LOVETT PS, 1991, J BACTERIOL, V173, P1810, DOI 10.1128/jb.173.5.1810-1812.1991; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MECHULAM Y, 1991, NUCLEIC ACIDS RES, V19, P3673, DOI 10.1093/nar/19.13.3673; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J.H., 1972, EXPT MOL GENETICS; NASS G, 1967, BIOCHIM BIOPHYS ACTA, V134, P347, DOI 10.1016/0005-2787(67)90012-3; PUTZER H, 1992, EMBO J, V11, P3117, DOI 10.1002/j.1460-2075.1992.tb05384.x; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; TAYLOR BV, 1993, J BACTERIOL, V175, P2475, DOI 10.1128/JB.175.8.2475-2478.1993; VANDERHORN PB, 1992, J BACTERIOL, V174, P3928, DOI 10.1128/jb.174.12.3928-3935.1992; WAYE MMY, 1986, EUR J BIOCHEM, V158, P505, DOI 10.1111/j.1432-1033.1986.tb09783.x	35	218	222	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					475	482		10.1016/0092-8674(93)80049-K	http://dx.doi.org/10.1016/0092-8674(93)80049-K			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348614				2022-12-24	WOS:A1993LT73900009
J	HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H				HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H			MUTATIONS AT THE MOUSE MICROPHTHALMIA LOCUS ARE ASSOCIATED WITH DEFECTS IN A GENE ENCODING A NOVEL BASIC-HELIX-LOOP-HELIX-ZIPPER PROTEIN	CELL			English	Article							DNA-BINDING; SPLEEN-CELLS; INSERTIONAL MUTATION; WAARDENBURG SYNDROME; MYC ONCOGENE; C-FOS; MICE; DIFFERENTIATION; MOTIF; TRANSCRIPTION	Mice with mutations at the microphthalmia (mi) locus have some or all of the following defects: loss of pigmentation, reduced eye size, failure of secondary bone resorption, reduced numbers of mast cells, and early onset of deafness. Using a transgenic insertional mutation at this locus, we have identified a gene whose expression is disrupted in transgenic animals. This gene encodes a novel member of the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein family of transcription factors, is altered in mice carrying two independent mi alleles (mi and mi(ws)), and is expressed in the developing eye, ear, and skin, all anatomical sites affected by mi. The multiple spontaneous and induced mutations available at mi provide a unique biological resource for studying the role of a bHLH-ZIP protein in mammalian development.	NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LABS,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HODGKINSON, CA (corresponding author), NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892, USA.			Arnheiter, Heinz/0000-0003-2537-1134; Steingrimsson, Eirikur/0000-0001-5826-7486; Hodgkinson, Colin/0000-0002-5365-8119	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALNAR MA, 1992, SCIENCE, V256, P1014; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BEXEVANIS AD, 1993, CURR OPIN GENE DEV, V3, P278; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRER LA, 1992, J MED GENET, V27, P618; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; Green MC., 1989, GENETIC VARIANTS STR, P12; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRUNEBERG H, 1953, J GENET, V51, P359, DOI 10.1007/BF03023302; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; HERO I, 1991, INVEST OPHTH VIS SCI, V32, P2622; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HOLLANDER WF, 1968, GENETICS, V60, P189; HU YF, 1990, GENE DEV, V4, P167; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KONYUKHOV BV, 1968, SOV GENET, V4, P1457; LAMOREUX ML, 1992, J HERED, V83, P435, DOI 10.1093/oxfordjournals.jhered.a111247; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LERNER AB, 1986, MOUSE NEWS LETT, V74, P125; MARKS SC, 1981, AM J ANAT, V161, P1, DOI 10.1002/aja.1001610102; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MULLER G, 1950, Z MIKROSK ANAT FORSC, V56, P520; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PACKER SO, 1967, J EXP ZOOL, V165, P21, DOI 10.1002/jez.1401650103; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J., 1989, MOL CLONING LAB MANU; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; SOUTHARD JL, 1974, MOUSE NEWS LETT, V51, P23; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STELZNER KF, 1966, MOUSE NEWS LETT, V34, P41; STELZNER KF, 1964, MOUSE NEWS LETT, V31, P40; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; TASASBEHJI M, 1993, NAT GENET, V3, P26; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOLFE HG, 1964, GENET RES, V46, P309; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YOSHITAKA E, 1992, BLOOD, V80, P1454; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	929	965	4	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					395	404		10.1016/0092-8674(93)90429-T	http://dx.doi.org/10.1016/0092-8674(93)90429-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343963				2022-12-24	WOS:A1993LP72600019
J	PEREZMARTIN, J; ESPINOSA, M				PEREZMARTIN, J; ESPINOSA, M			PROTEIN-INDUCED BENDING AS A TRANSCRIPTIONAL SWITCH	SCIENCE			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; BACILLUS-SUBTILIS; POSITIVE CONTROL; PLASMID PLS1; DNA; ACTIVATOR; PROMOTER; REPA; INITIATION	The question of whether protein-induced DNA bending can act as a switch factor when placed upstream of an array of promoters located in tandem was investigated in vivo. The catabolite activating protein binding site of the fur operon was replaced by the binding site of the RepA repressor protein, which is able to bend DNA immediately after binding. Appropriately phased induced bending could act as a transcriptional switch factor in vivo.	CSIC,CTR INVEST BIOL,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Espinosa, Manuel/M-5282-2019; Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382				AIBA H, 1981, J BIOL CHEM, V256, P1905; BALLESTER S, 1990, GENE, V86, P71, DOI 10.1016/0378-1119(90)90115-8; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DELORENZO V, 1988, EUR J BIOCHEM, V173, P537; DELSOLAR G, 1992, MOL MICROBIOL, V6, P83; DELSOLAR G, IN PRESS MOL MICROBI; DELSOLAR GH, 1990, J BIOL CHEM, V265, P12569; DELSOLAR GH, 1989, NUCLEIC ACIDS RES, V17, P2405, DOI 10.1093/nar/17.7.2405; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; KUHNKE G, 1989, EMBO J, V8, P1247, DOI 10.1002/j.1460-2075.1989.tb03498.x; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; Miller J.H., 1972, EXPT MOL GENETICS; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; PEREZMARTIN J, 1989, J BIOL CHEM, V264, P21334; PEREZMARTIN J, UNPUB; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; ROJO F, 1991, EMBO J, V10, P3429, DOI 10.1002/j.1460-2075.1991.tb04907.x; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; TIMMIS K, IN PRESS METHODS ENZ; TOBIN JF, 1990, J MOL BIOL, V211, P713; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	32	70	70	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					805	807		10.1126/science.8387228	http://dx.doi.org/10.1126/science.8387228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	8387228				2022-12-24	WOS:A1993LA74400029
J	BURGER, MPM; HOLLEMA, H; GOUW, ASH; PIETERS, WJLM; QUINT, WGV				BURGER, MPM; HOLLEMA, H; GOUW, ASH; PIETERS, WJLM; QUINT, WGV			CIGARETTE-SMOKING AND HUMAN PAPILLOMAVIRUS IN PATIENTS WITH REPORTED CERVICAL CYTOLOGICAL ABNORMALITY	BRITISH MEDICAL JOURNAL			English	Article							POLYMERASE CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; UTERINE CERVIX; CARCINOMA INSITU; CANCER; SCRAPES; MUCUS; DNA	Objective-To assess the relation between two risk factors for cervical neoplasia: smoking and infection with oncogenic human papillomavirus. It has been suggested that smoking causes a local immunological defect, which could facilitate the infection and persistence of human papillomavirus. Design-Cross sectional epidemiological study. Completion of a structured questionnaire by the patients, analysis of cervical scrapes for human papillomavirus, and morphological examination of biopsy specimens. Setting-Outpatient gynaecological clinic. Subjects-181 women with a report of cervical cytological abnormality. Main outcome measures-Prevalence of infection with oncogenic human papillomavirus and smoking habits. Results-Oncogenic human papillomavirus was found in the cervix of 26 (41%) of the 63 women who did not smoke, 22 (58%) of the 38 who smoked 1-10 cigarettes a day, 28 (61%) of the 46 who smoked 11-20 cigarettes a day, and 26 (76%) of the 34 who smoked greater-than-or-equal-to 21 cigarettes a day. The prevalence of the virus thus increased in accordance with the number of cigarettes smoked (p=0.001). This relation remained after adjustment for age at first intercourse and lifetime number of sexual partners. Of the 63 non-smokers, 23 had previously smoked at least 10 cigarettes a day at some time. Of these 23 women, 14 (61%) had oncogenic human papillomavirus in their cervix. Of the 40 women who had never smoked at least 10 cigarettes a day, 12 (30%) had the virus. The prevalence of oncogenic human papillomavirus in non-smokers therefore depended on previous smoking habits (p=0.03). Conclusion-The dose dependent effect of cigarette smoking on the occurrence of oncogenic human papillomavirus favours a causal relation between these risk factors for cervical neoplasia.	UNIV GRONINGEN HOSP,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS; DEPT PATHOL,9675 HJ WINSCHOTEN,NETHERLANDS; DIAGNOST CTR SSDZ,DEPT MOLEC BIOL,2625 AD DELFT,NETHERLANDS	University of Groningen	BURGER, MPM (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,9713 EZ GRONINGEN,NETHERLANDS.							BARRASSO R, 1987, GYNECOL ONCOL, V27, P197, DOI 10.1016/0090-8258(87)90293-9; BARTON SE, 1988, LANCET, V2, P652; BRESLOW NE, 1980, IARC SCI PUBL, V32, P146; BRINTON LA, 1986, JAMA-J AM MED ASSOC, V255, P3265, DOI 10.1001/jama.255.23.3265; CAMPION MJ, 1986, LANCET, V2, P237; CLAAS ECJ, 1989, AM J PATHOL, V135, P703; CLARKE EA, 1982, AM J EPIDEMIOL, V115, P59, DOI 10.1093/oxfordjournals.aje.a113279; CORNELISSEN MTE, 1989, J GEN VIROL, V70, P2555, DOI 10.1099/0022-1317-70-10-2555; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; HOLLY EA, 1986, J NATL CANCER I, V76, P983; IKENBERG H, 1990, GENITAL PAPILLOMAVIR, P87; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P12; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P60; LYON JL, 1983, AM J PUBLIC HEALTH, V73, P558, DOI 10.2105/AJPH.73.5.558; MELCHERS W, 1989, J MED VIROL, V27, P329, DOI 10.1002/jmv.1890270413; RICHART RM, 1990, OBSTET GYNECOL, V75, P131; RICHART RM, 1973, PATHOLOGY ANN 1973, P301; ROHAN T, 1991, INT J CANCER, V49, P856, DOI 10.1002/ijc.2910490609; ROTKIN ID, 1973, CANCER RES, V33, P1353; SAITO K, 1987, CANCER, V59, P2064, DOI 10.1002/1097-0142(19870615)59:12<2064::AID-CNCR2820591217>3.0.CO;2-7; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SYRJANEN K, 1989, ACTA OBSTET GYN SCAN, V68, P613, DOI 10.3109/00016348909013280; TREVATHAN E, 1983, JAMA-J AM MED ASSOC, V250, P499, DOI 10.1001/jama.250.4.499; VANDENBRULE AJC, 1990, INT J CANCER, V45, P644, DOI 10.1002/ijc.2910450412; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; ZURHAUSEN H, 1989, JNCI-J NATL CANCER I, V81, P1680; 1991, DFPHS1990 DUTCH F PU	27	72	77	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					749	752		10.1136/bmj.306.6880.749	http://dx.doi.org/10.1136/bmj.306.6880.749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8387842	Green Published, Bronze			2022-12-24	WOS:A1993KU17300020
J	ERREDE, B; GARTNER, A; ZHOU, ZQ; NASMYTH, K; AMMERER, G				ERREDE, B; GARTNER, A; ZHOU, ZQ; NASMYTH, K; AMMERER, G			MAP KINASE-RELATED FUS3 FROM SACCHAROMYCES-CEREVISIAE IS ACTIVATED BY STE7 INVITRO	NATURE			English	Article							SIGNAL TRANSDUCTION; YEAST; CLN2; GENE	PHEROMONE-STIMULATED haploid yeast cells undergo a differentiation process that allows them to mate1. Transmission of the intracellular signal involves threonine and tyrosine phosphorylation of the redundant FUS3 and KSS1 kinases, which are members. of the MAP kinase family2-4. FUS3/KSS1 phosphorylation depends on two additional kinases, STE11 and STE7 (refs 2, 5, 6). Genetic analyses predict an ordered pathway where STE11 acts before STE7 and FUS3/KSS1 (refs 2, 7). Here we report that STE7 is a dual-specificity kinase that modifies FUS3 at the appropriate sites and stimulates its catalytic activity in vitro. From these data and previous genetic results, we argue that STE7 is the physiological activator of FUS3. Recent indications that MA kinase activators are related to STE7 suggest that signal transduction pathways in many, if not all, eukaryotic organisms use homologous kinase cascades8-10.	INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV VIENNA,INST ALLGEMEINE BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,LUDWIG BOLTZMANN FORSCHUNGSSTELLE,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of North Carolina; University of North Carolina Chapel Hill; University of Vienna; Ludwig Boltzmann Institute; University of Vienna				Nasmyth, Kim/0000-0001-7030-4403; Gartner, Anton/0000-0003-4639-9902				BOULTON TG, 1990, SCIENCE, V249, P476; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GEITZ RD, 1988, GENE, V74, P527; HOWE LR, 1992, CELL, V71, P355; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; ZHOU Z, IN PRESS MOL CELL BI	21	160	165	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					261	264		10.1038/362261a0	http://dx.doi.org/10.1038/362261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384702				2022-12-24	WOS:A1993KT02600061
J	DIMARIO, JX; FERNYAK, SE; STOCKDALE, FE				DIMARIO, JX; FERNYAK, SE; STOCKDALE, FE			MYOBLASTS TRANSFERRED TO THE LIMBS OF EMBRYOS ARE COMMITTED TO SPECIFIC FIBER FATES	NATURE			English	Article							MYOGENIC CELL LINEAGES; SKELETAL-MUSCLE FIBERS; HEAVY-CHAIN ISOFORMS; THYROID-HORMONE; NEURAL CONTROL; AVIAN LIMB; MYOSIN; EXPRESSION	IN the limb bud of the 5-day-old avian embryo, when primary muscle fibre formation is beginning and before specific muscles appear, differences in the expression of fast and slow myosin heavy chain genes can be detected among primary fibres of the premuscle masses1,2. Myoblasts that form colonies of fibres of specific types can be isolated from these limb buds3. To assess the role of myoblast commitment in specifying fibre types during embryonic development, we cloned myoblasts of specific types from embryonic and adult muscles, transfected them with a reporter gene, and transferred them into developing limb buds. After transfer, cloned myoblasts formed fibres in the limb with the same patterns of myosin heavy chain gene expression as the fibres they formed in cell culture. These results demonstrate that initial skeletal muscle fibre type diversity during avian limb development can originate, in part, from the commitment of distinct myoblast types to the formation of specific fibre types.	STANFORD UNIV,MED CTR,SCH MED,STANFORD,CA 94305	Stanford University								BUTLER J, 1988, DEVELOPMENT, V102, P763; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GAUTHIER GF, 1984, DEV BIOL, V105, P144, DOI 10.1016/0012-1606(84)90270-7; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; MCLENNAN IS, 1983, DEV BIOL, V98, P287, DOI 10.1016/0012-1606(83)90359-7; MILLER JB, 1989, DEV BIOL, V136, P393, DOI 10.1016/0012-1606(89)90265-0; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; ORDAHL CP, 1986, UCLA S MOL CELL BIOL, V29, P547; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; SOFER W, 1968, J BIOL CHEM, V243, P3110; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R	18	91	91	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					165	167		10.1038/362165a0	http://dx.doi.org/10.1038/362165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383807				2022-12-24	WOS:A1993KR02800062
J	ITOHARA, S; MOMBAERTS, P; LAFAILLE, J; IACOMINI, J; NELSON, A; CLARKE, AR; HOOPER, ML; FARR, A; TONEGAWA, S				ITOHARA, S; MOMBAERTS, P; LAFAILLE, J; IACOMINI, J; NELSON, A; CLARKE, AR; HOOPER, ML; FARR, A; TONEGAWA, S			T-CELL RECEPTOR DELTA-GENE MUTANT MICE - INDEPENDENT GENERATION OF ALPHA-BETA T-CELLS AND PROGRAMMED REARRANGEMENTS OF GAMMA-DELTA TCR GENES	CELL			English	Article							DENDRITIC EPIDERMAL-CELLS; JUNCTIONAL SEQUENCES; ANTIGEN RECEPTORS; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; CHAIN DIVERSITY; STEM-CELLS; SCID MICE; EXPRESSION; THYMOCYTES	T cells bearing T cell receptor (TCR) gamma and delta chain heterodimers are first generated early in ontogeny. They form distinct subsets that differ in their TCR repertoires and tissue distribution. Disruption of the mouse TCR Cdelta gene segment by a gene targeting method caused the complete loss of T cells bearing TCR gammadelta chains, but had little or no effect on the development of T cells bearing TCR alphabeta chains. The analyses of TCR gamma and delta genes in the mutant mice suggest that intracellular mechanisms acting at the level of DNA rearrangement play key roles in the differential gamma and delta gene rearrangements and in the generation of the highly restricted junctional sequences during fetal thymic development.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV EDINBURGH,AGR & FOOD RES COUNCIL,CTR GENOME RES,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle; University of Edinburgh			Itohara, Shigeyoshi/I-8769-2012; Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Itohara, Shigeyoshi/0000-0002-2410-9989; Clarke, Alan/0000-0002-4281-426X				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; AVNER PR, 1978, IMMUNOGENETICS, V7, P103, DOI 10.1007/BF01843995; BONNEVILLE M, 1990, J EXP MED, V171, P1015, DOI 10.1084/jem.171.4.1015; BONNEVILLE M, 1989, NATURE, V342, P931, DOI 10.1038/342931a0; BOORSMA DM, 1986, J MICROSC-OXFORD, V143, P197, DOI 10.1111/j.1365-2818.1986.tb02777.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; ELLIOTT JF, 1988, NATURE, V331, P627; FARR AG, 1991, J HISTOCHEM CYTOCHEM, V40, P651; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092-8674(89)90923-9; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; IWASATO T, 1992, EUR J IMMUNOL, V22, P101, DOI 10.1002/eji.1830220116; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KORMAN AJ, 1988, J EXP MED, V168, P1021, DOI 10.1084/jem.168.3.1021; KUBO RT, 1989, J IMMUNOL, V142, P2736; LACY MJ, 1989, P NATL ACAD SCI USA, V86, P1023, DOI 10.1073/pnas.86.3.1023; LAFAILLE JJ, 1990, IMMUNOL TODAY, V11, P75, DOI 10.1016/0167-5699(90)90030-D; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NIXONFULTON JL, 1988, J IMMUNOL, V141, P1897; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROTHENBERG E, 1983, J IMMUNOL, V130, P1627; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAGAKI Y, 1989, J IMMUNOL, V142, P2112; WINOTO A, 1989, NATURE, V338, P430, DOI 10.1038/338430a0	51	468	471	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					337	348		10.1016/0092-8674(93)90112-4	http://dx.doi.org/10.1016/0092-8674(93)90112-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381716				2022-12-24	WOS:A1993KM16200005
J	LU, Y; HALL, T; GAY, LS; DONELSON, JE				LU, Y; HALL, T; GAY, LS; DONELSON, JE			POINT MUTATIONS ARE ASSOCIATED WITH A GENE DUPLICATION LEADING TO THE BLOOD-STREAM REEXPRESSION OF A TRYPANOSOME METACYCLIC VSG	CELL			English	Article							SURFACE GLYCOPROTEIN GENE; VARIABLE ANTIGEN TYPES; BRUCEI-RHODESIENSE; BLOOD-STREAM; EXPRESSION; CONVERSION; DNA; TRANSCRIPTION; PSEUDOGENES; EQUIPERDUM	African trypanosomes evade the immune response of their hosts by sequentially expressing different variant surface glycoproteins (VSGs). We isolated a bloodstream trypanosome clone of Trypanosoma brucei rhodesiense that expresses a VSG normally present during the metacyclic stage of the parasite in the insect vector. Associated with the bloodstream reexpression of this metacyclic VSG is a gene conversion in which the duplicated, expressed gene of 1650 nt contains 11 scattered point mutations when compared with its donor gene. Analysis of an uncloned population of bloodstream trypanosomes revealed another VSG reexpressor of the same donor gene in which the coding region had undergone 24 point mutations. The mutations are unique to the duplicated gene and appear to be nontemplated. The generation of these mutations provides a way for the trypanosome to increase further its antigenic diversity.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242; WALTER REED ARMY INST RES,DEPT IMMUNOL,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307	University of Iowa; Howard Hughes Medical Institute; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	LU, Y (corresponding author), UNIV IOWA,GENET PHD PROGRAM,IOWA CITY,IA 52242, USA.		Donelson, John E/F-5795-2010					BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; BARNES DA, 1990, MOL BIOCHEM PARASIT, V41, P101, DOI 10.1016/0166-6851(90)90101-Q; BLACKBURN EH, 1984, CELL, V36, P447, DOI 10.1016/0092-8674(84)90238-1; BORST P, 1982, MOL BIOCHEM PARASIT, V6, P13, DOI 10.1016/0166-6851(82)90049-4; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1983, GENETIC REARRANGEMEN, P207; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CROWE JS, 1983, NATURE, V306, P389, DOI 10.1038/306389a0; DELAUW MF, 1987, MOL BIOCHEM PARASIT, V23, P9, DOI 10.1016/0166-6851(87)90181-2; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; ESSER KM, 1982, J IMMUNOL, V129, P1715; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LUMSDEN WHR, 1982, SYST PARASITOL, V4, P373, DOI 10.1007/BF00009977; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; MATTHEWS KR, 1990, NUCLEIC ACIDS RES, V18, P7219, DOI 10.1093/nar/18.24.7219; MCCORMACK WT, 1991, ANNU REV IMMUNOL, V9, P219; PAYS E, 1983, CELL, V34, P371, DOI 10.1016/0092-8674(83)90371-9; REDDY LV, 1990, BIOCHEM BIOPH RES CO, V169, P730, DOI 10.1016/0006-291X(90)90392-Z; RICEFICHT AC, 1982, NATURE, V298, P676, DOI 10.1038/298676a0; ROTH C, 1989, P NATL ACAD SCI USA, V86, P9375, DOI 10.1073/pnas.86.23.9375; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOLLER JK, 1989, MOL BIOCHEM PARASIT, V35, P11, DOI 10.1016/0166-6851(89)90137-0; SHAH JS, 1987, MOL BIOCHEM PARASIT, V24, P163, DOI 10.1016/0166-6851(87)90103-4; THON G, 1989, GENE DEV, V3, P1247, DOI 10.1101/gad.3.8.1247; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; TURNER CMR, 1986, PARASITOLOGY, V92, P67, DOI 10.1017/S0031182000063459; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; VANDERPLOEG LHT, 1984, CELL, V36, P459, DOI 10.1016/0092-8674(84)90239-3; VANDERPLOEG LHT, 1991, NEW BIOL, V3, P324; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905	36	48	48	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					397	406		10.1016/0092-8674(93)90116-8	http://dx.doi.org/10.1016/0092-8674(93)90116-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381717				2022-12-24	WOS:A1993KM16200009
J	MASON, RP; BESDINE, RW				MASON, RP; BESDINE, RW			ALUMINUM IN ALZHEIMERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NEUROFIBRILLARY TANGLES; DRINKING-WATER; PLAQUE CORES; MICROPROBE; ACCUMULATION; ABSENCE				MASON, RP (corresponding author), UNIV CONNECTICUT, CTR HLTH, FARMINGTON, CT 06032 USA.							CANDY JM, 1986, LANCET, V1, P354; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; LANDSBERG JP, 1992, NATURE, V360, P65, DOI 10.1038/360065a0; MARTYN CN, 1989, LANCET, V1, P59; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; NERI LC, 1991, LANCET, V338, P390, DOI 10.1016/0140-6736(91)90531-S; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; PETTEGREW JW, 1989, ANN NY ACAD SCI, V568, P5	10	1	1	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1868	1868		10.1001/jama.270.15.1868	http://dx.doi.org/10.1001/jama.270.15.1868			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411534				2022-12-24	WOS:A1993MB46400037
J	LOWE, SW; RULEY, HE; JACKS, T; HOUSMAN, DE				LOWE, SW; RULEY, HE; JACKS, T; HOUSMAN, DE			P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS	CELL			English	Article							PROGRAMMED CELL-DEATH; ACUTE LYMPHOBLASTIC-LEUKEMIA; P53 GENE-MUTATIONS; WILD-TYPE P53; LUNG-CANCER; E1A PROTEINS; MUTANT P53; C-MYC; DNA; ACTIVATION	Although the primary cellular targets of many anticancer agents have been identified, less is known about the processes leading to the selective cell death of cancer cells or the molecular basis of drug resistance. p53-deficient mouse embryonic fibroblasts were used to examine systematically the requirement for p53 in cellular sensitivity and resistance to a diverse group of anticancer agents. These results demonstrate that an oncogene, specifically the adenovirus E1A gene, can sensitize fibroblasts to apoptosis induced by ionizing radiation, 5-fluorouracil, etoposide, and adriamycin. Furthermore, the p53 tumor suppressor is required for efficient execution of the death program. These data reinforce the notion that the cytotoxic action of many anticancer agents involves processes subsequent to the interaction between drug and cellular target and indicate that divergent stimuli can activate a common cell death program. Consequently, the involvement of p53 in the apoptotic response suggests a mechanism whereby tumor cells can acquire cross-resistance to anticancer agents.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232	Massachusetts Institute of Technology (MIT); Vanderbilt University	LOWE, SW (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [5R27CA17575, P01-CA42063, R01CA40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602, R37CA017575, P01CA042063, R01CA017575] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CHIN KV, 1993, ADV CANCER RES, V60, P157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DAMICO D, 1992, ONCOGENE, V7, P3369; DAVIDOFF AM, 1991, SURGERY, V110, P259; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; HEIMDAL K, 1993, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; ISAACS WB, 1991, CANCER RES, V51, P4716; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; JONVEAUX P, 1991, LEUKEMIA, V5, P839; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NERI A, 1993, BLOOD, V81, P128; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHI YF, 1990, J IMMUNOL, V144, P3326; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRETCH JR, 1991, CANCER RES, V51, P5976; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THORLACIUS S, 1993, CANCER RES, V53, P1637; VANERP PEJ, 1988, CYTOMETRY, V9, P627, DOI 10.1002/cyto.990090618; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; WALKER GC, 1987, CELLULAR MOL BIOL, P1346; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEARGIN J, 1993, J CLIN INVEST, V91, P211	61	2961	3032	7	246	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					957	967		10.1016/0092-8674(93)90719-7	http://dx.doi.org/10.1016/0092-8674(93)90719-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402885				2022-12-24	WOS:A1993LY49300004
J	PAVLETICH, NP; PABO, CO				PAVLETICH, NP; PABO, CO			CRYSTAL-STRUCTURE OF A 5-FINGER GLI-DNA COMPLEX - NEW PERSPECTIVES ON ZINC FINGERS	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; 5S RNA GENE; WILMS-TUMOR LOCUS; KRUPPEL FAMILY; BINDING-SITES; YEAST ADR1; PROTEIN; XENOPUS; RECOGNITION; SEQUENCE	Zinc finger proteins, of the type first discovered in transcription factor IIIA (TFIIIA), are one of the largest and most important families of DNA-binding proteins. The crystal structure of a complex containing the five Zn fingers from the human GLI oncogene and a high-affinity DNA binding site has been determined at 2.6 angstrom resolution. Finger one does not contact the DNA. Fingers two through five bind in the major groove and wrap around the DNA, but lack the simple, strictly periodic arrangement observed in the Zif268 complex. Fingers four and five of GLI make extensive base contacts in a conserved nine base-pair region, and this section of the DNA has a conformation intermediate between B-DNA and A-DNA. Analyzing the GLI complex and comparing it with Zif268 offers new perspectives on Zn finger-DNA recognition.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR V2 1 MANUAL; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DICKERSON RE, 1989, PROGRAM NEWHELIX; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HUBER PW, 1991, J BIOL CHEM, V266, P3278; HUBER PW, 1991, P NATL ACAD SCI USA, V88, P10801, DOI 10.1073/pnas.88.23.10801; JACOBS G, 1990, New Biologist, V2, P583; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P9396, DOI 10.1021/bi00103a002; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MCCALL M, 1986, NATURE, V322, P661, DOI 10.1038/322661a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEKLUDOVA L, UNPUB; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PAVLETICH NP, UNPUB; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROBERTS WM, 1989, CANCER RES, V49, P5407; ROULD MR, 1989, PROGRAM DSCALEAD; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; 1979, SERC4 DAR LAB	49	632	672	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1993	261	5129					1701	1707		10.1126/science.8378770	http://dx.doi.org/10.1126/science.8378770			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378770				2022-12-24	WOS:A1993LY58400017
J	NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; SHINKAI, Y; LOUIE, MC; FIELDS, LE; LUCAS, PJ; STEWART, V; ALT, FW; LOH, DY				NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; SHINKAI, Y; LOUIE, MC; FIELDS, LE; LUCAS, PJ; STEWART, V; ALT, FW; LOH, DY			DISAPPEARANCE OF THE LYMPHOID SYSTEM IN BCL-2 HOMOZYGOUS MUTANT CHIMERIC MICE	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; FOLLICULAR LYMPHOMA; TRANSGENIC MICE; C-MYC; CHROMOSOMAL BREAKPOINT; B-CELLS; EXPRESSION; SURVIVAL; CLONING; PROTEIN	The bcl-2 proto-oncogene can prevent the death of many cell types. Mice were generated that were chimeric for the homozygous inactivation of bcl-2. Lymphocytes without Bcl-2 differentiated into phenotypically mature cells. However, in vitro, the mature T cells that lacked Bcl-2 had shorter life-spans and increased sensitivity to glucocorticoids and gamma-irradiation. In contrast, stimulation of CD3 inhibited the death of these cells. T and B cells with no Bcl-2 disappeared from the bone marrow, thymus, and periphery by 4 weeks of age. Thus, Bcl-2 was dispensable for lymphocyte maturation, but was required for a stable immune system after birth.	WASHINGTON UNIV, SCH MED, DEPT MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,DEPT GENET, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CTR BLOOD RES, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)			Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484	NIAID NIH HHS [AI 15322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015322] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maniatis T., 1982, MOL CLONING; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NAKAYAMA K, UNPUB; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROBERTSON EJ, 1987, EMBRYO DERIVED STEM; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786	36	386	396	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1584	1588		10.1126/science.8372353	http://dx.doi.org/10.1126/science.8372353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372353				2022-12-24	WOS:A1993LX47400032
J	MITRAKOU, A; FANELLI, C; VENEMAN, T; PERRIELLO, G; CALDERONE, S; PLATANISIOTIS, D; RAMBOTTI, A; RAPTIS, S; BRUNETTI, P; CRYER, P; GERICH, J; BOLLI, G				MITRAKOU, A; FANELLI, C; VENEMAN, T; PERRIELLO, G; CALDERONE, S; PLATANISIOTIS, D; RAMBOTTI, A; RAPTIS, S; BRUNETTI, P; CRYER, P; GERICH, J; BOLLI, G			REVERSIBILITY OF UNAWARENESS OF HYPOGLYCEMIA IN PATIENTS WITH INSULINOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFECTIVE GLUCOSE COUNTERREGULATION; DEPENDENT DIABETES-MELLITUS; GLYCEMIC THRESHOLDS; AUTONOMIC NEUROPATHY; RESPONSES; SYMPTOMS; PITUITARY; SECRETION; HUMANS	Background. A lack of appropriate autonomic warning symptoms before the development of neuroglycopenia occurs frequently in patients with diabetes mellitus. The pathogenesis of this phenomenon is unclear, but it is associated with intensive insulin therapy, prolonged duration of diabetes, frequent episodes of hypoglycemia, and impaired glucose counterregulation. Recently, it has been proposed that repeated episodes of hypoglycemia may themselves induce the phenomenon. Methods. To test this hypothesis and to determine whether the phenomenon is reversible, we assessed autonomic and neuroglycopenic symptoms, counterregulatory hormonal responses, and cognitive function during stepped hypoglycemic-clamp studies in 6 patients with insulinomas before and approximately six months after curative surgery and in 14 normal subjects matched for age, weight, and sex. Results. Before surgery, the patients with insulinomas had lower scores than the normal subjects for autonomic symptoms (mean [+/-SD], 3.5+/-0.8 vs. 9.6+/-4.5) and neuroglycopenic symptoms (2.8+/-1.5 vs. 8.9+/-5.3). The patients also had impaired counterregulatory hormonal responses (their plasma epinephrine, norepinephrine, glucagon, growth hormone, and cortisol responses before surgery were 187+/-227 pg per milliliter [1.03+/-1.25 nmol per liter], 223+/-85 pg per milliliter [1.32+/-0.50 nmol per liter], 86+/-21 ng per liter, 7.4+/-5.2 mug per liter, and 12.1+/-1.5 mug per deciliter [334+/-41 nmol per liter], respectively, as compared with 842+/-439 pg per milliliter [4.63+/-2.41 nmol per liter], 519+/-150 pg per milliliter [3.07+/-0.89 nmol per liter], 201+/-58 ng per liter, 25.3+/-13.7 mug per liter, and 26.3+/-1.2 mug per deciliter [726+/-33 nmol per liter in the normal subjects) and less deterioration in cognitive function than the normal subjects during hypoglycemia (sum of z scores for seven tests of cognitive function, 1.7+/-1.9 vs. 8.9+/-3,5) (P<0.02 for all comparisons). Surgical cure reversed all these abnormalities (P not significant for all comparisons with the normal subjects). Conclusions. Hypoglycemia itself can induce unawareness of the autonomic and neuroglycopenic symptoms of hypoglycemia and decrease the counterregulatory hormonal responses to hypoglycemia.	WHITTIER INST DIABET & ENDOCRINOL, 9894 GENESEE AVE, LA JOLLA, CA 92037 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV PERUGIA, IST MED INTERNA & SCI ENDOCRINE & METAB, I-06100 PERUGIA, ITALY; UNIV ATHENS, DEPT INTERNAL MED PROPAEDEUT 2, ATHENS, GREECE	Washington University (WUSTL); University of Perugia; National & Kapodistrian University of Athens				FANELLI, Carmine Giuseppe/0000-0003-4063-158X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00036, RR00056] Funding Source: Medline; NIDDK NIH HHS [DK29411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; ARKY RA, 1988, NEW ENGL J MED, V318, P1523; Banting FG, 1923, BRIT MED J, V1923, P8, DOI 10.1136/bmj.1.3236.8; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; DAVIDSON MB, 1986, NEW ENGL J MED, V314, P849; DAVIS MR, 1991, J CLIN ENDOCR METAB, V72, P788, DOI 10.1210/jcem-72-4-788; DAVIS MR, 1991, J CLIN ENDOCR METAB, V73, P995, DOI 10.1210/jcem-73-5-995; FANELLI C, 1992, DIABETES S1, V41, pA30; FANELLI C, 1992, GIORNALE ITALIANO DI, V12, P269; FRIER BM, 1988, DIABETOLOGIA, V31, P421, DOI 10.1007/BF00271586; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; GRIMALDI A, 1989, DIABETES METAB, V15, P209; GRIMALDI A, 1990, HORM METAB RES, V22, P90, DOI 10.1055/s-2007-1004858; HELLER SR, 1987, LANCET, V2, P359; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; MARAN A, 1992, DIABETIC MED, V9, P765, DOI 10.1111/j.1464-5491.1992.tb01889.x; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; VEA H, 1992, DIABETIC MED, V9, P950, DOI 10.1111/j.1464-5491.1992.tb01738.x; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; WIDOM B, 1992, DIABETES, V41, P1597, DOI 10.2337/diabetes.41.12.1597; Zar J.H., 2010, BIOSTAT ANAL	27	168	173	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					834	839		10.1056/NEJM199309163291203	http://dx.doi.org/10.1056/NEJM199309163291203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355741				2022-12-24	WOS:A1993LW55100003
J	CHOW, LML; FOURNEL, M; DAVIDSON, D; VEILLETTE, A				CHOW, LML; FOURNEL, M; DAVIDSON, D; VEILLETTE, A			NEGATIVE REGULATION OF T-CELL RECEPTOR SIGNALING BY TYROSINE PROTEIN-KINASE P50(CSK)	NATURE			English	Article							ANTIGEN RECEPTOR; C-SRC; RESPONSIVENESS; ACTIVATION; GENE; PHOSPHORYLATION; ENHANCEMENT; EXPRESSION; RETROVIRUS; CLONING	TYROSINE protein phosphorylation is necessary for antigen receptor-mediated activation of T lymphocytes1. This signal is generated at least in part by the Src-related tyrosine protein kinases p56lck and p59fynT (refs 2, 3). The activity of these two enzymes is repressed by phosphorylation of a conserved carboxy-terminal tyrosine residue2,3. Recent studies suggest that this inhibitory phosphorylation may be caused by p50csk (for C-terminal Src kinase), a tyrosine protein kinase which accumulates most abundantly in thymus and spleen4-8. To investigate the function of Csk in T lymphocytes and characterize the processes regulating T-cell receptor (TCR) signalling, we examined the effects of overexpression of Csk on the physiology of an antigen-specific mouse T-cell line. We report here that p50csk negatively regulates TCR-induced tyrosine protein phosphorylation and lymphokine production. This provides evidence for the involvement of Csk in the regulation of T-cell activation.	MCGILL UNIV,DEPT BIOCHEM,ROOM 715B,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MONTREAL GEN HOSP,DEPT MED,DIV MED ONCOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Sambrook J., 1989, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SILLATY SN, 1990, ANAL BIOCHEM, V185, P194; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAKEYA T, 1982, J VIROL, V44, P1; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	27	252	260	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					156	160		10.1038/365156a0	http://dx.doi.org/10.1038/365156a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371758				2022-12-24	WOS:A1993LW44200047
J	SCHNEIDER, W; NOLL, DC; COHEN, JD				SCHNEIDER, W; NOLL, DC; COHEN, JD			FUNCTIONAL TOPOGRAPHIC MAPPING OF THE CORTICAL RIBBON IN HUMAN VISION WITH CONVENTIONAL MRI SCANNERS	NATURE			English	Article							STRIATE CORTEX; BRAIN; ORGANIZATION; DEPENDENCE; AREAS; BLOOD; TIME	THE human brain has anatomically distinct areas in which processing is laid out in space at the millimetre level with substantial variation across individuals. Activity occurs along a cortical ribbon 1.5-3 mm thick1 in response to specific stimuli2,3. Here we report the first use of cortical ribbon analysis on humans using non-invasive functional magnetic resonance imaging techniques performed with a conventional 1.5 T MRI scanner. Changes in activation were detected using T2*-weighted, gradient echo imaging sequences. Subjects observed partial field, flashing checkerboard patterns (left-right, top-bottom, half rings, and wedges). Stimuli produced magnetic resonance signal changes in the 1-8% range, varying at the millimetre scale, which showed contralateral vertically reflected patterns of activation in the visual cortex. To compare the spatial topographies across subjects, computer algorithms were used to control for the subject-unique folding of cortex, providing a flattened cortical ribbon identifying four topographically distinct areas.	PITTSBURGH NMR INST, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT PSYCHOL, PITTSBURGH, PA 15213 USA	Carnegie Mellon University	SCHNEIDER, W (corresponding author), UNIV PITTSBURGH, 3939 O HARA ST, PITTSBURGH, PA 15260 USA.		Noll, Douglas C/D-8124-2014	Noll, Douglas C/0000-0002-0983-3805				BAILEY P, 1951, ISOCORTEX MAN; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRIEDMAN HR, 1989, J NEUROSCI, V9, P4111; GLASSNER AS, 1990, GRAPHIC GEMS, P587; GLICKSTEIN M, 1987, TRENDS NEUROSCI, V10, P350, DOI 10.1016/0166-2236(87)90066-X; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HAXBY JV, IN PRESS FUNCTIONAL; KENNEDY DN, 1989, IEEE T MED IMAGING, V8, P1, DOI 10.1109/42.20356; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; PRESS WH, 1986, NUMERICAL RECIPES AR; RAICHLE ME, 1988, HDB PHYSL, P643; SHULMAN RG, 1993, P NATL ACAD SCI USA, V90, P3127, DOI 10.1073/pnas.90.8.3127; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; TOOTELL RBH, 1988, J NEUROSCI, V8, P1531; ZEKI S, 1991, J NEUROSCI, V11, P641	19	166	169	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					150	152		10.1038/365150a0	http://dx.doi.org/10.1038/365150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371756				2022-12-24	WOS:A1993LW44200045
J	MYERS, LC; TERRANOVA, MP; FERENTZ, AE; WAGNER, G; VERDINE, GL				MYERS, LC; TERRANOVA, MP; FERENTZ, AE; WAGNER, G; VERDINE, GL			REPAIR OF DNA METHYLPHOSPHOTRIESTERS THROUGH A METALLOACTIVATED CYSTEINE NUCLEOPHILE	SCIENCE			English	Article							CD-113 NMR; BINDING-PROTEIN; GENE-32 PROTEIN; ZINC ENZYMES; COORDINATION; COMPLEXES; DOMAIN; SPECTROSCOPY; LIGANDS	The Escherichia coli Ada protein repairs methylphosphotriesters in DNA by direct, irreversible methyl transfer to one of its own cysteines. Upon methyl transfer, Ada acquires the ability to bind specific DNA sequences and thereby to induce genes that confer resistance to methylating agents. The amino-terminal domain of Ada, which comprises the methylphosphotriester repair and sequence-specific DNA binding elements, contains a tightly bound zinc ion. Analysis of the zinc binding site by cadmium-113 nuclear magnetic resonance and site-directed mutagenesis revealed that zinc participates in the autocatalytic activation of the active site cysteine and may also function as a conformational switch.	HARVARD UNIV,PROGRAM HIGHER DEGREES BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Harvard Medical School; Harvard University								BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BOBSEIN BR, 1981, J BIOL CHEM, V256, P5313; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CEDAR H, 1989, CELL, V53, P3; COLEMAN JE, 1971, PROGR BIOORGANIC CHE, V1, P159; COLEMAN JE, 1986, ZINC ENZYMES, P77; COTTON FA, 1988, ADV INORG CHEM RAD, P597; DEMPLE B, 1990, PROTEIN METHYLATION, P285; ELDER RC, 1978, INORG CHEM, V17, P1296, DOI 10.1021/ic50183a039; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; JACKOW F, UNPUB; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KUEHN CG, 1980, PROG INORG CHEM, V27, P154; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LINDOY LF, 1974, INORG CHEM, V13, P2494, DOI 10.1021/ic50140a037; LIVE D, 1985, J AM CHEM SOC, V107, P1775, DOI 10.1021/ja00292a062; MYERS LC, 1992, BIOCHEMISTRY-US, V31, P4541, DOI 10.1021/bi00134a002; MYERS LT, UNPUB; PAN T, 1990, BIOCHEMISTRY-US, V29, P3023, DOI 10.1021/bi00464a019; RAJANIKANTH B, 1984, INDIAN J CHEM B, V23, P1043; Singer B., 1983, MOL BIOL MUTAGENS CA; SOUTH TL, 1989, J AM CHEM SOC, V111, P395, DOI 10.1021/ja00183a074; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; TERRANOVA ML, UNPUB; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1990, P NATL ACAD SCI USA, V87, P220, DOI 10.1073/pnas.87.1.220; WORGOTTER E, 1986, J AM CHEM SOC, V108, P6162	33	180	182	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1164	1167		10.1126/science.8395079	http://dx.doi.org/10.1126/science.8395079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8395079				2022-12-24	WOS:A1993LU58600030
J	WARD, H; DAY, S; MEZZONE, J; DUNLOP, L; DONEGAN, C; FARRAR, S; WHITAKER, L; HARRIS, JRW; MILLER, DL				WARD, H; DAY, S; MEZZONE, J; DUNLOP, L; DONEGAN, C; FARRAR, S; WHITAKER, L; HARRIS, JRW; MILLER, DL			PROSTITUTION AND RISK OF HIV - FEMALE PROSTITUTES IN LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure the prevalence of HIV and to describe established risk factors in female prostitutes. Design-A cross sectional survey. Setting-A genitourinary medicine clinic, streets, and magistrates' courts in London. Subjects-280 female prostitutes recruited between April 1989 and August 1991. Main outcome measures-Infection with HIV-1, reported risk behaviours, and prevalence of sexually transmitted infections. Results-228 of the women had HIV tests, and two (0.9% (95% confidence interval 0% to 2.1%)) were infected with HIV-1. Reported use of condoms was high for commercial clients and low for non-paying partners: 98% (251/255) of women used condoms with all clients and 12% (25/207) with non-paying partners for vaginal intercourse. Twenty two women were current or past injecting drug users. Of the 193 women examined for sexually transmitted infections, 27 had an acute infection (gonorrhoea, chlamydia, trichomonas, or primary genital herpes) at the time of interview. Infection was associated with younger age and increasing numbers of non-paying sexual partners, but not with duration of prostitution, numbers of clients, or reports of condom failures. When age and numbers of non-paying partners were analysed by logistic regression they remained significantly associated with sexually transmitted infections. Conclusions-A large and diverse sample of prostitutes had a low prevalence of infection with HIV and high levels of use of condoms in commercial sex. There was a significant risk of other sexually transmitted infections associated with prostitutes' non-commercial sexual relationships, in which unprotected sex is common. Interventions to reduce the risk of sexually transmitted infections in prostitutes should address both commercial and non-commercial sexual partnerships.	ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON W2 1PG,ENGLAND	Imperial College London	WARD, H (corresponding author), ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.		Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036; Day, Sophie/0000-0002-9822-9094				DAY S, 1988, BRIT MED J, V297, P1585, DOI 10.1136/bmj.297.6663.1585; Day S., 1990, AIDS DRUGS PROSTITUT, P61; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MCKEGANEY N, 1992, BMJ-BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; THOMAS RM, 1989, BMJ-BRIT MED J, V299, P148, DOI 10.1136/bmj.299.6692.148; WARD H, 1992, BRIT MED J, V304, P1635, DOI 10.1136/bmj.304.6842.1635-e; WARD H, 1992, 9 P INT C AIDS 3 STD, pC276; 1993, AIDS, V7, P401	8	59	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					356	358		10.1136/bmj.307.6900.356	http://dx.doi.org/10.1136/bmj.307.6900.356			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374417	Green Published, Bronze			2022-12-24	WOS:A1993LR76800018
J	ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C				ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C			IDENTIFICATION OF JAK2 AS A GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE	CELL			English	Article							BINDING-PROTEIN; CELLS; METABOLISM; GH; PHOSPHORYLATION; PURIFICATION; DOMAINS; PRODUCT; SERUM; DNA	Growth hormone receptor (GHR) forms a complex with a tyrosine kinase, suggesting involvement of a ligand-activated tyrosine kinase in intracellular signaling by growth hormone (GH). Here we identify JAK2, a nonreceptor tyrosine kinase, as a GHR-associated tyrosine kinase. Immunological approaches were used to establish GH-dependent complex formation between JAK2 and GHR, activation of JAK2 tyrosine kinase activity, and tyrosyl phosphorylation of both JAK2 and GHR. The JAK2-GHR and JAK2-erythropoietin receptor interactions described here and in the accompanying paper provide a molecular basis for involvement of tyrosyl phosphorylation in physiological responses to these ligands and suggest a shared signaling mechanism among members of the cytokine/hematopoietin receptor family.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital	ARGETSINGER, LS (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA.		witthuhn, bruce/GSE-3193-2022		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK034171, R01-DK34171, R01 DK042932, R01-DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MOLLER C, 1992, THESIS NOVUM HUDDING, P1; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TAI PKK, 1990, J BIOL CHEM, V265, P21828; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	34	854	873	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 30	1993	74	2					237	244		10.1016/0092-8674(93)90415-M	http://dx.doi.org/10.1016/0092-8674(93)90415-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343952	Green Submitted			2022-12-24	WOS:A1993LP72600005
J	CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ				CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ			CRYSTAL-STRUCTURE OF THE HHAL DNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYL-L-METHIONINE	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; DETERMINES METHYLATION; CATALYTIC MECHANISM; ESCHERICHIA-COLI; SEQUENCE MOTIFS; MET REPRESSOR; BINDING; PROTEIN; EXPRESSION	The first three-dimensional structure of a DNA methyltransferase is presented. The crystal structure of the DNA (cytosine-5)-methyltransferase, M.Hhal (recognition sequence: GCGC), complexed with S-adenosyl-L-methionine has been determined and refined at 2.5 angstrom resolution. The core of the structure is dominated by sequence motifs conserved among all DNA (cytosine-5)-methyltransferases, and these are responsible for cofactor binding and methyltransferase function.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915		CHENG, XD (corresponding author), COLD SPRING HARBOR LAB,WM KECK STRUCT BIOL LAB,COLD SPRING HARBOR,NY 11724, USA.		Kumar, Sanjay/AAO-2593-2021	Roberts, Richard/0000-0002-4348-0169	NCI NIH HHS [CA 45508] Funding Source: Medline; NIGMS NIH HHS [GM 46127, GM 49245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049245, R01GM046127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASERTA M, 1987, J BIOL CHEM, V262, P4770; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GUNTHERT U, 1986, EUR J BIOCHEM, V159, P485, DOI 10.1111/j.1432-1033.1986.tb09912.x; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; INGROSSO D, 1989, J BIOL CHEM, V264, P20130; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANN MB, 1979, P C TRANSMETHYLATION, P483; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; ROBERTS RJ, 1976, J MOL BIOL, V103, P199, DOI 10.1016/0022-2836(76)90060-7; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SANTI DV, 1984, FOLATES PTERIDINES, V1, P343; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WU JC, 1987, J BIOL CHEM, V262, P4778; WU JC, 1988, NUCLEIC ACIDS RES, V16, P703, DOI 10.1093/nar/16.2.703; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	53	364	370	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					299	307		10.1016/0092-8674(93)90421-L	http://dx.doi.org/10.1016/0092-8674(93)90421-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343957				2022-12-24	WOS:A1993LP72600011
J	HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP				HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP			TRANSCYTOSIS OF THE POLYMERIC IG RECEPTOR REQUIRES PHOSPHORYLATION OF SERINE-664 IN THE ABSENCE BUT NOT THE PRESENCE OF DIMERIC IGA	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; TRANS-EPITHELIAL TRANSPORT; SODIUM DODECYL-SULFATE; AMINO-ACID CHANGE; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; SECRETORY COMPONENT; COATED PITS; PROTEINS	MDCK cells expressing the polymeric immunoglobulin (poly-Ig) receptor, cocultured with IgA-producing hybridoma cells, transported dimeric IgA (dIgA) from the basolateral into the lumenal compartment, where it was recovered as secretory component-dIgA complexes. The tail of the receptor was phosphorylated on serines 664 and 726. Each serine was mutated to alanine. Appearance of A726 receptor at the basolateral surface was reduced approximately 5-fold. This was accompanied by a approximately 5-fold reduction in dIgA transcytosis. Basolateral delivery of receptor was not affected by mutation A664, and in the absence of dIgA, the receptor accumulated in recycling basolateral endosomes. In coculture, however, dIgA transcytosis by A664 receptor was normal. Thus, entry of receptor into the transcytotic pathway requires Ser-664 phosphorylation only in the absence of dIgA.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV GENEVA, CTR MED, DEPT MED BIOCHEM, CH-1211 GENEVA, SWITZERLAND; CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Swiss Institute Experimental Cancer Research; University of Lausanne; University of Geneva; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Poulain-Godefroy, Odile/AAF-5474-2021; Hirt, Robert/R-5429-2017	Hirt, Robert/0000-0002-3760-9958; POULAIN-GODEFROY, Odile/0000-0001-8805-9450	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017557, R37HD017557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021505] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17557] Funding Source: Medline; NIDDK NIH HHS [DK21505] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; EGGERT M, 1991, FEBS LETT, V292, P205, DOI 10.1016/0014-5793(91)80868-4; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HANLY WC, 1987, J IMMUNOL, V139, P1597; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUHN LC, 1981, J BIOL CHEM, V256, P2490; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PACCOLAT MP, 1987, AM J PHYSIOL, V252, pC468, DOI 10.1152/ajpcell.1987.252.5.C468; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SCHAERER E, 1991, J MEMBRANE BIOL, V123, P93, DOI 10.1007/BF01998081; SCHULTE TH, 1978, BIOCHIM BIOPHYS ACTA, V508, P425, DOI 10.1016/0005-2736(78)90089-5; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOLARI R, 1985, J BIOL CHEM, V260, P1141; Solari R., 1987, The mammary gland. Development, regulation, and function., P269; SOLARI R, 1985, IMMUNOL TODAY, V6, P17, DOI 10.1016/0167-5699(85)90163-X; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	47	83	86	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					245	255		10.1016/0092-8674(93)90416-N	http://dx.doi.org/10.1016/0092-8674(93)90416-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343953				2022-12-24	WOS:A1993LP72600006
J	SAKA, Y; YANAGIDA, M				SAKA, Y; YANAGIDA, M			FISSION YEAST CUT5+, REQUIRED FOR S-PHASE ONSET AND M-PHASE RESTRAINT, IS IDENTICAL TO THE RADIATION-DAMAGE REPAIR GENE RAD4+	CELL			English	Article							CELL-DIVISION CYCLE; SISTER-CHROMATID EXCHANGE; DNA TOPOISOMERASE-II; STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; MITOSIS	Fission yeast cut5 mutants cause cytokinesis in the absence of normal nuclear division. We show here that cut5+ is required for both the onset of S phase and the restraint of M phase before the completion of S phase. The primary defects in cut5 mutants occur prior to S phase, but cells suffer lethal damage during M phase. Mitosis and cytokinesis occur in the presence of hydroxyurea or in the double mutant cdc10-cut5 (the cdc10 mutation alone blocks progression from G1 to S). Gene cloning shows that cut5+ is identical to the fission yeast rad4+ gene, which is similar to human XRCC1. The rad4+/cut5+ gene is unique in its positive role for replication/repair and in its negative role for mitosis/cytokinesis. We propose a single/twin chromatid marking model for rad4+/cut5+ function in cell cycle control.			SAKA, Y (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KITASHIRAKAWA OIWAKECHO,SAKYO KU,KYOTO 606,JAPAN.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1992, EMBO J, V114, P59; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DUCK P, 1976, J BACTERIOL, V128, P536, DOI 10.1128/JB.128.2.536-539.1976; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMEJIMA I, 1993, IN PRESS J CELL SCI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	56	205	209	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					383	393		10.1016/0092-8674(93)90428-S	http://dx.doi.org/10.1016/0092-8674(93)90428-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343962				2022-12-24	WOS:A1993LP72600018
J	VISWANATHAN, R; ZASADZINSKI, JA; SCHWARTZ, DK				VISWANATHAN, R; ZASADZINSKI, JA; SCHWARTZ, DK			STRAINED-LAYER VAN-DER-WAALS EPITAXY IN A LANGMUIR-BLODGETT-FILM	SCIENCE			English	Article							ATOMIC FORCE MICROSCOPY; MOLECULAR-RESOLUTION IMAGES; AIR-WATER-INTERFACE; ELECTRON-DIFFRACTION; REENTRANT APPEARANCE; 2 DIMENSIONS; MONOLAYER; ACID; GROWTH; SURFACE	Atomic force microscope images of Langmuir-Blodgett films of lead and manganese fatty acid salts show that these monolayers have long-range order and are oriented with respect to the mica substrate, although the lattice symmetries of the monolayers and substrate are dramatically different. The surface lattice of sequentially thicker films evolves toward the bulk structure while retaining the substrate alignment. This behavior is in distinct contrast to films of cadmium fatty acid salts on mica, or all films on amorphous silicon oxide, in which the monolayer structure is disordered and a three-layer-thick film displays the bulk structure.	UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles			Schwartz, Daniel K/H-5153-2012	Schwartz, Daniel K/0000-0001-5397-7200	NIGMS NIH HHS [GM 47334] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn D.J., 1991, J CHEM PHYS, V95, P8486, DOI 10.1063/1.461278; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOHM C, 1989, THIN SOLID FILMS, V178, P511, DOI 10.1016/0040-6090(89)90346-5; BONNEROT A, 1985, CHEM PHYS, V97, P365, DOI 10.1016/0301-0104(85)87045-2; BOURDIEU L, 1991, PHYS REV LETT, V67, P2029, DOI 10.1103/PhysRevLett.67.2029; ECKHARDT CJ, 1992, LANGMUIR, V8, P2591, DOI 10.1021/la00047a003; ECKHARDT CJ, 1992, CHEM PHYS LETT, V194, P370, DOI 10.1016/0009-2614(92)86067-R; EGGER M, 1990, J STRUCT BIOL, V103, P89, DOI 10.1016/1047-8477(90)90089-U; GARNAES J, 1992, NATURE, V357, P5; GAROFF S, 1986, J PHYS-PARIS, V47, P701, DOI 10.1051/jphys:01986004704070100; HANSMA HG, 1991, LANGMUIR, V7, P1051, DOI 10.1021/la00054a005; Kitaigorodskii A.I., 1961, ORGANIC CHEM CRYSTAL; KOMA A, 1989, APPL SURF SCI, V41-2, P451, DOI 10.1016/0169-4332(89)90102-5; LEVEILLER F, 1991, SCIENCE, V252, P1532, DOI 10.1126/science.252.5012.1532; MARTI O, 1988, SCIENCE, V239, P50, DOI 10.1126/science.3336773; MEYER E, 1991, NATURE, V349, P398, DOI 10.1038/349398a0; OHUCHI FS, 1990, J APPL PHYS, V68, P2168, DOI 10.1063/1.346574; PRAKASH M, 1986, CHEM PHYS LETT, V128, P354, DOI 10.1016/0009-2614(86)80376-1; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; ROBERTS GG, 1985, ADV PHYS, V34, P475, DOI 10.1080/00018738500101801; SCHLOSSMAN ML, 1991, PHYS REV LETT, V66, P1599, DOI 10.1103/PhysRevLett.66.1599; SCHWARTZ DK, 1992, J PHYS CHEM-US, V96, P10444, DOI 10.1021/j100204a059; SCHWARTZ DK, 1992, J CHEM PHYS, V96, P2356, DOI 10.1063/1.462032; SCHWARTZ DK, 1992, SCIENCE, V257, P508, DOI 10.1126/science.257.5069.508; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267; STEITZ R, 1991, THIN SOLID FILMS, V205, P124, DOI 10.1016/0040-6090(91)90483-E; TIPPMANNKRAYER P, 1992, THIN SOLID FILMS, V210, P577, DOI 10.1016/0040-6090(92)90346-D; UENO K, 1990, J VAC SCI TECHNOL A, V8, P68, DOI 10.1116/1.576983; VISWANATHAN R, 1992, LANGMUIR, V8, P1603, DOI 10.1021/la00042a018; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003; YAZDANIAN M, 1990, LANGMUIR, V6, P1093, DOI 10.1021/la00096a012; YAZDANIAN M, 1992, LANGMUIR, V8, P630, DOI 10.1021/la00038a055; ZASADZINSKI JAN, 1991, BIOPHYS J, V59, P755, DOI 10.1016/S0006-3495(91)82288-3	33	65	65	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					449	452		10.1126/science.8392751	http://dx.doi.org/10.1126/science.8392751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392751				2022-12-24	WOS:A1993LN62300029
J	DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G				DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G			CASE-CONTROL STUDY OF CONGENITAL-ANOMALIES IN CHILDREN OF CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; SURVIVORS; PREGNANCY; POPULATION; FERTILITY; MUTATION; MICE	Objectives-To determine whether the offspring of cancer survivors are at an increased risk of congenital anomalies and whether cancer therapy before conception is associated with such an increase. Design-Case-control study using computerised record linkage. Setting-Ontario, Canada. Subjects-Parents of children born during April 1979 to December 1986 who had a congenital anomaly diagnosed within the first year of life (45 200 mothers and 41 158 fathers) and a matched sample of parents whose children did not have a congenital anomaly (45 200 mothers and 41 158 fathers). Main outcome measures-Cancer diagnosed in either parent before conception and radiotherapy to the pelvis or abdomen or chemotherapy with an alkylating agent. Results-Among the mothers, 54 cases and 52 controls were identified as having had cancer diagnosed in Ontario (relative risk=1.04, 95% confidence interval 0.7 to 1.5) and among the fathers, 61 cases and 65 controls were identified (0.9, 0.7 to 1.4). No significant associations were found between congenital anomalies in the offspring and any type of cancer treatment in either the mothers or the fathers. Conclusions-The risk of congenital anomalies among liveborn offspring whose parents have had cancer or been treated for cancer is not higher than that in the general population.	ONTARIO CANC TREATMENT & RES FDN,TORONTO M4H 1A8,ON,CANADA; HLTH & WELF CANADA,LAB CTR DIS CONTROL,OTTAWA K1A 0L2,ONTARIO,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO M5S 1A8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of Toronto; McMaster University								BAIRD PA, 1988, AM J HUM GENET, V42, P677; BALIS FM, 1989, PRINCIPLES PRACTICE, P165; BLATT J, 1989, PRINCIPLES PRACTICE, P1003; BRESLOW NE, 1980, IARC32 INT AG RES CA; BYRNE J, 1987, NEW ENGL J MED, V317, P1315, DOI 10.1056/NEJM198711193172104; Chabner B. A., 1982, CANCER PRINCIPLES PR, P156; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREEN DM, 1991, NEW ENGL J MED, V325, P141, DOI 10.1056/NEJM199107183250301; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1989, INT J CANCER, V43, P399, DOI 10.1002/ijc.2910430309; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KIRK M, 1982, MUTAT RES, V106, P73, DOI 10.1016/0027-5107(82)90191-9; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P216, DOI 10.1001/jama.257.2.216; MULVIHILL JJ, 1987, CANCER, V60, P1143, DOI 10.1002/1097-0142(19870901)60:5<1143::AID-CNCR2820600537>3.0.CO;2-E; MULVIHILL JJ, 1990, PROG CLIN BIOL RES, V340, P179; NOMURA T, 1988, MUTAT RES, V198, P309, DOI 10.1016/0027-5107(88)90008-5; ROTHMAN KJ, 1986, MODERN EPIDMIOLOGY; TRASLER JM, 1985, NATURE, V316, P144, DOI 10.1038/316144a0; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1985, SAS VERSION 5; 1977, INT CLASSIFICATION C; 1988, EGRET	24	70	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					164	168		10.1136/bmj.307.6897.164	http://dx.doi.org/10.1136/bmj.307.6897.164			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343744	Bronze, Green Published			2022-12-24	WOS:A1993LN18400019
J	ELLINOR, PT; ZHANG, JF; RANDALL, AD; ZHOU, M; SCHWARZ, TL; TSIEN, RW; HORNE, WA				ELLINOR, PT; ZHANG, JF; RANDALL, AD; ZHOU, M; SCHWARZ, TL; TSIEN, RW; HORNE, WA			FUNCTIONAL EXPRESSION OF A RAPIDLY INACTIVATING NEURONAL CALCIUM-CHANNEL	NATURE			English	Article							CHICK SENSORY NEURONS; ELECTRIC ORGAN; OMEGA-CONOTOXIN; NERVE-TERMINALS; CELLS; RECEPTOR; CURRENTS; BINDING	DIVERSE types of calcium channels in vertebrate neurons are important in linking electrical activity to transmitter release, gene expression and modulation of membrane excitability1. Four classes of Ca2+ channels (T, N, L and P-type) have been distinguished2-6 on the basis of their electrophysiological and pharmacological properties. Most of the recently cloned Ca2+ channels7-16 fit within this functional classification. But one major branch of the Ca2+ channel gene family, including BII (ref. 15) and doe-1 (ref. 16), has not been functionally characterized. We report here the expression of doe-1 and show that it is a high-voltage-activated (HVA) Ca2+ channel that inactivates more rapidly than previously expressed calcium channels. Unlike L-type or P-type channels, doe-1 is not blocked by dihydropyridine antagonists or the peptide toxin omega-Aga-IVA, respectively. In contrast to a previously cloned N-type channel14, doe-I block by omega-CTx-GVIA requires micromolar toxin and is readily reversible. Unlike most HVA channels, doe-1 also shows unusual sensitivity to block by Ni2+. Thus, doe-1 is an HVA Ca2+ channel with novel functional properties. We have identified a Ca2+ channel current in rat cerebellar granule neurons that resembles doe-1 in many kinetic and pharmacological features.	STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Stanford University; Cornell University				Ellinor, Patrick/0000-0002-2067-0533; Randall, Andrew/0000-0001-8852-3671				AHMAD SN, 1988, BRAIN RES, V453, P247; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; Hille B., 1992, IONIC CHANNELS EXCIT; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HORNE WA, 1991, J BIOL CHEM, V266, P13719; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, INTRACELLULAR CALCIU, P97; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NARAHASHI T, 1987, J PHYSIOL-LONDON, V383, P231; NGSEE JK, 1991, J BIOL CHEM, V226, P2625; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, J NEUROSCI, V11, P2259; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WANG XM, 1992, J PHYSIOL-LONDON, V445, P181, DOI 10.1113/jphysiol.1992.sp018919; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	33	247	253	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					455	458		10.1038/363455a0	http://dx.doi.org/10.1038/363455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8389006				2022-12-24	WOS:A1993LE93800060
J	LASALLE, GL; ROBERT, JJ; BERRARD, S; RIDOUX, V; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; MALLET, J				LASALLE, GL; ROBERT, JJ; BERRARD, S; RIDOUX, V; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; MALLET, J			AN ADENOVIRUS VECTOR FOR GENE-TRANSFER INTO NEURONS AND GLIA IN THE BRAIN	SCIENCE			English	Article							COLI BETA-GALACTOSIDASE; MOUSE; VIRUS; RAT; EXPRESSION; SYSTEM	The efficient introduction of genetic material into quiescent nerve cells is important in the study of brain function and for gene therapy of neurological disorders. A replication-deficient adenoviral vector that contained a reporter gene encoding beta-galactosidase infected rat nerve cells in vitro and in vivo. Beta-galactosidase was expressed in almost all sympathetic neurons and astrocytes in culture. After stereotactic inoculations into the rat hippocampus and the substantia nigra, beta-galactosidase activity was detected for 2 months. Infected cells were identified as microglial cells, astrocytes, or neurons with anatomical, morphological, and immunohistochemical criteria. No obvious cytopathic effect was observed.	CNRS,GENET MOLEC NEUROTRANSMISS & PROC DEGENERAT LAB,C9923,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INST ALFRED FESSARD,UNITE PROPRE RECH 2212,F-91198 GIF SUR YVETTE,FRANCE; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								CHIOCCA E A, 1990, New Biologist, V2, P739; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; FINK DJ, 1992, HUM GENE THER, V3, P11, DOI 10.1089/hum.1992.3.1-11; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; Hawrot E, 1979, Methods Enzymol, V58, P574; HAYES CE, 1974, J BIOL CHEM, V249, P1904; KRISTENSSON K, 1974, BRAIN RES, V69, P189, DOI 10.1016/0006-8993(74)90001-8; LAFAY F, 1991, VIROLOGY, V183, P320, DOI 10.1016/0042-6822(91)90145-2; MARTIN X, 1983, BRAIN RES, V273, P253, DOI 10.1016/0006-8993(83)90850-8; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STRATFORDPERRIC.L, 1991, HUMAN GENE TRANSFER, P51; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902	19	422	710	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					988	990		10.1126/science.8382374	http://dx.doi.org/10.1126/science.8382374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8382374				2022-12-24	WOS:A1993KL80000048
J	JACOBSON, MD; BURNE, JF; KING, MP; MIYASHITA, T; REED, JC; RAFF, MC				JACOBSON, MD; BURNE, JF; KING, MP; MIYASHITA, T; REED, JC; RAFF, MC			BCL-2 BLOCKS APOPTOSIS IN CELLS LACKING MITOCHONDRIAL-DNA	NATURE			English	Article							MEMBRANE PROTEIN; SURVIVAL; DEATH; TRANSLOCATION; FIBROBLASTS; EXPRESSION; ANTIBODIES; PRODUCT; LINES	WHEN the mammalian proto-oncogene bcl-2 is overexpressed it can protect various types of cells both from normal and from experimentally induced apoptosis1-6, but the molecular mechanisms involved are unknown. Although the Bcl-2 protein is membrane-associated7-10, its subcellular location is controversial: two studies have suggested that it is mainly associated with the nuclear envelope and endoplasmic reticulum8,10, whereas another study has suggested that it is mainly located in the inner mitochondrial membrane9. The latter study has suggested that Bcl-2 might protect cells from apoptosis by altering mitochondrial function and that mitochondria may be involved in apoptosis9,11. Here we report that human mutant cell lines that lack mitochondrial DNA (mtDNA), and therefore do not have a functional respiratory chain, can still be induced to die by apoptosis, and that they can be protected from apoptosis by the overexpression of bcl-2, suggesting that neither apoptosis nor the protective effect of bcl-2 depends on mitochondrial respiration. We also show that the Bcl-2 protein in overexpressing cells is associated with the nuclear envelope and endoplasmic reticulum, as well as with mitochondria.	COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; LA JOLLA CANC RES FDN,INST CANC RES,LA JOLLA,CA 92037	Columbia University; Sanford Burnham Prebys Medical Discovery Institute	JACOBSON, MD (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,MEDAWAR BLDG,LONDON WC1E 6BT,ENGLAND.							ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ATTARDI G, 1991, PROGR NEUROPATHOLOGY, P75; ATTARDI G, 1988, REV CELL BIOL, V41, P278; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASSENDINE MF, 1992, HEPATOLOGY, V15, P545, DOI 10.1002/hep.1840150329; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; FUNG CH, 1980, J BIOL CHEM, V255, P676; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HARTSCH M, 1985, EUR J BIOCHEM, V150, P559; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NAKAGAWA M, 1987, EXP CELL RES, V168, P44, DOI 10.1016/0014-4827(87)90414-9; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; NAPIER RM, 1992, J CELL SCI, V102, P261; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDOYO H, 1990, J NEUROL SCI, V98, P185, DOI 10.1016/0022-510X(90)90259-P; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	32	736	763	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					365	369		10.1038/361365a0	http://dx.doi.org/10.1038/361365a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381212				2022-12-24	WOS:A1993KJ59000062
J	VEIS, DJ; SORENSON, CM; SHUTTER, JR; KORSMEYER, SJ				VEIS, DJ; SORENSON, CM; SHUTTER, JR; KORSMEYER, SJ			BCL-2-DEFICIENT MICE DEMONSTRATE FULMINANT LYMPHOID APOPTOSIS, POLYCYSTIC KIDNEYS, AND HYPOPIGMENTED HAIR	CELL			English	Article							PROGRAMMED CELL-DEATH; C-MYC; B-CELL; CAENORHABDITIS-ELEGANS; FOLLICULAR LYMPHOMA; TRANSGENIC MICE; MESSENGER-RNA; BCL-2; MOUSE; DISEASE	bcl-2 -/- mice complete embryonic development, but display growth retardation and early mortality postnatally. Hematopoiesis including lymphocyte differentiation is initially normal, but thymus and spleen undergo massive apoptotic involution. Thymocytes require an apoptotic signal to manifest accelerated cell death. Renal failure results from severe polycystic kidney disease characterized by dilated proximal and distal tubular segments and hyperproliferation of epithelium and interstitium. bcl-2 -/- mice turn gray with the second hair follicle cycle, implicating a defect in redox-regulated melanin synthesis. The abnormalities in these loss of function mice argue that Bcl-2 is a death repressor molecule functioning in an antioxidant pathway.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	VEIS, DJ (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.			Novack, Deborah/0000-0001-7101-5582	NATIONAL EYE INSTITUTE [T32EY007108] Funding Source: NIH RePORTER; NEI NIH HHS [5T32 EY 07108-04] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AVNER ED, 1988, PEDIATR NEPHROL, V2, P210, DOI 10.1007/BF00862593; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOISSY RE, 1988, DERMATOL CLIN, V6, P161, DOI 10.1016/S0733-8635(18)30663-6; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; COLES HSR, 1993, DEVELOPMENT, V118, P777; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN AP, 1978, LAB INVEST, V38, P244; EVAN AP, 1976, LAB INVEST, V35, P93; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GABOW PA, 1993, DIS KIDNEY, P535; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HJELLE JT, 1990, TOXICOLOGY, V60, P211; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKSON IJ, 1990, GENETICS, V126, P451; JOHNSON E, 1958, J ENDOCRINOL, V16, P337, DOI 10.1677/joe.0.0160337; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEBRUN DP, 1993, AM J PATHOL, V142, P743; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIATTELLI M, 1962, TETRAHEDRON, V18, P941, DOI 10.1016/S0040-4020(01)92747-4; PROTA G, 1980, J INVEST DERMATOL, V75, P122, DOI 10.1111/1523-1747.ep12521344; RAHILLY MA, 1992, J PATHOL, V168, P335, DOI 10.1002/path.1711680315; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPANAKIS E, 1992, DEVELOPMENT, V114, P675; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI H, 1991, J AM SOC NEPHROL, V1, P980; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, J IMMUNOL, V151, P2546; YOHN JJ, 1991, J INVEST DERMATOL, V97, P405, DOI 10.1111/1523-1747.ep12480983; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; ZDARSKY E, 1990, GENETICS, V126, P443	57	1425	1465	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					229	240		10.1016/0092-8674(93)80065-M	http://dx.doi.org/10.1016/0092-8674(93)80065-M			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402909				2022-12-24	WOS:A1993MD88500005
J	MARS, JS				MARS, JS			DRIVERS WHO DEFY THE LAW	BRITISH MEDICAL JOURNAL			English	Article																		FONDA G, 1989, OPHTHALMOLOGY, V96, P1457; KELLNER JL, 1987, OPHTHALMOLOGY, V94, P1180; KELLNER JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1697; MCCAGHREY GE, 1987, OPTOMETRY TODAY, V27, P178; TAYLOR SP, 1988, OPTICIAN, V196, P14	5	3	3	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					844	845		10.1136/bmj.307.6908.844	http://dx.doi.org/10.1136/bmj.307.6908.844			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401127	Green Published, Bronze			2022-12-24	WOS:A1993MA29300022
J	HIGGINS, M; DAGOSTINO, R; KANNEL, W; COBB, J				HIGGINS, M; DAGOSTINO, R; KANNEL, W; COBB, J			BENEFITS AND ADVERSE-EFFECTS OF WEIGHT-LOSS - OBSERVATIONS FROM THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; FOLLOW-UP; CARDIOVASCULAR-DISEASE; MORTALITY; VARIABILITY; LONGEVITY; HEALTH; RISK	Objective: To identify the benefits and adverse effects of weight loss. Design: Longitudinal, epidemiologic study in a defined population. Participants: Men and women (n = 2500) who were between 35 and 54 years old at baseline, followed for 20 years in Framingham, Massachusetts. Measurements: Height, weight, lipid levels, blood pressure, smoking status, diet, physical activity, prevalent and incident cardiovascular disease, diabetes, other diseases, and mortality rate were assessed. Results: Compared with those whose body mass index (BMI) or weight changed least, men and women who lost weight during a 10-year period were older, heavier, and had higher blood pressures and cholesterol levels initially but had the smallest gains in blood pressure and cholesterol levels. However, rates of cigarette smoking were higher, and rates of smoking cessation were lower. During 20 years of further follow-up, death rates were highest in those whose BMI decreased and in those with the highest BMI at study entry. Relative risks for death from cardiovascular disease, coronary heart disease, and all causes were significantly greater by 33% to 61% in men whose BMI decreased after adjusting for age and risk factors for cardiovascular disease. In women, weight loss and weight gain were associated with higher relative risks for cardiovascular disease and coronary heart disease, but only the 38% increase in total mortality rate among women who lost weight was statistically significant after adjusting for age. Conclusions: Weight loss was associated with improvements in blood pressure and cholesterol levels but also with continued cigarette smoking, prevalent and incident cardiovascular disease, diabetes mellitus, other diseases, and higher death rates. Leanness and maintenance of stable weight were beneficial to risk factors, and to the prevention of morbidity, and death.			HIGGINS, M (corresponding author), NHLBI, DEPT EPIDEMIOL & BIOMETRY, 2C08 FED BLDG, 7550 WISCONSIN AVE, BETHESDA, MD 20892 USA.							ANDERSON KM, 1992, OBESITY; [Anonymous], 1992, Ann Intern Med, V116, P942; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; CUPPLES LA, 1986, FRAMINGHAM STUDY EPI; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KANNEL WB, 1989, EATING SLEEPING SEX; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; STEVENS J, 1990, INT J OBESITY, V14, P385; TERRY RB, 1992, INT J OBESITY, V16, P417	19	118	122	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				758	763		10.7326/0003-4819-119-7_Part_2-199310011-00025	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363211				2022-12-24	WOS:A1993MA33000025
J	LEVY, AS; HEATON, AW				LEVY, AS; HEATON, AW			WEIGHT CONTROL PRACTICES OF UNITED-STATES ADULTS TRYING TO LOSE WEIGHT	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIOR; OBJECTIVES	Objective: To estimate the relative prevalence of different types and combinations of practices among weight-loss practitioners and to describe the relations between individual characteristics and various features of weight-loss regimens. Design: A telephone survey of a random digit-dialed probability sample of adults in the continental United States who reported that they were trying to lose weight. Participants: A total of 1431 persons 18 years or older who were attempting to lose weight. Measurements: Self-reports of a detailed inventory of more than 35 specific practices that might be used as part of a voluntary weight-loss plan, along with information about individual characteristics such as current weight, weight-loss history, demographic profile, motivations to lose weight, sources of information, and knowledge about diet and health. Results: The average respondent had a current weight-loss attempt lasting from 5 to 6 months, had tried a similar plan before, and had averaged one attempt a year for the past 2 years. Seventy-one percent of women and 62% of men reported that they were both changing their diet and exercising more as part of a current weight-loss attempt. Frequently reported weight-loss practices included weighing oneself regularly (71% and 70% for women and men, respectively), walking (58% and 44%), using diet soft drinks (52% and 45%), taking vitamins and minerals (33% and 26%), counting calories (25% and 17%), skipping meals (21% and 20%), using commercial meal replacements, (15% and 13%), taking diet pills (14% and 7%), and participating in organized weight-loss programs (13% and 5%). Sex, education, and overweight status influenced the choice of a weight-loss practice. Conclusions: Individual approaches to weight-loss vary and are characterized by their duration and by their recurrent nature. Policy efforts should be directed toward increasing the long-term effectiveness of individual weight-loss plans.			LEVY, AS (corresponding author), USDA, CTR FOOD SAFETY & APPL NUTR, DIV MARKET STUDIES, HFS-727, 200 C ST NW, WASHINGTON, DC 20204 USA.							DAGNOLI J, ADVERTISING AGE 1223, P3; DAGNOLI J, ADVERTISING AGE 1223, P25; DANFORD DE, 1991, J AM DIET ASSOC, V91, P1517; DWYER JT, 1970, J AM DIET ASSOC, V56, P510; EMMONS L, 1992, J AM DIET ASSOC, V92, P306; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; STEPHENSON MG, 1987, PUBLIC HEALTH REP, V102, P61; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1992, FACTS WEIGHT LOSS PR; 1988, DHHS PHS8850210 US D	13	151	153	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				661	666		10.7326/0003-4819-119-7_Part_2-199310011-00007	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363193				2022-12-24	WOS:A1993MA33000007
J	MATTER, K; WHITNEY, JA; YAMAMOTO, EM; MELLMAN, I				MATTER, K; WHITNEY, JA; YAMAMOTO, EM; MELLMAN, I			COMMON SIGNALS CONTROL LOW-DENSITY-LIPOPROTEIN RECEPTOR SORTING IN ENDOSOMES AND THE GOLGI-COMPLEX OF MDCK CELLS	CELL			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE PROTEINS; LYMPHOCYTE FC-RECEPTORS; BREFELDIN-A; CYTOPLASMIC DOMAIN; SELECTIVE-INHIBITION; LYSOSOMAL MEMBRANE; APICAL DOMAIN	The cytoplasmic domain of the LDL receptor bears two tyrosine-containing determinants that can independently target receptors from the Golgi to the basolateral plasma membrane of MDCK cells. We found that these determinants, localized to the membrane-proximal and -distal regions of the receptor's cytoplasmic domain, also control polarized sorting in endosomes. Inactivation of the distal determinant reduced receptors' ability to return to the basolateral domain following endocytosis, resulting instead in receptor transcytosis from basolateral endosomes to the apical plasma membrane. Similarly, receptors internalized from the apical surface were transported from apical endosomes to the basolateral surface, owing to the proximal basolateral targeting determinant. Thus, receptor recycling in endosomes is directed by the same signals as polarized sorting in the Golgi, indicating that sorting on the endocytic and biosynthetic pathways involves similar mechanisms. The observation that brefeldin A interfered with sorting but not transport in both endosomes and the Golgi further supports this.			MATTER, K (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.		Mellman, Ira/ABG-5896-2020; Matter, Karl/C-4880-2008	Matter, Karl/0000-0001-8026-7220				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BREITFELD PP, 1989, J CELL BIOL, V109, P475, DOI 10.1083/jcb.109.2.475; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, J BIOL CHEM, V266, P24428; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1991, Semin Cell Biol, V2, P397; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SLOT JW, 1991, J CELL BIOL, V113, P1232; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WAN JS, 1992, J BIOL CHEM, V267, P13446; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923	54	151	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1053	1064		10.1016/0092-8674(93)90727-8	http://dx.doi.org/10.1016/0092-8674(93)90727-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402881				2022-12-24	WOS:A1993LY49300012
J	DAVIES, GJ; DODSON, GG; HUBBARD, RE; TOLLEY, SP; DAUTER, Z; WILSON, KS; HJORT, C; MIKKELSEN, JM; RASMUSSEN, G; SCHULEIN, M				DAVIES, GJ; DODSON, GG; HUBBARD, RE; TOLLEY, SP; DAUTER, Z; WILSON, KS; HJORT, C; MIKKELSEN, JM; RASMUSSEN, G; SCHULEIN, M			STRUCTURE AND FUNCTION OF ENDOGLUCANASE-V	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; PROTEIN STRUCTURES; CELLULASES; REFINEMENT	CELLULOSE is the major polysaccharide component of plant cell walls and is the most abundant organic compound on the planet. A number of bacterial1 and fungal2 organisms can use cellulose as a food source, possessing cellulases (cellobiohydrolases and endoglucanases) that can catalyse the hydrolysis of the beta-(1,4) glycosidic bonds. They can be classified into seven distinct families3. The three-dimensional structures of members of two of these families are known4,5. Here we report the structure of a third cellulase, endoglucanase V, whose sequence is not represented in any of the above families. The enzyme is structurally distinct from the previously determined cellulases but is similar to a recently characterized plant defence protein6. The active site region resembles that of lysozyme, despite the lack of structural similarity between these two enzymes.	DESY,EMBL,HAMBURG OUTSTN,W-2000 HAMBURG 52,GERMANY; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Novo Nordisk	DAVIES, GJ (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Wilson, Keith/0000-0002-3581-2194				BEGUIN P, 1992, BIOCHEM SOC T, V20, P42, DOI 10.1042/bst0200042; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDVIGSEN S, 1992, BIOCHEMISTRY-US, V31, P8783, DOI 10.1021/bi00152a014; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; WOOD TM, 1992, BIOCHEM SOC T, V20, P46, DOI 10.1042/bst0200046; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; 1979, SUITE PROGRAMS PROTE	20	122	128	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					362	364		10.1038/365362a0	http://dx.doi.org/10.1038/365362a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377830				2022-12-24	WOS:A1993LY49600059
J	SCHUSTER, SC; SWANSON, RV; ALEX, LA; BOURRET, RB; SIMON, MI				SCHUSTER, SC; SWANSON, RV; ALEX, LA; BOURRET, RB; SIMON, MI			ASSEMBLY AND FUNCTION OF A QUATERNARY SIGNAL-TRANSDUCTION COMPLEX MONITORED BY SURFACE-PLASMON RESONANCE	NATURE			English	Article							BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; PROTEIN-PHOSPHORYLATION; KINASE CHEA; RECEPTOR; PATHWAY; SYSTEM; SITE	WE have used surface plasmon resonance biosensor technology to monitor the assembly and dynamics of a signal transduction complex which controls chemotaxis in Escherichia coli. A quaternary complex formed which consisted of the response regulator CheY, the histidine protein kinase CheA, a coupling protein CheW and a membrane-bound chemoreceptor Tar. Using various experimental conditions and mutant proteins, we have shown that the complex dissociates under conditions that favour phosphorylation of CheY. Direct physical analysis of interactions among proteins in this signal transduction pathway provides evidence for a previously unrecognized binding interaction between the kinase and its substrate. This interaction may be important for enhancing substrate specificity and preventing 'crosstalk' with other systems. The approach is generally applicable to furthering our understanding of how signalling complexes transduce intracellular messages.			SCHUSTER, SC (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220; Swanson, Ronald/0000-0002-6486-2676				BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, REV BIOCH, V60, P401; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NINFA EG, 1991, J BIOL CHEM, V266, P9764; SAMBLES JR, 1991, CONTEMP PHYS, V32, P173, DOI 10.1080/00107519108211048; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	25	223	229	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					343	347		10.1038/365343a0	http://dx.doi.org/10.1038/365343a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377825				2022-12-24	WOS:A1993LY49600053
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA GUIDELINE ON WOMEN IN CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, JAMA-J AM MED ASSOC, V265, P182	1	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1290	1290		10.1001/jama.270.11.1290	http://dx.doi.org/10.1001/jama.270.11.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360956				2022-12-24	WOS:A1993LW34500006
J	WAGNER, H; FROST, B				WAGNER, H; FROST, B			DISPARITY-SENSITIVE CELLS IN THE OWL HAVE A CHARACTERISTIC DISPARITY	NATURE			English	Article							CATS VISUAL-CORTEX; INTERAURAL TIME DIFFERENCE; BARN OWL; BINOCULAR ORGANIZATION; BRAIN-STEM; NEURONS; TELENCEPHALON; WULST; DEPTH	WE experience the visual world as being three-dimensional. A major source of depth information derives from the slightly different views of each eye, leading to small variations in the retinal images ('disparities'). Neurons sensitive to visual disparities are thought to form the neural basis of stereo vision1-10. Barn owls2,3 as well as several mammalian species1,4-10 have neurons that are sensitive to visual disparities. But how visual disparities are represented in the brain has been a matter of discussion ever since the first disparity-sensitive neurons were found some 25 years ago. Here we adopt a new approach to this problem and study the neural computation of visual disparities with a paradigm borrowed from auditory research. The measurement of interaural time difference (ITD) has many similarities with the measurement of visual disparity on the formal, algorithmic level. We speculate that the similarities might extend to the level of neural computation. The neural representation of ITD is well understood11-18, and we have studied the representation of disparities with visual stimuli analogous to those successfully used in acoustic experiments. For example, ITD is converted in the brain to a pathlength on an axon that, owing to the finite conduction velocity in neurons, exactly matches the external ITD. This pathlength is called 'characteristic delay,12. Our results suggest that there is an analogue of the characteristic delay in stereo vision which we propose to call 'characteristic disparity'.	MAX PLANCK INST BIOL CYBERNET,D-72076 TUBINGEN,GERMANY	Max Planck Society	WAGNER, H (corresponding author), QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA.		Wagner, Hermann/G-5454-2012	Wagner, Hermann/0000-0002-8191-7595				BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BLAKE R, 1991, TRENDS NEUROSCI, V14, P445, DOI 10.1016/0166-2236(91)90043-T; CARR CE, 1990, J NEUROSCI, V10, P3227; DEANGELIS GC, 1991, NATURE, V352, P156, DOI 10.1038/352156a0; HAMMOND P, 1991, EXP BRAIN RES, V87, P615; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KARTEN HJ, 1973, J COMP NEUROL, V150, P253, DOI 10.1002/cne.901500303; Konishi M., 1988, AUDITORY FUNCTION NE, P721; MASKE R, 1984, VISION RES, V24, P1921, DOI 10.1016/0042-6989(84)90026-9; MOISEFF A, 1989, J COMP PHYSIOL A, V164, P637, DOI 10.1007/BF00614506; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; NOMURA M, 1990, BIOL CYBERN, V63, P237, DOI 10.1007/BF00195863; OHZAWA I, 1986, J NEUROPHYSIOL, V56, P243, DOI 10.1152/jn.1986.56.1.243; OHZAWA I, 1986, J NEUROPHYSIOL, V56, P221, DOI 10.1152/jn.1986.56.1.221; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; Pettigrew J.D., 1990, P283; PETTIGREW JD, 1979, PROC R SOC SER B-BIO, V204, P435, DOI 10.1098/rspb.1979.0038; PETTIGREW JD, 1976, SCIENCE, V193, P675, DOI 10.1126/science.948741; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; ROSE JE, 1966, J NEUROPHYSIOL, V29, P288, DOI 10.1152/jn.1966.29.2.288; STEINBACH MJ, 1973, VISION RES, V13, P889, DOI 10.1016/0042-6989(73)90055-2; SULLIVAN WE, 1986, P NATL ACAD SCI USA, V83, P8400, DOI 10.1073/pnas.83.21.8400; TAKAHASHI T, 1986, J NEUROSCI, V6, P3413; WAGNER H, 1987, J NEUROSCI, V7, P3105; Yin T.C.T., 1984, DYNAMIC ASPECTS NEOC, P263	27	54	54	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					796	798		10.1038/364796a0	http://dx.doi.org/10.1038/364796a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355804				2022-12-24	WOS:A1993LU58100054
J	OATES, BC; SIDEBOTTOM, AJ; MAXWELL, SRJ				OATES, BC; SIDEBOTTOM, AJ; MAXWELL, SRJ			EFFICACY OF HEPATITIS-B VACCINATION - KNOWLEDGE AMONG CLINICAL MEDICAL-STUDENTS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,BIRMINGHAM MED SCH,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								FOLLETT EAC, 1990, S SERIES, V28, P32; GILSON R, 1992, PRESCRIBER, V3, P94; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; ZANETTI AR, 1990, VACCINE, V8, P205, DOI 10.1016/0264-410X(90)90046-O	5	11	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					301	301		10.1136/bmj.307.6899.301	http://dx.doi.org/10.1136/bmj.307.6899.301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374379	Bronze, Green Published			2022-12-24	WOS:A1993LQ51600021
J	POSTEL, EH; BERBERICH, SJ; FLINT, SJ; FERRONE, CA				POSTEL, EH; BERBERICH, SJ; FLINT, SJ; FERRONE, CA			HUMAN C-MYC TRANSCRIPTION FACTOR PUF IDENTIFIED AS NM23-H2 NUCLEOSIDE DIPHOSPHATE KINASE, A CANDIDATE SUPPRESSOR OF TUMOR-METASTASIS	SCIENCE			English	Article							MOLECULAR-CLONING; RNA LEVELS; GENE; PROMOTER; PROTEINS; CELLS; DIFFERENTIATION; EXPRESSION; ACTIVATION	A human gene encoding the c-myc purine-binding transcription factor PuF was identified by screening of a cervical carcinoma cell complementary DNA library with a DNA fragment containing PuF binding sites. The 17-kilodalton bacterially produced PuF was shown to have biological activity and properties similar to that of human PuF. DNA sequence analysis of recombinant PuF revealed perfect identity with the human nm23-H2 nucleoside diphosphate kinase gene, a potential negative regulator of cancer metastasis. These results provide a link between nm23 and the c-myc oncogene and suggest that the nm23 protein can function in vitro in the transcriptional regulation of c-myc expression.			POSTEL, EH (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POSTEL EH, UNPUB; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAHL JA, 1991, CANCER RES, V51, P445; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	29	492	509	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					478	480		10.1126/science.8392752	http://dx.doi.org/10.1126/science.8392752			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392752				2022-12-24	WOS:A1993LN62300038
J	GUNZBURG, WH; HEINEMANN, F; WINTERSPERGER, S; MIETHKE, T; WAGNER, H; ERFLE, V; SALMONS, B				GUNZBURG, WH; HEINEMANN, F; WINTERSPERGER, S; MIETHKE, T; WAGNER, H; ERFLE, V; SALMONS, B			ENDOGENOUS SUPERANTIGEN EXPRESSION CONTROLLED BY A NOVEL PROMOTER IN THE MMTV LONG TERMINAL REPEAT	NATURE			English	Article							MAMMARY-TUMOR VIRUS; OPEN READING FRAME; MESSENGER-RNA; ENV GENE; T-CELLS; REGION; IDENTIFICATION; SEQUENCES; SYSTEM; MICE	ENDOGENOUS superantigens are encoded by the open reading frame contained within the mouse mammary tumour virus long terminal repeat (MMTV LTR). Superantigen expression results in T-cell proliferation and, during early ontogeny, T-cell deletion1,2. Here we identify a novel promoter located upstream of the previously described MMTV promoter. Transcripts from this promoter initiate within the U3 region of the MMTV LTR and splice to the acceptor for endogenous superantigen coding region. The novel U3 promoter is active in B lymphocytes, which are cognate antigen-presenting cells for endogenous superantigen, and is able to direct expression of superantigen in the absence of the previously described MMTV promoter.	TECH UNIV MUNICH,INST MED MICROBIOL & HYG,D-81675 MUNICH,GERMANY; LUDWIG MAXIMILIANS UNIV MUNCHEN,INST MOLEC ANIM BREEDING,D-80539 MUNICH,GERMANY	Technical University of Munich; University of Munich	GUNZBURG, WH (corresponding author), GSF RES CTR ENVIRONM & HLTH,INST MOLEC VIROL,D-85758 OBERSCHLEISSHEIM,GERMANY.		Gunzburg, Walter/ABI-6076-2020; Salmons, Brian/E-3001-2010	Gunzburg, Walter/0000-0001-8907-1021; Salmons, Brian/0000-0002-9490-9447				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CRANDELL RA, 1973, IN VITRO CELL DEV B, V9, P176, DOI 10.1007/BF02618435; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; HORNSBY PJ, 1992, BIOTECHNIQUES, V12, P244; HUBER B T, 1992, Current Biology, V2, P495; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KENNEDY N, 1982, NATURE, V295, P622, DOI 10.1038/295622a0; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; LUND FE, 1991, J EXP MED, V174, P1439, DOI 10.1084/jem.174.6.1439; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MAJORS JE, 1983, J VIROL, V47, P495, DOI 10.1128/JVI.47.3.495-504.1983; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; REDMOND SMS, 1983, EMBO J, V2, P125, DOI 10.1002/j.1460-2075.1983.tb01393.x; RINGOLD GM, 1977, CELL, V10, P19, DOI 10.1016/0092-8674(77)90135-0; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SALMONS B, 1985, VIROLOGY, V144, P101, DOI 10.1016/0042-6822(85)90309-5; TSUBURA A, 1988, CANCER RES, V48, P6555; VANOOYEN AJJ, 1983, J VIROL, V46, P362, DOI 10.1128/JVI.46.2.362-370.1983; WHEELER DA, 1983, J VIROL, V46, P42, DOI 10.1128/JVI.46.1.42-49.1983	26	47	49	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					154	158		10.1038/364154a0	http://dx.doi.org/10.1038/364154a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8391646				2022-12-24	WOS:A1993LL36700052
J	MADUKE, M; ROISE, D				MADUKE, M; ROISE, D			IMPORT OF A MITOCHONDRIAL PRESEQUENCE INTO PROTEIN-FREE PHOSPHOLIPID-VESICLES	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; SYNTHETIC PRESEQUENCE; YEAST MITOCHONDRIA; SIGNAL PEPTIDE; TRANSLOCATION; INSERTION; HYPOTHESIS; BILAYERS	A synthetic mitochondrial presequence has been shown to translocate across pure phospholipid bilayers. The presequence was fluorescently labeled so that its association with membranes could be monitored spectroscopically. In the presence of large unilamellar vesicles, the presequence showed time- and potential-dependent protection from reaction with added trypsin and dithionite. The protection was rapidly reversed by treatment of the vesicles with detergent. If the vesicles contained trypsin, the added presequence became sensitive to digestion by,the protease. The results show that a mitochondrial presequence can translocate across phospholipid bilayers that lack a hydrophilic translocation pore.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Maduke, Merritt/0000-0001-7787-306X	NIGMS NIH HHS [T32-GM08326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHEN LB, 1981, COLD SPRING HARB SYM, V46, P141, DOI 10.1101/SQB.1982.046.01.018; DEKROON AIPM, 1991, BIOCHIM BIOPHYS ACTA, V1068, P111, DOI 10.1016/0005-2736(91)90199-I; DUMONT ME, 1984, J BIOL CHEM, V259, P4147; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; MADUKE M, UNPUB; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; Penefsky H S, 1979, Methods Enzymol, V56, P527; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; SKERJANC IS, 1987, EMBO J, V6, P3117, DOI 10.1002/j.1460-2075.1987.tb02621.x; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	39	81	81	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1993	260	5106					364	367		10.1126/science.8385804	http://dx.doi.org/10.1126/science.8385804			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385804				2022-12-24	WOS:A1993KX80000042
J	TSAY, YF; FRANK, MJ; PAGE, T; DEAN, C; CRAWFORD, NM				TSAY, YF; FRANK, MJ; PAGE, T; DEAN, C; CRAWFORD, NM			IDENTIFICATION OF A MOBILE ENDOGENOUS TRANSPOSON IN ARABIDOPSIS-THALIANA	SCIENCE			English	Article							NITRATE REDUCTASE; PUTATIVE TRANSPOSASE; ELEMENT FAMILY; DNA; GENE; PROTEIN; MUTANTS; PLANTS; AC; CHLORATE	A mobile endogenous transposable element, Tag1, has been identified in the plant Arabidopsis thaliana. Tag1 was found in the nitrate transporter gene, CHL1, of a chlorate-resistant mutant present in a population of plants containing an active maize Ac transposon. Tag1 excises from the chl1 gene producing chlorate-sensitive revertants with Tag1 or Tag1-related elements at different loci. Tag1 and related elements are present in the Landsberg but not Columbia or Wassilewskija ecotypes of Arabidopsis. Thus, Tag1 provides a tool for the insertional mutagenesis of plant genes essential for biological processes of agronomic importance.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; AFRC,IPSR,JOHN INNES CTR,DEPT MOLEC GENET,NORWICH NR4 7UJ,ENGLAND; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of California System; University of California San Diego			Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687	NCI NIH HHS [5T32CA09345-12] Funding Source: Medline; NIGMS NIH HHS [GM 40672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040672, R29GM040672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG B, 1947, ANN R AGR COLL SWEDE, V15, P37; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; Berg D. E., 1989, MOBILE DNA; BRAAKSMA FJ, 1982, THEOR APPL GENET, V64, P83, DOI 10.1007/BF00303657; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; Crawford N. M., 1992, Genetic engineering: principles and methods. Volume 14., P89; DEAN C, 1992, PLANT J, V2, P69, DOI 10.1111/j.1365-313X.1992.00069.x; DODDEMA H, 1979, PHYSIOL PLANTARUM, V45, P332, DOI 10.1111/j.1399-3054.1979.tb02593.x; DODDEMA H, 1978, PHYSIOL PLANTARUM, V43, P343, DOI 10.1111/j.1399-3054.1978.tb01592.x; FELDMANN KA, 1989, SCIENCE, V243, P1351, DOI 10.1126/science.243.4896.1351; FELDMANN KA, 1991, PLANT J, V1, P1; FELDMAR S, 1991, EMBO J, V10, P4003, DOI 10.1002/j.1460-2075.1991.tb04975.x; GREVELDING C, 1992, P NATL ACAD SCI USA, V89, P6085, DOI 10.1073/pnas.89.13.6085; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; KONIECZNY A, 1991, GENETICS, V127, P801; KUNZE R, 1989, EMBO J, V8, P3177, DOI 10.1002/j.1460-2075.1989.tb08476.x; MARKS MD, 1989, PLANT CELL, V1, P1043, DOI 10.1105/tpc.1.11.1043; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; Nelson O, 1988, PLANT TRANSPOSABLE E; PELEMAN J, 1991, P NATL ACAD SCI USA, V88, P3618, DOI 10.1073/pnas.88.9.3618; PESCHKE VM, 1987, SCIENCE, V238, P804, DOI 10.1126/science.238.4828.804; SCHMIDT R, 1989, MOL GEN GENET, V220, P17, DOI 10.1007/BF00260850; SCHOLTEN HJ, 1986, PHYSIOL PLANTARUM, V66, P265, DOI 10.1111/j.1399-3054.1986.tb02418.x; SHIELDS R, 1989, NATURE, V337, P308, DOI 10.1038/337308a0; SWINBURNE J, 1992, PLANT CELL, V4, P583, DOI 10.1105/tpc.4.5.583; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; VANSLUYS MA, 1987, EMBO J, V6, P3881, DOI 10.1002/j.1460-2075.1987.tb02728.x; VOYTAS DF, 1988, NATURE, V336, P242, DOI 10.1038/336242a0; VOYTAS DF, 1990, GENETICS, V126, P713; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WILKINSON JQ, 1991, PLANT CELL, V3, P461, DOI 10.1105/tpc.3.5.461; Wray J.L., 1989, MOL GENETIC ASPECTS; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	89	98	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					342	344		10.1126/science.8385803	http://dx.doi.org/10.1126/science.8385803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	8385803				2022-12-24	WOS:A1993KX80000035
J	GOLDBERG, YP; ROMMENS, JM; ANDREW, SE; HUTCHINSON, GB; LIN, BY; THEILMANN, J; GRAHAM, R; GLAVES, ML; STARR, E; MCDONALD, H; NASIR, J; SCHAPPERT, K; KALCHMAN, MA; CLARKE, LA; HAYDEN, MR				GOLDBERG, YP; ROMMENS, JM; ANDREW, SE; HUTCHINSON, GB; LIN, BY; THEILMANN, J; GRAHAM, R; GLAVES, ML; STARR, E; MCDONALD, H; NASIR, J; SCHAPPERT, K; KALCHMAN, MA; CLARKE, LA; HAYDEN, MR			IDENTIFICATION OF AN ALU RETROTRANSPOSITION EVENT IN CLOSE PROXIMITY TO A STRONG CANDIDATE GENE FOR HUNTINGTONS-DISEASE	NATURE			English	Article							DNA-SEQUENCES; INSERTION; REGIONS; FAMILY; D4S95	HUNTINGTON'S disease (HD) is a late-onset autosomal dominant neuropsychiatric disorder presenting in mid-adult life with personality disturbance and involuntary movements, cognitive and affective disturbance, and inexorable progression to death1. The underlying genetic defect has been mapped to chromosomal band 4p16.3 (refs 2, 3). Analysis of specific recombination events in some families with HD has further refined the location of the HD defect to a 2.2 megabase DNA interval4,5. Using a direct complementary DNA selection strategy we have identified at least seven transcriptional units within the minimal region believed to contain the HD gene. Screening with one of the cDNA clones identified an Alu insertion in genomic DNA from two persons with HD which showed complete cosegregation with the disease in these families but was not found in 1,000 control chromosomes. Two genes including the previously identified alpha-adducin gene and another that encodes for a 12-kilobase transcript, map in close proximity to the Alu insertion site. The 12-kilobase transcript should be regarded as a strong candidate for the HD gene.	HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z4,BC,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia			Rommens, Johanna/AAT-7465-2021; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Clarke, Lorne/0000-0003-0512-7281; Nasir, Jamal/0000-0001-6378-5616				ANDREW S, 1992, GENOMICS, V13, P301, DOI 10.1016/0888-7543(92)90246-O; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELS GR, 1985, NUCLEIC ACIDS RES, V13, P8939, DOI 10.1093/nar/13.24.8939; Goldberg Y. P., 1992, Human Molecular Genetics, V1, P669, DOI 10.1093/hmg/1.9.669; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HUTCHINSON GB, 1992, NUCLEIC ACIDS RES, V20, P3453, DOI 10.1093/nar/20.13.3453; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MATERZ AG, 1990, NUCLEIC ACIDS RES, V18, P6091; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; ROBBINS C, 1989, AM J HUM GENET, V44, P422; SNELL RG, 1989, J MED GENET, V26, P673, DOI 10.1136/jmg.26.11.673; SNELL RG, 1992, AM J HUM GENET, V51, P357; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Vidaud Dominique, 1993, European Journal of Human Genetics, V1, P30; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG HS, 1986, AM J HUM GENET, V3, P392; WEBER B, 1992, NAT GENET, V2, P216, DOI 10.1038/ng1192-216; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149	25	41	46	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					370	373		10.1038/362370a0	http://dx.doi.org/10.1038/362370a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8384324				2022-12-24	WOS:A1993KU17600070
J	HOLZ, GG; KUHTREIBER, WM; HABENER, JF				HOLZ, GG; KUHTREIBER, WM; HABENER, JF			PANCREATIC BETA-CELLS ARE RENDERED GLUCOSE-COMPETENT BY THE INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1(7-37)	NATURE			English	Article							ELECTRICAL-ACTIVITY; B-CELLS; GENE-EXPRESSION; CA-2+ CHANNELS; PROTEIN-KINASE; ATP; CURRENTS; RELEASE; ACTIVATION; MODULATION	NON-INSULIN-DEPENDENT diabetes mellitus (NIDDM, type 2 diabetes) is a disorder of glucose homeostasis characterized by hyperglycaemia, peripheral insulin resistance, impaired hepatic glucose metabolism, and diminished glucose-dependent secretion of insulin from pancreatic beta-cells1. Glucagon-like-peptide-1(7-37) (GLP-1)2 is an intestinally derived hormone that may be useful for the treatment of NIDDM because it acts in vivo to increase the level of circulating insulin, and thus lower the concentration of blood glucose3,4. This therapeutic effect may result from the ability of GLP-1 to compensate for a defect in the glucose signalling pathway that regulates insulin secretion from beta-cells. In support of this concept we report here that GLP-1 confers glucose sensitivity to glucose-resistant beta-cells, a phenomenon we term glucose competence. Induction of glucose competence by GLP-1 results from its synergistic interaction with glucose to inhibit metabolically regulated potassium channels that are also targeted for inhibition by sulphonylurea drugs commonly used in the treatment of NIDDM5. Glucose competence allows membrane depolarization, the generation of action potentials, and Ca2+ influx, events that are known to trigger insulin secretion6,7.			HOLZ, GG (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114, USA.		Holz, George G/A-3386-2012	Holz, George/0000-0002-1781-3580	NIDDK NIH HHS [R01 DK045817, R01 DK045817-06A2] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BLACKMORE PF, 1991, FEBS LETT, V283, P7, DOI 10.1016/0014-5793(91)80541-A; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; NICHOLS CG, 1991, J GEN PHYSIOL, V97, P1095, DOI 10.1085/jgp.97.5.1095; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RIBALET B, 1989, J GEN PHYSIOL, V94, P693, DOI 10.1085/jgp.94.4.693; SHERMAN A, 1988, BIOPHYS J, V54, P411, DOI 10.1016/S0006-3495(88)82975-8; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNGER RH, 1992, WILLIAMS TXB ENDOCRI, P1255; WANG J, 1992, ENDOCRINOLOGY, V131, P146, DOI 10.1210/en.131.1.146; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338	32	475	513	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					362	365		10.1038/361362a0	http://dx.doi.org/10.1038/361362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381211	Green Accepted			2022-12-24	WOS:A1993KJ59000061
J	BERRIOS, DC; HEARST, N; COATES, TJ; STALL, R; HUDES, ES; TURNER, H; EVERSLEY, R; CATANIA, J				BERRIOS, DC; HEARST, N; COATES, TJ; STALL, R; HUDES, ES; TURNER, H; EVERSLEY, R; CATANIA, J			HIV ANTIBODY TESTING AMONG THOSE AT RISK FOR INFECTION - THE NATIONAL AIDS BEHAVIORAL SURVEYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SEXUAL-BEHAVIOR; CONDOM USE; PREVALENCE; FREQUENCY; ADULTS; BIAS	Objective.-To determine the prevalence of testing for human immunodeficiency virus (HIV) antibody among adults with various risk factors for infection, particularly those residing in large metropolitan areas where the bulk of cases of acquired immunodeficiency syndrome (AIDS) have occurred. Design.-A nationwide, population-based telephone survey eliciting testing, sexual, and injection drug use histories. Participants.-A total of 2673 randomly chosen US residents and 8263 randomly chosen residents of 23 metropolitan areas containing 64% of reported cases of AIDS. Interventions.-None. Main Outcome Measure.-Testing for HIV antibody. Main Results.-Overall, rates of individuals ever tested were only slightly higher in the urban areas (23%) than in the nation as a whole (21%). Testing frequencies were low among all risk groups (less than 40%), except men engaging in same-sex sexual activity (60%) and male and female injection drug users (46% and 73%, respectively). The low rate of testing (35%) among the largest risk group, heterosexual men and women engaging in unprotected sexual intercourse with multiple partners, was particularly worrisome. Conclusions.-To encourage antibody testing among the many at risk for infection who have not yet been tested, promotional campaigns should explain the universal susceptibility to infection among those at risk, and the availability of prophylactic medical therapies and social support services to persons who are HIV-seropositive. As there were comparable levels of risk-taking behavior among subjects in both samples, these campaigns must be designed to reach all segments of the population.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94105 USA	University of California System; University of California San Francisco	BERRIOS, DC (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94105 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043892, P50MH042459, R01MH046240] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459, MH43892, MH46240] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAJOS N, 1991, 7TH INT C AIDS FLOR, V1, P405; BERRIOS DC, 1992, ARCH INTERN MED, V152, P397, DOI 10.1001/archinte.152.2.397; BIDDLECOM MA, 1991, VITAL HLTH STAT 207, V13; Bradburn NM, 1979, IMPROVING INTERVIEW; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; CATANIA JA, 1990, EVAL PROGRAM PLANN, V13, P19, DOI 10.1016/0149-7189(90)90005-H; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P565; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; FAY RE, 1989, SCIENCE, V244, P1531; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; HARDY AM, 1991, VITAL HLTH STAT 206, V13; HARDY AM, 1991, VITAL HLTH STAT 204, V13; HINGSON R, 1989, PREV MED, V18, P806, DOI 10.1016/0091-7435(89)90016-9; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KANOUSE D, 1991, AIDS RELATED KNOWLED; KEETER S, 1988, AM J PREV MED, V4, P146, DOI 10.1016/S0749-3797(18)31187-5; LAVRAKAS PJ, 1987, TELEPHONE SURVEY MET; LINDENBAUM S, 1991, EVALUATING AIDS PREV, P223; MCQUEEN D, 1989, 1 U ED RES UN HLTH B; MICHAEL RT, 1989, MMWR-MORBID MORTAL W, V38, P429; MICHAEL RT, 1989, MMWR-MORBID MORTAL W, V38, P423; ROWE M, 1989, INTERGOVERNMENTAL AI, P2; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; THORNBERRY OT, 1988, WILEY S PRO, P25; WEISS R, 1988, NEW ENGL J MED, V319, P1010, DOI 10.1056/NEJM198810133191509; 1987, RTILOGIT PROCEDURE L; 1991, HIV AIDSD SURVEILLAN, P1; 1991, MMWR MORB MORTAL WKL, V40, P666; 1987, MMET MOTN MOTYSL EKL, V36, P509; 1982, RTIFREQS PROGRAM COM	33	99	100	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1576	1580		10.1001/jama.270.13.1576	http://dx.doi.org/10.1001/jama.270.13.1576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371468				2022-12-24	WOS:A1993LZ33400031
J	CARDOSO, MC; LEONHARDT, H; NADALGINARD, B				CARDOSO, MC; LEONHARDT, H; NADALGINARD, B			REVERSAL OF TERMINAL DIFFERENTIATION AND CONTROL OF DNA-REPLICATION - CYCLIN-A AND CDK2 SPECIFICALLY LOCALIZE AT SUBNUCLEAR SITES OF DNA-REPLICATION	CELL			English	Article							TEMPERATURE-SENSITIVE MUTANTS; XENOPUS EGG EXTRACTS; CELL NUCLEAR ANTIGEN; PRE-MESSENGER-RNA; CASEIN KINASE-II; SIMIAN-VIRUS 40; S-PHASE; PROTEIN-A; AUXILIARY PROTEIN; TOPOISOMERASE-II	DNA replication in mammalian cells occurs in discrete nuclear foci. Here we show that terminally differentiated myotubes can be induced to reenter S phase and show the same pattern of replication foci as cycling cells. We used this cellular system to analyze the interaction of cell cycle proteins with these foci in vivo. Cyclin A and cdk2, but not cyclin B1 and cdc2, were specifically localized at nuclear replication foci, just like the replication protein proliferating cell nuclear antigen. A potential target of cyclin A and cdk2 is the 34 kd subunit of replication protein A (RPA34). In contrast with the 70 kd subunit, which localizes to the foci, RPA34 was not detected at these replication sites, which may reflect a transient interaction. The specific localization of cyclin A and cdk2 at nuclear replication foci provides a direct link between cell cycle regulation and DNA replication.	CHILDRENS HOSP MED CTR, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	CARDOSO, MC (corresponding author), CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA.		Leonhardt, Heinrich/B-2791-2014					ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; BALDIN V, 1993, IN PRESS GENES DEV; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1987, EMBO J, V6, P1997, DOI 10.1002/j.1460-2075.1987.tb02463.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CALZA RE, 1984, CELL, V36, P689, DOI 10.1016/0092-8674(84)90349-0; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CARTER KC, 1993, OSCIENCE, V259, P1330; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DANDREA AD, 1983, NUCLEIC ACIDS RES, V11, P4753, DOI 10.1093/nar/11.14.4753; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1991, COLD SH Q B, V56, P315; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EKI T, 1991, J BIOL CHEM, V266, P3087; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; Endo T., 1989, CELLULAR MOL BIOL MU, P95; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEY EG, 1986, J CELL SCI, P99; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; FOX MH, 1991, J CELL SCI, V99, P247; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HASTINGS KEM, 1984, RECOMBINANT DNA CELL, P219; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; KENNY MK, 1990, J BIOL CHEM, V265, P769; KONIGSBERG IR, 1960, J BIOPHYS BIOCHEM CY, V8, P333, DOI 10.1083/jcb.8.2.333; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LEHNER CF, 1991, COLD SH Q B, V56, P465; LENO GH, 1991, J CELL BIOL, V112, P557, DOI 10.1083/jcb.112.4.557; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; MILLS AD, 1989, J CELL SCI, V94, P471; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RAY S, 1992, J VIROL, V66, P6509, DOI 10.1128/JVI.66.11.6509-6516.1992; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, 1993, IN PRESS ONCOGENE; VANDIERENDONCK JH, 1989, CYTOMETRY, V10, P143, DOI 10.1002/cyto.990100205; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEISBLUM B, 1974, CHROMOSOMA, V46, P255; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	83	373	376	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					979	992		10.1016/0092-8674(93)90721-2	http://dx.doi.org/10.1016/0092-8674(93)90721-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402887	Green Submitted			2022-12-24	WOS:A1993LY49300006
J	LARNER, AC; DAVID, M; FELDMAN, GM; IGARASHI, K; HACKETT, RH; WEBB, DSA; SWEITZER, SM; PETRICOIN, EF; FINBLOOM, DS				LARNER, AC; DAVID, M; FELDMAN, GM; IGARASHI, K; HACKETT, RH; WEBB, DSA; SWEITZER, SM; PETRICOIN, EF; FINBLOOM, DS			TYROSINE PHOSPHORYLATION OF DNA-BINDING PROTEINS BY MULTIPLE CYTOKINES	SCIENCE			English	Article							INTERFERON-ALPHA; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; GENE; ACTIVATOR; ISGF-3; GAMMA	Interferon-alpha (IFN-alpha) and IFN-gamma regulate gene expression by tyrosine phosphorylation of several transcription factors that have the 91-kilodalton (p91) protein of interferon-stimulated gene factor-3 (ISGF-3) as a common component. Interferon-activated protein complexes bind enhancers present in the promoters of early response genes such as the high-affinity Fcgamma receptor gene (FcgammaRI). Treatment of human peripheral blood monocytes or basophils with interleukin-3 (IL-3), IL-5, IL-10, or granulocyte-macrophage colony-stimulating factor (GM-CSF) activated DNA binding proteins that recognized the IFN-gamma response region (GRR) located in the promoter of the FcgammaRI gene. Although tyrosine phosphorylation was required for the assembly of each of these GRR binding complexes, only those formed as a result of treatment with IFN-gamma or IL-10 contained p91. Instead, complexes activated by IL-3 or GM-CSF contained a tyrosine-phosphorylated protein of 80 kilodaltons. Induction of FcgammaRI RNA occurred only with IFN-gamma and IL-10, whereas pretreatment of cells with GM-CSF or IL-3 inhibited IFN-gamma induction of FcgammaRI RNA. Thus, several cytokines other than interferons can activate putative transcription factors by tyrosine phosphorylation.			LARNER, AC (corresponding author), CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892, USA.							DAVID M, 1993, J BIOL CHEM, V268, P6593; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; LARNER AC, UNPUB; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	14	355	364	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1730	1733		10.1126/science.8378773	http://dx.doi.org/10.1126/science.8378773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378773				2022-12-24	WOS:A1993LY58400025
J	FANG, GW; CECH, TR				FANG, GW; CECH, TR			THE BETA-SUBUNIT OF OXYTRICHA TELOMERE-BINDING PROTEIN PROMOTES G-QUARTET FORMATION BY TELOMERIC DNA	CELL			English	Article							MACRONUCLEAR DNA; MESSENGER-RNA; ATP HYDROLYSIS; 3' TERMINUS; COMPLEX; RIBONUCLEOPROTEIN; DIMERIZATION; SPLICEOSOME; MECHANISM; GENES	Telomeres, the ends of linear chromosomes, typically consist of tandem repeats of simple G-rich sequences. At high concentrations, single-stranded telomeric DNA can form dimers and tetramers involving G-quartets. We show that under physiological conditions, the beta subunit of the Oxytricha telomere-binding protein greatly accelerates G-quartet formation. The reaction occurs with oligonucleotides ending in the Oxytricha (T4G4T4G4) and Tetrahymena (T2G4T2G4) telomeric sequences; the sequence preceding these telomeric repeats can be nontelomeric, single-, or double-stranded. Protein deletion analysis indicates that the carboxy-terminal highly basic domain of the beta subunit, which is dispensible for telomeric complex formation, is sufficient for mediating G-quartet formation. The finding that a telomeric protein acts as a molecular chaperone for G-quartet formation provides a strong argument that such DNA structures exist in vivo at chromosome telomeres.			FANG, GW (corresponding author), UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.				NIGMS NIH HHS [GM28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028039, R37GM028039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARPEL RL, 1980, BIOCHEMISTRY-US, V19, P4674, DOI 10.1021/bi00561a021; KARPEL RL, 1982, BIOCHEM, V21, P2101; Klobutcher L.A., 1986, P111; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; ROTH M, 1985, CELL, V41, P411, DOI 10.1016/S0092-8674(85)80014-3; SAMBROOK J, 1989, MOL CLONING, pB16; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	53	250	253	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					875	885		10.1016/0092-8674(93)90467-5	http://dx.doi.org/10.1016/0092-8674(93)90467-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374954				2022-12-24	WOS:A1993LX29200013
J	ROBINSON, PJ; SONTAG, JM; LIU, JP; FYKSE, EM; SLAUGHTER, C; MCMAHON, H; SUDHOF, TC				ROBINSON, PJ; SONTAG, JM; LIU, JP; FYKSE, EM; SLAUGHTER, C; MCMAHON, H; SUDHOF, TC			DYNAMIN GTPASE REGULATED BY PROTEIN-KINASE-C PHOSPHORYLATION IN NERVE-TERMINALS	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; REVERSIBLE BLOCKAGE; INTACT SYNAPTOSOMES; MEMBRANE RETRIEVAL; DROSOPHILA; ENDOCYTOSIS; DEPHOSPHORYLATION; MICROTUBULES; SHIBIRE; RELEASE	DYNAMIN is a microtubule-binding protein with a microtubule-activated GTPase activity1-3. The gene encoding dynamin is mutated in shibire4,5, a Drosophila mutant defective in endocytosis in nerve terminals and other cells6-9. These observations place dynamin into two distinct functional contexts, suggesting roles in microtubule-based motility or in endocytosis. We report here that dynamin is identical to the neuronal phosphoprotein dephosphin (P96), originally identified by its stimulus-dependent dephosphorylation in nerve terminals10-13. Dynamin is a protein doublet of M(r) 94 and 96K arising by alternative splicing of its primary transcript. In the nerve terminal, both forms of dynamin are phosphorylated by protein kinase C (PKC) and are quantitatively dephosphorylated on excitation. In vitro, dynamin is also phosphorylated by casein kinase II which inhibits PKC phosphorylation. Phosphorylation by PKC but not by casein kinase II enhances the GTPase activity of dynamin 12-fold. The dynamins are therefore a group of nerve terminal phosphoproteins whose GTPase is regulated by phosphorylation in parallel with synaptic vesicle recycling. The regulation of dynamin GTPase could serve as the trigger for the rapid endocytosis of synaptic vesicles after exocytosis.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; JOHN HUNTER HOSP, ENDOCRINE UNIT, NEWCASTLE, NSW 2310, AUSTRALIA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; John Hunter Hospital; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Liu, Jun-Ping/AAA-5521-2020; Robinson, Phillip J/G-4008-2011	Liu, Jun-Ping/0000-0001-7442-2116; Robinson, Phillip J/0000-0002-7878-0313				CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; HARLOW E, 1988, ANTIBODIES LABORATOR; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; [No title captured]	21	259	264	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					163	166		10.1038/365163a0	http://dx.doi.org/10.1038/365163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371759				2022-12-24	WOS:A1993LW44200049
J	HELD, W; WAANDERS, GA; SHAKHOV, AN; SCARPELLINO, L; ACHAORBEA, H; MACDONALD, HR				HELD, W; WAANDERS, GA; SHAKHOV, AN; SCARPELLINO, L; ACHAORBEA, H; MACDONALD, HR			SUPERANTIGEN-INDUCED IMMUNE STIMULATION AMPLIFIES MOUSE MAMMARY-TUMOR VIRUS-INFECTION AND ALLOWS VIRUS TRANSMISSION	CELL			English	Article							T-CELL RECEPTOR; LONG TERMINAL REPEAT; OPEN READING FRAME; TRANSGENIC MICE; GENE-PRODUCTS; ENDOGENOUS SUPERANTIGEN; SERINE PROTEASES; CLONAL DELETION; EXPRESSION; MLS	Endogenous and infectious mouse mammary tumor viruses (MMTVs) encode in their 3' long terminal repeat a protein that exerts superantigen activity; that is, it is able to interact with T cells via the variable domain of the T cell receptor (TCR) beta chain. We show here that transmission of an infectious MMTV is prevented when superantigen-reactive cells are absent through either clonal deletion due to the expression of an endogenous MTV with identical superantigen specificity or exclusion due to expression of a transgenic TCR beta chain that does not interact with the viral superantigen. A strict requirement for superantigen-reactive T cells is also seen for a local immune response following MMTV infection. This immune response locally amplifies the number of MMTV-infected B cells, most likely owing to their clonal expansion. Collectively, our data indicate that a superantigen-induced immune response is critical for the MMTV life cycle.			HELD, W (corresponding author), LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.							ABE R, 1989, ANNU REV IMMUNOL, V7, P683, DOI 10.1146/annurev.iy.07.040189.003343; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1992, J EXP MED, V176, P1769, DOI 10.1084/jem.176.6.1769; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; ACHAORBEA H, 1993, IMMUNOL REV, V131, P5, DOI 10.1111/j.1600-065X.1993.tb01527.x; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BRANDTCARLSON C, 1993, VIROLOGY, V193, P171, DOI 10.1006/viro.1993.1113; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRADIN G, 1984, NATURE, V308, P547, DOI 10.1038/308547a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DICKSON C, 1981, J VIROL, V37, P36, DOI 10.1128/JVI.37.1.36-47.1981; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FASEL N, 1982, EMBO J, V1, P3, DOI 10.1002/j.1460-2075.1982.tb01115.x; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FESTENSTEIN H, 1983, TRANSPLANTATION, V37, P322; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GOODING LR, 1992, CELL, V71, P5; HAINAUT P, 1990, CANCER RES, V50, P3754; HAPP MP, 1989, P NATL ACAD SCI USA, V86, P6293, DOI 10.1073/pnas.86.16.6293; HELD W, 1993, J EXP MED, V177, P359, DOI 10.1084/jem.177.2.359; HELD W, 1992, J EXP MED, V175, P1623, DOI 10.1084/jem.175.6.1623; HELD W, 1990, INT IMMUNOL, V2, P57, DOI 10.1093/intimm/2.1.57; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KATZ ME, 1986, J IMMUNOL, V136, P1; KENNEDY N, 1982, NATURE, V295, P622, DOI 10.1038/295622a0; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1991, NATURE, V349, P525; MOHAN N, 1993, J EXP MED, V177, P351, DOI 10.1084/jem.177.2.351; MUELLER C, 1988, J EXP MED, V167, P1124, DOI 10.1084/jem.167.3.1124; NANDA NK, 1991, P NATL ACAD SCI USA, V88, P9503, DOI 10.1073/pnas.88.21.9503; OKADA CY, 1990, J IMMUNOL, V144, P3473; PAYNE J, 1988, P NATL ACAD SCI USA, V85, P7695, DOI 10.1073/pnas.85.20.7695; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER R, 1989, J EXP MED, V169, P2149, DOI 10.1084/jem.169.6.2149; SMITH GH, 1987, J GEN VIROL, V68, P473, DOI 10.1099/0022-1317-68-2-473; SQUARTINI F, 1970, CANCER RES, V30, P2069; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TSUBURA A, 1988, CANCER RES, V48, P6555; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; WAANDERS GA, 1992, EUR J IMMUNOL, V22, P291, DOI 10.1002/eji.1830220144; WAANDERS GA, 1993, J EXP MED, V177, P1359, DOI 10.1084/jem.177.5.1359; Weiss R, 1985, RNA TUMOR VIRUSES; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255	62	195	195	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					529	540		10.1016/0092-8674(93)80054-I	http://dx.doi.org/10.1016/0092-8674(93)80054-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8394220				2022-12-24	WOS:A1993LT73900014
J	SCHMIDTZACHMANN, MS; DARGEMONT, C; KUHN, LC; NIGG, EA				SCHMIDTZACHMANN, MS; DARGEMONT, C; KUHN, LC; NIGG, EA			NUCLEAR EXPORT OF PROTEINS - THE ROLE OF NUCLEAR RETENTION	CELL			English	Article							XENOPUS-LAEVIS OOCYTES; PORE COMPLEX; MESSENGER-RNA; NUCLEOCYTOPLASMIC TRANSPORT; MONOCLONAL-ANTIBODIES; LOCALIZATION SIGNAL; BINDING-PROTEIN; MITOTIC EVENTS; LAMIN PROTEINS; CAAX MOTIF	Proteins that shuttle between nucleus and cytoplasm are implicated in transport and signal transduction processes. Using assays based on interspecies heterokaryons and microinjection of Xenopus oocytes, we examined what structural features determine nuclear export of shuttling proteins. Three classes of proteins were studied: first, wild-type and mutant forms of nucleolin, one of the first shuttling proteins identified; second, artificial nuclear reporter proteins derived from cytoplasmic pyruvate kinase; and third, wild-type and mutant lamins differing in their abilities to be incorporated into the lamina. Our results show that a protein does not require positively acting export signals to be transported from nucleus to cytoplasm; instead, its shuttling ability is limited primarily by intranuclear interactions. We conclude that nucleocytoplasmic shuttling is a general phenomenon not restricted to proteins involved in nucleocytoplasmic transport.	SWISS INST EXPTL CANC RES,CELL PROLIFERAT UNIT,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research				nigg, erich/0000-0003-4835-5719				AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DAVIS L I, 1992, Current Opinion in Cell Biology, V4, P424, DOI 10.1016/0955-0674(92)90007-Y; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HEITLINGER E, 1992, J STRUCT BIOL, V108, P74, DOI 10.1016/1047-8477(92)90009-Y; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; KITTEN GT, 1991, J CELL BIOL, V113, P13, DOI 10.1083/jcb.113.1.13; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOIR RD, 1991, J CELL SCI, V99, P363; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Ris H., 1989, I PHYS C SER, V98, P657; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SCHMIDTZACHMANN MS, 1993, IN PRESS J CELL SCI, V105; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stewart M, 1992, Semin Cell Biol, V3, P267, DOI 10.1016/1043-4682(92)90028-T; STICK R, 1988, J CELL BIOL, V107, P397, DOI 10.1083/jcb.107.2.397; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; [No title captured]	73	191	194	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					493	504		10.1016/0092-8674(93)80051-F	http://dx.doi.org/10.1016/0092-8674(93)80051-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348616				2022-12-24	WOS:A1993LT73900011
J	JEPPESEN, P; TURNER, BM				JEPPESEN, P; TURNER, BM			THE INACTIVE X-CHROMOSOME IN FEMALE MAMMALS IS DISTINGUISHED BY A LACK OF HISTONE-H4 ACETYLATION, A CYTOGENETIC MARKER FOR GENE-EXPRESSION	CELL			English	Article							HUMAN METAPHASE CHROMOSOMES; HUMAN-CELLS; XIST GENE; HETEROCHROMATIN; ANTIBODIES; ISLANDS; LOCALIZATION; REPLICATION; ISOFORMS; NUCLEUS	We have immunolabeled human and mouse metaphase chromosomes with antibodies specific for the acetylated isoforms of histone H4. All chromosomes were labeled in regions corresponding to conventional R bands (regions enriched in coding DNA), except for a single chromosome in female cells, which was largely unlabeled and which we have identified as the inactive X (Xi). Three sharply defined immunofluorescent bands, enhanced by butyrate pretreatment, were observed in homologous positions on the human and mouse Xi, showing limited, regional persistence of H4 acetylation. Two of these bands are in cytogenetic regions known to contain genes expressed on Xi. We propose that H4 hyperacetylation defines regions of the genome containing potentially transcriptionally active chromatin, while virtual absence of H4 acetylation defines both constitutive and facultative heterochromatin.	UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	JEPPESEN, P (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIES K, 1991, NATURE, V349, P15, DOI 10.1038/349015a0; DAVIES KE, 1991, CYTOGENET CELL GENET, V58, P853, DOI 10.1159/000133183; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; KANDA N, 1973, EXP CELL RES, V80, P463, DOI 10.1016/0014-4827(73)90324-8; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LATT SA, 1973, P NATL ACAD SCI USA, V70, P3395, DOI 10.1073/pnas.70.12.3395; LUCCHESI JC, 1987, ADV GENET, V24, P271; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1992, GENET RES, V8, P169; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SAVAGE JRK, 1984, J MED GENET, V21, P204, DOI 10.1136/jmg.21.3.204; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1990, J CELL SCI, V96, P335; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13	44	603	608	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					281	289		10.1016/0092-8674(93)90419-Q	http://dx.doi.org/10.1016/0092-8674(93)90419-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343956				2022-12-24	WOS:A1993LP72600009
J	LOPEZCASILLAS, F; WRANA, JL; MASSAGUE, J				LOPEZCASILLAS, F; WRANA, JL; MASSAGUE, J			BETAGLYCAN PRESENTS LIGAND TO THE TGF-BETA SIGNALING RECEPTOR	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; HEMATOPOIETIC PROGENITOR CELLS; FIBROBLAST GROWTH; PROTEOGLYCAN BETAGLYCAN; EXPRESSION CLONING; ENDOTHELIAL-CELLS; TRK PROTOONCOGENE; MOLECULAR-CLONING; HEPARAN-SULFATE; NGF RECEPTOR	Transforming growth factor beta (TGFbeta) signals through a heteromeric protein kinase receptor that has a limited ability to bind ligand. This limitation is overcome by the action of betaglycan (TGFbeta type III receptor), a separate TGFbeta-binding membrane protein of previously unknown function. Betaglycan presents TGFbeta directly to the kinase subunit of the signaling receptor, forming a high affinity ternary complex. Membrane betaglycan increases TGFbeta binding to the signaling receptor, enhances cell responsiveness to TGFbeta, and eliminates marked biological differences between TGFbeta isoforms. Thus, betaglycan is a direct regulator of TGFbeta access to the signaling receptors.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	LOPEZCASILLAS, F (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1990, J BIOL CHEM, V265, P20533; CHIEFETZ S, 1988, J BIOL CHEM, V263, P16984; CHIEFETZ S, 1987, CELL, V48, P409; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; EVAN GI, 1985, MOL CELL BIOL, V5, P360; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MERWIN JR, 1991, AM J PATHOL, V138, P37; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SAUNDERS S, 1989, J CELL BIOL, V108, P547; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SMITH DB, 1990, CURRENT PROTOCOLS MO; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	55	785	828	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1435	1444		10.1016/0092-8674(93)90368-Z	http://dx.doi.org/10.1016/0092-8674(93)90368-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391934	Bronze			2022-12-24	WOS:A1993LL20900017
J	MESZAROS, LG; BAK, J; CHU, A				MESZAROS, LG; BAK, J; CHU, A			CYCLIC ADP-RIBOSE AS AN ENDOGENOUS REGULATOR OF THE NONSKELETAL TYPE RYANODINE RECEPTOR CA2+ CHANNEL	NATURE			English	Article							CA-2+ RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CALCIUM RELEASE; MUSCLE; MEMBRANES; CONDUCTANCE; ACTIVATION; METABOLITE; MECHANISM; BINDING	THE skeletal and cardiac isoforms1 of the ryanodine receptor Ca2+ channel (RyRC) constitute the Ca2+ release pathway in sarcoplasmic reticulum of skeletal and cardiac muscles, respectively2,3. A direct mechanical and a Ca2+-triggered mechanism (Ca2+-induced Ca2+ release) have been respectively proposed to explain the in situ activation of Ca2+ release in skeletal and cardiac muscle4,5. In non-muscle cells, however, where the RyRC also participates in Ca2+ signalling6-11 the mechanism of RyRC activation is unknown. Cyclic adenosine 5'-diphosphoribose (cADPR)12, which is present in many mammalian tissues13, has been reported to induce Ca2+ release from ryanodine-sensitive intracellular Ca2+ stores in sea urchin eggs14. Here we provide evidence that cADPR directly activates the cardiac but not the skeletal isoform of the RyRC. This, together with results on sea urchin eggs14, suggests that cADPR is an endogenous activator of the non-skeletal type of RyRC and may thus have a role similar to inositol 1,4,5-trisphosphate15 in Ca2+ signalling.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine	MESZAROS, LG (corresponding author), MED COLL GEORGIA,DEPT PHYSIOL & ENDOCRINOL,AUGUSTA,GA 30912, USA.							ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CHU A, 1991, J BIOL CHEM, V266, P7699; CHU A, 1990, MOL PHARMACOL, V37, P735; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; EDELMAN AM, 1985, J NEUROSCI, V5, P2609; FABIATO A, 1989, MOL CELL BIOCHEM, V89, P135; FAOLATO C, 1991, J BIOL CHEM, V266, P20159; FILL M, 1990, BIOPHYS J, V50, P471; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; IKEMOTO N, 1989, J BIOENERG BIOMEMBR, V21, P247, DOI 10.1007/BF00812071; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LAI FA, 1990, ADV EXP MED BIOL, V269, P73; LEE HC, 1989, J BIOL CHEM, V264, P1608; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MESZAROS LG, 1991, AM J PHYSIOL, V261, pC1048, DOI 10.1152/ajpcell.1991.261.6.C1048; MESZAROS LG, 1985, J BIOL CHEM, V260, P6076; OTSU K, 1990, J BIOL CHEM, V265, P13472; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SHOSHANBARMATZ V, 1991, BIOCHEM J, V276, P41, DOI 10.1042/bj2760041; SUMIDA M, 1978, J BIOL CHEM, V253, P8772; WASETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113	29	337	341	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					76	79		10.1038/364076a0	http://dx.doi.org/10.1038/364076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8391127				2022-12-24	WOS:A1993LK81800062
J	ROULEAU, GA; MEREL, P; LUTCHMAN, M; SANSON, M; ZUCMAN, J; MARINEAU, C; HOANGXUAN, K; DEMCZUK, S; DESMAZE, C; PLOUGASTEL, B; PULST, SM; LENOIR, G; BIJLSMA, E; FASHOLD, R; DUMANSKI, J; DEJONG, P; PARRY, D; ELDRIGE, R; AURIAS, A; DELATTRE, O; THOMAS, G				ROULEAU, GA; MEREL, P; LUTCHMAN, M; SANSON, M; ZUCMAN, J; MARINEAU, C; HOANGXUAN, K; DEMCZUK, S; DESMAZE, C; PLOUGASTEL, B; PULST, SM; LENOIR, G; BIJLSMA, E; FASHOLD, R; DUMANSKI, J; DEJONG, P; PARRY, D; ELDRIGE, R; AURIAS, A; DELATTRE, O; THOMAS, G			ALTERATION IN A NEW GENE ENCODING A PUTATIVE MEMBRANE-ORGANIZING PROTEIN CAUSES NEUROFIBROMATOSIS TYPE-2	NATURE			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; GRADIENT GEL-ELECTROPHORESIS; HUMAN-CHROMOSOME 22; SUBUNIT NF-H; POLYPOSIS-COLI; DNA FRAGMENTS; MENINGIOMA; TALIN; EZRIN; HOMOLOGY	Neurofibromatosis type 2 (NF2) is a monogenic dominantly inherited disease predisposing carriers to develop nervous system tumours. To identify the genetic defect, the region between two flanking polymorphic markers on chromosome 22 was cloned and several genes identified. One is the site of germ-line mutations in NF2 patients and of somatic mutations in NF2-related tumours. Its deduced product has homology with proteins at the plasma membrane and cytoskeleton interface, a previously unknown site of action of tumour suppressor genes in humans.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,QUEBEC,CANADA; INST CURIE,GENET TUMEURS LAB,INSERM,CJF 9201,F-75231 PARIS 05,FRANCE; CEDARS SINAI MED CTR,NEUROGENET LAB,LOS ANGELES,CA 90048; INT AGCY RES CANC,F-69372 LYON,FRANCE; UNIV AMSTERDAM,INST HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; UNIV ERLANGEN NURNBERG,INST HUMAN GENET,W-8520 ERLANGEN,GERMANY; KAROLINSKA INST,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cedars Sinai Medical Center; World Health Organization; International Agency for Research on Cancer (IARC); University of Amsterdam; University of Erlangen Nuremberg; Karolinska Institutet; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ROULEAU, GA (corresponding author), MCGILL UNIV,CTR RECH NEUROSCI,MONTREAL H3A 2T5,QUEBEC,CANADA.		j, zucman-rossi/AAV-3594-2021; Plougastel-Douglas, Beatrice/Q-3186-2019; zucman-rossi, Jessica/B-5098-2009; Hoang-Xuan, Khe/O-7527-2017	j, zucman-rossi/0000-0002-5687-0334; Plougastel-Douglas, Beatrice/0000-0002-6389-561X; zucman-rossi, Jessica/0000-0002-5687-0334; Desmaze, Chantal/0000-0003-0777-8854				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; CHEN LC, 1991, CANCER RES, V32, P300; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; DELATTRE O, 1991, GENOMICS, V9, P721, DOI 10.1016/0888-7543(91)90366-M; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESMAZE C, 1992, GENE CHROMOSOME CANC, V5, P30, DOI 10.1002/gcc.2870050105; DUMANSKI JP, 1990, HUM GENET, V84, P219, DOI 10.1007/BF00200562; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HENIKOFF S, 1984, GENE, V28, P357; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; KAHRE O, 1992, MOL CELL BIOL, V12, P4242; KOZAC M, 1966, NUCLEIC ACIDS RES, V16, P8125; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maniatis T, 1989, DECONTAMINATION DILU; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MATTEI MG, 1988, HUM GENET, V80, P293, DOI 10.1007/BF01790100; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAROD SA, 1992, AM J HUM GENET, V51, P486; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; RUTTLEDGE MH, IN PRESS NEUROLOGY; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; TOS M, 1984, J LARYNGOL OTOL, V98, P685, DOI 10.1017/S0022215100147292; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; VANLEEUWEN C, 1991, NUCLEIC ACIDS RES, V19, P5805, DOI 10.1093/nar/19.20.5805; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	43	1138	1172	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					515	521		10.1038/363515a0	http://dx.doi.org/10.1038/363515a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8379998				2022-12-24	WOS:A1993LF93900040
J	PIMPLIKAR, SW; SIMONS, K				PIMPLIKAR, SW; SIMONS, K			REGULATION OF APICAL TRANSPORT IN EPITHELIAL-CELLS BY A G(S) CLASS OF HETEROTRIMERIC G-PROTEIN	NATURE			English	Article							GTP-BINDING PROTEINS; MDCK CELLS; SURFACE; MASTOPARAN; MEMBRANES; DOMAINS	THE role of heterotrimeric GTP-binding proteins in signal transduction is well established1. They might also be involved in vesicular transport2-6. Here we show that in the epithelial cell line Madin-Darby Canine Kidney, transport of influenza haemagglutinin protein to the apical surface is stimulated and that of vesicular stomatitis virus glycoprotein to the basolateral surface is retarded by AlF(3-5) treatment. Treatment of cells with the reagents known to influence the G(i) class of G proteins affected only the basolateral pathway whereas reagents acting on the G(s) class of G proteins specifically affected the apical pathway. In permeabilized cells, antibodies raised against the N-terminal domain of the alpha-subunit of G(s) inhibited the transport of haemagglutinin from the trans-Golgi network to apical surface but not between the endoplasmic reticulum and Golgi complex. These observations demonstrate involvement of a G(s) class of heterotrimeric G proteins, besides that of the G(i), in vesicular transport2. Moreover, the apical and the basolateral pathways in epithelial cells seem to be regulated by G(s) and G(i) proteins, respectively, in the trans-Golgi network.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Simons, Kai/0000-0002-9231-9996				BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1991, Journal of Cell Biology, V115, p195A; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DONALDSON JG, 1991, SCIENCE, V254, P850; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1991, REV BIOCH, V60, P349; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; SARGIACOMO M, 1989, J CELL BIOL, V109, P2117; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	23	187	189	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					456	458		10.1038/362456a0	http://dx.doi.org/10.1038/362456a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385268				2022-12-24	WOS:A1993KV42400086
J	LINDEGREN, ML; ATKINSON, WL; FARIZO, KM; STEHRGREEN, PA				LINDEGREN, ML; ATKINSON, WL; FARIZO, KM; STEHRGREEN, PA			MEASLES VACCINATION IN PEDIATRIC EMERGENCY DEPARTMENTS DURING A MEASLES OUTBREAK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MEDICAL SETTINGS; IMMUNIZATION; TRANSMISSION; CHILDREN; OPPORTUNITIES; INFANTS; HEALTH; CARE	Objective.-To determine the proportion of preschool-aged patients attending two inner-city hospital pediatric emergency departments (EDs) who were eligible for measles vaccination, to describe their demographic and clinical characteristics, and to assess the performance of the ED immunization programs that were implemented during a measles outbreak in vaccinating eligible children. Design.-Cross-sectional study. Setting.-Pediatric EDs of two urban hospitals in Chicago, Ill, in 1989. Participants.-Children 6 months to 5 years of age seen in the EDs. Intervention.-None. Main Outcome Measures.-The proportion of preschool-aged patients attending the two EDs who were eligible for measles vaccination and the proportion of vaccine-eligible children who were given measles vaccine. Results.-508 ED patients at hospital A and 255 patients at hospital B, 18% and 29%, respectively, were considered to be vaccine eligible. The most common discharge diagnoses of eligible patients were viral syndrome, otitis media, and minor trauma. Of vaccine-eligible patients, 59% at hospitals A and B were not vaccinated in the ED. At hospital B, patients with an infectious or respiratory disease diagnosis were less likely to be vaccinated than those with other diagnoses (P<.05). Conclusions.-Many children seen in these EDs were eligible for measles vaccination, and many eligible patients were not vaccinated. During community outbreaks of measles, optimal vaccination programs in pediatric EDs could increase vaccination coverage among inner-city preschool-aged children who may have limited access to health care.	CTR DIS CONTROL & PREVENT,DIV IMMUNIZAT,MAILSTOP EO5,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								[Anonymous], 1989, MMWR-MORBID MORTAL W, V38, P49; ATKINSON W, 1992, 32ND P INT C ANT AG; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; ATKINSON WL, 1991, SEMIN PEDIATR INFECT, V2, P100; BELL LM, 1992, AJDC, V146, P474; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DALES LG, 1985, WESTERN J MED, V142, P415; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; FARIZO KM, 1991, PEDIATRICS, V87, P74; FARIZO KM, 1992, PEDIATRICS, V89, P589; HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904; HOEKELMAN RA, 1976, CLIN PEDIATR, V15, P261, DOI 10.1177/000992287601500305; HUTCHINS SS, 1993, AM J PUBLIC HEALTH, V83, P862, DOI 10.2105/AJPH.83.6.862; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; ISTRE GR, 1987, PEDIATRICS, V79, P356; KROBER MS, 1991, JAMA-J AM MED ASSOC, V265, P2095, DOI 10.1001/jama.265.16.2095; LINDEGREN ML, 1991, 31ST P INT C ANT AG; MCCONNOCHIE KM, 1992, PEDIATRICS, V89, P1019; NDIKUYEZE A, 1988, INT J EPIDEMIOL, V17, P448, DOI 10.1093/ije/17.2.448; PETER G, 1991, JAMA-J AM MED ASSOC, V265, P2111, DOI 10.1001/jama.265.16.2111; POLIS MA, 1987, ARCH INTERN MED, V147, P1999, DOI 10.1001/archinte.147.11.1999; RODEWALD LE, 1993, PEDIATRICS, V91, P605; SCOTT RM, 1984, PEDIATRICS, V73, P777; WOOD DL, 1990, PEDIATRICS, V86, P666; 1991, MMWR MORB MORTAL WKL, V40, P369; 1991, REPORT COMMITTEE INF, P7; 1992, MMWR CDC SURVEILL SU, V41, P1; 1990, MMWR MORB MORTAL WKL, V39, P317; 1989, MMWR MORB MORTAL WKL, V38, P57; 1990, MMWR MORB MORTAL WKL, V39, P325; 1989, MMWR MORB MORTAL WKL, V38, P219; 1989, MMWR MORB MORTAL WKL, V38, P205; 1992, MMWR MORB MORTAL WKL, V41, P103; 1941, MMWR MORB MORTAL WKL, V40, P305; 1990, MMWR MORB MORTAL WKL, V39, P353; 1991, MMWR MORB MORTAL WKL, V40, P36; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1989, MMWR MORB MORTAL WKL, V38, P1; 1990, MMWR MORB MORTAL WKL, V39, P361; 1993, MMWR MORB MORTAL WKL, V42, P1	41	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2185	2189		10.1001/jama.270.18.2185	http://dx.doi.org/10.1001/jama.270.18.2185			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411600				2022-12-24	WOS:A1993ME81600028
J	NORTH, RL; ROTHENBERG, KH				NORTH, RL; ROTHENBERG, KH			PARTNER NOTIFICATION AND THE THREAT OF DOMESTIC VIOLENCE AGAINST WOMEN WITH HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREGNANCY				NORTH, RL (corresponding author), UNIV MARYLAND,SCH LAW,BALTIMORE,MD 21201, USA.							AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; Beauchamp TLC, 2019, PRINCIPLES BIOMEDICA; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; WEISSMAN G, 1991, Journal of Primary Prevention, V12, P49, DOI 10.1007/BF01326541; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1990, VOLUNTARY HIV COUNSE; 1992, MMWR MORB MORTAL WKL, V41; 1992, HIV AM REPORT NATION; 1991, VIOLENCE WOMEN; 1993, MMWR MORB MORTAL WKL, V42, P47	12	78	78	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1194	1196		10.1056/NEJM199310143291612	http://dx.doi.org/10.1056/NEJM199310143291612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA667	8377787	Green Published			2022-12-24	WOS:A1993MA66700012
J	KASHLEV, M; NUDLER, E; GOLDFARB, A; WHITE, T; KUTTER, E				KASHLEV, M; NUDLER, E; GOLDFARB, A; WHITE, T; KUTTER, E			BACTERIOPHAGE-T4 ALC PROTEIN - A TRANSCRIPTION TERMINATION FACTOR SENSING LOCAL MODIFICATION OF DNA	CELL			English	Article							COLI RNA-POLYMERASE; STRUCTURAL-ANALYSIS; TERNARY COMPLEXES; GENE-PRODUCT; BETA-SUBUNIT; MUTATION	Bacteriophage T4 Alc protein Participates in shutting off host transcription after infection of E. coli. It is demonstrated that Alc acts as a site-specific termination factor. The Alc sites occur frequently in E. coli DNA, resulting in early cessation of elongation in several tested transcription units. Alc-dependent termination requires unimpeded propagation of the elongating complex as it approaches the Alc site. Temporary halting of RNA polymerase within 10-15 bp before the Alc site prevents termination. Bacteriophage T4 transcription is protected from the action of Alc by overall substitution of cytosine with 5-hydroxymethyl cytosine in T4 DNA. In vitro methylation of CpG sequences in the vicinity of an Alc site abolishes the effect of Alc. Thus, Alc-dependent termination involves local sensing of the state of cytosine modification and a short-term ''memory'' of recent pausing.	EVERGREEN STATE COLL,OLYMPIA,WA 98505		KASHLEV, M (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016, USA.			Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD VD, 1978, NUCLEIC ACIDS RES, V10, P3549; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHAN CL, 1993, IN PRESS TRANSCRIPTI; DRIVDAHL RH, 1990, J BACTERIOL, V172, P2716, DOI 10.1128/jb.172.5.2716-2727.1990; FREIDMAN DJ, 1983, LAMBDA, V2; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUTTER E, 1984, GENETICS, V108, P291; KUTTER E, 1975, J MOL BIOL, V99, P591, DOI 10.1016/S0022-2836(75)80174-4; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; MUSTAEV A, 1993, IN PRESS J BIOL CHEM; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	20	42	44	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					147	154		10.1016/S0092-8674(05)80091-1	http://dx.doi.org/10.1016/S0092-8674(05)80091-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402894				2022-12-24	WOS:A1993MB66700015
J	BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM				BEARDON, PHG; MCGILCHRIST, MM; MCKENDRICK, AD; MCDEVITT, DG; MACDONALD, TM			PRIMARY NONCOMPLIANCE WITH PRESCRIBED MEDICATION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article							NONCOMPLIANCE	Objective-To determine the rate of patients not redeeming their prescriptions (primary non-compliance) and assess the factors influencing this. Design-Observational study comparing copies of prescriptions written by general practitioners with those dispensed by pharmacists and subsequent case record review. Setting-A large rural general practice in Tayside. Subjects-All 4854 patients who received prescriptions (20 921) written between january 1989 and March 1989. Main outcome measures-The rate of non-redemption of prescriptions. Results-Seven hundred and two patients (14.5%) did not redeem 1072 (5.2%) prescriptions during the study period, amounting to 11.5% of men and 16.3% of women. Non-redemption was highest in women aged 16-29 (27.6% of women) and men aged 40-49 (18.3% of men). Of prescriptions issued to women for oral contraceptives 24.8% were not redeemed during the study period. In those who redeemed prescriptions 17% were not exempt from prescription charges compared with 33% of patients who failed to redeem them. The non-redemption rate was highest for prescriptions issued at the weekends, although this was a small proportion of all prescribing. Prescriptions issued by trainee general practitioners were also less likely to be redeemed. Conclusions-Non-redemption varies with age, sex, general practitioner, exemption status, and with day of the week the prescription was written. Observational studies of drug exposure can be more accurately estimated from dispensing rather than prescribing data.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT PHARMACOL & CLIN PHARMACOL,MED MONITORING UNIT,DUNDEE DD1 9SY,SCOTLAND; CARNOUSTIE HLTH CTR,TAYSIDE DD7 7RB,ENGLAND	University of Dundee				MacDonald, Thomas/0000-0001-5189-6669				BEGG D, 1984, J ROY COLL GEN PRACT, V34, P272; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; FEELY M, 1989, GERIATRIC MED    JUN, P14; GRAHAM D J, 1988, American Journal of Preventive Medicine, V4, P15; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; RASHID A, 1982, BRIT MED J, V284, P24, DOI 10.1136/bmj.284.6308.24; WATERS WHR, 1976, BRIT MED J, V1, P1062, DOI 10.1136/bmj.1.6017.1062; WISEMAN IC, 1991, S AFR MED J, V79, P155; WONNACOTT TH, 1977, INTRO STATISTICS, P223	9	264	273	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					846	848		10.1136/bmj.307.6908.846	http://dx.doi.org/10.1136/bmj.307.6908.846			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401129	Bronze, Green Published			2022-12-24	WOS:A1993MA29300024
J	CARSON, JL; STROM, BL; DUFF, A; GUPTA, A; SHAW, M; LUNDIN, FE; DAS, K				CARSON, JL; STROM, BL; DUFF, A; GUPTA, A; SHAW, M; LUNDIN, FE; DAS, K			ACUTE-LIVER-DISEASE ASSOCIATED WITH ERYTHROMYCINS, SULFONAMIDES, AND TETRACYCLINES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, TOXIC; ERYTHROMYCIN; SULFONAMIDES; TETRACYCLINES; HOSPITALIZATION	TRIMETHOPRIM-SULFAMETHOXAZOLE; INTRAHEPATIC CHOLESTASIS; HEPATIC CHOLESTASIS; SKIN RASH; HEPATOTOXICITY; SULFASALAZINE; MINOCYCLINE; ETHYLSUCCINATE; FAILURE	Objective: To determine whether erythromycins, sulfonamides, and tetracyclines are associated with an increased risk for acute hepatitis. Design: Case-control study. Setting: Medicaid billing data from Michigan and Florida between 1980 and 1987. Patients: The 107 cases included patients hospitalized with acute symptomatic hepatitis without an identifiable cause of liver disease noted in the medical record. Four controls per case were randomly selected and were matched for age, sex, and state. Results: Five cases (4.7%) and four controls (0.9%) were exposed to erythromycins, yielding an odds ratio of 5.2 (95% CI, 1.1 to 26.6). No case or control was exposed to erythromycin estolate. Eight cases (7.5%) and three controls (0.7%) were exposed to oral sultonamides, yielding an odds ratio of 11.4 (CI, 2.7 to 67.8). All (except one control) had received trimethoprimsulfamethoxazole. Five cases (4.7%) and four controls (0.9%) were exposed to tetracyclines, yielding an odds ratio of 5.2 (CI, 1.4 to 19.7). The results did not change substantively for erythromycin or sulfonamides after adjustment using multiple logistic regression for age, sex, state, and use of other hepatotoxic drugs. With tetracyclines, however, the odds ratio decreased to 3.6 (CI, 0.9 to 14.3). Associations were also seen with isoniazid (P = 0.008) and rifampicin (P = 0.04). The number of patients developing acute symptomatic liver disease resulting in hospitalization for each million patients treated with a 10-day course of erythromycin was 2.28 cases; for sulfonamides, this figure was 4.8 cases; and for tetracycline, the figure was 1.56 cases. Conclusion: Erythromycin, sulfonamides, and tetracyclines are associated with acute symptomatic hepatitis resulting in hospitalization. Given the widespread use of these drugs, they will be among the more common drugs associated with hepatitis.	UNIV PENN, SCH MED, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA; HLTH INFORMAT DESIGNS INC, ARLINGTON, VA USA; US FDA, DIV DRUG & BIOL PROD EXPERIENCE, EPIDEMIOL DEV BRANCH, ROCKVILLE, MD 20857 USA	University of Pennsylvania; US Food & Drug Administration (FDA)	CARSON, JL (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DIV GEN INTERNAL MED, 97 PATERSON ST, NEW BRUNSWICK, NJ 08903 USA.				FDA HHS [FD-U-000079] Funding Source: Medline	FDA HHS		ALBERTIFLOR JJ, 1989, AM J GASTROENTEROL, V84, P1577; BAUM C, 1989, SPONTANEOUS REPORTIN, P107; BURETTE A, 1984, ARCH INTERN MED, V144, P1491, DOI 10.1001/archinte.144.7.1491; CARSON JL, 1992, CLIN PHARMACOL THER, V52, P214, DOI 10.1038/clpt.1992.132; CARSON JL, 1993, ARCH INTERN MED, V153, P1331, DOI 10.1001/archinte.153.11.1331; CARSON JL, 1989, MEDICAID DATA BASES, P173; CHATHAM WW, 1983, SOUTHERN MED J, V76, P1195, DOI 10.1097/00007611-198309000-00040; Combes B, 1972, Prog Liver Dis, V4, P589; COTO H, 1981, SOUTHERN MED J, V74, P897, DOI 10.1097/00007611-198107000-00035; DAVIES MG, 1989, BRIT MED J, V298, P1523, DOI 10.1136/bmj.298.6686.1523-c; DIEHL AM, 1984, AM J MED, V76, P931, DOI 10.1016/0002-9343(84)91013-1; DITTLER EL, 1962, AM J GASTROENTEROL, V38, P691; DUJOVNE CA, 1967, NEW ENGL J MED, V277, P785, DOI 10.1056/NEJM196710122771503; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FARMER CD, 1963, GASTROENTEROLOGY, V45, P157; FRENEAUX E, 1988, HEPATOLOGY, V8, P1056, DOI 10.1002/hep.1840080513; FRIES J, 1966, NEW ENGL J MED, V274, P95, DOI 10.1056/NEJM196601132740209; GAFTER U, 1979, NY STATE J MED, P87; GHISHAN FK, 1983, CLIN PEDIATR, V22, P212, DOI 10.1177/000992288302200310; GILBERT FI, 1962, JAMA-J AM MED ASSOC, V182, P1048; GULLEY RM, 1979, AM J GASTROENTEROL, V72, P561; HAVENS WP, 1962, JAMA-J AM MED ASSOC, V180, P30, DOI 10.1001/jama.1962.03050140032007; INMAN WHW, 1983, BRIT MED J, V286, P1954, DOI 10.1136/bmj.286.6382.1954; IWARSON S, 1979, ACTA MED SCAND, V206, P219; JACOBS E, 1978, GASTROENTEROLOGY, V75, P1193; JOHNSON DF, 1961, NEW ENGL J MED, V265, P1200, DOI 10.1056/NEJM196112142652407; JONES JK, 1989, DETERMINING CAUSATIO, P275; KEEFFE EB, 1982, DIGEST DIS SCI, V27, P701, DOI 10.1007/BF01393764; KLATSKIN G, 1956, DISEASE LIVER, P367; KOHLSTAEDT KG, 1961, JAMA-J AM MED ASSOC, V178, P89, DOI 10.1001/jama.1961.03040400091023; KONTTINEN A, 1972, ACTA MED SCAND, V191, P389; Lessler JT, 1984, MEDICAID DATA SOURCE; LUNZER MR, 1975, GASTROENTEROLOGY, V68, P1284; MAGEE G, 1982, DIGEST DIS SCI, V27, P1044, DOI 10.1007/BF01391754; MANTEL N, 1959, J NATL CANCER I, V22, P719; MIHAS AA, 1978, JAMA-J AM MED ASSOC, V239, P2590, DOI 10.1001/jama.239.24.2590; MIN DI, 1992, PHARMACOTHERAPY, V12, P68; MUNOZ SJ, 1990, HEPATOLOGY, V12, P342, DOI 10.1002/hep.1840120223; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; POLAND GA, 1986, AM J MED, V81, P707, DOI 10.1016/0002-9343(86)90562-0; RANSOHOFF DF, 1981, GASTROENTEROLOGY, V80, P816; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; SCHENKER S, 1975, DRUGS LIVER, P269; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHULTZ JC, 1963, NEW ENGL J MED, V269, P999, DOI 10.1056/NEJM196311072691903; SHARP JR, 1980, ANN INTERN MED, V92, P14, DOI 10.7326/0003-4819-92-1-14; SMITH MD, 1982, AUST NZ J MED, V12, P76, DOI 10.1111/j.1445-5994.1982.tb02433.x; SOTOLONGO RP, 1978, GASTROENTEROLOGY, V75, P95; Strieker BH, 1985, DRUG INDUCED HEPATIC, P153; STROM BL, 1985, CLIN PHARMACOL THER, V38, P359, DOI 10.1038/clpt.1985.188; SULLIVAN D, 1980, JAMA-J AM MED ASSOC, V243, P1074; TANNER AR, 1986, BRIT MED J, V293, P1072, DOI 10.1136/bmj.293.6554.1072-a; THIES PW, 1984, ARCH INTERN MED, V144, P1691, DOI 10.1001/archinte.144.8.1691; TONDER M, 1974, SCAND J GASTROENTERO, V9, P93; ZIMMERMAN HJ, 1987, DISEASES LIVER, P591; 1973, ADVERSE REACTIONS SE, V10; 1984, AUST DRUG REACTIONS, V2; 1980, ICD9CM COMM PROF HOS	58	56	57	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				576	583		10.7326/0003-4819-119-7_Part_1-199310010-00005	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363168				2022-12-24	WOS:A1993MA29100005
J	DRAMAIX, M; HENNART, P; BRASSEUR, D; BAHWERE, P; MUDJENE, O; TONGLET, R; DONNEN, P; SMETS, R				DRAMAIX, M; HENNART, P; BRASSEUR, D; BAHWERE, P; MUDJENE, O; TONGLET, R; DONNEN, P; SMETS, R			SERUM-ALBUMIN CONCENTRATION, ARM CIRCUMFERENCE, AND EDEMA AND SUBSEQUENT RISK OF DYING IN CHILDREN IN CENTRAL-AFRICA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL-STATUS; MALNUTRITION; SURVIVAL; DIARRHEA; INDEXES; DEATH	Objective-To measure the prognostic value of Clinical, anthropometric, and biological indicators of protein energy malnutrition in hospitalised children. Design-Hospital based follow up study from admission to discharge or death of a cohort of children. Setting-Paediatric hospital in Zaire. Subjects-1129 children consecutively admitted between August 1986 and October 1988. Main outcome measures-Height, weight, arm circumference, skinfold thicknesses, serum albumin concentration, and mortality. Results-Mortality was higher in wasted children and in those with a mid-upper arm circumference <125 mm, a serum albumin concentration <16 g/l, and oedema. After multivariate analysis, serum albumin concentration was the best predictor of subsequent risk of dying. Mid-upper arm circumference and oedema, however, still contributed considerably to evaluation of mortality. Conclusions-In this specific environment of central Africa an isolated clinical sign such as oedema is not enough to detect children with a high risk of dying among those admitted to paediatric wards with severe protein energy malnutrition. Measurement of additional indicators such as arm circumference and serum albumin concentration seems to be of crucial importance.	FREE UNIV BRUSSELS, SCH PUBL HLTH, EPIDEMIOL & SOCIAL MED LAB, ROUTE LENNIX 808, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, CUMUBAC MED TEAM, B-1050 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, QUEEN FABIOLA CHILDRENS HOSP, B-1050 BRUSSELS, BELGIUM; NAT SCI RES CTR, LWIRO, DEM REP CONGO	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel								Alleyne GAO, 1977, PROTEIN ENERGY MALNU; [Anonymous], 1970, LANCET, V2, P302; ARMITAGE P, 1987, STATISTICAL METHODS, P205; BEAU JP, 1987, J TROP PEDIATRICS, V33, P4, DOI 10.1093/tropej/33.1.4; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; BRIEND A, 1988, Indian Pediatrics, V25, P930; BRIEND A, 1989, EUR J CLIN NUTR, V43, P715; COWARD WA, 1972, BRIT J NUTR, V28, P433, DOI 10.1079/BJN19720053; Dixon W. J., 1990, BMDP STATISTICAL SOF; GOLDEN MHN, 1982, AM J CLIN NUTR, V35, P1159, DOI 10.1093/ajcn/35.5.1159; GOLDEN MHN, 1980, LANCET, V1, P114, DOI 10.1016/S0140-6736(80)90603-0; Gomez Federico, 1956, J Trop Pediatr (Lond), V2, P77; HAY RW, 1975, LANCET, V2, P427; HENNART P, 1984, CHILDREN TROPICS, V149, P38; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JELIFFE DB, 1966, WHO MONOGR, V53, P194; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P12; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P103; MCFARLANE H, 1970, BMJ-BRIT MED J, V4, P268, DOI 10.1136/bmj.4.5730.268; MCLAREN DS, 1982, TXB PAEDIATRIC NUTRI; NORUSSIS MJ, 1990, JSPSS STATISTICAL DA; SACHDEV HPS, 1991, J PEDIATR GASTR NUTR, V12, P76, DOI 10.1097/00005176-199101000-00016; SONNET J, 1952, Rev Belg Pathol Med Exp, V22, P226; TOLBOOM JJM, 1986, TROP GEOGR MED, V38, P351; TROWBRIDGE FL, 1982, AM J CLIN NUTR, V36, P691, DOI 10.1093/ajcn/36.4.691; VANROOSMALENWIEBENGA MW, 1986, J TROP PEDIATRICS, V32, P240, DOI 10.1093/tropej/32.5.240; WATERLOW JC, 1972, BRIT MED J, V3, P566, DOI 10.1136/bmj.3.5826.566; WATRLOW JC, 1992, PROTEIN ENERGY MALNU; 1977, VITAL HLTH STATISTIC, V2	29	24	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 18	1993	307	6906					710	713		10.1136/bmj.307.6906.710	http://dx.doi.org/10.1136/bmj.307.6906.710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401093	Green Published, Bronze			2022-12-24	WOS:A1993LY29200020
J	SCHNEIDER, R; UNGER, G; STARK, R; SCHNEIDERSCHERZER, E; THIEL, HJ				SCHNEIDER, R; UNGER, G; STARK, R; SCHNEIDERSCHERZER, E; THIEL, HJ			IDENTIFICATION OF A STRUCTURAL GLYCOPROTEIN OF AN RNA VIRUS AS A RIBONUCLEASE	SCIENCE			English	Article							HOG-CHOLERA VIRUS; VIRAL DIARRHEA VIRUS; SELF-INCOMPATIBILITY; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; NICOTIANA-ALATA; SEMINAL RNASE; PESTIVIRUS; ACID	One of the three structural glycoproteins of classical swine fever virus (CSFV) is E0, a disulfide-bonded homodimer that induces virus-neutralizing antibodies and occurs in a virion-bound as well as a secreted form. E0 was shown to be similar to a family of fungal and plant ribonucleases. Purified E0 from CSFV-infected cells was a potent ribonuclease specific for uridine and inhibitable by zinc ions.	FED RES CTR VIRUS DIS ANIM, D-72076 TUBINGEN, GERMANY		SCHNEIDER, R (corresponding author), UNIV INNSBRUCK, FAC NAT SCI, DEPT BIOCHEM, A-6020 INNSBRUCK, AUSTRIA.							ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BENNER SA, 1989, TRENDS BIOCHEM SCI, V14, P396, DOI 10.1016/0968-0004(89)90282-X; BROWN PH, 1986, PLANT PHYSIOL, V82, P801, DOI 10.1104/pp.82.3.801; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HORIUCHI H, 1988, J BIOCHEM-TOKYO, V103, P408, DOI 10.1093/oxfordjournals.jbchem.a122284; KAWATA Y, 1988, EUR J BIOCHEM, V176, P683, DOI 10.1111/j.1432-1033.1988.tb14331.x; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9; RUMENAPF T, 1993, J VIROL, V67, P3288; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; STARK RE, UNPUB; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; THIEL HJ, 1991, J VIROL, V65, P4705, DOI 10.1128/JVI.65.9.4705-4712.1991; VESCIA S, 1980, CANCER RES, V40, P3740; WEILAND E, 1992, J VIROL, V66, P3677, DOI 10.1128/JVI.66.6.3677-3682.1992	21	157	179	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1169	1171		10.1126/science.8356450	http://dx.doi.org/10.1126/science.8356450			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356450				2022-12-24	WOS:A1993LU58600032
J	HALL, CG; SANCHO, J; TERHORST, C				HALL, CG; SANCHO, J; TERHORST, C			RECONSTITUTION OF T-CELL RECEPTOR ZETA-MEDIATED CALCIUM MOBILIZATION IN NONLYMPHOID CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; PHOSPHATASE CD45; ACTIVATION; PHOSPHORYLATION; CHAIN; STIMULATION	T cell antigen receptor (TCR) activation involves interactions between receptor subunits and nonreceptor protein tyrosine kinases (PTKs). Early steps in signaling through the zeta chain of the TCR were examined in transfected COS-1 cells. Coexpression of the PTK p59fynT, but not p56lck, with zeta or with a homodimeric TCRbeta-zeta fusion protein produced tyrosine phosphorylation of both zeta and phospholipase C (PLC)-gamma1, as well as calcium ion mobilization in response to receptor cross-linking. CD45 coexpression enhanced these effects. No requirement for the PTKZAP-70 was observed. Thus, p59fynT may link zeta directly to the PLC-gamma1 activation pathway.			HALL, CG (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02215, USA.		Sancho, Jaime/K-5989-2019; Sancho, Jaime/O-3228-2013	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951	NATIONAL CANCER INSTITUTE [K08CA001486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015066, R01AI015066] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01486] Funding Source: Medline; NIAID NIH HHS [AI 15066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HALL CA, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J BIOL CHEM, V267, P3375; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MASLINSKI W, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	45	80	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					915	918		10.1126/science.8346442	http://dx.doi.org/10.1126/science.8346442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346442				2022-12-24	WOS:A1993LR89700039
J	TOYOSHIMA, C; SASABE, H; STOKES, DL				TOYOSHIMA, C; SASABE, H; STOKES, DL			3-DIMENSIONAL CRYOELECTRON MICROSCOPY OF THE CALCIUM-ION PUMP IN THE SARCOPLASMIC-RETICULUM MEMBRANE	NATURE			English	Article							FUNCTIONAL CONSEQUENCES; TRANSMEMBRANE DOMAIN; X-RAY; CA-2+-ATPASE; MUTATIONS; ORGANIZATION; DIFFRACTION; LOCATION; PROTEINS; SECTOR	THE ATP-driven calcium pump (Ca2+-ATPase) is an integral membrane protein (M(r) 110K) which relaxes striated muscle by pumping calcium out of the cytoplasm into the sarcoplasmic reticulum against a large concentration gradient1. Recent efforts have attempted to relate the sequence of Ca2+-ATPase to its structure and function. In particular, site-directed mutagenesis has identified critical amino-acid residues2-6, and its predicted secondary structure, which includes ten transmembrane helices7, has gained experimental support8-10. But direct visualization of the molecule has so far been limited to the cytoplasmic domains at low resolution11,12. We present here the three-dimensional structure of Ca2+-ATPase in the native sarcoplasmic reticulum membrane at 14 angstrom resolution, determined by cryo-electron microscopy and helical image analysis. The structure shows an unexpected transmembrane organization, consisting of three distinct segments, one of which is highly inclined. These features can be related to earlier predictions of secondary structure.	UNIV VIRGINIA, HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS, JORDAN HALL,BOX 449, CHARLOTTESVILLE, VA 22908 USA; TOKYO INST TECHNOL, DEPT BIOL SCI, MEGURO KU, TOKYO 152, JAPAN; RIKEN, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN	University of Virginia; Tokyo Institute of Technology; RIKEN			Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DUPONT Y, 1973, NATURE, V244, P555, DOI 10.1038/244555a0; DUX L, 1983, J BIOL CHEM, V258, P2599; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HERBETTE L, 1985, BIOCHIM BIOPHYS ACTA, V817, P103, DOI 10.1016/0005-2736(85)90073-2; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; VILSEN B, 1989, J BIOL CHEM, V264, P21024	21	217	217	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					469	471		10.1038/362469a0	http://dx.doi.org/10.1038/362469a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385269				2022-12-24	WOS:A1993KV42400090
J	OHTSUBO, M; ROBERTS, JM				OHTSUBO, M; ROBERTS, JM			CYCLIN-DEPENDENT REGULATION OF G(1) IN MAMMALIAN FIBROBLASTS	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CELL-DIVISION CYCLE; DNA-REPLICATION; FISSION YEAST; PROTEIN-KINASE; G1-SPECIFIC CYCLINS; GENETIC-CONTROL; SIZE CONTROL; G1 CYCLIN; S-PHASE	Eukaryotic cells become committed to proliferate during the G1 phase of the cell cycle. In budding yeast, commitment occurs when the catalytic subunit of a protein kinase, encoded by the CDC28 gene (the homolog of the fission yeast cdc2+ gene), binds to a positively acting regulatory subunit, a cyclin. Related kinases are also required for progression through the G1 phase in higher eukaryotes. The role of cyclins in controlling G1 progression in mammalian cells was tested by construction of fibroblasts that constitutively overexpress human cyclin E. This was found to shorten the duration of G1, decrease cell size, and diminish the serum requirement for the transition from G1 to S phase. These observations show that cyclin levels can be rate-limiting for G1 progression in mammalian cells and suggest that cyclin synthesis may be the target of physiological signals that control cell proliferation.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98145 USA	University of Washington; University of Washington Seattle	OHTSUBO, M (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA.			ohtsubo, motoaki/0000-0002-2479-3178				BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, COMMUNICATOIN; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; FIRPO EJ, UNPUB; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P2286; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KARN J, 1989, ONCOGENE, V4, P773; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MACIEIRACOELHO A, 1973, TISSUE CULTURE METHO, P412; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1979, J CELL SCI, V39, P215; NASMYTH KA, 1979, J CELL SCI, V36, P155; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NORWOOD T, UNPUB; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OHTSUBO M, UNPUB; OYAMA VI, 1956, P SOC EXP BIOL MED, V91, P305, DOI 10.3181/00379727-91-22245; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1990, NEW BIOL, V2, P289; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBERTS JAG, UNPUB; SHERR C, COMMUNICATION; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANCEL G, 1978, P NATL ACAD SCI USA, V75, P6295; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	57	719	745	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	1993	259	5103					1908	1912		10.1126/science.8384376	http://dx.doi.org/10.1126/science.8384376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8384376				2022-12-24	WOS:A1993KU17200035
J	SHIN, YK; LEVINTHAL, C; LEVINTHAL, F; HUBBELL, WL				SHIN, YK; LEVINTHAL, C; LEVINTHAL, F; HUBBELL, WL			COLICIN-E1 BINDING TO MEMBRANES - TIME-RESOLVED STUDIES OF SPIN-LABELED MUTANTS	SCIENCE			English	Article							CHANNEL; PEPTIDE; INSERTION; SPECTRA	To investigate the mechanism of interaction of the toxin colicin E1 with membranes, three cysteine substitution mutants and the wild type of the channel-forming fragment were spin labeled at the unique thiol. Time-resolved interaction of these labeled proteins with phospholipid vesicles was investigated with stopped-flow electron paramagnetic resonance spectroscopy. The fragment interacts with neutral bilayers at low pH, indicating that the interaction is hydrophobic rather than electrostatic. The interaction occurs in at least two distinct steps: (i) rapid adsorption to the surface; and (ii) slow, rate-limiting insertion of the hydrophobic central helices into the membrane interior.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Columbia University; University of California System; University of California Los Angeles			Barker, Gareth J/C-9616-2009	Barker, Gareth J/0000-0002-5214-7421	NEI NIH HHS [EY05216] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BERLINER LJ, 1982, ANAL BIOCHEM, V119, P450, DOI 10.1016/0003-2697(82)90612-1; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BULLOCK JO, 1983, J BIOL CHEM, V258, P9908; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CLEVELAND MV, 1983, P NATL ACAD SCI-BIOL, V80, P3706, DOI 10.1073/pnas.80.12.3706; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V202, P1299, DOI 10.1111/j.1432-1033.1991.tb16503.x; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; JIANG JJ, 1992, BIOCHEMISTRY-US, V31, P1331, DOI 10.1021/bi00120a008; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P559; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; MEIROVITCH E, 1984, J PHYS CHEM-US, V88, P3454, DOI 10.1021/j150660a018; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WORMALD MR, 1990, EUR J BIOCHEM, V191, P155, DOI 10.1111/j.1432-1033.1990.tb19105.x; WU G, 1992, THESIS U CALIFORNIA	30	147	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					960	963		10.1126/science.8382373	http://dx.doi.org/10.1126/science.8382373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8382373				2022-12-24	WOS:A1993KL80000039
J	ROSSDEGNAN, D; SOUMERAI, SB; FORTESS, EE; GURWITZ, JH				ROSSDEGNAN, D; SOUMERAI, SB; FORTESS, EE; GURWITZ, JH			EXAMINING PRODUCT RISK IN CONTEXT - MARKET WITHDRAWAL OF ZOMEPIRAC AS A CASE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARE; PROPOXYPHENE; MORTALITY; PAYMENT; THERAPY	Objective.-To examine changes in the prescribing of analgesics after the market entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti-inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths. Design.-To evaluate this natural quasi experiment, we conducted time-series analyses to compare prescribing in two cohorts of primary care physicians from July 1980 through September 1983. Setting.-Study physicians provided outpatient pharmaceutical care to patients enrolled in the New Jersey Medicaid program. Participants.-We identified 260 primary care physicians who provided 10 or more prescriptions for zomepirac (zomepirac prescribers) and 308 who provided 10 or more prescriptions for NSAIDs other than zomepirac (other-NSAID prescribers) in Medicaid during the study period. Main Outcome Measures.-Monthly rates of prescribing for zomepirac and several categories of substitute analgesics among Medicaid patients seen by study physicians. Main Results.-Zomepirac accounted for a stable 11.0% of analgesic prescribing among the zomepirac-prescriber cohort; label changes and manufacturer product-risk warnings 11 months before the product's withdrawal from the market had no impact on use. After market entry, zomepirac prescribers reduced use of other NSAIDs and propoxyphene (hydrochloride or napsylate) in comparison with other-NSAID prescribers (-8.1% and -2.80% of total analgesic prescribing, respectively; P<.001). After the product's withdrawal from the market, zomepirac prescribers showed significant increases in relative prescribing of other NSAIDs (+6.8%; P<.001), propoxyphene (+2.1%; P<.05), and analgesics containing barbiturates (+2.7%; P<.001). Conclusions.-The sudden withdrawal of zomepirac from the market resulted in substitutions not only of other NSAIDs, but also of alternative analgesics that carry risks of habituation and adverse effects. Apparent gains in patient safety resulting from market withdrawal of medications must be evaluated in comparison with risks of medications likely to be substituted.	HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SOCIAL MED,DRUG POLICY RES GRP,BOSTON,MA 02115; SUFFOLK UNIV,DEPT PUBL MANAGEMENT HLTH ADM CONCENTRAT,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Suffolk University; Harvard University; Brigham & Women's Hospital					AHRQ HHS [HS 05554] Funding Source: Medline; NIA NIH HHS [KO8 AG00510] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1982, SAS USERS GUIDE; BAUM C, 1985, ARTHRITIS RHEUM, V28, P686, DOI 10.1002/art.1780280613; BAUM C, 1983, DRUG USE US 1982 4TH, P25; BRAHAMS D, 1991, LANCET, V338, P938, DOI 10.1016/0140-6736(91)91792-S; CORRE KA, 1988, ANN EMERG MED, V17, P145, DOI 10.1016/S0196-0644(88)80300-7; EKEBERG O, 1987, ACTA MED SCAND, V221, P483; FERRANDO C, 1987, DRUG INTEL CLIN PHAR, V21, P653, DOI 10.1177/1060028087021007-819; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; GORTMAKER SL, 1987, HEALTH SERV RES, V22, P91; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; KOCH H, 1984, NCHS ADV DATA, V96, P1; MARSHALL E, 1985, SCIENCE, V229, P1071, DOI 10.1126/science.4035348; RALL T, 1990, GOODMAN GILMANS PHAR, P358; RAO P, 1971, APPLIED ECONOMETRICS; ROSS SR, 1982, ANN ALLERGY, V48, P233; SAMUEL SA, 1981, NEW ENGL J MED, V304, P978; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Shochet RB, 1988, J INTENSIVE CARE MED, V3, P246; SHORR RI, 1992, J GERONTOL, V47, pM111, DOI 10.1093/geronj/47.4.M111; SMITH VT, 1982, JAMA-J AM MED ASSOC, V247, P1172; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; STROM BL, 1987, ARTHRITIS RHEUM, V30, P1142, DOI 10.1002/art.1780301009; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WEISER B, 1988, WASHINGTON POST 1026, pA1; 1981, SCRIP WORLD PHARM NE, V590, P10; 1986, DRUG INFORMATION 86; 1983, WKLY PHARM REP, V32, P2; 1983, WASHINGTON POST 0927, pD12; STATISTICAL SERIES G; 1983, AMA DRUG EVALUATION, P98; 1980, SCRIP WORLD PHARM NE, V539, P13; 1981, SCRIP WORLD PHARM NE, V591, P9; 1983, DRUG FACTS COMP; STATISTICAL SERIES 1	39	72	73	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1937	1942		10.1001/jama.270.16.1937	http://dx.doi.org/10.1001/jama.270.16.1937			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411550	Green Submitted			2022-12-24	WOS:A1993MC51300024
J	WANG, LM; MYERS, MG; SUN, XJ; AARONSON, SA; WHITE, M; PIERCE, JH				WANG, LM; MYERS, MG; SUN, XJ; AARONSON, SA; WHITE, M; PIERCE, JH			IRS-1 - ESSENTIAL FOR INSULIN-STIMULATED AND IL-4-STIMULATED MITOGENESIS IN HEMATOPOIETIC-CELLS	SCIENCE			English	Article							TYROSINE KINASE-ACTIVITY; GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; JUXTAMEMBRANE REGION; ATP-BINDING; RECEPTOR; PHOSPHORYLATION; GROWTH; RAS	Although several interleukin-3 (IL-3)-dependent cell lines proliferate in response to IL-4 or insulin, the 32D line does not. Insulin and IL-4 sensitivity was restored to 32D cells by expression of IRS-1, the principal substrate of the insulin receptor. Although 32D cells possessed receptors for both factors, they lacked the IRS-1-related protein, 4PS, which becomes phosphorylated by tyrosine in insulin- or IL-4-responsive lines after stimulation. These results indicate that factors that bind unrelated receptors can use similar mitogenic signaling pathways in hematopoietic cells and that 4PS and IRS-1 are functionally similar proteins that are essential for insulin- and IL-4-induced proliferation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK-43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUANG LM, IN PRESS P NATL ACAD; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GREENBERGER JS, 1983, FED PROC, V42, P2762; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MOSELY B, 1989, CELL, V59, P335; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIERCE JR, UNPUB; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	31	415	419	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1591	1594		10.1126/science.8372354	http://dx.doi.org/10.1126/science.8372354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372354				2022-12-24	WOS:A1993LX47400034
J	COLLMAN, JP; ZHANG, XM; LEE, VJ; UFFELMAN, ES; BRAUMAN, JI				COLLMAN, JP; ZHANG, XM; LEE, VJ; UFFELMAN, ES; BRAUMAN, JI			REGIOSELECTIVE AND ENANTIOSELECTIVE EPOXIDATION CATALYZED BY METALLOPORPHYRINS	SCIENCE			English	Article							SPANNING STEROIDAL METALLOPORPHYRINS; CYTOCHROME-P-450 MODEL COMPOUNDS; PICNIC-BASKET PORPHYRINS; TWIN-CORONET PORPHYRINS; OXYGEN ATOM TRANSFER; ASYMMETRIC EPOXIDATION; UNFUNCTIONALIZED OLEFINS; MANGANESE(V)-OXO COMPLEX; IRON PORPHYRINS; ACTIVE-SITE	Recent progress in regioselective and enantioselective epoxidations catalyzed by metalloporphyrins is discussed here, with an explanation of the biomimetic antecedents of this area and its relevance to synthetic applications. Classification of the catalysts that have been studied allows useful conclusions to be drawn about the development of this field. In particular, both the most promising biomimetic and practical catalysts have arisen from systems that can be systematically modified by convenient synthetic methodology.			COLLMAN, JP (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.		Zhang, Xumu/K-8746-2013	Zhang, Xumu/0000-0001-5700-0608	NIGMS NIH HHS [5R37-GM 17880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartok M, 1980, CHEM ETHERS CROW 1 S, P609; COLLINS TJ, 1989, J AM CHEM SOC, V111, P4511, DOI 10.1021/ja00194a063; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; COLLMAN JP, 1985, J AM CHEM SOC, V107, P2000, DOI 10.1021/ja00293a034; COLLMAN JP, 1990, J AM CHEM SOC, V112, P5356, DOI 10.1021/ja00169a056; COLLMAN JP, 1984, P NATL ACAD SCI USA, V81, P3245, DOI 10.1073/pnas.81.10.3245; COLLMAN JP, 1993, J AM CHEM SOC, V115, P3834, DOI 10.1021/ja00062a083; COLLMAN JP, 1992, J CHEM SOC CHEM COMM, P1647, DOI 10.1039/c39920001647; COLLMAN JP, 1992, ADV CHEM SER, V230, P153; COLLMAN JP, 1988, J AM CHEM SOC, V110, P3477, DOI 10.1021/ja00219a023; COLLMAN JP, UNPUB; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DECARVALHO ME, 1986, NEW J CHEM, V10, P223; DEMONTELLANO PR, 1986, CYTOCHROME P450 REAC; Fox B. G., 1990, BIOL OXIDATION SYSTE, V1, P367; GAO Y, 1987, J AM CHEM SOC, V109, P5765, DOI 10.1021/ja00253a032; GROVES JT, 1989, J AM CHEM SOC, V111, P2900, DOI 10.1021/ja00190a026; GROVES JT, 1990, J CHEM SOC CHEM COMM, P436, DOI 10.1039/c39900000436; GROVES JT, 1988, J AM CHEM SOC, V110, P8628, DOI 10.1021/ja00234a009; GROVES JT, 1990, J ORG CHEM, V55, P3628, DOI 10.1021/jo00298a046; GROVES JT, 1983, J AM CHEM SOC, V105, P5791, DOI 10.1021/ja00356a016; GROVES JT, 1987, J AM CHEM SOC, V109, P5045, DOI 10.1021/ja00250a059; GROVES JT, 1983, J AM CHEM SOC, V105, P5786, DOI 10.1021/ja00356a015; GUNTER MJ, 1991, COORDIN CHEM REV, V108, P115, DOI 10.1016/0010-8545(91)84001-L; HALTERMAN RL, 1991, J ORG CHEM, V56, P5253, DOI 10.1021/jo00018a008; HANSON RM, 1986, J ORG CHEM, V51, P1922, DOI 10.1021/jo00360a058; Hill C. L., 1989, ACTIVATION FUNCTIONA; IRIE R, 1990, TETRAHEDRON LETT, V31, P7345, DOI 10.1016/S0040-4039(00)88562-7; IRIE R, 1991, TETRAHEDRON-ASYMMETR, V2, P481, DOI 10.1016/S0957-4166(00)86102-9; IRIE R, 1991, TETRAHEDRON LETT, V32, P1055, DOI 10.1016/S0040-4039(00)74486-8; JACOBSEN EN, 1991, J AM CHEM SOC, V113, P6703, DOI 10.1021/ja00017a069; JACOBSEN EN, 1991, J AM CHEM SOC, V113, P7063, DOI 10.1021/ja00018a068; JACOBSEN EN, 1992, J ORG CHEM, V57, P4320; JERINA DM, 1974, SCIENCE, V185, P573, DOI 10.1126/science.185.4151.573; Johnson R.A, 1991, COMPR ORG SYNTH, V7, P389; JORGENSEN KA, 1990, CHEM REV, V90, P1483; JORGENSEN KA, 1989, CHEM REV, V89, P431; KATSUKI T, 1980, J AM CHEM SOC, V102, P5976; KONISHI K, 1992, J AM CHEM SOC, V114, P1313, DOI 10.1021/ja00030a029; LEE NH, 1991, TETRAHEDRON LETT, V32, P5055, DOI 10.1016/S0040-4039(00)93426-9; LEE NH, 1991, TETRAHEDRON LETT, V32, P6533, DOI 10.1016/0040-4039(91)80212-O; LICOCCIA S, 1991, MAGN RESON CHEM, V29, P1084, DOI 10.1002/mrc.1260291103; MAILLARD P, 1991, TETRAHEDRON LETT, V32, P4904; MANSUY D, 1985, J CHEM SOC CHEM COMM, P155, DOI 10.1039/c39850000155; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; MIRAFZAL GA, 1992, J AM CHEM SOC, V114, P10968, DOI 10.1021/ja00053a047; MUKAIYAMA T, 1993, CHEM LETT, P327, DOI 10.1246/cl.1993.327; NARUTA Y, 1989, CHEM LETT, P1269, DOI 10.1246/cl.1989.1269; NARUTA Y, 1993, B CHEM SOC JPN, V66, P158, DOI 10.1246/bcsj.66.158; NARUTA Y, 1991, J AM CHEM SOC, V113, P6865, DOI 10.1021/ja00018a024; NUGENT WA, 1993, SCIENCE, V259, P479, DOI 10.1126/science.259.5094.479; OKITA RT, 1992, TXB BIOCH CLIN CORRE, P981; OMALLEY S, 1989, J AM CHEM SOC, V111, P9116, DOI 10.1021/ja00207a027; OSTOVIC D, 1992, ACCOUNTS CHEM RES, V25, P314, DOI 10.1021/ar00019a007; OZAKI S, 1990, J CHEM SOC PERK T 2, P353, DOI 10.1039/p29900000353; PIRKLE WH, 1979, J ORG CHEM, V44, P1025, DOI 10.1021/jo01321a001; SAMSEL EG, 1985, J AM CHEM SOC, V107, P7606, DOI 10.1021/ja00311a064; SCHURIG V, 1992, CHEM REV, V92, P873, DOI 10.1021/cr00013a006; SRINIVASAN K, 1986, J AM CHEM SOC, V108, P2309, DOI 10.1021/ja00269a029; STILL WC, 1979, J AM CHEM SOC, V101, P2493, DOI 10.1021/ja00503a048; STINSON SC, 1992, CHEM ENG NEWS, V70, P46, DOI 10.1021/cen-v070n039.p046; SUSLICK KS, 1987, J CHEM SOC CHEM COMM, P200, DOI 10.1039/c39870000200; SUSLICK KS, 1989, ACTIVATION FUNCTIONA, P219; TABUSHI I, 1984, J AM CHEM SOC, V106, P6871, DOI 10.1021/ja00334a083; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P2775, DOI 10.1021/ja00060a027; WAGLER TR, 1989, J ORG CHEM, V54, P1584, DOI 10.1021/jo00268a019; YAMADA T, 1992, CHEM LETT, P2231, DOI 10.1246/cl.1992.2231; ZHANG W, 1990, J AM CHEM SOC, V112, P2801, DOI 10.1021/ja00163a052; ZHANG W, 1991, J ORG CHEM, V56, P2296, DOI 10.1021/jo00007a012	69	444	462	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1404	1411		10.1126/science.8367724	http://dx.doi.org/10.1126/science.8367724			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367724				2022-12-24	WOS:A1993LW54900022
J	ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA				ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA			ALCOHOL-RELATED HOSPITALIZATIONS OF ELDERLY PEOPLE - PREVALENCE AND GEOGRAPHIC-VARIATION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE PATIENTS; CONSUMPTION; DRINKERS; DRINKING; ABUSE; AGE	Objective.- To determine the prevalence, geographic variation, and charges to Medicare of alcohol-related hospitalizations among elderly people in the United States. Design.- A cross-sectional prevalence study using 1989 hospital claims data from the Health Care Financing Administration (HCFA). Rates were determined using (1) hospital claims records from the HCFA's Medicare Provider Analysis and Review Record (MEDPAR) database for all Medicare Part A beneficiaries aged 65 years and older, (2) county population estimates for 1985 from the Bureau of the Census; and (3) per capita consumption of alcohol by state in 1989 as estimated by the US Department of Health and Human Services. Setting.- Data include all hospital inpatient Medicare Part A beneficiaries aged 65 years and older in the United States in 1989. Results.- The prevalence of alcohol-related hospitalizations among people aged 65 years and older nationality in 1989 was 54.7 per 10 000 population for men and 14.8 per 10 000 for women. Comparison with hospital records showed that MEDPAR data had a sensitvity of 77% to detect alcohol-related hospitalizations. There was considerable geographic variation; prevalence ranged from 18.9 per 10 000 in Arkansas to 77.0 per 10 000 in Alaska. A strong correlation existed between alcohol-related hospitalizations and per capita consumption of alcohol by state (Spearman correlation coefficient, .64; P<.0001). In 1989, the hospital-associated charges to Medicare for all admissions where the primary diagnosis was alcohol related (N=33 039) totaled $233 543 500. Median charge per hospital stay was $4514. Conclusions.- Alcohol-related hospitalizations among elderly people are common; rates were similar to those for myocardial infarction as detected by the same method. The charges to Medicare for this preventable problem are considerable. Ecological analysis suggests that per capita consumption in the total US population predicts alcohol-related hospitalizations in the elderly population.	MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin								ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; BAILEY MB, 1965, Q J STUD ALCOHOL, V26, P19; BARNES GM, 1979, J AM GERIATR SOC, V27, P244, DOI 10.1111/j.1532-5415.1979.tb06125.x; BLAZER D, 1987, ARCH GEN PSYCHIAT, V44, P736; BRISTOW MF, 1992, BRIT J ADDICT, V87, P291; CAHALAN D, 1968, J STUD ALCOHOL, V29, P139; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Kirkpatrick B, 1988, Psychiatr Med, V6, P65; MANDERSCHEID RW, 1990, ADM901708 US DEP HLT; MANN RE, 1991, J STUD ALCOHOL, V52, P361, DOI 10.15288/jsa.1991.52.361; MCKIM WA, 1991, CAN J PUBLIC HEALTH, V82, P231; MEYERS A R, 1981, International Journal of Aging and Human Development, V14, P31, DOI 10.2190/XCDE-9EQY-5DNR-BUX7; Molgaard C A, 1990, J Community Health, V15, P239, DOI 10.1007/BF01350290; MOORE RD, 1986, J MED EDUC, V61, P46; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHUCKIT MA, 1980, J CLIN PSYCHIAT, V41, P412; SMART RG, 1981, J PSYCHOACTIVE DRUGS, V13, P153, DOI 10.1080/02791072.1981.10524297; SMART RG, 1987, BRIT J ADDICT, V82, P285; STINSON FS, 1989, ALCOHOL HEALTH RES W, V13, P80; 1980, PHS801260 US DEP HLT; 1991, 20 US DEP HLTH HUM S; 1989, COUNTY POPULATION ES	29	172	173	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1222	1225		10.1001/jama.270.10.1222	http://dx.doi.org/10.1001/jama.270.10.1222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV649	8355385				2022-12-24	WOS:A1993LV64900028
J	KAPPEN, LS; GOLDBERG, IH				KAPPEN, LS; GOLDBERG, IH			DNA CONFORMATION INDUCED ACTIVATION OF AN ENEDIYNE FOR SITE-SPECIFIC CLEAVAGE	SCIENCE			English	Article							NEOCARZINOSTATIN CHROMOPHORE; MISMATCHES; MECHANISM; DAMAGE; STRAND; BASES	Neocarzinostatin chromophore (NCS chrom) was found to induce site-specific cleavage at the 3' side of a bulge in single-stranded DNA in the absence of thiol. This reaction involved the oxidative formation of a DNA fragment with a nucleoside 5'-aldehyde at its 5' terminus and generated an ultraviolet light-absorbing and fluorescent species of post-activated drug containing tritium abstracted from the carbon at the 5' position of the target nucleotide. The DNAs containing point mutations that disrupt the bulge were not cleavage substrates and did not generate this drug product. Thus, DNA is an active participant in its own destruction, and NCS chrom may be useful as a probe for bulged structures in nucleic acids.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA044257] Funding Source: NIH RePORTER; NCI NIH HHS [CA44257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHIN DH, 1988, BIOCHEMISTRY-US, V27, P8106, DOI 10.1021/bi00421a020; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; HATAYAMA T, 1978, P NATL ACAD SCI USA, V75, P3603, DOI 10.1073/pnas.75.8.3603; HENSENS OD, UNPUB; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; KAPPEN LS, 1988, BIOCHEMISTRY-US, V27, P4331, DOI 10.1021/bi00412a021; KAPPEN LS, 1983, BIOCHEMISTRY-US, V22, P4872, DOI 10.1021/bi00290a002; KAPPEN LS, UNPUB; LAMOTHE M, 1993, J AM CHEM SOC, V115, P4483, DOI 10.1021/ja00064a010; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P191; MYERS AG, 1987, TETRAHEDRON LETT, V28, P4493, DOI 10.1016/S0040-4039(00)96545-6; NAPIER MA, 1983, MOL PHARMACOL, V23, P500; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; SUGIURA Y, 1989, P NATL ACAD SCI USA, V86, P7672, DOI 10.1073/pnas.86.20.7672; ZEIN N, 1993, P NATL ACAD SCI USA, V90, P2822, DOI 10.1073/pnas.90.7.2822	16	74	75	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1319	1321		10.1126/science.8362243	http://dx.doi.org/10.1126/science.8362243			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8362243				2022-12-24	WOS:A1993LV65600027
J	PEREZMORGA, DL; ENGLUND, PT				PEREZMORGA, DL; ENGLUND, PT			THE ATTACHMENT OF MINICIRCLES TO KINETOPLAST DNA NETWORKS DURING REPLICATION	CELL			English	Article							CRITHIDIA-FASCICULATA; 2 SITES; TRYPANOSOMES; LOCALIZATION	Kinetoplast DNA (kDNA), the trypanosomatid mitochondrial DNA, is a network containing several thousand interlocked minicircles. During kDNA synthesis, minicircles dissociate from the network, and after replication their progeny reattach to the network periphery. Using electron microscopy autoradiography, we found that newly synthesized H-3-labeled minicircles, after short labeling periods, are concentrated in two peripheral zones on opposite sides of the network. These must be minicircle attachment sites, adjacent to the two diametrically opposed complexes of replication proteins observed previously. From the pattern of radiolabeling during longer pulses, we reached the unexpected conclusion that minicircle attachment around the entire network periphery may be due to a relative movement of the kinetoplast and the two complexes. The kinetoplast probably rotates between two fixed complexes.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University				Perez-Morga, David/0000-0002-7168-1865	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BOUTEILLE M, 1976, J MICROSC BIOL CELL, V27, P121; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; RAUCH CA, 1993, EMBO J, V12, P403, DOI 10.1002/j.1460-2075.1993.tb05672.x; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SIMPSON L, 1974, BIOCHIM BIOPHYS ACTA, V349, P161, DOI 10.1016/0005-2787(74)90077-X; Steinert M., 1976, P193; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X	19	81	81	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					703	711		10.1016/0092-8674(93)90517-T	http://dx.doi.org/10.1016/0092-8674(93)90517-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395351				2022-12-24	WOS:A1993LU59200013
J	HUERTA, PT; LISMAN, JE				HUERTA, PT; LISMAN, JE			HEIGHTENED SYNAPTIC PLASTICITY OF HIPPOCAMPAL CA1 NEURONS DURING A CHOLINERGICALLY INDUCED RHYTHMIC STATE	NATURE			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; THETA-RHYTHM; PATTERNED STIMULATION; RECEPTOR SUBTYPES; RAT HIPPOCAMPUS; VISUAL-CORTEX; INDUCTION; RESPONSES	BRAIN cholinergic neurons are critical for memory function1,2 and their loss may contribute to memory impairment in Alzheimer's disease3. One role of cholinergic neurons is to elicit an oscillatory activity called theta rhythm4 in the hippocampus, a brain region involved in memory processing5. Theta rhythm occurs during periods of learning6,7, but its effect on the synaptic plasticity that underlies learning remains unclear. We have studied synaptic plasticity in hippocampal slices during theta-frequency oscillations induced by a cholinergic agonist8-10. Here we report that during these oscillations, synapses are in a state of heightened plasticity and can be modified by what would otherwise be ineffective stimulation. This heightened plasticity is sensitive to the timing of incoming stimuli with respect to the oscillatory activity. The results suggest that cholinergic systems may affect memory formation through the induction of an oscillatory state in which the requirements for synaptic plasticity are dramatically altered.	BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University	HUERTA, PT (corresponding author), BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA.			Huerta, Patricio/0000-0003-0270-2308				AIGNER TG, 1986, BEHAV NEURAL BIOL, V45, P81, DOI 10.1016/S0163-1047(86)80008-5; Alger B.E., 1984, BRAIN SLICES, P381; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BROCHER S, 1992, BRAIN RES, V573, P27, DOI 10.1016/0006-8993(92)90110-U; BURGARD EC, 1990, NEUROSCI LETT, V116, P34, DOI 10.1016/0304-3940(90)90382-J; CHRISTIE BR, 1992, NEURON, V9, P79, DOI 10.1016/0896-6273(92)90222-Y; Colom L V, 1991, Hippocampus, V1, P381, DOI 10.1002/hipo.450010406; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DUTAR P, 1988, J NEUROSCI, V8, P4214; EICHENBAUM H, 1987, J NEUROSCI, V7, P716; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HALLIWELL JV, 1990, PROG BRAIN RES, V84, P255; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; KONOPACKI J, 1988, BRAIN RES, V455, P110, DOI 10.1016/0006-8993(88)90119-9; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MACVICAR BA, 1989, J PHYSIOL-LONDON, V417, P197, DOI 10.1113/jphysiol.1989.sp017797; MARKRAM H, 1992, J PHYSIOL-LONDON, V447, P513, DOI 10.1113/jphysiol.1992.sp019015; MARKRAM H, 1990, J PHYSIOL-LONDON, V427, P381, DOI 10.1113/jphysiol.1990.sp018177; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SCHULZ PE, 1990, SOC NEUR ABSTR, V16, P655; Squire L. R., 1987, MEMORY BRAIN; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; TRAUB RD, 1992, J PHYSIOL-LONDON, V451, P653, DOI 10.1113/jphysiol.1992.sp019184; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	29	459	465	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					723	725		10.1038/364723a0	http://dx.doi.org/10.1038/364723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355787				2022-12-24	WOS:A1993LT67700060
J	PERRY, IJ; GOSLING, P; SANGHERA, K; CHURCHILL, D; LUESLEY, DM; BEEVERS, DG				PERRY, IJ; GOSLING, P; SANGHERA, K; CHURCHILL, D; LUESLEY, DM; BEEVERS, DG			URINARY MICROALBUMIN EXCRETION IN EARLY-PREGNANCY AND GESTATIONAL-AGE AT DELIVERY	BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN EXCRETION		SELLY OAK HOSP,DEPT BIOCHEM,BIRMINGHAM B29 6JD,ENGLAND; UNIV BIRMINGHAM,DUDLEY RD HOSP,DEPT MED,BIRMINGHAM B18 7QH,ENGLAND; UNIV BIRMINGHAM,DUDLEY RD HOSP,DEPT OBSTET,BIRMINGHAM B18 7QH,ENGLAND	University of Birmingham; University of Birmingham	PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND.			Perry, Ivan/0000-0002-4965-9792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CUNDY TF, 1992, DIABETIC MED, V9, P138, DOI 10.1111/j.1464-5491.1992.tb01750.x; LOPEZESPINOZA I, 1986, BRIT J OBSTET GYNAEC, V93, P176, DOI 10.1111/j.1471-0528.1986.tb07883.x; RODRIGUEZ MH, 1988, AM J OBSTET GYNECOL, V159, P1452, DOI 10.1016/0002-9378(88)90573-X; SALAFIA CM, 1991, AM J OBSTET GYNECOL, V165, P934, DOI 10.1016/0002-9378(91)90443-U; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					420	421		10.1136/bmj.307.6901.420	http://dx.doi.org/10.1136/bmj.307.6901.420			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374454	Bronze, Green Published			2022-12-24	WOS:A1993LR89500017
J	THOMSEN, GH; MELTON, DA				THOMSEN, GH; MELTON, DA			PROCESSED VG1 PROTEIN IS AN AXIAL MESODERM INDUCER IN XENOPUS	CELL			English	Article							MATERNAL MESSENGER-RNA; ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL POLARITY; EARLY AMPHIBIAN EMBRYOS; TGF-BETA FAMILY; DROSOPHILA EMBRYO; ACTIVIN-A; CRESCENT FORMATION; SPEMANN ORGANIZER	Vg1 is a TGFbeta-related growth factor encoded by a maternal mRNA localized to vegetal blastomeres in Xenopus embryos. Vg1 precursor protein is abundant in vegetal cells, but the processed mature form has not been readily detected and no activity has been demonstrated for the putative Vg1 mature protein. We have engineered a BMP2-Vg1 fusion (BVg1) that promotes formation of mature Vg1 protein in vivo. Injection of BVg1 mRNA induces dorsal mesoderm in animal cap cells, and BVg1 expression in ultraviolet-ventralized embryos fully restores a normal dorsal axis. Blastomeres expressing BVg1 act as a Nieuwkoop center, the region that induces the Spemann organizer. Our results lead us to suggest that localized posttranslational processing of Vg1 precursor protein on the future dorsal side of the embryo is a key step in generating dorsal mesoderm and the body axis in Xenopus.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1992, DEVELOPMENT, V115, P573; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; FERGUSON EL, 1991, CURR TOP DEV BIOL, V25, P17; GALLAGHER BC, 1991, DEVELOPMENT, V112, P1103; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1989, ANTIBODIES LABORATOR, V106, P611; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO K, 1991, METHOD CELL BIOL, V36, P271; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANES ME, 1980, ROUX ARCH DEV BIOL, V189, P73, DOI 10.1007/BF00848569; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; New HV, 1991, CURR OPIN GENET DEV, V1, P196, DOI 10.1016/S0959-437X(05)80070-X; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SAMBROOK J, 1990, MOL CLONING LABORATO; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WU M, 1991, METHOD CELL BIOL, V36, P3; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	61	390	405	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					433	441		10.1016/0092-8674(93)80045-G	http://dx.doi.org/10.1016/0092-8674(93)80045-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348610				2022-12-24	WOS:A1993LT73900005
J	GORMAN, DM				GORMAN, DM			WAR ON DRUGS CONTINUES IN UNITED-STATES UNDER NEW LEADERSHIP	BRITISH MEDICAL JOURNAL			English	Article								Criticism of the ''war on drugs'' pursued under Republican administrations has grown in the United States. With the election of Bill Clinton many experts expected a shift from law enforcement policies to an approach favouring treatment and prevention. The budget announced in April, however, revealed no such shift in allocation of resources. Although the war on drugs has apparently failed to reduce the supply of cheap heroin and cocaine to the United States, the prevention strategy favoured by its opponents-school based prevention programmes-has not yet been shown to be effective in dealing with the concentration of drug misuse among the socially disadvantaged. In looking for new strategies Clinton must satisfy both liberals and conservatives in Congress, and community policing might therefore prove to be a politically expedient option.			GORMAN, DM (corresponding author), RUTGERS UNIV,CTR ALCOHOL STUDIES,BUSCH CAMPUS,POB 969,PISCATAWAY,NJ 08855, USA.							BAGNALL G, 1991, ED YOUNG DRINKERS; CLINTON B, 1992, PUTTING PEOPLE 1ST W; Currie E., 1993, RECKONING DRUGS CITI; DUNLAP E, 1992, J PSYCHOACTIVE DRUGS, V24, P307, DOI 10.1080/02791072.1992.10471656; Dunlap E., 1992, DRUGS CRIME SOCIAL I, P181; FALCO M, 1992, MAKING DRUG FREE AM; GORMAN DM, 1992, ALCOHOL ALCOHOLISM, V27, P583; GREENE JR, 1993, DRUGS COMMUNITY INVO, P141; KANDEL DB, 1991, AM J PUBLIC HEALTH, V81, P1064, DOI 10.2105/AJPH.81.8.1064; KELLY M, 1993, NY TIMES        0523, P20; LORION RP, 1992, J COMMUNITY PSYCHOL, V20, P3, DOI 10.1002/1520-6629(199201)20:1<3::AID-JCOP2290200102>3.0.CO;2-G; MASING M, 1993, NY TIMES BOOK R 0124, P10; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; REUTER P, 1993, WASHINGTON POST 0228, P1; Skogan W. G., 1993, DRUGS COMMUNITY INVO, P162; STALEY S, 1992, DRUG POLICY DECLINE; TABOR MBW, 1992, NY TIMES        1001, P1; TIERNEY J, 1993, NY TIMES        0620, P1; TREASTER JB, 1993, NY TIMES        0428, P15; TREASTER JB, 1993, NY TIMES        0417, P1; TREASTER JB, 1992, NY TIMES        0614; TREASTER JB, 1993, NY TIME         0412, P10; TREASTER JB, 1993, NY TIMES        0424, P8; WEIGHLEY RF, 1993, NEW YORK TIMES BK R, P12; WILLIAMS T, 1992, J CONTEMP ETHNOGR, V21, P343, DOI 10.1177/089124192021003003; 1993, INT J ADDICT, V28, pR2; 1992, DRUGS CRIME JUSTICE	27	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					369	371		10.1136/bmj.307.6900.369	http://dx.doi.org/10.1136/bmj.307.6900.369			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374422	Green Published, Bronze			2022-12-24	WOS:A1993LR76800025
J	ASARNOW, DM; CADO, D; RAULET, DH				ASARNOW, DM; CADO, D; RAULET, DH			SELECTION IS NOT REQUIRED TO PRODUCE INVARIANT T-CELL RECEPTOR GAMMA-GENE JUNCTIONAL SEQUENCES	NATURE			English	Article							DELTA-ANTIGEN RECEPTORS; DIVERSITY; IDENTIFICATION; REARRANGEMENT; RECOGNITION; GENERATION; EPITHELIUM; ENHANCER; SEGMENTS; LOCUS	RECOMBINATION of V-, D- and J-gene segments can generate an enormous diversity of T-cell antigen receptor (TCR) gene sequences1,2. Although many gammadelta T cells fully exploit this diversification process, those in the epidermal and vaginal epithelium do not3,4, predominantly expressing invariant gammadelta receptors in which the V-(D)-J junctional sequences in almost all the productive rearrangements are identical. The almost exclusive use of identical TCRs by cells in these sites is thought to reflect recognition of a stress-induced autologous antigen5-8. To explain the prevalence of the invariant junctional sequences, it has been proposed that thymic selection operates on a population of originally diverse progenitor cells, resulting in a homogeneous repertoire9,10. Alternatively the invariant sequences may result from biases in the recombination machinery in the fetal thymic progenitors of these cells8,11,12. We report here the use of mice into which mutated TCR gamma-gene rearrangement substrates have been introduced as transgenes to demonstrate directly that the canonical TCR Vgamma3-Jgamma1 and Vgamma4-Jgamma1 sequences occur at high frequency in the absence of the possibility of selection for the protein products.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,489 LSA,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ENGLER P, 1992, J EXP MED, V176, P1399, DOI 10.1084/jem.176.5.1399; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GOLDMAN J, IN PRESS J EXP MED; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HELIG JS, 1986, NATURE, V322, P836; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P2204, DOI 10.1073/pnas.88.6.2204; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; NANDI D, 1991, J IMMUNOL, V147, P1773; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; SPENCER DM, 1991, P NATL ACAD SCI USA, V88, P800, DOI 10.1073/pnas.88.3.800; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	21	97	97	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					158	160		10.1038/362158a0	http://dx.doi.org/10.1038/362158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383806				2022-12-24	WOS:A1993KR02800060
J	SHAFER, MA; SCHACHTER, J; MONCADA, J; KEOGH, J; PANTELL, R; GOURLAY, L; EYRE, S; BOYER, CB				SHAFER, MA; SCHACHTER, J; MONCADA, J; KEOGH, J; PANTELL, R; GOURLAY, L; EYRE, S; BOYER, CB			EVALUATION OF URINE-BASED SCREENING STRATEGIES TO DETECT CHLAMYDIA-TRACHOMATIS AMONG SEXUALLY ACTIVE ASYMPTOMATIC YOUNG MALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ENZYME-IMMUNOASSAY; NEISSERIA-GONORRHOEAE; GENITAL SPECIMENS; ADOLESCENT MALES; MEN; URETHRITIS; ANTIGENS; INFECTIONS; DIAGNOSIS	Objective.-To evaluate the performances of diagnostic screening tests alone or in combination to detect asymptomatic chlamydial urethral infection in young males. Design.-Comparisons of the performance profiles of the following chlamydia screening strategies were done: urethral culture; identification of polymorphonucleocytes (PMNs) on spun first-void urine (FVU); urinary leukocyte esterase test (LET) on unspun FVU; chlamydial enzyme immunoassay (EIA) applied to FVU sediment; combining LET on unspun FVU followed by EIA with or without direct fluorescent antibody (DFA) confirmation on FVU sediment; and combining PMNs on spun FVU followed by EIA with or without DFA confirmation. Setting.-General clinics at a youth detention center, university-based teen clinic, college health service, and a military screening clinic. Patients.-A total of 618 males aged 12 to 35 years (mean, 17 years) were recruited as a convenience sample; site participation rates ranged from 50% to 80%. Eligible subjects were sexually active, denied symptoms of urethritis, and had taken no antibiotics in the prior 2 weeks. Main Outcome Measures.-Sensitivity, specificity, and positive and negative predictive values of each test strategy's ability to detect Chlamydia trachomatis infection, and cost to confirm each positive case. Results.-With a 7% prevalence of chlamydial infection, tissue culture had a sensitivity of only 61%. However, two strategies yielded significantly better performance profiles compared with the others: EIA confirmed by DFA test with a sensitivity of 84%, a specificity of 100%, and a cost to identify each positive case of $434; and PMNs followed by EIA confirmed by DFA test with a sensitivity of 78%, a specificity of 100%, and a cost to identify each positive case of $199. The LET followed by EIA-DFA had a similar performance profile to the PMN test strategies. Conclusions.-A combination of a nonspecific screening of FVU for PMNs or LET followed by specific testing with EIA with DFA confirmation has superior clinical and cost-effective performance for detecting asymptomatic C trachomatis urethritis in young males compared with other strategies. However, an evaluation of the medical, fiscal, and psychological benefits and risks associated with a specific screening strategy for sexually transmitted diseases must be made before adopting a specific strategy for a particular population.	MED INTELLIGENCE,CAMBRIDGE,MA; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SHAFER, MA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV ADOLESCENT MED,400 PARNASSUS AVE,ROOM AC-01,BOX 0374,SAN FRANCISCO,CA 94143, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028481] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28481] Funding Source: Medline; NICHD NIH HHS [R01-HD-24801] Funding Source: Medline; PHS HHS [CCR902728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADGER H, 1984, LANCET, V2, P944; BOWIE WR, 1990, SEXUALLY TRANSMITTED, P627; Cates Jr, 1990, Adolesc Med, V1, P409; CHERNESKY M, 1990, J INFECT DIS, V161, P124; CHERNESKY MA, 1986, J INFECT DIS, V154, P141, DOI 10.1093/infdis/154.1.141; CLARK A, 1992, J CLIN MICROBIOL, V30, P2762, DOI 10.1128/JCM.30.11.2762-2764.1992; FERRIS DG, 1991, J FAM PRACTICE, V33, P73; GAYDOS CA, 1990, J CLIN MICROBIOL, V28, P1541, DOI 10.1128/JCM.28.7.1541-1544.1990; JASCHEK O, 1993, J CLIN MICROBIOL, V31, P1209; JENSEN IP, 1992, SEX TRANSM DIS, V19, P165, DOI 10.1097/00007435-199205000-00011; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; LOEFFELHOLZ MJ, 1992, J CLIN MICROBIOL, V30, P2847, DOI 10.1128/JCM.30.11.2847-2851.1992; MONCADA J, 1992, J DIAGN MICROBIOL IN, V15, P663; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PODGARE J, 1982, J INFECT DIS, V148, P828; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; SCHWEBKE JR, 1991, J CLIN MICROBIOL, V29, P2446, DOI 10.1128/JCM.29.11.2446-2449.1991; SELLORS J, 1991, J CLIN MICROBIOL, V29, P407, DOI 10.1128/JCM.29.2.407-409.1991; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; SHAFER MA, 1987, J INFECT DIS, V156, P223, DOI 10.1093/infdis/156.1.223; STAMM WE, 1984, ANN INTERN MED, V100, P47, DOI 10.7326/0003-4819-100-1-47; WERNER MJ, 1991, J ADOLESCENT HEALTH, V12, P326, DOI 10.1016/0197-0070(91)90008-A; WU CH, 1992, SEX TRANSM DIS, V19, P193, DOI 10.1097/00007435-199207000-00002	23	63	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2065	2070		10.1001/jama.270.17.2065	http://dx.doi.org/10.1001/jama.270.17.2065			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411573				2022-12-24	WOS:A1993MD88200025
J	ATKINSON, RL				ATKINSON, RL			PROPOSED STANDARDS FOR JUDGING THE SUCCESS OF THE TREATMENT OF OBESITY	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CALORIE DIET; WEIGHT	The purpose of this report is to propose standards for the successful treatment of obesity. This process is somewhat arbitrary because obesity is a multifactorial disease and because standards need revision as diagnostic and treatment techniques improve. Weight loss, the classic standard of success, does not account for individual variability. Reduction in other measures of body size, such as body mass index, percentage of excess weight, and body fat, may be preferable. Improvement in known complications of obesity (diabetes mellitus, hypertension, hyperlipoproteinemia, sleep apnea, and psychosocial problems) are equally valid measures of success. Because obesity is a chronic disease, maintenance of weight loss is included as a standard of success. Response to obesity treatment varies, and thus criteria to define minimal, intermediate, and full success for each variable are necessary.			ATKINSON, RL (corresponding author), DEPT VET AFFAIRS MED CTR, MED RES SERV, HAMPTON, VA 23667 USA.		Atkinson, Richard/AAK-4953-2021					ANDERSEN T, 1988, INT J OBESITY, V12, P277; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; Bray GA., 1976, OBESE PATIENT, P215; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MILLER A, 1974, AM J MED, V56, P144, DOI 10.1016/0002-9343(74)90591-9; PORIES WJ, 1992, AM J CLIN NUTR, V55, P582; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; Stunkard AJ., 1976, PAIN OBESITY; WADDEN TA, 1989, INT J OBESITY, V13, P39; 1959, STAT B METROP LIFE F, V40, P1; 1985, ANN INTERN MED, V103, P977; 1980, HLTH NUTRITION EXAMI; 1989, DIET HLTH IMPLICATIO, P99	15	49	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				677	680		10.7326/0003-4819-119-7_Part_2-199310011-00010	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363196				2022-12-24	WOS:A1993MA33000010
J	SANCHO, S; MONGINI, T; TANJI, K; TAPSCOTT, SJ; WALKER, WF; WEINTRAUB, H; MILLER, AD; MIRANDA, AF				SANCHO, S; MONGINI, T; TANJI, K; TAPSCOTT, SJ; WALKER, WF; WEINTRAUB, H; MILLER, AD; MIRANDA, AF			ANALYSIS OF DYSTROPHIN EXPRESSION AFTER ACTIVATION OF MYOGENESIS IN AMNIOCYTES, CHORIONIC-VILLUS CELLS, AND FIBROBLASTS - A NEW METHOD FOR DIAGNOSING DUCHENNE MUSCULAR-DYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL MUSCLE BIOPSY; PRENATAL-DIAGNOSIS; CDNA ANALYSIS; GENE; POLYMORPHISMS; DELETIONS; PROTEIN; POINT; LINES; MYOD	Background. DNA analysis of peripheral-blood leukocytes is routinely used to demonstrate mutations in the dystrophin gene in patients with Duchenne's or Becker's muscular dystrophy. In approximately 35 percent of patients, DNA studies are not informative; in these patients immunochemical analysis of a muscle-biopsy specimen can determine whether dystrophin, the protein product of the gene for Duchenne's dystrophy, is present at reduced levels or absent. DNA analysis can be performed in amniocytes or chorionic-villus cells to identify mutations of the dystrophic gene prenatally, but immunochemical testing for dystrophin cannot be performed because the protein is not expressed in these cells. Methods. To circumvent this limitation in prenatal diagnosis, we induced myogenesis in 21 cultures of skin fibroblasts, 49 amniocyte cultures, and 6 chorionic-villus cell cultures by infecting the cells with a retrovirus vector containing MyoD, a gene regulating myogenesis. Transfection of MyoD into cells that do not normally develop into muscle cells results in the production of a protein that switches on myogenesis. We performed immunocytochemical analysis for dystrophin in the MyoD-converted muscle cells. Results. We found that 60 of 61 myotube cultures from subjects with no family history of Duchenne's dystrophy expressed dystrophin. Both myotube cultures from the two patients with Becker's dystrophy also expressed dystrophin, but all cultures from nine patients and two fetuses with Duchenne's dystrophy were dystrophin-deficient. Conclusions. Immunocytochemical analysis of dystrophin in genetically altered non-muscle cells is feasible and may be applicable to the prenatal and postnatal diagnosis of Duchenne's muscular dystrophy when conventional DNA analysis is not informative.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; UNIV TURIN,NEUROL CLIN 2,I-10124 TURIN,ITALY; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104	Columbia University; Columbia University; University of Turin; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center			Mongini, Tiziana/E-9257-2012	Miller, Dusty/0000-0002-3736-3660	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045203] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Fondazione Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BYERS TJ, 1992, NEUROLOGY, V42, P570; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; EVANS MI, 1991, AM J OBSTET GYNECOL, V165, P728, DOI 10.1016/0002-9378(91)90318-L; FEENER CA, 1991, AM J HUM GENET, V48, P621; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1989, AM J HUM GENET, V45, P498; KULLER JA, 1992, HUM GENET, V90, P34; LEV AA, 1987, J BIOL CHEM, V262, P15817; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIRANDA AF, 1990, ADV EXP MED BIOL, V280, P205; MIRANDA AF, 1988, AM J PATHOL, V132, P410; MIRANDA AF, 1979, MUSCLE REGENERATION, P453; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1991, AM J HUM GENET, V49, P298; SKLAR RM, 1990, NEUROLOGY, V40, P1854, DOI 10.1212/WNL.40.12.1854; SPECHT LA, 1993, MOL GENETIC BASIS NE, P613; WARD PA, 1989, AM J HUM GENET, V44, P270; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	26	34	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					915	920		10.1056/NEJM199309233291303	http://dx.doi.org/10.1056/NEJM199309233291303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361505	Bronze			2022-12-24	WOS:A1993LX75100003
J	LUCARELLI, G; GALIMBERTI, M; POLCHI, P; ANGELUCCI, E; BARONCIANI, D; GIARDINI, C; ANDREANI, M; AGOSTINELLI, F; ALBERTINI, F; CLIFT, RA				LUCARELLI, G; GALIMBERTI, M; POLCHI, P; ANGELUCCI, E; BARONCIANI, D; GIARDINI, C; ANDREANI, M; AGOSTINELLI, F; ALBERTINI, F; CLIFT, RA			MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLOPHOSPHAMIDE; GRAFT	Background. Patients with homozygous beta-thalassemia, who have a good prognosis during treatment with conventional therapy, appear to have an especially high probability of hematologic cure with bone marrow transplantation, although the morbidity and mortality associated with such treatment are not established. Methods. The records of all patients with thalassemia who received bone marrow transplants from HLA-identical donors in Pesaro, Italy, were examined from October 1982 through May 1992. Detailed evaluation of the outcome was conducted in the 89 patients identified as being in class 1 according to the Pesaro classification, in which hepatomegaly, portal fibrosis, and the inadequacy of iron chelation therapy are considered independent risk factors, and the patients are classified as being in class 1 if none of these factors are present, class 2 if one or two of the factors are present, and class 3 if all three factors are present. Sixty-four of the patients had been prepared for transplantation with a drug regimen in current use that includes busulfan and cyclophosphamide followed by cyclosporine as prophylaxis against acute graft-versus-host disease (protocol 6). Results. There were seven deaths, all within 101 days of transplantation. Two of the 64 patients treated according to protocol 6 died. The probabilities of survival, rejection-free survival, death from causes unrelated to rejection, and rejection were 0.92, 0.85, 0.06, and 0.08, respectively, in the total group and 0.97, 0.93, 0.03, and 0.04 in the 64 patients treated according to protocol 6. Preliminary evidence suggests that there was useful unloading of tissue iron deposits. Conclusions. The high probability of cure with little early or late morbidity and mortality suggests that patients with class 1 thalassemia who have HLA-identical donors available should be treated by bone marrow transplantation. However, this was not a controlled trial, so we cannot directly compare the outcome with that of conventional treatment.	OSPED PESARO, CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA, PESARO, ITALY; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; OSPED PESARO, DIV EMATOL, PESARO, ITALY	Fred Hutchinson Cancer Center			Andreani, Marco/AAA-5208-2020; Angelucci, Emanuele/AAC-1855-2021	Andreani, Marco/0000-0003-3451-3624; Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1992, BLOOD, V80, P1603; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Muretto P, 1989, Prog Clin Biol Res, V309, P299; NESCI S, 1992, BONE MARROW TRANSPL, V10, P143; OLIVIERI NF, 1990, BLOOD S, V76, pA559; SANTOS GW, 1989, BONE MARROW TRANSPL, V4, P236; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; STORB R, 1991, BLOOD, V78, P1144, DOI 10.1182/blood.V78.4.1144.bloodjournal7841144; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; WEATHERALL D, 1992, BLOOD, V80, P1379	17	192	194	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					840	844		10.1056/NEJM199309163291204	http://dx.doi.org/10.1056/NEJM199309163291204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355742				2022-12-24	WOS:A1993LW55100004
J	BENNER, SA				BENNER, SA			CATALYSIS - DESIGN VERSUS SELECTION	SCIENCE			English	Editorial Material							ENZYMATIC INCORPORATION; BASE PAIR; RNA; DNA				BENNER, SA (corresponding author), SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND.							ALLENMANN RK, 1989, THESIS EIDGENOSSISCH; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CAMPBELL AP, IN PRESS P NATL ACAD; CHAKRAVARTY PK, 1973, EXPERIENTIA, V29, P786, DOI 10.1007/BF01946284; GILBERT W, 1986, NATURE, V319, P818; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; JOHNSSON K, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P166; JOHNSSON K, 1992, THESIS EIDGENOSSISCH; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIOTTA LJ, 1993, J AM CHEM SOC, V115, P350, DOI 10.1021/ja00054a053; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; Rich A., 1962, HORIZONS BIOCH, P103; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; VONKIEDROWSKI G, 1992, NACHR CHEM TECH LAB, V40, P578; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468	21	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1402	1403		10.1126/science.8367723	http://dx.doi.org/10.1126/science.8367723			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367723				2022-12-24	WOS:A1993LW54900021
J	SPENGLER, D; WAEBER, C; PANTALONI, C; HOLSBOER, F; BOCKAERT, J; SEEBURG, PH; JOURNOT, L				SPENGLER, D; WAEBER, C; PANTALONI, C; HOLSBOER, F; BOCKAERT, J; SEEBURG, PH; JOURNOT, L			DIFFERENTIAL SIGNAL-TRANSDUCTION BY 5 SPLICE VARIANTS OF THE PACAP RECEPTOR	NATURE			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; METABOTROPIC GLUTAMATE RECEPTORS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; SYMPATHETIC NEUROBLASTS; CALCIUM RELEASE; BINDING-SITES; RAT-BRAIN; EXPRESSION; PEPTIDE	THE two forms of pituitary adenylyl cyclase-activating polypeptide (PACAP-27 and -38) are neuropeptides of the secretin/glucagon/vasoactive intestinal polypeptide/growth-hormone-releasing hormone family and regulate hormone release from the pituitary and adrenal gland1-3. They may also be involved in spermatogenesis4, and PACAP-38 potently stimulates neuritogenesis and survival of cultured rat sympathetic neuroblast5,6 and promotes neurite outgrowth of PC-12 cells7. The PACAP type-I receptor (found in hypothalamus, brain stem, pituitary, adrenal gland and testes), specific for PACAP, is positively coupled to adenylyl cyclase and phospholipase C. The recently cloned type II receptor does not discriminate between PACAP and vasoactive intestinal polypeptide and is coupled to only adenylyl cyclase8. Here we have used a new expression cloning strategy, based on the induction of a reporter gene by cyclic AMP, to isolate a complementary DNA encoding the type-I PACAP receptor. On transfection of this cDNA, both PACAP-27 and -38 stimulate adenylyl cyclase with similar EC50 values (50% effective concentration, 0.1-0.4 nM), whereas only PACAP-38 stimulates phospholipase C with high potency (EC50 = 15 nM). Four other splice variants were isolated with insertions at the C-terminal end of the third intracellular loop. Expression of these cDNAs revealed altered patterns of adenylyl cyclase and phospholipase C stimulation, suggesting a novel mechanism for fine tuning of signal transduction.	CCIPE,CNRS,UPR 9023,RUE CARDONILLE,F-34094 MONTPELLIER 05,FRANCE; UNIV HEIDELBERG,ZMBH,MOLEC NEUROENDOCRINOL LAB,W-6900 HEIDELBERG 1,GERMANY; MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,W-8000 MUNICH 40,GERMANY	Centre National de la Recherche Scientifique (CNRS); Ruprecht Karls University Heidelberg; Max Planck Society			Waeber, Christian/B-3171-2016; Journot, Laurent/T-9652-2018; Waeber, Christian/A-8333-2009	Waeber, Christian/0000-0001-6078-0027; Journot, Laurent/0000-0003-3499-8887; Waeber, Christian/0000-0001-6078-0027				ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; COLSON P, 1992, AM J PHYSIOL, V263, pE1054; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; GAYLINN BD, 1993, MOL ENDOCRINOL, V7, P77, DOI 10.1210/me.7.1.77; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GOTTSCHALL PE, 1991, FASEB J, V5, P194, DOI 10.1096/fasebj.5.2.1848519; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KOCH B, 1992, REGUL PEPTIDES, V38, P45, DOI 10.1016/0167-0115(92)90071-2; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MENGOD G, 1991, MOL BRAIN RES, V10, P185, DOI 10.1016/0169-328X(91)90110-J; MINKES RK, 1992, AM J PHYSIOL, V263, pH1659, DOI 10.1152/ajpheart.1992.263.6.H1659; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W	33	1127	1138	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					170	175						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8396727				2022-12-24	WOS:A1993LW44200051
J	WANG, H; KUNKEL, DD; MARTIN, TM; SCHWARTZKROIN, PA; TEMPEL, BL				WANG, H; KUNKEL, DD; MARTIN, TM; SCHWARTZKROIN, PA; TEMPEL, BL			HETEROMULTIMERIC K+ CHANNELS IN TERMINAL AND JUXTAPARANODAL REGIONS OF NEURONS	NATURE			English	Article							POTASSIUM-CHANNEL; SODIUM-CHANNELS; ION CHANNELS; FIBERS; SHAKER; BRAIN	VOLTAGE-GATED potassium (K+) channels display a wide variety of conductances and gating properties in vivo1-3. This diversity can be attributed not only to the presence of many K+-channel gene products, but also to the possibility that different K+-channel subunits co-assemble to form heteromultimeric channels in vivo. When expressed in Xenopus oocytes or transfected cells, K+-channel polypeptides assemble to form tetramers4. Certain combinations of Shaker-like subunits have been shown to co-assemble, forming heteromultimeric channels with distinct properties5-7. It is not known, however, whether K+-channel polypeptides form heteromultimeric channels in vivo. Here we describe the co-localization of two Shaker-like voltage-gated K+-channel proteins, mKv1.1 and mKv1.2, in the juxtaparanodal regions of nodes of Ranvier in myelinated axons, and in terminal fields of basket cells in mouse cerebellum. We also show that mKv1.1 and mKv1.2 can be co-immunoprecipitated with specific antibodies that recognize only one of them. These data indicate that the two polypeptides occur in subcellular regions where rapid membrane repolarization may be important and that they form heteromultimeric channels in vivo.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN 182-B,SEATTLE,WA 98108; UNIV WASHINGTON,SCH MED,DEPT MED & PHARMACOL SJ30,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT NEUROL SURG & PHYSIOL BIOPHYS RI20,SEATTLE,WA 98195	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLACK JA, 1989, GLIA, V2, P353, DOI 10.1002/glia.440020508; BOSMA MM, 1993, NEUR ABSTR, V19, P712; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; HARLOW E, 1988, ANTIBODIES LABORATOR; Hille B., 1991, IONIC CHANNELS EXCIT; HOPKINS WF, IN PRESS J NEUROSCI; HOPKINS WF, 1993, NEUR ABSTR, V19, P707; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KUNKEL DD, 1993, MICROSC RES TECHNIQ, V24, P67, DOI 10.1002/jemt.1070240107; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; OERTEL WH, 1981, NEUROSCIENCE, V6, P2715, DOI 10.1016/0306-4522(81)90115-9; Palay S. L., 1974, CEREBELLAR CORTEX CY; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; ROPER J, 1989, J PHYSIOL-LONDON, V416, P93; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SAFRONOV BV, 1993, J PHYSIOL-LONDON, V460, P675, DOI 10.1113/jphysiol.1993.sp019493; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; WILSON GF, 1990, J NEUROSCI, V10, P3263	27	529	532	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					75	79		10.1038/365075a0	http://dx.doi.org/10.1038/365075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361541				2022-12-24	WOS:A1993LV64600058
J	GILFILLAN, S; DIERICH, A; LEMEUR, M; BENOIST, C; MATHIS, D				GILFILLAN, S; DIERICH, A; LEMEUR, M; BENOIST, C; MATHIS, D			MICE LACKING TDT - MATURE ANIMALS WITH AN IMMATURE LYMPHOCYTE REPERTOIRE	SCIENCE			English	Article							T-CELL RECEPTOR; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; N-REGION DIVERSITY; PRE-B-CELLS; JUNCTIONAL DIVERSITY; SEQUENCE HOMOLOGIES; ANTIGEN RECEPTORS; CHAIN DIVERSITY; EXPRESSION; THYMUS	In adult animals, template-independent (or N) nucleotides are frequently added during the rearrangement of variable (V), diversity (D), and joining (J) segments of lymphocyte receptor genes, greatly enhancing junctional diversity. Receptor genes from adult mice carrying a mutation in the terminal deoxynucleotidyl transferase (TdT) gene have few N nucleotides, providing proof that this enzyme is essential for creating diversity. Unlike those from normal adults, receptor genes from adult mutant mice show extensive evidence of homology-directed recombination, suggesting that TdT blocks this process. Thus, switch-on of the TdT gene during the first week after birth provokes an even greater expansion of lymphocyte receptor diversity than had previously been thought.	INST CHIM BIOL,INSERM,U184,UNITE BIOL MOLEC,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	GILFILLAN, S (corresponding author), INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.							AGUILAR LK, 1991, J IMMUNOL, V146, P1348; ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BENOIST C, 1992, CURR OPIN IMMUNOL, V4, P2; BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; BOGUE M, 1991, EMBO J, V10, P3647, DOI 10.1002/j.1460-2075.1991.tb04931.x; Bollum F.J., 1974, ENZYMES, P145; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CARLSSON L, 1990, INT IMMUNOL, V2, P639, DOI 10.1093/intimm/2.7.639; CARLSSON L, 1992, INT IMMUNOL, V4, P549, DOI 10.1093/intimm/4.5.549; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; ELLIOTT JF, 1988, NATURE, V331, P627; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FEENEY AJ, 1991, J EXP MED, V174, P115, DOI 10.1084/jem.174.1.115; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GEORGE JF, 1992, J IMMUNOL, V148, P1230; GILFILLAN S, UNPUB; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LAFAILLE JJ, 1990, IMMUNOL TODAY, V11, P75, DOI 10.1016/0167-5699(90)90030-D; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MCCORMACK WT, 1991, P NATL ACAD SCI USA, V88, P7699, DOI 10.1073/pnas.88.17.7699; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHLEUSSNER C, 1992, THYMUS, V20, P195; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	37	350	354	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1175	1178		10.1126/science.8356452	http://dx.doi.org/10.1126/science.8356452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356452				2022-12-24	WOS:A1993LU58600034
J	WHITFIELD, LS; LOVELLBADGE, R; GOODFELLOW, PN				WHITFIELD, LS; LOVELLBADGE, R; GOODFELLOW, PN			RAPID-SEQUENCE EVOLUTION OF THE MAMMALIAN SEX-DETERMINING GENE SRY	NATURE			English	Article							Y-CHROMOSOME; NUCLEOTIDE SUBSTITUTION; DETERMINING REGION; DNA; SELECTION; PROTEIN; ZFY	IN mammals, induction of male sex determination requires the Y-chromosome gene SRY1. SRY encodes a protein with a central 'high mobility group' domain (HMG box) of about 78 amino acids1-3 . HMG boxes are found in a wide variety of proteins that bind to DNA with high affinity but differing degrees of sequence specificity4. The human SRY protein binds to linear DNA with sequence specificity5 and to cruciform DNA structures without sequence specificity6. The DNA-binding activity of the SRY protein resides in the HMG box and mutations in this region are associated with sex reversal in XY females6-8. No function has been ascribed to the portions of the SRY protein outside the HMG box. SRY belongs to a family of genes that are related by sequence homology within the DNA-binding domain: the genes most similar to SRY (>60%) have been named SOX genes (SRY box genes). None of the known SOX genes is homologous to SRY outside the HMG-box region. Although SRY is an important developmental regulator, its sequence is poorly conserved between species apart from the HMG-box domain. Here we investigate the coding sequence of SR Y in primates and find that evolution has been rapid in the regions flanking the conserved domain. The high degree of sequence divergence and the frequency of non-synonymous mutations suggest either that the majority of the coding sequence has no functional significance or that directional selection has occurred.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research	WHITFIELD, LS (corresponding author), UNIV CAMBRIDGE, DEPT GENET, DOWNING ST, CAMBRIDGE CB2 2EH, ENGLAND.			Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; Felsenstein J, 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1991, GENETICS, V127, P345; HUGHES AL, 1990, MOL BIOL EVOL, V7, P515; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LI WH, 1985, MOL BIOL EVOL, V2, P150; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; PALMER MS, 1990, P NATL ACAD SCI USA, V87, P1681, DOI 10.1073/pnas.87.5.1681; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SU H, 1993, AM J HUM GENET, V52, P24; 1991, GCG PROGRAM MANUAL G	22	338	371	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					713	715		10.1038/364713a0	http://dx.doi.org/10.1038/364713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355783				2022-12-24	WOS:A1993LT67700056
J	CHUNG, JH; WHITELEY, M; FELSENFELD, G				CHUNG, JH; WHITELEY, M; FELSENFELD, G			A 5' ELEMENT OF THE CHICKEN BETA-GLOBIN DOMAIN SERVES AS AN INSULATOR IN HUMAN ERYTHROID-CELLS AND PROTECTS AGAINST POSITION EFFECT IN DROSOPHILA	CELL			English	Article							LOCUS-CONTROL REGION; DOMINANT CONTROL REGION; TOPOISOMERASE-II SITES; GENE-EXPRESSION; WHITE GENE; HYPERSENSITIVE SITES; ACTIVATION REGION; SENSITIVE DOMAIN; CHROMATIN DOMAIN; TRANSGENIC MICE	We have characterized an element near the 5' boundary of the chicken beta-globin domain that insulates a reporter gene from the activating effects of a nearby beta-globin locus control region (5'HS2) when assayed in the human erythroid cell line K562. We show that the insulation mechanism is directional, that it operates at the level of transcription, and that it involves the alteration of chromatin structure over the promoter of the gene. The insulator has no significant stimulatory or inhibitory effects of its own. In transgenic Drosophila, the insulator protects the white minigene from position effects. The action of the insulator thus is not restricted to erythroid or mammalian cells, suggesting that such elements may serve an important and widely distributed function in the organization of chromatin structure.	US FDA,DIV CELLULAR & GENE THERAPY,BETHESDA,MD 20892	US Food & Drug Administration (FDA)	CHUNG, JH (corresponding author), NIH,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; JIMENEZ G, 1992, NUCLEIC ACIDS RES, V20, P5797, DOI 10.1093/nar/20.21.5797; KASSIS JA, 1991, GENETICS, V128, P751; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PSRADLING AC, 1985, DROSOPHILA PRACTICAL, P175; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; RENKAWITZ R, 1990, TRENDS GENET, V6, P162; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; STALDER J, 1980, CELL, V20, P451, DOI 10.1016/0092-8674(80)90631-5; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANHOLDE KE, 1989, CHROMATIN, P355; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7	51	755	820	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					505	514		10.1016/0092-8674(93)80052-G	http://dx.doi.org/10.1016/0092-8674(93)80052-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348617				2022-12-24	WOS:A1993LT73900012
J	VERITY, CM; ROSS, EM; GOLDING, J				VERITY, CM; ROSS, EM; GOLDING, J			OUTCOME OF CHILDHOOD STATUS EPILEPTICUS AND LENGTHY FEBRILE CONVULSIONS - FINDINGS OF NATIONAL COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; SEIZURES; MORTALITY; EPILEPSY; BIRTH; LIFE	Objective-To study outcome after lengthy febrile convulsions and status epilepticus in children. Design-Population based birth cohort study. Setting-The child health and education study (16 004 neonatal survivors born in one week in April 1970). Subjects-Information available for 14 676 children. Outcome measures-Clinical information and tests of intellectual performance at five and 10 years after birth. Results-19 children had lengthy febrile convulsions and 18 had status epilepticus. Two children with status epilepticus died (one at 5 years old); neither death was directly due to the status epilepticus. Four of the 19 (21%) developed afebrile seizures after lengthy febrile convulsions compared with 14 of the 17 (82%) survivors after status epilepticus. Measures of intellectual performance were available for 33 of the 35 survivors: 23 were normal and 10 were not normal but eight of them had preceding developmental delay or neurological abnormality. Conclusion-The outcome in children after lengthy febrile convulsions and status epilepticus is better than reported from studies of selected groups and seems determined more by the underlying cause than by the seizures themselves.	UNIV LONDON KINGS COLL HOSP, DEPT COMMUNITY PAEDIAT, LONDON SE5 8RX, ENGLAND; UNIV BRISTOL, INST CHILD HLTH, DEPT PAEDIAT & PERINATAL EPIDEMIOL, BRISTOL BS8 1TH, AVON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				AICARDI J, 1971, DEV MED CHILD NEUROL, V13, P660; AICARDI J, 1970, EPILEPSIA, V11, P187, DOI 10.1111/j.1528-1157.1970.tb03880.x; Aicardi J, 1983, Adv Neurol, V34, P115; [Anonymous], 1981, Epilepsia, V22, P489; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; Corsellis J A, 1983, Adv Neurol, V34, P129; DUNN DW, 1988, J CHILD NEUROL, V3, P167, DOI 10.1177/088307388800300303; ELLENBERG JH, 1986, NEW ENGL J MED, V314, P1085, DOI 10.1056/NEJM198604243141705; ELLENBERG JH, 1978, ARCH NEUROL-CHICAGO, V35, P17, DOI 10.1001/archneur.1978.00500250021004; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FOWLER M, 1957, ARCH DIS CHILD, V32, P67, DOI 10.1136/adc.32.162.67; FREEMAN JM, 1989, PEDIATRICS, V83, P444; HAUSER WA, 1990, NEUROLOGY, V40, P9; LEPPIK IE, 1990, NEUROLOGY, V40, P4; LOTHMAN E, 1990, NEUROLOGY, V40, P13; MAYTAL J, 1989, PEDIATRICS, V83, P323; MAYTAL J, 1990, PEDIATRICS, V86, P611; NELSON KB, 1978, PEDIATRICS, V61, P720; OXBURY JM, 1971, BRAIN, V94, P733, DOI 10.1093/brain/94.4.733; PHILLIPS SA, 1989, ARCH NEUROL-CHICAGO, V46, P74, DOI 10.1001/archneur.1989.00520370076023; SOFFER D, 1986, ANN NEUROL, V20, P737, DOI 10.1002/ana.410200616; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857; WALLACE SJ, 1979, DEV MED CHILD NEUROL, V21, P28; YAGER JY, 1988, CAN J NEUROL SCI, V15, P402, DOI 10.1017/S0317167100028134; 1987, LANCET, V1, P958; [No title captured]	29	134	135	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					225	228		10.1136/bmj.307.6898.225	http://dx.doi.org/10.1136/bmj.307.6898.225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369681	Bronze, Green Published			2022-12-24	WOS:A1993LP31400019
J	RUEL, L; BOUROUIS, M; HEITZLER, P; PANTESCO, V; SIMPSON, P				RUEL, L; BOUROUIS, M; HEITZLER, P; PANTESCO, V; SIMPSON, P			DROSOPHILA SHAGGY KINASE AND RAT GLYCOGEN-SYNTHASE KINASE-3 HAVE CONSERVED ACTIVITIES AND ACT DOWNSTREAM OF NOTCH	NATURE			English	Article							PRONEURAL CLUSTERS; GENE; PROTEIN; EXPRESSION; PRODUCT; HOMOLOG; LOCUS; SEQUENCE; REPEATS; CELLS	DURING neurogenesis in Drosophila, groups of equipotential, neurally competent cells choose between epidermal and neural fates1-4. Notch, a phylogenetically conserved transmembrane protein5-9, may act as a receptor4,10 in a lateral signalling pathway in which a single neural precursor is chosen from each group and the neural fate of the other cells is inhibited, causing them to differentiate into epidermis11-13. Possible intracellular trans duction events mediating signals from Notch are, however, unknown. shaggy is also required for the lateral signal4,14 and encodes serine/threonine protein kinases15,16 with homology to the glycogen synthase kinase-3 (GSK-3) enzymes17 that act in signal transduction pathways in vertebrates17. We report here that, in transgenic flies, GSK-3beta can substitute for shaggy, and we also present a study of epistatic relationships between shaggy and gain and loss of function alleles of Notch. The results indicate that shaggy/GSK-3 is part of a signalling pathway downstream of Notch.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAMPOSORTEGA J, IN PRESS DEV DROSOPH; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HEITZLER P, IN PRESS DEVELOPMENT; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUEL L, IN PRESS EMBO J; SAKSELA K, 1992, ONCOGENE, V7, P347; SEKATH JB, 1992, DEVELOPMENT, V114, P939; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STERN CURT, 1954, AMER SCI, V42, P213; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	28	186	188	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					557	560		10.1038/362557a0	http://dx.doi.org/10.1038/362557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8385271				2022-12-24	WOS:A1993KW45300059
J	BAINTON, RJ; KUBO, KM; FENG, JN; CRAIG, NL				BAINTON, RJ; KUBO, KM; FENG, JN; CRAIG, NL			TN7 TRANSPOSITION - TARGET DNA RECOGNITION IS MEDIATED BY MULTIPLE TN7-ENCODED PROTEINS IN A PURIFIED INVITRO SYSTEM	CELL			English	Article							MU-B-PROTEIN; ESCHERICHIA-COLI; STRAND-TRANSFER; GEL-ELECTROPHORESIS; A-PROTEIN; SEQUENCE; ENDS; PURIFICATION; IMMUNITY; CLEAVAGE	We have reconstituted the transposition of the bacterial transposon Tn7 into its specific insertion site attTn7 with four purified Tn7-encoded proteins, TnsA+TnsB+ TnsC+TnsD, and ATP. TnsA+TnsB+TnsC form a ''core'' recombination machine that recognizes the transposon ends and executes DNA breakage and joining; TnsD specifically recognizes attTn7. TnsA+TnsB+TnsC are specifically targeted to attTn7 through the TnsD-dependent interaction of TnsC, a nonspecific DNA-binding protein, with attTn7. Recombination appears to be activated by the assembly of a nucleoprotein complex containing the DNA substrates and Tns proteins. We suggest that TnsC plays a central role in communication between the transposon and the target DNA, particularly in directing insertion away from DNAs already containing a copy of Tn7.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	BAINTON, RJ (corresponding author), UNIV CALIF SAN FRANCISCO, GEORGE W HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ARCISZEWSKA LK, 1991, J BIOL CHEM, V266, P21736; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BARTH PT, 1976, J BACTERIOL, V125, P800, DOI 10.1128/JB.125.3.800-810.1976; Berg D. E., 1989, MOBILE DNA; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1992, NUCLEIC ACIDS RES, V20, P2525, DOI 10.1093/nar/20.10.2525; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GRINGAUZ E, 1988, J BACTERIOL, V170, P2832, DOI 10.1128/jb.170.6.2832-2840.1988; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1983, P NATL ACAD SCI-BIOL, V80, P6765, DOI 10.1073/pnas.80.22.6765; LICHTENSTEIN C, 1982, NATURE, V297, P601, DOI 10.1038/297601a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKOWN RL, 1988, J BACTERIOL, V170, P352, DOI 10.1128/jb.170.1.352-358.1988; MCKOWN RL, 1987, P NATL ACAD SCI USA, V84, P7807, DOI 10.1073/pnas.84.22.7807; ORLE KA, 1991, GENE, V104, P125, DOI 10.1016/0378-1119(91)90478-T; QADRI MI, 1989, J MOL BIOL, V207, P85, DOI 10.1016/0022-2836(89)90442-7; ROBINSON MK, 1977, J BACTERIOL, V129, P407, DOI 10.1128/JB.129.1.407-414.1977; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; SHAND RF, 1991, BIOCHEMISTRY-US, V30, P3082, DOI 10.1021/bi00226a015; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; TANG Y, 1991, NUCLEIC ACIDS RES, V19, P3395, DOI 10.1093/nar/19.12.3395; WADDELL CS, 1989, P NATL ACAD SCI USA, V86, P3958, DOI 10.1073/pnas.86.11.3958; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119	45	140	144	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					931	943		10.1016/0092-8674(93)90581-A	http://dx.doi.org/10.1016/0092-8674(93)90581-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8384534				2022-12-24	WOS:A1993KU17500013
J	ELIOT, LS; KANDEL, ER; SIEGELBAUM, SA; BLUMENFELD, H				ELIOT, LS; KANDEL, ER; SIEGELBAUM, SA; BLUMENFELD, H			IMAGING TERMINALS OF APLYSIA SENSORY NEURONS DEMONSTRATES ROLE OF ENHANCED CA2+ INFLUX IN PRESYNAPTIC FACILITATION	NATURE			English	Article							LONG-TERM POTENTIATION; GILL-WITHDRAWAL REFLEX; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; CALCIUM; MODULATION; MECHANISM; SEROTONIN; CHANNELS	MODULATION of transmitter release underlies several forms of learning-related synaptic plasticity, including presynaptic facilitation and long-term potentiation1-4. Although the presynaptic terminals of most neurons are not accessible for direct study, it has often been possible to correlate changes in calcium influx in the cell body, owing to modulation of K+ or Ca2+ channels, with changes in release5-7. Some forms of presynaptic plasticity, however, do not involve changes in Ca2+ influx8-12. Moreover, the presence of multiple types of K+ and Ca2+ channels with different subcellular distributions makes the direct measurement of Ca2+ influx into presynaptic terminals essential. Using synapses reconstituted in culture between Aplysia sensory and motor neurons13, we have imaged Ca2+ influx in presynaptic terminal regions in response to action potentials, and demonstrate that presynaptic facilitation produced by 5-hydroxytryptamine involves enhanced Ca2+ influx through dihydropyridine (DHP)-insensitive Ca2+ channels14 present near release sites. This increased influx is attributable to spike broadening and is significantly correlated with the magnitude of presynaptic facilitation. By contrast, DHP-sensitive channels appear to aid the recovery from depression due to high-frequency stimulation.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute								BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLUMENFELD H, 1990, NEURON, V5, P487, DOI 10.1016/0896-6273(90)90088-W; BLUMENFELD H, 1992, BIOPHYS J, V63, P1146, DOI 10.1016/S0006-3495(92)81670-3; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BRAHA O, IN PRESS J NEUROSCI; BYRNE JH, 1982, J NEUROPHYSIOL, V48, P431, DOI 10.1152/jn.1982.48.2.431; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DELANEY K, 1991, J NEUROSCI, V11, P2631; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; EDMONDS B, 1990, SCIENCE, V250, P1142, DOI 10.1126/science.2174573; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWKINS RD, IN PRESS A REV NEURO; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; KLEIN M, 1980, P NATL ACAD SCI-BIOL, V77, P6912, DOI 10.1073/pnas.77.11.6912; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANSONHING H, 1989, NATURE, V341, P237, DOI 10.1038/341237a0; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; NERBONNE JM, 1987, J NEUROSCI, V7, P882; RAYPORT SG, 1986, J NEUROSCI, V6, P759; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SMITH SJ, 1985, P NATL ACAD SCI USA, V82, P622, DOI 10.1073/pnas.82.2.622	30	65	66	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					634	637		10.1038/361634a0	http://dx.doi.org/10.1038/361634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8382344				2022-12-24	WOS:A1993KM77600063
J	RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR				RONCO, JJ; FENWICK, JC; TWEEDDALE, MG; WIGGS, BR; PHANG, PT; COOPER, DJ; CUNNINGHAM, KF; RUSSELL, JA; WALLEY, KR			IDENTIFICATION OF THE CRITICAL OXYGEN DELIVERY FOR ANAEROBIC METABOLISM IN CRITICALLY ILL SEPTIC AND NONSEPTIC HUMANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; PATHOLOGICAL SUPPLY DEPENDENCE; GLUCOSE TRANSPORTER; SKELETAL-MUSCLE; CRITICAL-LEVEL; O-2 UPTAKE; CONSUMPTION; SEPSIS; SHOCK; SURVIVORS	Objectives.-To determine the critical oxygen delivery threshold for anaerobic metabolism and to compare its value between septic and nonseptic critically ill patients. Design.-Cohort analytic study, consecutive sample. Setting.-Two tertiary care medical and surgical intensive care units in university hospitals. Patients.-Nine septic and nine nonseptic critically ill humans. A diagnosis of sepsis was established by the presence of sepsis syndrome, positive cultures obtained within 48 hours of study, and autopsy evidence of a source of infection. Methods and Interventions.-The O2 consumption (determined by indirect calorimetry), O2 delivery (calculated from the Fick equation), and concentration of arterial plasma lactate were simultaneously determined at 5- to 20-minute intervals while life support was discontinued. Main Outcome Measures.-Critical O2 delivery, critical O2 extraction ratio, and maximal O2 extraction ratio. Results.-In all septic and eight nonseptic patients, O2 delivery and O2 consumption displayed a biphasic relationship over the range of O2 delivery studied. There were no differences in critical O2 delivery threshold (3.8+/-1.5 vs 4.5+/-1.3 mL.min-1.kg-1; P>.28), Critical O2 extraction ratio (0.61+/-0.05 vs 0.59+/-0.16; P>.64), and maximal O2 extraction ratio (0.74+/-0.08 vs 0.80+/-0.11; P>.29) between septic and nonseptic patients. These data have greater than 90% power to detect a difference of 2 mL.min-1.kg-1 in the critical O2 delivery and 0.1 in the critical and maximal O2 extraction ratios between the septic and nonseptic groups. Conclusions.-The critical O2 delivery for anaerobic metabolism was identified from the biphasic relationship between O2 delivery and O2 consumption in individual humans. The critical O2 delivery is considerably lower than previously reported in humans with the use of pooled group data. Sepsis does not alter the critical O2 delivery for anaerobic metabolism or tissue O2 extraction ability. Interventions to increase O2 delivery to supranormal levels in critically ill humans in the hope of increasing O2 consumption may be inappropriate.	UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER V6T 1W5,BC,CANADA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	RONCO, JJ (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,PROGRAM CRIT CARE MED,INTENS CARE UNIT ADM,LSP 2,VANCOUVER V5Z 1M9,BC,CANADA.		Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051				BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DANEK SJ, 1980, AM REV RESPIR DIS, V122, P387; DANTZKER DR, 1991, AM REV RESPIR DIS, V143, P675, DOI 10.1164/ajrccm/143.3.675; FENWICK JC, 1990, J CRIT CARE, V5, P81, DOI 10.1016/0883-9441(90)90052-B; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HARGROVE DM, 1988, AM J PHYSIOL, V254, pE16; HAUPT MT, 1985, AM REV RESPIR DIS, V131, P912; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOMATSU T, 1987, CRIT CARE MED, V15, P194, DOI 10.1097/00003246-198703000-00002; KRUSE JA, 1987, AM J MED, V83, P77, DOI 10.1016/0002-9343(87)90500-6; MOHSENIFAR Z, 1983, CHEST, V84, P267, DOI 10.1378/chest.84.3.267; NELSON DP, 1987, J APPL PHYSIOL, V63, P1487, DOI 10.1152/jappl.1987.63.4.1487; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; RONCO JJ, 1991, J CRIT CARE, V6, P36, DOI 10.1016/0883-9441(91)90031-N; RONCO JJ, 1991, AM REV RESPIR DIS, V143, P1267, DOI 10.1164/ajrccm/143.6.1267; RUSSELL JA, 1990, AM REV RESPIR DIS, V141, P659, DOI 10.1164/ajrccm/141.3.659; SAMSEL RW, 1988, J APPL PHYSIOL, V65, P1377, DOI 10.1152/jappl.1988.65.3.1377; SCHUMACKER PT, 1989, J APPL PHYSIOL, V67, P1234, DOI 10.1152/jappl.1989.67.3.1234; SHIBUTANI K, 1983, CRIT CARE MED, V11, P640, DOI 10.1097/00003246-198308000-00010; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VERMEIJ CG, 1991, CHEST, V99, P1438, DOI 10.1378/chest.99.6.1438; VINCENT JL, 1990, AM REV RESPIR DIS, V142, P2, DOI 10.1164/ajrccm/142.1.2; WIDNELL CC, 1990, FASEB J, V4, P1634, DOI 10.1096/fasebj.4.6.2156742; WOLL PJ, 1979, EUR J CLIN INVEST, V9, P397, DOI 10.1111/j.1365-2362.1979.tb00903.x; Zar JH., 1999, BIOSTAT ANAL; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A	32	218	226	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1993	270	14					1724	1730		10.1001/jama.270.14.1724	http://dx.doi.org/10.1001/jama.270.14.1724			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA294	8411504				2022-12-24	WOS:A1993MA29400030
J	DALY, E; GRAY, A; BARLOW, D; MCPHERSON, K; ROCHE, M; VESSEY, M				DALY, E; GRAY, A; BARLOW, D; MCPHERSON, K; ROCHE, M; VESSEY, M			MEASURING THE IMPACT OF MENOPAUSAL SYMPTOMS ON QUALITY-OF-LIFE	BRITISH MEDICAL JOURNAL			English	Article							HORMONE REPLACEMENT THERAPY; HEALTH-CARE; OF-LIFE; GENERAL-PRACTICE; ESTROGEN; QALYS; WOMEN	Objective-To examine the impact of menopausal symptoms on the overall quality of life of women. Design-Data collection with a questionnaire administered by an interviewer, incorporating two different quality of life measurement techniques (time trade off and rating scale). Setting-Specialist menopause clinic and two general practices in Oxford. Subjects-63 women aged 45-60 years recruited opportunistically during a clinic or appointment with a general practitioner; no exclusion criteria. Results-Subjects gave very low quality of life ratings for health states with menopausal symptoms. The time trade off method of measuring preferences for these health states (on a scale from 0 to 1, where preference for full health is given as 1) yielded utility values of 0.64 for severe menopausal symptoms and 0.85 for mild symptoms. The rating scale measurement technique yielded even lower values: utilities of 0.30 and 0.65 were obtained for severe and mild symptoms respectively. Kappa scores indicated that the two methods produced results that were poorly related but not contradictory. Comparison of quality of life ratings before and after treatment with hormone replacement therapy showed significant improvements: with the rating scale measurement technique mean increases in utility values after the relief of severe and mild menopausal symptoms were 0.56 and 0.18 respectively. Conclusions-Quality of life may be severely compromised in women with menopausal symptoms, and perceived improvements in quality of life in users of hormone replacement therapy seem to be substantial. This emphasises the need to include quality of life measurements when assessing outcomes of hormone replacement therapy. Several limitations may exist with widely applied measurement techniques, calling for the development of appropriate and well validated instruments for measuring quality of life associated with reduced health states.	UNIV OXFORD WOLFSON COLL,CTR SOCIOLEGAL STUDIES,OXFORD OX2 6UD,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE MATERN HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; OXFORD AREA HLTH AUTHOR,OXFORD OX3 7LG,ENGLAND	University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	DALY, E (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Barlow, David/F-8738-2011					[Anonymous], 1991, LANCET, V338, P350; AVIS NE, 1991, MATURITAS, V13, P65, DOI 10.1016/0378-5122(91)90286-Y; BRYAN S, 1991, HEALTH POLICY, V18, P169, DOI 10.1016/0168-8510(91)90098-I; BUNGAY GT, 1980, BRIT MED J, V2, P181; BUXTON M, 1987, ALTERNATIVE METHODS; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; COAST J, 1992, BMJ-BRIT MED J, V305, P87, DOI 10.1136/bmj.305.6845.87; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COOPE J, 1975, BRIT MED J, V4, P139, DOI 10.1136/bmj.4.5989.139; CUBBON J, 1991, J MED ETHICS, V17, P181, DOI 10.1136/jme.17.4.181; DALY E, 1992, BRIT MED BULL, V48, P368, DOI 10.1093/oxfordjournals.bmb.a072552; DITKOFF EC, 1991, OBSTET GYNECOL, V78, P991; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; Fletcher Astrid, 1992, British Medical Journal, V305, P1145; GREENBLATT RB, 1950, J CLIN ENDOCRINOL, V10, P1547, DOI 10.1210/jcem-10-12-1547; Gudex C, 1988, QALY TOOLKIT; HARRIS J, 1991, J MED ETHICS, V17, P185, DOI 10.1136/jme.17.4.185; HOLLAND G, 1985, TECHNIQUES HLTH STAT; HUNT K, 1988, J ROY COLL GEN PRACT, V38, P398; HUNT K, 1991, CURR OBSTET GYNAECOL, V1, P21; KANIS JA, 1992, OSTEOPOROSIS INT, V2, P161, DOI 10.1007/BF01623919; MCKINLAY SM, 1974, BRIT J PREV SOC MED, V28, P108; MCTURK L, 1991, BRIT MED J, V302, P1601, DOI 10.1136/bmj.302.6792.1601-b; RICHARDSON J, 1992, RES HLTH CARE DESIGN; ROBERTS PJ, 1991, BRIT J GEN PRACT, V41, P421; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SACKETT DL, 1978, J CHRON DIS, V31, P679; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; THOMSON J, 1977, BRIT MED J, V2, P1317, DOI 10.1136/bmj.2.6098.1317; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; WADE DT, 1991, BRIT MED J, V303, P1136; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILKES HC, 1991, BRIT MED J, V302, P1317, DOI 10.1136/bmj.302.6788.1317; Willard A, 1988, MAPPING MORAL DOMAIN, P225; WREN BG, 1990, MATURITAS, V13, P17	35	217	221	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					836	840		10.1136/bmj.307.6908.836	http://dx.doi.org/10.1136/bmj.307.6908.836			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401125	Green Published, Bronze			2022-12-24	WOS:A1993MA29300020
J	KOCH, C; MOLL, T; NEUBERG, M; AHORN, H; NASMYTH, K				KOCH, C; MOLL, T; NEUBERG, M; AHORN, H; NASMYTH, K			A ROLE FOR THE TRANSCRIPTION FACTORS MBP1 AND SWI4 IN PROGRESSION FROM G1 TO S-PHASE	SCIENCE			English	Article							DNA-SYNTHESIS GENES; CELL-CYCLE CONTROL; YEAST HO GENE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DEPENDENT TRANSCRIPTION; PROTEIN; START	In budding yeast genes that encode G1 cyclins and proteins involved in DNA synthesis are transcriptionally activated in late G1. A transcription factor, called SBF, is composed of Swi4 and Swi6 proteins and activates transcription of G1 cyclin genes. A different, but related, complex called MBF binds to MCB elements (Mlu I cell cycle box) found in the promoter of most DNA synthesis genes. MBF contains Swi6 and a 120-kilodalton protein (p120). MBF was purified and the gene encoding p120 (termed MBP1) was cloned. A deletion of MBP1 was not lethal but led to deregulated expression of DNA synthesis genes, indicating a direct regulatory role for MBF in MCB-driven transcription. Mbp1 is related to Swi4. Strains deleted for both MBP1 and SWI4 were inviable, demonstrating that transcriptional activation by MBF and SBF has an important role in the transition from G1 to S phase.	BENDER & CO,A-1121 VIENNA,AUSTRIA		KOCH, C (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Koch, Christian/W-5731-2019; Koch, Christian/J-5716-2013	Koch, Christian/0000-0001-8407-4952; Nasmyth, Kim/0000-0001-7030-4403				AMON A, IN PRESS CELL; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BORK P, COMMUNICATION; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; BURGLIN T, COMMUNICATION; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KOCH C, UNPUB; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MILLER KY, 1992, GENE DEV, V6, P1770, DOI 10.1101/gad.6.9.1770; MOLL T, 1993, PHILOS T ROY SOC B, V340, P351, DOI 10.1098/rstb.1993.0078; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; TABA H, 1991, GENE DEV, V5, P200; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	42	323	331	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1551	1557		10.1126/science.8372350	http://dx.doi.org/10.1126/science.8372350			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372350				2022-12-24	WOS:A1993LX47400022
J	INOUYE, SK; VISCOLI, CM; HORWITZ, RI; HURST, LD; TINETTI, ME				INOUYE, SK; VISCOLI, CM; HORWITZ, RI; HURST, LD; TINETTI, ME			A PREDICTIVE MODEL FOR DELIRIUM IN HOSPITALIZED ELDERLY MEDICAL PATIENTS BASED ON ADMISSION CHARACTERISTICS	ANNALS OF INTERNAL MEDICINE			English	Article						DELIRIUM; VISION DISORDERS; SEVERITY OF ILLNESS INDEX; COGNITION DISORDERS; BLOOD UREA NITROGEN	ACUTE CONFUSIONAL STATES; MINI-MENTAL STATE; COGNITIVE IMPAIRMENT; RISK-FACTORS; DEMENTIA; ILLNESS; INPATIENTS; MORTALITY; CRITERIA; FRACTURE	Objective: To prospectively develop and validate a predictive model for the occurrence of new delirium in hospitalized elderly medical patients based on characteristics present at admission. Design: Two prospective cohort studies done in tandem. Setting: University teaching hospital. Patients: The development cohort included 107 hospitalized general medical patients 70 years or older who did not have dementia or delirium at admission. The validation cohort included 174 comparable patients. Measurements: Patients were assessed daily for delirium using a standardized, validated instrument. The predictive model developed in the initial cohort was then validated in a separate cohort of patients. Results: Delirium developed in 27 of 107 patients (25%) in the development cohort. Four independent baseline risk factors for delirium were identified using proportional hazards analysis: These included vision impairment (adjusted relative risk, 3.5; 95% CI, 1.2 to 10.7); severe illness (relative risk, 3.5; CI, 1.5 to 8.2); cognitive impairment (relative risk, 2.8; CI, 1.2 to 6.7); and a high blood urea nitrogen/creatinine ratio (relative risk, 2.0; CI, 0.9 to 4.6). A risk stratification system was developed by assigning 1 point for each risk factor present. Rates of delirium for low- (0 points), intermediate-(1 to 2 points), and high-risk (3 to 4 points) groups were 9%, 23%, and 83% (P < 0.0001), respectively. The corresponding rates in the validation cohort, in which 29 of 174 patients (17%) developed delirium, were 3%, 16%, and 32% (P < 0.002). The rates of death or nursing home placement, outcomes potentially related to delirium, were 9%, 16%, and 42% (P = 0.02) in the development cohort and 3%, 14%, and 26% (P = 0.007) in the validation cohort. Conclusions: Delirium among elderly hospitalized patients is common, and a simple predictive model based on four risk factors can be used at admission to identify elderly persons at the greatest risk.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University			Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE ON AGING [K08AG000524] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05443] Funding Source: Medline; NIA NIH HHS [1K08AG00524-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECK S, 1981, RANDR226214HHS RAND, V14, P72; BEDFORD PD, 1959, BRIT MED J, V2, P185, DOI 10.1136/bmj.2.5145.185; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P78; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Brannstrom B, 1991, Scand J Caring Sci, V5, P3; Cameron DE, 1941, PSYCHIAT QUART, V15, P47, DOI 10.1007/BF01613953; CAMERON DJ, 1987, J AM GERIATR SOC, V35, P1007, DOI 10.1111/j.1532-5415.1987.tb04004.x; CAVANAUGH SV, 1983, GEN HOSP PSYCHIAT, V5, P15, DOI 10.1016/0163-8343(83)90038-5; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; Chisholm S E, 1982, J Gerontol Nurs, V8, P87; Cox D. R., 1984, ANAL SURVIVAL DATA; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P343; FEINSTEIN AR, 1987, CLINIMETRICS, P195; FIELDS SD, 1986, J AM GERIATR SOC, V34, P579, DOI 10.1111/j.1532-5415.1986.tb05763.x; FIELDS SD, 1986, ARCH INTERN MED, V146, P1593, DOI 10.1001/archinte.146.8.1593; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; GUZE SB, 1964, AM J PSYCHIAT, V120, P878, DOI 10.1176/ajp.120.9.878; GUZE SB, 1967, ARCH GEN PSYCHIAT, V17, P365; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAY DWK, 1956, J MENT SCI, V102, P129, DOI 10.1192/bjp.102.426.129; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P283; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAMONT CT, 1983, J AM GERIATR SOC, V31, P282, DOI 10.1111/j.1532-5415.1983.tb04872.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Levkoff S E, 1986, Annu Rev Gerontol Geriatr, V6, P1; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; PURDLE FR, 1981, ANN EMERG MED, V10, P455, DOI 10.1016/S0196-0644(81)80276-4; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; ROCKWOOD K, 1990, J CLIN EPIDEMIOL, V43, P971, DOI 10.1016/0895-4356(90)90080-9; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; ROSIN AJ, 1966, J CHRON DIS, V19, P307, DOI 10.1016/0021-9681(66)90134-2; ROTH M, 1955, J MENT SCI, V101, P281, DOI 10.1192/bjp.101.423.281; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEEMAN TE, 1988, SOC SCI MED, V26, P737, DOI 10.1016/0277-9536(88)90065-2; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; WARSHAW GA, 1982, JAMA-J AM MED ASSOC, V248, P847, DOI 10.1001/jama.248.7.847; WEDDINGTON WW, 1982, PSYCHOSOMATICS, V23, P1232; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; 1984, BMDP COMPUTER PROGRA; 1988, SAS SOFTWARE SYSTEM	58	586	609	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					474	481		10.7326/0003-4819-119-6-199309150-00005	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357112				2022-12-24	WOS:A1993LZ27500005
J	RANDRIAMAMPITA, C; TSIEN, RY				RANDRIAMAMPITA, C; TSIEN, RY			EMPTYING OF INTRACELLULAR CA2+ STORES RELEASES A NOVEL SMALL MESSENGER THAT STIMULATES CA2+ INFLUX	NATURE			English	Article							PLASMA-MEMBRANE; HUMAN-NEUTROPHILS; CALCIUM CHANNELS; MAST-CELLS; T-CELLS; CA-2+; PERMEABILITY; ENTRY; LYMPHOCYTES; FIBROBLASTS	INTRACELLULAR Ca2+ signals that last more than a few minutes after the onset of stimulation depend critically on influx of extracellular Ca2+. Such Ca2+ influx can be triggered in many cell types by depletion of intracellular Ca2+ stores without detectable elevations of known messengers. The mechanism by which store depletion can control plasma membrane Ca2+ permeability remains controversial1-7. Here we present evidence for a novel soluble mediator. Calcium depletion of a lymphocyte cell line caused the messenger to be released from intracellular organelles into the cytoplasm and to a much lesser extent into the extracellular medium. The messenger caused Ca2+ influx when applied to macrophages, astrocytoma cells, and fibroblasts and was therefore named CIF (or Ca2+-influx factor). CIF appears to have hydroxyls (or hydroxyl and amino groups) on adjacent carbons, a phosphate, and a M(r) under 500.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; ECOLE NORMALE SUPER,NEUROBIOL LAB,F-75231 PARIS 05,FRANCE; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Howard Hughes Medical Institute; University of California System; University of California San Diego				Randriamampita, Clotilde/0000-0001-8594-7831				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHOW SC, 1990, J BIOL CHEM, V265, P902; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FULCERI R, 1993, BIOCHEM J, V289, P299, DOI 10.1042/bj2890299; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JALINK K, 1990, J BIOL CHEM, V265, P12232; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LI WWF, 1993, J BIOL CHEM, V268, P12003; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	31	860	865	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					809	814		10.1038/364809a0	http://dx.doi.org/10.1038/364809a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355806				2022-12-24	WOS:A1993LU58100058
J	STRUHL, G; FITZGERALD, K; GREENWALD, I				STRUHL, G; FITZGERALD, K; GREENWALD, I			INTRINSIC ACTIVITY OF THE LIN-12 AND NOTCH INTRACELLULAR DOMAINS IN-VIVO	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; EPIDERMAL GROWTH-FACTOR; CELL-CELL-INTERACTIONS; CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; LATERAL INHIBITION; EARLY NEUROGENESIS; HOMOLOGOUS GENES	The lin-12 gene of C. elegans and the Notch gene of D. melanogaster encode structurally related transmembrane proteins that mediate intercellular signaling. We show that truncated forms of these proteins consisting of only the intracellular domains cause cell fate transformations associated with constitutive activity in their respective organisms. This activity does not depend on endogenous gene function. Our results indicate that the intracellular domains of Lin-12 and Notch have intrinsic activity and that the principal role of the extracellular domains in the intact proteins is to regulate this activity. Our results also suggest that equivalent truncated forms of lin-12/Notch family members in vertebrates, including known oncogenes, are similarly active.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Princeton University	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37602] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BRENNER S, 1974, GENETICS, V77, P71; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHOU TB, 1992, GENETICS, V131, P643; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FREYD G, 1991, THESIS MIT CAMBRIDGE; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1982, ROUX ARCH DEVEL BIOL, V191, P62; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE E, 1990, DEVELOPMENT, V112, P231; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER HJ, 1932, P INT C GENET, V6, P213; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1993, IN PRESS DEV BIOL; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1989, DEVELOPMENT, V106, P57; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	77	442	456	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					331	345		10.1016/0092-8674(93)90424-O	http://dx.doi.org/10.1016/0092-8674(93)90424-O			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343960				2022-12-24	WOS:A1993LP72600014
J	STATHAM, H; GREEN, J				STATHAM, H; GREEN, J			SERUM SCREENING FOR DOWNS-SYNDROME - SOME WOMENS EXPERIENCES	BRITISH MEDICAL JOURNAL			English	Article							AMNIOCENTESIS	Objectives-To describe the experiences of a small group of women who had positive results after serum screening for Down's syndrome. Design-Semistructured telephone interviews and correspondence with women after a positive screening result (four women) negative amniocentesis results (eight), or termination of a pregnancy with a confirmed abnormality (eight). Subjects-20 women who contacted Support After Termination For Abnormality about their experiences of serum screening for Down's syndrome. Main outcome measures-Women's knowledge and understanding of the test; staff misconceptions; communication of results; how women coped with the diagnostic process; attitudes to the test and to termination of abnormal fetuses. Results-All women were made anxious by their positive screening test, no matter how they were told. The women's experiences suggested that medical staff were unclear about the implications of screening tests and how to interpret risk. Even after receipt of negative amniocentesis results some women remained anxious. Staff did not always recognise women's concerns while awaiting amniocentesis results. Conclusions-The way in which serum screening is being implemented does not always meet the needs of women with positive results. Some of the problems were not specific to screening for Down's syndrome. When screening tests are introduced policies should be adopted to ensure appropriate support for participants.			STATHAM, H (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							CLARKE A, 1993, BRIT MED J, V306, P209, DOI 10.1136/bmj.306.6871.209-a; CUCKLE HS, 1988, LANCET, V2, P851; FARRANT W, 1980, BRIT MED J, V281, P452, DOI 10.1136/bmj.281.6237.452; GREEN J, 1990, CRITICAL REV PSYCHOL; GREEN J, 1993, PREGNANCY TESTING TI; KEATINGE RM, 1991, BRIT MED J, V303, P54, DOI 10.1136/bmj.303.6793.54-d; MARTEAU TM, 1988, BRIT MED J, V297, P1469, DOI 10.1136/bmj.297.6661.1469-b; MARTEAU TM, 1989, BRIT J OBSTET GYNAEC, V96, P739, DOI 10.1111/j.1471-0528.1989.tb03295.x; MARTEAU TM, 1992, BMJ, V305, P1434; ROELOFSEN EEC, 1993, J REPROD INFANT PSYC, V11, P41; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391	14	74	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					174	176		10.1136/bmj.307.6897.174	http://dx.doi.org/10.1136/bmj.307.6897.174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343748	Bronze, Green Published			2022-12-24	WOS:A1993LN18400023
J	GIRARD, S; CLAPHAM, D				GIRARD, S; CLAPHAM, D			ACCELERATION OF INTRACELLULAR CALCIUM WAVES IN XENOPUS-OOCYTES BY CALCIUM INFLUX	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; LAEVIS OOCYTES; ENDOPLASMIC-RETICULUM; 2ND MESSENGERS; CA-2+; RELEASE; CELLS; RECEPTORS; 1,4,5-TRISPHOSPHOROTHIOATE; OSCILLATIONS	Many cell membrane receptors stimulate the phosphoinositide (PI) cycle, which produces complex intracellular calcium signals that regulate diverse processes such as secretion and transcription. A major messenger of this cycle, inositol 1,4,5-trisphosphate (IP3), stimulates its receptor channel on the endoplasmic reticulum to release calcium into the cytosol. Activation of the PI cycle also induces calcium influx, which refills the intracellular calcium stores. Confocal microscopy was used to show that receptor-activated calcium influx, enhanced by hyperpolarization, modulates the frequency and velocity of IP3-dependent calcium waves in Xenopus laevis oocytes. These results demonstrate that transmembrane voltage and calcium influx pathways may regulate spatial and temporal patterns of IP3-dependent calcium release.	MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	Mayo Clinic			Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428				ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEMENT WM, 1990, J ELECTRON MICR TECH, V16, P202, DOI 10.1002/jemt.1060160303; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DELISLE S, 1990, J BIOL CHEM, V265, P11726; DELISLE S, 1992, AM J PHYSIOL, V262, pC1456, DOI 10.1152/ajpcell.1992.262.6.C1456; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FERGUSON JE, 1990, BIOCHEM BIOPH RES CO, V172, P229, DOI 10.1016/S0006-291X(05)80198-6; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIIRARD S, IN PRESS METHODS CEL; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LUPUMEIRI M, 1990, FEBS LETT, V262, P165, DOI 10.1016/0014-5793(90)80180-Q; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.biophys.20.1.153; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; POTTER BVL, 1990, DUPONT BIOTECH UPDAT, V5, P1; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; TAYLOR CW, 1988, BIOCHEM BIOPH RES CO, V150, P626, DOI 10.1016/0006-291X(88)90438-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1991, NEW BIOL, V3, P3	42	152	152	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1993	260	5105					229	232		10.1126/science.8385801	http://dx.doi.org/10.1126/science.8385801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	8385801				2022-12-24	WOS:A1993KW45200043
J	KOLLEF, MH				KOLLEF, MH			VENTILATOR-ASSOCIATED PNEUMONIA - A MULTIVARIATE-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; CONTINUOUS MECHANICAL VENTILATION; HOSPITAL-ACQUIRED PNEUMONIA; NOSOCOMIAL PNEUMONIA; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; RISK-FACTORS; FAILURE; ASPIRATION; PROGNOSIS	Objectives.-To identify factors associated with the development of ventilator-associated pneumonia (VAP) and to examine the incidence of VAP in different intensive care unit (ICU) populations. Design.-An inception cohort study. Setting.-Barnes Hospital, St Louis, Mo, an academic tertiary care center. Patients or Other Participants.-A total of 277 consecutive patients required mechanical ventilation for longer than 24 hours from a medical ICU (75 patients), surgical ICU (100 patients), or cardiothoracic ICU (102 patients). Interventions.-Prospective patient surveillance and data collection. Main Outcome Measures.-Ventilator-associated pneumonia and ICU mortality. Results.-Ventilator-associated pneumonia occurred in 43 patients (15.5%). Stepwise logistic regression analysis identified four factors to be independently associated with VAP (P<.05): an organ system failure index of 3 or greater (adjusted odds ratio [AOR]=10.2; 95% confidence interval [CI], 4.5 to 23; P<.001); patient age of 60 years or older (AOR=5.1; 95% CI, 1.9 to 14.1; P=.002); prior administration of antibiotics (AOR=3.1; 95% CI, 1.4 to 6.9; P=.004); and supine head positioning during the first 24 hours of mechanical ventilation (AOR=2.9; 95% Cl, 1.3 to 6.8; P=.013). Ventilator-associated pneumonia occurred more often in cardiothoracic patients (21.6%) compared with medical patients (9.3%) (P=.03). Patients with VAP also had a higher mortality (37.2%) than those without; VAP (8.5%) (P<.001). An organ system failure index of 3 or greater (AOR=16.1; 95% CI, 6.1 to 42; P<.001), a premorbid lifestyle score of 2 or greater (AOR=3.1; 95% CI, 1.3 to 7.3; P=.012), and supine head positioning during the first 24 hours of mechanical ventilation (AOR=3.1; 95% CI, 1.2 to 7.8; P=.016) were independently associated with mortality. Conclusions.-These data suggest potential interventions that might affect the incidence of VAP or outcome associated with VAP. Additionally, they indicate that different ICU populations may have different incidences of VAP.			KOLLEF, MH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE,BOX 8052,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							BARTLETT JG, 1986, ARCH INTERN MED, V146, P868, DOI 10.1001/archinte.146.5.868; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BEALE R, 1993, CRIT CARE MED, V21, pS1, DOI 10.1097/00003246-199302001-00001; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONTEN MJM, 1993, NEW ENGL J MED, V328, P209, DOI 10.1056/NEJM199301213280311; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUNAGAN WC, 1991, REV INFECT DIS, V13, P405; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, AM REV RESPIR DIS, V147, pA105; FIDDIANGREEN RG, 1991, CRIT CARE MED, V19, P763; FIDDIANGREEN RG, 1993, CRIT CARE MED, V21, pS103, DOI 10.1097/00003246-199302001-00017; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GRAYBILL JR, 1973, AM REV RESPIR DIS, V108, P1130; HAMMOND JMJ, 1992, LANCET, V340, P5, DOI 10.1016/0140-6736(92)92422-C; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; Horan T C, 1986, MMWR CDC Surveill Summ, V35, p17SS; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; HUDSON L D, 1989, American Review of Respiratory Disease, V140, pS19; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLLEF MH, IN PRESS CHEST; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MENZIES R, 1989, CHEST, V95, P398, DOI 10.1378/chest.95.2.398; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; STEVENS RM, 1974, ARCH INTERN MED, V134, P106, DOI 10.1001/archinte.134.1.106; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; 1992, NEW ENGL J MED, V327, P234; 1990, SAS STAT USERS GUIDE, P1	39	492	514	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1965	1970		10.1001/jama.270.16.1965	http://dx.doi.org/10.1001/jama.270.16.1965			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411554				2022-12-24	WOS:A1993MC51300029
J	FARRER, M; GAME, FL; ALBERS, CJ; NEIL, HAW; WINOCOUR, PH; LAKER, MF; ADAMS, PC; ALBERTI, KGMM				FARRER, M; GAME, FL; ALBERS, CJ; NEIL, HAW; WINOCOUR, PH; LAKER, MF; ADAMS, PC; ALBERTI, KGMM			ASSOCIATION BETWEEN IMPAIRED GLUCOSE-TOLERANCE AND CIRCULATING CONCENTRATION OF LP(A) LIPOPROTEIN IN RELATION TO CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; MIDDLE-AGED MEN; GLYCOPROTEIN PHENOTYPES; MYOCARDIAL-INFARCTION; GEL-ELECTROPHORESIS; INSULIN ACTION; PIMA-INDIANS; PLASMA; POPULATION; APOLIPOPROTEIN-(A)	Objective-To examine whether impaired glucose tolerance and raised Lp(a) lipoprotein concentrations are associated in subjects with coronary artery disease. Design-Study of two subject populations, one with and one without symptomatic coronary artery disease. Case-control analysis of patients with impaired glucose tolerance and normal glucose tolerance performed in each subject population independently. Setting-A general practice and a hospital ward in Newcastle upon Tyne. Subjects-517 apparently healthy subjects, 13 with impaired glucose tolerance, and 245 patients who had undergone coronary artery bypass graft surgery 12 months before, 51 with impaired glucose tolerance. Main outcome measures-Serum Lp(a) lipoprotein concentration, plasma glucose concentration before and after oral challenge with 75 g glucose monohydrate, and Lp(a) lipoprotein isoforms. Results-In both the asymptomatic subjects and the subjects with coronary artery disease there was no significant difference between subjects with impaired glucose tolerance and subjects with normal glucose tolerance who were matched for age, sex, and body mass index in serum Lp(a) lipoprotein concentrations (geometric mean 61 (geometric SD 4) mg/l v 83 (5) mg/l for asymptomatic subjects, 175 (3) v 197 (2) for subjects with heart disease), nor was there any difference in the proportion of subjects who had Lp(a) lipoprotein concentrations >300 mg/l (31% v 23% for asymptomatic subjects, 37% v 37% for subjects with heart disease). For both subject groups there was no significant correlation between Lp(a) lipoprotein concentration and plasma glucose concentration after a glucose tolerance test, nor did Lp(a) lipoprotein concentration vary by quintile of glucose concentration after the test. Examination of Lp(a) lipoprotein isoforms in the subjects with coronary artery disease revealed an inverse relation between isoform size and plasma Lp(a) lipoprotein concentration, but there was no evidence that impaired glucose tolerance was associated with particular Lp(a) lipoprotein isoforms. Conclusion-Raised Lp(a) lipoprotein concentrations are not responsible for the association between impaired glucose tolerance and coronary artery disease.	ROYAL VICTORIA INFIRM,DEPT CARDIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; University of Oxford; Newcastle University - UK				Game, Frances/0000-0002-5294-4789	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMS ME, 1969, BRIT MED J, V1, P599, DOI 10.1136/bmj.1.5644.599; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BERG K, 1974, CLIN GENET, V6, P230; BOERWINKLE E, 1989, HUM GENET, V82, P73, DOI 10.1007/BF00288277; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; CAPALDO B, 1983, DIABETES CARE, V6, P575, DOI 10.2337/diacare.6.6.575; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIES M, 1992, BRIT MED J, V304, P1610, DOI 10.1136/bmj.304.6842.1610; DURRINGTON PN, 1988, LANCET, V1, P1070; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FARRER M, 1992, CLIN CHIM ACTA, V207, P215, DOI 10.1016/0009-8981(92)90120-F; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; FULLER JH, 1980, LANCET, V1, P1374; HARRIS MI, 1985, DIABETES CARE, V8, P562, DOI 10.2337/diacare.8.6.562; HOWARD BV, 1984, ARTERIOSCLEROSIS, V4, P462, DOI 10.1161/01.ATV.4.5.462; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P59; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; MANN JI, 1988, BMJ, V296, P1701; MODAN M, 1988, ARTERIOSCLEROSIS, V8, P227, DOI 10.1161/01.ATV.8.3.227; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; ORAHILLY SP, 1986, LANCET, V2, P360; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCHAEFER EJ, 1992, CIRCULATION, V86, P812; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHARP CL, 1964, P ROY SOC MED, V57, P193, DOI 10.1177/003591576405700319; STAMLER R, 1979, J CHRON DIS, V32, P683, DOI 10.1016/0021-9681(79)90047-X; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VACCARO O, 1984, ARTERIOSCLEROSIS, V4, P592, DOI 10.1161/01.ATV.4.6.592; WINOCOUR PH, 1992, ATHEROSCLEROSIS, V93, P71, DOI 10.1016/0021-9150(92)90201-Q; ZAVARONI I, 1987, AM J MED, V83, P609, DOI 10.1016/0002-9343(87)90887-4	35	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					832	836		10.1136/bmj.307.6908.832	http://dx.doi.org/10.1136/bmj.307.6908.832			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401124	Bronze, Green Published			2022-12-24	WOS:A1993MA29300019
J	PAMUK, ER; WILLIAMSON, DF; SERDULA, MK; MADANS, J; BYERS, TE				PAMUK, ER; WILLIAMSON, DF; SERDULA, MK; MADANS, J; BYERS, TE			WEIGHT-LOSS AND SUBSEQUENT DEATH IN A COHORT OF UNITED-STATES ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; CORONARY-DISEASE; MORTALITY; FRAMINGHAM; LONGEVITY; HEALTH; MEN; VARIABILITY; POPULATION; OBESITY	Objective: Because we previously found that weight loss was associated with increased risk for death in all but very overweight men in a cohort of U.S. adults, we undertook a new analysis to determine whether inadequate control for preexisting illness or cigarette smoking contributed to this association. Design: Cohort study. Setting: The first National Health and Nutrition Examination Survey (NHANES I, 1971 to 1975) collected information on maximum lifetime weight and measured current weight on a probability sample of U.S. adults. The NHANES I Epidemiologic Follow-up Study determined the vital status of participants through 1987. Participants: Men (n = 2453) and women (n = 2739) who were 45 to 74 years old at the time of the NHANES I examination. Results: The effect of excluding persons who died within the first 5 and first 8 years after baseline was examined to limit the influence of weight loss due to preexisting illness. For women, extension of the exclusionary period weakened the association between weight loss and increased risk for death from noncardiovascular disease. However, excluding death for as much as 8 years after baseline did not affect the strong association between weight loss and increased risk for death from cardiovascular disease among men and women with maximum body mass indexes between 26 and 29 (relative risks of up to 2.1 and 3.6 for men and women, respectively, after excluding deaths in the first 8 years). Results were not substantially altered by limiting the analysis to persons who never smoked. Conclusions: Preexisting illness may influence the association between weight loss and death principally through deaths from noncardiovascular disease. For some persons, weight loss is associated with an increased risk for death, even after excluding deaths occurring in the first 8 years.			PAMUK, ER (corresponding author), CTR DIS CONTROL & PREVENT, DIV NUTR K-26, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; AVONS P, 1983, LANCET, V1, P1104; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; DEEG DJH, 1990, ARCH GERONTOL GERIAT, V10, P97, DOI 10.1016/0167-4943(90)90048-B; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HOVELL MF, 1982, AM J PUBLIC HEALTH, V72, P359, DOI 10.2105/AJPH.72.4.359; LEAN MEJ, 1990, DIABETIC MED, V7, P228, DOI 10.1111/j.1464-5491.1990.tb01375.x; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; RHOADS GG, 1983, LANCET, V1, P492; SCHROLL M, 1981, DAN MED BULL, V28, P106; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1959, BUILD BLOOD PRESSURE, V0001; [No title captured]	23	130	133	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				744	748		10.7326/0003-4819-119-7_Part_2-199310011-00023	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00023			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363209				2022-12-24	WOS:A1993MA33000023
J	MOORE, MJ; SHARP, PA				MOORE, MJ; SHARP, PA			EVIDENCE FOR 2 ACTIVE-SITES IN THE SPLICEOSOME PROVIDED BY STEREOCHEMISTRY OF PREMESSENGER RNA SPLICING	NATURE			English	Article							SMALL NUCLEAR-RNA; TETRAHYMENA RIBOZYME; MUTATIONAL ANALYSIS; BINDING-SITE; YEAST; STEP; SUBSTITUTION; POLYMERASE; ADENOSINE; CLEAVAGE	EXCISION of introns from nuclear precursors to messenger RNAs (pre-mRNAs) by the spliceosome requires two distinct phosphodiester transfer (transesterification) reactions: exchange of a 3'-5' for a 2'-5' bond in the first step (lariat formation) and exchange of one 3'-5' phosphodiester for another in the second step (exon ligation)1-3. We report here determination of the stereochemical course of each step using splicing substrates that contained a chiral phosphorothioate. This has provided strong evidence that both steps occur as single 'in-line' SN2 nucleophilic displacement reactions, analogous to the mechanism of group I self-splicing introns4,5. Additionally, because both steps are strongly inhibited by the R(P) phosphorothioate diastereomer, but not by S(P), the spliceosome probably shifts between two active sites in catalysis of the two steps. Chemical and stereochemical similarities suggest that the catalytic site for the second step of spliceosomal processing is related to that of group I self-splicing introns.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	MOORE, MJ (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.							AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BRYANT FR, 1979, BIOCHEMISTRY-US, V18, P2825, DOI 10.1021/bi00580a022; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HORNIG H, 1986, NATURE, V324, P589, DOI 10.1038/324589a0; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; MASCHHOFF KL, 1992, NUCLEIC ACIDS RES, V20, P1949, DOI 10.1093/nar/20.8.1949; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOORE MJ, 1983, RNA WORLD, P303; NELSON PS, 1984, J ORG CHEM, V49, P2314, DOI 10.1021/jo00187a003; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; REILLY JD, 1989, METHOD ENZYMOL, V180, P177; RUBY SW, 1991, TRENDS GENET, V7, P79; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; 1987, APPLIED BIOSYSTEMS M, V44, P1	36	188	195	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1993	365	6444					364	368		10.1038/365364a0	http://dx.doi.org/10.1038/365364a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397340				2022-12-24	WOS:A1993LY49600060
J	RYDER, REJ				RYDER, REJ			NATURAL FAMILY-PLANNING - EFFECTIVE BIRTH-CONTROL SUPPORTED BY THE CATHOLIC-CHURCH	BRITISH MEDICAL JOURNAL			English	Article							OVULATION; SYMPTOMS; EFFICACY; MUCUS	During 20-22 September Manchester is to host the 1993 follow up to last year's ''earth summit'' in Rio de janeiro. At that summit the threat posed by world overpopulation received considerable attention. Catholicism was perceived as opposed to birth control and therefore as a particular threat. This was based on the notion that the only method of birth control approved by the church-natural family planning-is unreliable, unacceptable, and ineffective. In the 20 years since E L Billings and colleagues first described the cervical mucus symptoms associated with ovulation natural family planning has incorporated these symptoms and advanced considerably. Ultrasonography shows that the symptoms identify ovulation precisely. According to the World Health Organisation, 93%. of women everywhere can identify the symptoms, which distinguish adequately between the fertile and infertile phases of the menstrual cycle. Most pregnancies during trials of natural family planning occur after intercourse at times recognised by couples as fertile. Thus pregnancy rates have depended on the motivation of couples. Increasingly studies show that rates equivalent to those with other contraceptive methods are readily achieved in the developed and developing worlds. Indeed, a study of 19843 poor women in India had a pregnancy rate approaching zero. Natural family planning is cheap, effective, without side effects, and may be particularly acceptable to and efficacious among people in areas of poverty.			RYDER, REJ (corresponding author), DUDLEY RD GEN HOSP,DEPT ENDOCRINOL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.		Ryder, Robert Elford/AAC-9014-2022	Ryder, Robert Elford/0000-0003-4424-355X				[Anonymous], 1981, FERTIL STERIL, V36, P591; [Anonymous], 1987, FERTIL STERIL, V47, P765; BALL M, 1976, European Journal of Obstetrics and Gynecology and Reproductive Biology, V6, P63, DOI 10.1016/0028-2243(76)90004-6; Barbato M, 1988, Int J Fertil, V33 Suppl, P48; BILLINGS EL, 1972, LANCET, V1, P282, DOI 10.1016/s0140-6736(72)90291-7; BILLINGS JJ, 1976, LANCET, V2, P969; BILLINGS JJ, 1976, LANCET, V2, P579; BONNYMAN J, 1982, Australian Radiation Laboratory Technical Report Series ARL-TR, P1; BROMWICH P D, 1985, British Journal of Sexual Medicine, V12, P124; CLUBB EM, 1990, NATURAL FAMILY PLANN, P130; DEPARES J, 1986, BRIT MED J, V292, P1562, DOI 10.1136/bmj.292.6535.1562; DORAIRAJ K, 1991, AM J OBSTET GYNECOL, V165, P2066, DOI 10.1016/S0002-9378(11)90584-5; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; FLYNN AM, 1976, BRIT J OBSTET GYNAEC, V83, P656, DOI 10.1111/j.1471-0528.1976.tb00906.x; FLYNN AM, 1991, MATERNAL CHILD HLTH, V16, P148; FRANCE JT, 1982, RECENT ADV OBSTETRIC, P215; FRANCIOLI P, 1987, SCHWEIZ MED WSCHR, P27; FRANKHERRMANN P, 1991, AM J OBSTET GYNECOL, V165, P2052, DOI 10.1016/S0002-9378(11)90580-8; Ghosh AK, 1982, J OBSTET GYNAECOL, V32, P443; GODLEE F, 1992, BRIT MED J, V304, P1525; KAMBIC RT, 1991, AM J OBSTET GYNECOL, V165, P2078; KELLY J, 1992, J TROP PEDIATRICS, V38, P206, DOI 10.1093/tropej/38.4.206; LAING JE, 1984, STUD FAMILY PLANN, V15, P49, DOI 10.2307/1966046; MARSHALL J, 1968, LANCET, V2, P8; MARSHALL J, 1976, LANCET, V2, P1085; MARSHALL J, 1976, LANCET, V2, P685; MARSHALL J, 1976, LANCET, V2, P282; MILLS A, 1984, CLIN OBSTET GYNAECOL, V11, P641; Parenteau-Carreau S, 1976, VIIE MED CANADA FRAN, V4, P145; Perez A, 1983, Rev Chil Obstet Ginecol, V48, P97; POOLE J, 1992, LANCET, V339, P1340; REID KM, 1985, HDB FAMILY PLANNING, P25; RICE FJ, 1981, INT J FERTIL, V26, P222; ROETZER J, 1981, INT REV NATURAL FAMI, V5, P200; RYDER REJ, 1985, CLIN SCI, V69, pP17, DOI 10.1042/cs069017Pa; VESSEY M, 1982, LANCET, V1, P841; WEISSMANN MC, 1972, LANCET, V2, P813; 1993, FERTIL STERIL, V40, P773; 1981, FERTIL STERIL, V36, P152; 1984, FERTIL STERIL, V41, P593	40	52	52	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					723	726		10.1136/bmj.307.6906.723	http://dx.doi.org/10.1136/bmj.307.6906.723			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401097	Bronze, Green Published			2022-12-24	WOS:A1993LY29200024
J	PEARSON, MG; SPENCE, DPS; RYLAND, I; HARRISON, BDW				PEARSON, MG; SPENCE, DPS; RYLAND, I; HARRISON, BDW			VALUE OF PULSUS PARADOXUS IN ASSESSING ACUTE SEVERE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									W NORWICH HOSP,NORWICH,ENGLAND		PEARSON, MG (corresponding author), FAZAKERLEY DIST GEN HOSP,AINTREE CHEST CTR,LIVERPOOL L9 7AL,ENGLAND.							British Thoracic Society (BTS), 1993, THORAX, V48, pS1; COCHRANE GM, 1990, RESPIRATORY MED, P614; EDELSON JD, 1985, ARCH INTERN MED, V145, P321, DOI 10.1001/archinte.145.2.321; KNOWLES GK, 1973, LANCET, V2, P1356; 1990, BMJ, V301, P797	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					659	659		10.1136/bmj.307.6905.659	http://dx.doi.org/10.1136/bmj.307.6905.659			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401053	Bronze, Green Published			2022-12-24	WOS:A1993LX47000019
J	ARMBRUST, EV; FERRIS, PJ; GOODENOUGH, UW				ARMBRUST, EV; FERRIS, PJ; GOODENOUGH, UW			A MATING-TYPE LINKED GENE-CLUSTER EXPRESSED IN CHLAMYDOMONAS ZYGOTES PARTICIPATES IN THE UNIPARENTAL INHERITANCE OF THE CHLOROPLAST GENOME	CELL			English	Article							MATERNAL INHERITANCE; PREFERENTIAL DESTRUCTION; INTRAGENOMIC CONFLICT; MICROSCOPIC EVIDENCE; REINHARDTII SHARE; PROTEIN-SYNTHESIS; SOMATIC FUSION; MALE ORIGIN; DNA; TRANSMISSION	A characteristic feature of early zygote development in Chlamydomonas is the selective degradation of chloroplast DNA from the mating type minus parent. The zygote-specific gene cluster ezy-1 is linked to the mating type locus and is transcribed almost immediately upon zygote formation. We show here that the acidic Ezy-1 polypeptide is rapidly transported to both the plus and minus chloroplasts, where it interacts with each chloroplast nucleoid. Expression of ezy-1 is selectively inhibited when pius, but not minus, gametes are briefly ultraviolet irradiated just prior to mating, a treatment known to disrupt the uniparental inheritance of chloroplast traits. We propose that the Ezy-1 polypeptide participates in the destruction of the minus chloroplast DNA in zygotes and thus the uniparental inheritance of chloroplast traits. The ezy-1 gene represents a valuable molecular probe for dissecting mechanisms underlying organelle inheritance.			ARMBRUST, EV (corresponding author), WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA.				NCRR NIH HHS [S10-RR04775-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BALDAN B, 1991, J CELL BIOL, V114, P905, DOI 10.1083/jcb.114.5.905; CAVALIERSMITH T, 1970, NATURE, V228, P333, DOI 10.1038/228333a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN AW, 1984, EXP CELL RES, V152, P528, DOI 10.1016/0014-4827(84)90655-4; COSMIDES LM, 1981, J THEOR BIOL, V89, P83, DOI 10.1016/0022-5193(81)90181-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EBERSOLD WT, 1962, GENETICS, V47, P531; FERRIS PJ, 1989, GENETICS, V122, P363; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; GILLHAM NW, 1974, GENETICS, V78, P439; GILLHAM NW, 1963, NATURE, V200, P294, DOI 10.1038/200294a0; GILLHAM NW, 1987, GENETICS, V115, P677; GILLHAM NW, 1991, CELL CULT SOMATIC A, V7, P55; GILLHAM NW, 1978, ORGANELLE HEREDITY; Goodenough U.W., 1991, MICROBIAL CELL CELL, P71; GOODENOUGH UW, 1987, GENETIC REGULATION D, P171; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1989, GENETICS, V123, P281; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; KUROIWA T, 1985, MICROBIOL SCI, V2, P267; KUROIWA T, 1982, NATURE, V298, P481, DOI 10.1038/298481a0; KUROIWA T, 1983, P JPN ACAD B-PHYS, V59, P182, DOI 10.2183/pjab.59.182; KUROIWA T, 1983, P JPN ACAD B-PHYS, V59, P177, DOI 10.2183/pjab.59.177; KUROIWA T, 1991, INT REV CYTOL, V128, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RP, 1960, ANNU REV MICROBIOL, V14, P197, DOI 10.1146/annurev.mi.14.100160.001213; MARTIN NC, 1975, J CELL BIOL, V67, P587, DOI 10.1083/jcb.67.3.587; MATAGNE RF, 1987, CURR GENET, V12, P251, DOI 10.1007/BF00435286; MATAGNE RF, 1980, CURR GENET, V1, P127, DOI 10.1007/BF00446958; MATAGNE RF, 1983, P NATL ACAD SCI-BIOL, V80, P4780, DOI 10.1073/pnas.80.15.4780; MATAGNE RF, 1981, CURR GENET, V3, P31, DOI 10.1007/BF00419578; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; MUNAUT C, 1990, CURR GENET, V18, P259, DOI 10.1007/BF00318390; NAKAMURA S, 1988, PLANT SCI, V56, P129, DOI 10.1016/0168-9452(88)90026-X; RIS H, 1962, J CELL BIOL, V13, P383, DOI 10.1083/jcb.13.3.383; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROESLER KR, 1990, PLANT PHYSIOL, V94, P1837, DOI 10.1104/pp.94.4.1837; ROSEN H, 1991, CURR GENET, V19, P35, DOI 10.1007/BF00362085; SAGER R, 1954, P NATL ACAD SCI USA, V40, P356, DOI 10.1073/pnas.40.5.356; SAGER R, 1967, P NATL ACAD SCI USA, V58, P931, DOI 10.1073/pnas.58.3.931; Sager R., 1985, MBL (Marine Biology Laboratory) Lectures in Biology, V7, P113; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH GM, 1950, P NATL ACAD SCI USA, V36, P246, DOI 10.1073/pnas.36.4.246; Sprague G F Jr, 1990, Adv Genet, V27, P33; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBO Y, 1984, CURR GENET, V8, P223, DOI 10.1007/BF00417820; VANWINKLESWIFT KP, 1988, CURR GENET, V13, P331, DOI 10.1007/BF00424428; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WHATLEY JM, 1982, BIOL REV, V57, P527, DOI 10.1111/j.1469-185X.1982.tb00373.x; WOESSNER JP, 1992, PLANT SCI, V83, P65, DOI 10.1016/0168-9452(92)90063-R; WOESSNER JP, 1989, PLANT CELL, V1, P901	62	56	59	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					801	811		10.1016/0092-8674(93)90460-8	http://dx.doi.org/10.1016/0092-8674(93)90460-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374951				2022-12-24	WOS:A1993LX29200006
J	COZART, JC				COZART, JC			THE LEGACY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1160	1160		10.1001/jama.270.10.1160	http://dx.doi.org/10.1001/jama.270.10.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355366				2022-12-24	WOS:A1993LV64900001
J	SHARP, D; BLINDERMAN, L; COMBS, KA; KIENZLE, B; RICCI, B; WAGERSMITH, K; GIL, CM; TURCK, CW; BOUMA, ME; RADER, DJ; AGGERBECK, LP; GREGG, RE; GORDON, DA; WETTERAU, JR				SHARP, D; BLINDERMAN, L; COMBS, KA; KIENZLE, B; RICCI, B; WAGERSMITH, K; GIL, CM; TURCK, CW; BOUMA, ME; RADER, DJ; AGGERBECK, LP; GREGG, RE; GORDON, DA; WETTERAU, JR			CLONING AND GENE DEFECTS IN MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ASSOCIATED WITH ABETALIPOPROTEINEMIA	NATURE			English	Article							HEP G2 CELLS; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; DISULFIDE ISOMERASE; SECRETION; LIPOPROTEINS; COMPLEX; SITES	THE microsomal triglyceride transfer protein (MTP), which catalyses the transport of triglyceride, cholesteryl ester and phospholipid between phospholipid surfaces, is a heterodimer composed of the multifunctional protein, protein disulphide isomerase, and a unique large subunit with an apparent M(r) of 88K (refs 1-3). It is isolated as a soluble protein from the lumen of the microsomal fraction of liver and intestine4. The large subunit of MTP was not detectable in four unrelated subjects with abetatipoproteinaemia5, a rare autosomal recessive disease characterized by a defect in the assembly or secretion of plasma lipoproteins that contain apolipoprotein B (ref. 6). We report here the isolation and sequencing of complementary DNA encoding the large subunit of MTP. A comparison of this sequence to corresponding genomic sequences from two abetatipoproteinaemic subjects revealed a homozygous frameshift mutation in one subject and a homozygous nonsense mutation in the other. The results indicate that a defect in the gene for die large subunit of MTP is the proximal cause of abetalipoproteinaemia in these two subjects, and that MTP is required for the secretion of plasma lipoproteins that contain apolipoprotein B.	BRISTOL MYERS SQUIBB,DEPT METAB DIS,PRINCETON,NJ 08543; UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV PARIS 07,INSERM,U327,F-75018 PARIS,FRANCE; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE	Bristol-Myers Squibb; University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Eckhardt, Erik/G-1567-2010					CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DAVIS RA, 1989, J LIPID RES, V30, P1185; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITE AL, 1992, J BIOL CHEM, V267, P15657; 1988, ARCH INTERN MED, V18, P36	17	362	383	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					65	69		10.1038/365065a0	http://dx.doi.org/10.1038/365065a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361539				2022-12-24	WOS:A1993LV64600055
J	LIEBERMAN, DE				LIEBERMAN, DE			LIFE-HISTORY VARIABLES PRESERVED IN DENTAL CEMENTUM MICROSTRUCTURE	SCIENCE			English	Article							BONE	The age and season of death of mammals, as well as other aspects of their life history, can be estimated from seasonal bands in dental cementum that result from variations in microstructure. Scanning electron micrographs of goats fed controlled diets demonstrate that cementum bands preserve variations in the relative orientation of collagen fibers that reflect changes in the magnitude and frequency of occlusal forces from chewing different quality diets. Changes in the rate of tissue growth are also reflected in cementum bands as variations in the degree of mineralization.	HARVARD UNIV,SOC FELLOWS,CAMBRIDGE,MA 02138	Harvard University	LIEBERMAN, DE (corresponding author), HARVARD UNIV,DEPT ANTHROPOL,11 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Self, Casey J/B-6871-2011					BOURQUE BJ, 1978, SCIENCE, V199, P530, DOI 10.1126/science.199.4328.530; Boyde A, 1972, DEV ASPECTS ORAL BIO, P243; BURGER E, 1991, BONE, V7, pCH2; CASTANET J, 1991, BONE, V7, pCH9; DERICQLES A, 1991, BONE, V3, pCH1; Fancy S.G., 1980, Wildlife Society Bulletin, V8, P242; GLIMCHER M, 1987, NATURE MINERAL COMPO, P49; Grue H., 1979, Danish Review of Game Biology, V11, P1; HYLANDER WL, 1986, ARCH ORAL BIOL, V31, P149, DOI 10.1016/0003-9969(86)90120-2; JONES SJ, 1987, SCANNING MICROSCOPY, V1, P2003; JONES SJ, 1981, DENTAL ANATOMY EMBRY, P66; Klevezal G.A., 1967, AGE DETERMINATION MA; LANYON L, 1991, BONE, V3, pCH2; LAWS RM, 1952, NATURE, V169, P972, DOI 10.1038/169972b0; Lieberman D.E., 1993, THESIS HARVARD U; LIEBERMAN DE, 1992, MAMMAL REV, V22, P57, DOI 10.1111/j.1365-2907.1992.tb00120.x; Lowenstam HA, 1989, BIOMINERALIZATION; MARTIN RB, 1989, STRUCTURE FUNCTION A; PEABODY FE, 1961, J MORPHOL, V108, P11, DOI 10.1002/jmor.1051080103; Portigliatti Barbos M, 1984, Metab Bone Dis Relat Res, V5, P309, DOI 10.1016/0221-8747(84)90018-3; SAXON A, 1969, AM ANTIQUITY, V34, P303, DOI 10.2307/278413; SCHMIDT WJ, 1972, POLARIZING MICROSCOP; Selvig K A, 1965, Acta Odontol Scand, V23, P423, DOI 10.3109/00016356509007523; WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838	25	94	95	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1162	1164		10.1126/science.8356448	http://dx.doi.org/10.1126/science.8356448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356448				2022-12-24	WOS:A1993LU58600029
J	THORN, P; LAWRIE, AM; SMITH, PM; GALLACHER, DV; PETERSEN, OH				THORN, P; LAWRIE, AM; SMITH, PM; GALLACHER, DV; PETERSEN, OH			LOCAL AND GLOBAL CYTOSOLIC CA2+ OSCILLATIONS IN EXOCRINE CELLS EVOKED BY AGONISTS AND INOSITOL TRISPHOSPHATE	CELL			English	Article							PANCREATIC ACINAR-CELLS; CALCIUM RELEASE; 1,4,5-TRISPHOSPHATE RECEPTOR; CHOLECYSTOKININ RECEPTORS; DIFFERENT PATTERNS; CHANNELS; RAT; ACTIVATION; SIGNALS; ACETYLCHOLINE	Submaximal stimulation with agonists generating inositol 1,4,5-trisphosphate (IP3) evokes cytosolic Ca2+ oscillations in many different cell types. In general, each Ca2+ rise is initiated from a specific region near the plasma membrane and then spreads as a wave throughout the cell. We now demonstrate that low (physiological) agonist concentrations evoke local cytosolic Ca2+ spikes in the secretory pole of single mouse pancreatic acinar cells that are particularly sensitive to blockade by the IP3 receptor antagonist heparin. These spikes can occur alone or repetitively or can precede longer lasting Ca2+ signals that spread throughout the cell. Intracellular IP3 application mimics these agonist actions. The short-lasting local Ca2+ spikes provide an economical signaling mechanism and are of physiological significance since they activate Ca2+-dependent Cl- and cation currents important for control of fluid secretion.			THORN, P (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,CROWN ST,LIVERPOOL L69 3BX,ENGLAND.		Thorn, Peter/F-7030-2010; Petersen, Ole H/E-8708-2010	Thorn, Peter/0000-0002-3228-770X; Petersen, Ole/0000-0002-6998-0380				ALBRITTON NL, 1992, SCIENCE, V258, P1812; AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; DELISLE S, 1992, J BIOL CHEM, V267, P7963; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FORSTER ER, 1992, EXP PHYSIOL, V77, P693, DOI 10.1113/expphysiol.1992.sp003635; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; INAGAKI N, 1991, P NATL ACAD SCI USA, V88, P4215, DOI 10.1073/pnas.88.10.4215; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MARTY A, 1991, J MEMBRANE BIOL, V124, P189, DOI 10.1007/BF01994353; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NOBLE NJ, 1992, BIOORG MED CHEM LETT, V2, P471, DOI 10.1016/S0960-894X(00)80172-9; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PETERSEN CCH, 1991, FEBS LETT, V293, P179, DOI 10.1016/0014-5793(91)81181-7; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHNEFEL S, 1988, FEBS LETT, V230, P125, DOI 10.1016/0014-5793(88)80655-0; SMITH PM, 1992, J PHYSIOL-LONDON, V446, pP72; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; STREB H, 1985, J BIOL CHEM, V260, P7309; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; THORN P, 1992, PFLUG ARCH EUR J PHY, V422, P173, DOI 10.1007/BF00370417; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TONES MA, 1989, FEBS LETT, V252, P105, DOI 10.1016/0014-5793(89)80898-1; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	51	440	441	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					661	668		10.1016/0092-8674(93)90513-P	http://dx.doi.org/10.1016/0092-8674(93)90513-P			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395347				2022-12-24	WOS:A1993LU59200009
J	KUBO, Y; REUVENY, E; SLESINGER, PA; JAN, YN; JAN, LY				KUBO, Y; REUVENY, E; SLESINGER, PA; JAN, YN; JAN, LY			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A RAT G-PROTEIN-COUPLED MUSCARINIC POTASSIUM CHANNEL	NATURE			English	Article							SENSITIVE K+-CHANNEL; GAMMA-SUBUNIT; ION CHANNELS; INWARD RECTIFICATION; XENOPUS OOCYTES; BETA-SUBUNIT; ACTIVATION; RECEPTOR; NEURONS; CONDUCTANCE	PARASYMPATHETIC nerve stimulation causes slowing of the heart rate by activation of muscarinic receptors and the subsequent opening of muscarinic K+ channels in the sinoatrial node and atrium1-4. This inwardly rectifying K- channel is coupled directly with G protein5-10. Based on sequence homology with cloned inwardly rectifying K+ channels, ROMK1 (ref. 11) and IRK1 (ref. 12), we have isolated a complementary DNA for a G-protein-coupled inwardly rectifying K+ channel (GIRK1) from rat heart. The GIRK1 channel probably corresponds to the muscarinic K+ channel because (1) its functional properties resemble those of the atrial muscarinic K+ channel and (2) its messenger RNA is much more abundant in the atrium than in the ventricle. In addition, GIRK1 mRNA is expressed not only in the heart but also in the brain.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Kubo, Yoshihiro/0000-0001-6707-0837				ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1990, REV PHYSL, V52, P197; BROWN DA, 1990, REV PHYSL, V52, P215; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GERBER U, 1991, J NEUROSCI, V11, P3861; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MORIE M, 1989, J PHYSL, V408, P313; NOMA A, 1979, PFLUG ARCH EUR J PHY, V381, P255, DOI 10.1007/BF00583257; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	35	594	608	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					802	806		10.1038/364802a0	http://dx.doi.org/10.1038/364802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355805				2022-12-24	WOS:A1993LU58100056
J	ROTHE, J; LESSLAUER, W; LOTSCHER, H; LANG, Y; KOEBEL, P; KONTGEN, F; ALTHAGE, A; ZINKERNAGEL, R; STEINMETZ, M; BLUETHMANN, H				ROTHE, J; LESSLAUER, W; LOTSCHER, H; LANG, Y; KOEBEL, P; KONTGEN, F; ALTHAGE, A; ZINKERNAGEL, R; STEINMETZ, M; BLUETHMANN, H			MICE LACKING THE TUMOR-NECROSIS-FACTOR RECEPTOR-1 ARE RESISTANT TO TNF-MEDIATED TOXICITY BUT HIGHLY SUSCEPTIBLE TO INFECTION BY LISTERIA-MONOCYTOGENES	NATURE			English	Article							VIRUS-REPLICATION; GAMMA INTERFERON; FACTOR-ALPHA; MOUSE; EXPRESSION; CLONING; INTERLEUKIN-1; ENDOTOXIN; CACHECTIN; INVIVO	TUMOUR necrosis factor (TNF), jointly referring to TNFalpha and TNFbeta, is a central mediator of immune and inflammatory responses; its activities are mediated by two distinct receptors, TNFR1 (p55) and TNFR2 (p75) (reviewed in refs 1-3). The cytoplasmic domains of the TNFRs are unrelated, suggesting that they link to different intracellular signalling pathways4. Although most TNF responses have been assigned to one or the other of the TNF receptors (mostly TNFR1), there is no generally accepted model for the physiological role of the two receptor types. To investigate the role of TNFR1 in beneficial and detrimental activities of TNF, we generated TNFR1-deficient mice by gene targeting. We report here that mice homozygous for a disrupted Tnfr1 allele (Tnfr1(0)) are resistant to the lethal effect of low doses of lipopolysaccharide after sensitization with D-galactosamine, but remain sensitive to high doses of lipopolysaccharide. The increased susceptibility of Tnfr1(0)/Tnfr1(0) mutant mice to infection with the facultative intracellular bacterium Listeria monocytogenes indicates an essential role of TNF in nonspecific immunity.	F HOFFMANN LA ROCHE & CO LTD, DEPT BIOL, PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; UNIV ZURICH, INST EXPTL IMMUNOL, CH-8057 ZURICH, SWITZERLAND	Roche Holding; University of Zurich								ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AGGARWAL BB, 1992, TUMOUR NECROSIS FACT; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1992, TUMOUR NECROSIS FACT; Blanden R V, 1972, Scand J Immunol, V1, P379, DOI 10.1111/j.1365-3083.1972.tb03304.x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; FEDUCHI E, 1989, J VIROL, V63, P1354, DOI 10.1128/JVI.63.3.1354-1359.1989; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GEHR G, 1992, J IMMUNOL, V149, P911; HAUSER T, 1990, MED MICROBIOL IMMUN, V179, P95; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KONTGEN F, IN PRESS INT IMMUN; LEIST TP, 1989, J VIROL, V63, P2813, DOI 10.1128/JVI.63.6.2813-2819.1989; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; NAKANE A, 1988, INFECT IMMUN, V56, P2563, DOI 10.1128/IAI.56.10.2563-2569.1988; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; ROTHE JG, 1991, IMMUNOGENETICS, V34, P338, DOI 10.1007/BF00211997; SHALABY MR, 1989, CLIN IMMUNOL IMMUNOP, V53, P488, DOI 10.1016/0090-1229(89)90010-X; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; ZINKERNAGEL RM, 1988, J EXP MED, V168, P1187, DOI 10.1084/jem.168.3.1187	32	1138	1170	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	1993	364	6440					798	802		10.1038/364798a0	http://dx.doi.org/10.1038/364798a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8395024				2022-12-24	WOS:A1993LU58100055
J	ORCI, L; PALMER, DJ; AMHERDT, M; ROTHMAN, JE				ORCI, L; PALMER, DJ; AMHERDT, M; ROTHMAN, JE			COATED VESICLE ASSEMBLY IN THE GOLGI REQUIRES ONLY COATOMER AND ARF PROTEINS FROM THE CYTOSOL	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; CLATHRIN; TRANSPORT; STACK; PITS; ENDOCYTOSIS; DISSECTION; MEMBRANES	TRANSPORT vesicles derived from the Golgi apparatus are thought to mediate biosynthetic transport across the Golgi stack1-3. These vesicles are surrounded by a protein coat4 whose principal constituents are coatomer (a complex of seven distinct subunits or COPs)5 and ADP-ribosylation factor (ARF, an N-myristylated small GTP-binding protein). The coat proteins of the COP-coated vesicles were originally defined by ultrastructural criteria4-9, however, and it is possible that important but minor coat proteins or cytoplasmic proteins needed for coat assembly may have been overlooked. Here we show that coatomer and ARF are the only cytoplasmic proteins needed for the assembly and budding of COP-coated vesicles. COP-coated buds may therefore form essentially by self-assembly from Golgi cisternae after an initial step in which GTP is used to allow ARF binding.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	ORCI, L (corresponding author), UNIV GENEVA, MED CTR, DEPT MORPHOL, 1 RUE MICHEL SERVET, CH-1211 GENEVA, SWITZERLAND.							CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; KAHN RA, 1992, J BIOL CHEM, V267, P13039; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	26	203	208	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					732	734		10.1038/364732a0	http://dx.doi.org/10.1038/364732a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355790				2022-12-24	WOS:A1993LT67700063
J	GODFREY, KM; BARKER, DJP; PEACE, J; CLOKE, J; OSMOND, C				GODFREY, KM; BARKER, DJP; PEACE, J; CLOKE, J; OSMOND, C			RELATION OF FINGERPRINTS AND SHAPE OF THE PALM TO FETAL GROWTH AND ADULT-BLOOD PRESSURE	BRITISH MEDICAL JOURNAL			English	Article							LIFE	Objective-To examine how finger and palm prints are related to fetal growth and adult blood pressure. Design-Follow up study of babies born around 50 years ago whose birth weight, placental weight, head circumference, and length at birth were recorded. Setting-Preston, Lancashire. Subjects-139 men and women born in Sharoe Green Hospital in Preston during 1935-43 and still living in Lancashire. Main outcome measures-Finger and palm prints and current blood pressure. Results-People who were thin at birth had more whorl patterns on their fingers. People who were short at birth in relation to their head circumference had longer hands and a narrower palmar angle. Mean systolic blood presure was 8 mmHg higher (95% confidence interval 2 to 13; p=0.01) in the 93 men and women with a whorl pattern on one or more fingers compared with the 46 who had no whorls. The greater the number of fingers with whorls the higher the systolic blood pressure. Whorls on the right hand were more strongly associated with higher systolic pressure than whorls on the left, mean systolic pressure rising by 2.2 mmHg (0.2 to 4.1; p = 0.03) for each additional whorl on the right hand. People with long hands and a narrow palmar angle also had higher systolic pressure. Again, these associations were stronger for the right hand. Mean systolic pressure rose by 0-49 mm Hg (-0.03 to 1.01; p = 0.06) for each degree decrease in palmar angle on the right hand. Conclusions-Fingertip whorls and a narrow palmar angle are indelible markers of impaired fetal development at different stages in pregnancy. Both are associated with raised blood pressure in adult life.	SCENES CRIME DEPT,FINGERPRINT SECT,LONDON SW1,ENGLAND		GODFREY, KM (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Godfrey, Keith/0000-0002-4643-0618				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARRY A, 1951, ANAT RECORD, V111, P221, DOI 10.1002/ar.1091110207; CHERRILL FR, 1954, FINGERPRINT SYSTEM S; DAWES GS, 1990, FETAL AUTONOMY ADAPT, P27; Jain P K, 1984, J Assoc Physicians India, V32, P335; KINMONTH JB, 1974, J CARDIOVASC SURG, V15, P447; LACROIX B, 1984, EARLY HUM DEV, V9, P127, DOI 10.1016/0378-3782(84)90093-8; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; MULVIHIL.JJ, 1969, J PEDIATR, V75, P579, DOI 10.1016/S0022-3476(69)80453-1; PENROSE LS, 1968, BRIT MED J, V2, P321, DOI 10.1136/bmj.2.5601.321; Pursnani M L, 1989, Indian Heart J, V41, P119; PURVISSMITH SG, 1968, LANCET, V2, P141; RASHAD MN, 1975, AM J PHYS ANTHROPOL, V42, P281, DOI 10.1002/ajpa.1330420218; REED T, 1978, AM J HUM GENET, V30, P383; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; YOUNG AE, 1983, CIBA F SYMP, V100, P222	21	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					405	409		10.1136/bmj.307.6901.405	http://dx.doi.org/10.1136/bmj.307.6901.405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374451	Green Published, Bronze			2022-12-24	WOS:A1993LR89500013
J	WILKINSON, R; MILLEDGE, JS; LANDON, MJ				WILKINSON, R; MILLEDGE, JS; LANDON, MJ			MICROALBUMINURIA IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC COR-PULMONALE; PROTEINURIA		NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London; Medical Research Council Clinical Trials Unit				Wilkinson, Robert/0000-0002-2753-1800				CAMPBELL JL, 1982, THORAX, V37, P607, DOI 10.1136/thx.37.8.607; DAGGETT P, 1977, POSTGRAD MED J, V53, P24, DOI 10.1136/pgmj.53.615.24; SKLAR AH, 1988, ARCH INTERN MED, V148, P87; STEWART AG, 1991, THORAX, V46, P829, DOI 10.1136/thx.46.11.829; WINTERBORN MH, 1987, POSTGRAD MED J, V63, P179, DOI 10.1136/pgmj.63.737.179	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					239	239		10.1136/bmj.307.6898.239	http://dx.doi.org/10.1136/bmj.307.6898.239			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369685	Green Published, Bronze			2022-12-24	WOS:A1993LP31400023
J	KAKU, DA; GIFFARD, RG; CHOI, DW				KAKU, DA; GIFFARD, RG; CHOI, DW			NEUROPROTECTIVE EFFECTS OF GLUTAMATE ANTAGONISTS AND EXTRACELLULAR ACIDITY	SCIENCE			English	Article							DEPRIVATION NEURONAL INJURY; D-ASPARTATE ANTAGONIST; ISCHEMIC BRAIN-DAMAGE; GLUCOSE DEPRIVATION; HIPPOCAMPAL-NEURONS; CORTICAL CULTURES; CEREBRAL HYPOXIA; CALCIUM-BINDING; AMINO-ACIDS; PH CHANGES	Glutamate antagonists protect neurons from hypoxic injury both in vivo and in vitro, but in vitro studies have not been done under the acidic conditions typical of hypoxia-ischemia in vivo. Consistent with glutamate receptor antagonism, extracellular acidity reduced neuronal death in murine cortical cultures that were deprived of oxygen and glucose. Under these acid conditions, N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-kainate antagonists further reduced neuronal death, such that some neurons tolerated prolonged oxygen and glucose deprivation almost as well as did astrocytes. Neuroprotection induced by this combination exceeded that induced by glutamate antagonists alone, suggesting that extracellular acidity has beneficial effects beyond the attenuation of ionotropic glutamate receptor activation.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305	Washington University (WUSTL); Stanford University				Giffard, Rona/0000-0003-2173-4436	NINDS NIH HHS [NS 26907, NS 01425] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026907, K08NS001425] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; BING OHL, 1973, SCIENCE, V180, P1297, DOI 10.1126/science.180.4092.1297; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUCHAN AM, 1992, ARCH NEUROL-CHICAGO, V49, P420, DOI 10.1001/archneur.1992.00530280114032; BURNIER M, 1988, AM J PHYSIOL, V254, pC839, DOI 10.1152/ajpcell.1988.254.6.C839; CHESNAIS JM, 1975, J MOL CELL CARDIOL, V7, P627, DOI 10.1016/0022-2828(75)90140-6; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J PHARMACOL EXP THER, V242, P713; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1987, J NEUROSCI, V7, P357; CHURCH J, 1985, EUR J PHARMACOL, V111, P185, DOI 10.1016/0014-2999(85)90755-1; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1987, NEUROSCI LETT, V80, P11, DOI 10.1016/0304-3940(87)90486-1; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KAKU D A, 1991, Society for Neuroscience Abstracts, V17, P1266; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KIM D, 1987, AM J PHYSIOL, V253, pC137, DOI 10.1152/ajpcell.1987.253.1.C137; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LANGER GA, 1985, CIRC RES, V57, P374, DOI 10.1161/01.RES.57.3.374; LEHMANN J, 1988, EUR J PHARMACOL, V154, P89, DOI 10.1016/0014-2999(88)90368-8; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MONYER H, 1988, BRAIN RES, V446, P144, DOI 10.1016/0006-8993(88)91304-2; MONYER H, 1989, BRAIN RES, V483, P347, DOI 10.1016/0006-8993(89)90179-0; NAKAMARU Y, 1972, J GEN PHYSIOL, V59, P22, DOI 10.1085/jgp.59.1.22; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; PENTTILA A, 1976, LIFE SCI, V18, P1419, DOI 10.1016/0024-3205(76)90359-3; PENTTILA A, 1974, SCIENCE, V185, P277, DOI 10.1126/science.185.4147.277; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN S, 1988, J PHARMACOL EXP THER, V246, P137; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHURR A, 1988, BRAIN RES, V438, P311, DOI 10.1016/0006-8993(88)91354-6; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104	46	180	183	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1516	1518		10.1126/science.8389056	http://dx.doi.org/10.1126/science.8389056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	8389056				2022-12-24	WOS:A1993LF05800040
J	CONKLIN, BR; FARFEL, Z; LUSTIG, KD; JULIUS, D; BOURNE, HR				CONKLIN, BR; FARFEL, Z; LUSTIG, KD; JULIUS, D; BOURNE, HR			SUBSTITUTION OF 3 AMINO-ACIDS SWITCHES RECEPTOR SPECIFICITY OF G(Q)ALPHA TO THAT OF G(I)ALPHA	NATURE			English	Article							G-PROTEINS; ADRENERGIC-RECEPTOR; ADENYLYL CYCLASE; ALPHA-SUBUNITS; INHIBITION; RHODOPSIN; CLONING; SITE; GENE; IDENTIFICATION	AGONIST-BOUND receptors activate heterotrimeric (alphabetagamma) G proteins by catalysing replacement of GDP bound to the alpha-subunit by GTP1-5. Mutations in the C terminus of the alpha-subunit6,7, its covalent modification by pertussis toxin-catalysed ribosylation of ADP8, peptide-specific antibodies directed against it9-11, and peptides mimicking C-terminal sequences12, all inhibit receptor-mediated activation of G proteins. The logical prediction-that specific amino-acid residues at the C-termini of alpha-subunits can determine the abilities of individual G proteins to discriminate among specific subsets of receptors-has so far not been tested experimentally. Different hormone receptors specifically activate G(q) or G(i), whose alpha-subunits (alpha(q) or alpha(i)) stimulate phosphatidylinositol-specific phospholipase C or inhibit adenylyl cyclase, respectively1-5. Here we replace C-terminal amino acids of alpha(q) with the corresponding residues of alpha(i2) to create alpha(q)/alpha(i2) chimaeras that can mediate stimulation of phospholipase C by receptors otherwise coupled exclusively to G(i). A minimum of three alpha(i2) amino acids, including a glycine three residues from the C terminus, suffices to switch the receptor specificity of the alpha(q)/alpha(i2) chimaeras. We propose that a C-terminal turn, centred on this glycine, plays an important part in specifying receptor interactions of G proteins in the G(i)/G(o)/G(z) family.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, S1212 BOX 0450, SAN FRANCISCO, CA 94143 USA; TEL AVIV UNIV, CHAIM SHEBA MED CTR, DEPT MED E, IL-52621 TEL AVIV, ISRAEL; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Chaim Sheba Medical Center; Tel Aviv University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Conklin, Bruce/E-4738-2019	Conklin, Bruce/0000-0003-1463-6061				ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; AVIGAN J, 1992, BIOCHEMISTRY-US, V31, P7736, DOI 10.1021/bi00148a039; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1991, CELL MOL NEUROBIOL, V11, P563, DOI 10.1007/BF00741446; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAURENT E, 1987, MOL CELL ENDOCRINOL, V52, P273, DOI 10.1016/0303-7207(87)90055-4; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; WEST RE, 1985, J BIOL CHEM, V260, P4428; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957	37	596	647	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					274	276		10.1038/363274a0	http://dx.doi.org/10.1038/363274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387644				2022-12-24	WOS:A1993LC86600056
J	MCGLADEMCCULLOH, E; YAMAMOTO, H; TAN, SE; BRICKEY, DA; SODERLING, TR				MCGLADEMCCULLOH, E; YAMAMOTO, H; TAN, SE; BRICKEY, DA; SODERLING, TR			PHOSPHORYLATION AND REGULATION OF GLUTAMATE RECEPTORS BY CALCIUM CALMODULIN-DEPENDENT PROTEIN KINASE-II	NATURE			English	Article							POSTSYNAPTIC DENSITY PROTEIN; MOLECULAR-CLONING; SUBUNIT; EXPRESSION; BRAIN; BINDING; KAINATE; SYSTEM; AMPA	THE major postsynaptic density (PSD) protein1,2 at glutaminergic synapses is calcium/calmodulin-dependent protein kinase II (CaM-K II), but its function in the PSD is not known. We have examined glutamate receptors (GluRs) as substrates for CaM-K II because (1) they are colocalized in the PSD3, (2) cloned GluRs4-7 contain consensus phosphorylation sites for protein kinases including CaM-K II, and (3) several GluRs are regulated by other protein kinases8-12. Regulation of GluRs, which are involved in excitatory synaptic transmission and in mechanisms of learning and memory13, by CaM-K II is of interest because of the postulated role of CaM-K II in synaptic plasticity14,15 and its known involvement in induction of long-term potentiation16. Furthermore, mice lacking the major neural isoform of CaM-K II exhibit deficits in models of learning and memory that require hippocampal input17,18. We report here that CaM-K II phosphorylates GluR in several in vitro systems, including the PSD, and that activated CaM-K II enhances kainate-induced ion current three- to fourfold in cultured hippocampal neurons. These results are consistent with a role for PSD CaM-K II in strengthening postsynaptic GluR responses in synaptic plasticity.	OREGON HLTH SCI UNIV,VOLLUM INST,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201	Oregon Health & Science University								BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; LESTER RAJ, 1989, MOL PHARMACOL, V35, P565; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; SIEKEVITZ P, 1985, P NATL ACAD SCI USA, V82, P3494, DOI 10.1073/pnas.82.10.3494; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SUMMNERS MD, 1988, TEXAS AGR EXPT STATI, V1555; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG LY, 1992, NEUR ABSTR, V18, P653; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WESTBROOK GL, 1989, SEMINARS NEUROSCIENC, V1, P103; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x	30	347	348	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					640	642		10.1038/362640a0	http://dx.doi.org/10.1038/362640a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	8385275				2022-12-24	WOS:A1993KX43800051
J	MEHLER, MF; ROZENTAL, R; DOUGHERTY, M; SPRAY, DC; KESSLER, JA				MEHLER, MF; ROZENTAL, R; DOUGHERTY, M; SPRAY, DC; KESSLER, JA			CYTOKINE REGULATION OF NEURONAL DIFFERENTIATION OF HIPPOCAMPAL PROGENITOR CELLS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; CHOLINERGIC NEURONS; NERVOUS-SYSTEM; GROWTH; INTERLEUKIN-11; NEUROFILAMENTS; INVITRO; INSITU; INVIVO; LINE	THE signalling mechanisms governing haematolymphopoiesis and those regulating neural development may be closely related, as indicated by similarities of higher-order structure and function of the cytokines involved1, of the regional and temporal regulation of their transcription and translation2-6, and of their bioactivity7-10. Here we investigate this possible evolutionary connection using retroviral transduction of a temperature-sensitive mutant form of the SV40 large T antigen to develop conditionally immortalized murine embryonic hippocampal progenitor cell lines11-14. Treatment of these cells with cytokines that are thought to participate in progressive lymphoid maturation, immunoglobulin synthesis15-18 and erythropoiesis19,20 causes progressive neuronal differentiation, as defined by morphological criteria, successive expression of increasingly mature neurofilament proteins21-23, and the generation of inward currents and action potentials. The cytokine interleukin(IL)-11 induces expression of action potentials that are insensitive to tetrodotoxin, which is indicative of developmentally immature sodium channels24. By contrast, for expression of more mature action potentials24 (tetrodotoxin-sensitive) one of the interleukins IL-5, IL-7 or IL-9 must be applied in association with transforming growth factor-alpha after pretreatment with basic fibroblast growth factor. Our results suggest that the mechanisms regulating lineage commitment and cellular differentiation in the neural and haematopoietic systems are similar. Further, they define an in vitro model system that may facilitate molecular analysis of graded stages of mammalian neuronal differentiation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; FED UNIV RIO DE JANEIRO,INST BIOPHYS CARLOS CHAGAS FILHO,BR-21941 RIO JANEIRO,BRAZIL	Yeshiva University; Albert Einstein College of Medicine	MEHLER, MF (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461, USA.		Rozental, Renato/D-5302-2012	Spray, David/0000-0001-8368-5073				BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; DAHL D, 1988, J NEUROSCI RES, V20, P431, DOI 10.1002/jnr.490200405; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FARRAR WL, 1989, BLOOD, V73, P137; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GALINOVICSCHWARTZ V, 1991, J NEUROSCI RES, V30, P124, DOI 10.1002/jnr.490300114; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAMEGAI M, 1990, NEURON, V2, P429; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PIETSCH T, 1990, KLIN PADIATR, V202, P235, DOI 10.1055/s-2007-1025526; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519	30	229	232	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					62	65		10.1038/362062a0	http://dx.doi.org/10.1038/362062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383296				2022-12-24	WOS:A1993KP97600060
J	DAWSON, TM; ARRIZA, JL; JAWORSKY, DE; BORISY, FF; ATTRAMADAL, H; LEFKOWITZ, RJ; RONNETT, GV				DAWSON, TM; ARRIZA, JL; JAWORSKY, DE; BORISY, FF; ATTRAMADAL, H; LEFKOWITZ, RJ; RONNETT, GV			BETA-ADRENERGIC-RECEPTOR KINASE-2 AND BETA-ARRESTIN-2 AS MEDIATORS OF ODORANT-INDUCED DESENSITIZATION	SCIENCE			English	Article							SENSITIVE ADENYLATE-CYCLASE; OLFACTORY NEURONS; MULTIGENE FAMILY; PROTEIN; CHANNEL; PHOSPHORYLATION; TRANSDUCTION; ACTIVATION; EXPRESSION; ARRESTIN	Beta-adrenergic receptor kinase (betaARK) and beta-arrestin function in the homologous or agonist-activated desensitization of G protein-coupled receptors. The isoforms betaARK-2 and beta-arrestin-2 are highly enriched in and localized to the dendritic knobs and cilia of the olfactory receptor neurons where the initial events of olfactory signal transduction occur. Odorants induce a rapid and transient elevation of adenosine 3',5'-monophosphate (cAMP), which activates a nonspecific cation channel and produces membrane depolarization. Preincubation of rat olfactory cilia with antibodies raised against betaARK-2 and beta-arrestin-2 increased the odorant-induced elevation of cAMP and attenuated desensitization. These results suggest that betaARK-2 and beta-arrestin-2 mediate agonist-dependent desensitization in olfaction.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED & BIOCHEM,DURHAM,NC 27710	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Attramadal, Havard/0000-0001-9506-0687	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002131, K08NS001578] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01578-01, NS-02131] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, IN PRESS J NEUROSCI; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CUNNIGHAM AC, 1991, SOC NEUR ABSTR, V17, P754; CUNNINGHAM A, UNPUB; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEIN WL, 1989, FASEB J, V3, P2132, DOI 10.1096/fasebj.3.10.2546848; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MARGOLIS FL, 1974, BRAIN RES, V81, P469, DOI 10.1016/0006-8993(74)90844-0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6974; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SKLAR PB, 1986, J BIOL CHEM, V261, P5538	33	179	183	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					825	829		10.1126/science.8381559	http://dx.doi.org/10.1126/science.8381559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8381559				2022-12-24	WOS:A1993KL11000037
J	DERR, LK; STRATHERN, JN				DERR, LK; STRATHERN, JN			A ROLE FOR REVERSE TRANSCRIPTS IN GENE CONVERSION	NATURE			English	Article							MITOTIC RECOMBINATION; YEAST; SELECTION	RECOMBINATION between a diffusible reverse transcript and its homologous chromosomal allele has been proposed as a mechanism for the precise removal of introns from DNA and gene conversion of dispersed repeated sequences1,2. We have reported that RNA-mediated recombination occurs in the yeast Saccharomyces cerevisiae3. This recombination requires expression of the retro-transposon Ty, and results in intron loss from a plasmid-borne marker gene and the formation of pseudogenes. Because the pseudogenes are embedded in Ty sequences, chromosomal insertion could have been mediated by Ty integrase or by homologous recombination with endogenous Ty sequences. The structure of the chromosomal recombinants and the fact that plasmid and chromosomal recombination can have different requirements demanded a direct demonstration of RNA-mediated gene conversion of a chromosomal allele. Here we report the first demonstration, to our knowledge, of recombination between a reverse transcript and its chromosomal homologue and describe an assay that specifically detects this novel recombination pathway.			DERR, LK (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,EUKARYOT GENE EXPRESS LAB,FREDERICK,MD 21701, USA.							ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINIAL M, 1987, CELL, V49, P93, DOI 10.1016/0092-8674(87)90759-8; MALONE RE, 1988, CURR GENET, V14, P211, DOI 10.1007/BF00376741; MCGILL CB, 1990, CURR GENET, V18, P29, DOI 10.1007/BF00321112; MELAMED C, 1992, MOL CELL BIOL, V4, P1613; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587	13	125	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					170	173		10.1038/361170a0	http://dx.doi.org/10.1038/361170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8380627	Green Published			2022-12-24	WOS:A1993KG46600065
J	KUHN, R; LOHLER, J; RENNICK, D; RAJEWSKY, K; MULLER, W				KUHN, R; LOHLER, J; RENNICK, D; RAJEWSKY, K; MULLER, W			INTERLEUKIN-10-DEFICIENT MICE DEVELOP CHRONIC ENTEROCOLITIS	CELL			English	Article							INHIBITS CYTOKINE PRODUCTION; CELL STIMULATORY FACTOR; T-CELLS; MONOCLONAL-ANTIBODY; B-CELLS; ACTIVATED MACROPHAGES; TARGETED DISRUPTION; INTERFERON-GAMMA; DOWN-REGULATION; STEM-CELLS	Interleukin-10 (IL-10) affects the growth and differentiation of many hemopoietic cells in vitro; in particular, it is a potent suppressor of macrophage and T cell functions. In IL-10-deficient mice, generated by gene targeting, lymphocyte development and antibody responses are normal, but most animals are growth retarded and anemic and suffer from chronic enterocolitis. Alterations in intestine include extensive mucosal hyperplasia, inflammatory reactions, and aberrant expression of major histocompatibility complex class II molecules on epithelia. In contrast, mutants kept under specific pathogen-free conditions develop only a local inflammation limited to the proximal colon. These results indicate that the bowel inflammation in the mutants originates from uncontrolled immune responses stimulated by enteric antigens and that IL-10 is an essential immunoregulator in the intestinal tract.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, PALO ALTO, CA 94304 USA	Heinrich Pette Institute; University of Hamburg; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	KUHN, R (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Muller, Werner/B-9044-2008; Kühn, Ralf/U-1278-2017	Muller, Werner/0000-0002-1297-9725; Kühn, Ralf/0000-0003-1694-9803				BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BOLLI, 1991, PRAKTISCHE BLUTZELLD; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Grutzmann R., 1981, THESIS U COLOGNE COL; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISHIDA H, 1992, J EXP MED, V175, P1213, DOI 10.1084/jem.175.5.1213; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KASSAI T, 1982, HDB NIPPOSTRONGYLUS; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; KIM JM, 1992, J IMMUNOL, V148, P3618; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MEANS RT, 1992, J AM SOC HEMATOL, V80, P1639; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN T, 1991, IMMUNOL TODAY, V12, P257, DOI 10.1016/0167-5699(91)90121-9; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; MOSMANN TR, 1990, J IMMUNOL, V145, P2938; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; RIZZO LV, 1992, J IMMUNOL, V22, P711; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHMITZ J, 1993, EUR J IMMUNOL, V23, P191, DOI 10.1002/eji.1830230130; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHER A, 1991, J IMMUNOL, V147, P2713; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x	54	3515	3610	4	153	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					263	274		10.1016/0092-8674(93)80068-P	http://dx.doi.org/10.1016/0092-8674(93)80068-P			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402911				2022-12-24	WOS:A1993MD88500008
J	MORGENSTERN, L				MORGENSTERN, L			THE REST OF HIM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1816	1816		10.1001/jama.270.15.1816	http://dx.doi.org/10.1001/jama.270.15.1816			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411524				2022-12-24	WOS:A1993MB46400023
J	YAN, RT; MALONEY, PC				YAN, RT; MALONEY, PC			IDENTIFICATION OF A RESIDUE IN THE TRANSLOCATION PATHWAY OF A MEMBRANE CARRIER	CELL			English	Article							MITOCHONDRIAL ASPARTATE GLUTAMATE; SUGAR PHOSPHATE-TRANSPORT; SITE-SPECIFIC MUTAGENESIS; ESCHERICHIA-COLI; LAC PERMEASE; CYSTEINE RESIDUES; ANION-EXCHANGE; SH-REAGENTS; MUTANTS; DNA	Preliminary work using directed mutagenesis proved that cysteine is not required for operation of UhpT, the anion exchange protein responsible for glucose 6-phosphate transport by E. coll. We then made a detailed study of C143 and C265, because these cysteines impart sensitivity to p-chloromercuribenzosulfonate (PCMBS), a sulfhydral agent resembling glucose 6-phosphate in size, shape, and charge. We showed that C143 was exposed to the cytoplasm, as expected from hydropathy analysis, but we found no sidedness for C265. Rather, C265 was accessible to PCMBS from both membrane surfaces. And since the attack at C265 was blocked by glucose 6-phosphate, position 265 must lie directly on the pathway taken by the substrate as it moves through this membrane carrier.			YAN, RT (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21209, USA.				NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; AQUILA H, 1987, FEBS LETT, V212, P109; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P281, DOI 10.1016/0005-2736(90)90177-P; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; FOX CF, 1965, P NATL ACAD SCI USA, V54, P891, DOI 10.1073/pnas.54.3.891; Frederick M., 1989, CURRENT PROTOCOLS MO; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; HOCHHAUSER SJ, 1978, J BACTERIOL, V134, P157, DOI 10.1128/JB.134.1.157-166.1978; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE JI, 1992, J BIOL CHEM, V267, P20758; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1990, RES MICROBIOL, V141, P374, DOI 10.1016/0923-2508(90)90015-I; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MITCHELL P, 1953, J GEN MICROBIOL, V9, P273, DOI 10.1099/00221287-9-2-273; MITCHELL P, 1990, RES MICROBIOL, V141, P286, DOI 10.1016/0923-2508(90)90002-8; RAO US, 1990, J BIOL CHEM, V265, P7227; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SAIER MH, 1993, TRENDS BIOCHEM SCI, V18, P13; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR HK, 1986, J BIOL CHEM, V261, P8914; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; WAGNER R, 1989, EUR J BIOCHEM, V182, P165, DOI 10.1111/j.1432-1033.1989.tb14813.x; WIDDAS WF, 1952, J PHYSIOL-LONDON, V118, P23, DOI 10.1113/jphysiol.1952.sp004770; WIDDAS WF, 1988, BIOCHIM BIOPHYS ACTA, V947, P385, DOI 10.1016/0304-4157(88)90001-9; YAMOTO I, 1988, J BIOL CHEM, V263, P16055	39	72	73	16	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					37	44		10.1016/S0092-8674(05)80082-0	http://dx.doi.org/10.1016/S0092-8674(05)80082-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402899				2022-12-24	WOS:A1993MB66700006
J	BROENE, RD; BUCHWALD, SL				BROENE, RD; BUCHWALD, SL			ZIRCONOCENE COMPLEXES OF UNSATURATED ORGANIC-MOLECULES - NEW VEHICLES FOR ORGANIC-SYNTHESIS	SCIENCE			English	Article							ANSA-METALLOCENE DERIVATIVES; BRIDGED TETRAHYDROINDENYL LIGANDS; METAL-COMPLEXES; POLYSUBSTITUTED NAPHTHALENES; REGIOSPECIFIC SYNTHESIS; MAGNESIUM REAGENTS; MEDIATED SYNTHESIS; CRYSTAL-STRUCTURE; ALLYLIC AMINES; ZIRCONIUM	Transition metals are known to stabilize high-energy species and to activate otherwise unreactive ones. The zirconocene unit stabilizes highly strained alkynes and alkenes, allowing their use in selective carbon-carbon bond-forming reactions. This unit also increases the reactivity of unactivated molecules, enabling them to participate in nontraditional transformations. A general route has been developed that allows a wider variety of unsaturated fragments to participate in these reactions. The use of these zirconocene complexes in organic synthesis has led to the development of novel routes to a number of polyfunctionalized organic molecules.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034917] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09112] Funding Source: Medline; NIGMS NIH HHS [GM 34917] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER BR, 1992, ORGANOMETALLICS, V11, P3427, DOI 10.1021/om00046a049; BENNETT MA, 1989, ANGEW CHEM INT EDIT, V28, P1296, DOI 10.1002/anie.198912961; BERK SC, 1993, J AM CHEM SOC, V115, P4912, DOI 10.1021/ja00064a071; BUCHWALD SL, 1988, CHEM REV, V88, P1047, DOI 10.1021/cr00089a004; BUCHWALD SL, 1987, J AM CHEM SOC, V109, P4396, DOI 10.1021/ja00248a046; BUCHWALD SL, 1991, J AM CHEM SOC, V113, P258, DOI 10.1021/ja00001a037; BUCHWALD SL, 1986, J AM CHEM SOC, V108, P7411, DOI 10.1021/ja00283a048; BUCHWALD SL, 1990, ANGEW CHEM INT EDIT, V29, P771, DOI 10.1002/anie.199007711; BUCHWALD SL, 1989, J AM CHEM SOC, V111, P2870, DOI 10.1021/ja00190a021; BUCHWALD SL, 1989, J ORG CHEM, V54, P2793, DOI 10.1021/jo00273a006; BUCHWALD SL, 1989, J AM CHEM SOC, V111, P4486, DOI 10.1021/ja00194a052; BUCHWALD SL, 1988, J AM CHEM SOC, V110, P3171, DOI 10.1021/ja00218a027; BUCHWALD SL, 1989, CHEM SCRIPTA, V29, P417; Cardin D. J., 1986, CHEM ORGANOZIRCONIUM; COLEMAN RS, 1989, STUDIES NATURAL PROD, V3, P301; COLES N, 1992, SYNLETT, P143; COLES N, 1990, SYNLETT, P271; COLLMAN JP, 1987, PRINCIPLES APPLICATI; Curran DP, 1991, COMPREHENSIVE ORGANI, P714; DZHEMILEV VM, 1989, IZV AKAD NAUK KAZ K, V38, P207; ERKER G, 1977, J ORGANOMET CHEM, V134, P189, DOI 10.1016/S0022-328X(00)81419-9; ERKER G, 1979, J AM CHEM SOC, V101, P3659, DOI 10.1021/ja00507a043; FAGAN PJ, 1988, J AM CHEM SOC, V110, P2310, DOI 10.1021/ja00215a057; FANG Q, UNPUB; GANT TG, 1992, J AM CHEM SOC, V114, P1010, DOI 10.1021/ja00029a032; GROSSMAN RB, 1991, J AM CHEM SOC, V113, P2321, DOI 10.1021/ja00006a071; HALTERMAN RL, 1992, CHEM REV, V92, P965, DOI 10.1021/cr00013a011; HEGEDUS LS, 1988, ANGEW CHEM INT EDIT, V27, P1113, DOI 10.1002/anie.198811133; HOVEYDA AH, 1992, J AM CHEM SOC, V114, P6692, DOI 10.1021/ja00043a012; HSU DP, 1990, TETRAHEDRON LETT, V31, P5563, DOI 10.1016/S0040-4039(00)97897-3; JENSEN M, 1989, J AM CHEM SOC, V111, P4495, DOI 10.1021/ja00194a053; JORDAN RF, 1989, J AM CHEM SOC, V111, P778, DOI 10.1021/ja00184a081; KNIGHT KS, 1991, J AM CHEM SOC, V113, P6268, DOI 10.1021/ja00016a052; LAUHER JW, 1976, J AM CHEM SOC, V98, P1729, DOI 10.1021/ja00423a017; LEWIS DP, 1991, TETRAHEDRON LETT, V32, P6797, DOI 10.1016/S0040-4039(00)93606-2; MASUI H, 1968, B CHEM SOC JPN, V41, P750; NEGISHI, 1989, J ORG CHEM, V54, P3521; NEGISHI E, 1989, CHEM SCRIPTA, V29, P457; NEGISHI EI, 1991, COMPREHENSIVE ORGANI, V5, P1163; NOYORI R, 1990, SCIENCE, V248, P1194, DOI 10.1126/science.248.4960.1194; NUGENT WA, 1989, CHEM SCRIPTA, V29, P439; NUGENT WA, 1993, SCIENCE, V259, P479, DOI 10.1126/science.259.5094.479; NUGENT WA, 1989, J AM CHEM SOC, V111, P6435, DOI 10.1021/ja00198a073; RADOM L, 1986, PURE APPL CHEM, V58, P75, DOI 10.1351/pac198658010075; SCHAFER A, 1987, J ORGANOMET CHEM, V328, P87, DOI 10.1016/S0022-328X(00)99770-5; Schore N. E., 1991, COMPREHENSIVE ORGANI, V5, P1037; SHUR VB, 1985, J ORGANOMET CHEM, V288, pC36; SPENCE REV, 1992, ORGANOMETALLICS, V11, P3492, DOI 10.1021/om00059a003; TAKAHASHI T, 1991, J AM CHEM SOC, V113, P6266, DOI 10.1021/ja00016a051; TIDWELL JH, 1992, J ORG CHEM, V57, P6380, DOI 10.1021/jo00050a003; TIDWELL JH, 1991, J AM CHEM SOC, V113, P4685, DOI 10.1021/ja00012a050; TIDWELL JH, UNPUB; Trost B M, 1991, COMPREHENSIVE ORGANI, V1-9; Trost B. M., 1991, COMPREHENSIVE ORGANI, V4; Trost B. M., 1991, COMPREHENSIVE ORGANI, V2; VOLPIN ME, 1971, J CHEM SOC CHEM COMM, P972; WILD FRWP, 1982, J ORGANOMET CHEM, V232, P233; WILD FRWP, 1985, J ORGANOMET CHEM, V288, P63, DOI 10.1016/0022-328X(85)80104-2; WISCHMEYER U, 1992, TETRAHEDRON LETT, V33, P7735, DOI 10.1016/0040-4039(93)88032-E; WULFF WD, 1988, J AM CHEM SOC, V110, P2312, DOI 10.1021/ja00215a058	60	168	169	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1696	1701		10.1126/science.8378769	http://dx.doi.org/10.1126/science.8378769			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378769				2022-12-24	WOS:A1993LY58400016
J	MILLER, C				MILLER, C			POTASSIUM SELECTIVITY IN PROTEINS - OXYGEN CAGE OR IN THE F-ACE	SCIENCE			English	Editorial Material							MOLECULAR RECOGNITION; ION; CHANNELS; BINDING; MEDIA		BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University	MILLER, C (corresponding author), BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Dobler M., 1981, IONOPHORES THEIR STR; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1962, Biophys J, V2, P259; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; Hille B., 1991, IONIC CHANNELS EXCIT; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; RENNER M, 1993, P NATL ACAD SCI USA, V90, P6493, DOI 10.1073/pnas.90.14.6493; SHEPODD TJ, 1988, J AM CHEM SOC, V110, P1983, DOI 10.1021/ja00214a063; SNYDER EE, 1990, BIOCHEMISTRY-US, V29, P3937, DOI 10.1021/bi00468a021; STAUFFER DA, 1988, TETRAHEDRON LETT, V29, P6039, DOI 10.1016/S0040-4039(00)82259-5; SUNNER J, 1981, J PHYS CHEM-US, V85, P1814, DOI 10.1021/j150613a011; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040	16	54	54	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1692	1693		10.1126/science.8397443	http://dx.doi.org/10.1126/science.8397443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8397443				2022-12-24	WOS:A1993LY58400014
J	DRISCOLL, J; BROWN, MG; FINLEY, D; MONACO, JJ				DRISCOLL, J; BROWN, MG; FINLEY, D; MONACO, JJ			MHC-LINKED LMP GENE-PRODUCTS SPECIFICALLY ALTER PEPTIDASE ACTIVITIES OF THE PROTEASOME	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; SUBUNITS; PATHWAY; CELLS	PROTEASOMES are highly conserved macromolecular structures which function as endopeptidases1-3. They are found in the cytoplasm and nucleus of eukaryotic tissues and consist of at least 14 non-identical subunits with molecular masses ranging from approximately 20 to 32K. Proteasomes are essential in the selective degradation of ubiquitinated and certain non-ubiquitinated proteins, acting as the proteolytic core of an energy-dependent 26S (1,500K) proteolytic complex. Two proteasome subunits, LMP2 and LMP7 (refs 4-7), are encoded within the major histocompatibility complex (MHC), implicating proteasomes in antigen processing8-9. Here we determine the function of these two MHC-linked subunits by comparing the proteolytic activities of purified proteasomes containing (LMP+) or lacking (LMP-) these components. We find that proteasomes of both types have endopeptidase activity against substrates bearing hydrophobic, basic or acidic residues immediately preceding the cleavage site (the P1 position) and at sites following asparagine, glycine and proline residues. The activity of LMP+ proteasomes is much higher than that of LMP- proteasomes against substrates with hydrophobic, basic or asparagine residues at P1, whereas their activities are comparable when acidic and glycine residues are present at P1. The MHC-linked LMP2 and LMP7 subunits therefore function to amplify specific endopeptidase activities of the proteasome.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Harvard University; Harvard Medical School; Virginia Commonwealth University			Brown, Michael G/AAX-5569-2021	Brown, Michael G/0000-0003-2872-7685; Driscoll, James/0000-0001-8364-0617				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BROWN MG, 1993, J IMMUNOL, V151, P1193; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	21	431	441	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					262	264		10.1038/365262a0	http://dx.doi.org/10.1038/365262a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371781				2022-12-24	WOS:A1993LX47100057
J	PARK, HO; CHANT, J; HERSKOWITZ, I				PARK, HO; CHANT, J; HERSKOWITZ, I			BUD2 ENCODES A GTPASE-ACTIVATING PROTEIN FOR BUD1/RSR1 NECESSARY FOR PROPER BUD-SITE SELECTION IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAS GTPASE; CELL POLARITY; GENE; PATHWAY; IRA2; GAP; PURIFICATION; REGULATOR; EXCHANGE	CELLS of the budding yeast Saccharomyces cerevisiae bud at either axial or bipolar sites depending on their cell type1. Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD52-4. Mutants defective in BUD1, BUD2 or BUD5 choose bud sites randomly. Bud1 protein (Bud1p) has sequence similarity to Ras, a small GTP-binding protein, and Bud5p is similar to Cdc25p (refs 4, 5), a GDP-GTP exchange factor6. Here we report that Bud2p is a GTPase-activating protein (GAP) for Bud1p with a sequence similar to the catalytic domain of rasGAPs, and that Bud2p purified from yeast stimulates GTP hydrolysis by Bud1p. Chromosomal deletion of BUD2 causes a random budding pattern but no obvious growth defect. Overexpression of BUD2 also causes a random budding pattern by wild-type cells11.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Park, Hay-Oak/0000-0001-5782-2257				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENDER A, IN PRESS P NATN ACAD; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	27	149	152	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1993	365	6443					269	274		10.1038/365269a0	http://dx.doi.org/10.1038/365269a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371782				2022-12-24	WOS:A1993LX47100060
J	GORE, RM				GORE, RM			CHOLECYSTOKININ-ENHANCED CHOLESCINTIGRAPHY IN THE DIAGNOSIS OF GALLBLADDER-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ACALCULOUS BILIARY PAIN; CHOLECYSTECTOMY				GORE, RM (corresponding author), NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201, USA.							Achord J L, 1992, Gastroenterology, V103, P1985; FINKBENNETT D, 1991, J NUCL MED, V32, P1695; HALVERSON JD, 1992, ARCH INTERN MED, V152, P1305, DOI 10.1001/archinte.152.6.1305; SHAFFER EA, 1992, HEPATOLOGY, V15, P737, DOI 10.1002/hep.1840150432; WESTLAKE PJ, 1990, AM J GASTROENTEROL, V85, P986; YAP L, 1991, GASTROENTEROLOGY, V101, P786, DOI 10.1016/0016-5085(91)90540-2; ZIESSMAN HA, 1992, J NUCL MED, V33, P537	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1370	1370		10.1001/jama.270.11.1370	http://dx.doi.org/10.1001/jama.270.11.1370			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360976				2022-12-24	WOS:A1993LW34500040
J	BERCHTOLD, H; RESHETNIKOVA, L; REISER, COA; SCHIRMER, NK; SPRINZL, M; HILGENFELD, R				BERCHTOLD, H; RESHETNIKOVA, L; REISER, COA; SCHIRMER, NK; SPRINZL, M; HILGENFELD, R			CRYSTAL-STRUCTURE OF ACTIVE ELONGATION-FACTOR TU REVEALS MAJOR DOMAIN REARRANGEMENTS	NATURE			English	Article							POLYPEPTIDE-CHAIN-ELONGATION; AMINOACYL-TRANSFER RNA; FACTOR-EF-TU; THERMUS-THERMOPHILUS HB8; ESCHERICHIA-COLI; BINDING-SITE; PROTEIN-BIOSYNTHESIS; EXTREME THERMOPHILE; NUCLEOTIDE BINDING; GTP HYDROLYSIS	The crystal structure of intact elongation factor Tu (EF-Tu) from Thermus thermophilus has been determined and refined at an effective resolution of 1.7 angstrom, with incorporation of data extending to 1.45 angstrom. The effector region, including interaction sites for the ribosome and for transfer RNA, is well defined. Molecular mechanisms are proposed for transduction and amplification of the signal induced by GTP binding as well as for the intrinsic and effector-enhanced GTPase activity of EF-Tu. Comparison of the structure with that of EF-Tu-GDP reveals major mutual rearrangements of the three domains of the molecule.	HOECHST AKT GESELL,CENT RES G865A,PROT CRYSTALLOG,D-65926 FRANKFURT,GERMANY; UNIV BAYREUTH,BIOCHEM LAB,D-95440 BAYREUTH,GERMANY; VA ENGELHARDT MOLEC BIOL INST,MOSCOW 117984,RUSSIA	Sanofi-Aventis; University of Bayreuth; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS			Hilgenfeld, Rolf/C-9675-2011					ANBORGH PH, 1991, EMBO J, V10, P779, DOI 10.1002/j.1460-2075.1991.tb08009.x; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR 2 1 MANUAL, P240; COOL RH, 1991, BIOCHEMISTRY-US, V30, P362, DOI 10.1021/bi00216a008; DUFFY LK, 1981, BIOCHEMISTRY-US, V20, P4663, DOI 10.1021/bi00519a022; ECCLESTON JF, 1985, J BIOL CHEM, V260, P6237; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; GAST WH, 1977, FEBS LETT, V74, P88, DOI 10.1016/0014-5793(77)80759-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HWANG YW, 1989, GUANINE NUCLEOTIDE B, P77; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1977, J MOL BIOL, V117, P999, DOI 10.1016/S0022-2836(77)80009-0; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSHIRO A, 1987, EUR J BIOCHEM, V170, P93, DOI 10.1111/j.1432-1033.1987.tb13671.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LUCASLEN.J, 1966, P NATL ACAD SCI USA, V55, P1562, DOI 10.1073/pnas.55.6.1562; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; NAKAMURA S, 1978, EUR J BIOCHEM, V92, P533, DOI 10.1111/j.1432-1033.1978.tb12775.x; OTT G, 1990, NUCLEIC ACIDS RES, V18, P437, DOI 10.1093/nar/18.3.437; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1987, P NATL ACAD SCI USA, V84, P3141, DOI 10.1073/pnas.84.10.3141; PETER ME, 1990, NUCLEIC ACIDS RES, V18, P6889, DOI 10.1093/nar/18.23.6889; PETER ME, 1990, BIOCHEMISTRY-US, V29, P2876, DOI 10.1021/bi00463a033; PINGOUD A, 1982, EUR J BIOCHEM, V123, P261, DOI 10.1111/j.1432-1033.1982.tb19762.x; RESHETNIKOVA LS, 1991, J MOL BIOL, V221, P375, DOI 10.1016/0022-2836(91)80058-3; RESHETNIKOVA LS, 1992, J CRYST GROWTH, V122, P360, DOI 10.1016/0022-0248(92)90270-S; SEIDLER L, 1987, NUCLEIC ACIDS RES, V15, P9263, DOI 10.1093/nar/15.22.9263; THOMPSON RC, 1982, P NATL ACAD SCI-BIOL, V79, P4922, DOI 10.1073/pnas.79.16.4922; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; 1979, SERC4 DAR LAB COLL C	50	511	518	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					126	132		10.1038/365126a0	http://dx.doi.org/10.1038/365126a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371755				2022-12-24	WOS:A1993LW44200038
J	TEAHON, K; BATEMAN, DN				TEAHON, K; BATEMAN, DN			A SURVEY OF INTRAVENOUS DRUG ADMINISTRATION BY PREREGISTRATION HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article							WORKLOAD				TEAHON, K (corresponding author), REG DRUG & THERAPEUT CTR,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 4LP,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				BAIN PG, 1990, BRIT MED J, V300, P1463; CUNNINGHAM S, 1990, BRIT MED J, V300, P1342; DYER C, 1991, BRIT MED J, V303, P1218, DOI 10.1136/bmj.303.6812.1218; LESLIE PJ, 1990, BRIT MED J, V300, P1038, DOI 10.1136/bmj.300.6731.1038; TOMFORD JW, 1984, ARCH INTERN MED, V144, P1191, DOI 10.1001/archinte.144.6.1191	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					605	606		10.1136/bmj.307.6904.605	http://dx.doi.org/10.1136/bmj.307.6904.605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401018	Bronze, Green Published			2022-12-24	WOS:A1993LW14900019
J	KREIDBERG, JA; SARIOLA, H; LORING, JM; MAEDA, M; PELLETIER, J; HOUSMAN, D; JAENISCH, R				KREIDBERG, JA; SARIOLA, H; LORING, JM; MAEDA, M; PELLETIER, J; HOUSMAN, D; JAENISCH, R			WT-1 IS REQUIRED FOR EARLY KIDNEY DEVELOPMENT	CELL			English	Article							WILMS-TUMOR GENE; ZINC-FINGER GENE; WT1 GENE; EMBRYONIC KIDNEY; GROWTH-FACTOR; UROGENITAL DEVELOPMENT; ORGAN-CULTURE; WAGR SYNDROME; LOCUS; MUTATIONS	In humans, germline mutations of the WT-1 tumor suppressor gene are associated with both Wilms' tumors and urogenital malformations. To develop a model system for the molecular analysis of urogenital development, we introduced a mutation into the murine WT-1 tumor suppressor gene by gene targeting in embryonic stem cells. The mutation resulted in embryonic lethality in homozygotes, and examination of mutant embryos revealed a failure of kidney and gonad development. Specifically, at day 11 of gestation, the cells of the metanephric blastema underwent apoptosis, the ureteric bud failed to grow out from the Wolffian duct, and the inductive events that lead to formation of the metanephric kidney did not occur. In addition, the mutation caused abnormal development of the mesothelium, heart, and lungs. Our results establish a crucial role for WT-1 in early urogenital development.	UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,SF-00100 HELSINKI 10,FINLAND; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3A 2T5,QUEBEC,CANADA; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	University of Helsinki; University of Helsinki; McGill University; McGill University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	KREIDBERG, JA (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BAIRD PN, 1992, ONCOGENE, V7, P2141; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COWELL JK, 1991, ONCOGENE, V6, P595; CROISILLE Y, 1976, TESTS TERATOGENICITY, P149; DAVIS LM, 1991, GENOMICS, V10, P588, DOI 10.1016/0888-7543(91)90440-P; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GLASER T, 1989, GENOMICS, V5, P880, DOI 10.1016/0888-7543(89)90130-4; GROBSTEIN C, 1953, SCIENCE, V118, P52, DOI 10.1126/science.118.3054.52; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANTIBODIES LABORATOR; HUFF V, 1991, AM J HUM GENET, V48, P997; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEINEBRECHT J, 1982, ANAT ANZEIGER, V152, P313; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MORRIS JF, 1991, ONCOGENE, V6, P2339; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J., 1989, MOL CLONING LAB MANU; SAXEN L, 1976, NATURE, V259, P662, DOI 10.1038/259662a0; SAXEN L, 1987, DIFFERENTIATION, V36, P2, DOI 10.1111/j.1432-0436.1987.tb00176.x; Saxen L., 1987, ORGANOGENESIS KIDNEY; SUKHATME VP, 1992, KIDNEY INT, V41, P550, DOI 10.1038/ki.1992.79; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4	52	1557	1602	1	60	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					679	691		10.1016/0092-8674(93)90515-R	http://dx.doi.org/10.1016/0092-8674(93)90515-R			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395349				2022-12-24	WOS:A1993LU59200011
J	PHILLIPS, DM				PHILLIPS, DM			IMAGES IN CLINICAL MEDICINE - STREPTOCOCCUS-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,NEW YORK,NY 10021, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					477	477						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8355767				2022-12-24	WOS:A1993LR44300006
J	CHEN, P; JOHNSON, P; SOMMER, T; JENTSCH, S; HOCHSTRASSER, M				CHEN, P; JOHNSON, P; SOMMER, T; JENTSCH, S; HOCHSTRASSER, M			MULTIPLE UBIQUITIN-CONJUGATING ENZYMES PARTICIPATE IN THE IN-VIVO DEGRADATION OF THE YEAST MAT-ALPHA-2 REPRESSOR	CELL			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATOR; PROTEIN-DEGRADATION; BETA-GALACTOSIDASE; GENE; RAD6; BIOGENESIS; ENCODES	Attachment of ubiquitin to proteins is catalyzed by a family of ubiquitin-conjugating (UBC) enzymes. Although these enzymes are essential for many cellular processes, their molecular functions remain unclear because no physiological target has been identified for any of them. Here we show that four UBC proteins (UBC4, UBC5, UBC6, and UBC7) target the yeast MATalpha2 transcriptional regulator for intracellular degradation by two distinct ubiquitination pathways. UBC6 and UBC7 define one of the pathways and can physically associate. The UBC6/UBC7-containing complex targets the Deg1 degradation signal of alpha2, a conclusion underscored by the finding that UBC6 is encoded by DOA2, a gene previously implicated in Deg1-mediated degradation. These data reveal an unexpected overlap in substrate specificity among diverse UBC enzymes and suggest a combinatorial mechanism of substrate selection in which UBC enzymes partition into multiple ubiquitination complexes.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,W-7400 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society	CHEN, P (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637, USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183, R37GM046904, R01GM046904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07183-18, GM46904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BELL JB, 1991, J BIOL CHEM, V266, P12662; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COOK WJ, 1992, J BIOL CHEM, V267, P15116; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1991, GENETIC ENG, P307; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; MYLIN LM, 1990, METHOD ENZYMOL, V185, P297; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICOLOGLOU S, 1990, MOL CELL BIOL, V10, P1017, DOI 10.1128/MCB.10.3.1017; PRAKASH L, 1989, GENOME, V31, P597, DOI 10.1139/g89-111; QIN S, 1991, J BIOL CHEM, V266, P15549; RONNE H, 1988, P NATL ACAD SCI USA, V85, P2696, DOI 10.1073/pnas.85.8.2696; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1986, METHODS YEAST GENETI; SILICIANO PG, 1986, P NATL ACAD SCI USA, V83, P2320, DOI 10.1073/pnas.83.8.2320; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; Stryer L., 1988, BIOCHEMISTRY-US; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VASSAL A, 1992, BIOCHIM BIOPHYS ACTA, V1132, P211, DOI 10.1016/0167-4781(92)90015-R; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	45	290	299	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					357	369		10.1016/0092-8674(93)90426-Q	http://dx.doi.org/10.1016/0092-8674(93)90426-Q			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8393731				2022-12-24	WOS:A1993LP72600016
J	LEE, HC; AARHUS, R; WALSETH, TF				LEE, HC; AARHUS, R; WALSETH, TF			CALCIUM MOBILIZATION BY DUAL RECEPTORS DURING FERTILIZATION OF SEA-URCHIN EGGS	SCIENCE			English	Article							CYCLIC ADP-RIBOSE; RELEASE; METABOLITE; NAD+; TISSUES; ENZYME	Fertilization is accompanied by a transient increase in the concentration of intracellular Ca2+, which serves as a signal for initiating development. Some of the Ca2+ appears to be released from intracellular stores by the binding of inositol trisphosphate (IP3) to its receptor. However, in sea urchin eggs, other mechanisms appear to participate. Cyclic adenosine diphosphate-ribose (cADPR), a naturally occurring metabolite of nicotinamide adenine dinucleotide, is as potent as IP3 in mobilizing Ca2+ in sea urchin eggs. Experiments with antagonists of the cADPR and IP3 receptors revealed that both Ca2+ mobilizing systems were activated during fertilization. Blockage of either of the systems alone was not sufficient to prevent the sperm-induced Ca2+ transient. This study provides direct evidence for a physiological role of cADPR in the Ca2+ signaling process.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CIAPA B, 1986, FEBS LETT, V195, P347, DOI 10.1016/0014-5793(86)80191-0; CROSSLEY I, 1991, CELL REGUL, V2, P121, DOI 10.1091/mbc.2.2.121; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DUPONT G, 1990, CELL REGUL, V1, P853, DOI 10.1091/mbc.1.11.853; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; Epel D, 1980, Ann N Y Acad Sci, V339, P74, DOI 10.1111/j.1749-6632.1980.tb15970.x; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TURNER PR, 1984, NATUE, V310, P464; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WALSETH TF, IN PRESS BIOCH BIOPH; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; WHITAKER MJ, 1982, Q REV BIOPHYS, V15, P593, DOI 10.1017/S0033583500003760	25	284	287	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					352	355		10.1126/science.8392749	http://dx.doi.org/10.1126/science.8392749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392749				2022-12-24	WOS:A1993LM67800036
J	DAVODEAU, F; PEYRAT, MA; HOUDE, I; HALLET, MM; DELIBERO, G; VIE, H; BONNEVILLE, M				DAVODEAU, F; PEYRAT, MA; HOUDE, I; HALLET, MM; DELIBERO, G; VIE, H; BONNEVILLE, M			SURFACE EXPRESSION OF 2 DISTINCT FUNCTIONAL ANTIGEN RECEPTORS ON HUMAN-GAMMA-DELTA T-CELLS	SCIENCE			English	Article							PERIPHERAL-BLOOD; LYMPHOCYTES-T; GENES; REARRANGEMENT; REGION; POLYMORPHISM; DIVERSITY; SUBSETS; BEARING	Lymphocytes recognize antigens with highly variable heterodimeric surface receptors. Although four distinct antigen receptors could in principle be produced by any lymphocyte, only one functional combination of receptor chains has thus far been found expressed on their surface. Examination of human gammadelta T cells revealed a population that violated this rule by expressing on their surface two distinct functional gammadelta T cell receptors (TCRs) that used different TCRgamma gene alleles. Thus, current models for T cell clonal selection may need modification and a possible escape mechanism for autoreactive TCRs is suggested.	INST BIOL,INSERM,U211,F-44035 NANTES,FRANCE; INST EXPTL IMMUNOL,DEPT RES,CH-4031 BASEL,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm)			Davodeau, Francois/M-1888-2015; François, Davodeau/GLU-4061-2022; Vie, Henri/L-2651-2015	François, Davodeau/0000-0001-8181-0192; 				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORST J, 1989, EUR J IMMUNOL, V19, P1559, DOI 10.1002/eji.1830190907; DAVODEAU F, IN PRESS J BIOL CHEM; DAVODEAU F, UNPUB; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; EZQUERRA A, 1992, EUR J IMMUNOL, V22, P491, DOI 10.1002/eji.1830220230; FERRINI S, 1989, EUR J IMMUNOL, V19, P57, DOI 10.1002/eji.1830190110; HEILIG JS, 1987, P NATL ACAD SCI USA, V84, P8070, DOI 10.1073/pnas.84.22.8070; JITSUKAWA S, 1987, J EXP MED, V166, P1192, DOI 10.1084/jem.166.4.1192; KABELITZ D, 1992, CRIT REV IMMUNOL, V11, P251; KONING F, 1988, J IMMUNOL, V141, P2057; LEFRANC MP, 1985, NATURE, V316, P464, DOI 10.1038/316464a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LEFRANC MP, 1986, NATURE, V319, P420, DOI 10.1038/319420a0; LEFRANC MP, 1986, P NATL ACAD SCI USA, V83, P9596, DOI 10.1073/pnas.83.24.9596; LEFRANC MP, 1990, RES IMMUNOL, V141, P267; LITTMAN DR, 1987, NATURE, V326, P85, DOI 10.1038/326085a0; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; TAKIHARA Y, 1989, J EXP MED, V169, P393, DOI 10.1084/jem.169.2.393; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VIE H, 1989, BLOOD, V74, P285; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0	28	69	69	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1800	1802		10.1126/science.8390096	http://dx.doi.org/10.1126/science.8390096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8390096				2022-12-24	WOS:A1993LH20500048
J	LEE, MS; KLIEWER, SA; PROVENCAL, J; WRIGHT, PE; EVANS, RM				LEE, MS; KLIEWER, SA; PROVENCAL, J; WRIGHT, PE; EVANS, RM			STRUCTURE OF THE RETINOID-X RECEPTOR-ALPHA DNA-BINDING DOMAIN - A HELIX REQUIRED FOR HOMODIMERIC DNA-BINDING	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; GLUCOCORTICOID RECEPTOR; PROTEINS; SPECTROSCOPY; ELEMENTS; ACIDS; NMR	The three-dimensional solution structure of the DNA binding domain (DBD) of the retinoid X receptor alpha (RXRalpha) was determined by nuclear magnetic resonance spectroscopy. The two zinc fingers of the RXR DBD fold to form a single structural domain that consists of two perpendicularly oriented helices and that resembles the corresponding regions of the glucocorticoid and estrogen receptors (GR and ER, respectively). However, in contrast to the DBDs of the GR and ER, the RXR DBD contains an additional helix immediately after the second zinc finger. This third helix mediates both protein-protein and protein-DNA interactions required for cooperative, dimeric binding of the RXR DBD to DNA. Identification of the third helix in the RXR DBD thus defines a structural feature required for selective dimerization of the RXR on hormone response elements composed of half-sites (5'-AGGTCA-3') arranged as tandem repeats.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Wright, Peter/0000-0002-1368-0223				BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAX A, 1987, J AM CHEM SOC, V109, P7188; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAVEL T, 1984, B MATH BIOL, V46, P673, DOI 10.1007/BF02459510; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATAHIRA M, 1992, BIOCHEMISTRY-US, V31, P6474, DOI 10.1021/bi00143a017; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lee M., UNPUB; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAO T, UNPUB; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	40	253	256	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1117	1121		10.1126/science.8388124	http://dx.doi.org/10.1126/science.8388124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8388124				2022-12-24	WOS:A1993LC94200027
J	LUTTRELL, LM; OSTROWSKI, J; COTECCHIA, S; KENDALL, H; LEFKOWITZ, RJ				LUTTRELL, LM; OSTROWSKI, J; COTECCHIA, S; KENDALL, H; LEFKOWITZ, RJ			ANTAGONISM OF CATECHOLAMINE RECEPTOR SIGNALING BY EXPRESSION OF CYTOPLASMIC DOMAINS OF THE RECEPTORS	SCIENCE			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING PROPERTIES; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; BETA-2-ADRENERGIC RECEPTOR; GS; TRANSDUCIN; ACTIVATION; AFFINITY; DOPAMINE	The actions of many hormones and neurotransmitters are mediated by the members of a superfamily of receptors coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins). These receptors are characterized by a highly conserved topographical arrangement in which seven transmembrane domains are connected by intracellular and extracellular loops. The interaction between these receptors and G proteins is mediated in large part by the third intracellular loop of the receptor. Coexpression of the third intracellular loop of the alpha1B-adrenergic receptor with its parent receptor inhibited receptor-mediated activation of phospholipase C. The inhibition extended to the closely related alpha1C-adrenergic receptor subtype, but not the phospholipase C-coupled M1 muscarinic acetylcholine receptor nor the adenylate cyclase-coupled D1A dopamine receptor. These results suggest that the receptor-G protein interface may represent a target for receptor antagonist drugs.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COTECCHIA S, UNPUB; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KENT RS, 1980, MOL PHARMACOL, V17, P14; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LUTTRELL LM, UNPUB; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MUKAI H, 1992, J BIOL CHEM, V267, P16237; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WU D, IN PRESS J BIOL CHEM	37	104	109	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1453	1457		10.1126/science.8383880	http://dx.doi.org/10.1126/science.8383880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8383880				2022-12-24	WOS:A1993KP97800036
J	HENDERSON, BE; ROSS, RK; PIKE, MC				HENDERSON, BE; ROSS, RK; PIKE, MC			HORMONAL CHEMOPREVENTION OF CANCER IN WOMEN	SCIENCE			English	Article							ESTROGEN REPLACEMENT THERAPY; NEGATIVE BREAST-CANCER; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; ADJUVANT TAMOXIFEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE AGENTS; CONJUGATED ESTROGENS; ORAL-CONTRACEPTIVES; INCESSANT OVULATION	The use of oral contraceptives in the United States during the past three decades has led to a dramatic decline in the incidence of cancers of the ovary and endometrium. The magnitude of these declines was predictable both from epidemiologic data and from the biologic effects of oral contraceptives on these tissues. Although the incidence of breast cancer has not been substantially affected by current oral contraceptives, it may be possible to develop alternative forms of contraception that provide protection against all three cancers. The major goal of hormonal chemoprevention of cancer is to reduce cell proliferation in the relevant epithelial tissue. New chemopreventive agents such as tamoxifen exemplify the application of this principle.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California					NCI NIH HHS [CA-17054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA017054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1987, JAMA, V257, P796; BAUM M, 1988, BRIT J CANCER, V57, P608; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CASAGRANDE JT, 1979, LANCET, V2, P170; CHERKOWSKI R, 1986, NEW ENGL J MED, V314, P1615; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; Cummings F J, 1986, NCI Monogr, P119; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FALKSON HC, 1990, J CLIN ONCOL, V8, P599, DOI 10.1200/JCO.1990.8.4.599; FATHALLA MF, 1971, LANCET, V2, P163; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; GAL D, 1983, AM J OBSTET GYNECOL, V146, P316, DOI 10.1016/0002-9378(83)90754-8; GAMBRELL RD, 1982, J REPROD MED, V27, P531; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1988, CANCER RES, V48, P246; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1981, J NATL CANCER I, V67, P815; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; JORDAN VC, 1987, CANCER RES, V47, P4517; JORDAN VC, 1990, CANCER PREVENTION, P1; KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LIPTON A, 1984, CANCER TREAT REP, V68, P887; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; LONGSTAFF S, 1989, EUR J CANCER CLIN ON, V25, P1805, DOI 10.1016/0277-5379(89)90351-9; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; NOTELOVITZ M, 1987, OBSTET GYNECOL, V70, P749; Palshof T., 1985, REV ENDOCR REL CAN S, V17, P43; PARLIDIS NA, 1992, CANCER, V60, P2961; PERSSON I, 1992, LANCET, V340, P1044, DOI 10.1016/0140-6736(92)93064-T; PHARRISS BB, 1978, J REPROD MED, V20, P155; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; PIKE MC, 1986, LANCET, V1, P264; PIKE MC, IN PRESS CONTRACEPTI; PIKE MC, 1983, CURRENT THERAPY ONCO, P292; PIPER JM, 1987, INT J EPIDEMIOL, V16, P215, DOI 10.1093/ije/16.2.215; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRITCHARD KI, 1987, ADJUVANT THERAPY CAN, P391; RIES LA, 1990, CANCER STATISTICS RE; RILEY D, 1988, BRIT J CANCER, V57, P604; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROSS RK, 1988, AM J PUBLIC HEALTH, V78, P516, DOI 10.2105/AJPH.78.5.516; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SCHIFF I, 1982, FERTIL STERIL, V37, P79; SHARF M, 1985, GYNECOL OBSTET INVES, V19, P207, DOI 10.1159/000299035; SILVERBERG SG, 1975, OBSTET GYNECOL, V46, P503; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; Spicer D, 1990, Oncology (Williston Park), V4, P49; SPICER DV, 1991, LANCET, V337, P1414, DOI 10.1016/0140-6736(91)93096-R; SPICER DV, 1991, CONTRACEPTION, V44, P289, DOI 10.1016/0010-7824(91)90019-C; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; STEWART HJ, 1987, LANCET, V2, P171; STUDD JWW, 1980, MENOPAUSE POSTMENOPA, P127; TARONE RE, 1992, J NATL CANCER I, V84, P1402, DOI 10.1093/jnci/84.18.1402; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WATERHOUSE J, 1976, CANCER INCIDENCE 5 C; WEISS NS, 1980, NEW ENGL J MED, V302, P551, DOI 10.1056/NEJM198003063021004; WEN EJO, 1992, BRIT J OBSTET GYNAEC, V99, P671; WHITEHEAD M, 1983, SEMIN REPROD ENDOCR, V1, P41, DOI 10.1055/s-2007-1022574; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YAGER JD, 1980, CANCER RES, V40, P3680; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1983, JAMA-J AM MED ASSOC, V249, P1600; 1987, JAMA-J AM MED ASSOC, V249, P796; 1989, PHS891232 US DEP HLT, P52	82	233	238	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					633	638		10.1126/science.8381558	http://dx.doi.org/10.1126/science.8381558			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8381558				2022-12-24	WOS:A1993KJ68800031
J	THEODOROPOULOS, DS; KRASNEWICH, D; KAISERKUPFER, MI; GAHL, WA				THEODOROPOULOS, DS; KRASNEWICH, D; KAISERKUPFER, MI; GAHL, WA			CLASSIC NEPHROPATHIC CYSTINOSIS AS AN ADULT DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NERVOUS-SYSTEM INVOLVEMENT; AGE 10 YEARS; CYSTEAMINE; COMPLICATIONS; INSUFFICIENCY; CHILDREN; PATIENT	Objective.-To delineate the clinical characteristics of infantile nephropathic cystinosis in adult patients who have undergone renal transplantation. Design.-Case series. Setting.-Clinical research unit. Patients.-All 36 adult patients with nephropathic cystinosis referred to the National Institutes of Health. Outcome Measures.-Longevity, growth, renal allograft survival, visual acuity, endocrine insufficiency, myopathy and swallowing dysfunction, cerebral calcifications, and occupational status. Results.-Of the 36 patients, seven were dead, five with functioning allografts. The 1-year and 5-year graft survival rates for 30 cadaveric allografts were 90% and 75%, respectively. The patients' mean height and weight were severely retarded. Five patients were legally blind, and three others had severely impaired vision in one eye. Thirty-one (86%) of 36 patients required thyroid hormone replacement therapy. One third had a distal myopathy, and 21 had moderate to severe swallowing abnormalities. Eight patients had cerebral calcifications on computed tomographic scan. Despite these complications, the sighted patients engaged in a normal variety of occupations. Only 11 patients were receiving adequate cystine-depleting therapy with cysteamine (mercaptamine) or phosphocysteamine. Conclusions.-Adult patients with nephropathic cystinosis suffer serious complications of the disease.	NIH, CTR CLIN, INTERINST MED GENET PROGRAM, BETHESDA, MD 20892 USA; NICHHD, HUMAN GENET BRANCH, HUMAN BIOCHEM GENET SECT, BETHESDA, MD 20892 USA; NEI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								CHAN AM, 1970, AM J MED, V48, P678, DOI 10.1016/S0002-9343(70)80002-X; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1986, J PEDIATR-US, V109, P605, DOI 10.1016/S0022-3476(86)80221-9; GAHL WA, 1990, PEDIATR NEPHROL, V4, P129, DOI 10.1007/BF00858823; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1992, BIOCHEM MED METAB B, V48, P275, DOI 10.1016/0885-4505(92)90074-9; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; GRETZ N, 1982, P EUR DIAL TRANS, V19, P582; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; KAISERKUPFER MI, 1987, NEW ENGL J MED, V316, P775, DOI 10.1056/NEJM198703263161304; KAISERKUPFER MI, 1990, ARCH OPHTHALMOL-CHIC, V108, P689, DOI 10.1001/archopht.1990.01070070075038; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRASNEWICH DM, 1991, ENDOCRINOLOGIST, V1, P111; MARKELLO TC, 1993, NEW ENGL J MED, V328, P1157, DOI 10.1056/NEJM199304223281604; OSHIMA RG, 1974, J BIOL CHEM, V249, P6033; SMOLIN LA, 1988, PEDIATR RES, V23, P616, DOI 10.1203/00006450-198806000-00018; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; THOROGOOD J, 1992, TRANSPLANTATION, V54, P152, DOI 10.1097/00007890-199207000-00027; VOGEL DG, 1990, J NEUROPATH EXP NEUR, V49, P591, DOI 10.1097/00005072-199011000-00005	28	70	74	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1993	270	18					2200	2204		10.1001/jama.270.18.2200	http://dx.doi.org/10.1001/jama.270.18.2200			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME816	8411603				2022-12-24	WOS:A1993ME81600031
J	FEDSON, DS; WAJDA, A; NICOL, JP; HAMMOND, GW; KAISER, DL; ROOS, LL				FEDSON, DS; WAJDA, A; NICOL, JP; HAMMOND, GW; KAISER, DL; ROOS, LL			CLINICAL EFFECTIVENESS OF INFLUENZA VACCINATION IN MANITOBA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RESPIRATORY-DISEASE; PROTECTIVE EFFICACY; ADMINISTRATIVE DATA; EXCESS MORTALITY; UNITED-STATES; PNEUMONIA; EPIDEMICS; POPULATION; REDUCTION; HOSPITALIZATIONS	Objective.-To assess the clinical effectiveness of influenza vaccination in preventing influenza-associated hospitalization and death. Design.-Case-control study. Setting and Patients.-Noninstitutionalized persons aged 45 years or older living in Manitoba, on December 1, 1982, and December 1, 1985. Methods.-Linked records of the Manitoba population registry, hospital-discharge abstracts, physician claims for ambulatory-patient visits and influenza vaccination, and vital statistics were used. A matched-set analysis estimated the clinical effectiveness of influenza vaccination in preventing hospital admissions and deaths from influenza-associated conditions during influenza A (H3N2) outbreak periods in 1982 to 1983 (12 weeks) and 1985 to 1986 (10 weeks). The analysis adjusted for hospital discharge and ambulatory care for high-risk conditions within the previous 15 months and 3 months, respectively. Results.-Influenza vaccination prevented 32% to 39% of hospital admissions with pneumonia and influenza and 15% to 34% of admissions with all respiratory conditions. Vaccination was 43% to 65% effective in preventing hospital deaths with these conditions (all listed diagnoses) and 27% to 30% effective in preventing deaths from all causes. Conclusion.-Influenza vaccination has substantial clinical effectiveness in preventing hospital admission and death from influenza-associated conditions in noninstitutionalized individuals.	MANITOBA CTR HLTH POLICY & EVALUAT,WINNIPEG,MB,CANADA; UNIV MANITOBA,DEPT MED MICROBIOL & INFECT DIS,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT COMMUNITY HLTH SCI,WINNIPEG R3T 2N2,MANITOBA,CANADA; CADHAM PROV LAB,WINNIPEG,MB,CANADA	University of Manitoba; University of Manitoba	FEDSON, DS (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MED,BOX 494,CHARLOTTESVILLE,VA 22908, USA.			Roos, Leslie L./0000-0002-4215-8346	NATIONAL INSTITUTE ON AGING [R01AG009145] Funding Source: NIH RePORTER; NIA NIH HHS [5-R01AG09145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ARDEN NH, 1986, OPTIONS CONTROL INFL, P155; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; BARKER WH, 1981, AM J PUBLIC HEALTH, V71, P643, DOI 10.2105/AJPH.71.6.643; BARKER WH, 1986, OPTIONS CONTROL INFL, P169; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P5111; Cohen M M, 1993, Ann Epidemiol, V3, P93; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; FEDSON DS, 1992, ANN INTERN MED, V116, P550, DOI 10.7326/0003-4819-116-7-550; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GHENDON Y, 1991, B WORLD HEALTH ORGAN, V69, P509; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1992, 920056 AG HLTH CAR P, P83; LAMONTAGNE JR, 1983, REV INFECT DIS, V5, P723; LIU KJ, 1987, AM J PUBLIC HEALTH, V77, P712; MARRIE TJ, 1987, MED CARE, V25, P20, DOI 10.1097/00005650-198701000-00003; MAZUMDAR S, 1986, AM J PUBLIC HEALTH, V76, P803, DOI 10.2105/AJPH.76.7.803; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; ROMANO PS, 1992, 920056 AG HLTH CAR P, P57; ROOS LL, 1987, J CHRON DIS, V40, P41, DOI 10.1016/0021-9681(87)90095-6; ROOS LL, 1991, J CLIN EPIDEMIOL, V44, P881, DOI 10.1016/0895-4356(91)90050-J; ROOS LL, 1990, MED INN CR, V1, P47; ROOS LL, 1993, MED CARE, V31, P201, DOI 10.1097/00005650-199303000-00002; ROOS LL, 1992, 920056 AG HLTH CAR P, P119; ROOS NP, 1989, SOC SCI MED, V28, P109, DOI 10.1016/0277-9536(89)90137-8; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SAITZ EW, 1978, JAMA-J AM MED ASSOC, V239, P2372, DOI 10.1001/jama.239.22.2372; SCHOENBA.SC, 1969, B WORLD HEALTH ORGAN, V41, P531; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; 1986, SUGI SUPPLEMENTAL LI, P307; 1989, INT CLASSIFICATION D; 1993, AB933 DEP HLTH HUM S; 1980, RELIABILITY NATIONAL	46	240	245	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1956	1961		10.1001/jama.270.16.1956	http://dx.doi.org/10.1001/jama.270.16.1956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MC513	8411553				2022-12-24	WOS:A1993MC51300027
J	ZAPP, ML; STERN, S; GREEN, MR				ZAPP, ML; STERN, S; GREEN, MR			SMALL MOLECULES THAT SELECTIVELY BLOCK RNA-BINDING OF HIV-1 REV PROTEIN INHIBIT REV FUNCTION AND VIRAL PRODUCTION	CELL			English	Article							CHRONICALLY INFECTED-CELLS; TRANS-ACTIVATOR GENE; ARGININE-RICH MOTIF; MESSENGER-RNA; VIRUS-REPLICATION; SPLICING INVITRO; HTLV-III; EXPRESSION; TRANSCRIPTION; RECOGNITION	Replication of RNA viruses, such as the human immunodeficiency virus (HIV), is dependent upon multiple specific interactions between viral RNAs and viral and cellular proteins. A small molecule that interferes specifically with one or more of these RNA-protein interactions could be an efficacious antiviral agent. Here we show that certain aminoglycoside antibiotics, in particular neomycin B, can block binding of the HIV Rev protein to its viral RNA recognition element. Inhibition appears to be highly selective, resulting from competitive binding of the drug to a small viral RNA region within the Rev-binding site. We further demonstrate that neomycin B can specifically antagonize Rev f unction in vitro and in vivo and can inhibit production of HIV. Our results establish the feasibility for developing antiviral drugs that act by selectively blocking RNA-protein interactions.			ZAPP, ML (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BEVEC D, 1992, P NATL ACAD SCI USA, V89, P9870, DOI 10.1073/pnas.89.20.9870; BOTTO RE, 1983, J AM CHEM SOC, V105, P1021, DOI 10.1021/ja00342a062; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CUNDLIFFE E, 1987, BIOCHIMIE, V69, P863, DOI 10.1016/0300-9084(87)90213-6; CUNDLIFFE E, 1990, RIBOSOME, P479; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Green MR, 1993, AIDS RES REV, V3, P41; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANESSIAN S, 1970, CARBOHYDRATES      A, V2, P139; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOPE TJ, 1990, P NATL ACAD SCI USA, V87, P7787, DOI 10.1073/pnas.87.19.7787; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MICHAEL NL, 1991, J VIROL, V65, P1291, DOI 10.1128/JVI.65.3.1291-1303.1991; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MOORE MJ, 1992, RNA WORLD, P1; NIWA M, 1991, GENE EXPRESSION, V1, P5; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; PRICE KE, 1977, STRUCTURE ACTIVITY R, P239; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; Umezewa S., 1982, AMINOGLYCOSIDE ANTIB, P37; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VONAHSEN U, 1991, NUCLEIC ACIDS RES, V19, P2261, DOI 10.1093/nar/19.9.2261; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	62	374	395	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					969	978		10.1016/0092-8674(93)90720-B	http://dx.doi.org/10.1016/0092-8674(93)90720-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402886				2022-12-24	WOS:A1993LY49300005
J	DU, W; THANOS, D; MANIATIS, T				DU, W; THANOS, D; MANIATIS, T			MECHANISMS OF TRANSCRIPTIONAL SYNERGISM BETWEEN DISTINCT VIRUS-INDUCIBLE ENHANCER ELEMENTS	CELL			English	Article							NF-KAPPA-B; INTERFERON-BETA GENE; LEUCINE ZIPPER PROTEINS; ATF CDNA CLONES; DNA-BINDING; IFN-BETA; C-JUN; NUCLEOPROTEIN STRUCTURES; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM	The high mobility group protein HMG I(Y) and the transcription factor NF-kappaB are required for the activity of positive regulatory domain II (PRDII), a virus-inducible regulatory element of the human interferon-beta gene promoter. In this paper we provide evidence that HMG I(Y) is also required for the activity of PRDIV, a regulatory element that synergizes with PRDII. In this case, HMG I(Y) stimulates binding of activating transcription factor 2 (ATF-2) and the assembly of inducible complexes containing ATF-2 and c-Jun. Remarkably, HMG I(Y) also specifically interacts with the leucine zipper/basic region of ATF-2, and ATF-2 in turn interacts with NF-kappaB. We therefore propose that the HMG I(Y) plays a critical structural role in establishing transcriptional synergy between PRDII and PRDIV by promoting the activities and/or binding of NF-kappaB and ATF-2 and by facilitating their interaction.			DU, W (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Demaeyer E., 1988, INTERFERONS OTHER RE; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ECHOLS H, 1984, COLD SPRING HARB SYM, V49, P727, DOI 10.1101/SQB.1984.049.01.082; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; JONAT G, 1990, CELL, V62, P1189; JVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PTASHNE M, 1992, GENETIC SWITCH GENE; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VILCEK J, 1990, HDB EXPT PHARM, V95, P1; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	51	438	444	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					887	898		10.1016/0092-8674(93)90468-6	http://dx.doi.org/10.1016/0092-8674(93)90468-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374955				2022-12-24	WOS:A1993LX29200014
J	ZHOU, J; MOCHIZUKI, T; SMEETS, H; ANTIGNAC, C; LAURILA, P; DEPAEPE, A; TRYGGVASON, K; REEDERS, ST				ZHOU, J; MOCHIZUKI, T; SMEETS, H; ANTIGNAC, C; LAURILA, P; DEPAEPE, A; TRYGGVASON, K; REEDERS, ST			DELETION OF THE PAIRED ALPHA-5(IV) AND ALPHA-6(IV) COLLAGEN GENES IN INHERITED SMOOTH-MUSCLE TUMORS	SCIENCE			English	Article							BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; ALPORT SYNDROME; BIDIRECTIONAL PROMOTER; DIFFUSE LEIOMYOMATOSIS; CELL-ADHESION; CHAIN; IDENTIFICATION; DOMAIN; LOCALIZATION	The gene encoding alpha6(IV) collagen, COL4A6, was identified on the human X chromosome in a head-to-head arrangement and within 452 base pairs of the alpha5(IV) collagen gene, COL4A5. In earlier studies, intragenic deletions of COL4A5 were detected in a subset of patients with Alport syndrome (AS), a hereditary defect of basement membranes. In some families, AS cosegregates with diffuse leiomyomatosis (DL), a benign smooth muscle tumor diathesis. Here it is shown that patients with AS-DL harbor deletions that disrupt both COL4A5 and COL4A6. Thus, type IV collagen may regulate smooth muscle differentiation and morphogenesis.	UNIV HOSP NIJMEGEN,CTR CLIN GENET,NIJMEGEN,NETHERLANDS; HOP NECKER ENFANTS MALAD,INSERM,U192,PARIS,FRANCE; UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; STATE UNIV GHENT HOSP,DEPT HUMAN GENET,B-9000 GHENT,BELGIUM; UNIV OULU,BIOCTR,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90100 OULU 10,FINLAND	Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Ghent University; Ghent University Hospital; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	ZHOU, J (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,295 CONGRESS AVE,NEW HAVEN,CT 06510, USA.		ANTIGNAC, Corinne/H-8945-2017	ANTIGNAC, Corinne/0000-0002-9934-4940				ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BORG TK, 1984, DEV BIOL, V104, P86, DOI 10.1016/0012-1606(84)90038-1; BRUNNER H, 1988, KIDNEY INT, V34, P507, DOI 10.1038/ki.1988.210; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; CHELBERG MK, 1989, CANCER RES, V49, P4796; COCHAT P, 1988, J PEDIATR-US, V113, P339, DOI 10.1016/S0022-3476(88)80280-4; DESJARDINS M, 1990, LAB INVEST, V63, P637; FLINTER FA, 1988, LANCET, V2, P1005, DOI 10.1016/S0140-6736(88)90753-2; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMAGATA Y, 1992, J BIOL CHEM, V267, P23753; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARIYAMA M, UNPUB; MARSHALL JB, 1990, AM J GASTROENTEROL, V85, P303; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NETZER KO, 1992, KIDNEY INT, V42, P1336, DOI 10.1038/ki.1992.425; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHEN GQ, 1990, CONNECT TISSUE RES, V24, P289, DOI 10.3109/03008209009152156; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	38	248	262	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1167	1169		10.1126/science.8356449	http://dx.doi.org/10.1126/science.8356449			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356449				2022-12-24	WOS:A1993LU58600031
J	BALKAU, B; ESCHWEGE, E; PAPOZ, L; RICHARD, JL; CLAUDE, JR; WARNET, JM; DUCIMETIERE, P				BALKAU, B; ESCHWEGE, E; PAPOZ, L; RICHARD, JL; CLAUDE, JR; WARNET, JM; DUCIMETIERE, P			RISK-FACTORS FOR EARLY DEATH IN NON-INSULIN-DEPENDENT DIABETES AND MEN WITH KNOWN GLUCOSE-TOLERANCE STATUS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; ALCOHOL-CONSUMPTION; MORTALITY; POPULATION; MELLITUS	Objective-To identify risk factors for all cause mortality according to glucose tolerance status. Design-Cohort study with an average 15.6 years' follow up. Setting-Paris, France. Subjects-7166 working men aged 44-55 in 1968-72 in the Paris prospective study cohort, with non-insulin dependent diabetes or known result of two hour 75 g oral glucose tolerance test. Main outcome measure-Risk factors for death from all causes. Results-128 men were known to be diabetic, 180 had diabetes diagnosed, and 697 had impaired glucose tolerance diagnosed. Compared with normoglycaemic men the relative risks of death in these groups were 2.0 (95% confidence interval 1.4 to 3.0), 2.7 (2.0 to 3.6), and 1.6 (1.3 to 2.0) respectively. Obesity, smoking, high blood pressure, and high non-esterified fatty acid concentration were risk factors for death in all subjects and were unaffected by glucose tolerance. The risks for fasting and two hour insulin concentrations and mean corpuscular volume were two times higher in known diabetic men than in men not known to be diabetic. Central obesity was significant only in men not known to be diabetic (1.6 (1.4 to 1.9)). In known diabetic men a two hour glucose concentration higher than 11.1 mmol/l carried a relative risk of death of 3.8 (1.4 to 9.4). Conclusions-Diabetic men have similar risk factors for early mortality to other men but are at higher risk from hyperinsulinaemia, hyperglycaemia, and high mean corpuscular volume.	HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE; CTR MEDICO SOCIAL,DIRECT ACT SOCIALE ENFANCE & SANTE LAB,F-75013 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	BALKAU, B (corresponding author), HOP PAUL BROUSSE,INSERM,U21,F-94807 VILLEJUIF,FRANCE.							ANDERSON P, 1988, BRIT MED J, V297, P824, DOI 10.1136/bmj.297.6652.824; ANTONIS A, 1965, J LIPID RES, V6, P307; BALKAU B, 1991, J CLIN EPIDEMIOL, V44, P465, DOI 10.1016/0895-4356(91)90209-R; BALKAU B, 1992, DIABETOLOGIA, V35, P39, DOI 10.1007/BF00400850; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BJORNTORP P, 1990, DIABETES ANN, V5, P373; CLAUDE JR, 1968, ANN BIOL CLIN-PARIS, V26, P451; COPPACK SW, 1990, Q J MED, V75, P451; COX DR, 1972, J R STAT SOC B, V34, P187; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DUCIMETIERE P, 1989, INT J OBESITY, V13, P111; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; DUCIMETIERE P, 1981, CARDIOPATHIES ISCHEM, P9; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; ETIENNE G, 1963, ANN BIOL CLIN, V21, P851; FITZGERALD AP, 1991, DIABETIC MED, V8, P475, DOI 10.1111/j.1464-5491.1991.tb01635.x; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; JARRETT J, 1990, Q J MED, V75, P413; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; KNUIMAN MW, 1992, AM J EPIDEMIOL, V135, P638, DOI 10.1093/oxfordjournals.aje.a116343; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; SASAKI A, 1989, DIABETES RES CLIN PR, V7, P33, DOI 10.1016/0168-8227(89)90042-9; SCHMITZ A, 1988, DIABETES METAB, V14, P193; TOUNTAS C, 1987, DIABETOLOGIA, V330, pA589; 1968, MANUAL INT CLASSIFIC; 1963, METHODOLOGIE TECHNIC; 1985, WHO TECH REP SERIES, V727	32	89	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					295	299		10.1136/bmj.307.6899.295	http://dx.doi.org/10.1136/bmj.307.6899.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374376	Green Published, Bronze			2022-12-24	WOS:A1993LQ51600018
J	REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S				REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S			SPECIFIC TRUNCATIONS OF DROSOPHILA NOTCH DEFINE DOMINANT ACTIVATED AND DOMINANT-NEGATIVE FORMS OF THE RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GENE SERRATE ENCODES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION PATTERN; EARLY NEUROGENESIS; LOCUS; MELANOGASTER; HOMOLOG; REPEATS	The Notch gene of Drosophila plays an important role in cell fate specification throughout development. To investigate the functions of specific structural domains of the Notch protein in vivo, a series of deletion mutants have been ectopically expressed under the hsp70 heat shock promoter. Two classes of dominant phenotypes are observed, one suggestive of Notch loss-of-function mutations and the other of Notch gain-of-function,mutations. Dominant activated phenotypes result from overexpression of a protein lacking most extracellular sequences, while dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results support the notion that Notch functions as a receptor whose extracellular domain mediates ligand binding, resulting in the transmission of developmental signals by the cytoplasmic domain. Finally, the phenotypes observed suggest that the cdc10/ankyrin repeat region within the intracellular domain plays an essential role in the postulated signal transduction events.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06536	Yale University	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29093] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; APPELLA E, 1987, FEBS LETT, V231, P1; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1991, GENETICS, V129, P803; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1978, GENETICS, V88, P469; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Maniatis T, 1989, DECONTAMINATION DILU; MOFFAT KG, 1992, DEVELOPMENT, V114, P681; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBERTSON HM, 1988, GENETICS, V118, P461; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; THOMAS U, 1991, DEVELOPMENT, V111, P749; THOMPSON JN, 1974, HEREDITY, V33, P389, DOI 10.1038/hdy.1974.105; THUMMEL CS, 1991, DROSOPH INFO NEWS, V2; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1992, DEVELOPMENT, V115, P913; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	53	375	393	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					319	329		10.1016/0092-8674(93)90423-N	http://dx.doi.org/10.1016/0092-8674(93)90423-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343959				2022-12-24	WOS:A1993LP72600013
J	LIN, SC; LIN, CJR; GUKOVSKY, I; LUSIS, AJ; SAWCHENKO, PE; ROSENFELD, MG				LIN, SC; LIN, CJR; GUKOVSKY, I; LUSIS, AJ; SAWCHENKO, PE; ROSENFELD, MG			MOLECULAR-BASIS OF THE LITTLE MOUSE PHENOTYPE AND IMPLICATIONS FOR CELL-TYPE-SPECIFIC GROWTH	NATURE			English	Article							HORMONE-RELEASING-FACTOR; ANTERIOR-PITUITARY CELLS; PANCREATIC-ISLET TUMOR; TRANSGENIC MICE; MESSENGER-RNA; DWARF MICE; THYROID-CELLS; CYCLIC-AMP; PROTEIN; GENE	The molecular basis for the little (lit) mouse phenotype, characterized by a hypoplastic anterior pituitary gland, is the mutation of a single nucleotide that alters Asp 60 to Gly in the growth hormone releasing factor receptor. Detailed analysis of the lit mouse anterior pituitary reveals spatially distinct proliferative zones of growth hormone-producing stem cells and mature somatotrophs, each regulated by a different trophic factor. This sequential growth factor requirement for a specific cell type may exemplify a common strategy for regulating cellular proliferation in other mammalian organs.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Salk Institute	LIN, SC (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.		Lin, SC/G-4666-2010					AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AYLINN BD, 1993, MOL ENDOCRINOL, V7, P77; BARINAGA M, 1983, NATURE, V306, P84, DOI 10.1038/306084a0; BEHRINGER RR, 1988, GENE DEV, V2, P453, DOI 10.1101/gad.2.4.453; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CARBAJOPEREZ E, 1990, CELL TISSUE RES, V261, P333, DOI 10.1007/BF00318674; CHENG TC, 1983, ENDOCRINOLOGY, V113, P1669, DOI 10.1210/endo-113-5-1669; DIETRICH W, 1992, GENETICS, V3, P425; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; ELLIOTT RW, 1992, MAMM GENOME, V3, pS81, DOI 10.1007/BF00648424; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/edrv-12-4-337; FROHMAN MA, 1989, MOL ENDOCRINOL, V3, P1529, DOI 10.1210/mend-3-10-1529; GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; HEN R, 1989, P NATL ACAD SCI USA, V86, P4785, DOI 10.1073/pnas.86.12.4785; IKEDA H, 1991, CELL TISSUE RES, V263, P41, DOI 10.1007/BF00318398; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISHIHARA T, 1992, NEURON, V8, P815; JANSSON JO, 1986, SCIENCE, V232, P511, DOI 10.1126/science.3008329; JAPPNER H, 1991, SCIENCE, V254, P1024; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVINE MA, 1988, P NATL ACAD SCI USA, V85, P617, DOI 10.1073/pnas.85.2.617; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RIVIER J, 1982, NATURE, V300, P276, DOI 10.1038/300276a0; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROUSE M, 1982, CELL TISSUE RES, V223, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; SEIFERT H, 1985, NATURE, V313, P487, DOI 10.1038/313487a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SLABAUGH MB, 1981, ENDOCRINOLOGY, V109, P1040, DOI 10.1210/endo-109-4-1040; Sneil GD, 1929, P NATL ACAD SCI USA, V15, P733, DOI 10.1073/pnas.15.9.733; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; TSANG BK, 1980, J CELL PHYSIOL, V102, P19, DOI 10.1002/jcp.1041020104; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WARDEN CH, IN PRESS J CLIN INVE; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILSON DB, 1986, ANAT EMBRYOL, V174, P277, DOI 10.1007/BF00824343	54	416	421	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1993	364	6434					208	213		10.1038/364208a0	http://dx.doi.org/10.1038/364208a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391647				2022-12-24	WOS:A1993LM68300047
J	CULVER, GM; MCCRAITH, SM; ZILLMANN, M; KIERZEK, R; MICHAUD, N; LAREAU, RD; TURNER, DH; PHIZICKY, EM				CULVER, GM; MCCRAITH, SM; ZILLMANN, M; KIERZEK, R; MICHAUD, N; LAREAU, RD; TURNER, DH; PHIZICKY, EM			AN NAD DERIVATIVE PRODUCED DURING TRANSFER-RNA SPLICING - ADP-RIBOSE 1''-2'' CYCLIC PHOSPHATE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; PURIFICATION; NUCLEOTIDES; METABOLITE; SUBSTRATE; MECHANISM; LIGASE; ENZYME	Transfer RNA (tRNA) splicing is essential in Saccharomyces cerevisiae as well as in humans, and many of its features are the same in both. In yeast, the final step of this process is removal of the 2' phosphate generated at the splice junction during ligation. A nicotinamide adenine dinucleotide (NAD)-dependent phosphotransferase catalyzes removal of the 2' phosphate and produces a small molecule. It is shown here that this small molecule is an NAD derivative: adenosine diphosphate (ADP)-ribose 1''-2'' cyclic phosphate. Evidence is also presented that this molecule is produced in Xenopus laevis oocytes as a result of dephosphorylation of ligated tRNA.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,601 ELMWOOD AVE,ROCHESTER,NY 14642; POLISH ACAD SCI,INST BIOORGAN CHEM,PL-60704 POZNAN,POLAND; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; University of Rochester; University of Rochester			Schroeder, Susan/D-3946-2011	Kierzek, Ryszard/0000-0002-7644-0016	NIDCR NIH HHS [DE07202-02] Funding Source: Medline; NIGMS NIH HHS [GM 25349, GM 22939] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349, R01GM022939] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BARTON RA, 1977, J CHROMATOGR, V130, P145, DOI 10.1016/S0021-9673(00)89790-3; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; COLLIER RJ, 1990, ADP RIBOSYLATING TOX, pCH1; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; CULVER GM, UNPUB; FERNLEY HN, 1971, ENZYMES, V4, pCH18; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HOPPER AK, 1992, MOL CELLULAR BIOL YE, P99; KALCKAR HM, 1947, J BIOL CHEM, V167, P477; KIERZEK R, UNPUB; KNAPP G, 1979, CELL, V18, P37, DOI 10.1016/0092-8674(79)90351-9; LASKI FA, 1983, J BIOL CHEM, V258, P1974; LEE HC, 1989, J BIOL CHEM, V264, P1608; LITTLE JW, 1972, ANAL BIOCHEM, V48, P217, DOI 10.1016/0003-2697(72)90184-4; LOWRY OH, 1946, J BIOL CHEM, V162, P421; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MCCRAITH SM, 1990, MOL CELL BIOL, V10, P1049, DOI 10.1128/MCB.10.3.1049; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; NEU HC, 1964, J BIOL CHEM, V239, P2927; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4597; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REED TW, 1971, ENZYMES, V4, pCH17; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; SZEKELY E, 1988, J BIOL CHEM, V263, P13839; TYC K, 1987, J BIOL CHEM, V262, P12994; UCHIDA T, 1967, J BIOCHEM-TOKYO, V61, P44, DOI 10.1093/oxfordjournals.jbchem.a128519; VONTOL H, 1988, NUCLEIC ACIDS RES, V16, P1951; WALDRON C, 1975, J BACTERIOL, V122, P855, DOI 10.1128/JB.122.3.855-865.1975; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; ZILLMANN M, 1992, J BIOL CHEM, V267, P10289	39	79	81	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					206	208		10.1126/science.8392224	http://dx.doi.org/10.1126/science.8392224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8392224				2022-12-24	WOS:A1993LL59600039
J	DAVIS, S; ALDRICH, TH; STAHL, N; PAN, L; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; STAHL, N; PAN, L; TAGA, T; KISHIMOTO, T; IP, NY; YANCOPOULOS, GD			LIFR-BETA AND GP-130 AS HETERODIMERIZING SIGNAL TRANSDUCERS OF THE TRIPARTITE CNTF RECEPTOR	SCIENCE			English	Article							LEUKEMIA-INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; INTERLEUKIN-6; EXPRESSION; CLONING; GP130; CHAIN	The ciliary neurotrophic factor (CNTF) receptor complex is shown here to include the CNTF binding protein (CNTFRalpha) as well as the components of the leukemia inhibitory factor (LIF) receptor, LIFRbeta (the LIF binding protein) and gp130 [the signal transducer of interleukin-6 (IL-6)]. Thus, the conversion of a bipartite LIF receptor into a tripartite CNTF receptor apparently occurs by the addition of the specificity-conferring element CNTFRalpha. Both CNTF and LIF trigger the association of initially separate receptor components, which in turn results in tyrosine phosphorylation of receptor subunits. Unlike the IL-6 receptor complex in which homodimerization of gp130 appears to be critical for signal initiation, signaling by the CNTF and LIF receptor complexes depends on the heterodimerization of gp130 with LIFRbeta. Ligand-induced dimerization of signal-transducing receptor components, also seen with receptor tyrosine kinases, may provide a general mechanism for the transmission of a signal across the cell membrane.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,FUKUSHIMA KU,OSAKA 553,JAPAN	Osaka University; Osaka University	DAVIS, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Kishimoto, Tadamitsu/C-8470-2009					BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURAKAMI M, UNPUB; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, UNPUB; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	31	623	660	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 18	1993	260	5115					1805	1808		10.1126/science.8390097	http://dx.doi.org/10.1126/science.8390097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LH205	8390097				2022-12-24	WOS:A1993LH20500050
J	FFRENCHCONSTANT, RH; ROCHELEAU, TA; STEICHEN, JC; CHALMERS, AE				FFRENCHCONSTANT, RH; ROCHELEAU, TA; STEICHEN, JC; CHALMERS, AE			A POINT MUTATION IN A DROSOPHILA GABA RECEPTOR CONFERS INSECTICIDE RESISTANCE	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; ALPHA-SUBUNIT; PICROTOXININ; SEQUENCE; CHANNELS; DIELDRIN; CLONING; REGION; FORM; CDNA	VERTEBRATES and invertebrates both have GABA (gamma-aminobutyric acid) as a major inhibitory neurotransmitter1,2. GABA(A) receptors in vertebrates assemble as heteromultimers to form an integral chloride ion channel3. These receptors are targets for drugs and pesticides4 and are also implicated in seizure-related diseases5,6. Picrotoxinin (PTX) and cyclodiene insecticides are GABA(A) receptor antagonists which competitively displace each other from the same binding site7. Insects8 and vertebrates9 showing resistance to cyclodienes also show cross-resistance to PTX. Previously, we used a field-isolated Drosophila mutant Rdl (Resistant to dieldrin)10 insensitive to PTX and cyclodienes to clone a putative GABA receptor11. Here we report the functional expression and novel pharmacology of this GABA receptor and examine the functionality of a resistance-associated point mutation (alanine to serine) within the second membrane-spanning domain, the region thought to line the chloride ion channel pore. This substitution is found globally in Drosophila populations12. This mutation not only identifies a single amino acid conferring high levels of resistance to the important GABA receptor antagonist PTX but also, by conferring resistance to cyclodienes, may account for over 60% of reported cases of insecticide resistance13.	RHONE POULENC AG CO,RES TRIANGLE PK,NC 27709		FFRENCHCONSTANT, RH (corresponding author), UNIV WISCONSIN,DEPT ENTOMOL,RUSSELL LABS 237,1630 LINDEN DR,MADISON,WI 53706, USA.			ffrench-Constant, Richard/0000-0001-5385-9888				BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BLOOMQUIST JR, 1991, PESTIC SCI, V32, P463, DOI 10.1002/ps.2780320408; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; ELDEFRAWI AT, 1987, FASEB J, V1, P262, DOI 10.1096/fasebj.1.4.2443413; FEIGENSPAN A, 1993, NATURE, V361, P159, DOI 10.1038/361159a0; FFRENCHCONSTANT R, IN PRESS P NATN ACAD; FFRENCHCONSTANT RH, 1991, GENET RES, V57, P17, DOI 10.1017/S0016672300028986; FFRENCHCONSTANT RH, 1990, J ECON ENTOMOL, V83, P1733, DOI 10.1093/jee/83.5.1733; FFRENCHCONSTANT RH, 1992, J NEUROCHEM, V59, P1562, DOI 10.1111/j.1471-4159.1992.tb08475.x; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GEORGHIOU GP, 1986, PEST RESISTANCE PEST; HARVEY RJ, 1991, EMBO J, V10, P3239, DOI 10.1002/j.1460-2075.1991.tb04887.x; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KADOUS AA, 1983, PESTIC BIOCHEM PHYS, V19, P157, DOI 10.1016/0048-3575(83)90135-9; KUFFLER SW, 1965, J NEUROPHYSIOL, V21, P589; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LUMMIS SCR, 1990, COMP BIOCHEM PHYS C, V95, P1, DOI 10.1016/0742-8413(90)90073-I; MATSUMURA F, 1983, J ENVIRON SCI HEAL B, V18, P1, DOI 10.1080/03601238309372355; MEDLRUM BS, 1989, BR J CLIN PHARM, V27, pS3; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QIAN HH, 1993, NATURE, V361, P162, DOI 10.1038/361162a0; ROUSH RT, 1987, ANNU REV ENTOMOL, V32, P361, DOI 10.1146/annurev.en.32.010187.002045; SATELLE DB, 1992, TRANSMITTER AMINO AC, P273; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; USHERWOOD PN, 1965, J NEUROPHYSIOL, V28, P497, DOI 10.1152/jn.1965.28.3.497; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; YARBROUGH JD, 1986, EXPERIENTIA, V42, P851, DOI 10.1007/BF01941551	32	461	489	2	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					449	451		10.1038/363449a0	http://dx.doi.org/10.1038/363449a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	8389005				2022-12-24	WOS:A1993LE93800058
J	MALLICK, CA; DUDLEY, EC; VINEY, JL; OWEN, MJ; HAYDAY, AC				MALLICK, CA; DUDLEY, EC; VINEY, JL; OWEN, MJ; HAYDAY, AC			REARRANGEMENT AND DIVERSITY OF T-CELL RECEPTOR BETA-CHAIN GENES IN THYMOCYTES - A CRITICAL ROLE FOR THE BETA-CHAIN IN DEVELOPMENT	CELL			English	Article							TRANSGENIC MICE; LYMPHOCYTES-B; PRE-B; EXPRESSION; DNA; ORGANIZATION; REPERTOIRE; SEGMENTS; LAMBDA-5; THYMUS	Thymocytes from mice congenitally deficient for TCR alpha chain synthesis were examined for the status of their TCR beta chain genes, by DNA sequencing and by a novel technique that analyzes populations of gene rearrangements. TCR beta chain genes were predominantly productively rearranged, in contrast with the statistical prediction for a quasi-random rearrangement process. Therefore, productive TCR beta chain gene rearrangement appears to be a critical step in thymocyte maturation, independent of TCR alpha chain expression. Moreover, the beta chain gene rearrangements in TCRalpha-/- mice are typical of those found in the thymus and periphery of normal mice. Thus, the extent of junctional diversity is a property of TCR genes that is imposed prior to selection on the mature alphabeta TCR.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	MALLICK, CA (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.		Yang, Chen/G-1379-2010		NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEHKLE MA, 1985, SCIENCE, V229, P566; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; CHOU HS, 1987, SCIENCE, V238, P545, DOI 10.1126/science.2821625; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; Kisielow P, 1990, Semin Immunol, V2, P35; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; Maniatis T., 1982, MOL CLONING; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OKADA CY, 1989, J EXP MED, V169, P1703, DOI 10.1084/jem.169.5.1703; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOLLAY R, 1978, NATURE, V276, P79, DOI 10.1038/276079a0; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	34	183	186	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					513	519		10.1016/0092-8674(93)90138-G	http://dx.doi.org/10.1016/0092-8674(93)90138-G			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387894				2022-12-24	WOS:A1993LA74300012
J	GU, W; SCHNEIDER, JW; CONDORELLI, G; KAUSHAL, S; MAHDAVI, V; NADALGINARD, B				GU, W; SCHNEIDER, JW; CONDORELLI, G; KAUSHAL, S; MAHDAVI, V; NADALGINARD, B			INTERACTION OF MYOGENIC FACTORS AND THE RETINOBLASTOMA PROTEIN MEDIATES MUSCLE-CELL COMMITMENT AND DIFFERENTIATION	CELL			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; SV40 LARGE-T; TUMOR SUPPRESSOR GENES; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; C-MYC; E1A PROTEINS; RB PROTEIN; MYOD	The experiments reported here document that the tumor suppressor retinoblastoma protein (pRB) plays an important role in the production and maintenance of the terminally differentiated phenotype of muscle cells. We show that pRB inactivation, through either phosphorylation, binding to T antigen, or genetic alteration, inhibits myogenesis. Moreover, inactivation of pRB in terminally differentiated cells allows them to reenter the cell cycle. In addition to its involvement in the myogenic activities of MyoD, pRB is also required for the cell growth-inhibitory activity of this myogenic factor. We also show that pRB and MyoD directly bind to each other, both in vivo and in vitro, through a region that involves the pocket and the basic-helix-loop-helix domains, respectively. All the results obtained are consistent with the proposal that the effects of MyoD on the cell cycle and of pRB on the myogenic pathway result from the direct binding of the two molecules.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	GU, W (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gianluigi/0000-0003-0481-6843				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KONIGSBERG IR, 1960, J BIOPHYS BIOCHEM CY, V8, P333, DOI 10.1083/jcb.8.2.333; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE W, 1987, SCIENCE, V235, P1395; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELLINGTON EL, 1992, P NATL ACAD SCI USA, V89, P1755; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	98	705	713	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					309	324		10.1016/0092-8674(93)90110-C	http://dx.doi.org/10.1016/0092-8674(93)90110-C			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381715				2022-12-24	WOS:A1993KM16200003
J	PEREZVELAZQUEZ, JL; ANGELIDES, KJ				PEREZVELAZQUEZ, JL; ANGELIDES, KJ			ASSEMBLY OF GABA(A) RECEPTOR SUBUNITS DETERMINES SORTING AND LOCALIZATION IN POLARIZED CELLS	NATURE			English	Article							HIPPOCAMPAL-NEURONS; FUNCTIONAL EXPRESSION; MEMBRANE GLYCOPROTEIN; EPITHELIAL-CELLS; MESSENGER-RNA; PROTEINS; RAT; HETEROGENEITY; BIOGENESIS; DOMAINS	THE GABA(A) receptor, the principal inhibitory receptor in the CNS, is distributed on cell bodies, dendrites, and in some cells at axon hillocks and presynaptic terminals1-6. The dendritic distribution is crucial for shunting of excitatory synaptic inputs7,8. Molecular cloning has revealed that the GABA(A) receptor can be formed by a diverse set of subunits and by separately encoded subunit isoforms9,10, the expression of each of which differs in distinct areas of the central nervous system11-13 and during development14,15. Why different genes exist to encode these isoforms is not clear, but may be linked to functional differences16-19. Here we show that assembly of specific isoforms also codes for sorting and localization of the receptor complex. Confocal microscopy and immunoblot analysis of epithelial cells transfected with the complementary DNAs encoding the alpha1 and beta1 GABA(A) receptor subunits and probed with subunit isoform-specific antibodies show that the alpha1 subunit is targeted to the basolateral surface, and that the beta1 subunit is sorted to the apical membrane. In cells where alpha1 and beta1 isoforms are co-expressed, assembly of the beta1 with the alpha1 subunit isoform re-routes the alpha1 subunit to the apical surface. The ability to assemble complexes of different isoform composition and to target these to specific regions of the cell surface would enable neurons to modulate GABA(A) receptor distribution and possibly alter the composition of its synapses in response to transcriptional levels of specific subunit isoforms.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								AYOUB GS, 1991, NEUROREPORT, V2, P809, DOI 10.1097/00001756-199112000-00020; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENKE D, 1991, J BIOL CHEM, V266, P4478; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; GAMBARANA C, 1990, J NEUROBIOL, V21, P1169, DOI 10.1002/neu.480210803; GU Q, 1992, NEUROREPORT, V3, P169, DOI 10.1097/00001756-199202000-00012; HERZ RE, 1989, J BIOL CHEM, V264, P4605; HOUSER CR, 1988, J NEUROSCI, V8, P1370; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; KILLISCH I, 1991, NEURON, V7, P927, DOI 10.1016/0896-6273(91)90338-Z; KLAUSNER R D, 1989, New Biologist, V1, P3; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MONYER A, 1992, SCIENCE, V256, P1217; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; PADILLA MM, 1990, J COGNITIVE NEUROSCI, V2, P180; PEREZVELAZQUEZ JL, 1989, J NEUROSCI, V9, P2163; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHOCH P, 1986, GABAERGIC TRANSMISSI, P11; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VU ET, 1992, SCIENCE, V255, P1710, DOI 10.1126/science.1553559; WADINGERNESS A, 1990, J CELL BIOL, V111, P987; WISDEN W, 1992, NEUROSCIENCE, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	43	67	68	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					457	460		10.1038/361457a0	http://dx.doi.org/10.1038/361457a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8381522				2022-12-24	WOS:A1993KK71300063
J	FRASURESMITH, N; LESPERANCE, F; TALAJIC, M				FRASURESMITH, N; LESPERANCE, F; TALAJIC, M			DEPRESSION FOLLOWING MYOCARDIAL-INFARCTION - IMPACT ON 6-MONTH SURVIVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; HEART-RATE VARIABILITY; AFFECTIVE-DISORDERS; MORTALITY; VARIABLES; SEROTONIN; PLATELETS; THERAPY	Objective.-To determine if the diagnosis of major depression in patients hospitalized following myocardial infarction (MI) would have an independent impact on cardiac mortality over the first 6 months after discharge. Design.-Prospective evaluation of the impact of depression assessed using a modified version of the National Institute of Mental Health Diagnostic Interview Schedule for major depressive episode. Cox proportional hazards regression was used to evaluate the independent impact of depression after control for significant clinical predictors in the data set. Setting.-A large, university-affiliated hospital specializing in cardiac care, located in Montreal, Quebec. Patients.-All consenting patients (N=222) who met established criteria for MI between August 1991 and July 1992 and who survived to be discharged from the hospital. Patients were interviewed between 5 and 15 days following the MI and were followed up for 6 months. There were no age limits (range, 24 to 88 years; mean, 60 years). The sample was 78% male. Primary Outcome Measure.-Survival status at 6 months. Results.-By 6 months, 12 patients had died. All deaths were due to cardiac causes. Depression was a significant predictor of mortality (hazard ratio, 5.74; 95% confidence interval, 4.61 to 6.87; P=.0006). The impact of depression remained after control for left ventricular dysfunction (Killip class) and previous MI, the multivariate significant predictors of mortality in the data set (adjusted hazard ratio, 4.29; 95% confidence interval, 3.14 to 5.44; P=.013). Conclusion.-Major depression in patients hospitalized following an MI is an independent risk factor for mortality at 6 months. Its impact is at least equivalent to that of left ventricular dysfunction (Killip class) and history of previous MI. Additional study is needed to determine whether treatment of depression can influence post-MI survival and to assess possible underlying mechanisms.	MCGILL UNIV,DEPT PSYCHIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV MONTREAL,DEPT PSYCHIAT,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL H3C 3J7,QUEBEC,CANADA	McGill University; Universite de Montreal; Universite de Montreal	FRASURESMITH, N (corresponding author), MONTREAL HEART INST,RES CTR,5000 BELANGER E,MONTREAL H1T 1C8,QUEBEC,CANADA.		Lesperance, Francois/C-4716-2015	Lesperance, Francois/0000-0003-4604-2823; Talajic, Mario/0000-0001-8469-4748				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; BEACH ML, 1989, CONTROL CLIN TRIALS, V10, pS161; Beck AT., 1996, BECK DEPRESSION INVE; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLUMENTHAL JA, 1982, PSYCHOSOM MED, V44, P519, DOI 10.1097/00006842-198212000-00003; CARNEY RM, 1987, AM J CARDIOL, V60, P1273, DOI 10.1016/0002-9149(87)90607-2; CARNEY RM, 1988, J PSYCHOSOM RES, V32, P159, DOI 10.1016/0022-3999(88)90050-5; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; COX DR, 1972, J R STAT SOC B, V34, P187; DALACK GW, 1990, J CLIN PSYCHIAT, V51, P4; Dixon W. J., 1990, BMDP STATISTICAL SOF; FIELDING R, 1991, SOC SCI MED, V32, P1017, DOI 10.1016/0277-9536(91)90159-A; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; GORKIN L, IN PRESS CONTROLLED; HAGA DA, 1991, PSYCHOL BULL, V110, P215; HOUSE A, 1988, J PSYCHOSOM RES, V32, P345, DOI 10.1016/0022-3999(88)90017-7; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KUSUMI I, 1991, BIOL PSYCHIAT, V30, P310, DOI 10.1016/0006-3223(91)90114-2; LADWIG KH, 1991, EUR HEART J, V12, P959; MCGEE HM, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283-a; MELTZER HY, 1991, 5 HYDROXYTRYPTAMINE, P50; Meltzer HY., 1987, PSYCHOPHARMACOLOGY 3, VVol. 1, P513; MIKUNI M, 1992, PSYCHOPHARMACOLOGY, V106, P311, DOI 10.1007/BF02245410; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; PENKOFER S, 1991, CIRCULATION S2, V84, P59; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; REGIER DA, 1984, ARCH GEN PSYCHIAT, V41, P934; RICHARDSON JL, 1987, HEALTH PSYCHOL, V6, P183, DOI 10.1037/0278-6133.6.3.183; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROOSE SP, 1992, J CLIN PSYCHIAT, V53, P25; ROOSE SP, 1991, J CLIN PSYCHIAT, V52, P34; RUBERMAN W, 1984, NEW ENGL J MED, V311, P522; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; STOKES JP, 1989, ANXIETY DEPRESSION D, P253; VANHOUTTE PM, 1991, J CARDIOVASC PHARM, V17, pS6; Yamaguchi K., 1991, EVENT HIST ANAL; ZUNG W W K, 1990, Journal of Clinical Psychiatry, V51, P77; 1987, DIAGNOSTIC STATISTIC; 1991, NEW ENGL J MED, V325, P293; 1982, JAMA-J AM MED ASSOC, V247, P1707	41	1511	1544	0	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1819	1825		10.1001/jama.270.15.1819	http://dx.doi.org/10.1001/jama.270.15.1819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MB464	8411525				2022-12-24	WOS:A1993MB46400024
J	CHENEY, RE; OSHEA, MK; HEUSER, JE; COELHO, MV; WOLENSKI, JS; ESPREAFICO, EM; FORSCHER, P; LARSON, RE; MOOSEKER, MS				CHENEY, RE; OSHEA, MK; HEUSER, JE; COELHO, MV; WOLENSKI, JS; ESPREAFICO, EM; FORSCHER, P; LARSON, RE; MOOSEKER, MS			BRAIN MYOSIN-V IS A 2-HEADED UNCONVENTIONAL MYOSIN WITH MOTOR-ACTIVITY	CELL			English	Article							CALMODULIN-BINDING PROTEINS; PROTEOLYTIC FRAGMENTS; INVITRO MOTILITY; ACTIN-FILAMENTS; CHICKEN BRAIN; LIGHT-CHAINS; MUSCLE; COMPLEX; CALCIUM; PURIFICATION	Chicken myosin-V is a member of a recently recognized class of myosins distinct from both the myosins-I and the myosins-II. We report here the purification, electron microscopic visualization, and motor properties of a protein of this class. Myosin-V molecules consist of two heads attached to an approximately 30 nm stalk that ends in a globular region of unknown function. Myosin-V binds to and decorates F-actin, has actin-activated magnesium-ATPase activity, and is a barbed-end-directed motor capable of moving actin filaments at rates of up to 400 nm/s. Myosin-V does not form filaments. Each myosin-V heavy chain is associated with approximately four calmodulin light chains as well as two less abundant proteins of 23 and 17 kd.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; UNIV SAO PAULO, SCH MED RIBEIRAO PRETO, DEPT BIOCHEM, BR-14049 RIBEIRAO PRETO, SP, BRAZIL	Washington University (WUSTL); Universidade de Sao Paulo	CHENEY, RE (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.		Heuser, John/H-5940-2012; Espreafico, Enilza/AAW-4658-2021; Espreafico, Enilza/O-3053-2016	Espreafico, Enilza/0000-0002-7552-4234; Espreafico, Enilza/0000-0002-7552-4234; Cheney, Richard/0000-0001-6565-7888	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025387, R01DK025387, R56DK025387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028695] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25387] Funding Source: Medline; NIGMS NIH HHS [GM-29647] Funding Source: Medline; NINDS NIH HHS [NS-28695] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P659, DOI 10.1073/pnas.90.2.659; HALSALL DJ, 1990, FEBS LETT, V267, P126, DOI 10.1016/0014-5793(90)80305-3; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANSON LW, 1992, CELL MOTIL CYTOSKEL, V22, P274, DOI 10.1002/cm.970220407; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KENDRICKJONES J, 1981, J MUSCLE RES CELL M, V2, P347, DOI 10.1007/BF00711965; KIELLEY WW, 1960, BIOCHIM BIOPHYS ACTA, V41, P401; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LARSON RE, 1990, J NEUROCHEM, V54, P1288, DOI 10.1111/j.1471-4159.1990.tb01961.x; LARSON RE, 1988, BRAZ J MED BIOL RES, V21, P213; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; MERCER JA, 1991, NATURE, V352, P547, DOI 10.1038/352547b0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOOSEKER MS, 1991, CURR TOP MEMBR, V38, P31; PLANCKE YD, 1983, MOL CELL BIOL, V3, P1412, DOI 10.1128/MCB.3.8.1412; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SCOPES RK, 1987, PROTEIN PURFICATION; SHEETZ MP, 1986, METHOD ENZYMOL, V134, P531; SILVERS WK, 1979, COAT COLORS MICE, P83; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; TAKIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P671, DOI 10.1093/oxfordjournals.jbchem.a123106; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1993, IN PRESS J EXP ZOOL	45	386	391	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					13	23		10.1016/0092-8674(93)90675-G	http://dx.doi.org/10.1016/0092-8674(93)90675-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402892	hybrid			2022-12-24	WOS:A1993MB66700004
J	PENDERGAST, AM; QUILLIAM, LA; CRIPE, LD; BASSING, CH; DAI, ZH; LI, NX; BATZER, A; RABUN, KM; DER, CJ; SCHLESSINGER, J; GISHIZKY, ML				PENDERGAST, AM; QUILLIAM, LA; CRIPE, LD; BASSING, CH; DAI, ZH; LI, NX; BATZER, A; RABUN, KM; DER, CJ; SCHLESSINGER, J; GISHIZKY, ML			BCR-ABL-INDUCED ONCOGENESIS IS MEDIATED BY DIRECT INTERACTION WITH THE SH2 DOMAIN OF THE GRB-2 ADAPTER PROTEIN	CELL			English	Article							MITOGENIC SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; RAS PROTEINS; GENE-PRODUCT; SEVENLESS GENE; C-ABL; GROWTH; CELLS	BCR-ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph1)-positive human leukemias. Sequences within the first exon of BCR are required to activate the transforming potential of BCR-ABL. The SH2/SH3 domain-containing GRB-2 protein links tyrosine kinases to Ras signaling. We demonstrate that BCR-ABL exists in a complex with GRB-2 in vivo. Binding of GRB-2 to BCR-ABL is mediated by the direct interaction of the GRB-2 SH2 domain with a phosphorylated tyrosine, Y177, within the BCR first exon. The BCR-ABL-GRB-2 interaction is required for activation of the Ras signaling pathway. Mutation of Y177 to phenylalanine (Y177F) abolishes GRB-2 binding and abrogates BCR-ABL-induced Ras activation. The BCR-ABL (Y177F) mutant is unable to transform primary bone marrow cultures and is impaired in its ability to transform Rat1 fibroblasts. These findings implicate activation of Ras function as an important component in BCR-ABL-mediated transformation and demonstrate that GRB-2 not only functions in normal development and mitogenesis but also plays a role in oncogenesis.	UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; DUKE UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, DURHAM, NC 27710 USA; NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; SUGEN INC, REDWOOD CITY, CA 94063 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; New York University	PENDERGAST, AM (corresponding author), DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	Pendergast, Ann Marie/0000-0002-1250-6880; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978] Funding Source: Medline; NIDDK NIH HHS [DK01965] Funding Source: Medline; NIGMS NIH HHS [GM07184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K12DK001965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HAUSER CA, 1993, IN PRESS METH ENZYMO; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU JX, 1993, ONCOGENE, V8, P101; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMONS MS, 1989, ONCOGENE, V4, P559; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	64	620	641	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					175	185		10.1016/S0092-8674(05)80094-7	http://dx.doi.org/10.1016/S0092-8674(05)80094-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402896	hybrid			2022-12-24	WOS:A1993MB66700018
J	AMON, A; TYERS, M; FUTCHER, B; NASMYTH, K				AMON, A; TYERS, M; FUTCHER, B; NASMYTH, K			MECHANISMS THAT HELP THE YEAST-CELL CYCLE CLOCK TICK - G2 CYCLINS TRANSCRIPTIONALLY ACTIVATE G2 CYCLINS AND REPRESS G1 CYCLINS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PROTEIN-KINASE; DNA-SYNTHESIS; S-PHASE; POSITIVE FEEDBACK; GENE-EXPRESSION; HO GENE; COMPLEX; MITOSIS	In budding yeast, G1 cyclins such as CLN1 and CLN2 are expressed in G1 and S phases, while mitotic cyclins such as CLB1 and CLB2 are expressed in G2 and M phases. We find that the CLBs play a central role in the transition from CLNs to CLBs: the CLBs stimulate their own expression while repressing that of CLNs. This negative regulation of CLNs may occur via the transcription factor SW14, because CLBs are necessary for G2 repression of SCB-regulated genes like CLN1 and CLN2 but not for repression of MCB-regulated genes like DNA polymerase and CLBS. Furthermore, SW14 associates with CLB2 protein and is a substrate for the CLB2-associated CDC28 kinase in vitro.			AMON, A (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Tyers, Michael/ABE-3194-2021	Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039978, R01GM045410] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39978, GM45410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; Kaufman T C, 1990, Adv Genet, V27, P309; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Maniatis T., 1982, MOL CLONING; MCKINNEY J, 1992, Current Biology, V2, P421, DOI 10.1016/0960-9822(92)90322-2; MOLL T, 1992, J CELL SCI S, V16, P87; MORTIMER RK, 1969, YEASTS, V1, P385; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PINES J, 1990, New Biologist, V2, P389; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Rubin G M, 1975, Methods Cell Biol, V12, P45; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SOCKANATHAN S, 1991, THESIS U CAMBRIDGE C; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	56	310	314	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					993	1007		10.1016/0092-8674(93)90722-3	http://dx.doi.org/10.1016/0092-8674(93)90722-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402888				2022-12-24	WOS:A1993LY49300007
J	RUFFJAMISON, S; CHEN, K; COHEN, S				RUFFJAMISON, S; CHEN, K; COHEN, S			INDUCTION BY EGF AND INTERFERON-GAMMA OF TYROSINE-PHOSPHORYLATED DNA-BINDING PROTEINS IN MOUSE-LIVER NUCLEI	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATOR; IFN-GAMMA; ALPHA; RECEPTOR; KINASES; DOMAINS	Intraperitoneal injection of epidermal growth factor (EGF) into mice resulted in the appearance in liver nuclei of three tyrosine phosphorylated proteins (84, 91, and 92 kilodaltons) within minutes after administration of EGF. Administration of interferon-gamma (IFN-gamma) resulted in the appearance in liver nuclei of two tyrosine phosphorylated proteins (84 and 91 kilodaltons). The 84- and 91-kilodalton proteins detected after either EGF or IFN-gamma administration were identified as the IFN-gamma activation factors (GAF). Furthermore, gel shift analysis revealed that these GAF proteins, detected after either EGF or IFN-gamma administration, specifically bound to the sis-inducible element of the c-fos promoter. Thus, GAF proteins participate in nuclear signaling in both IFN-gamma and EGF pathways.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NICHD NIH HHS [HD-00700] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEVY D, 1990, New Biologist, V2, P923; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RUFFJAMISON S, 1993, PROTEIN ENG, V6, P661, DOI 10.1093/protein/6.6.661; RUFFJAMISON S, UNPUB; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	296	303	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1733	1736		10.1126/science.8378774	http://dx.doi.org/10.1126/science.8378774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378774				2022-12-24	WOS:A1993LY58400026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LEVOMETHADYL APPROVED FOR THE TREATMENT OF OPIATE DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1290	1290		10.1001/jama.270.11.1290	http://dx.doi.org/10.1001/jama.270.11.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360956				2022-12-24	WOS:A1993LW34500007
J	SHENG, M; LIAO, YJ; JAN, YN; JAN, LY				SHENG, M; LIAO, YJ; JAN, YN; JAN, LY			PRESYNAPTIC A-CURRENT BASED ON HETEROMULTIMERIC K+ CHANNELS DETECTED IN-VIVO	NATURE			English	Article							POTASSIUM CHANNELS; XENOPUS-OOCYTES; RAT-BRAIN; DIVERSITY; SHAKER; HIPPOCAMPUS; SUBUNITS; PROTEINS; NEURONS; APLYSIA	A WIDE variety of voltage-gated K+ channels are involved in the regulation of neuronal excitability and synaptic transmission. Their heterogeneity arises in part from the large number of genes encoding different K+ channel subunits (reviewed in ref. 1). In addition, heterologous expression studies indicate that assembly of distinct subunits into heteromultimeric channels may contribute further to K+ channel diversity2-6. A question has been whether heteromeric K+ channels actually form in vivo, and if so, whether specific combinations of subunits could account for major K+ currents identified in neurons. We present here biochemical evidence that Kv1.4 and Kv1.2, two K+ channel subunits of the Shaker subfamily, co-assemble in rat brain. The Kv1.4/Kv1.2 heteromultimer combines features of both parent subunits, resulting in an A-type K+ channel6. Immunocytochemical evidence suggests that the heteromultimers are localized in axons and nerve terminals. We propose that Kv1.4/Kv1.2 heteromultimers may form the molecular basis of a presynaptic A-type K+ channel involved in the regulation of neurotransmitter release.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	SHENG, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Sheng, Morgan/0000-0002-8703-5366; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JAN YN, 1977, PROC R SOC SER B-BIO, V198, P87, DOI 10.1098/rspb.1977.0087; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SHIMAHARA T, 1981, NEUROSCI LETT, V24, P139, DOI 10.1016/0304-3940(81)90237-8; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TIBBS GR, 1989, J NEUROCHEM, V52, P201, DOI 10.1111/j.1471-4159.1989.tb10917.x; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y	18	313	318	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					72	75		10.1038/365072a0	http://dx.doi.org/10.1038/365072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361540				2022-12-24	WOS:A1993LV64600057
J	BAKER, TA; MIZUUCHI, M; SAVILAHTI, H; MIZUUCHI, K				BAKER, TA; MIZUUCHI, M; SAVILAHTI, H; MIZUUCHI, K			DIVISION-OF-LABOR AMONG MONOMERS WITHIN THE MU-TRANSPOSASE TETRAMER	CELL			English	Article							DNA STRAND-TRANSFER; P ELEMENT TRANSPOSITION; BACTERIOPHAGE-MU; B-PROTEIN; PHAGE-MU; INVITRO TRANSPOSITION; A-PROTEIN; CLEAVAGE; SITE; ENDS	A single tetramer of Mu transposase (MuA) pairs the recombination sites, cleaves the donor DNA, and joins these ends to a target DNA by strand transfer. Analysis of C-terminal deletion derivatives of MuA reveals that a 30 amino acid region between residues 575 and 605 is critical for these three steps. Although inactive on its own, a deletion protein lacking this region assembles with the wild-type protein. These mixed tetramers carry out donor cleavage but do not promote strand transfer, even when the donor cleavage stage is by-passed. These data suggest that the active center of the transposase is composed of the C-terminus of four MuA monomers; one dimer carries out donor cleavage while all four monomers contribute to strand transfer.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Savilahti, Harri/0000-0002-6246-2572				ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BETERMIER M, 1990, MOL MICROBIOL, V3, P1159; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DESMET L, 1989, MOL MICROBIOL, V3, P1145, DOI 10.1111/j.1365-2958.1989.tb00265.x; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; ENGELMAN A, 1993, IN PRESS EMBO J, V12; HANIFORD DB, 1991, CELL, V64, P171; JONES KS, 1992, J BIOL CHEM, V267, P16037; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEUNG PC, 1991, J MOL BIOL, V219, P189, DOI 10.1016/0022-2836(91)90561-J; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RIO DC, 1991, TRENDS GENET, V7, P282, DOI 10.1016/0168-9525(91)90176-Q; STUDIER TA, 1990, METHOD ENZYMOL, V185, P60; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; ZOU A, 1991, J BIOL CHEM, V266, P20476	40	98	100	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					723	733		10.1016/0092-8674(93)90519-V	http://dx.doi.org/10.1016/0092-8674(93)90519-V			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395353				2022-12-24	WOS:A1993LU59200015
J	KASAI, H; LI, YX; MIYASHITA, Y				KASAI, H; LI, YX; MIYASHITA, Y			SUBCELLULAR-DISTRIBUTION OF CA2+ RELEASE CHANNELS UNDERLYING CA2+ WAVES AND OSCILLATIONS IN EXOCRINE PANCREAS	CELL			English	Article							ACINAR-CELLS; INOSITOL TRISPHOSPHATE; CALCIUM-CONCENTRATION; ENDOPLASMIC-RETICULUM; CA-2+; RECEPTOR; LOCALIZATION; STIMULATION; SECRETION; MECHANISM	Agonists trigger Ca2+ waves and oscillations in exocrine gland cells. Our confocal Ca2+ imaging revealed three distinct phases during the Ca2+ waves in the rat pancreatic acinar cell. Rises in Ca2+ concentration were initiated at a small trigger zone, or T zone, in the granular area; then, Ca2+ waves rapidly spread within the area and, at high agonist concentrations, propagated slowly toward the basal pole. Injection of inositol 1,4,5-trisphosphate (IP3) or Ca2+ from patch pipettes demonstrated the presence of high sensitivity IP3 receptors at the T zone, Ca2+-induced Ca2+ release channels in the granular area, and low sensitivity IP3 receptors in the basal area. The IP3 receptors at the T zone appeared to generate autonomous Ca2+ spikes and to initiate patterned Ca2+ oscillations. Thus, heterogeneous cytosolic localization of Ca2+ release channels plays a key role in Ca2+ waves and oscillations.			KASAI, H (corresponding author), UNIV TOKYO, FAC MED, DEPT PHYSIOL, BUNKYO KU, TOKYO 113, JAPAN.		Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637; Kasai, Haruo/0000-0003-2327-9027				AMSTERDA.A, 1974, J CELL BIOL, V63, P1037, DOI 10.1083/jcb.63.3.1037; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kern HF, 1986, EXOCRINE PANCREAS BI, P9; LASKEY RE, 1992, P NATL ACAD SCI USA, V89, P1690, DOI 10.1073/pnas.89.5.1690; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; MARUYAMA Y, 1993, J PHYSIOL-LONDON, V463, P729, DOI 10.1113/jphysiol.1993.sp019619; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIYAZAKI S, 1988, DEV GROWTH DIFFER, V30, P603; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOMOGYI R, 1991, J BIOL CHEM, V266, P11068; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145	43	344	345	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					669	677		10.1016/0092-8674(93)90514-Q	http://dx.doi.org/10.1016/0092-8674(93)90514-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395348				2022-12-24	WOS:A1993LU59200010
J	MCLAUGHLIN, PJ; GOOCH, JT; MANNHERZ, HG; WEEDS, AG				MCLAUGHLIN, PJ; GOOCH, JT; MANNHERZ, HG; WEEDS, AG			STRUCTURE OF GELSOLIN SEGMENT-1-ACTIN COMPLEX AND THE MECHANISM OF FILAMENT SEVERING	NATURE			English	Article							ACTIN-BINDING PROTEINS; HUMAN ANNEXIN-V; F-ACTIN; PLASMA GELSOLIN; SITES; SEQUENCE; DOMAINS; ACID; CRYSTALLIZATION; IDENTIFICATION	The structure of the segment 1 domain of gelsolin, a protein that fragments actin filaments in cells, is reported in complex with actin. Segment 1 binds monomer using an apolar patch rimmed by hydrogen bonds in a cleft between actin domains. On the actin filament model it binds tangentially, disrupting only those contacts between adjacent subunits in one helical strand. The segment 1 fold is general for all segments of the gelsolin family because the conserved residues form the core of the structure. It also provides a basis for understanding the origin of an amyloidosis caused by a gelsolin variant.	UNIV MARBURG,INST CYTOBIOL & CYTOPATHOL,W-3550 MARBURG,GERMANY	Philipps University Marburg	MCLAUGHLIN, PJ (corresponding author), MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND.		Mannherz, Hans Georg/HHM-2867-2022	Mannherz, Hans Georg/0000-0001-8158-5722				AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BREMER A, 1991, J CELL BIOL, V115, P689, DOI 10.1083/jcb.115.3.689; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELACHAPELLE A, 1992, NAT GENET, V2, P157, DOI 10.1038/ng1092-157; DELCASTILLO AR, 1992, J CELL BIOL, V119, P797, DOI 10.1083/jcb.119.4.797; DOI Y, 1984, J BIOL CHEM, V259, P1868; DOI Y, 1992, BIOCHEMISTRY-US, V31, P10061, DOI 10.1021/bi00156a028; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MANNHERZ HG, 1992, J MOL BIOL, V226, P899, DOI 10.1016/0022-2836(92)90641-V; MATSUDAIRA P, 1988, CELL, V54, P139, DOI 10.1016/0092-8674(88)90542-9; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCLAUGHLIN PJ, 1992, FEBS LETT, V302, P253, DOI 10.1016/0014-5793(92)80453-N; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VANDEKERCKHOVE J, 1984, J MOL BIOL, V179, P391, DOI 10.1016/0022-2836(84)90072-X; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1988, BIOESSAYS, V7; YU FX, 1992, J BIOL CHEM, V267, P14616; [No title captured]	46	524	536	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					685	692		10.1038/364685a0	http://dx.doi.org/10.1038/364685a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8395021				2022-12-24	WOS:A1993LT67700047
J	HANDEL, TM; WILLIAMS, SA; DEGRADO, WF				HANDEL, TM; WILLIAMS, SA; DEGRADO, WF			METAL-ION DEPENDENT MODULATION OF THE DYNAMICS OF A DESIGNED PROTEIN	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 4-HELIX BUNDLE PROTEIN; MOLTEN GLOBULE STATE; FOLDING INTERMEDIATE; STRUCTURAL CHARACTERIZATION; SECONDARY STRUCTURE; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; DENOVO DESIGN; CYTOCHROME-C	The peptide a 4 is a designed four-helix bundle that contains a highly simplified hydrophobic core composed exclusively of leucine residues; its tertiary structure is therefore largely dictated by hydrophobic forces. This small protein adopts a structure with properties intermediate between those of the native and molten globule states of proteins: it is compact, globular, and has very stable helices, but its apolar side chains are mobile and not as well packed as in many natural proteins. To induce a more native-like state, two Zn2+-binding sites were introduced into the protein, thereby replacing some of the nonspecific hydrophobic interactions with more geometrically restrictive metal-ligand interactions. In the metal-bound state, this protein has properties that approach those of native proteins. Thus, hydrophobic interactions alone are sufficient to drive polypeptide chain folding nearly to completion, but specific interactions are required for a unique structure.	UNIV PENN,REG LASER & BIOTECHNOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	HANDEL, TM (corresponding author), DUPONT MERCK PHARMACEUT CO,POB 80328,WILMINGTON,DE 19880, USA.		Williams, Scott/AAG-7029-2020					AKKE M, 1991, J MOL BIOL, V220, P173, DOI 10.1016/0022-2836(91)90389-N; AKKE M, 1992, BIOCHEMISTRY-US, V31, P1011, DOI 10.1021/bi00119a009; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; DEGRADO WF, 1987, COLD SPRING HARB SYM, V52, P521, DOI 10.1101/SQB.1987.052.01.059; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; GODZIK A, IN PRESS P NATL ACAD; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MATOUSCHEK A, 1992, J MOL BIOL, V224, P837, DOI 10.1016/0022-2836(92)90565-2; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; MORII H, 1991, PROTEINS, V11, P133, DOI 10.1002/prot.340110206; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REGAN L, 1988, SCIENCE, V241, P76; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STEINER RF, 1984, BIOPOLYMERS, V22, P1121; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC	52	268	274	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					879	885		10.1126/science.8346440	http://dx.doi.org/10.1126/science.8346440			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346440				2022-12-24	WOS:A1993LR89700028
J	NABESHIMA, Y; HANAOKA, K; HAYASAKA, M; ESUMI, E; LI, SW; NONAKA, I; NABESHIMA, Y				NABESHIMA, Y; HANAOKA, K; HAYASAKA, M; ESUMI, E; LI, SW; NONAKA, I; NABESHIMA, Y			MYOGENIN GENE DISRUPTION RESULTS IN PERINATAL LETHALITY BECAUSE OF SEVERE MUSCLE DEFECT	NATURE			English	Article							MYOD; FIBROBLASTS; EXPRESSION; MYOBLASTS; INACTIVATION; SOMITES; FAMILY; MYF-5; MRF4	MYOGENIN is a member of the basic helix-loop-helix (bHLH) gene family and converts multipotential mesodermal cells to myoblasts1-4. The four members of the myoD family show unique spatio-temporal expression patterns5 and therefore may have different functions during myogenesis. Here we inactivate the myogenin gene in order to understand its role in myogenesis. Homozygous mutations are lethal perinatally owing to the resulting major defects in skeletal muscle. The extent of disorganization of muscle tissue differs in three regions. In the latero-ventral body wall, most cells, including myogenic cells, disappear and there is rapid accretion of fluid. In the limbs, cells of the myogenic lineage exist, but they are severely disrupted, and some of them are mono-nucleate with properties of myoblasts. In contrast, there are many axial, intercostal and back muscle fibres to be seen, although fibres are mainly disorganized and Z-lines are not present in most myofibrils. These findings are evidence that myogenin is crucial for muscle development in utero and demonstrate that other members of the myogenic gene family cannot compensate for the defect.	NATL INST NEUROSCI,DEPT ANIM MODEL HUMAN DIS,KODAIRA,TOKYO 187,JAPAN; NATL INST NEUROSCI,DEPT ULTRASTRUCT RES,KODAIRA,TOKYO 157,JAPAN; JICHI MED SCH,DEPT NEUROL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Jichi Medical University	NABESHIMA, Y (corresponding author), NATL INST NEUROSCI,DEPT MOLEC GENET,NCNP 4-1-1,OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN.							ABE H, 1989, DEV BIOL, V118, P42; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CUSELLADEANGELIS MG, 1992, J CELL BIOL, V116, P1243, DOI 10.1083/jcb.116.5.1243; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDE DA, 1986, SOMITES DEV EMBRYOS, P209; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KIM DW, 1990, GENE, V9, P217; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LYONS GE, 1992, SEM DEV BIOL, V3, P243; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILAIRE J, 1976, Archives de Biologie, V87, P315; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; OLSEN EN, 1992, DEV BIOL, V154, P261; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SAWAI S, 1991, NEW BIOL, V3, P861; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	26	732	755	3	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					532	535		10.1038/364532a0	http://dx.doi.org/10.1038/364532a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8393146				2022-12-24	WOS:A1993LQ66700056
J	CONE, RW; HACKMAN, RC; HUANG, MLW; BOWDEN, RA; MEYERS, JD; METCALF, M; ZEH, J; ASHLEY, R; COREY, L				CONE, RW; HACKMAN, RC; HUANG, MLW; BOWDEN, RA; MEYERS, JD; METCALF, M; ZEH, J; ASHLEY, R; COREY, L			HUMAN HERPESVIRUS-6 IN LUNG-TISSUE FROM PATIENTS WITH PNEUMONITIS AFTER BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; CYTOMEGALO-VIRUS INFECTION; INTERSTITIAL PNEUMONITIS; EXANTHEM-SUBITUM; RAPID DIAGNOSIS; RISK-FACTORS; HHV-6; DNA; AMPLIFICATION; HEPATITIS	Background. Human herpesvirus 6 (HHV-6) is a recently described herpesvirus that is epidemiologically and biologically similar to cytomegalovirus. It is the cause of exanthem subitum (roseola) in children. Methods. To evaluate the possible role of HHV-6 infection in pneumonitis in immunocompromised patients, we used quantitative HHV-6 polymerase chain reactions to study lung-biopsy specimens from 15 patients with pneumonitis after bone marrow transplantation and lung tissue from 15 immunocompetent subjects without pneumonitis and 6 fetuses. Results. HHV-6 DNA was detected in lung tissue from all 15 patients, from 14 seropositive control subjects, and from none of the 7 seronegative control subjects. Six patients had levels of HHV-6 DNA in lung tissue that were 10 to 500 times higher than those in any of the other patients or control subjects. Increased levels of HHV-6 DNA correlated with a decreased risk of death from pneumonitis (P = 0.015), an increased severity of graft-versus-host disease (P = 0.023), and the presence of idiopathic pneumonitis (P = 0.037). Levels of HHV-6 DNA correlated directly with the changes in HHV-6 antibody titers in the interval between the pretransplantation period and the open-lung biopsy (P = 0.002). Low levels of HHV-6 antibody at the time of the open-lung biopsy were also associated with the diagnosis of idiopathic pneumonitis (P = 0.002). Conclusions. The concentrations of HHV-6 genome in lung tissue and their relation to changes in serologic titers support an association between HHV-6 infection and idiopathic pneumonitis in immunocompromised hosts.	UNIV WASHINGTON, DEPT LAB MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT STAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DEPT PATHOL, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, DEPT INFECT DIS, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NCI NIH HHS [CA 15704, CA 18029] Funding Source: Medline; NIAID NIH HHS [1 R29 AI30648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; ASANO Y, 1991, NEW ENGL J MED, V324, P634; ASHLEY R, 1988, 13TH INT HERP WORKSH; BIBERFELD P, 1988, J VIROL METHODS, V21, P49, DOI 10.1016/0166-0934(88)90051-1; BROWN MB, 1974, J AM STAT ASSOC, V69, P364, DOI 10.2307/2285659; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; CONE RW, 1990, LANCET, V336, P686, DOI 10.1016/0140-6736(90)92180-P; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; DUBEDAT S, 1989, LANCET, V2, P1463; FOX JD, 1990, LANCET, V336, P590, DOI 10.1016/0140-6736(90)93392-3; GLEAVES CA, 1987, AM J CLIN PATHOL, V88, P354, DOI 10.1093/ajcp/88.3.354; GOPAL MR, 1990, LANCET, V335, P1598, DOI 10.1016/0140-6736(90)91433-B; HACKMAN RC, 1985, J INFECT DIS, V151, P325, DOI 10.1093/infdis/151.2.325; KONDO K, 1990, J CLIN MICROBIOL, V28, P970, DOI 10.1128/JCM.28.5.970-974.1990; LARCHER C, 1988, LANCET, V2, P963; LAWRENCE GL, 1990, J VIROL, V64, P287, DOI 10.1128/JVI.64.1.287-299.1990; LEVY JA, 1990, LANCET, V335, P1047, DOI 10.1016/0140-6736(90)92628-U; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; OKUNO T, 1990, TRANSPLANTATION, V49, P519, DOI 10.1097/00007890-199003000-00009; PIETROBONI GR, 1988, LANCET, V1, P1059; PIETROBONI GR, 1988, J CLIN PATHOL, V41, P1310, DOI 10.1136/jcp.41.12.1310; PIETROBONI GR, 1988, LANCET, V1, P1235; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; QAVI HB, 1989, CURR EYE RES, V8, P379, DOI 10.3109/02713688908996385; RAMSEY PG, 1982, ANN INTERN MED, V97, P813, DOI 10.7326/0003-4819-97-6-813; WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168; YAMANISHI K, 1988, LANCET, V1, P1065; YOSHIYAMA H, 1990, PEDIATR INFECT DIS J, V9, P71; Zar JH., 1999, BIOSTAT ANAL	33	248	253	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					156	161		10.1056/NEJM199307153290302	http://dx.doi.org/10.1056/NEJM199307153290302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL460	8390614				2022-12-24	WOS:A1993LL46000002
J	NEUHAUS, G; BOWLER, C; KERN, R; CHUA, NH				NEUHAUS, G; BOWLER, C; KERN, R; CHUA, NH			CALCIUM/CALMODULIN-DEPENDENT AND CALCIUM/CALMODULIN-INDEPENDENT PHYTOCHROME SIGNAL-TRANSDUCTION PATHWAYS	CELL			English	Article							CHLOROPLAST GENE-EXPRESSION; PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; G-PROTEINS; MOLECULAR ANALYSIS; AUREA MUTANT; TOMATO; MEMBRANES; CONTAINS; CALCIUM	Phytochrome is a well-characterized plant photoreceptor, able to modulate many morphological, physiological, and biochemical events through as yet undefined mechanisms. By developing single-cell assays to visualize phytochrome responses, we have studied the effects of microinjecting putative signaling intermediates into phytochrome-deficient tomato cells. We demonstrate that phytochrome phototransduction initially involves the activation of one or more G proteins that are coupled to at least two different pathways; one pathway requires calcium and activated calmodulin and can stimulate expression of a photoregulated cab-GUS reporter gene together with the synthesis and assembly of some, but not all, of the photosynthetic complexes. The other pathway, controlling anthocyanin biosynthesis, does not require calcium. Furthermore, our results reveal that phytochrome signaling is cell autonomous and is not likely to require any light-activated steps downstream of the G protein.	SWISS FED INST TECHNOL,CH-8092 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	NEUHAUS, G (corresponding author), ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021, USA.		Bowler, Chris/AAC-6256-2019	Bowler, Chris/0000-0003-3835-6187	PHS HHS [44640] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BOSSEN ME, 1991, J PLANT PHYSIOL, V137, P706, DOI 10.1016/S0176-1617(11)81226-5; CHAI YG, 1987, ANAL BIOCHEM, V163, P322, DOI 10.1016/0003-2697(87)90231-4; CHORY J, 1992, DEVELOPMENT, V115, P337; DANON L, 1991, EMBO J, V13, P3993; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; ERICKSON JM, 1986, EMBO J, V5, P1745, DOI 10.1002/j.1460-2075.1986.tb04422.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GILROY S, 1991, PLANT CELL, V3, P333, DOI 10.1105/tpc.3.4.333; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GRIFFITHS WT, 1978, BIOCHEM J, V174, P681, DOI 10.1042/bj1740681; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JEFFERSON RA, 1987, EMBO J, V6, P3901; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIERMAYER O, 1968, PLANTA, V83, P223, DOI 10.1007/BF00385332; KIERMAYER O, 1970, PROTOPLASMA, V69, P97, DOI 10.1007/BF01276654; Koornneef M., 1981, Induced mutations -- a tool in plant research. Proceedings of an international symposium. Vienna, 9-13 March 1981, P227; KOORNNEEF M, 1985, J PLANT PHYSIOL, V120, P153, DOI 10.1016/S0176-1617(85)80019-5; LAM E, 1989, MOL CELL BIOL, V9, P4819, DOI 10.1128/MCB.9.11.4819; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MISHKIND ML, 1983, PLANT PHYSIOL, V72, P847, DOI 10.1104/pp.72.3.847; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NAGY F, 1987, EMBO J, V6, P2537, DOI 10.1002/j.1460-2075.1987.tb02541.x; NEBENFUHR A, 1991, PLANTA, V185, P65, DOI 10.1007/BF00194516; NEUHAUS G, 1986, EMBO J, V5, P1437, DOI 10.1002/j.1460-2075.1986.tb04380.x; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; PARKS BM, 1987, PLANT MOL BIOL, V9, P97, DOI 10.1007/BF00015642; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; ROMERO LC, 1991, FEBS LETT, V282, P341, DOI 10.1016/0014-5793(91)80509-2; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SEXTON TB, 1990, EMBO J, V9, P4485, DOI 10.1002/j.1460-2075.1990.tb07899.x; SHACKLOCK PS, 1992, NATURE, V358, P753, DOI 10.1038/358753a0; SHARROCK RA, 1988, MOL GEN GENET, V213, P9, DOI 10.1007/BF00333391; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SOHN G, 1991, J HISTOCHEM CYTOCHEM, V39, P921, DOI 10.1177/39.7.1865109; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; THORNE SW, 1971, BIOCHIM BIOPHYS ACTA, V226, P113, DOI 10.1016/0005-2728(71)90183-6; TRETYN A, 1991, PHOTOCHEM PHOTOBIOL, V54, P1135, DOI 10.1111/j.1751-1097.1991.tb02136.x; WARPEHA KMF, 1992, PHOTOCHEM PHOTOBIOL, V55, P595, DOI 10.1111/j.1751-1097.1992.tb04282.x; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925	51	432	448	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					937	952		10.1016/0092-8674(93)90272-R	http://dx.doi.org/10.1016/0092-8674(93)90272-R			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8388782	Bronze			2022-12-24	WOS:A1993LF06100010
J	CHEN, RH; EBNER, R; DERYNCK, R				CHEN, RH; EBNER, R; DERYNCK, R			INACTIVATION OF THE TYPE-II RECEPTOR REVEALS 2 RECEPTOR PATHWAYS FOR THE DIVERSE TGF-BETA ACTIVITIES	SCIENCE			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; EXPRESSION; INHIBITION; CELLS; PURIFICATION	Transforming growth factor-beta (TGF-beta) is a multifunctional protein that regulates cell proliferation and differentiation and extracellular matrix production. Although two receptor types, the type I and type II receptors, have been implicated in TGF-beta-induced signaling, it is unclear how the many activities of TGF-beta are mediated through these receptors. With the use of cells overexpressing truncated type II receptors as dominant negative mutants to selectively block type II receptor signaling, the existence of two receptor pathways was shown. The type II receptors, possibly in conjunction with type I receptors, mediate the induction of growth inhibition and hypophosphorylation of the retinoblastoma gene product pRB. The type I receptors are responsible for effects on extracellular matrix, such as the induction of fibronectin and plasminogen activator inhibitor I, and for increased JunB expression. Selective inactivation of the type II receptors alters the TGF-beta response in a similar manner to the functional inactivation of pRB, suggesting a role for pRB in the type II, but not the type I, receptor pathway.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chen, Ruey-Hwa/G-6121-2019	Chen, Ruey-Hwa/0000-0001-8124-5832				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Chen R., UNPUB; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIKE B, 1986, J BIOL CHEM, V261, P3426; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	28	392	403	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 28	1993	260	5112					1335	1338		10.1126/science.8388126	http://dx.doi.org/10.1126/science.8388126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	8388126				2022-12-24	WOS:A1993LE02500046
J	MACK, DH; VARTIKAR, J; PIPAS, JM; LAIMINS, LA				MACK, DH; VARTIKAR, J; PIPAS, JM; LAIMINS, LA			SPECIFIC REPRESSION OF TATA-MEDIATED BUT NOT INITIATOR-MEDIATED TRANSCRIPTION BY WILD-TYPE-P53	NATURE			English	Article							MAMMALIAN-CELLS; P53; PROMOTER; ACTIVATION; ANTIGEN; PROTEIN	THE p53 protein is apparently central to the development of human cancers because both alleles are often found to be mutated in different tumour types1. In addition, wild-type p53 can inhibit transformation by viral and cellular oncogenes in vitro, so p53 has been classified as a tumour suppressor2. Investigations of the normal function of p53 have indicated that at least one of its functions could involve the activation of gene expression through the binding of specific DNA-regulatory sequences3,4. Also, overexpression of p53 can mediate growth arrest5 and repress transcription from a variety of promoters6,7. We demonstrate here both in vivo and in vitro that expression of wild-type p53 specifically represses the activity of promoters whose initiation is dependent on the presence of a TATA box. Promoters whose accurate transcription is directed by a pyrimidine-rich initiator element, however, are immune to the effects of p53. Furthermore, we observe that repression is mediated by an interaction of p53 with basal transcription factor(s). Thus, p53 appears to repress the activity of certain promoters through direct communication with TATA box-dependent basal transcription machinery.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INOSTROZA JA, 1992, CELL, V70, P477; KASTAN MB, 1991, CANCER RES, V51, P6304; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	26	345	351	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					281	283		10.1038/363281a0	http://dx.doi.org/10.1038/363281a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	8387645				2022-12-24	WOS:A1993LC86600058
J	RAINIER, S; JOHNSON, LA; DOBRY, CJ; PING, AJ; GRUNDY, PE; FEINBERG, AP				RAINIER, S; JOHNSON, LA; DOBRY, CJ; PING, AJ; GRUNDY, PE; FEINBERG, AP			RELAXATION OF IMPRINTED GENES IN HUMAN CANCER	NATURE			English	Article							WIEDEMANN-BECKWITH SYNDROME; WILMS-TUMOR; H19 GENE; HETEROZYGOSITY; CHROMOSOME-11; HYPOMETHYLATION; CARCINOMA; DISOMY; 11P; RNA	GENOMIC imprinting, or parental allele-specific expression of genes, has been demonstrated at the molecular level in insects and mice1,2 but not in man. Imprinting as a potential mechanism of human disease is suggested by paternal uniparental disomy of 11p15 in Beckwith-Wiedemann syndrome3 and by maternal uniparental disomy of 15q11-12 in Prader-Willi syndrome4. Beckwith-Wiedemann syndrome is characterized by multiorgan overgrowth and predisposition to embryonal tumours such as Wilms' tumour of the kidneys. A loss of heterozygosity of 11p15 is also frequently found in a wide variety of tumours, including Wilms' tumour and lung, bladder, ovarian, liver and breast cancers6-11; 11p15 also directly suppresses tumour growth in vitro 12 . Two genes in this band, H19 and insulin-like growth factor-11 (IGF2) undergo reciprocal imprinting in the mouse., with maternal expression of H19 (ref. 13) and paternal expression of IGF2 (ref. 14). Here we find that both of these genes show monoallelic expression in human tissues and, as in mouse, H19 is expressed from the maternal allele and IGF2 from the paternal allele. In contrast, 69% of Wilms' tumours not undergoing loss of heterozygosity at 11p showed biallelic expression of one or both genes, suggesting that relaxation or loss of imprinting could represent a new epigenetic mutational mechanism in carcinogenesis.	UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,4520 MSRB 1,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; CROSS CANC INST,DEPT PEDIAT,EDMONTON T6G 1Z2,ALBERTA,CANADA; UNIV ALBERTA,EDMONTON T6G 1Z2,AB,CANADA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Alberta; University of Alberta			Feinberg, Andrew/AAY-7666-2020	Feinberg, Andrew/0000-0002-8364-1991				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; Beckers J. M., 1990, ESO Messenger, P1; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVISSON MT, 1991, CYTOGENET CELL GENET, V58, P1152, DOI 10.1159/000133726; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUJIMORI M, 1991, CANCER RES, V51, P89; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; HAIG D, 1991, CELL, V64, P1045; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOLLIDAY R, 1990, DEVELOPMENT, P125; HOOVERS JMN, 1992, LANCET, V339, P1228, DOI 10.1016/0140-6736(92)91164-4; JONES PA, 1986, CANCER RES, V46, P461; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOI M, IN PRESS SCIENCE; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1991, MOL GENETICS WILMS T; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; PETTENATI MJ, 1986, HUM GENET, V74, P143, DOI 10.1007/BF00282078; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHULDINER AR, 1991, BIOTECHNIQUES, V11, P760; SKINNER MA, 1990, CANCER RES, V50, P2303; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; WADEY RB, 1990, ONCOGENE, V5, P901; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807; WILLISON K, 1991, TRENDS GENET, V7, P107, DOI 10.1016/0168-9525(91)90441-R; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	39	742	762	0	48	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 22	1993	362	6422					747	749		10.1038/362747a0	http://dx.doi.org/10.1038/362747a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	8385745	Green Published			2022-12-24	WOS:A1993KY45000055
J	PACE, J; HAYMAN, MJ; GALAN, JE				PACE, J; HAYMAN, MJ; GALAN, JE			SIGNAL TRANSDUCTION AND INVASION OF EPITHELIAL-CELLS BY SALMONELLA-TYPHIMURIUM	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MAMMALIAN-CELLS; SALMONELLA-TYPHIMURIUM; FACTOR RECEPTOR; PHOSPHOLIPASE-A2 ACTIVITY; MOLECULAR-CLONING; ESCHERICHIA-COLI; PROTEIN; CALCIUM; ENTRY	Invasion of host cells is essential for the pathogenicity of Salmonella. We have recently shown that invasion of cultured epithelial cells by S. typhimurium is accompanied by activation of the epidermal growth factor receptor. In this report we show that S. typhimurium invasion stimulated a rapid increase in the levels of free intracellular calcium ([Ca2+]i) in cultured epithelial cells. Mutants defective in invasion were unable to induce these calcium fluxes, and addition of calcium antagonists blocked wild-type S. typhimurium entry. These results indicate that [Ca2+]i increase is required for bacterial entry. Further analysis demonstrated that phospholipase A2 and 5-lipoxygenase activities resulting in production of leukotrienes are required for bacterial entry. Addition of the leukotriene D4 to Henle-407 cells caused both an increase in [Ca2+]i and the internalization of an invasion-defective mutant of S. typhimurium. Furthermore, S. typhimurium caused the activation of mitogen-activated protein (also known as extracellular signal-regulated protein) kinase in infected cells.			PACE, J (corresponding author), SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.				NIAID NIH HHS [AI30492] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030492, R01AI030492, R29AI030492] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BUKHOLM G, 1984, ACTA PATH MICRO IM B, V92, P145; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GALAN JE, 1991, INFECT IMMUN, V59, P2901; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HIRATA F, 1984, P NATL ACAD SCI-BIOL, V81, P4717, DOI 10.1073/pnas.81.15.4717; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KIHLSTROM E, 1977, ACTA PATH MICRO IM B, V85, P322; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARGOLIS BL, 1988, BIOCHEM J, V256, P469, DOI 10.1042/bj2560469; MARKS PW, 1990, CELL CALCIUM, V11, P18, DOI 10.1016/0143-4160(90)90069-7; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; ORNING L, 1980, J BIOL CHEM, V255, P8023; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIPER PJ, 1983, BRIT MED BULL, V39, P255, DOI 10.1093/oxfordjournals.bmb.a071829; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TYLER KL, 1990, VIROLOGY, P191; WEISS GB, 1974, ANNU REV PHARMACOL, V14, P343, DOI 10.1146/annurev.pa.14.040174.002015; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030	69	235	241	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					505	514		10.1016/0092-8674(93)90070-7	http://dx.doi.org/10.1016/0092-8674(93)90070-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8382566				2022-12-24	WOS:A1993KP16500006
J	SEABRA, MC; BROWN, MS; GOLDSTEIN, JL				SEABRA, MC; BROWN, MS; GOLDSTEIN, JL			RETINAL DEGENERATION IN CHOROIDEREMIA - DEFICIENCY OF RAB GERANYLGERANYL TRANSFERASE	SCIENCE			English	Article							GTP-BINDING PROTEIN; SYNDROME TYPE-II; RETINITIS-PIGMENTOSA; SMG P25A; GENE; CHROMOSOME-1Q; CLONING	Rab geranylgeranyl transferase (GG transferase) is a two-component enzyme that attaches 20-carbon isoprenoid groups to cysteine residues in Rab proteins, a family of guanosine triphosphate-binding proteins that regulate vesicular traffic. The mutant gene in human choroideremia, an X-linked form of retinal degeneration, encodes a protein that resembles component A of rat Rab GG transferase. Lymphoblasts from choroideremia subjects showed a marked deficiency in the activity of component A, but not component B, of Rab GG transferase. The deficiency was more pronounced when the substrate was Rab3A, a synaptic vesicle protein, than it was when the substrate was Rab1A, a protein of the endoplasmic reticulum. The data imply the existence of multiple component A proteins, one of which is missing in choroideremia.			SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SK, UNPUB; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BERMAN ER, 1991, BIOCH EYE, P1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; HALLGREN B, 1959, ACTA PSYCHIAT N S138, V34, P9; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P159; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VALLE D, 1989, METABOLIC BASIS INHE, P599; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	29	281	287	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					377	381		10.1126/science.8380507	http://dx.doi.org/10.1126/science.8380507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8380507				2022-12-24	WOS:A1993KG62400037
J	GOODWIN, EB; OKKEMA, PG; EVANS, TC; KIMBLE, J				GOODWIN, EB; OKKEMA, PG; EVANS, TC; KIMBLE, J			TRANSLATIONAL REGULATION OF TRA-2 BY ITS 3' UNTRANSLATED REGION CONTROLS SEXUAL IDENTITY IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EMBRYONIC CELL LINEAGES; DETERMINING GENE; GERM-LINE; 3'-UNTRANSLATED REGION; DNA-POLYMERASE; MESSENGER-RNA; FEM GENES; SPERMATOGENESIS; HERMAPHRODITE	C. elegans hermaphrodites make sperm and then oocytes in an otherwise female animal. Gain-of-function mutations in the sex-determining gene tra-2 (tra-2(gf)) transform hermaphrodites into females (spermless hermaphrodites). The tra-2(gf) mutations map to a perfect direct repeat in the 3' untranslated region; each repeat is called a direct repeat element (DRE). Three experiments demonstrate that DREs repress tra-2 at the translational level. First, tra-2(gf) mRNAs are associated with larger polysomes than are their wild-type counterparts. Second, translation of a reporter RNA is inhibited by DREs. Third, disruption of DREs does not increase tra-2 mRNA levels. An RNA binding activity specifically associates with the DREs. We propose that tra-2 translation is inhibited by association of an RNA binding-factor with the DREs and that this translational control is essential for development of C. elegans as a hermaphrodite/male species.	CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA	Carnegie Institution for Science	GOODWIN, EB (corresponding author), UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA.							Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ARASU P, 1991, GENE DEV, V5, P1825, DOI 10.1101/gad.5.10.1825; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARTON MK, 1990, GENETICS, V125, P29; BARTON MK, 1987, GENETICS, V115, P107; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; DONIACH T, 1986, GENETICS, V114, P53; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GRAHAM PL, 1993, GENETICS, V133, P919; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN JA, 1977, GENETICS, V86, P275; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KLASS M, 1976, DEV BIOL, V52, P1, DOI 10.1016/0012-1606(76)90002-6; KUWABARA PE, 1992, MOL BIOL CELL, V3, P461, DOI 10.1091/mbc.3.4.461; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LHERNAULT SW, 1988, GENETICS, V120, P435; MADL JE, 1979, GENETICS, V93, P393; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NELSON GA, 1978, DEV BIOL, V66, P386, DOI 10.1016/0012-1606(78)90247-6; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEDL T, 1989, GENETICS, V123, P755; SCHEDL T, 1988, GENETICS, V119, P43; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; STANDART N, 1993, SEMIN DEV BIOL, V3, P367; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRENT C, 1988, GENETICS, V120, P145; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813	48	171	186	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					329	339		10.1016/0092-8674(93)80074-O	http://dx.doi.org/10.1016/0092-8674(93)80074-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402916				2022-12-24	WOS:A1993MD88500014
J	BUTLER, JC; BREIMAN, RF; CAMPBELL, JF; LIPMAN, HB; BROOME, CV; FACKLAM, RR				BUTLER, JC; BREIMAN, RF; CAMPBELL, JF; LIPMAN, HB; BROOME, CV; FACKLAM, RR			PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; PROTECTIVE EFFICACY; ANTIBODY-RESPONSES; HIGH-RISK; DISEASE; REVACCINATION; IMMUNIZATION; EPIDEMIOLOGY	Objective.-To determine pneumococcal polysaccharide vaccine efficacy in selected populations at risk for serious pneumococcal infection for whom vaccination is currently recommended and to assess duration of protection after vaccination. Design.-Vaccine efficacy was estimated using indirect cohort analysis to compare the proportion of pneumococcal infections caused by serotypes included in the vaccines of vaccinated and unvaccinated persons who were identified during 14 years of national surveillance. Setting.-Hospital laboratories in the United States that submitted pneumococcal isolates to the Centers for Disease Control and Prevention between May 1978 and April 1992. Participants.-A total of 2837 persons older than 5 years who had pneumococcus isolated from blood or cerebrospinal fluid. Results.-Overall efficacy for preventing infection caused by serotypes included in the vaccine was 57% (95% confidence interval [CI], 45% to 66%). Efficacy among persons with diabetes mellitus was 84% (95% CI, 50% to 95%); with coronary vascular disease, 73% (95% CI, 23% to 90%); with congestive heart failure, 69% (95% CI, 17% to 88%); with chronic pulmonary diseases, 65% (95% CI, 26% to 83%); and with anatomic asplenia, 77% (95% CI, 14% to 95%). Efficacy was not documented for patients with alcoholism or cirrhosis, sickle cell disease, chronic renal failure, lymphoma, leukemia, or multiple myeloma, although sample sizes were small for these groups. Efficacy for immunocompetent persons older than 65 years was 75% (95% CI, 57% to 85%). Efficacy did not decline with increasing interval after vaccination: 5 to 8 years after vaccination it was 71% (95% CI, 24% to 89%), and 9 years or more after vaccination it was 80% (95% CI, 16% to 95%). Conclusions.-Intensified efforts to improve pneumococcal vaccine coverage among certain populations for whom vaccination is currently recommended is indicated, but universal revaccination is not warranted at this time.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BUTLER, JC (corresponding author), CTR DIS CONTROL & PREVENT,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,MS C-09,1600 CLIFTON RD,ATLANTA,GA 30333, USA.							APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; AUSTRIAN R, 1984, NEW ENGL J MED, V310, P651, DOI 10.1056/NEJM198403083101010; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; Austrian R, 1976, Trans Assoc Am Physicians, V89, P184; BOLAN G, 1986, ANN INTERN MED, V104, P1, DOI 10.7326/0003-4819-104-1-1; BORGONO JM, 1978, P SOC EXP BIOL MED, V157, P148, DOI 10.3181/00379727-157-40010; BROOME CV, 1981, REV INFECT DIS, V3, P277; BROOME CV, 1980, NEW ENGL J MED, V303, P549, DOI 10.1056/NEJM198009043031003; BRUYN GAW, 1992, CLIN INFECT DIS, V14, P251, DOI 10.1093/clinids/14.1.251; BUTLER JC, 1993, 33RD INT C ANT AG CH; CANO FR, 1983, P SOC EXP BIOL MED, V173, P57; CARLSON AJ, 1979, P SOC EXP BIOL MED, V161, P558; CLEMENS JD, 1984, REV INFECT DIS, V6, P589; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FEDSON DS, 1987, CHEST, V91, P436, DOI 10.1378/chest.91.3.436; FEDSON DS, 1988, VACCINES, P271; FLEISS JL, 1981, STATISTICAL METHODS, P71; HILLEMAN MR, 1981, REV INFECT DIS S, V3, P531; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KRAUS C, 1985, MED MICROBIOL IMMUN, V174, P51, DOI 10.1007/BF02123671; LAMOTHE F, 1984, CAN MED ASSOC J, V130, P737; LANDESMAN SH, 1981, REV INFECT DIS, V3, pS184; LINNEMANN CC, 1986, ARCH INTERN MED, V146, P1554, DOI 10.1001/archinte.146.8.1554; LINNEMANN CC, 1981, ARCH INTERN MED, V146, P1554; MINOR DR, 1979, ANN INTERN MED, V90, P887, DOI 10.7326/0003-4819-90-6-887; MUFSON MA, 1983, P SOC EXP BIOL MED, V173, P270, DOI 10.3181/00379727-173-41643; MUFSON MA, 1987, AM J MED SCI, V293, P279, DOI 10.1097/00000441-198705000-00001; MUFSON MA, 1985, J INFECT DIS, V151, P749, DOI 10.1093/infdis/151.4.749; MUFSON MA, 1991, VACCINE, V9, P403, DOI 10.1016/0264-410X(91)90126-Q; MUFSON MA, 1984, P SOC EXP BIOL MED, V177, P220, DOI 10.3181/00379727-177-41934; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; MUSHER DM, 1990, J INFECT DIS, V161, P736, DOI 10.1093/infdis/161.4.736; MUSHER DM, 1990, AM J MED SCI, V300, P45, DOI 10.1097/00000441-199007000-00011; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; OVERTURF GD, 1982, AM J PEDIAT HEMATOL, V4, P19; OXTOBY MJ, 1986, ANN INTERN MED, V104, P587, DOI 10.7326/0003-4819-104-4-587_3; PENN RL, 1982, INFECT IMMUN, V36, P1261, DOI 10.1128/IAI.36.3.1261-1262.1982; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; REYNOLDS HY, 1991, PHYSIOL REV, V71, P1117, DOI 10.1152/physrev.1991.71.4.1117; RIGAUPEREZ JG, 1983, PEDIATR INFECT DIS J, V2, P199, DOI 10.1097/00006454-198305000-00005; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCHMID GP, 1981, J INFECT DIS, V143, P590, DOI 10.1093/infdis/143.4.590; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SHAPIRO ED, 1987, NEW ENGL J MED, V316, P1272; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SMIT P, 1977, JAMA-J AM MED ASSOC, V238, P2613, DOI 10.1001/jama.238.24.2613; SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; VELLA PP, 1980, P SOC EXP BIOL MED, V164, P435; WEINTRUB PS, 1984, J PEDIATR-US, V105, P261, DOI 10.1016/S0022-3476(84)80124-9; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1984, MMWR MORB MORTAL WKL, V33, P273; 1989, MMWR MORB MORTAL WKL, V38, P64; 1991, MMWR MORB MORTAL WKL, V40, P42	60	516	547	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1826	1831		10.1001/jama.270.15.1826	http://dx.doi.org/10.1001/jama.270.15.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411526				2022-12-24	WOS:A1993MB46400025
J	COON, WW				COON, WW			VENA-CAVAL FILTERS AND ANTICOAGULANTS FOR PULMONARY EMBOLI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											COON, WW (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1867	1868						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	8411533				2022-12-24	WOS:A1993MB46400035
J	STEIMLE, V; OTTEN, LA; ZUFFEREY, M; MACH, B				STEIMLE, V; OTTEN, LA; ZUFFEREY, M; MACH, B			COMPLEMENTATION CLONING OF AN MHC CLASS-II TRANSACTIVATOR MUTATED IN HEREDITARY MHC CLASS-II DEFICIENCY (OR BARE LYMPHOCYTE SYNDROME)	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL LINES; PROMOTER-BINDING-PROTEIN; HLA-DRA GENE; TRANSCRIPTIONAL REGULATION; MAMMALIAN-CELLS; WILD-TYPE; EXPRESSION; DEFECT; DNA	Hereditary major histocompatibility complex (MHC) class II deficiency (or bare lymphocyte syndrome) is a form of severe primary immunodeficiency with a total lack of MHC class II expression. It is due to a defect in the regulation of MHC class II genes. A novel gene was isolated by complementation cloning, using an MHC class II-negative mutant cell line. This gene (CIITA) functions as a transactivator of MHC class II gene expression and restores expression of all MHC class II isotypes in mutant cells. In addition, CIITA fully corrects the MHC class II regulatory defect of cells from patients with bare lymphocyte syndrome. In this disease we have identified a splicing mutation that results in a 24 amino acid deletion in CIITA, resulting in loss of function of the transactivator. Hence, the CIITA gene is essential for MHC class II gene expression and has been shown to be responsible for hereditary MHC class II deficiency.			STEIMLE, V (corresponding author), UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,JEANTET LAB MOLEC GENET,CH-1211 GENEVA 4,SWITZERLAND.							ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; ACCOLLA RS, 1991, INT J CANCER S, V6, P20; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREWS PW, 1987, CANCER RES, V47, P740; [Anonymous], 1985, DNA REPAIR; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; CALMAN AF, 1987, J IMMUNOL, V139, P2489; CARREL S, 1976, CANCER RES, V36, P3978; CASPER JT, 1990, J PEDIATR-US, V116, P262, DOI 10.1016/S0022-3476(05)82885-9; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; DEPREVAL C, 1985, NATURE, V318, P219; GIORDANO TJ, 1990, GENE, V88, P285, DOI 10.1016/0378-1119(90)90045-S; GLADSTONE P, 1978, NATURE, V271, P459, DOI 10.1038/271459a0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GONCZY P, 1989, MOL CELL BIOL, V9, P296; Griscelli C, 1989, Immunodefic Rev, V1, P135; GRISCELLI C, 1980, PRIMARY IMMUNODEFICI, P499; GROSS N, 1987, INT J CANCER, V39, P521, DOI 10.1002/ijc.2910390420; GUARDIOLA J, 1986, P NATL ACAD SCI USA, V83, P7415, DOI 10.1073/pnas.83.19.7415; HADAM MR, 1984, HISTOCOMPATIBILITY T, P645; HASEGAWA SL, 1993, J IMMUNOL, V150, P1781; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HUME CR, 1989, HUM IMMUNOL, V26, P288, DOI 10.1016/0198-8859(89)90007-4; HUME CR, 1989, HUM IMMUNOL, V25, P1, DOI 10.1016/0198-8859(89)90065-7; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARA CJ, 1993, IMMUNOGENETICS, V37, P227; KOCH W, 1988, J EXP MED, V167, P1781, DOI 10.1084/jem.167.6.1781; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAWCZAK M, 1992, HUM GENET, V90, P41; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LISOWSKAGROSPIERRE B, 1985, J CLIN INVEST, V76, P381, DOI 10.1172/JCI111974; LONG EO, 1984, IMMUNOGENETICS, V19, P349, DOI 10.1007/BF00345408; MACH B, 1986, COLD SPRING HARB SYM, V51, P67, DOI 10.1101/SQB.1986.051.01.009; MACH B, 1993, HLA SYSTEM CLIN TRAN, P82; MACH B, 1990, MOL BIOL HLA CLASS 2, P201; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MANNHALTER JW, 1991, IMMUNOL INVEST, V20, P151, DOI 10.3109/08820139109050783; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SLOAN JH, 1988, P NATL ACAD SCI USA, V85, P8186, DOI 10.1073/pnas.85.21.8186; SPICKOFSKY N, 1990, DNA PROT ENG TECH, V2, P14; STIMAC E, 1991, J IMMUNOL, V146, P4398; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; ZIEGLER A, 1986, IMMUNOBIOLOGY, V171, P77, DOI 10.1016/S0171-2985(86)80019-5	66	759	787	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 8	1993	75	1					135	146		10.1016/0092-8674(93)90685-J	http://dx.doi.org/10.1016/0092-8674(93)90685-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402893				2022-12-24	WOS:A1993MB66700014
J	EWEN, ME; SLUSS, HK; WHITEHOUSE, LL; LIVINGSTON, DM				EWEN, ME; SLUSS, HK; WHITEHOUSE, LL; LIVINGSTON, DM			TGF-BETA INHIBITION OF CDK4 SYNTHESIS IS LINKED TO CELL-CYCLE ARREST	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; GROWTH-FACTOR-BETA; SUSCEPTIBILITY GENE; PROTEIN-KINASE; FACTOR-BINDING; G1 PHASE; EXPRESSION; PHOSPHORYLATION; SUPPRESSION	Transforming growth factor beta1 (TGFbeta1) causes G1 growth arrest and the accumulation of unphosphorylated retinoblastoma protein (Rb) in responsive cells. Cdk4 (cyclin-dependent kinase), a major catalytic subunit of the mammalian D-type G1 cyclins, can phosphorylate Rb in vitro, and at least one D-type cyclin, D2, directs the phosphorylation of Rb in vivo. Here we show that TGFbetga1 induces suppression of cdk4 synthesis in G1 in mink lung epithelial cells. Constitutive cdk4 synthesis in these cells led to TGFbeta1 resistance. It also resulted in growth in low serum medium when these cells were released from contact inhibition. Cdk2 activity was also suppressed by TGFbeta1 action, but its constitutive expression failed to override a TGFbeta1-induced G1 block. Hence, the TGFbeta1 block is primarily mediated by cdk4 modulation. Further evidence suggests that TGFbeta1-induced down-modulation of cdk4 leads to inhibition of cdk2 activation and that both events might contribute to TGFbeta1 growth suppression.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	EWEN, ME (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COCKS BG, 1992, J BIOL CHEM, V267, P12307; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULBECCO R, 1970, NATURE, V227, P802, DOI 10.1038/227802a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, J VIROL, V52, P4565; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KATO JY, 1993, OGENES DEV, V7, P331; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	56	535	541	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1009	1020		10.1016/0092-8674(93)90723-4	http://dx.doi.org/10.1016/0092-8674(93)90723-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	8402878				2022-12-24	WOS:A1993LY49300008
J	WILSON, MA; MCNAUGHTON, BL				WILSON, MA; MCNAUGHTON, BL			DYNAMICS OF THE HIPPOCAMPAL ENSEMBLE CODE FOR SPACE	SCIENCE			English	Article							LONG-LASTING POTENTIATION; SINGLE UNIT-ACTIVITY; SYNAPTIC ENHANCEMENT; RAT HIPPOCAMPUS; CELLS; STIMULATION; ENVIRONMENT; NEURONS; SYSTEM	Ensemble recordings of 73 to 148 rat hippocampal neurons were used to predict accurately the animals' movement through their environment, which confirms that the hippocampus transmits an ensemble code for location. In a novel space, the ensemble code was initially less robust but improved rapidly with exploration. During this period, the activity of many inhibitory cells was suppressed, which suggests that new spatial information creates conditions in the hippocampal circuitry that are conducive to the synaptic modification presumed to be involved in learning. Development of a new population code for a novel environment did not substantially alter the code for a familiar one, which suggests that the interference between the two spatial representations was very small. The parallel recording methods outlined here make possible the study of the dynamics of neuronal interactions during unique behavioral events.	UNIV ARIZONA, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA	University of Arizona	WILSON, MA (corresponding author), UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85724 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046823, R01MH046823] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46823] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; BARNES CA, 1990, PROG BRAIN RES, V83, P287; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; EICHENBAUM H, 1988, TRENDS NEUROSCI, V11, P244, DOI 10.1016/0166-2236(88)90100-2; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GARDNERMEDWIN AR, 1976, PROC R SOC SER B-BIO, V194, P375, DOI 10.1098/rspb.1976.0084; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LARSON J, 1988, NEUROL NEUR, V46, P411; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1983, J NEUROSCI METH, V8, P391, DOI 10.1016/0165-0270(83)90097-3; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; McNaughton BL, 1990, NEUROSCIENCE CONNECT, P1; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; RECCE M K, 1989, Society for Neuroscience Abstracts, V15, P1250; Rolls E.T., 1989, NEURAL MODELS PLASTI, P240; SCHARFMAN HE, 1985, BRAIN RES, V331, P267, DOI 10.1016/0006-8993(85)91552-5; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEGAL M, 1972, J NEUROPHYSIOL, V35, P680, DOI 10.1152/jn.1972.35.5.680; Skaggs WE, 1993, ADV NEURAL INFORM PR, V5, P1030, DOI DOI 10.1109/PROC.1977.10559; SQUIRE LR, 1989, NEURAL MODELS PLASTI, P208; SWANSON LW, 1987, HDB CHEM NEUROANATOM, V5, pCH2; THOMPSON LT, 1989, J NEUROSCI, V9, P2382; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WILSON M A, 1991, Society for Neuroscience Abstracts, V17, P1395; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	40	1495	1518	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1055	1058		10.1126/science.8351520	http://dx.doi.org/10.1126/science.8351520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351520				2022-12-24	WOS:A1993LT74700037
J	QIAN, YW; WANG, YCJ; HOLLINGSWORTH, RE; JONES, D; LING, N; LEE, EYHP				QIAN, YW; WANG, YCJ; HOLLINGSWORTH, RE; JONES, D; LING, N; LEE, EYHP			A RETINOBLASTOMA-BINDING PROTEIN RELATED TO A NEGATIVE REGULATOR OF RAS IN YEAST	NATURE			English	Article							SV40 T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; MESSENGER-RNAS; IDENTIFICATION; TRANSCRIPTION; CLONING; TRANSLATION; REGION	THE growth suppression function of the retinoblastoma protein (Rb) is thought to be mediated by Rb binding to cellular proteins1. p48 is one of the major proteins that binds to a putative functional domain at the carboxy terminus of the Rb protein2. Here we report the isolation of a full-length complementary DNA (RbAp48) encoding p48. Complex formation between p48 and Rb occurs in vitro and in vivo, and apparently involves direct interaction between the proteins. Like Rb, p48 is a ubiquitously expressed nuclear protein. RbAp48 share sequence homology with MSI1, a negative regulator of the Ras-cyclic AMP pathway in the yeast Saccharomyces cerevisiae3. Furthermore, like MSI1, human RbAp48 suppresses the heat-shock sensitivity of the yeast ira1 strains and RAS2val19 strains. Interaction with p48 may be one of the mechanisms for suppression of growth mediated by Rb.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245; WHITTIER INST,LA JOLLA,CA 92037	University of Texas System; University of Texas Health San Antonio								Barbacid M., 1987, REV BIOCH, V56, P779; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GODRICH DW, IN PRESS BIOCH BIOPH; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, COLD SPRING HARB SYM, V5, P211; Matsudaira P, 1989, PRACTICAL GUIDE PROT; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERMAN F, 1986, LABORATORY COURSE MA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233	22	250	267	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					648	652		10.1038/364648a0	http://dx.doi.org/10.1038/364648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350924				2022-12-24	WOS:A1993LR77100059
J	MCCARTHY, M; LAYZELL, S				MCCARTHY, M; LAYZELL, S			FUNDING POLICIES FOR HIV AND AIDS - TIME FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article								Funding for HIV and AIDS in England has been allocated to regions by a formula based on the number of cases of AIDS and HIV infection and on population size. Regions have distributed the resources directly to hospitals and community services. A survey of staff and managers in North East Thames region showed that funding arrangements have led to unsatisfactory development of services for HIV and AIDS. Firstly, because hospitals are funded according to current numbers of patients services are highly developed at the central London hospitals and underdeveloped in outer districts. Secondly, specialised community care teams have been established rather than integrating care for HIV and AIDS into generic primary care. Thirdly, the information on district of residence of infected patients is inaccurate, limiting allocation of funds according to population needs. Fourthly, prevention of infection has been given far less attention than treatment and care despite the lack of effective treatment. In future allocations for HIV and AIDS should be made to purchasers rather than directly to providers.	UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London	MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR, LONDON NW1 2LJ, ENGLAND.		McCarthy, Mark/C-1117-2009					ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; LAYZELL S, 1992, COMMUNITY BASED HLTH; LAYZELL S, 1992, AIDS CARE, V4, P205; 1992, AIDS HIV Q SURVEILLA; 1993, AIDS HIV INFECTED HL; 1992, EL9218 NHS MAN EX DE; 1992, EL9216 NHS MAN EX DE; 1991, HIV AIDS RELATED HLT; 1993, CAMDEN ISLINGTON HIV; 1993, EL9319 NHS MAN EX DE	10	10	10	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					367	369		10.1136/bmj.307.6900.367	http://dx.doi.org/10.1136/bmj.307.6900.367			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374421	Green Published, Bronze			2022-12-24	WOS:A1993LR76800024
J	GEHRING, K; LEROY, JL; GUERON, M				GEHRING, K; LEROY, JL; GUERON, M			A TETRAMERIC DNA-STRUCTURE WITH PROTONATED CYTOSINE.CYTOSINE BASE-PAIRS	NATURE			English	Article							ACID	OLIGOMERS containing tracts of-cytidine form hemiprotonated base pairs at acid pH and have been considered to be double-stranded. We have solved the structure of the DNA oligomer 5'-d(TCCCCC) at acid pH and find that it is a four-stranded complex in which two base-paired parallel-stranded duplexes are intimately associated, with their base pairs fully intercalated. The relative orientation of the duplexes is antiparallel, so that each base pair is face-to-face with its neighbours. The NMR spectrum displays only six spin systems, showing that the structure is highly symmetrical on the NMR timescale; the four strands are equivalent. A model derived by energy minimization and constrained molecular dynamics shows excellent compatibility with the observed nuclear Overhauser effects (NOEs) particularly for the very unusual inter-residue sugar-sugar NOEs H1'-H1', H1'-H2'' and H1'-H4'. These NOEs are probably diagnostic for such tetrameric structures.	CNRS, URA D1254, F-91128 PALAISEAU, FRANCE; ECOLE POLYTECH, BIOPHYS GRP, F-91128 PALAISEAU, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris			Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; AHMED S, 1992, NUCLEIC ACIDS RES, V20, P507, DOI 10.1093/nar/20.3.507; AKRINIMISKI EO, 1963, BIOCHEMISTRY-US, V2, P340; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; ARNOTT S, 1976, J MOL BIOL, V106, P735, DOI 10.1016/0022-2836(76)90262-X; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; HARTMAN KA, 1965, J AM CHEM SOC, V87, P2033, DOI 10.1021/ja01087a031; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KELLOGG GW, 1992, J MAGN RESON, V98, P176, DOI 10.1016/0022-2364(92)90122-N; KISTENMACHER TJ, 1978, BIOPOLYMERS, V17, P2581, DOI 10.1002/bip.1978.360171106; KOCHOYAN M, 1990, BIOCHEMISTRY-US, V29, P4799, DOI 10.1021/bi00472a008; LANGRIDGE R, 1963, NATURE, V198, P725, DOI 10.1038/198725a0; LEROY JL, IN PRESS BIOCHEMISTR; LEROY JL, 1992, 15 INT C MAGN RES BI; LEROY JL, 1990, 14 INT C MAGN RES BI; LUO J, 1992, FEBS LETT, V306, P223, DOI 10.1016/0014-5793(92)81005-7; LYAMICHEV VI, 1989, NATURE, V339, P634, DOI 10.1038/339634a0; MARSH RE, 1962, ACTA CRYSTALLOGR, V15, P310, DOI 10.1107/S0365110X62000791; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WESTHOF E, 1980, P NATL ACAD SCI-BIOL, V77, P1852, DOI 10.1073/pnas.77.4.1852; WESTHOF E, 1992, NATURE, V358, P459, DOI 10.1038/358459b0; WESTHOF E, 1980, J MOL BIOL, V142, P331, DOI 10.1016/0022-2836(80)90276-4; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P211; 1989, EMBO J, V8, P1	28	918	939	11	222	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1993	363	6429					561	565		10.1038/363561a0	http://dx.doi.org/10.1038/363561a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8389423				2022-12-24	WOS:A1993LF93900056
J	LUGINBUHL, LM; ORAV, EJ; MCINTOSH, K; LIPSHULTZ, SE				LUGINBUHL, LM; ORAV, EJ; MCINTOSH, K; LIPSHULTZ, SE			CARDIAC MORBIDITY AND RELATED MORTALITY IN CHILDREN WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; EPSTEIN-BARR-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; VENTRICULAR-TACHYCARDIA; AUTONOMIC NEUROPATHY; PENTAMIDINE THERAPY; RAPID DETECTION; SYNDROME AIDS; DE-POINTES	Objective.-Dysrhythmias, hemodynamic instability, congestive heart failure, and sudden death are serious complications of human immunodeficiency virus (HIV) infection that, to our knowledge, have not been studied systematically. We sought to determine the cumulative incidence and clinical predictors of these adverse events in a cohort of HIV-infected children Design.-Historical cohort study. Setting.-University-affiliated, primary and tertiary care pediatric hospital and ambulatory care center. Participants.-Eighty-one HIV-infected children who had one or more cardiac evaluations between 1984 and 1991 form the study cohort. The initial cardiac evaluation occurred at a median age of 1.5 years, and children were followed up to a median age of 3.6 years. Main Outcome Measures.-Mortality (related to cardiac dysfunction as well as noncardiac causes), tachycardia, bradycardia, hypertension, hypotension, marked sinus arrhythmia, cardiac arrest, and chronic congestive heart failure. Results.-Hemodynamic abnormalities and dysrhythmias occurred frequently. Eight unexpected cardiorespiratory arrests occurred in seven children (9%). Chronic congestive heart failure was noted in 10% of patients. Thirty children died, 10 with significant cardiac dysfunction. As HIV-infected children progressed from acquired immunodeficiency syndrome (AIDS)-related complex to AIDS, significant cardiac problems were more likely to occur. Both nonneurologic AIDS and encephalopathy were strongly associated with most severe cardiac outcomes. However, encephalopathy was the strongest correlate of cardiorespiratory arrest (P=.002). Epstein-Barr virus coinfection was the strongest correlate of chronic congestive heart failure (P<.001). Conclusions.-Cardiac morbidity and mortality are more common with advanced HIV infection. The presence of encephalopathy or Epstein-Barr virus coinfection identifies HIV-infected children at especially high risk for adverse cardiac outcomes.	CHILDRENS HOSP MED CTR, DEPT CARDIOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DIV INFECT DIS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [1NO1HR96041] Funding Source: Medline; NIAID NIH HHS [UO1AI25934, R01AI28076] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR096041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025934, R01AI028076] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1988, J AM COLL CARDIOL, V11, P792, DOI 10.1016/0735-1097(88)90213-6; ANDERSON DW, 1990, HUM PATHOL, V21, P253, DOI 10.1016/0046-8177(90)90224-S; ANDIMAN WA, 1985, LANCET, V2, P1390; [Anonymous], 1987, PEDIATRICS, V79, P1; BHARATI S, 1989, CHEST, V96, P406, DOI 10.1378/chest.96.2.406; BRADY M T, 1988, Pediatric Pathology, V8, P205; BUTLER T, 1981, J INFECTION, V3, P172, DOI 10.1016/S0163-4453(81)91411-0; CALABRESE LH, 1987, ANN INTERN MED, V107, P691, DOI 10.7326/0003-4819-107-5-691; CAPPEL R, 1978, ARCH VIROL, V58, P253, DOI 10.1007/BF01317608; CENACCHI G, 1990, MICROBIOLOGICA, V13, P145; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; COHEN JA, 1989, NEUROLOGY, V39, P1111, DOI 10.1212/WNL.39.8.1111; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; COTTON P, 1990, JAMA-J AM MED ASSOC, V263, P2149, DOI 10.1001/jama.263.16.2149; CRADDOCK C, 1987, LANCET, V2, P16; DAVIGNON A, 1980, PEDIATR CARDIOL, V1, P123, DOI 10.1007/BF02083144; De Castro S., 1993, Journal of the American College of Cardiology, V21, p280A; FISH M, 1958, ARCH INTERN MED, V101, P636, DOI 10.1001/archinte.1958.00260150124016; FLEISHER G, 1979, J INFECT DIS, V139, P553, DOI 10.1093/infdis/139.5.553; FLOMENBAUM M, 1989, J ACQ IMMUN DEF SYND, V2, P129; FREEMAN R, 1990, NEUROLOGY, V40, P575, DOI 10.1212/WNL.40.4.575; FRISHMAN W, 1977, CHEST, V72, P535, DOI 10.1378/chest.72.4.535; Garson AJ, 1983, ELECTROCARDIOGRAM IN; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; GOLDBLUM N, 1990, DEV BIOLOGICALS, V72, P309; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; HSIA J, 1992, CIRCULATION, V86, P795; JACOB AJ, 1991, BRIT HEART J, V66, P1, DOI 10.1136/hrt.66.1.1; JOSHI VV, 1988, HUM PATHOL, V19, P69, DOI 10.1016/S0046-8177(88)80318-6; KAPLAN LD, 1991, AIDS UPDATES, V4, P1; KAUL S, 1991, AM HEART J, V122, P535, DOI 10.1016/0002-8703(91)91013-D; KAVANAUGH-MCHUGH A L, 1992, Pediatric Research, V31, p166A; KELLY JW, 1992, CLIN INFECT DIS, V14, P1034, DOI 10.1093/clinids/14.5.1034; KOVACS A, 1992, Pediatric Research, V31, p167A; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LENNETTE ET, 1988, LABORATORY DIAGNOSIS, V2, P230; Lewis W, 1992, Cardiovasc Pathol, V1, P53, DOI 10.1016/1054-8807(92)90007-B; LIPSHULTZ SE, 1990, AM J CARDIOL, V66, P246, DOI 10.1016/0002-9149(90)90603-X; LIPSHULTZ SE, 1992, NEW ENGL J MED, V327, P1260, DOI 10.1056/NEJM199210293271802; LIPSHULTZ SE, 1989, AM J CARDIOL, V63, P1489, DOI 10.1016/0002-9149(89)90014-3; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA183; LIPSHULTZ SE, 1991, CIRCULATION, V84, P660; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MILLER R, 1973, CHEST, V63, P102, DOI 10.1378/chest.63.1.102; MOISEEV VS, 1990, TERAPEVT ARKH, V62, P77; Ogurtsov P P, 1988, Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR, V11, P18; REILLY JM, 1988, AM J CARDIOL, V62, P789, DOI 10.1016/0002-9149(88)91223-4; RUTTIMANN S, 1991, ARCH INTERN MED, V151, P2441, DOI 10.1001/archinte.151.12.2441; SCOTT G, 1990, AIDS, V4, P1279, DOI 10.1097/00002030-199012000-00017; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; STEIN KM, 1990, AM J CARDIOL, V66, P888, DOI 10.1016/0002-9149(90)90380-J; STEIN KM, 1991, AM J CARDIOL, V68, P1091, DOI 10.1016/0002-9149(91)90502-C; STEWART JM, 1989, AM HEART J, V117, P140, DOI 10.1016/0002-8703(89)90668-6; TYSON AA, 1989, SOUTHERN MED J, V82, P1184, DOI 10.1097/00007611-198909000-00033; VILLA A, 1992, AIDS, V6, P85, DOI 10.1097/00002030-199201000-00011; Villa A, 1990, Acta Neurol (Napoli), V12, P14; WEBSTER BH, 1957, AM J MED SCI, V234, P62, DOI 10.1097/00000441-195707000-00008; WELBY SB, 1991, J INFECTION, V23, P123, DOI 10.1016/0163-4453(91)91958-Z; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; WU AYY, 1990, MODERN PATHOL, V3, P625; WU TC, 1992, AIDS, V6, P777, DOI 10.1097/00002030-199208000-00002; 1987, MMWR MORB MORTAL WKL, V36, P225	64	82	84	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2869	2875		10.1001/jama.269.22.2869	http://dx.doi.org/10.1001/jama.269.22.2869			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8388521				2022-12-24	WOS:A1993LE93600023
J	KAWAMURA, S				KAWAMURA, S			RHODOPSIN PHOSPHORYLATION AS A MECHANISM OF CYCLIC-GMP PHOSPHODIESTERASE REGULATION BY S-MODULIN	NATURE			English	Article							ROD OUTER SEGMENTS; LIGHT-ACTIVATED PHOSPHODIESTERASE; RETINAL RODS; GUANYLATE-CYCLASE; FREE CALCIUM; ADAPTATION; ATP; MEMBRANES; KINETICS; CASCADE	DURING light-adaptation by the vertebrate eye, the rods are desensitized and the light response is accelerated1,2. When light is absorbed by the rods, a phosphodiesterase is activated that hydrolyses cyclic GMP3,4. A light-induced decrease in cytoplasmic Ca2+ concentration5-7 is part of this light-adaptation process8,9. The protein S-modulin (M(r) 26,000) is known to increase the fraction of light-activated cyclic GMP-phosphodiesterase (PDE) at high Ca2+ concentrations in frog rod photoreceptors10. Here I present evidence that S-modulin lengthens the lifetime of active PDE (PDE*) at high Ca2+ Concentrations. These S-modulin effects are observed in the physiological range of Ca2+ concentration (30 nM to 1 muM; half-maximum effects at 200-400 nM). At the high Ca2+ concentrations at which S-modulin prolongs the lifetime of PDE*, S-modulin inhibits rhodopsin phosphorylation (half-maximum effect at approximately 100 nM Ca2+). ATP is necessary for the S-modulin effects on PDE activation. I therefore conclude that the Ca2+-dependent regulation of PDE by S-modulin is mediated by rhodopsin phosphorylation. This regulation seems to be the principal mechanism of light adaptation in vertebrate photoreceptors.			KAWAMURA, S (corresponding author), KEIO UNIV,SCH MED,DEPT PHYSIOL,SHINANO MACHI 35,SHINJUKU KU,TOKYO 160,JAPAN.							BARKDOLL AE, 1989, J GEN PHYSIOL, V93, P1091, DOI 10.1085/jgp.93.6.1091; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1986, BIOCHIM BIOPHYS ACTA, V870, P256, DOI 10.1016/0167-4838(86)90230-X; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1981, J GEN PHYSIOL, V77, P571, DOI 10.1085/jgp.77.5.571; KAWAMURA S, 1989, J GEN PHYSIOL, V94, P649, DOI 10.1085/jgp.94.4.649; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KAWAMURA S, 1983, BIOCHIM BIOPHYS ACTA, V732, P276, DOI 10.1016/0005-2736(83)90212-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; RATTO GM, 1988, J NEUROSCI, V8, P3240; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; YEE R, 1978, J BIOL CHEM, V253, P8902	23	340	346	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					855	857		10.1038/362855a0	http://dx.doi.org/10.1038/362855a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	8386803				2022-12-24	WOS:A1993KZ56300062
J	RIBEIRO, JMC; HAZZARD, JMH; NUSSENZVEIG, RH; CHAMPAGNE, DE; WALKER, FA				RIBEIRO, JMC; HAZZARD, JMH; NUSSENZVEIG, RH; CHAMPAGNE, DE; WALKER, FA			REVERSIBLE BINDING OF NITRIC-OXIDE BY A SALIVARY HEME PROTEIN FROM A BLOODSUCKING INSECT	SCIENCE			English	Article							HUMAN-HEMOGLOBIN; LIGAND-BINDING; COMPLEXES; RESONANCE	The bloodsucking bug Rhodnius prolixus has a salivary vasodilator, previously characterized as a nitrovasodilator, with salivary smooth muscle-relaxing and antiplatelet activity. Rhodnius salivary glands are bright red owing to the abundance of heme proteins. Electron paramagnetic resonance and optical spectroscopic experiments indicated that the salivary vasodilator is a nitrosylheme protein with an Fe(III) heme that binds nitric oxide (NO) reversibly. Dilution of the protein in neutral pH promoted NO release. This protein thus appears to be the NO carrier that helps R. prolixus to feed on blood.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85721	University of Arizona; University of Arizona	RIBEIRO, JMC (corresponding author), UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721, USA.		Walker, Frances A/O-4395-2016	Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018694, R37AI018694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK031038, R01DK031038] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18694] Funding Source: Medline; NIDDK NIH HHS [DK-31038] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONINI E, 1966, J BIOL CHEM, V241, P3236; BRUNORI M, 1974, P NATL ACAD SCI USA, V71, P2470, DOI 10.1073/pnas.71.6.2470; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; CHAMPAGNE DE, UNPUB; DOLPHIN D, 1979, PORPHYRINS, V4, pCH6; EBEL RE, 1975, FEBS LETT, V55, P198, DOI 10.1016/0014-5793(75)80991-4; HILLE R, 1979, J BIOL CHEM, V254, P2110; HORI H, 1990, J BIOL CHEM, V265, P15028; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; RADOMSKI MW, 1991, PHILOS T ROY SOC B, V334, P129, DOI 10.1098/rstb.1991.0102; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; ROMBERG RW, 1979, BIOCHEMISTRY-US, V18, P5387, DOI 10.1021/bi00591a020; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; TODD P, 1969, ANAL BIOCHEM, V28, P369, DOI 10.1016/0003-2697(69)90192-4; WIGGLESWORTH VB, 1942, P ROYAL SOC LOND B, V131, P313; YASHIMURA T, 1983, J INORG BIOCHEM, V18, P263	20	284	295	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					539	541		10.1126/science.8386393	http://dx.doi.org/10.1126/science.8386393			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	8386393				2022-12-24	WOS:A1993KY50400033
J	SOLOMON, EI; LOWERY, MD				SOLOMON, EI; LOWERY, MD			ELECTRONIC-STRUCTURE CONTRIBUTIONS TO FUNCTION IN BIOINORGANIC CHEMISTRY	SCIENCE			English	Article							COPPER ACTIVE-SITE; PLASTOCYANIN SINGLE-CRYSTALS; MAGNETIC CIRCULAR-DICHROISM; RESONANCE RAMAN; NATIVE LACCASE; OXYGEN-BINDING; MODEL COMPLEX; RHUS LACCASE; HEMOCYANIN; TYROSINASE	Many metalloenzymes exhibit distinctive spectral features that are now becoming well understood. These reflect active site electronic structures that can make significant contributions to catalysis. Copper proteins provide well-characterized examples in which the unusual electronic structures of their active sites contribute to rapid, long-range electron transfer reactivity, oxygen binding and activation, and the multielectron reduction of dioxygen to water.			SOLOMON, EI (corresponding author), STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA.			Solomon, Edward/0000-0003-0291-3199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-31450] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; BALDWIN MJ, 1991, J AM CHEM SOC, V113, P8671, DOI 10.1021/ja00023a014; BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; BATES CA, 1962, P PHYS SOC LOND, V79, P73, DOI 10.1088/0370-1328/79/1/311; BRILL AS, 1968, J CHEM PHYS, V48, P4398, DOI 10.1063/1.1668007; BROWN JM, 1980, J AM CHEM SOC, V102, P4210, DOI 10.1021/ja00532a037; CO MS, 1981, J AM CHEM SOC, V103, P984, DOI 10.1021/ja00394a066; COLE JL, 1991, J AM CHEM SOC, V113, P8544, DOI 10.1021/ja00022a064; COLE JL, 1990, J AM CHEM SOC, V112, P9534, DOI 10.1021/ja00182a013; COLE JL, 1990, J AM CHEM SOC, V112, P2243, DOI 10.1021/ja00162a025; COLE JR, UNPUB; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DOOLEY DM, 1978, P NATL ACAD SCI USA, V75, P3019, DOI 10.1073/pnas.75.7.3019; EICKMAN NC, 1979, P NATL ACAD SCI USA, V76, P2094, DOI 10.1073/pnas.76.5.2094; EICKMAN NC, 1978, J AM CHEM SOC, V100, P6529, DOI 10.1021/ja00488a059; FARVER O, 1978, FEBS LETT, V94, P383, DOI 10.1016/0014-5793(78)80983-1; FEE JA, 1975, STRUCT BONDING BERLI, V23, P1; FREEDMAN TB, 1976, J AM CHEM SOC, V98, P2809, DOI 10.1021/ja00426a023; GEORGE SJ, IN PRESS J AM CHEM S; GEWIRTH AA, 1988, J AM CHEM SOC, V110, P3811, DOI 10.1021/ja00220a015; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GRAZIANI MT, 1976, FEBS LETT, V70, P87, DOI 10.1016/0014-5793(76)80732-6; GUSS JM, 1983, J MOL BIOL, V169, P521; HAY PJ, 1975, J AM CHEM SOC, V97, P4884, DOI 10.1021/ja00850a018; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; HUGHEY JL, 1979, J AM CHEM SOC, V101, P2617, DOI 10.1021/ja00504a020; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KARLIN KD, 1988, J AM CHEM SOC, V110, P6769, DOI 10.1021/ja00228a027; KARLIN KD, 1987, J AM CHEM SOC, V109, P2668, DOI 10.1021/ja00243a019; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; LARRABEE JA, 1980, J AM CHEM SOC, V102, P4217, DOI 10.1021/ja00532a038; LARRABEE JA, 1977, J AM CHEM SOC, V99, P1979, DOI 10.1021/ja00448a053; LOWERY MD, IN PRESS J AM CHEM S; MAGNUS K, 1992, Journal of Inorganic Biochemistry, V47, P20, DOI 10.1016/0162-0134(92)84091-Z; MAGNUS KA, COMMUNICATION; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MORIEBEBEL MM, 1984, J AM CHEM SOC, V106, P3677, DOI 10.1021/ja00324a048; NAKAGAWA KH, UNPUB; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; NIEDERHOFFER EC, 1984, CHEM REV, V84, P137, DOI 10.1021/cr00060a003; PALMER GA, 1991, STRUCT BOND, V75, P1; PATE JE, 1987, J AM CHEM SOC, V109, P2624, DOI 10.1021/ja00243a013; PENFIELD KW, 1981, J AM CHEM SOC, V103, P4382, DOI 10.1021/ja00405a016; PENFIELD KW, 1985, J AM CHEM SOC, V107, P4519, DOI 10.1021/ja00301a024; REINHAMMAR B, 1981, J INORG BIOCHEM, V15, P27, DOI 10.1016/S0162-0134(00)80133-6; Rheinhammar B., 1984, COPPER PROTEINS COPP, V3, P1; ROBERTS JE, 1980, J AM CHEM SOC, V102, P825, DOI 10.1021/ja00522a063; ROSS PK, 1991, J AM CHEM SOC, V113, P3246, DOI 10.1021/ja00009a005; SCOTT RA, 1982, J AM CHEM SOC, V104, P5364, DOI 10.1021/ja00384a020; SHADLE SE, 1993, J AM CHEM SOC, V115, P767, DOI 10.1021/ja00055a057; Solomon E. I., 1984, COMMENTS INORG CHEM, V3, P227; SOLOMON EI, 1976, P NATL ACAD SCI USA, V73, P1389, DOI 10.1073/pnas.73.5.1389; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1992, ACCOUNTS CHEM RES, V25, P343, DOI 10.1021/ar00020a004; SOLOMON EI, 1976, J AM CHEM SOC, V98, P1029, DOI 10.1021/ja00420a035; SOLOMON EI, IN PRESS METHODS ENZ; SOLOMON EI, 1988, STRUCT BOND, V53, P1; SPIRASOLOMON DJ, 1987, J AM CHEM SOC, V109, P6421, DOI 10.1021/ja00255a031; SPIRASOLOMON DJ, 1986, J AM CHEM SOC, V108, P5318, DOI 10.1021/ja00277a043; SPIRO T, 1981, METAL IONS BIOL, V3; SYKES AG, 1991, ADV INORG CHEM, V36, P377, DOI 10.1016/S0898-8838(08)60044-6; SYKES AG, 1991, STRUCT BOND, V75, P175; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; WILCOX DE, 1984, J AM CHEM SOC, V106, P2186, DOI 10.1021/ja00319a046; WINKLER ME, 1981, J AM CHEM SOC, V103, P7001, DOI 10.1021/ja00413a055; WOOLERY GL, 1984, J AM CHEM SOC, V106, P86, DOI 10.1021/ja00313a019	72	400	407	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1575	1581		10.1126/science.8384374	http://dx.doi.org/10.1126/science.8384374			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8384374				2022-12-24	WOS:A1993KR54300029
J	TAPSCOTT, SJ; THAYER, MJ; WEINTRAUB, H				TAPSCOTT, SJ; THAYER, MJ; WEINTRAUB, H			DEFICIENCY IN RHABDOMYOSARCOMAS OF A FACTOR REQUIRED FOR MYOD ACTIVITY AND MYOGENESIS	SCIENCE			English	Article							CELL-LINES; MUSCLE; EXPRESSION; ACTIVATION; DIFFERENTIATION; FIBROBLASTS; PROTEINS; MYOBLASTS; FAMILY; GENES	Rhabdomyosarcoma cells express the myogenic helix-loop-helix proteins of the MyoD family but do not differentiate into skeletal muscle cells. Gel shift and transient transfection assays revealed that MyoD in the rhabdomyosarcoma cells was capable of binding DNA but was relatively nonfunctional as a transcriptional activator. Heterokaryon formation with fibroblasts resulted in the restoration of transcriptional activation by MyoD and the differentiation of the rhabdomyosarcoma cells into skeletal muscle cells. These results suggest that rhabdomyosarcomas are deficient in a factor required for MyoD activity.			TAPSCOTT, SJ (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIAS P, 1990, AM J PATHOL, V137, P1283; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; HAZELTON BJ, 1987, CANCER RES, V47, P4501; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOUGHTON P, COMMUNICATION; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TAPSCOTT S, UNPUB; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YALE J, 1992, GENE DEV, V6, P1466	23	164	166	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1450	1453		10.1126/science.8383879	http://dx.doi.org/10.1126/science.8383879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8383879				2022-12-24	WOS:A1993KP97800035
J	SWACKHAMER, K				SWACKHAMER, K			CHINA TALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2105	2105						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411580				2022-12-24	WOS:A1993MD88200035
J	MCPHERSON, CE; SHIM, EY; FRIEDMAN, DS; ZARET, KS				MCPHERSON, CE; SHIM, EY; FRIEDMAN, DS; ZARET, KS			AN ACTIVE TISSUE-SPECIFIC ENHANCER AND BOUND TRANSCRIPTION FACTORS EXISTING IN A PRECISELY POSITIONED NUCLEOSOMAL ARRAY	CELL			English	Article							TUMOR VIRUS PROMOTER; YEAST ALPHA-2 REPRESSOR; FORK HEAD DOMAIN; GLUCOCORTICOID RECEPTOR; GENE FAMILY; ALBUMIN ENHANCER; NUCLEAR-PROTEIN; DNA; CHROMATIN; MOUSE	Nucleosomes positioned over promoters are usually inhibitory to protein binding and activity. We analyzed at the nucleotide level of resolution the nucleosomal organization of a distal, liver-specific enhancer in various mouse tissues and found that the enhancer exists in an array of three precisely positioned nucleosomes only in liver chromatin, where the enhancer is active. In vivo footprinting reveals that essential transcription factor-binding sites are occupied on apparent nucleosome surfaces, in one case leading to a perturbed nucleosomal structure. A similar nucleosomal array is generated with an in vitro chromatin assembly system in which nucleosome positioning is dependent upon binding to the enhancer of proteins related to hepatocyte nuclear factor 3. We suggest that certain transcription factors can organize nucleosomal structures that define an active enhancer element.			MCPHERSON, CE (corresponding author), BROWN UNIV, BIOCHEM SECT, PROVIDENCE, RI 02912 USA.				NIGMS NIH HHS [GM36477] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036477, R37GM036477] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KIOUSSIS D, 1981, J BIOL CHEM, V256, P1960; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEVITT M, 1978, P NATL ACAD SCI USA, V75, P640, DOI 10.1073/pnas.75.2.640; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POWELL DJ, 1984, MOL BIOL, V170, P21; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WOLFFE A P, 1991, Current Biology, V1, P366, DOI 10.1016/0960-9822(91)90195-3; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	64	298	299	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					387	398		10.1016/0092-8674(93)80079-T	http://dx.doi.org/10.1016/0092-8674(93)80079-T			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402920				2022-12-24	WOS:A1993MD88500019
J	RACINE, A; JOYCE, T; ANDERSON, R				RACINE, A; JOYCE, T; ANDERSON, R			THE ASSOCIATION BETWEEN PRENATAL-CARE AND BIRTH-WEIGHT AMONG WOMEN EXPOSED TO COCAINE IN NEW-YORK-CITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERINATAL COCAINE; PREGNANCY; DRUG; ABUSE; TERATOGENICITY; PREVALENCE; POPULATION; COHORT; IMPACT	Objectives.-Although the association between antenatal cocaine use and adverse birth outcomes has been well documented, relatively little is known about interventions that may ameliorate these consequences. We therefore examined the relationship between prenatal care and birth weight among a population of prenatal cocaine users. Design.-Population-based retrospective analysis. Patients.-All single-gestation live births to white non-Hispanic, black non-Hispanic, and Hispanic residents of New York City who gave birth between 1988 and 1990 with a positive indication for cocaine recorded on birth certificates (N=7923). Main Outcome Measures.-We contrasted mean birth weight and rates of low birth weight (<2500 g) among cocaine users with one to three prenatal care visits, four or more visits, and unknown numbers of visits with users who reported no prenatal care. We used ordinary least squares and logistic regression to control for age, parity, smoking, alcohol, other drugs, weight gain, prepregnancy weight, employment, marital status, participation in the Supplemental Food Program for Women, Infants and Children, and method of finance. Main Results.-Adjusted odds ratios of low birth weight for cocaine users with four prenatal care visits or more as compared with those who had none were 0.51 for blacks (95% confidence interval [CI], 0.44 to 0.59), 0.39 for whites (95% CI, 0.23 to 0.66), and 0.37 for Hispanics (95% CI, 0.28 to 0.48). Adjusted mean birth weight differences between users with four visits or more and those with none were 262 g for blacks (P<.001), 247 g for whites (P<.001), and 317 g for Hispanics (P<.001). Conclusions.-The receipt of prenatal care among cocaine users is associated with significant improvements in birth weight. Enrollment of cocaine users in prenatal care may be an effective start to a more comprehensive approach to this problem.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; CUNY,BARUCH COLL,DEPT ECON & FINANCE,NEW YORK,NY 10021; SUNY COLL FARMINGDALE,DEPT ECON,FARMINGDALE,NY 11735	Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Baruch College (CUNY); State University of New York (SUNY) System	RACINE, A (corresponding author), NATL BUR ECON RES,269 MERCER ST,8TH FLOOR,NEW YORK,NY 10003, USA.							BATEMAN DA, 1993, AM J PUBLIC HEALTH, V83, P190, DOI 10.2105/AJPH.83.2.190; BINGOL N, 1987, J PEDIATR-US, V110, P93, DOI 10.1016/S0022-3476(87)80297-4; BURKETT G, 1990, J REPROD MED, V35, P35; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHASNOFF IJ, 1989, JAMA-J AM MED ASSOC, V261, P1741, DOI 10.1001/jama.261.12.1741; CHAVEZ GF, 1989, JAMA-J AM MED ASSOC, V262, P795, DOI 10.1001/jama.262.6.795; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; CHERUKURI R, 1988, OBSTET GYNECOL, V72, P147; CHOUTEAU M, 1988, OBSTET GYNECOL, V72, P351; FANTEL AG, 1982, TERATOLOGY, V26, P17, DOI 10.1002/tera.1420260104; FELDMAN JG, 1992, AM J PUBLIC HEALTH, V82, P726, DOI 10.2105/AJPH.82.5.726; FINGERHUT MA, 1985, VITAL HLTH STAT 99, V2; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HADEED AJ, 1989, PEDIATRICS, V84, P205; HANDLER A, 1991, AM J EPIDEMIOL, V133, P812; KAYE K, 1989, NEW YORK STATE J MED, V89, P256; LITTLE BB, 1989, OBSTET GYNECOL, V73, P157; MACGREGOR SN, 1989, OBSTET GYNECOL, V74, P882; MACGREGOR SN, 1987, AM J OBSTET GYNECOL, V157, P686, DOI 10.1016/S0002-9378(87)80029-7; MCCALLA S, 1991, AM J OBSTET GYNECOL, V164, P625, DOI 10.1016/S0002-9378(11)80036-0; McLachlan G., 1992, WILEY SERIES PROBABI, DOI DOI 10.1002/0471725293; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; OSTREA EM, 1992, PEDIATRICS, V89, P107; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; SCHUTZMAN DL, 1991, PEDIATRICS, V88, P825; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1990, MMWR MORB MORTAL WKL, V39, P225; 1973, CONTRASTS HLTH STATU, P1; 1991, DEP HLTH HUMAN SERV	31	58	58	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1581	1586		10.1001/jama.270.13.1581	http://dx.doi.org/10.1001/jama.270.13.1581			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ334	8371469				2022-12-24	WOS:A1993LZ33400032
J	BEATH, SV; BROOK, GD; KELLY, DA; CASH, AJ; MCMASTER, P; MAYER, AD; BUCKELS, JAC				BEATH, SV; BROOK, GD; KELLY, DA; CASH, AJ; MCMASTER, P; MAYER, AD; BUCKELS, JAC			SUCCESSFUL LIVER-TRANSPLANTATION IN BABIES UNDER 1 YEAR	BRITISH MEDICAL JOURNAL			English	Article							HEPATIC TRANSPLANTATION; NUTRITIONAL-STATUS; BILIARY ATRESIA; MUSCLE AREAS; CHILDREN; PEDIATRICS; SURVIVAL; INFANCY; GROWTH; AGE	Objective-To review the outcome of liver transplantation in babies aged less than 1 year. Design-Prospective evaluation of survival, clinical complications, and nutritional and developmental status before and one year after liver transplantation. Setting-The Children's Hospital and Queen Elizabeth Hospital, Birmingham. Subjects-All 25 babies who received liver transplantation from january 1989 to December 1992 were included. Median age was 9 months and median weight was 7.0 kg. Seven babies were assessed but were not given transplants because they died while on the waiting list (two) or had severe extrahepatic disease (five). Results-24 babies had severe decompensated liver disease and 20 were severely malnourished despite nutritional support. Six babies received a whole liver graft and 19 received a reduction hepatectomy. Postoperative complications included primary nonfunction of the transplanted liver (one baby), hepatic artery thrombosis (two), biliary obstruction (seven), acute and chronic rejection (six), and sepsis (18). Three babies required a second transplant; all survived. Three babies, two of whom presented with fulminant hepatic failure, died. The overall actuarial survival rate (4 months to 4 years) is 88%. Review at 12 months showed a dramatic improvement in growth (p<0.001) and normal psychosocial development with good quality of life. Conclusion-The improvement in survival rates and quality of life in this group of very sick babies is related not only to the development of reduction hepatectomy but also to advances in medical and nursing expertise. Early referral for liver transplantation is justified even if babies are critically ill.	CHILDRENS HOSP,LIVER UNIT,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								BADGER IL, 1992, BRIT J SURG, V79, P47, DOI 10.1002/bjs.1800790115; Brooke O. G., 1986, Energy and protein needs during infancy, P3; BUCKELS JAC, 1989, TRANSPLANT P, V21, P2460; CHIN SE, 1991, J PAEDIATR CHILD H, V27, P380, DOI 10.1111/j.1440-1754.1991.tb00424.x; CHIYENDE J, 1992, ARCH DIS CHILD, V67, P1124, DOI 10.1136/adc.67.9.1124; ESQUIVEL CO, 1987, J PEDIATR-US, V110, P545, DOI 10.1016/S0022-3476(87)80545-0; FRISANCHO AR, 1981, AM J CLIN NUTR, V34, P2540, DOI 10.1093/ajcn/34.11.2540; HARRIS G, 1992, MONOGRAPHS CLIN PEDI, P61; HOUSSIN D, 1992, SURGERY, V111, P532; JORDAN MD, 1987, CDC ANTHROPOMETRIC S; KALAYOGLU M, 1989, J PEDIATR SURG, V24, P70, DOI 10.1016/S0022-3468(89)80305-7; KAUFMAN SS, 1987, J PEDIATR-US, V110, P679, DOI 10.1016/S0022-3476(87)80002-1; LYNCH SV, 1992, TRANSPLANT P, V24, P186; MALATACK JJ, 1987, J PEDIATR-US, V111, P479, DOI 10.1016/S0022-3476(87)80105-1; MIYAWAKI T, 1981, IMMUNOL REV, V57, P61, DOI 10.1111/j.1600-065X.1981.tb00442.x; MORGAN GE, 1992, CLIN ANAESTHESIOLOGY, P630; MOUKARZEL AA, 1990, TRANSPLANT P, V22, P1560; OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P222; RYCKMAN FC, 1991, J PEDIATR SURG, V26, P422, DOI 10.1016/0022-3468(91)90989-7; SALT A, 1992, BMJ-BRIT MED J, V304, P416, DOI 10.1136/bmj.304.6824.416; SANN L, 1988, ARCH DIS CHILD, V63, P256, DOI 10.1136/adc.63.3.256; SMITH D E, 1989, Journal of Human Nutrition and Dietetics, V2, P217, DOI 10.1111/j.1365-277X.1989.tb00025.x; SOKAL EM, 1990, J PEDIATR-US, V117, P205, DOI 10.1016/S0022-3476(05)80531-1; STEWART SM, 1989, J PEDIATR-US, V114, P574, DOI 10.1016/S0022-3476(89)80696-1; WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0; 1986, GRIFFITHS MENTAL DEV	27	61	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					825	828		10.1136/bmj.307.6908.825	http://dx.doi.org/10.1136/bmj.307.6908.825			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401122	Green Published, Bronze			2022-12-24	WOS:A1993MA29300017
J	GORTMAKER, SL; MUST, A; PERRIN, JM; SOBOL, AM; DIETZ, WH				GORTMAKER, SL; MUST, A; PERRIN, JM; SOBOL, AM; DIETZ, WH			SOCIAL AND ECONOMIC CONSEQUENCES OF OVERWEIGHT IN ADOLESCENCE AND YOUNG ADULTHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBESITY; TRANSITION; ATTAINMENT	Background and Methods. Overweight in adolescents may have deleterious effects on their subsequent self-esteem, social and economic characteristics, and physical health. We studied the relation between overweight and subsequent educational attainment, marital status, household income, and self-esteem in a nationally representative sample of 10,039 randomly selected young people who were 16 to 24 years old in 1981. Follow-up data were obtained in 1988 for 65 to 79 percent of the original cohort, depending on the variable studied. The characteristics of the subjects who had been overweight in 1981 were compared with those for young people with asthma, musculoskeletal abnormalities, and other chronic health conditions. Overweight was defined as a body-mass index above the 95th percentile for age and sex. Results. ln 1981, 370 of the subjects were overweight. Seven years later, women who had been overweight had completed fewer years of school (0.3 year less; 95 percent confidence interval, 0.1 to 0.6; P = 0.009), were less likely to be married (20 percent less likely; 95 percent confidence interval, 13 to 27 percent; P<0.001), had lower household incomes ($6,71 0 less per year; 95 percent confidence interval, $3,942 to $9,478; P<0.001), and had higher rates of household poverty (10 percent higher; 95 percent confidence interval, 4 to 16 percent; P<0.001) than the women who had not been overweight, independent of their base-line socioeconomic status and aptitude-test scores. Men who had been overweight were less likely to be married (11 percent less likely; 95 percent confidence interval, 3 to 18 percent; P = 0.005). In contrast, people with the other chronic conditions we studied did not differ in these ways from the nonoverweight subjects. We found no evidence of an effect of overweight on self-esteem. Conclusions. Overweight during adolescence has important social and economic consequences, which are greater than those of many other chronic physical conditions. Discrimination against overweight persons may account for these results.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Tufts Medical Center; Harvard University; Harvard Medical School	GORTMAKER, SL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Fahimifar, Sepideh/M-5303-2019	Perrin, James/0000-0002-1810-3708				Baker P. C., 1989, NLSY CHILD HDB 1989; Berscheid Ellen, 1974, ADV EXP SOC PSYCHOL, P157, DOI [10.1016/S0065- 2601(08)60037-4, DOI 10.1016/S0065-2601(08)60037-4]; CANNING H, 1966, NEW ENGL J MED, V275, P1172, DOI 10.1056/NEJM196611242752107; CANNING H, 1967, AM J CLIN NUTR, V20, P352, DOI 10.1093/ajcn/20.4.352; DEJONG W, 1980, J HEALTH SOC BEHAV, V21, P75, DOI 10.2307/2136696; GOLDBLATT PB, 1965, J AMER MED ASSOC, V192, P1039, DOI 10.1001/jama.1965.03080250017004; GORTMAKER SL, 1987, AM J DIS CHILD, V141, P535, DOI 10.1001/archpedi.1987.04460050077035; GORTMAKER SL, 1990, J AM DIET ASSOC, V90, P1247; GORTMAKER SL, 1993, J RES ADOLESCENCE, V0003; HOGAN DP, 1986, ANNU REV SOCIOL, V12, P109, DOI 10.1146/annurev.so.12.080186.000545; MADDOX GL, 1968, J HEALTH SOC BEHAV, V9, P287, DOI 10.2307/2948537; MARINI MM, 1978, AM SOCIOL REV, V43, P483, DOI 10.2307/2094774; Martel LF., 1987, STATURE STIGMA BIOPS; MONELLO LF, 1972, J PEDIATR, V13, P35; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V54, P773, DOI 10.1093/ajcn/54.5.773; Nunnally J., 1978, PSYCHOMETRIC METHODS; PLESS IB, 1989, CARING FOR CHILDREN WITH CHRONIC ILLNESS : ISSUES AND STRATEGIES, P147; REVICKI DA, 1986, AM J PUBLIC HEALTH, V76, P992, DOI 10.2105/AJPH.76.8.992; Roe D A, 1976, J Am Med Womens Assoc (1972), V31, P193; Rosenberg M., 1965, MEASUREMENT SELF EST, DOI [10.1515/9781400876136, DOI 10.1515/9781400876136]; ROSS JG, 1987, J PHYSICAL ED RECREA, V58, P74; ROTHBLUM ED, IN PRESS FEMINIST PE; Rowland M L, 1989, Stat Bull Metrop Insur Co, V70, P2; Sewell WH., 1975, ED OCCUPATION EARNIN; SHEAR CL, 1988, AM J PUBLIC HEALTH, V78, P75, DOI 10.2105/AJPH.78.1.75; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; SONNEHOLM S, 1986, BRIT MED J, V292, P586, DOI 10.1136/bmj.292.6520.586; STEIN REK, 1987, LANCET, V2, P1506; STUNKARD A J, 1992, American Journal of Clinical Nutrition, V55, p524S, DOI 10.1093/ajcn/55.2.524s; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; TANNER JM, 1990, FETUS MAN PHYSICAL G; WADDEN TA, 1987, ANN NY ACAD SCI, V499, P55, DOI 10.1111/j.1749-6632.1987.tb36197.x; WEST J, 1991, MILBANK Q S, V69; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; 1992, NLS USERS GUIDE 1992	36	1032	1043	2	84	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1008	1012		10.1056/NEJM199309303291406	http://dx.doi.org/10.1056/NEJM199309303291406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LY587	8366901	Green Published			2022-12-24	WOS:A1993LY58700006
J	STEHLE, JH; FOULKES, NS; MOLINA, CA; SIMONNEAUX, V; PEVET, P; SASSONECORSI, P				STEHLE, JH; FOULKES, NS; MOLINA, CA; SIMONNEAUX, V; PEVET, P; SASSONECORSI, P			ADRENERGIC SIGNALS DIRECT RHYTHMIC EXPRESSION OF TRANSCRIPTIONAL REPRESSOR CREM IN THE PINEAL-GLAND	NATURE			English	Article							MELATONIN; GENE; RAT; ANTAGONIST; ACTIVATOR; RECEPTOR; HAMSTER	Transcription factor CREM appears to play a key physiological and developmental role within the hypothalamic-pituitary-gonadal axis. This axis is modulated by the pineal hormone melatonin, whose production is in turn driven by the endogenous clock. There is striking circadian fluctuation of a novel CREM isoform, ICER, which is expressed at high levels during the night. ICER is generated from an alternative, intronic promoter and functions as a powerful repressor of cyclic AMP-induced transcription. Rhythmic adrenergic signals originated by the clock direct ICER expression by stimulation of the cAMP signal transduction pathway.	FAC MED STRASBOURG, CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE; UNIV STRASBOURG 1, CNRS, URA 1332, F-67070 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				ASCHOFF J, 1981, HDB BEHAV NEUROBIOLO, V4, P1; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; CARTER DS, 1983, ENDOCRINOLOGY, V113, P1261, DOI 10.1210/endo-113-4-1261; CRAFT CM, 1984, NEUROENDOCRINOLOGY, V38, P193, DOI 10.1159/000123890; Darwin C, 1880, POWER MOVEMENT PLANT; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HOFFMANN K, 1981, HDB BEHAVIOURAL NEUR, V4, P449; ILLNEROVA H, 1979, J NEUROCHEM, V32, P673, DOI 10.1111/j.1471-4159.1979.tb00407.x; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1985, PHOTOPERIODISM MELAT; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MEIJER GH, 1991, SUPRACHIASMATIC NUCL; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MOLINA CA, IN PRESS CELL; MOORE RY, 1983, FED PROC, V42, P2783; PERLOW MJ, 1980, BRAIN RES, V182, P211, DOI 10.1016/0006-8993(80)90848-3; PEVET P, 1988, REPROD NUTR DEV, V28, P443, DOI 10.1051/rnd:19880310; REITER RJ, 1991, TRENDS ENDOCRIN MET, V2, P13, DOI 10.1016/1043-2760(91)90055-R; ROMERO JA, 1974, SCIENCE, V184, P1091, DOI 10.1126/science.184.4141.1091; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; SIMONNEAUX V, 1989, J PINEAL RES, V7, P63, DOI 10.1111/j.1600-079X.1989.tb00443.x; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDGEN D, 1985, NATURE, V314, P359; TAKAHASHI JS, 1992, SCIENCE, V258, P238, DOI 10.1126/science.1384127; TAKAHASHI JS, 1993, CURR OPIN GENET DEV, V3, P301, DOI 10.1016/0959-437X(93)90038-Q; TAMARKIN L, 1985, SCIENCE, V227, P714, DOI 10.1126/science.3881822; TAMARKIN L, 1979, ENDOCRINOLOGY, V104, P385, DOI 10.1210/endo-104-2-385; VANECEK J, 1985, ENDOCRINOLOGY, V116, P2167, DOI 10.1210/endo-116-6-2167; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171; WILLIAMS JG, 1987, NUCL ACID HYBRIDISAT, P139; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; [No title captured]	48	377	378	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1993	365	6444					314	320		10.1038/365314a0	http://dx.doi.org/10.1038/365314a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397338				2022-12-24	WOS:A1993LY49600043
J	DUTTA, A; RUPPERT, JM; ASTER, JC; WINCHESTER, E				DUTTA, A; RUPPERT, JM; ASTER, JC; WINCHESTER, E			INHIBITION OF DNA-REPLICATION FACTOR RPA BY P53	NATURE			English	Article							PROTEIN-A; SV40 ORIGIN; T-ANTIGEN; INVITRO; BINDING; INITIATION; MUTATIONS; SUBUNIT; GENE	THE tumour suppressor p53 specifically interferes with the onset of S phase. The mechanism of the growth suppression action of the protein is unclear, though recent evidence points to transcriptional activation and repression functions of the protein1. A competing hypothesis suggests that p53 interacts with the DNA replication apparatus and directly interferes with DNA replication. The major evidence for this hypothesis is that p53 interacts with the simian virus 40 (SV40)-encoded protein T antigen and interferes with the ability of T antigen to unwind the SV40 origin of DNA replication, and recruit DNA polymerase alpha to the replication initiation complex2,3. Here we report that p53 physically interacts with and inhibits the function of a cellular DNA replication factor, the single-stranded DNA-binding protein complex RPA.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL & HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University	DUTTA, A (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOLEC ONCOL,20 SHATTUCK ST,BOSTON,MA 02115, USA.		Dutta, Anindya/P-3203-2016; Aster, Jon C/B-6857-2009	Dutta, Anindya/0000-0002-4319-0073				BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GANNON J V, 1990, New Biologist, V2, P84; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	22	378	378	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					79	82		10.1038/365079a0	http://dx.doi.org/10.1038/365079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361542				2022-12-24	WOS:A1993LV64600059
J	SHIDARA, M; KAWANO, K; GOMI, H; KAWATO, M				SHIDARA, M; KAWANO, K; GOMI, H; KAWATO, M			INVERSE-DYNAMICS MODEL EYE-MOVEMENT CONTROL BY PURKINJE-CELLS IN THE CEREBELLUM	NATURE			English	Article							OCULAR FOLLOWING RESPONSES; VESTIBULOOCULAR REFLEX; PRIMATE FLOCCULUS; ALERT MONKEY	MANY lines of evidence suggest that the cerebellum is involved in motor control1. But what features of these movements are encoded by cerebellar neurons? For slow-tracking eye movements, the activity of Purkinje cells in the ventral paraflocculus of the cerebellum is known to be correlated with eye velocity2-5 and acceleration5. Here we show that the complex temporal pattern of the firing frequency that occurs during the ocular following response elicited by movements of a large visual scene6-8 can be reconstructed by an inverse-dynamics representation, which uses the position, velocity and acceleration of eye movements. Further analysis reveals that the velocity and acceleration components can provide appropriate dynamic drive signals to ocular motor neurons, whereas the position component often has the wrong polarity. We conclude that these Purkinje cells primarily contribute dynamic command signals.	ATR,HUMAN INFORMAT PROC RES LAB,KYOTO 61902,JAPAN; HOKKAIDO UNIV,ELECTR SCI RES INST,PARALLEL DISTRIBUTED PROC LAB,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	SHIDARA, M (corresponding author), ELECTROTECH LAB,NEUROSCI SECT,1-1-4 UMEZONO,TSUKUBA,IBARAKI 305,JAPAN.		Gomi, Hiroaki/AEL-2645-2022; Gomi, Hiroaki/C-5269-2013	Gomi, Hiroaki/0000-0003-3541-2251				ATKESON CG, 1989, ANNU REV NEUROSCI, V12, P157, DOI 10.1146/annurev.ne.12.030189.001105; Barto A. G., 1990, NEURAL NETWORKS CONT, P5; BETHIER NE, 1991, BIOL CYBERN, V65, P99; GOMI H, 1992, BIOL CYBERN, V68, P105, DOI 10.1007/BF00201432; HOLLERBACH JM, 1982, ROBOT MOTION; Ito M, 1984, CEREBELLUM NEURAL CO; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KAWANO K, 1992, J NEUROPHYSIOL, V67, P680, DOI 10.1152/jn.1992.67.3.680; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KAWATO M, 1993, TRENDS NEUROSCI, V18, P177; KELLER EL, 1973, VISION RES, V13, P1565, DOI 10.1016/0042-6989(73)90015-1; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; MILES FA, 1975, SCIENCE, V189, P1000, DOI 10.1126/science.1083068; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; Robinson DA., 1981, HDB PHYSL AM PHYSL 1, V2, P1275; SHIDARA M, 1993, EXP BRAIN RES, V93, P185; STONE LS, 1990, J NEUROPHYSIOL, V63, P1241, DOI 10.1152/jn.1990.63.5.1241; WALPOLE RE, 1978, PROBABILITY STATISTI	21	243	243	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					50	52		10.1038/365050a0	http://dx.doi.org/10.1038/365050a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361536				2022-12-24	WOS:A1993LV64600051
J	DALY, AK; THOMAS, DJ; COOPER, J; PEARSON, WR; NEAL, DE; IDLE, JR				DALY, AK; THOMAS, DJ; COOPER, J; PEARSON, WR; NEAL, DE; IDLE, JR			HOMOZYGOUS DELETION OF GENE FOR GLUTATHIONE S-TRANSFERASE-M1 IN BLADDER-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV VIRGINIA,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	Newcastle University - UK; University of Virginia	DALY, AK (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,PHARMACOGENET RES UNIT,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Pearson, William/K-4908-2019; Daly, Ann/H-3144-2011; Idle, Jeff/B-1152-2012	Pearson, William/0000-0002-0727-3680; Daly, Ann/0000-0002-7321-0629; Idle, Jeff/0000-0002-6143-1520; Neal, David/0000-0002-6033-5086				BOARD P, 1990, PHARMACOL THERAPEUT, V48, P357, DOI 10.1016/0163-7258(90)90054-6; MILLER AB, 1977, CANCER RES, V37, P2939; PEARSON WR, 1993, AM J HUM GENET, V53, P220; Roots I, 1992, PHARMACOGENETICS DRU, P815; SEIDEGARD J, 1990, CARCINOGENESIS, V11, P33, DOI 10.1093/carcin/11.1.33	5	79	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1993	307	6902					481	482		10.1136/bmj.307.6902.481	http://dx.doi.org/10.1136/bmj.307.6902.481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU590	8400932	Green Published, Bronze			2022-12-24	WOS:A1993LU59000022
J	TOTH, PT; BINDOKAS, VP; BLEAKMAN, D; COLMERS, WF; MILLER, RJ				TOTH, PT; BINDOKAS, VP; BLEAKMAN, D; COLMERS, WF; MILLER, RJ			MECHANISM OF PRESYNAPTIC INHIBITION BY NEUROPEPTIDE-Y AT SYMPATHETIC-NERVE TERMINALS	NATURE			English	Article							CALCIUM CHANNELS; SYNAPTIC FUNCTIONS; NEURONS; RELEASE; MODULATION; MICROCULTURES; NOREPINEPHRINE; ACETYLCHOLINE; RECEPTOR; CELLS	CALCIUM influx through voltage-sensitive Ca2+ channels is the normal physiological stimulus for the activity-dependent release of neurotransmitters at synaptic contacts. It has been postulated that presynaptic inhibition of transmitter release is due to a reduction in Ca2+ influx at the nerve terminal, which could result from the direct inhibition of Ca2+ channels. Neuropeptide Y and noradrenaline act as cotransmitters at many sympathetic synapses. Both of these substances produce presynaptic inhibition and can inhibit Ca2+ currents in the soma of sympathetic neurons1-5. Here we provide direct evidence that presynaptic inhibition produced by neuropeptide Y at sympathetic nerve terminals is associated with a reduction in Ca2+ influx and that this is due to the selective inhibition of neuronal N-type Ca2+ channels.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Chicago; University of Alberta			Colmers, William/C-3106-2013	Colmers, William/0000-0001-7902-3560; Toth, Peter/0000-0003-2168-0124				BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DALHOF K, 1985, N-S ARCH PHARMACOL, V328, P327; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; ELLIS JL, 1990, BRIT J PHARMACOL, V100, P457, DOI 10.1111/j.1476-5381.1990.tb15828.x; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V456, P107, DOI 10.1113/jphysiol.1992.sp019329; FOUCART S, 1993, J PHARMACOL EXP THER, V265, P903; FURSHPAN EJ, 1986, J NEUROSCI, V6, P1061; HAASS M, 1989, N-S ARCH PHARMACOL, V339, P71; Higgins D., 1991, CULTURING NERVE CELL, P177; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; KLAPSTEIN GJ, 1992, BRIT J PHARMACOL, V105, P470, DOI 10.1111/j.1476-5381.1992.tb14277.x; LANDIS SC, 1976, P NATL ACAD SCI USA, V73, P4220, DOI 10.1073/pnas.73.11.4220; MAINS RE, 1973, J CELL BIOL, V59, P329, DOI 10.1083/jcb.59.2.329; Marubio L. M., 1992, Society for Neuroscience Abstracts, V18, P1138; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; POTTER DD, 1986, J NEUROSCI, V6, P1080; SCHOFIELD GG, 1990, EUR J PHARMACOL, V180, P37, DOI 10.1016/0014-2999(90)90590-3; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SUETAKE K, 1981, BRAIN RES, V205, P436, DOI 10.1016/0006-8993(81)90357-7; Toth P. T., 1992, Society for Neuroscience Abstracts, V18, P1353; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; WILEY JW, 1990, J NEUROPHYSIOL, V63, P1499, DOI 10.1152/jn.1990.63.6.1499; ZIDICHOUSKI JA, 1990, NEUROSCI LETT, V117, P123, DOI 10.1016/0304-3940(90)90130-2	25	142	143	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					635	639		10.1038/364635a0	http://dx.doi.org/10.1038/364635a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8394510				2022-12-24	WOS:A1993LR77100055
J	CHAMBERLAIN, J; MOSS, SM; KIRKPATRICK, AE; MICHELL, M; JOHNS, L				CHAMBERLAIN, J; MOSS, SM; KIRKPATRICK, AE; MICHELL, M; JOHNS, L			NATIONAL-HEALTH-SERVICE BREAST SCREENING-PROGRAM RESULTS FOR 1991-2	BRITISH MEDICAL JOURNAL			English	Article							TRIAL	Objectives-To report the results of the NHS breast screening programme for the year March 1991 to April 1992. Design-A report of statistics was derived from Korner (K62) returns and from the radiology quality assurance programme. Main outcome measures-Detection rates for breast cancer and small (less-than-or-equal-to 10 mm diameter) invasive cancer, benign biopsy rates, and recall and acceptance rates. Results-The acceptance rate for screening across the United Kingdom was 71.3%. The referral rate for further investigation was 6.2% (regional 4.3-9.0%). The breast cancer detection rate was 6.2 cancers per 1000 women screened (5.1-9.0) and the detection rate of invasive cancers less-than-or-equal-to 10 mm was 1.4/1000 (1.0-2.3). 72% of screening programmes reached the target 70% acceptance rate, and 95% of programmes achieved a recall rate of less than 10%. 75% of programmes had a cancer detection rate of more than 5/1000, but only 32% had a detection rate for invasive cancers less-than-or-equal-to 10 mm of more than 1.5/1000. Conclusions-Overall, the results of the screening programme for the year 1991-2 can be regarded as extremely satisfactory, given the size and complexity of the operation.	SE SCOTLAND BREAST SCREENING PROGRAM,ARDMILLAN TERRACE,EDINBURGH EH11 2JL,SCOTLAND; INST CANC RES,CANC SCREENING EVALUAT UNIT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV LONDON KINGS COLL HOSP,BREAST SCREENING UNIT,LONDON SE5 9RS,ENGLAND	University of London; Institute of Cancer Research - UK; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								FORREST APM, 1986, BREAST CANCER SCREEN; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; 1992, HLTH NATION STRATEGY; 1988, NHSBSP PUBLICATIONS; 1993, BREAST, V2, P13; IN PRESS UKCCCRN NHS	7	78	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					353	356		10.1136/bmj.307.6900.353	http://dx.doi.org/10.1136/bmj.307.6900.353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374416	Bronze, Green Published			2022-12-24	WOS:A1993LR76800017
J	STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD				STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD			SHORT AND LONG-TERM PROGNOSIS OF ACUTE MYOCARDIAL-INFARCTION SINCE INTRODUCTION OF THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; MINNESOTA-HEART-SURVEY; FOLLOW-UP; SURVIVAL; TRIAL; MORTALITY; THERAPY; RECOVERY; STRATIFICATION; STREPTOKINASE	Objective-To record prognosis and determinants of outcome in patients with acute myocardial infarction since thrombolysis was introduced. Design-Observational study. Setting-London district general hospital. Patients-608 consecutive patients admitted to the coronary care unit with acute myocardial infarction between 1 January 1988 and 31 December 1991. Main outcome measure-All cause mortality, non-fatal ischaemic events (myocardial infarction, unstable angina), and revascularisation. Results-Of the 608 patients, 89 (14.6%) died in hospital. 596 patients were followed up after discharge from hospital. Mortality (95% confidence interval) at 30 days, one year, and three years was 16.0% (13.4% to 19.2%), 21.7% (18.6% to 25.2%), and 29.4% (25.3% to 33.9%) respectively. Event free survival (survival without a non-fatal ischaemic event) was 80.4% (77.0% to 83.4%) at 30 days, 66.8% (62.8% to 70.5%) at one year, and 56.1% (51.3% to 60.6%) at three years. Survival in patients treated with thrombolysis was considerably higher than in those not given thrombolysis (three year survival: 76.7% v 54.3%), although the incidence of non-fatal ischaemic events was the same in the two groups. Multivariate determinants of six month survival were left ventricular failure, treatment with thrombolysis and aspirin, smoking history, bundle branch block, and age. For patients who survived six months, age was the only factor related to long term survival. Conclusions-Although patients treated by thrombolysis had a relatively good prognosis, long term mortality and the incidence of non-fatal recurrent ischaemic events remained high. Effective strategies for the identification and treatment of high risk patients need to be reassessed.	NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON E13, ENGLAND; LONDON CHEST HOSP, EPIDEMIOL RES UNIT, LONDON E2, ENGLAND		STEVENSON, R (corresponding author), LONDON CHEST HOSP, DEPT CARDIOL, LONDON E2, ENGLAND.			Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1987, LANCET, V2, P871; BARBASH GI, 1992, J AM COLL CARDIOL, V20, P36, DOI 10.1016/0735-1097(92)90134-9; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CLEEMPOEL H, 1988, BRIT HEART J, V60, P98; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERS JW, 1987, AM HEART J, V113, P90, DOI 10.1016/0002-8703(87)90014-7; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; FRABICIUSBJERRE N, 1979, AM J MED, V66, P986; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; HARRISON DG, 1984, CIRCULATION, V69, P991, DOI 10.1161/01.CIR.69.5.991; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; MARTIN CA, 1983, CIRCULATION, V68, P961, DOI 10.1161/01.CIR.68.5.961; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MURRAY DP, 1987, BRIT HEART J, V57, P313; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1985, LANCET, V2, P578; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; WOLFFENBUTTEL BHR, 1983, BRIT HEART J, V50, P266; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1990, LANCET, V335, P545; 1968, LANCET, V2, P349	33	147	150	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	1993	307	6900					349	353		10.1136/bmj.307.6900.349	http://dx.doi.org/10.1136/bmj.307.6900.349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374415	Bronze, Green Published			2022-12-24	WOS:A1993LR76800016
J	NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J				NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J			THE CHONDROITIN SULFATE FORM OF INVARIANT CHAIN CAN ENHANCE STIMULATION OF T-CELL RESPONSES THROUGH INTERACTION WITH CD44	CELL			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE HOMING RECEPTOR; HLA-DR MOLECULES; PANCREATIC BETA-CELLS; ANTIGEN PRESENTATION; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; B-CELL; SURFACE EXPRESSION	Invariant chain (Ii) is a nonpolymorphic glycoprotein that associates with major histocompatibility complex class II molecules and has been shown to mediate several functions in class II-restricted antigen presentation. A small proportion of Ii is modified by the addition of chondroitin sulfate (Ii-CS), and this form of Ii is associated with class II on the surface of antigen-presenting cells. In this report we show that expression of Ii-CS dramatically enhanced the ability of class II-positive EL4 transfectants to stimulate class II-dependent allogeneic and mitogenic T cell responses. Antibody blocking studies and the ability of CD44 to bind directly to Ii-CS suggest that Ii-CS can function as an accessory molecule during T cell responses through interactions with CD44.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637	University of Chicago	NAUJOKAS, MF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK42857] Funding Source: Medline; NIGMS NIH HHS [GM42071, GM07281] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042071, T32GM007281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1985, J IMMUNOL, V134, P3265; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BUTTERFIELD K, 1989, J EXP MED, V169, P1461, DOI 10.1084/jem.169.4.1461; CONRAD P, 1992, J IMMUNOL, V149, P1833; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DENNING SM, 1990, J IMMUNOL, V144, P7; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FELL HP, 1992, J BIOL CHEM, V267, P15552; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUAGLIARDI L, 1990, NATURE, V345, P172; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HOLT GD, 1985, J IMMUNOL, V135, P399; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LIU ZR, 1992, J EXP MED, V175, P1663, DOI 10.1084/jem.175.6.1663; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MILLER J, 1990, J IMMUNOL, V144, P334; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MOST J, 1992, J IMMUNOL, V148, P1635; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; MURAKAMI S, 1991, J IMMUNOL, V146, P1422; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NORTON SD, 1992, J IMMUNOL, V149, P1556; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROSAMOND S, 1988, J IMMUNOL, V139, P1946; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANT AJ, 1985, J IMMUNOL, V135, P416; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIVAK LE, 1987, J IMMUNOL, V138, P1319; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; YAGI JJ, 1990, J IMMUNOL, V144, P892	89	215	217	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					257	268		10.1016/0092-8674(93)90417-O	http://dx.doi.org/10.1016/0092-8674(93)90417-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343954				2022-12-24	WOS:A1993LP72600007
J	WITCHER, DR; DEWAARD, M; SAKAMOTO, J; FRANZINIARMSTRONG, C; PRAGNELL, M; KAHL, SD; CAMPBELL, KP				WITCHER, DR; DEWAARD, M; SAKAMOTO, J; FRANZINIARMSTRONG, C; PRAGNELL, M; KAHL, SD; CAMPBELL, KP			SUBUNIT IDENTIFICATION AND RECONSTITUTION OF THE N-TYPE CA2+ CHANNEL COMPLEX PURIFIED FROM BRAIN	SCIENCE			English	Article							SENSITIVE CALCIUM-CHANNEL; CONOTOXIN GVIA RECEPTOR; OMEGA-CONOTOXIN; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; TRANSMITTER RELEASE; VERTEBRATE CELLS; DYSTROPHIN; PROTEIN; ALPHA-2-SUBUNIT	Calcium channels play an important role in regulating various neuronal processes, including synaptic transmission and cellular plasticity. The N-type calcium channels, which are sensitive to omega-conotoxin, are involved in the control of transmitter release from neurons. A functional N-type calcium channel complex was purified from rabbit brain. The channel consists of a 230-kilodalton subunit (alpha1B) that is tightly associated with a 160-kilodalton subunit (alpha2delta), a 57-kilodalton subunit (beta3), and a 95-kilodalton glycoprotein subunit. The complex formed a functional calcium channel with the same pharmacological properties and conductance as those of the native omega-conotoxin-sensitive calcium channel in neurons.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; UNIV PENN,DEPT ANAT,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Pennsylvania			De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889; Kahl, Steven/0000-0001-7085-9556				ABE T, 1986, NEUROSCI LETT, V71, P203, DOI 10.1016/0304-3940(86)90559-8; AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; COHEN MW, 1991, J NEUROSCI, V11, P1032; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FOX AP, 1987, J PHYSIOL-LONDON, V394, P173, DOI 10.1113/jphysiol.1987.sp016865; FUKUNAGA H, 1982, MUSCLE NERVE, V5, P687; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAY SD, 1991, J BIOL CHEM, V266, P3287; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PLUMMER MR, 1989, NEURON, V2, P453; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	36	195	197	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					486	489		10.1126/science.8392754	http://dx.doi.org/10.1126/science.8392754			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392754				2022-12-24	WOS:A1993LN62300041
J	BALTENSPERGER, K; KOZMA, LM; CHERNIACK, AD; KLARLUND, JK; CHAWLA, A; BANERJEE, U; CZECH, MP				BALTENSPERGER, K; KOZMA, LM; CHERNIACK, AD; KLARLUND, JK; CHAWLA, A; BANERJEE, U; CZECH, MP			BINDING OF THE RAS ACTIVATOR SON OF SEVENLESS TO INSULIN-RECEPTOR SUBSTRATE-1 SIGNALING COMPLEXES	SCIENCE			English	Article							TYROSINE KINASE; PROTEIN; STIMULATION; ONCOGENES; TRANSDUCTION; EXPRESSION; P21RAS; CELLS; GAP	Signal transmission by insulin involves tyrosine phosphorylation of a major insulin receptor substrate (IRS-1) and exchange of Ras-bound guanosine diphosphate for guanosine triphosphate. Proteins containing Src homology 2 and 3 (SH2 and SH3) domains, such as the p85 regulatory subunit of phosphatidylinositol-3 kinase and growth factor receptor-bound protein 2 (GRB2), bind tyrosine phosphate sites on IRS-1 through their SH2 regions. Such complexes in COS cells were found to contain the heterologously expressed putative guanine nucleotide exchange factor encoded by the Drosophila son of sevenless gene (dSos). Thus, GRB2, p85, or other proteins with SH2-SH3 adapter sequences may link Sos proteins to IRS-1 signaling complexes as part of the mechanism by which insulin activates Ras.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles	BALTENSPERGER, K (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020	Cherniack, Andrew D./0000-0003-0470-0111	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, UNPUB; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KOZMA LM, UNPUB; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TOBE K, 1993, J BIOL CHEM, V268, P11167; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	47	292	294	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1950	1952		10.1126/science.8391166	http://dx.doi.org/10.1126/science.8391166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8391166				2022-12-24	WOS:A1993LJ34900045
J	AARTS, MGM; DIRKSE, WG; STIEKEMA, WJ; PEREIRA, A				AARTS, MGM; DIRKSE, WG; STIEKEMA, WJ; PEREIRA, A			TRANSPOSON TAGGING OF A MALE-STERILITY GENE IN ARABIDOPSIS	NATURE			English	Article							TRANSGENIC TOBACCO; SPM ELEMENT; MAIZE; CELLS	TRANSFORMATION of the well-studied maize transposable elements into other plant species1 should enable transposon tagging methodology2 to be used for the isolation of interesting genes in the heterologous host. Here we describe the isolation of a transposon-tagged male sterile mutant in Arabidopsis thaliana using the maize Enhancer-Inhibitor3,4 transposable element system introduced into Arabidopsis. The mutant lacks pollen, preventing normal self-fertilization, a characteristic important for production of hybrid seed in many crop plants. We have identified an Enhancer-transposase-mediated Inhibitor element insertion responsible for the male sterile phenotype, and isolated the corresponding gene named MALE STERILITY 2. Critical evidence that the Inhibitor-element-containing gene is involved in the male sterile phenotype is provided by the DNA sequences of new excision-derived alleles from independent stable fertile and male sterile progeny of the original mutant.	DLO,CTR PLANT BREEDING & REPROD RES,DEPT MOLEC BIOL,POB 16,6700 AA WAGENINGEN,NETHERLANDS				Pereira, Andy/AAF-4781-2020; Aarts, Mark/O-1706-2019; Aarts, Mark G.M./G-8929-2013	Pereira, Andy/0000-0003-1378-4273; Aarts, Mark/0000-0001-5257-0740; Aarts, Mark G.M./0000-0001-5257-0740				BAKER B, 1986, P NATL ACAD SCI USA, V83, P4844, DOI 10.1073/pnas.83.13.4844; BEDINGER P, 1992, PLANT CELL, V4, P879, DOI 10.1105/tpc.4.8.879; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREY M, 1989, MOL GEN GENET, V217, P172, DOI 10.1007/BF00330958; HANSON MR, 1991, ANNU REV GENET, V25, P461, DOI 10.1146/annurev.ge.25.120191.002333; Kaul, 1988, MALE STERILITY HIGHE; MASSON P, 1989, P NATL ACAD SCI USA, V86, P2219, DOI 10.1073/pnas.86.7.2219; McClintock B., 1954, CARNEGIE I WASH YB, V53, P254; OCHMAN H, 1988, GENETICS, V120, P621; PEREIRA A, 1989, EMBO J, V8, P1315, DOI 10.1002/j.1460-2075.1989.tb03511.x; PEREIRA A, 1985, EMBO J, V4, P17, DOI 10.1002/j.1460-2075.1985.tb02311.x; PETERSON PA, 1953, GENETICS, V38, P682; SCHWARZSOMMER Z, 1985, EMBO J, V4, P591, DOI 10.1002/j.1460-2075.1985.tb03671.x; SCHWARZSOMMER Z, 1985, EMBO J, V4, P2439, DOI 10.1002/j.1460-2075.1985.tb03953.x; SCOTT R, 1991, PLANT SCI, V80, P167, DOI 10.1016/0168-9452(91)90281-C; SPENCER DF, 1992, PLANT MOL BIOL, V20, P347, DOI 10.1007/BF00014506; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANDENELZEN PJM, 1985, PLANT MOL BIOL, V5, P299, DOI 10.1007/BF00020627; VANDERVEEN JH, 1968, EUPHYTICA, V17, P371, DOI 10.1007/BF00056238; WALBOT V, 1992, ANNU REV PLANT PHYS, V43, P49, DOI 10.1146/annurev.pp.43.060192.000405; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N	22	155	197	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 24	1993	363	6431					715	717		10.1038/363715a0	http://dx.doi.org/10.1038/363715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ339	8390620				2022-12-24	WOS:A1993LJ33900054
J	LOHNES, D; KASTNER, P; DIERICH, A; MARK, M; LEMEUR, M; CHAMBON, P				LOHNES, D; KASTNER, P; DIERICH, A; MARK, M; LEMEUR, M; CHAMBON, P			FUNCTION OF RETINOIC ACID RECEPTOR-GAMMA IN THE MOUSE	CELL			English	Article							DIFFERENTIAL PATTERN; NUCLEAR RECEPTORS; BINDING-PROTEINS; EXPRESSION; TRANSCRIPTION; PROMOTER; ISOFORMS; EMBRYOS; ALPHA; GENES	Null mutant mice for retinoic acid receptor gamma2 (RARgamma2) or all RARgamma isoforms were generated. RARgamma2 mutants appeared normal, whereas RARgamma mutants exhibited growth deficiency, early lethality, and male sterility due to squamous metaplasia of the seminal vesicles and prostate. These defects were previously observed in vitamin A-deficient animals and could be prevented by RA administration, demonstrating that RARgamma mediates some of the retinoid signal in vivo. Congenital defects included Harderian gland agenesis, tracheal cartilage malformations, and homeotic transformations along the rostral axial skeleton, establishing a direct link between RA and patterning of the axial skeleton. We also show that in utero RA-induced lumbosacral truncations are mediated by RARgamma. The observed RARgamma null phenotype suggests a high degree of functional redundancy among the RARs. The variable penetrance of some of the observed defects is discussed in light of this redundancy and stochastic variation of gene activity.			LOHNES, D (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.							ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BROOKFIELD J, 1992, EVOL GENET, V2, P553; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONLON RA, 1992, DEVELOPMENT, V116, P357; DE LUCA LM, 1991, FASEB J, V5, P2924; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DUBOULE D, 1992, BIOESSAYS, V14, P375, DOI 10.1002/bies.950140606; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; Hamilton HL, 1952, INTRO EMBRYOLOGY; HOWELL JMG, 1963, J REPROD FERTIL, V5, P159, DOI 10.1530/jrf.0.0050159; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KASTNER P, 1993, IN PRESS VITAMIN HLT; KESSEL M, 1992, DEVELOPMENT, V115, P487; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMURA M, 1962, GENETICS, V47, P713; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KO MSH, 1992, BIOESSAYS, V14, P341, DOI 10.1002/bies.950140510; Kraft J, 1992, RETINOIDS NORMAL DEV, P267; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAUDET V, 1992, Current Biology, V2, P293; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; LIVREA MA, 1993, RETINOIDS; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MOHANTYHEJMADI P, 1992, NATURE, V355, P352, DOI 10.1038/355352a0; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGPAL S, 1993, IN PRESS EMBO J; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; POPPERL H, 1993, MOL CELL BIOL, V13, P257; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J., 1989, MOL CLONING LAB MANU; SHARMA RP, 1993, RETINOIDS, P569; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; THOMPSON JN, 1964, PROC R SOC SER B-BIO, V159, P510, DOI 10.1098/rspb.1964.0017; UNDERWOOD BA, 1984, RETINOIDS, V1, P282; VANPELT AMM, 1991, ENDOCRINOLOGY, V128, P697, DOI 10.1210/endo-128-2-697; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WEBSTER WS, 1986, J CRAN GENET DEV BIO, V6, P211; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yu Victor C., 1992, Current Opinion in Biotechnology, V3, P597, DOI 10.1016/0958-1669(92)90002-Z; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	84	528	542	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					643	658		10.1016/0092-8674(93)90246-M	http://dx.doi.org/10.1016/0092-8674(93)90246-M			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	8388780				2022-12-24	WOS:A1993LD83000005
J	SURANA, R; QUINN, F; PURI, P				SURANA, R; QUINN, F; PURI, P			IS IT NECESSARY TO PERFORM APPENDECTOMY IN THE MIDDLE OF THE NIGHT IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS		OUR LADYS HOSP SICK CHILDREN,DUBLIN 12,IRELAND	Our Ladys Children Hospital Crumlin								Buck N, 1987, REPORT CONFIDENTIAL; MAXWELL JM, 1991, AM SURGEON, V57, P282; NEILSON IR, 1990, J PEDIATR SURG, V25, P1113, DOI 10.1016/0022-3468(90)90742-R; WILLIAMS N, 1991, ARCH DIS CHILD, V66, P1270, DOI 10.1136/adc.66.11.1270; WYATT MG, 1990, ANN ROY COLL SURG, V72, P236	5	84	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1168	1168		10.1136/bmj.306.6886.1168	http://dx.doi.org/10.1136/bmj.306.6886.1168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8369045	Green Published, Bronze			2022-12-24	WOS:A1993LA68500022
J	RASTINEJAD, F; BLAU, HM				RASTINEJAD, F; BLAU, HM			GENETIC COMPLEMENTATION REVEALS A NOVEL REGULATORY ROLE FOR 3' UNTRANSLATED REGIONS IN GROWTH AND DIFFERENTIATION	CELL			English	Article							NF-KAPPA-B; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; ACTIN GENE; MESSENGER-RNAS; MUSCLE-CELLS; ALPHA-ACTIN; TRANSIENT HETEROKARYONS; MOLECULAR-CLONING; MAMMALIAN-CELLS	Differentiated skeletal muscle cells cease dividing and sustain expression of a battery of tissue-specific genes. To identify regulators of growth and differentiation, we used a genetic complementation approach. Following introduction of a cDNA expression library into a differentiation-defective myoblast mutant (NMU2), cDNAs were isolated that activated muscle-specific promoters. The complementing cDNAs were identified as muscle structural genes, troponin I, tropomyosin, and alpha-cardiac actin, and their activity was mapped to the 3' untranslated region (3'UTR). The 3'UTRs augmented the differentiation of wild-type muscle cells. Upon expression in 10T1/2 fibroblasts, proliferation was suppressed, indicating that the effects of the 3'UTRs are not limited to myogenic cells. These data suggest that 3'UTRs of certain differentiation-specific RNAs are trans-acting regulators in a feedback loop that inhibits cell division and promotes differentiation.			RASTINEJAD, F (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.				NICHD NIH HHS [HD-07249, HD-20203] Funding Source: Medline; NIGMS NIH HHS [GM-14588] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014588] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACK RA, 1985, P NATL ACAD SCI USA, V82, P124, DOI 10.1073/pnas.82.1.124; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAU HM, 1988, CELL, V53, P673, DOI 10.1016/0092-8674(88)90082-7; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOUCK N, 1982, MOL CELL BIOL, V2, P97, DOI 10.1128/MCB.2.2.97; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELALUNA S, 1988, GENE, V62, P121; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRECO A, 1987, P NATL ACAD SCI USA, V84, P1565, DOI 10.1073/pnas.84.6.1565; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNNING P, 1984, J MOL EVOL, V20, P202, DOI 10.1007/BF02104727; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; HARDEMAN EC, 1988, J CELL BIOL, V106, P1027, DOI 10.1083/jcb.106.4.1027; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HERSKOWITZ I, 1985, COLD SPRING HARB SYM, V50, P565, DOI 10.1101/SQB.1985.050.01.069; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN CS, 1988, MOL CELL BIOL, V8, P160, DOI 10.1128/MCB.8.1.160; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PAN LC, 1992, SOMAT CELL MOLEC GEN, V18, P163, DOI 10.1007/BF01233162; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PETERSON CA, 1992, DEV BIOL, V151, P626, DOI 10.1016/0012-1606(92)90201-Q; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHARP SB, 1989, GENE, V80, P293, DOI 10.1016/0378-1119(89)90293-X; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WELLS D, 1987, NUCLEIC ACIDS RES, V15, P2871, DOI 10.1093/nar/15.7.2871; WRIGHT WE, 1984, J CELL BIOL, V98, P436, DOI 10.1083/jcb.98.2.436; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	86	246	255	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					903	917		10.1016/0092-8674(93)90579-F	http://dx.doi.org/10.1016/0092-8674(93)90579-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8384533				2022-12-24	WOS:A1993KU17500011
J	FRIEDEN, TR; STERLING, T; PABLOSMENDEZ, A; KILBURN, JO; CAUTHEN, GM; DOOLEY, SW				FRIEDEN, TR; STERLING, T; PABLOSMENDEZ, A; KILBURN, JO; CAUTHEN, GM; DOOLEY, SW			THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES	Background. in the past decade the incidence of tuberculosis has increased nationwide and more than doubled in New York City, where there have been recent nosocomial outbreaks of multidrug-resistant tuberculosis. Methods. We collected information on every patient in New York City with a positive culture for Mycobacterium tuberculosis during April 1991. Drug-susceptibility testing was performed at the Centers for Disease Control and Prevention. Results. Of the 518 patients with positive cultures, 466 (90 percent) had isolates available for testing. Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin. Of the 239 patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin. Among the patients who had never been treated, the proportion with resistance to one or more drugs increased from 10 percent in 1982 through 1984 to 23 percent in 1991 (P = 0.003). Patients who had never been treated and who were infected with the human immunodeficiency virus (HIV) or reported injection-drug use were more likely to have resistant isolates. Among patients with the acquired immunodeficiency syndrome, those with resistant isolates were more likely to die during follow-up through January 1992 (80 percent vs. 47 percent, P = 0.02). A history of antituberculosis therapy was the strongest predictor of the presence of resistant organisms (odds ratio, 2.7; P < 0.001). Conclusions. There has been a marked increase in drug-resistant tuberculosis in New York City. Previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance. Measures to control and prevent drug-resistant tuberculosis are urgently needed.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,PROGRAM OFF,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV MYCOT & BACTERIAL DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA; NEW YORK CITY DEPT HLTH,DIV DIS INTERVENT,NEW YORK,NY 10013; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene; Columbia University; NewYork-Presbyterian Hospital								ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BENDOV I, 1987, AM REV RESPIR DIS, V135, P1307; BERLINER DS, 1987, AVIAT SPACE ENVIR MD, V58, P83; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; COSTELLO HD, 1980, AM REV RESPIR DIS, V121, P313; Dean A. G., 1990, EPI INFO VERSION 5 W; DIPERRI G, 1989, LANCET, V2, P1502; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; GIBSON J, 1986, TUBERCLE, V67, P119, DOI 10.1016/0041-3879(86)90005-X; Goble M, 1986, Semin Respir Infect, V1, P220; Grange J M, 1990, Bull Int Union Tuberc Lung Dis, V65, P57; HOBBY GL, 1964, AM REV RESPIR DIS, V89, P337; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Kent PT, 1985, GUIDE LEVEL 3 LAB; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V244, P2736, DOI 10.1001/jama.244.24.2736; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; Safi M I, 1988, J Pak Med Assoc, V38, P73; SALOMON N, 1991, 31ST INT C ANT AG CH, P152; SBARBARO JA, 1985, AM J MED, V79, P34, DOI 10.1016/0002-9343(85)90085-3; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SHENNAN D H, 1964, Tubercle, V45, P1, DOI 10.1016/S0041-3879(64)80080-5; STEINER P, 1986, AM REV RESPIR DIS, V134, P446; Valenzuela P, 1988, Bull Pan Am Health Organ, V22, P175; VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59; 1991, MMWR MORB MORTAL WKL, V40, P585; 1983, MMWR MORB MORTAL WKL, V32, P521; 1989, HIVCID990006 CTR DIS; 1990, SAS LANGUAGE VERSION; 1991, MMWR MORB MORTAL WKL, V40, P129; 1987, MMWR MORB MORTAL WKL, V36, P785; 1989, MMWR MORB MORTAL WKL, V38, P313; 1991, TUBERCULOSIS NEW YOR; 1990, MMWR MORB MORTAL WKL, V39, P718	43	776	806	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					521	526		10.1056/NEJM199302253280801	http://dx.doi.org/10.1056/NEJM199302253280801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8381207				2022-12-24	WOS:A1993KP05300001
J	NATARAJAN, S; KAUL, S; MIRON, A; BASTIA, D				NATARAJAN, S; KAUL, S; MIRON, A; BASTIA, D			A 27 KD PROTEIN OF ESCHERICHIA-COLI PROMOTES ANTITERMINATION OF REPLICATION INVITRO AT A SEQUENCE-SPECIFIC REPLICATION TERMINUS	CELL			English	Article							DNA-BINDING PROTEIN; ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; PLASMID REPLICATION; TERMINATION PROTEIN; BACILLUS-SUBTILIS; IDENTIFICATION; HELICASE; SITES; R6K	We have discovered a 27 kd protein of E. coli that binds to a terminator site (tau)-terminator protein (ter) complex and abrogates the replication fork-arresting activity of ter protein in vitro. The 27 kd protein also neutralizes the contrahelicase activity of ter protein, allowing dnaB helicase to unwind DNA past a tau-ter complex. The stimulatory activity of low levels of ter protein on helicase II is also abolished by the 27 kd protein. The binding of the 27 kd protein to a tau-ter complex does not appear to dissociate the ter protein from the DNA. Although the in vivo function of the 27 kd protein is unknown at this time, it has the major attributes of a novel replication antiterminator in vitro.			NATARAJAN, S (corresponding author), DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710, USA.							BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BASTIA D, 1981, GENE, V41, P81; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; HIASA H, 1992, J BIOL CHEM, V267, P11379; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V73, P3927; LEBOWITZ JO, 1976, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOUARN J, 1977, J MOL BIOL, V115, P295, DOI 10.1016/0022-2836(77)90156-5; LOVETT MA, 1975, P NATL ACAD SCI USA, V72, P2905, DOI 10.1073/pnas.72.8.2905; MACALLISTER T, 1990, P NATL ACAD SCI USA, V87, P2828, DOI 10.1073/pnas.87.7.2828; MATSON SW, 1986, J BIOL CHEM, V261, P169; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; NATARAJAN S, 1991, P NATL ACAD SCI USA, V88, P3867, DOI 10.1073/pnas.88.9.3867; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6	29	11	11	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					113	120		10.1016/0092-8674(93)90055-U	http://dx.doi.org/10.1016/0092-8674(93)90055-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8380756				2022-12-24	WOS:A1993KG95500015
J	CASEY, LC; BALK, RA; BONE, RC				CASEY, LC; BALK, RA; BONE, RC			PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						SEPSIS SYNDROME; TUMOR NECROSIS FACTORS; LIPOPOLYSACCHARIDES; INTERLEUKIN-1; INTERLEUKIN-6	TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; HUMAN SEPTIC SHOCK; MONOCLONAL-ANTIBODY; SERUM LEVELS; INTERLEUKIN-1; CACHECTIN; INJURY; ASSOCIATION; BACTEREMIA	Objective: To determine whether plasma tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and lipopolysaccharide are detectable in patients when they first present with the sepsis syndrome and to determine whether levels correlate with patient survival. Design: Prospective study comparing patients with the sepsis syndrome, critically ill patients without sepsis, and normal healthy volunteers. Setting: Tertiary care hospital affiliated with a medical school. Patients: The study included 97 consecutive patients on a medical service who met the criteria for the sepsis syndrome; 20 critically ill patients without sepsis who were in the medical intensive care unit; and 20 healthy volunteers who served as comparison groups. Measurements: Plasma tumor necrosis factor-alpha, IL-1beta, interleukin-6, and endotoxin (lipopolysaccharide) levels were measured when a patient was first identified as having the sepsis syndrome. Survival was defined as being alive 30 days after the sepsis syndrome was diagnosed. Results. Fifty-four percent of patients with the sepsis syndrome had detectable levels of TNF-alpha (median, 26 pg/mL; range, nondetectable to 1000 pg/mL); 37% had detectable levels of IL-1 (median, 20 pg/mL; range, nondetectable to 2850 pg/mL); 80% had detectable levels of IL-6 (median, 415 pg/mL; range, nondetectable to 2380 pg/mL); and 89% had detectable levels of lipopolysaccharide (median, 2.6; range, nondetectable to 12.5 endotoxin units [EU]/mL). In all cases, levels were higher than those in critically ill patients without sepsis and normal healthy controls (P < 0.001 for all comparisons). Plasma levels of TNF-alpha, IL-1beta, IL-6, and lipopolysaccharide were detectable in patients regardless of culture status. The IL-6 level was 69%. (95% CI, 30% to 108%) higher in patients who died compared with those who survived. The scores for the individual levels of TNF-alpha IL-1beta, IL-6, and lipopolysaccharide were summed to arrive at a total lipopolysaccharide-cytokine score, and mortality increased with lipopolysaccharide-cytokine score (P < 0.001). Conclusions: Patients with the sepsis syndrome have detectable levels of circulating TNF-alpha, IL-1, IL-6, and lipopolysaccharide independent of culture-documented infection. Lipopolysaccharide and cytokines may play a pathogenic role in sepsis, and the combination of several elevated factors may be important in determining patient survival.			CASEY, LC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PULM & CRIT CARE MED, 1725 W HARRISON ST, SUITE 306, CHICAGO, IL 60612 USA.		Fahimifar, Sepideh/M-5303-2019					ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; AYALA A, 1991, AM J PHYSIOL, V260, pR167, DOI 10.1152/ajpregu.1991.260.1.R167; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DAVIDSON M, 1976, JAMA-J AM MED ASSOC, V235, P158, DOI 10.1001/jama.235.2.158; DEITCH EA, 1987, ARCH SURG-CHICAGO, V122, P185; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; ELIAS JA, 1987, J IMMUNOL, V138, P3812; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GUICE KS, 1989, ANN SURG, V210, P740, DOI 10.1097/00000658-198912000-00008; HACK CE, 1989, BLOOD, V74, P1704; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LUGER A, 1986, CRIT CARE MED, V14, P458, DOI 10.1097/00003246-198605000-00004; MARANO MA, 1988, ARCH SURG-CHICAGO, V123, P1383; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MAURY CPJ, 1987, J EXP MED, V166, P1132, DOI 10.1084/jem.166.4.1132; MAURY CPJ, 1989, ARTHRITIS RHEUM, V32, P146, DOI 10.1002/anr.1780320206; MICHIE HR, 1988, SURGERY, V104, P280; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MORRISON DC, 1978, AM J PATHOL, V93, P526; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; OFFNER F, 1990, J LAB CLIN MED, V116, P100; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PREISER JC, 1991, CYTOKINE, V3, P1, DOI 10.1016/1043-4666(91)90002-U; ROTH RI, 1990, J LAB CLIN MED, V116, P153; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WHITE CW, 1987, J CLIN INVEST, V79, P1868, DOI 10.1172/JCI113029; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR, V39, P31	44	880	922	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					771	778		10.7326/0003-4819-119-8-199310150-00001	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379598				2022-12-24	WOS:A1993MB49600001
J	MODELL, M				MODELL, M			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - A GENERAL-PRACTITIONERS PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							REPRODUCTIVE-BEHAVIOR; PRENATAL-DIAGNOSIS; CONSEQUENCES; COMMUNITY; ATTITUDES; FAMILIES; RISK	The identification of the gene for cystic fibrosis has led to the possibility of population based screening for carriers of cystic fibrosis to identify couples at risk of having an affected child. Pilot studies have shown that screening is feasible and does not cause untoward anxiety, though the uptake of testing varies considerably with the setting and method of invitation. Screening offered at times when individuals (and health professionals) perceive it as directly relevant will probably gradually become established in the United Kingdom. This review examines the role of general practice in genetic carrier screening as exemplified by cystic fibrosis. General practice has a pivotal role from the beginning in providing individuals and couples with information, facilitating testing of patients' relatives and of carriers identified by screening elsewhere (such as antenatal clinics), and offering testing in the context of reproduction. Screening for the cystic fibrosis gene will probably be followed by other genetic screening programmes.			MODELL, M (corresponding author), UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY HLTH CARE, LONDON N19 5NF, ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BORGO G, 1992, PRENATAL DIAG, V12, P821, DOI 10.1002/pd.1970121008; BOUE J, 1991, PRENATAL DIAG, V11, P209, DOI 10.1002/pd.1970110402; BURN J, 1993, BRIT MED J, V306, P1558, DOI 10.1136/bmj.306.6892.1558; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HARRIS HJ, 1992, LANCET, V339, P1539, DOI 10.1016/0140-6736(92)91303-P; HARRIS R, 1992, J ROY COLL PHYS LOND, V26, P437; KABACK M, 1984, CYSTIC FIBROSIS HORI, P15; MAGNAY D, 1992, J ROY COLL PHYS LOND, V26, P69; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL B, 1980, BMJ-BRIT MED J, V280, P1347, DOI 10.1136/bmj.280.6228.1347; MODELL B, 1991, WHO EUROPEAN SERIES, V38; Modell M., 1992, HLTH BABY CONGENITAL; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WALD NJ, 1991, LANCET, V338, P1318, DOI 10.1016/0140-6736(91)92605-2; WALTERS S, 1993, BRIT MED J, V306, P549, DOI 10.1136/bmj.306.6877.549; WATSON EK, 1992, LANCET, V340, P217, DOI 10.1016/0140-6736(92)90477-K; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WILLIAMSON R, 1993, NAT GENET, V3, P195, DOI 10.1038/ng0393-195; 1989, REPORT PRENATAL DIAG	23	19	19	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 2	1993	307	6908					849	852		10.1136/bmj.307.6908.849	http://dx.doi.org/10.1136/bmj.307.6908.849			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA293	8401130	Bronze, Green Published			2022-12-24	WOS:A1993MA29300025
J	SILVENNOINEN, O; SCHINDLER, C; SCHLESSINGER, J; LEVY, DE				SILVENNOINEN, O; SCHINDLER, C; SCHLESSINGER, J; LEVY, DE			RAS-INDEPENDENT GROWTH-FACTOR SIGNALING BY TRANSCRIPTION FACTOR TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							DNA-BINDING PROTEIN; C-FOS PROMOTER; INTERFERON-ALPHA; STIMULATED TRANSCRIPTION; KINASE-ACTIVITY; SH3 DOMAINS; ACTIVATION; RECEPTOR; CELLS; REQUIREMENT	Interferons induce transcriptional activation through tyrosine phosphorylation of the latent, cytoplasmic transcription factor interferon-stimulated gene factor-3 (ISGF-3). Growth factors and cytokines were found to use a similar pathway: The 91-kilodalton subunit of ISGF-3 was activated and tyrosine phosphorylated in response to epidermal growth factor (EGF), platelet-derived growth factor, and colony stimulating factor-1. The tyrosine phosphorylated factor acquired DNA binding activity and accumulated in nuclei. Activation required the major sites for autophosphorylation on the EGF receptor that bind Src homology region 2 domain-containing proteins implicated in Ras activation. However, activation of this factor was independent of the normal functioning of Ras.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	New York University; New York University; New York University; Columbia University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI N, UNPUB; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZAKISADCOCK M, 1993, NATURE, V363, P45; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, UNPUB; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x	47	357	364	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1736	1739		10.1126/science.8378775	http://dx.doi.org/10.1126/science.8378775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378775				2022-12-24	WOS:A1993LY58400027
J	ROY, AL; MALIK, S; MEISTERERNST, M; ROEDER, RG				ROY, AL; MALIK, S; MEISTERERNST, M; ROEDER, RG			AN ALTERNATIVE PATHWAY FOR TRANSCRIPTION INITIATION INVOLVING TFII-I	NATURE			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; GENE-TRANSCRIPTION; COMPLEX; ACTIVATION; PROMOTER	THE minimal promoter elements required for initiation by RNA polymerase II include the TATA box and/or an initiator element (Inr) at or near the transcription start site1-4. Studies of the adeno-virus major late core promoter (containing both elements) have demonstrated an initiation pathway that involves binding of the transcription factor TFIID (or the derived subunit, the TATA-binding protein TBP (TFIIDtau)) to the TATA element, which is facilitated by transcription factor TFIIA, followed by sequential interactions of other general factors4-8. Here we describe a novel pathway that requires an intact Inr and the Inr-binding factor TFII-I (ref. 3). Sequential addition of the general factors generated TFII-I-dependent preinitiation complexes different from those formed with TFIIA. Furthermore, TBP bound cooperatively (with only TFII-I) to an Inr-containing TATA-less promoter, suggesting a means for activation of TATA-less promoters, which nonetheless require TFIID (refs 9-11). These observations provide support for functionally distinct pathways which could be subject to differential regulation by specific activators or repressors.			ROY, AL (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P9999; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; INOSTROZA JA, 1992, CELL, V70, P477; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEITERERNST M, 1991, CELL, V67, P557; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	20	151	153	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					355	359		10.1038/365355a0	http://dx.doi.org/10.1038/365355a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377828				2022-12-24	WOS:A1993LY49600057
J	GACZYNSKA, M; ROCK, KL; GOLDBERG, AL				GACZYNSKA, M; ROCK, KL; GOLDBERG, AL			GAMMA-INTERFERON AND EXPRESSION OF MHC GENES REGULATE PEPTIDE HYDROLYSIS BY PROTEASOMES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION; LYMPHOCYTE-T; LINKED LMP; PROTEINASE; UBIQUITIN; SUBUNITS	THE presentation of intracellular proteins to the immune system requires their degradation to small peptides1,2 that then become associated with major histocompatibility complex (MHC) class I molecules3,4. The generation of these peptides may involve the 20S or 26S proteasome particles, which contain multiple proteolytic activities5-14 including distinct sites that preferentially cleave small peptides on the carboxyl side of hydrophobic, basic or acidic residues6,13,14. Degradation of most cell proteins requires their conjugation to ubiquitin before hydrolysis by the 26S proteasome6,13-16. This large complex contains the 20S proteasome as its proteolytic core6,14,16-18. This ubiquitin-dependent proteolytic pathway is implicated in MHC class I presentation11,12. Gamma-interferon (gamma-IFN, a stimulator of antigen presentation1, induces a subclass of proteasomes that contain two MHC-encoded subunits, LMP2 and 7 (refs 5-10). Here we show that gamma-interferon alters the peptidase activities of the 20S and 26S proteasomes without affecting the rates of breakdown of proteins or of ubiquitinated proteins. By enhancing the expression of MHC genes, gamma-IFN increases the proteasomes' capacity to cleave small peptides after hydrophobic and basic residues but reduces cleavage after acidic residues. Moreover, proteasomes of mutants lacking LMP subunits show decreased rates of cleavage after hydrophobic and basic residues. Thus, gamma-IFN and expression of these MHC genes should favour the production by proteasomes of the types of peptides found on MHC class I molecules, which terminate almost exclusively with hydrophobic or basic residues19.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GACZYNSKA, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.							AHN JY, 1991, J BIOL CHEM, V266, P15746; ARMON T, 1990, J BIOL CHEM, V265, P20723; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FINLEY D, 1991, REV CELL BIOL, V7, P25; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PARHAM P, 1992, NATURE, V360, P300, DOI 10.1038/360300a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V218, P1; SCHERRER K, 1990, MOL BIOL REP, V14, P1, DOI 10.1007/BF00422709; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WAXMAN L, 1987, J BIOL CHEM, V262, P2451; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	28	535	546	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					264	267		10.1038/365264a0	http://dx.doi.org/10.1038/365264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396732				2022-12-24	WOS:A1993LX47100058
J	ZHU, TF; MO, HM; WANG, N; NAM, DS; CAO, YZ; KOUP, RA; HO, DD				ZHU, TF; MO, HM; WANG, N; NAM, DS; CAO, YZ; KOUP, RA; HO, DD			GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF HIV-1 IN PATIENTS WITH PRIMARY INFECTION	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL TROPISM; SOLUBLE CD4; GP120; TRANSMISSION; DEFINITION; MACROPHAGE; VARIANTS; DISEASE; REGIONS	Better characterization of human immunodeficiency virus-type 1 (HIV-1) in patients with primary infection has important implications for the development of an acquired immunodeficiency syndrome (AIDS) vaccine because vaccine strategies should target viral isolates with the properties of transmitted viruses. In five HIV-1 seroconverters, the viral phenotype was found to be uniformly macrophage-tropic and non-syncytium-inducing. Furthermore, the viruses were genotypically homogeneous within each patient, but a common signature sequence was not discernible among transmitted viruses. In the two cases where the sexual partners were also studied, the sequences of the transmitted viruses matched best with minor variants in the blood of the transmitters. There was also a stronger pressure to conserve sequences in gp120 than in gp41, nef, and p17, suggesting that a selective mechanism is involved in transmission.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016	New York University			Zhu, Tuofu/G-6158-2010		NIAID NIH HHS [AI24030, AI25541, AI27742] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025541, P30AI027742, R01AI024030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CICHUTEK K, 1992, P NATL ACAD SCI USA, V89, P7365, DOI 10.1073/pnas.89.16.7365; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KOUP RA, UNPUB; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU T, UNPUB	28	1110	1144	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1179	1181		10.1126/science.8356453	http://dx.doi.org/10.1126/science.8356453			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356453				2022-12-24	WOS:A1993LU58600035
J	FORREST, S				FORREST, S			GENETIC ALGORITHMS - PRINCIPLES OF NATURAL-SELECTION APPLIED TO COMPUTATION	SCIENCE			English	Article								A genetic algorithm is a form of evolution that occurs on a computer. Genetic algorithms are a search method that can be used for both solving problems and modeling evolutionary systems. With various mapping techniques and an appropriate measure of fitness, a genetic algorithm can be tailored to evolve a solution for many types of problems, including optimization of a function or determination of the proper order of a sequence. Mathematical analysis has begun to explain how genetic algorithms work and how best to use them. Recently, genetic algorithms have been used to model several natural evolutionary systems, including immune systems.			FORREST, S (corresponding author), UNIV NEW MEXICO, DEPT COMP SCI, ALBUQUERQUE, NM 87131 USA.							[Anonymous], 1991, HDB GENETIC ALGORITH; ANTONISSE HJ, 1987, 2ND P INT C GEN ALG, P69; Axelrod R., 1987, GENETIC ALGORITHMS S; AXELROD R, 1986, AM POLIT SCI REV, P80; Back T, 1993, EVOL COMPUT, V1, P1, DOI 10.1162/evco.1993.1.1.1; BEAN JC, IN PRESS J COMPUT; BELEW RK, 1991, 4TH P INT C GEN ALG; BERGMAN A, 1992, PHYSICA D, V56, P57, DOI 10.1016/0167-2789(92)90050-W; Bethke A., 1980, THESIS U MICHIGAN AN; Booker L. B, 1993, FDN GENETIC ALGORITH, V2, P29; BOOKER LB, IN PRESS BASIC PARAD, V1; BOX GEP, 1957, APPLIED STATISTICS, V6, P81; Davidor Y., 1991, WORLD SCI SERIES ROB; DAVIS L, 1987, 2ND P INT C GEN ALG, P252; Davis LD, 1991, HDB GENETIC ALGORITH, DOI DOI 10.1.1.87.3586; Dawkins R, 1989, ARTIF LIFE, P201; DeJong K, 1975, THESIS U MICHIGAN AN; FARMER JD, 1986, PHYSICA D, V22, P187, DOI 10.1016/0167-2789(86)90240-X; FOGEL DB, 1990, BIOL CYBERN, V63, P111, DOI 10.1007/BF00203032; Fogel L. J., 1966, ARTIF INTELL; FORREST S, IN PRESS EVOL COMPUT; FORREST S, IN PRESS MACH LEARN; GLOVER DE, 1987, GENETIC ALGORITHMS S, P12; Goldberg D. E., 1991, Complex Systems, V5, P139; Goldberg D. E., 1992, Complex Systems, V6, P333; Goldberg D. E., 1989, Complex Systems, V3, P153; Goldberg D. E., 1989, COMPLEX SYST, V3, P493, DOI DOI 10.1007/978-1-4757-3643-4; Goldberg D.E., 1985, P INT C GEN ALG THEI, V154, P154; GOLDBERG DE, IN PRESS COMMUN ACM; GOLDBERG DE, 1989, GENETIC ALGORITHSM S; Grefenstette J., 1985, P 1 INT C GEN ALG TH, V160, P160; GREFENSTETTE JJ, 1987, 2ND P INT C GEN ALG; GREFENSTETTE JJ, 1989, 3RD P INT C GEN ALG; GREFENSTETTE JJ, 1985, P INT C GENETIC ALGO; HIGHTOWER R, IN PRESS 2ND EUR C A; HILLIS WD, 1990, PHYSICA D, V42, P228, DOI 10.1016/0167-2789(90)90076-2; Holland J., 1962, J ACM, V3, P297; Holland J. H., 1986, INDUCTION PROCESSES; Holland J.H., 1975, ADAPTATION NATURAL A; HOLLAND JH, IN PRESS INTEGRATIVE; HOLLAND JH, 1988, EVOLUTION LEARNING C; Koza JR, 1992, GENETIC PROGRAMMING; Liepins G. E., 1990, Journal of Experimental and Theoretical Artificial Intelligence, V2, P101, DOI 10.1080/09528139008953717; MANDERICK B, 1991, 4TH P INT C GEN ALG; MUHLENBEIN H, 1988, PARALLEL COMPUT, V7, P65, DOI 10.1016/0167-8191(88)90098-1; PACKARD NH, 1990, COMPLEX SYST, V4; Rechenberg I, 1965, CYBERNETIC SOLUTION, V1122; ROS JP, 1993, FDN GENETIC ALGORITH, V2, P257; SCHAFER CG, 1987, 2ND P INT C GEN ALG, P50; SCHAFER JD, 1989, 3RD P INT C GEN ALGO; Schaffer J, 1985, P 1 INT C GEN ALG, P93; SCHAFFER JD, 1989, 3RD P INT C GEN ALG; SCHRAUDOLPH NN, 1992, MACH LEARN, V9, P9, DOI 10.1007/BF00993252; SIMS K, 1991, COMP GRAPH, V25, P319, DOI 10.1145/127719.122752; SMITH D, 1985, P INT C GENETIC ALGO, P202; Smith R. E., 1992, Complex Systems, V6, P251; SMITH RE, IN PRESS EVOL COMPUT; SYSWERDA G, 1989, 3RD P INT C GEN ALGO; Tanese R., 1989, DISTRIBUTED GENETIC; ULDER NLJ, 1991, LECT NOTES COMPUT SC, V496, P109, DOI 10.1007/BFb0029740; Walsh JL, 1923, AM J MATH, V45, P5, DOI 10.2307/2387224; Wilson S. W., 1987, Machine Learning, V2, P199, DOI 10.1023/A:1022655214215; [No title captured]	63	571	599	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					872	878		10.1126/science.8346439	http://dx.doi.org/10.1126/science.8346439			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346439				2022-12-24	WOS:A1993LR89700027
J	RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C				RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C			DOWN-REGULATION OF THE DROSOPHILA MORPHOGEN BICOID BY THE TORSO RECEPTOR-MEDIATED SIGNAL-TRANSDUCTION CASCADE	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; HEAD DEVELOPMENT; TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATOR; ORTHODENTICLE GENE; ANTERIOR PATTERN; TERMINAL ANLAGEN; EMPTY SPIRACLES; GAP GENE; EMBRYO	Anterior body pattern in Drosophila is specified by the graded distribution of the bicoid protein (bcd), which activates subordinate genes in distinct anterior domains. Subsequently, transcription of these target genes is repressed at the anterior pole owing to the activity of the receptor tyrosine kinase torso (tor). We show that both activation by bcd and repression by tor can be reproduced by a minimal promoter containing only bcd-binding sites upstream of a naive transcriptional start site. Repression requires the D-raf kinase and is associated with phosphorylation of bcd protein. Repression does not require either tailless or huckebein, which were previously thought to constitute the sole zygotic output of the tor signaling system. Finally, addition of a heterologous transcriptional activation domain to bcd renders the protein insensitive to tor-mediated repression. We propose that phosphorylation resulting from the activity of the tor signal transduction cascade down-regulates transcriptional activation by the bcd morphogen.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RONCHI, E (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.			Desplan, Claude/0000-0002-6914-1413; Treisman, Jessica/0000-0002-7453-107X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CHOU TB, 1992, GENETICS, V131, P643; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT S1, V13, P1; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, CELL, V59, P553; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	45	90	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					347	355		10.1016/0092-8674(93)90425-P	http://dx.doi.org/10.1016/0092-8674(93)90425-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343961				2022-12-24	WOS:A1993LP72600015
J	RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H				RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H			PATIENTS WITH FATIGUE IN GENERAL-PRACTICE - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the characteristics of patients attending their general practitioners and complaining of fatigue or being ''tired all the time.'' Design-Prospective study of cohort aged 16 years and older with follow up at two weeks and by questionnaires at two and six months. Subjects-220 patients (164 women) with mean age 43 years and an age-sex matched comparison group. Settings-Doctors and patients in four practices in Lancashire, Mid Glamorgan, Suffolk, and Surrey. Main outcome measure-General clinical data, results from standard group of laboratory tests, fatigue questionnaire, and 12 item general health questionnaire. Results-Over twice as many patients with fatigue had high scores on the health questionnaire compared with the comparison group (156 (75%) v 69 (34%)). Results of laboratory tests were abnormal and contributed to the diagnosis in 19 patients. 59 out of 102 patients who responded had high fatigue scores six months later. Patients with persistent fatigue were more likely to have a history of anxiety or depression and to have had fatigue for more than three months on entry to the study. Conclusions-Women are particularly at risk of fatigue. The outcome is better if patients have had symptoms for three months or less or there is no history of emotional illness.	UNIV LEEDS, ST JAMES HOSP, DEPT GEN PRACTICE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; OLD SCH SURG, PONTYCLUN, M GLAM, WALES; THE SURGERY, SUFFOLK IP16 4ES, ENGLAND	Saint James's University Hospital; University of Leeds	RIDSDALE, L (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND.			Ridsdale, Leone/0000-0002-2234-2859				CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Hannay D R, 1978, J R Coll Gen Pract, V28, P492; JERRETT WA, 1981, PRACTITIONER, V225, P731; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; MORRELL DC, 1972, J ROY COLL GEN PRACT, V22, P295; RIDSDALE L, 1991, BRIT MED J, V303, P1490, DOI 10.1136/bmj.303.6816.1490; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	11	85	85	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					103	106		10.1136/bmj.307.6896.103	http://dx.doi.org/10.1136/bmj.307.6896.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343705	Green Published, Bronze			2022-12-24	WOS:A1993LM58500027
J	HOLLOWAY, SL; GLOTZER, M; KING, RW; MURRAY, AW				HOLLOWAY, SL; GLOTZER, M; KING, RW; MURRAY, AW			ANAPHASE IS INITIATED BY PROTEOLYSIS RATHER THAN BY THE INACTIVATION OF MATURATION-PROMOTING FACTOR	CELL			English	Article							DNA TOPOISOMERASE-II; PROTO-ONCOGENE PRODUCT; XENOPUS EGGS; SACCHAROMYCES-CEREVISIAE; MICROTUBULE DYNAMICS; MULTIUBIQUITIN CHAIN; MITOTIC SPINDLE; CELL-CYCLE; M-PHASE; MITOSIS	We have used frog egg extracts that assemble mitotic spindles to identify the event that triggers sister chromatid separation. Adding a nondegradable form of cyclin B prevents maturation-promoting factor (MPF) inactivation but does not block sister chromatid separation, showing that MPF inactivation is not needed to initiate anaphase. In contrast, adding an N-terminal fragment of cyclin, which acts as a specific competitor for cyclin degradation, produces a dose-dependent delay in MPF inactivation and sister chromatid separation. Methylated ubiquitin, which inhibits ubiquitin-mediated proteolysis, also delays sister chromatid separation, suggesting that ubiquitin-mediated proteolysis is necessary to initiate anaphase. The N-terminal cyclin fragment inhibits chromosome separation even in extracts that contain only nondegradable forms of cyclin, suggesting that proteins other than the known cyclins must be degraded to dissolve the linkage between sister chromatids.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	HOLLOWAY, SL (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.			King, Randall/0000-0001-7882-8180				ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN GL, 1984, J BIOL CHEM, V259, P3560; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HARLOW E, 1988, ANTIBODIES; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER CW, 1990, METHOD ENZYMOL, V182, P721; PELECH SL, 1987, BIOCHEMISTRY-US, V26, P7960, DOI 10.1021/bi00398a062; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0	40	520	534	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1393	1402		10.1016/0092-8674(93)90364-V	http://dx.doi.org/10.1016/0092-8674(93)90364-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8391932	Bronze			2022-12-24	WOS:A1993LL20900013
J	JI, H; MOORE, DP; BLOMBERG, MA; BRAITERMAN, LT; VOYTAS, DF; NATSOULIS, G; BOEKE, JD				JI, H; MOORE, DP; BLOMBERG, MA; BRAITERMAN, LT; VOYTAS, DF; NATSOULIS, G; BOEKE, JD			HOTSPOTS FOR UNSELECTED TY1 TRANSPOSITION EVENTS ON YEAST CHROMOSOME-III ARE NEAR TRANSFER-RNA GENES AND LTR SEQUENCES	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPOSABLE ELEMENTS; REPETITIVE ELEMENT; SIGMA-ELEMENTS; PHYSICAL MAP; COPY NUMBER; INTEGRATION; INSERTION; INVITRO; EXPRESSION	A collection of yeast strains bearing single marked Ty1 insertions on chromosome III was generated. Over 100 such insertions were physically mapped by pulsed-field gel electrophoresis. These insertions are very nonrandomly distributed. Thirty-two such insertions were cloned by the inverted PCR technique, and the flanking DNA sequences were determined. The sequenced insertions all fell within a few very limited regions of chromosome III. Most of these regions contained tRNA coding regions and/or LTRs of pre-existing transposable elements. Open reading frames were disrupted at a far lower frequency than expected for random transposition. The results suggest that the Ty1 integration machinery can detect regions of the genome that may represent ''safe havens'' for insertion. These regions of the genome do not contain any special DNA sequences, nor do they behave as particularly good targets for Ty1 integration in vitro, suggesting that the targeted regions have special properties allowing specific recognition in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University				Voytas, Daniel/0000-0002-4944-1224	NIGMS NIH HHS [GM36481, T32GM07445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445, R01GM036481] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOEKE JD, 1991, GENETICS, V129, P1043; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; BRODEUR GM, 1983, P NATL ACAD SCI-BIOL, V80, P3292, DOI 10.1073/pnas.80.11.3292; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BYSTROM AS, 1989, MOL GEN GENET, V216, P276, DOI 10.1007/BF00334366; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DUTCHER SK, 1981, MOL CELL BIOL, V1, P246; EIBEL H, 1984, NATURE, V307, P386, DOI 10.1038/307386a0; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EIGEL A, 1982, EMBO J, V1, P1245, DOI 10.1002/j.1460-2075.1982.tb00020.x; Elder R T, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 2, P581; ERREDE B, 1980, CELL, V22, P427, DOI 10.1016/0092-8674(80)90353-0; GABER RF, 1982, GENE, V19, P163, DOI 10.1016/0378-1119(82)90002-6; GARFINKEL DJ, 1988, GENETICS, V120, P95; GENBAUFFE FS, 1984, J BIOL CHEM, V259, P518; HALLING SM, 1982, CELL, V28, P155, DOI 10.1016/0092-8674(82)90385-3; KANG XL, 1992, GENETICS, V130, P285; KITAMURA UY, 1992, P NATL ACAD SCI USA, V89, P5532; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LINK AJ, 1991, GENETICS, V127, P681; MCCORMICK M K, 1990, Technique (Philadelphia), V2, P65; NATSOULIS G, 1989, GENETICS, V123, P269; NELBOCK P, 1985, BIOL CHEM H-S, V366, P1041, DOI 10.1515/bchm3.1985.366.2.1041; NEWLON CS, 1991, GENETICS, V129, P343; OCHMAN H, 1988, GENETICS, V120, P621; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; RILES L, 1993, IN PRESS GENETICS, V134; Rose MD., 1990, METHODS YEAST GENETI; SANDMEYER SB, 1982, P NATL ACAD SCI-BIOL, V79, P7674, DOI 10.1073/pnas.79.24.7674; SANDMEYER SB, 1988, NUCLEIC ACIDS RES, V16, P1499, DOI 10.1093/nar/16.4.1499; SCHERER S, 1982, NATURE, V298, P815, DOI 10.1038/298815a0; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; STUCKA R, 1987, CURR GENET, V12, P323, DOI 10.1007/BF00405754; STUCKA R, 1989, NUCLEIC ACIDS RES, V17, P4993, DOI 10.1093/nar/17.13.4993; Varmus H., 1989, MOBILE DNA; VOYTAS DF, 1992, NATURE, V358, P717, DOI 10.1038/358717a0; WARMINGTON JR, 1986, NUCLEIC ACIDS RES, V14, P3475, DOI 10.1093/nar/14.8.3475; WARMINGTON JR, 1987, NUCLEIC ACIDS RES, V15, P8963, DOI 10.1093/nar/15.21.8963; WARMINGTON JR, 1985, NUCLEIC ACIDS RES, V13, P6679, DOI 10.1093/nar/13.18.6679; WILKE CM, 1989, GENETICS, V123, P655; XU H, 1991, MOL CELL BIOL, V11, P2736, DOI 10.1128/MCB.11.5.2736; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; YOSHIKAWA A, 1990, YEAST, V6, P383, DOI 10.1002/yea.320060504	55	178	183	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1007	1018		10.1016/0092-8674(93)90278-X	http://dx.doi.org/10.1016/0092-8674(93)90278-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	8388781	Bronze			2022-12-24	WOS:A1993LF06100016
J	KERBER, RA; TILL, JE; SIMON, SL; LYON, JL; THOMAS, DC; PRESTONMARTIN, S; RALLISON, ML; LLOYD, RD; STEVENS, W				KERBER, RA; TILL, JE; SIMON, SL; LYON, JL; THOMAS, DC; PRESTONMARTIN, S; RALLISON, ML; LLOYD, RD; STEVENS, W			A COHORT STUDY OF THYROID-DISEASE IN RELATION TO FALLOUT FROM NUCLEAR-WEAPONS TESTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEVADA TEST SITE; RETROSPECTIVE COHORT; RADIOACTIVE FALLOUT; RADIATION; CANCER; NODULARITY; CHILDHOOD; CHILDREN; EXPOSURE; IRRADIATION	Objective.-To estimate individual radiation doses and current thyroid disease status for a previously identified cohort of 4818 schoolchildren potentially exposed to fallout from detonations of nuclear devices at the Nevada Test Site between 1951 and 1958. Design.-Cohort analytic study. Setting.-Communities in southwestern Utah, southeastern Nevada, and southeastern Arizona. Participants.-Individuals who were still residing in the three-state area (n=3122) were reexamined in 1985 and 1986, and information on the subjects' and their mothers' milk and vegetable consumption during the fallout period was obtained by telephone interview (n=3545). After exclusions to eliminate missing data and confounding factors, 2473 subjects were available for analysis. Main Outcome Measures.-Individual radiation doses to the thyroid were estimated by combining consumption data with radionuclide deposition rates provided by the US Department of Energy and a survey of milk producers. Relative risk models adjusted for age, sex, and state were fitted using maximum likelihood to period prevalence data for thyroid carcinomas, neoplasms, and nodules. Results.-Doses ranged from 0 mGy to 4600 mGy, and averaged 170 mGy in Utah. There was a statistically significant excess of thyroid neoplasms (benign and malignant; n=19), with an increase in excess relative risk of 0.7% per milligray. A relative risk- for thyroid neoplasms of 3.4 was observed among 169 subjects exposed to doses greater than 400 mGy. Positive but nonsignificant dose-response slopes were found for carcinomas and nodules. Conclusions.-Exposure to Nevada Test Site-generated radioiodines was associated with an excess of thyroid neoplasms. The conclusions are limited by the small number of exposed individuals and the low incidence of thyroid neoplasms.	RADIOL ASSESSMENTS CORP, NEESES, SC USA; UNIV UTAH, DEPT PEDIAT, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT RADIOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT ANAT, SALT LAKE CITY, UT 84132 USA; UNIV SO CALIF, DEPT PREVENT MED, LOS ANGELES, CA 90089 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Southern California	KERBER, RA (corresponding author), UNIV UTAH, DEPT FAMILY & PREVENT MED, SALT LAKE CITY, UT 84132 USA.		Kerber, Richard/B-8038-2009		NCI NIH HHS [N01-CO-23917] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO023917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS WH, 1992, J RADIOAN NUCL CH AR, V156, P269, DOI 10.1007/BF02038344; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BECK HL, 1990, NVO320 US DEP EN REP; HAMILTON PM, 1989, FDA898276 US DEP HLT; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; HICKS HG, 1982, HEALTH PHYS, V42, P585, DOI 10.1097/00004032-198205000-00003; HOLM LE, 1988, JNCI-J NATL CANCER I, V80, P1132, DOI 10.1093/jnci/80.14.1132; HOLM LE, 1980, J NATL CANCER I, V64, P1055; HOLM LE, 1984, RAD CARCINOGENESIS E; KOPECKY KJ, 1987, J STAT COMP SIMULAT, V27, P339; LAIRD NM, 1987, RISK ANAL, V7, P299, DOI 10.1111/j.1539-6924.1987.tb00465.x; LEE W, 1982, RADIAT RES, V92, P307, DOI 10.2307/3576007; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAYS CW, 1966, SCI CITIZEN, V8, P3; MCTIERNAN AM, 1984, AM J EPIDEMIOL, V120, P423, DOI 10.1093/oxfordjournals.aje.a113907; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; PRESTON DL, 1990, EPI CURE GENERALIZED; PRESTONMARTIN S, 1987, BRIT J CANCER, V55, P191, DOI 10.1038/bjc.1987.36; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, J PEDIATR-US, V86, P675, DOI 10.1016/S0022-3476(75)80350-7; RALLISON ML, 1990, HEALTH PHYS, V59, P739, DOI 10.1097/00004032-199011000-00021; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; ROBBINS J, 1989, RAD THYROID, P11; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; SHORE RE, 1985, J NATL CANCER I, V74, P1177; SHORE RE, 1986, RAD CARCINOGENESIS, P93; SIMON SL, 1990, HEALTH PHYS, V59, P669, DOI 10.1097/00004032-199011000-00017; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; THOMAS DC, IN PRESS BIOMETRICS; THOMPSON CB, TOWN DATABASE ESTIMA; WEISS ES, 1971, AM J PUBLIC HEALTH N, V61, P241, DOI 10.2105/AJPH.61.2.241; [No title captured]; 80 NAT COUNC RAD PRO	33	111	116	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2076	2082						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411574				2022-12-24	WOS:A1993MD88200027
J	ROY, AL; CARRUTHERS, C; GUTJAHR, T; ROEDER, RG				ROY, AL; CARRUTHERS, C; GUTJAHR, T; ROEDER, RG			DIRECT ROLE FOR MYC IN TRANSCRIPTION INITIATION MEDIATED BY INTERACTIONS WITH TFII-I	NATURE			English	Article							C-MYC; DNA-BINDING; PROTEINS; MAX; DIMERIZATION; ACTIVATION; ONCOGENE; SEQUENCE; MYOD; USF	THE nuclear proto-oncoprotein Myc has been implicated in the control of cell proliferation and differentiation1-3. Myc participates in transcription4,5 and belongs to the basic-helix-loop-helix (bHLH) family of regulatory proteins2,3. Here we show that Myc interacts with TFII-I, a transcription initiation factor that activates core promoters through an initiator element (Inr)6. As previously observed for the bHLH activator USF6, Myc was found to interact cooperatively with TFII-I at both Inr and upstream E-box promoter elements. However, in this case Myc interactions with TFII-I at the Inr lead to an inhibition of transcription initiation. This inhibition is selective for a TFII-I-dependent (as opposed to TFIIA-dependent) initiation pathway and correlates with the prevention of complex formation between the TATA-binding protein TBP (TFIIDtau), TFII-I and the promoter. TBP probably interacts with Myc, but only slowly. These observations indicate that Myc has the potential to interact physically and functionally with components of the general transcription machinery.			ROY, AL (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.			Gutjahr, Thomas/0000-0002-8395-5464				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENDERGAST GC, 1991, CELL, V65, P395; PENDERGAST GC, 1992, TIGS, V8, P91; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	27	249	250	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					359	361		10.1038/365359a0	http://dx.doi.org/10.1038/365359a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377829				2022-12-24	WOS:A1993LY49600058
J	KELLERMANN, AL; HACKMAN, BB; SOMES, G				KELLERMANN, AL; HACKMAN, BB; SOMES, G			PREDICTING THE OUTCOME OF UNSUCCESSFUL PREHOSPITAL ADVANCED CARDIAC LIFE-SUPPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL TECHNICIANS; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; IMPROVING SURVIVAL; ARREST; DEFIBRILLATION; FIELD; MANAGEMENT; SERVICES	Objective.-To determine if failure to achieve return of spontaneous circulation following prehospital advanced cardiac life support (ACLS) warrants termination of efforts at the scene. Design.-Retrospective case series. Setting.-Memphis, Tenn, a city of 610337 people that is served by a fire department-based emergency medical service system. All city ambulances provide ACLS. Patients.-Adult victims of out-of-hospital cardiac arrest due to heart disease. Intervention.-All patients received prehospital ACLS according to the 1986 American Heart Association guidelines. Following prehospital ACLS, all patients were transported to the nearest hospital emergency department whether or not a pulse was restored in the field. Main Outcome Measures.-Survival to hospital admission, survival to hospital discharge, and neurological status at discharge. Results.-Over the 39-month study interval, the Memphis Fire Department treated 1068 victims of out-of-hospital cardiac arrest. Three hundred ten of these (29%) had return of spontaneous circulation prior to transport for some period. The remaining 758 patients (71%) never regained a pulse and were transported with ongoing cardiopulmonary resuscitation. Patients who had return of spontaneous circulation prior to transport were more likely to be admitted (69% vs 7.0%) and far more likely to be discharged alive (26.5% vs 0.4%) than patients who failed to respond to prehospital ACLS. Three patients who survived to hospital discharge despite failure to achieve return of spontaneous circulation prior to emergency medical service transport sustained their cardiac arrest after paramedic arrival. All three were discharged with moderate to severe cerebral disability. Conclusion.-Rapid transport of adults who fail to respond to an adequate trial of prehospital ACLS does not result in meaningful rates of survival. In such cases, on-line emergency medical service physicians should authorize paramedics to cease efforts in the field.	UNIV TENNESSEE CTR HLTH SCI,DIV CARDIOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT INTERNAL MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DIV EMERGENCY MED,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					AHRQ HHS [HS 06094] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1985, ANN EMERG MED, V14, P1106, DOI 10.1016/S0196-0644(85)80932-X; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; FRANK M, 1989, ANN EMERG MED, V18, P594, DOI 10.1016/S0196-0644(89)80853-4; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HACKMAN BB, 1992, CONNS CURRENT THERAP, P209; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1987, AM J EMERG MED, V5, P548, DOI 10.1016/0735-6757(87)90197-5; KERBER RE, 1991, STATEMENT EARLY DEFI; LEWIS LM, 1990, AM J EMERG MED, V8, P118, DOI 10.1016/0735-6757(90)90196-7; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1992, JAMA-J AM MED ASSOC, V268, P2171	26	132	134	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1433	1436		10.1001/jama.270.12.1433	http://dx.doi.org/10.1001/jama.270.12.1433			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371442				2022-12-24	WOS:A1993LX17300026
J	MERINO, A; MADDEN, KR; LANE, WS; CHAMPOUX, JJ; REINBERG, D				MERINO, A; MADDEN, KR; LANE, WS; CHAMPOUX, JJ; REINBERG, D			DNA TOPOISOMERASE-I IS INVOLVED IN BOTH REPRESSION AND ACTIVATION OF TRANSCRIPTION	NATURE			English	Article							RNA POLYMERASE-II; BINDING; CLONING; PROTEIN; YEAST; GENE; COMPLEX; PURIFICATION; COACTIVATORS; INITIATION	Reconstituted transcription reactions containing the seven general transcription factors, in addition to RNA polymerase II, respond poorly to transcriptional activators. Two factors, Dr2 and ACF, necessary for high levels of transcription in response to an activator have been identified. ACF can enhance basal and activated transcription. Dr2 represses basal transcription, but this can be overcome by transcriptional activators or TFIIA. Dr2 is human DNA topoisomerase I. The DNA relaxation activity of topoisomerase I is dispensable for transcriptional repreSSion. The effect of Dr2 is specific for TATA-box-containing promoters and is mediated by the TATA-binding protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Washington; University of Washington Seattle; Harvard University				Reinberg, Danny/0000-0003-4288-2016				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG W, 1989, J BIOL CHEM, V164, P13373; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE PL, 1993, P NATL ACAD SCI USA, V90, P6656; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MADDEN KR, 1992, CANCER RES, V52, P525; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1989, J BIOL CHEM, V264, P21266; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STEWART AF, 1990, CELL, V60, P141; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; ZAWEL L, 1993, NUCLEIC ACID RES MOL, V44, P67; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	337	340	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					227	232		10.1038/365227a0	http://dx.doi.org/10.1038/365227a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396729				2022-12-24	WOS:A1993LX47100045
J	YAWO, H; CHUHMA, N				YAWO, H; CHUHMA, N			PREFERENTIAL INHIBITION OF OMEGA-CONOTOXIN-SENSITIVE PRESYNAPTIC CA2+ CHANNELS BY ADENOSINE AUTORECEPTORS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSMITTER RELEASE; CALCIUM CURRENTS; CELLS; RECEPTOR; RAT; HIPPOCAMPUS; BRADYKININ; NEURONS; ABSENCE	ADENOSINE is a potent modulator of transmitter release at a variety of synapses. The adenosine A1 receptor is assumed to reside in presynaptic terminals and to function as a negative autoreceptor1. How adenosine reduces transmitter release is uncertain2; it may reduce the calcium influx during nerve terminal depolarization by either activating K+ currents3,4 or inhibiting Ca2+, currents5,6, although other mechanisms have been proposed7-9. We have directly measured intracellular Ca2+ concentrations of giant presynaptic terminals in the chick ciliary ganglion. We report here that adenosine inhibited the nerve-evoked Ca2+ influx in the terminal by activating A1 receptors. Reduced Ca2+ influx was due largely to inhibition of omega-conotoxin GVIA-sensitive Ca2+ channels in the presynaptic terminal.			YAWO, H (corresponding author), KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 60601,JAPAN.		Yawo, Hiromu/I-4871-2015	Yawo, Hiromu/0000-0002-4299-3288; Chuhma, Nao/0000-0002-6846-3461				BENNETT MR, 1991, J PHYSIOL-LONDON, V440, P513, DOI 10.1113/jphysiol.1991.sp018722; BRANISTEANU DD, 1979, N-S ARCH PHARMACOL, V308, P273, DOI 10.1007/BF00501393; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; GERBER U, 1989, J PHYSIOL-LONDON, V417, P567, DOI 10.1113/jphysiol.1989.sp017819; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMILTON BR, 1991, J PHYSIOL-LONDON, V432, P327, DOI 10.1113/jphysiol.1991.sp018387; Haugland R.P., 1992, HDB FLUORESCENT PROB; KWAN CY, 1990, J BIOL CHEM, V265, P678; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SHIMAHARA T, 1990, BRAIN RES, V524, P219, DOI 10.1016/0006-8993(90)90694-7; SILINSKY EM, 1992, J PHYSIOL-LONDON, V457, P315, DOI 10.1113/jphysiol.1992.sp019380; SILINSKY EM, 1986, TRENDS PHARMACOL SCI, V7, P180, DOI 10.1016/0165-6147(86)90309-3; SYNDER SH, 1985, ANNU REV NEUROSCI, V8, P103; TRUSSELL LO, 1985, P NATL ACAD SCI USA, V82, P4857, DOI 10.1073/pnas.82.14.4857; YAWO H, 1993, J PHYSIOL-LONDON, V460, P153, DOI 10.1113/jphysiol.1993.sp019464; YAWO H, 1989, J PHYSIOL-LONDON, V417, P307, DOI 10.1113/jphysiol.1989.sp017803	22	145	149	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					256	258		10.1038/365256a0	http://dx.doi.org/10.1038/365256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8396730				2022-12-24	WOS:A1993LX47100055
J	KEMP, CJ; DONEHOWER, LA; BRADLEY, A; BALMAIN, A				KEMP, CJ; DONEHOWER, LA; BRADLEY, A; BALMAIN, A			REDUCTION OF P53 GENE DOSAGE DOES NOT INCREASE INITIATION OR PROMOTION BUT ENHANCES MALIGNANT PROGRESSION OF CHEMICALLY-INDUCED SKIN TUMORS	CELL			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; MOUSE SKIN; RAS GENE; HA-RAS; COLORECTAL TUMORIGENESIS; MULTISTEP CARCINOGENESIS; CANCER; MUTATIONS; ONCOGENE	The availability of p53 knockout mice generated by gene targeting has enabled us to investigate the functional role of the p53 tumor suppressor gene in initiation, promotion, and progression of carcinogenesis in vivo, using mouse skin as a model system. The number, size, and growth rate of benign papillomas were not increased in the p53 heterozygous mice in comparison with wild type. The p53 null mice showed a reduced yield of papillomas, but these underwent much more rapid malignant progression, with some poorly differentiated carcinomas developing after only 10 weeks of promotion. Progression rate was also greater in heterozygous than in wild-type mice and was associated with loss of the remaining wild-type allele. Most tumors from all groups had activating mutations in the H-ras gene. Absence of p53, therefore, does not augment the frequency of initiation or the rate of promotion but greatly enhances malignant progression.	BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	KEMP, CJ (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND.			Bradley, Allan/0000-0002-2349-8839				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BALMAIN A, 1992, PRINCESS TAKAMATSU S, V22, P97; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENNETT WP, 1992, CANCER RES, V52, P6092; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BURNS PA, 1991, ONCOGENE, V6, P2363; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FULTS D, 1992, CANCER RES, V52, P674; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P749, DOI 10.1093/carcin/10.4.749; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARVEY M, 1993, IN PRESS ONCOGENE; HECKER E, 1982, CARCINOGENESIS COMPR, V7; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LI FP, 1988, CANCER RES, V48, P5358; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NOWELL PC, 1989, CANCER CELL-MON REV, V1, P29; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RUGGERI B, 1991, CANCER RES, V51, P6615; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P184, DOI 10.1073/pnas.84.1.184; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; TEMIN HM, 1988, CANCER RES, V48, P1697; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WEINBERG RA, 1989, CANCER RES, V49, P3713; YANDELL DW, 1986, SOMAT CELL MOLEC GEN, V12, P255, DOI 10.1007/BF01570784; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUSPA SH, 1983, CANCER RES, V43, P6021	64	449	452	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 10	1993	74	5					813	822		10.1016/0092-8674(93)90461-X	http://dx.doi.org/10.1016/0092-8674(93)90461-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374952				2022-12-24	WOS:A1993LX29200007
J	PEZZELLA, F; TURLEY, H; KUZU, I; TUNGEKAR, MF; DUNNILL, MS; PIERCE, CB; HARRIS, A; GATTER, KC; MASON, DY				PEZZELLA, F; TURLEY, H; KUZU, I; TUNGEKAR, MF; DUNNILL, MS; PIERCE, CB; HARRIS, A; GATTER, KC; MASON, DY			BCL-2 PROTEIN IN NON-SMALL-CELL LUNG-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN FOLLICULAR LYMPHOMA; 14-18 TRANSLOCATION; B-CELLS; EXPRESSION; GENE; SURVIVAL; DEATH; CLONING; CANCER	Background. The proto-oncogene bcl-2 encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied bcl-2 expression in patients with non-small-cell lung carcinoma and correlated this phenomenon with survival. Methods. Immunochemical analysis with a monoclonal antibody specific for bcl-2 was used to detect the protein in tumor samples from 122 patients undergoing surgery for squamous-cell carcinoma (80 patients) or adenocarcinoma (42 patients). The possibility that bcl-2 expression correlated with survival was investigated with use of the log-rank test, hazard ratios, and their confidence intervals. Results. We detected bcl-2 protein in 25 percent of squamous-cell carcinomas (20 of 80) and 12 percent of adenocarcinomas (5 of 42). In adjacent normal respiratory epithelium, bcl-2 was expressed only in basal cells. Survival at five years was higher among patients with bcl-2-positive tumors, both in the group as a whole (P<0.1) and in the group with squamous-cell carcinoma (P<0.02). Patients 60 years of age or older who had bcl-2-positive tumors had the best prognoses, both in the group as a whole (P<0.02) and in the group with squamous-cell carcinoma (P<0.01). Conclusions. The proto-oncogene bcl-2 is abnormally expressed in some lung carcinomas, and its expression may have prognostic importance.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,CTR DATA,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; University of Oxford	PEZZELLA, F (corresponding author), JOHN RADCLIFFE HOSP,LEUKAEMIA RES FUND,IMMUNODIAGNOST UNIT,LEVEL 1,MATERN BLOCK,OXFORD OX3 9DU,ENGLAND.		Harris, Adrian L/ABA-3343-2020; KUZU, ISINSU/AAM-8967-2020	Harris, Adrian L/0000-0003-1376-8409; KUZU, ISINSU/0000-0001-5519-1009				AISENBERG AC, 1988, BLOOD, V71, P969; Altman D. G., 1991, PRACTICAL STAT MED R, DOI [10.1201/9780429258589, DOI 10.1201/9780429258589]; Armitage P., 1987, STAT METHODS MED RES, Vsecond, P186, DOI [10.1002/9780470773666, DOI 10.1002/9780470773666]; BAILAR JC, 1992, MED USES STATISTICS; CARR DT, 1983, LUNG CANCER CLIN DIA, P201; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; LEE JS, 1992, NEW ENGL J MED, V327, P47, DOI 10.1056/NEJM199207023270110; MACHIN D, 1989, STATISTICS CONFIDENC, P64; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCVIE JG, 1990, MANUAL CLIN ONCOLOGY, P217; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PEZZELLA F, 1990, LANCET, V336, P1510, DOI 10.1016/0140-6736(90)93216-C; PEZZELLA F, 1990, BRIT J HAEMATOL, V76, P58, DOI 10.1111/j.1365-2141.1990.tb07836.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0	28	660	674	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1993	329	10					690	694		10.1056/NEJM199309023291003	http://dx.doi.org/10.1056/NEJM199309023291003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU583	8393963				2022-12-24	WOS:A1993LU58300003
J	SHU, ZJ; SWINDALE, NV; CYNADER, MS				SHU, ZJ; SWINDALE, NV; CYNADER, MS			SPECTRAL MOTION PRODUCES AN AUDITORY AFTER-EFFECT	NATURE			English	Article							MOVEMENT AFTEREFFECTS CONTINGENT; FREQUENCY-MODULATED TONES; DIRECTION; CHANNELS; PATTERN; COLOR	DISTORTIONS of perception following prolonged exposure to an unvarying sensory stimulus have been observed since at least the third century BC1. The motion after-effect is a familiar experience2 in which, after a few minutes of viewing objects moving in a single direction, a stationary object appears to move in the opposite direction. Similar after-effects have been observed for many visual stimuli, including tilted lines, colours, stereoscopic depth, curvature, spatial frequency, contrast, rotation and motion in depth3-9. In contrast to the rich variety of visual after-effects reported since the 1960s, reports of analogous auditory adaptation effects only appeared in the 1970s10-12, but have continued since then13,14. Some effects of sound source spatial movement perception after adaptation to a spatially moving sound source have been reported15. Here we report an auditory perceptual after-effect analogous to the visual motion after-effect, which is caused by adaptation to auditory spectral (frequency) motion. After a few minutes of listening to a simple spectral pattern moving upwards or downwards in frequency space, the same pattern sounds as though it is drifting in the opposite direction when it is stationary. The effect shows binaural transfer, implying that it is generated at the level after binaural interaction. After-effects produced by the motion of spectral peaks are independent of those produced by spectral notches, suggesting separate processing channels for spectral peaks and notches.	UNIV BRITISH COLUMBIA,DEPT ELECT ENGN,VANCOUVER V6T 1Z4,BC,CANADA	University of British Columbia	SHU, ZJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT OPHTHALMOL,2550 WILLOW ST,VANCOUVER V5Z 3N9,BC,CANADA.							ANSTIS SM, 1967, SCIENCE, V155, P710, DOI 10.1126/science.155.3763.710; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; Blauert J., 1983, SPATIAL HEARING; BLOOM PJ, 1977, J AUDIO ENG SOC, V25, P560; BUTLER RA, 1983, AM J OTOLARYNG, V4, P165, DOI 10.1016/S0196-0709(83)80039-8; FAVREAU OE, 1976, VISION RES, V16, P181, DOI 10.1016/0042-6989(76)90096-1; Finney D.J., 1971, PROBIT ANAL; GARDNER RB, 1979, J ACOUST SOC AM, V66, P704, DOI 10.1121/1.383220; GRANTHAM DW, 1989, PERCEPT PSYCHOPHYS, V45, P129, DOI 10.3758/BF03208047; GREN GGR, 1976, J PHYSIOL-LONDON, V260, pP49; KAY RH, 1972, J PHYSIOL-LONDON, V225, P657, DOI 10.1113/jphysiol.1972.sp009962; KAY RH, 1982, PHYSIOL REV, V62, P894, DOI 10.1152/physrev.1982.62.3.894; MAYHEW JEW, 1972, PERCEPT PSYCHOPHYS, V12, P77, DOI 10.3758/BF03212847; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; MOORE BCJ, 1989, J ACOUST SOC AM, V85, P820, DOI 10.1121/1.397554; POTTS MJ, 1975, VISION RES, V15, P1225, DOI 10.1016/0042-6989(75)90166-2; REGAN D, 1979, J ACOUST SOC AM, V65, P1249, DOI 10.1121/1.382792; SEKULER RW, 1963, SCIENCE, V139, P419, DOI 10.1126/science.139.3553.419; WALKER JT, 1972, PSYCHON SCI, V28, P333; WILSON JP, 1992, BRIT J AUDIOL, V26, P188; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; ARISTOTLE PARVA NATU	22	58	63	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					721	723		10.1038/364721a0	http://dx.doi.org/10.1038/364721a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355786				2022-12-24	WOS:A1993LT67700059
J	CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA				CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA			GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES	SCIENCE			English	Article							LINKAGE; LOCUS; CHROMOSOME-14; PROTEIN	The apolipoprotein E type 4 allele (APOE-epsilon4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon4 alleles in 42 families with late onset AD. Thus APOE-epsilon4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon4 was virtually sufficient to cause AD by age 80.	DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROBIOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; UNIV CALIF LOS ANGELES,CTR HLTH SCI,NEUROPSYCHIAT INST & HOSP,LOS ANGELES,CA 90024; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital			Kennedy, Kristen M/B-4699-2008; Haines, Jonathan/C-3374-2012; Zito, Giancarlo/F-9008-2010	Kennedy, Kristen M/0000-0001-5373-9026; Haines, Jonathan/0000-0002-4351-4728; 				CORDER EH, UNPUB; Cox D. R., 1984, ANAL SURVIVAL DATA; FARID NR, 1979, J CLIN INVEST, V63, P108, DOI 10.1172/JCI109263; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENBERG DA, 1993, AM J HUM GENET, V52, P135; KOCH GG, 1985, ANAL CATEGORICAL DAT; LANGDON N, 1984, LANCET, V2, P1178; Miller R. G., 1981, SURVIVAL ANAL; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; SAUNDERS AM, IN PRESS NEUROLOGY; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHMECHEL DE, IN PRESS; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, IN PRESS P NATL ACAD; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; 1991, SAS P217 SAS I INC T; 1985, SAS USERS GUIDE STAT; 1988, SAS STAT USERS GUIDE	23	6915	7109	21	680	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					921	923		10.1126/science.8346443	http://dx.doi.org/10.1126/science.8346443			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346443				2022-12-24	WOS:A1993LR89700041
J	DEAR, SP; SIMMONS, JA; FRITZ, J				DEAR, SP; SIMMONS, JA; FRITZ, J			A POSSIBLE NEURONAL BASIS FOR REPRESENTATION OF ACOUSTIC SCENES IN AUDITORY-CORTEX OF THE BIG BROWN BAT	NATURE			English	Article							CORTICAL COMPUTATIONAL MAPS; TARGET RANGE; ECHOLOCATING BATS; MYOTIS-LUCIFUGUS; MUSTACHE BAT	BEHAVIOURAL studies1-4 and field observations5-7 demonstrate that echolocating bats simultaneously perceive range, direction and shape of multiple objects in the environment as acoustic images derived from echoes. Cortical echo delay-tuned neurons contribute to the perception of object range, because focal inactivation of these neurons disrupts behavioural discrimination of range8. We report here that response properties of delay-tuned neurons in the cortical tonotopic area of the bat, Eptesicus, transform the sequential arrival times of echoes with different delays into a concurrent, accumulating neural representation of multiple objects at different ranges. The sharpness of delay tuning systematically increases at each best delay in a subpopulation of these neurons while responses to echoes at different delays are accumulated. The resulting concurrent, multiresolution representation of echo delay corresponds to neural implementation of a common representation of images used in computational vision9-11 and may provide the basis for representing acoustic images of multiple objects as acoustic 'scenes'.	BROWN UNIV,DEPT PSYCHOL,PROVIDENCE,RI 02912	Brown University	DEAR, SP (corresponding author), BROWN UNIV,DEPT NEUROSCI,BOX 1853,PROVIDENCE,RI 02912, USA.			Fritz, Jonathan/0000-0002-0625-172X				Akansu AN, 1992, MULTIRESOLUTION SIGN; BERKOWITZ A, 1989, HEARING RES, V41, P255, DOI 10.1016/0378-5955(89)90017-8; BURT PJ, 1981, IEEE T SYST MAN CYB, V11, P802, DOI 10.1109/TSMC.1981.4308619; DEAR SP, IN PRESS J NEUROPHYS; FENG AS, 1978, SCIENCE, V202, P645, DOI 10.1126/science.705350; GRIFFIN DR, 1965, J EXP ZOOL, V158, P155, DOI 10.1002/jez.1401580204; Griffin DR, 1958, LISTENING DARK; HONG TH, 1984, IEEE T PATTERN ANAL, V6, P229, DOI 10.1109/TPAMI.1984.4767506; HONG TH, 1984, IEEE T PATTERN ANAL, V6, P222, DOI 10.1109/TPAMI.1984.4767505; KICK SA, 1984, J NEUROSCI, V4, P2725; MALLAT SG, 1989, IEEE T ACOUST SPEECH, V37, P2019; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1980, PROC R SOC SER B-BIO, V207, P187, DOI 10.1098/rspb.1980.0020; Marr D., 1982, VISION; NEUWEILER G, 1990, PHYSIOL REV, V70, P615, DOI 10.1152/physrev.1990.70.3.615; ONEILL WE, 1979, SCIENCE, V203, P69, DOI 10.1126/science.758681; RIQUIMAROUX H, 1991, SCIENCE, V251, P565, DOI 10.1126/science.1990432; ROSENFELD A, 1971, IEEE T COMPUT, VC 20, P562, DOI 10.1109/T-C.1971.223290; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHULLER G, 1991, EUR J NEUROSCI, V3, P1165, DOI 10.1111/j.1460-9568.1991.tb00051.x; SIMMONS JA, 1973, J ACOUST SOC AM, V54, P157, DOI 10.1121/1.1913559; SIMMONS JA, 1971, SCIENCE, V171, P925, DOI 10.1126/science.171.3974.925; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1978, SCIENCE, V200, P778, DOI 10.1126/science.644320; SULLIVAN WE, 1982, J NEUROPHYSIOL, V48, P1011, DOI 10.1152/jn.1982.48.4.1011; WEBSTER FA, 1968, AMRLTR67192 TECHN RE; WITKIN AP, 1984, IEEE ICASSP P, V39; WONG D, 1988, BRAIN RES, V453, P349, DOI 10.1016/0006-8993(88)90176-X	28	93	93	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					620	623		10.1038/364620a0	http://dx.doi.org/10.1038/364620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350920				2022-12-24	WOS:A1993LR77100051
J	LIPTON, SA; CHOI, YB; PAN, ZH; LEI, SZZ; CHEN, HSV; SUCHER, NJ; LOSCALZO, J; SINGEL, DJ; STAMLER, JS				LIPTON, SA; CHOI, YB; PAN, ZH; LEI, SZZ; CHEN, HSV; SUCHER, NJ; LOSCALZO, J; SINGEL, DJ; STAMLER, JS			A REDOX-BASED MECHANISM FOR THE NEUROPROTECTIVE AND NEURODESTRUCTIVE EFFECTS OF NITRIC-OXIDE AND RELATED NITROSO-COMPOUNDS	NATURE			English	Article							RECEPTOR-CHANNEL COMPLEX; NMDA RECEPTOR; GLUTAMATE NEUROTOXICITY; SUPEROXIDE-DISMUTASE; MODULATORY SITE; NEURONAL INJURY; NERVOUS-SYSTEM; PEROXYNITRITE; INHIBITION; OXIDATION	CONGENERS of nitrogen monoxide (NO) are neuroprotective and neurodestructive1-7. To address this apparent paradox, we considered the effects on neurons of compounds characterized by alternative redox states of NO: nitric oxide (NO.) and nitrosonium ion (NO+)8. Nitric oxide, generated from NO. donors or synthesized endogenously after NMDA (N-methyl-D-aspartate) receptor activation, can lead to neurotoxicity3,4. Here, we report that NO.-mediated neurotoxicity is engendered, at least in part, by reaction with superoxide anion (O2.-), apparently leading to formation of peroxynitrite (ONOO-), and not by NO. alone. In contrast, the neuroprotective effects of NO result from downregulation of NMDA-receptor activity by reaction with thiol group(s) of the receptor's redox modulatory site1. This reaction is not mediated by NO. itself, but occurs under conditions supporting S-nitrosylation of NMDA receptor thiol (reaction or transfer of NO+). Moreover, the redox versatility of NO allows for its interconversion from neuroprotective to neurotoxic species by a change in the ambient redox milieu. The details of this complex redox chemistry of NO may provide a mechanism for harnessing neuroprotective effects and avoiding neurotoxicity in the central nervous system.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT NEUROL,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BROCKTON W ROXBURY VET ADM MED CTR,CARDIOL SECT,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	LIPTON, SA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,CELLULAR & MOLEC NEUROSCI LAB,300 LONGWOOD AVE,ENDERS BLDG,BOSTON,MA 02115, USA.		Loscalzo, Joseph/ABD-8980-2021	Lipton, Stuart/0000-0002-3490-1259; Stamler, Jonathan/0000-0002-6866-1572; Sucher, Nikolaus/0000-0001-6233-1612				BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HOYT KR, 1992, BRAIN RES, V592, P310, DOI 10.1016/0006-8993(92)91690-G; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KINOUCH H, 1991, P NATL ACAD SCI USA, V89, P11158; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIU TH, 1989, AM J PHYSIOL, V256, P589; MANCHESTER KS, 1993, NEUROLOGY, V43, pA365; MARKS GS, 1992, CAN J PHYSIOL PHARM, V70, P308, DOI 10.1139/y92-039; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA C, 1992, NEUROREPORT, V3, P530; NOACK E, 1991, BASIC RES CARDIOL, V86, P37; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026; ZUMFT WG, 1982, BIOCHIM BIOPHYS ACTA, V681, P459, DOI 10.1016/0005-2728(82)90188-8	34	2250	2332	1	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					626	632		10.1038/364626a0	http://dx.doi.org/10.1038/364626a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8394509				2022-12-24	WOS:A1993LR77100053
J	GALIONE, A; MCDOUGALL, A; BUSA, WB; WILLMOTT, N; GILLOT, I; WHITAKER, M				GALIONE, A; MCDOUGALL, A; BUSA, WB; WILLMOTT, N; GILLOT, I; WHITAKER, M			REDUNDANT MECHANISMS OF CALCIUM-INDUCED CALCIUM-RELEASE UNDERLYING CALCIUM WAVES DURING FERTILIZATION OF SEA-URCHIN EGGS	SCIENCE			English	Article							CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; HAMSTER EGGS; OSCILLATIONS	Propagating Ca2+ waves are a characteristic feature of Ca2+-linked signal transduction pathways. Intracellular Ca2+ waves are formed by regenerative stimulation of Ca2+ release from intracellular stores by Ca2+ itself. Mechanisms that rely on either inositol trisphosphate or ryanodine receptor channels have been proposed to account for Ca2+ waves in various cell types. Both channel types contributed to the Ca2+ wave during fertilization of sea urchin eggs. Alternative mechanisms of Ca2+ release imply redundancy but may also allow for modulation and diversity in the generation of Ca2+ waves.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	Johns Hopkins University; University of London; University College London	GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011; McDougall, Alex/J-1930-2014	McDougall, Alex/0000-0003-0324-3836; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CROSSLEY I, 1988, BIOCHEM J, V252, P257, DOI 10.1042/bj2520257; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DELISLE S, 1992, J BIOL CHEM, V267, P7963; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, UNPUB; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; JACOB R, 1990, CELL CALCIUM, V11, P241, DOI 10.1016/0143-4160(90)90075-6; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KLINE D, 1988, SCIENCE, V241, P464, DOI 10.1126/science.3134693; KUBOTA HY, 1987, DEV BIOL, V119, P126; LEICHLEITER JD, 1992, CELL, V69, P283; McDougall Alex, 1993, Zygote, V1, P35; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; PALADE P, 1983, J BIOL CHEM, V258, P8098; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROONEY TA, 1991, PHARMACOL THERAPEUT, V49, P223, DOI 10.1016/0163-7258(91)90056-R; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SARDET C, 1992, DEV GROWTH DIFFER, V34, P37; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SPEKSNIJDER JE, 1990, DEV BIOL, V142, P246, DOI 10.1016/0012-1606(90)90168-I; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WHITAKER M, 1993, DEVELOPMENT, V117, P1	40	289	291	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					348	352		10.1126/science.8392748	http://dx.doi.org/10.1126/science.8392748			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8392748	Green Submitted			2022-12-24	WOS:A1993LM67800035
J	NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M				NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M			ASSOCIATION OF HORMONE-REPLACEMENT THERAPY WITH VARIOUS CARDIOVASCULAR RISK-FACTORS IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; IMPROVED LIPOLYTIC EFFICIENCY; CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BLOOD COLLECTION; PROTEIN-C; ENZYMATIC DETERMINATION; ANTITHROMBIN-III; HEPATIC LIPASE; SERUM-LIPIDS	Background. Most epidemiologic studies of cardiovascular disease in postmenopausal women suggest that estrogen-replacement therapy has a protective effect. The effects of the use of estrogen combined with progestin are less well studied. Methods. To examine the associations of hormone-replacement therapy with concentrations of plasma lipids and hemostatic factors, fasting serum concentrations of glucose and insulin, and blood pressure, we studied 4958 postmenopausal women participating in a population-based investigation. Using cross-sectional data, we classified the women into four groups according to their use of hormone-replacement therapy: current users of estrogen alone, current users of estrogen with progestin, nonusers who had formerly used these hormones, and nonusers who had never used them. Results. Current users had higher mean levels of high-density lipoprotein cholesterol, its subfractions high-density lipoprotein2 and high-density lipoprotein3, and apolipoprotein A-1 than nonusers, and lower mean levels of low-density lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), fibrinogen, antithrombin III, and fasting serum glucose and insulin. However, current users of estrogen alone had higher triglyceride, factor VII, and protein C levels than either nonusers or current users of estrogen with progestin. After making certain assumptions, we estimated that the findings, if causal, would translate into a reduction of 42 percent in the risk of coronary heart disease in users of hormones as compared with nonusers. Women using estrogen with progestin would have an even greater estimated benefit. Conclusions. A randomized trial is needed to eliminate possible selection biases in our observational study that are related to the prescription of replacement hormones. Nevertheless, hormone-replacement therapy appears to be associated with a favorable physiologic profile, which probably mediates its protective effects on cardiovascular disease. The use of estrogen combined with progestin appears to be associated with a better profile than the use of estrogen alone.	UNIV MINNESOTA, SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA; BURROUGHS WELLCOME CO, DIV ESP, RES TRIANGLE PK, NC 27709 USA; METHODIST HOSP, ATHEROSCLEROSIS CLIN LAB, HOUSTON, TX 77030 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV TEXAS, SCH MED, DIV HEMATOL ONCOL, HOUSTON, TX 77025 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	University of Minnesota System; University of Minnesota Twin Cities; Burroughs Wellcome Fund; The Methodist Hospital System; The Methodist Hospital - Houston; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; Johns Hopkins University			Wu, Kenneth Kun-Yu/B-1070-2010	Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055018] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, AM J EPIDEMIOL, V129, P687; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BALLEISEN L, 1987, LANCET, V2, P461; Barrett-Connor E L, 1989, Public Health Rep, V104 Suppl, P62; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BROWN SA, 1988, CLIN CHEM, V34, P920; BROWN SA, 1990, CLIN CHEM, V36, P1662; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; ESMON CT, 1983, BLOOD, V62, P1155; FARISH E, 1986, ACTA ENDOCRINOL-COP, V113, P123, DOI 10.1530/acta.0.1130123; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON EM, 1988, J LAB CLIN MED, V111, P52; HEGELE RA, 1989, CAN J CARDIOL, V5, P263; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LINDBERG UB, 1989, THROMB HAEMOSTASIS, V61, P65; LOBO RA, 1987, POSTGRAD MED    0914, P48; Lobo RA, 1990, ANN NY ACAD SCI, V592, P334; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MEADE TW, 1985, THROMB HAEMOSTASIS, V53, P198; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1984, ANTICOAGULANTS MYOCA, P91; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; NIKKILA EA, 1983, PROGESTERONE PROGEST, P411; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P1832, DOI 10.1016/S0002-9378(89)80003-1; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SACKS FM, 1990, ANN NY ACAD SCI, V592, P334; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SIEDEL J, 1983, CLIN CHEM, V29, P1075; SILFVERSTOLPE G, 1982, MATURITAS, V4, P103, DOI 10.1016/0378-5122(82)90036-6; SKARTLIEN AH, 1989, ARTERIOSCLEROSIS, V9, P798, DOI 10.1161/01.ATV.9.6.798; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; THALER E, 1981, CLIN HAEMATOL, V10, P369; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113; TIKKANEN MJ, 1981, ATHEROSCLEROSIS, V40, P365, DOI 10.1016/0021-9150(81)90147-7; TIKKANEN MJ, 1986, MATURITAS, V8, P7, DOI 10.1016/0378-5122(86)90003-4; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; 1987, ARIC ATHEROSCLEROSIS, V8; [No title captured]; 1988, SAS USERS GUIDE STAT; 1987, VITAL HLTH STATIS 11, V238	52	858	874	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1069	1075		10.1056/NEJM199304153281501	http://dx.doi.org/10.1056/NEJM199304153281501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8384316	Bronze			2022-12-24	WOS:A1993KX17800001
J	GENC, M; RUUSUVAARA, L; MARDH, PA				GENC, M; RUUSUVAARA, L; MARDH, PA			AN ECONOMIC-EVALUATION OF SCREENING FOR CHLAMYDIA-TRACHOMATIS IN ADOLESCENT MALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; URINE SEDIMENT; ENZYME-IMMUNOASSAY; DECISION-ANALYSIS; URETHRITIS; INFECTIONS; GONORRHEA; MEN; DIAGNOSIS; ANTIGENS	Objective.-To assess the cost-effectiveness of identifying asymptomatic carriers of Chlamydia trachomatis among adolescent males. Design.-Cost-effectiveness analysis based on cohort analytic studies previously reported and average salaries and costs of medical care in Sweden. Setting.-Adolescent males attending a primary care center for routine health checks. Participants.-Estimates of costs and benefits are based on a cohort of 1 000 adolescent males and their female contacts. Intervention.-Screening with enzyme immunoassay (EIA), either on leukocyte esterase (LE)-positive urine samples (LE-EIA screening) or on all urine samples (EIA screening), was compared with no screening (no treatment or contact tracing). The effects of confirming positive EIA results with a blocking assay and alternative antibiotic regimens on the outcome of the screening strategies were also evaluated. Results.-Compared with no screening, the LE-EIA and EIA screening strategies reduced the overall costs when the prevalence of chlamydial infection in males exceeded 2% and 10%, respectively. Enzyme immunoassay screening achieved an overall cure rate that was 12.2% to 12.6% (95% confidence interval) better, but reduced the incremental savings by at least $2144 per cured male, in comparison with LE-EIA screening. Confirmation of positive EIA results reduced the overall cost of the LE-EIA screening strategy when the prevalence of C trachomatis among males was less than 8%. Compared with a 7-day course of doxycycline, a single oral dose of azithromycin administered under supervision in the clinic improved the cure rates of both EIA and LE-EIA screening strategies by 15.1% to 16.3% and 11.2% to 12.0%, respectively, while reducing the corresponding overall costs by 5% and 9%, respectively, regardless of the prevalence of chlamydial infection in males. Conclusion.-The use of LE-EIA screening combined with treatment of positive cases with azithromycin was the most cost-effective intervention strategy focusing on asymptomatic male carriers of C trachomatis. Positive EIA results should be confirmed when screening low-risk populations.	UNIV UPPSALA, DEPT OBSTET & GYNECOL, ADOLESCENT HLTH CARE UNIT, S-75122 UPPSALA, SWEDEN	Uppsala University	GENC, M (corresponding author), UNIV UPPSALA, CTR STD RES, BOX 552, S-75122 UPPSALA, SWEDEN.							BEGLEY CE, 1989, SEX TRANSM DIS, V16, P63, DOI 10.1097/00007435-198904000-00004; BUHAUG H, 1989, MED CARE, V27, P833, DOI 10.1097/00005650-198908000-00007; CHERNESKY M, 1990, J INFECT DIS, V161, P124; EDGARDH K, 1987, LAKARTIDNINGEN, V84, P1845; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; FENG WC, 1977, JAMA-J AM MED ASSOC, V237, P896; GENC M, 1992, APMIS, V100, P645, DOI 10.1111/j.1699-0463.1992.tb03980.x; GODDEERIS JH, 1985, MED CARE, V23, P1242, DOI 10.1097/00005650-198511000-00003; HERRMANN BF, 1991, SEX TRANSM DIS, V18, P233, DOI 10.1097/00007435-199110000-00007; HILLIS SD, 1993, AM J OBSTET GYNECOL, V168, P1503, DOI 10.1016/S0002-9378(11)90790-X; JUDSON FN, 1989, J REP MED, V30, P269; KATZ BP, 1988, SEX TRANSM DIS, V15, P11, DOI 10.1097/00007435-198801000-00003; KAUFMAN RE, 1974, NEW ENGL J MED, V291, P1175, DOI 10.1056/NEJM197411282912208; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; MARDH PA, 1988, P EUROPEAN SOC CHLAM, P3; MARDH PA, 1989, CHLAMYDIA, P127; MARES I, 1992, GENITOURIN MED, V68, P344; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MOORE G, 1973, JAMA-J AM MED ASSOC, V224, P1499, DOI 10.1001/jama.224.11.1499; MUMTAZ G, 1991, INT J STD AIDS, V2, P359, DOI 10.1177/095646249100200510; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PALMER HM, 1991, J CLIN PATHOL, V44, P321, DOI 10.1136/jcp.44.4.321; PAPPIUS EM, 1984, SEX TRANSM DIS, V11, P123, DOI 10.1097/00007435-198407000-00002; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; Rahm V A, 1992, Lakartidningen, V89, P3675; RAHM VA, 1986, J SWED MED ASS, V83, P615; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; ROONGPISUTHIPONG A, 1988, SEX TRANSM DIS, V15, P192, DOI 10.1097/00007435-198810000-00003; SADOF MD, 1987, JAMA-J AM MED ASSOC, V258, P1932, DOI 10.1001/jama.258.14.1932; SCHACHTER J, 1986, NEW ENGL J MED, V314, P276, DOI 10.1056/NEJM198601303140503; SELLORS J, 1991, J CLIN MICROBIOL, V29, P407, DOI 10.1128/JCM.29.2.407-409.1991; SESTROM L, 1993, GENITORIN MED, V69, P9; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; STARY A, 1991, INFECTION, V19, P205, DOI 10.1007/BF01644946; THELIN I, 1982, GENITAL RELATED INFE, P163; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WASHINGTON AE, 1982, JAMA-J AM MED ASSOC, V22, pS157; WESTROM L, 1980, AM J OBSTET GYNECOL, V138, P880, DOI 10.1016/0002-9378(80)91077-7; Whatley J D, 1991, Int J STD AIDS, V2, P248; WOODS ER, 1991, J ADOLESCENT HEALTH, V12, P329, DOI 10.1016/0197-0070(91)90009-B; 1992, INCOME ALLOWANCES 19; 1990, GUIDELINES PREVENTIO, P38	44	57	57	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2057	2064		10.1001/jama.270.17.2057	http://dx.doi.org/10.1001/jama.270.17.2057			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8411572				2022-12-24	WOS:A1993MD88200024
J	HANCOCK, SL; TUCKER, MA; HOPPE, RT				HANCOCK, SL; TUCKER, MA; HOPPE, RT			FACTORS AFFECTING LATE MORTALITY FROM HEART-DISEASE AFTER TREATMENT OF HODGKINS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIATION-INDUCED PERICARDITIS; MEDIASTINAL IRRADIATION; BREAST-CANCER; CONSTRICTIVE PERICARDITIS; MYOCARDIAL-INFARCTION; CARDIAC DISEASE; RADIOTHERAPY; THERAPY; COMPLICATIONS; ADJUVANT	Objective.-To assess the risk of death from heart disease after Hodgkin's disease therapy. Design.-Retrospective study comparing treated patients with a matched general population. Setting.-Referral center. Patients.-A total of 2232 consecutive Hodgkin's disease patients treated from 1960 through 1991. Follow-up averaged 9.5 years. Main Outcome Measures.-Relative risks (RRs), the ratio of the observed to the expected cases with 95% confidence intervals (CIs), chi tests for trends, and Kaplan-Meier actuarial risks. Results.-Of the 2232 patients, 88 (3.9%) died of heart disease, 55 from acute myocardial infarction and 33 from other cardiac diseases, including congestive heart failure, radiation pericarditis or pancarditis, cardiomyopathy, or valvular heart disease. The RR for cardiac death was 3.1 (CI, 2.4 to 3.7). Mediastinal radiation of 30 Gy or less (n=385 patients) did not increase risk; above 30 Gy (n=1830), RR was 3.5 (CI, 2.7 to 4.3). Blocking to limit cardiac exposure reduced the RR for other cardiac diseases from 5.3 (CI, 3.1 to 7.5) to 1.4 (CI, 0.6 to 2.9), but not acute myocardial infarction (RR, 3.7 vs 3.4). The RRs increased with duration after treatment (trend in acute myocardial infarction, P=.02; in other cardiac diseases, P=.004). The RR for acute myocardial infarction was highest after irradiation before 20 years of age and decreased with increasing age at treatment (P<.0001 for trend). Conclusions.-Mediastinal irradiation for Hodgkin's disease increases the risk of subsequent death from heart disease. Risk increased with high mediastinal doses, minimal protective cardiac blocking, young age at irradiation, and increasing duration of follow-up.	NCI, GENET EPIDEMIOL BRANCH, ROCKVILLE, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HANCOCK, SL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.		Tucker, Margaret A/B-4297-2015		NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NCI NIH HHS [P0: CA-34233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNEST LS, 1983, J THORAC CARDIOV SUR, V85, P257; APPLEFELD MM, 1983, AM J CARDIOL, V51, P1679, DOI 10.1016/0002-9149(83)90209-6; BOICE JD, 1991, NIH913180 PUBL; BOIVIN JF, 1992, CANCER, V69, P1241; BOIVIN JF, 1982, CANCER-AM CANCER SOC, V49, P2470, DOI 10.1002/1097-0142(19820615)49:12<2470::AID-CNCR2820491210>3.0.CO;2-Y; BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; CAMERON J, 1987, AM HEART J, V113, P354, DOI 10.1016/0002-8703(87)90278-X; CARLSON RG, 1991, CHEST, V99, P538, DOI 10.1378/chest.99.3.538; CARMEL RJ, 1976, CANCER-AM CANCER SOC, V37, P2813, DOI 10.1002/1097-0142(197606)37:6<2813::AID-CNCR2820370637>3.0.CO;2-S; COHN KE, 1967, MEDICINE, V46, P281, DOI 10.1097/00005792-196705000-00003; COSSET JM, 1991, INT J RADIAT ONCOL, V21, P447, DOI 10.1016/0360-3016(91)90794-5; DONALDSON SS, 1990, SEMIN ONCOL, V17, P736; DONALDSON SS, 1982, CANCER TREAT REP, V66, P977; FOBAIR P, 1986, J CLIN ONCOL, V4, P805, DOI 10.1200/JCO.1986.4.5.805; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GOTTDIENER JS, 1983, NEW ENGL J MED, V308, P569, DOI 10.1056/NEJM198303103081005; GREENWOO.RD, 1974, CIRCULATION, V50, P1033, DOI 10.1161/01.CIR.50.5.1033; HANCOCK EW, 1983, NEW ENGL J MED, V308, P588, DOI 10.1056/NEJM198303103081010; HANCOCK SL, 1993, J CLIN ONCOL, V11, P1208, DOI 10.1200/JCO.1993.11.7.1208; HANCOCK SL, 1988, ANN INTERN MED, V109, P183, DOI 10.7326/0003-4819-109-3-183; HANCOCK SL, 1991, ANN INTERN MED, V114, P810, DOI 10.7326/0003-4819-114-9-810; HAYBITTLE JL, 1989, BRIT MED J, V298, P1611, DOI 10.1136/bmj.298.6688.1611; HORNING SJ, 1988, J CLIN ONCOL, V6, P1822, DOI 10.1200/JCO.1988.6.12.1822; JOENSUU H, 1989, CHEST, V95, P388, DOI 10.1378/chest.95.2.388; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN HS, 1980, HODGKINS DISEASE, P366; KAPLAN HS, 1972, HODGKINS DISEASE, P279; LEDERMAN GS, 1987, CANCER-AM CANCER SOC, V60, P772, DOI 10.1002/1097-0142(19870815)60:4<772::AID-CNCR2820600411>3.0.CO;2-A; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MILL WB, 1984, INT J RADIAT ONCOL, V10, P2061, DOI 10.1016/0360-3016(84)90203-7; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MORTON DL, 1973, CHEST, V64, P291, DOI 10.1378/chest.64.3.291; POHJOLASINTONEN S, 1987, CANCER-AM CANCER SOC, V60, P31, DOI 10.1002/1097-0142(19870701)60:1<31::AID-CNCR2820600107>3.0.CO;2-D; ROSENBERG SA, 1991, ANN ONCOL, V2, P29, DOI 10.1093/annonc/2.suppl_2.29; ROSENBERG SA, 1992, EUR J CANCER, V28A, P1379, DOI 10.1016/0959-8049(92)90524-6; RUBIN E, 1963, AM J MED, V34, P71, DOI 10.1016/0002-9343(63)90039-1; RUTQVIST LE, 1990, BRIT J CANCER, V61, P866, DOI 10.1038/bjc.1990.193; STEWART JR, 1984, PROG CARDIOVASC DIS, V27, P173; STEWART JR, 1971, RADIOLOGY, V99, P403, DOI 10.1148/99.2.403; STEWART JR, 1967, RADIOLOGY, V89, P302, DOI 10.1148/89.2.302; STRENDER LE, 1986, CANCER, V57, P929, DOI 10.1002/1097-0142(19860301)57:5<929::AID-CNCR2820570509>3.0.CO;2-6; 1993, MMWR MORB MORTAL WKL, V42, P230; 1988, PHS8811502 US DEP HL, P12; 1989, CDC898411 US DEP HLT	44	568	587	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	1993	270	16					1949	1955		10.1001/jama.270.16.1949	http://dx.doi.org/10.1001/jama.270.16.1949			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC513	8411552				2022-12-24	WOS:A1993MC51300026
J	SADLACK, B; MERZ, H; SCHORLE, H; SCHIMPL, A; FELLER, AC; HORAK, I				SADLACK, B; MERZ, H; SCHORLE, H; SCHIMPL, A; FELLER, AC; HORAK, I			ULCERATIVE COLITIS-LIKE DISEASE IN MICE WITH A DISRUPTED INTERLEUKIN-2 GENE	CELL			English	Article							INFLAMMATORY BOWEL-DISEASE; EMBRYONIC STEM-CELLS; GERM-LINE TRANSMISSION; T-CELLS; INTRAEPITHELIAL LYMPHOCYTES; RECOMBINANT INTERLEUKIN-2; PERIPHERAL-BLOOD; GUT EPITHELIUM; HPRT GENE; EXPRESSION	Mice deficient for interleukin-2 develop normally during the first 3-4 weeks of age. However, later on they become severely compromised, and about 50% of the animals die between 4 and 9 weeks after birth. Of the remaining mice, 100% develop an inflammatory bowel disease with striking clinical and histological similarity to ulcerative colitis in humans. The alterations of the immune system are characterized by a high number of activated T and B cells, elevated immunoglobin secretion, anti-colon antibodies, and aberrant expression of class II major histocompatibility complex molecules. The data provide evidence for a primary role of the immune system in the etiology of ulcerative colitis and strongly suggest that the disease results from an abnormal immune response to a normal antigenic stimulus.	MED UNIV LUBECK, INST PATHOL, D-23562 LUBECK, GERMANY	University of Lubeck	SADLACK, B (corresponding author), UNIV WURZBURG, INST VIROL & IMMUNOBIOL, VERSBACHER STR 7, D-97078 WURZBURG, GERMANY.		Schorle, Hubert/S-1713-2019; Schorle, Hubert/M-5001-2016; Feller, Alfred/E-3853-2010	Schorle, Hubert/0000-0001-8272-0076; 				BLAND P, 1988, IMMUNOL TODAY, V9, P174, DOI 10.1016/0167-5699(88)91293-5; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; BUDD RC, 1987, J IMMUNOL, V138, P3120; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; FUJIHASHI K, 1990, J IMMUNOL, V145, P2010; FUKUSHIMA K, 1991, GASTROENTEROLOGY, V101, P670, DOI 10.1016/0016-5085(91)90524-O; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HIBI T, 1990, GUT, V31, P1371, DOI 10.1136/gut.31.12.1371; HOANG P, 1991, CLIN EXP IMMUNOL, V85, P498; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; KAPLAN G, 1991, J EXP MED, V173, P993, DOI 10.1084/jem.173.4.993; KOBAYASHI K, 1988, J CLIN LAB IMMUNOL, V25, P63; KUSUGAMI K, 1991, GASTROENTEROLOGY, V101, P1594, DOI 10.1016/0016-5085(91)90397-4; LOWES JR, 1990, SPRINGER SEMIN IMMUN, V12, P251; MACDERMOTT RP, 1981, GASTROENTEROLOGY, V81, P844; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; ROSENBERG SA, 1988, IMMUNOL TODAY, V9, P58, DOI 10.1016/0167-5699(88)91261-3; RUDZIK O, 1974, LAB INVEST, V30, P260; SARTOR RB, 1992, INFLAMM BOWEL DIS, P337; SARTOR RB, 1990, CAN J GASTROENTEROL, V4, P271; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCOTT MG, 1986, CLIN EXP IMMUNOL, V66, P209; SEDGWICK JD, 1990, FOCUS LABORATORY MET, P103; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMITH KA, 1992, CURR OPIN IMMUNOL, V4, P271, DOI 10.1016/0952-7915(92)90076-Q; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P647, DOI 10.1016/0016-5085(88)90235-1; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	42	1495	1545	3	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					253	261		10.1016/0092-8674(93)80067-O	http://dx.doi.org/10.1016/0092-8674(93)80067-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	8402910				2022-12-24	WOS:A1993MD88500007
J	HALPERN, ME; HO, RK; WALKER, C; KIMMEL, CB				HALPERN, ME; HO, RK; WALKER, C; KIMMEL, CB			INDUCTION OF MUSCLE PIONEERS AND FLOOR PLATE IS DISTINGUISHED BY THE ZEBRAFISH NO TAIL MUTATION	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL-TUBE FORMATION; SPINAL-CORD; EXPRESSION PATTERN; MESODERM INDUCTION; BRACHYDANIO-RERIO; BRACHYURY T; NOTOCHORD; EMBRYOS; TISSUE	Dorsal mesoderm is thought to provide important signals for axis formation and neural differentiation invertebrate embryos. We have examined induction and patterning in a zebrafish mutant, no tail, that lacks a derivative of dorsal mesoderm, the notochord. Despite the absence of a differentiated notochord, development of the central nervous system including floor plate appears normal, likely owing to the presence of notochord precursor cells. In contrast, somites are misshapen, and muscle pioneer cells are absent. Wild-type cells transplanted into mutant hosts can autonomously differentiate into notochord and thereby rescue somitic defects, suggesting that interactions between notochord and paraxial mesoderm are necessary for proper somite patterning. Thus, cells derived from dorsal mesoderm may have multiple signaling functions during zebrafish embryogenesis.			HALPERN, ME (corresponding author), UNIV OREGON, INST NEUROSCI, EUGENE, OR 97403 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021132] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22486] Funding Source: Medline; NINDS NIH HHS [NS21132] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; Dobrovolskaia-Zavadskaia N, 1927, CR SOC BIOL, V97, P114; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; FELSENFELD AL, 1991, DEV BIOL, V148, P23, DOI 10.1016/0012-1606(91)90314-S; GERHART J, 1991, BOD MAR LAB, P57; GRIFFITH CM, 1992, ANAT EMBRYOL, V185, P101; HANNEMAN E, 1989, J COMP NEUROL, V284, P350, DOI 10.1002/cne.902840303; HATTA K, 1991, DEVELOPMENT, V112, P821; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; Ho R.K., 1992, Seminars in Developmental Biology, V3, P53; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HUMPHREY CD, 1974, STAIN TECHNOL, V49, P9, DOI 10.3109/10520297409116929; JESSELL TM, 1992, SEMIN NEUROSCI, V4, P317; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1991, CURR TOP DEV BIOL, V25, P77; KIMMEL CB, 1991, DEVELOPMENT, P47; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1985, DEV BIOL, V108, P94, DOI 10.1016/0012-1606(85)90012-0; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; LYONS GE, 1991, DEVELOPMENT, V111, P233; OPPENHEIMER JM, 1959, J EXP ZOOL, V140, P247, DOI 10.1002/jez.1401400205; PAPALOPULU N, 1992, SEMIN NEUROSCI, V4, P295; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PIKE SH, 1992, DEVELOPMENT, V114, P825; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; RASHBASS P, 1991, NATURE, V353, P348, DOI 10.1038/353348a0; RONG PM, 1992, DEVELOPMENT, V115, P657; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SHIH J, 1992, DEVELOPMENT, V116, P915; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; Spemann H., 1938, EMBRYONIC DEV INDUCT; STREISINGER G, 1986, GENETICS, V112, P311; STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0; THOROGOOD P, 1987, J CELL SCI, P395; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; VANRAAMSDONK W, 1978, ANAT EMBRYOL, V153, P137; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; VANSTRAATEN HWM, 1985, ACTA MORPHOL NEER SC, V23, P91; WALKER C, 1983, GENETICS, V103, P125; WARGA RM, 1990, DEVELOPMENT, V108, P569; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YANAGISAWA KO, 1981, DEV BIOL, V87, P242, DOI 10.1016/0012-1606(81)90147-0; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	54	466	481	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					99	111		10.1016/0092-8674(93)90682-G	http://dx.doi.org/10.1016/0092-8674(93)90682-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402905				2022-12-24	WOS:A1993MB66700011
J	JAIN, JN; MCCAFFREY, PG; MINER, Z; KERPPOLA, TK; LAMBERT, JN; VERDINE, GL; CURRAN, T; RAO, A				JAIN, JN; MCCAFFREY, PG; MINER, Z; KERPPOLA, TK; LAMBERT, JN; VERDINE, GL; CURRAN, T; RAO, A			THE T-CELL TRANSCRIPTION FACTOR NFAT(P) IS A SUBSTRATE FOR CALCINEURIN AND INTERACTS WITH FOS AND JUN	NATURE			English	Article							DNA-BINDING ACTIVITY; CYCLOSPORINE-A; SIGNAL TRANSDUCTION; ACTIVATION; IDENTIFICATION; FK-506; PROTEIN; DOMAINS; ASSOCIATION; ENHANCER	TRANSCRIPTION of lymphokine genes in activated T cells is inhibited by the immunosuppressive agents cyclosporin A and FK506, which act by blocking the phosphatase activity of calcineurin1-3. NFAT, a DNA-binding protein required for interleukin-2 gene transcription, is a potential target for calcineurin, cyclosporin A and FK506(4-11). NFAT contains a subunit (NFAT(p)) which is present in unstimulated T cells and which forms a complex with Fos and Jun proteins in the nucleus of activated T cells9,11. Here we report that NFAT(p) is a DNA-binding phosphoprotein of relative molecular mass approximately 120,000 and is a substrate for calcineurin in vitro. Purified NFAT(p) forms DNA-protein complexes with recombinant Jun homodimers or Jun-Fos heterodimers; the DNA-binding domains of Fos and Jun are essential for the formation of the NFAT(p)-Fos-Jun-DNA complex. The interaction between the lymphoid-specific factor NFAT(p) and the ubiquitous transcription factors Fos and Jun provides a novel mechanism for combinatorial regulation of interleukin-2 gene transcription, which integrates the calcium-dependent and the protein-kinase C-dependent pathways of T-cell activation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Roche Holding; Harvard University			Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018; Kerppola, Tom/AAG-4457-2022	Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL JP, 1993, P NATL ACAD SCI USA, V90, P2466; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; VAIGEARCHER VE, 1990, J IMMUNOL, V145, P4355; WALSH CT, 1992, J BIOL CHEM, V267, P13115; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	28	696	707	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					352	355		10.1038/365352a0	http://dx.doi.org/10.1038/365352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8397339				2022-12-24	WOS:A1993LY49600056
J	THIRMAN, MJ; GILL, HJ; BURNETT, RC; MBANGKOLLO, D; MCCABE, NR; KOBAYASHI, H; ZIEMINVANDERPOEL, S; KANEKO, Y; MORGAN, R; SANDBERG, AA; CHAGANTI, RSK; LARSON, RA; LEBEAU, MM; DIAZ, MO; ROWLEY, JD				THIRMAN, MJ; GILL, HJ; BURNETT, RC; MBANGKOLLO, D; MCCABE, NR; KOBAYASHI, H; ZIEMINVANDERPOEL, S; KANEKO, Y; MORGAN, R; SANDBERG, AA; CHAGANTI, RSK; LARSON, RA; LEBEAU, MM; DIAZ, MO; ROWLEY, JD			REARRANGEMENT OF THE MLL GENE IN ACUTE LYMPHOBLASTIC AND ACUTE MYELOID LEUKEMIAS WITH 11Q23 CHROMOSOMAL TRANSLOCATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL LYMPHOMA; CLINICAL CHARACTERISTICS; DROSOPHILA-TRITHORAX; T(4-11); BREAKPOINT; BAND-11Q23; T(11-19)(Q23-P13); T(4-11)(Q21-Q23); NEOPLASIA; INVITRO	Background. Translocations involving chromosome band 11q23 are very frequent in both acute lymphoblastic and acute myeloid leukemias and are the most common genetic alteration in infants with leukemia, In all age groups and all phenotypes of leukemia, an 11q23 translocation carries a poor prognosis. A major question has been whether one or several genes on band 11q23 are implicated in these leukemias. Previously, we identified the chromosomal breakpoint region in leukemias with the common 11q23 translocations and subsequently cloned a gene named MLL that spans the 11q23 breakpoint. Methods. We isolated a 0.74-kb BamHI fragment from a complementary DNA (cDNA) clone of the MLL gene. To determine the incidence of MLL rearrangements in patients with 11q23 abnormalities, we analyzed DNA from 61 patients with acute leukemia, 3 cell lines derived from such patients, and 20 patients with non-Hodgkin's lymphoma and 11q23 aberrations. Results. The 0.74-kb cDNA probe detected DNA rearrangements in the MLL gene in 58 of the patients with leukemia, in the 3 cell lines, and in 3 of the patients with lymphoma. All the breaks occurred in an 8.3-kb breakpoint cluster region within the MLL gene. The probe identified DNA rearrangements in all 48 patients with the five common 11q23 translocations involving chromosomes 4, 6,9, and 19, as well as in 16 patients with uncommon 11q23 aberrations. Twenty-one different chromosomal breakpoints involving the MLL gene were detected. Conclusions. MLL gene rearrangements were detected with a single probe and a single restriction-enzyme digest in all DNA samples from patients with the common 11q23 translocations as well as in 16 patients or cell lines with other 11q23 anomalies. The ability to detect an MLL gene rearrangement rapidly and reliably, especially in patients with limited material for cytogenetic analysis, should make it possible to identify patients who have a poor prognosis and therefore require aggressive chemotherapy or marrow transplantation.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; SW BIOMED RES INST,SCOTTSDALE,AZ; GENETRIX INC,SCOTTSDALE,AZ	University of Chicago; University of Chicago; Memorial Sloan Kettering Cancer Center	THIRMAN, MJ (corresponding author), UNIV CHICAGO,DEPT MED,HEMATOL & ONCOL SECT,CHICAGO,IL 60637, USA.			Larson, Richard/0000-0001-9168-3203	NCI NIH HHS [CA42557, CA40046, CA38725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA038725, R35CA042557, R01CA038725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1990, CANCER RES, V50, P4856; ARTHUR DC, 1982, BLOOD, V59, P96; BLOOMFIELD CD, 1992, LEUKEMIA, V6, P65; BURNETT RC, 1993, GENE CHROMOSOME CANC, V7, P38, DOI 10.1002/gcc.2870070107; CHEN CS, 1993, BLOOD, V81, P2386; CHEN CS, 1991, BLOOD, V78, P2498; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHERIF D, 1992, GENE CHROMOSOME CANC, V4, P107, DOI 10.1002/gcc.2870040202; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CUNEO A, 1992, BLOOD, V79, P720; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DREXLER HG, 1991, LEUKEMIA, V5, P637; FENAUX P, 1992, BLOOD, V80, P2176; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HUDSON MM, 1991, LEUKEMIA, V5, P1064; HURET JL, 1993, LEUKEMIA, V7, P152; KANEKO Y, 1988, LEUKEMIA, V2, P672; KARPAS A, 1977, LEUKEMIA RES, V1, P35, DOI 10.1016/0145-2126(77)90063-7; KOBAYASHI H, 1993, BLOOD, V82, P547; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1053, DOI 10.1159/000133721; MITELMAN F, 1991, INT SYSTEM HUMAN C S, V6; MITELMAN F, 1991, CATALOG CHROMOSOME A; NICHOLS J, 1992, BLOOD, V80, P2953; NUCIFORA G, 1993, BLOOD, V81, P2728; PUI CH, 1991, BLOOD, V77, P440; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SMITH SD, 1989, BLOOD, V73, P2182; STONG RC, 1985, BLOOD, V66, P439; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANDERPOEL SZ, 1992, P NATL ACAD SCI USA, V89, P4220; WESTBROOK CA, 1992, BLOOD, V80, P2983; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; 1984, CANCER GENET CYTOGEN, V11, P332; 1989, CANCER GENET CYTOGEN, V40, P171	46	480	488	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					909	914		10.1056/NEJM199309233291302	http://dx.doi.org/10.1056/NEJM199309233291302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361504				2022-12-24	WOS:A1993LX75100002
J	SHAW, AL; ROTHNAGEL, R; CHEN, D; RAMIG, RF; CHIU, W; PRASAD, BVV				SHAW, AL; ROTHNAGEL, R; CHEN, D; RAMIG, RF; CHIU, W; PRASAD, BVV			3-DIMENSIONAL VISUALIZATION OF THE ROTAVIRUS HEMAGGLUTININ STRUCTURE	CELL			English	Article							CELL-ATTACHMENT PROTEIN; CRYOELECTRON MICROSCOPY; ELECTRON-MICROGRAPHS; RHESUS ROTAVIRUS; INFLUENZA-VIRUS; RNA SEGMENT; REOVIRUS; IDENTIFICATION; SIGMA-1; GENE	Three-dimensional structures of a native simian and reassortant rotavirus have been determined by electron cryomicroscopy and computer image processing. The structural features of the native virus confirm that the hemagglutinin spike is a dimer of VP4, substantiated by in vivo radiolabeling studies. Exchange of native VP4 with a bovine strain equivalent results in a poorly infectious reassortant. No VP4 spikes are detected in the three-dimensional reconstruction of the reassortant. The difference map between the two structures reveals a novel large globular domain of VP4 buried within the virion that interacts extensively with the intermediate shell protein, VP6. Our results suggest that assembly of VP4 precedes that of VP7, the major outer shell protein, and that VP4 may play an important role in the receptor recognition and budding process through the rough endoplasmic reticulum during virus maturation.	BAYLOR COLL MED, WM KECK CTR COMPUTAT BIOL, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Baylor College of Medicine	SHAW, AL (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA.			Prasad, B.V.Venkataram/0000-0002-1172-2071	NCRR NIH HHS [RR02250] Funding Source: Medline; NIAID NIH HHS [AI16687] Funding Source: Medline; NIGMS NIH HHS [GM41064] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016687, R22AI016687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041064] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KS, 1993, VIROLOGY, V194, P665, DOI 10.1006/viro.1993.1306; AU KS, 1988, UCLA S MOL CELL BIOL, V90, P257; BAKER TS, 1990, J VIROL, V64, P563, DOI 10.1128/JVI.64.2.563-573.1990; BASS DM, 1991, VIROLOGY, V183, P602, DOI 10.1016/0042-6822(91)90989-O; BASSELDUBY R, 1987, J VIROL, V61, P1834, DOI 10.1128/JVI.61.6.1834-1841.1987; BURNS JW, 1989, VIROLOGY, V169, P427, DOI 10.1016/0042-6822(89)90168-2; CHEN DY, 1992, J VIROL, V66, P432, DOI 10.1128/JVI.66.1.432-439.1992; CHEN DY, 1992, VIROLOGY, V186, P228, DOI 10.1016/0042-6822(92)90077-3; CHEN DY, 1989, P NATL ACAD SCI USA, V86, P3743, DOI 10.1073/pnas.86.10.3743; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ENDRES MJ, 1989, J GEN VIROL, V70, P223, DOI 10.1099/0022-1317-70-1-223; ENDRES MJ, 1991, J VIROL, V65, P5465, DOI 10.1128/JVI.65.10.5465-5470.1991; ERICKSON HP, 1971, PHILOS T ROY SOC B, V261, P105, DOI 10.1098/rstb.1971.0040; ESPEJO RT, 1981, J VIROL, V37, P156, DOI 10.1128/JVI.37.1.156-160.1981; Estes M. K., 1990, VIROLOGY, P1329; ESTES MK, 1983, CURR TOP MICROBIOL, V105, P123; ESTES MK, 1981, J VIROL, V39, P879, DOI 10.1128/JVI.39.3.879-888.1981; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; HALL CE, 1966, INTRO ELECTRON MICRO; HIRST GK, 1962, COLD SPRING HARB SYM, V27, P303, DOI 10.1101/SQB.1962.027.001.028; HOGUE BG, 1989, J GEN VIROL, V70, P345, DOI 10.1099/0022-1317-70-2-345; JENG TW, 1988, J ELECTRON MICR TECH, V8, P343, DOI 10.1002/jemt.1060080402; KALICA AR, 1983, VIROLOGY, V125, P194, DOI 10.1016/0042-6822(83)90073-9; KALJOT KT, 1988, J VIROL, V62, P1136, DOI 10.1128/JVI.62.4.1136-1144.1988; Kapikian AZ, 1990, VIROLOGY, P1353; LABBE M, 1991, J VIROL, V65, P2946; LAVER WG, 1989, VIROLOGY, V171, P291; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; LIU M, 1988, VIROLOGY, V163, P26, DOI 10.1016/0042-6822(88)90230-9; MAASS DR, 1990, J VIROL, V64, P2632, DOI 10.1128/JVI.64.6.2632-2641.1990; MATTION NM, 1991, ARCH VIROL, V120, P109, DOI 10.1007/BF01310953; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; OFFIT PA, 1986, J VIROL, V57, P46, DOI 10.1128/JVI.57.1.46-49.1986; PEREIRA HG, 1984, J GEN VIROL, V65, P815, DOI 10.1099/0022-1317-65-4-815; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRASAD BVV, 1993, IN PRESS CURR TOPICS; RAMIG RF, 1991, ADV VIRUS RES, V39, P163; RITCHEY MB, 1976, J VIROL, V20, P307, DOI 10.1128/JVI.20.1.307-313.1976; RUGGERI FM, 1991, J VIROL, V65, P2211, DOI 10.1128/JVI.65.5.2211-2219.1991; SMITH MF, 1992, J MOL BIOL, V226, P763, DOI 10.1016/0022-2836(92)90631-S; STIRZAKER SC, 1987, J CELL BIOL, V105, P2897, DOI 10.1083/jcb.105.6.2897; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; WEINER HL, 1978, VIROLOGY, V86, P581, DOI 10.1016/0042-6822(78)90099-5; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; YEAGER M, 1990, J CELL BIOL, V110, P2133, DOI 10.1083/jcb.110.6.2133; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	54	111	116	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					693	701		10.1016/0092-8674(93)90516-S	http://dx.doi.org/10.1016/0092-8674(93)90516-S			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8395350	Green Published, Bronze			2022-12-24	WOS:A1993LU59200012
J	PAWLOWSKI, T; ELLIOTT, JD; LOH, DY; STAERZ, UD				PAWLOWSKI, T; ELLIOTT, JD; LOH, DY; STAERZ, UD			POSITIVE SELECTION OF T-LYMPHOCYTES ON FIBROBLASTS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL RECEPTOR; HEMATOPOIETIC-CELLS; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; MICE; THYMUS; LINE; DIFFERENTIATION; SPECIFICITY	THYMOCYTES are selected for expression of alphabeta T-cell antigen receptors (TCR) which recognize antigen in conjunction with self-major histocompatibility complex (MHC) molecules1,2. In the thymus the restriction element is imprinted on radioresistant stromal elements3-7 and on cells of haematopoietic origin8-10. In mice negative for beta2-microglobulin that are devoid of mature cytotoxic T lymphocytes11, we find that intrathymic injection of different fibroblasts causes the maturation of CD4-CD8+TCR(high) thymocytes with distinct patterns of TCR Vbeta distribution. Here we show that in TCR-transgenic mice, intrathymic injection of L cells expressing the selecting H-2K(b) molecule (L-K(b) cells) reconstitutes the maturation of thymocytes bearing the- transgenic TCR, and that in normal B10.BR (H-2k) mice, H-2K(b) Molecules expressed on L-K(b) cells lead to the development of T lymphocytes with recognition restricted to H-2K(b). A class I MHC restriction element can thus be selected by interaction with fibroblasts, that is, cells of other than epithelial or haematopoietic origin3-10.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT IMMUNOL,ST LOUIS,MO 63110; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	PAWLOWSKI, T (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.							ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BERNSTEIN ID, 1980, SCIENCE, V207, P68, DOI 10.1126/science.6965328; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; HUGO P, 1992, NATURE, V360, P679, DOI 10.1038/360679a0; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUBO RT, 1989, J IMMUNOL, V142, P2736; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW WC, 1990, P NATL ACAD SCI USA, V87, P6186; SHAW WC, 1988, NATURE, V333, P742; SPEISER DE, 1992, NATURE, V355, P170, DOI 10.1038/355170a0; SPRENT J, 1978, J EXP MED, V147, P1159, DOI 10.1084/jem.147.4.1159; STAERZ UD, 1986, EUR J IMMUNOL, V16, P263, DOI 10.1002/eji.1830160310; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	28	92	92	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					642	645		10.1038/364642a0	http://dx.doi.org/10.1038/364642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350923				2022-12-24	WOS:A1993LR77100057
J	SCULPTOREANU, A; SCHEUER, T; CATTERALL, WA				SCULPTOREANU, A; SCHEUER, T; CATTERALL, WA			VOLTAGE-DEPENDENT POTENTIATION OF L-TYPE CA2+ CHANNELS DUE TO PHOSPHORYLATION BY CAMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							SKELETAL-MUSCLE FIBERS; CALCIUM CHANNELS; CA-2+ CURRENT; CONTRACTION; FROG; TWITCHES; CELLS	THE force of contraction of motor units in skeletal muscle is graded by changing the discharge rate of motor neurons1, and cytosolic calcium transients are similarly increased2. During single twitches, contraction is not dependent on extracellular calcium3, and L-type Ca2+ channels may only function as voltage sensors for initiating Ca2+ release from the sarcoplasmic reticulum4-6. In contrast, forceful tetanic contractions triggered by action potentials at high frequency (20 to 200 Hz) are dependent on extracellular Ca2+ concentration and sensitive to L-type Ca2+ channel antagonists7-9, but the mechanism of regulation of contractile force is unknown. Here we report a large, voltage- and frequency-dependent potentiation of skeletal muscle L-type Ca2+ currents by trains of high-frequency depolarizing prepulses, which is caused by a shift in the voltage-dependence of channel activation to more negative membrane potentials and requires phosphorylation by cyclic AMP-dependent protein kinase in a voltage-dependent manner. This potentiation would substantially increase Ca2+ influx and contractile force in skeletal muscle fibres in response to tetanic stimuli.			SCULPTOREANU, A (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195, USA.							ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; ARREOLA J, 1987, J PHYSIOL-LONDON, V393, P307, DOI 10.1113/jphysiol.1987.sp016825; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; DULHUNTY AF, 1988, J PHYSIOL-LONDON, V399, P63; FEDIDA D, 1988, J PHYSIOL-LONDON, V405, P439, DOI 10.1113/jphysiol.1988.sp017341; FELDMEYER D, 1990, J PHYSIOL-LONDON, V425, P347, DOI 10.1113/jphysiol.1990.sp018107; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KERNELL D, 1983, EXP BRAIN RES, V50, P220; KOTSIAS BA, 1986, AM J PHYSIOL, V250, pC40, DOI 10.1152/ajpcell.1986.250.1.C40; LAWRENCE JC, 1981, J BIOL CHEM, V256, P6223; LEE KS, 1987, P NATL ACAD SCI USA, V84, P3941, DOI 10.1073/pnas.84.11.3941; MILEDI R, 1982, J PHYSIOL-LONDON, V333, P655, DOI 10.1113/jphysiol.1982.sp014474; OZ M, 1991, J PHARMACOL EXP THER, V257, P575; PIETROBON D, 1990, NATURE, V346, P651, DOI 10.1038/346651a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0	21	228	231	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					240	243		10.1038/364240a0	http://dx.doi.org/10.1038/364240a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8391648				2022-12-24	WOS:A1993LM68300058
J	PFEFFER, K; MATSUYAMA, T; KUNDIG, TM; WAKEHAM, A; KISHIHARA, K; SHAHINIAN, A; WIEGMANN, K; OHASHI, PS; KRONKE, M; MAK, TW				PFEFFER, K; MATSUYAMA, T; KUNDIG, TM; WAKEHAM, A; KISHIHARA, K; SHAHINIAN, A; WIEGMANN, K; OHASHI, PS; KRONKE, M; MAK, TW			MICE DEFICIENT FOR THE 55KD TUMOR-NECROSIS-FACTOR RECEPTOR ARE RESISTANT TO ENDOTOXIC-SHOCK, YET SUCCUMB TO L-MONOCYTOGENES INFECTION	CELL			English	Article							FACTOR TNF RECEPTOR; MOLECULAR-CLONING; FACTOR-ALPHA; STEM-CELLS; T-CELLS; KAPPA-B; ANTIBACTERIAL RESISTANCE; MONOCLONAL-ANTIBODIES; INDUCED HEPATITIS; BINDING PROTEIN	The multiple biological activities of tumor necrosis factor (TNF) are mediated by two distinct cell surface receptors of 55 kd (TNFRp55) and 75 kd (TNFRp75). Using gene targeting, we generated a TNFRp55-deficient mouse strain. Cells from TNFRp55-/- mutant mice lack expression of TNFRp55 but display normal numbers of high affinity TNFRp75 molecules. Thymocyte development and lymphocyte populations are unaltered, and clonal deletion of potentially self-reactive T cells is not impaired. However, TNF signaling is largely abolished, as judged by the failure of TNF to induce NF-kappaB in T lymphocytes from TNFRp55-deficient mice. The loss of TNFRp55 function renders mice resistant to lethal dosages of either lipopolysaccharides or S. aureus enterotoxin B. In contrast, TNFRp55-deficient mice are severely impaired to clear L. monocytogenes and readily succumb to infection. Thus, the 55 kd TNFR plays a decisive role in the host's defense against microorganisms and their pathogenic factors.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; TECH UNIV MUNICH,INST MED MICROBIOL & HYG,W-8000 MUNICH 80,GERMANY	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Technical University of Munich	PFEFFER, K (corresponding author), AMGEN INST,TORONTO M4X 1K9,ON,CANADA.			Pfeffer, Klaus/0000-0002-5652-6330; Ohashi, Pamela S./0000-0003-2915-9317				ABE R, 1992, J IMMUNOL, V149, P3429; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLANCHARD DK, 1989, J LEUKOCYTE BIOL, V45, P538, DOI 10.1002/jlb.45.6.538; BLANCHARD DK, 1992, TUMOR NECROSIS FACTO, P293; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BRADLEY A, 1986, CURR TOP DEV BIOL, V20, P357, DOI 10.1016/S0070-2153(08)60675-4; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CLARK IA, 1992, TUMOR NECROSIS FACTO, P303; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; DINARELLO CA, 1992, INT J TISSUE REACT, V14, P65; DURUM SK, 1985, ANNU REV IMMUNOL, V3, P263; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIROIR BP, 1992, J CLIN INVEST, V90, P693, DOI 10.1172/JCI115939; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOODING LR, 1992, CELL, V71, P5; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRAU GE, 1992, TUMOR NECROSIS FACTO, P329; GRAY PW, 1990, P NATL ACAD SCI USA, V87, P7380, DOI 10.1073/pnas.87.19.7380; GRONER B, 1980, J VIROL, V36, P734, DOI 10.1128/JVI.36.3.734-745.1980; HAUSER T, 1990, MED MICROBIOL IMMUN, V179, P95; HAVELL EA, 1989, J IMMUNOL, V143, P2894; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HELLER RA, 1992, CELL, V70, P47; HEPPNER G, 1965, J BACTERIOL, V90, P696, DOI 10.1128/JB.90.3.696-703.1965; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; KATO K, 1989, MED MICROBIOL IMMUN, V178, P337; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAKANE A, 1988, INFECT IMMUN, V56, P731; NAKANE A, 1992, TUMOR NECROSIS FACTO, P285; NAKANO Y, 1990, J IMMUNOL, V144, P1935; NAUME B, 1991, J IMMUNOL, V146, P3045; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OHSAWA T, 1989, DEV BIOL, V135, P459, DOI 10.1016/0012-1606(89)90194-2; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; ROLL JT, 1990, IMMUNOLOGY, V69, P316; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VOGEL SN, 1992, TUMOR NECROSIS FACTO, P485; WENDEL A, 1987, BIOCHEM PHARMACOL, V36, P2637, DOI 10.1016/0006-2952(87)90544-2; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	73	1541	1594	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					457	467		10.1016/0092-8674(93)90134-C	http://dx.doi.org/10.1016/0092-8674(93)90134-C			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8387893				2022-12-24	WOS:A1993LA74300008
J	FONG, TM; CASCIERI, MA; YU, H; BANSAL, A; SWAIN, C; STRADER, CD				FONG, TM; CASCIERI, MA; YU, H; BANSAL, A; SWAIN, C; STRADER, CD			AMINO AROMATIC INTERACTION BETWEEN HISTIDINE-197 OF THE NEUROKININ-1 RECEPTOR AND CP-96345	NATURE			English	Article							SUBSTANCE-P RECEPTOR; MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; ANTAGONIST; PEPTIDES; PROTEINS; NEURONS; BINDING; POTENT; RINGS	SUBSTANCE P is a peptide neurotransmitter that binds to the neurokinin-1 receptor and is involved in pain transmission and neurogenic inflammation1-4. Recently, a non-peptide substance P antagonist (CP 96345) has been shown to be effective in animal models of pain and inflammation5,6. An understanding of the molecular interactions responsible for ligand binding will be critical for the development of more specific and selective antagonists for the neurokinin-I receptor and for the discovery of new antagonists for related G-protein-coupled receptors. Here we report that histidine at position 197 in the fifth transmembrane helix of the human neurokinin-1 receptor binds specifically to CP 96345 but not to peptide agonists. Substitution of His 197 by different amino acids and analysis of structural analogues of antagonists suggest that His 197 is involved in an amino-aromatic interaction with the benzhydryl moiety of CP 96345.	MERCK SHARP & DOHME LTD, NEUROSCI RES CTR, HARLOW CM20 2PT, ESSEX, ENGLAND	Merck & Company	FONG, TM (corresponding author), MERCK RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM 80M213, POB 2000, RAHWAY, NJ 07065 USA.							BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DEAKYNE CA, 1985, J AM CHEM SOC, V107, P474; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, MOL PHARMACOL, V41, P24; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; KHORANA HG, 1992, J BIOL CHEM, V267, P1; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; NAKANISHI S, 1991, REV NEUROSCI, V14, P123; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	25	212	213	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					350	353						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8384323				2022-12-24	WOS:A1993KU17600063
J	WAHLESTEDT, C; PICH, EM; KOOB, GF; YEE, F; HEILIG, M				WAHLESTEDT, C; PICH, EM; KOOB, GF; YEE, F; HEILIG, M			MODULATION OF ANXIETY AND NEUROPEPTIDE-Y-Y1 RECEPTORS BY ANTISENSE OLIGODEOXYNUCLEOTIDES	SCIENCE			English	Article							PANCREATIC-POLYPEPTIDE; FEEDING-BEHAVIOR; PEPTIDE-YY; RAT-BRAIN; NPY; HETEROGENEITY; INVOLVEMENT; EXPRESSION; CELLS; MAZE	The function of neuropeptide Y, one of the most abundant peptide transmitters of the mammalian brain, remains unclear because of a lack of specific receptor antagonists. An antisense oligodeoxynucleotide corresponding to the NH2-terminus of the rat Y1 receptor was constructed and added to cultures of rat cortical neurons. This treatment resulted in a reduced density of Y1 (but not Y2) receptors and diminished the decrease in adenosine 3',5'-monophosphate (cAMP) usually seen after Y1 receptor activation. Repeated injection of the same oligodeoxynucleotide into the lateral cerebral ventricle of rats was followed by a similar reduction of cortical Y1 (but not Y2) receptors. Such antisense-treated animals displayed behavioral signs of anxiety. Thus, specific inhibition of neurotransmitter receptor expression can be accomplished in the living brain and demonstrates that altered central, neuropeptide Y transmission produces an anxiety-like state.	CORNELL UNIV, MED CTR,COLL MED,DEPT NEUROL & NEUROSCI, DIV NEUROBIOL, NEW YORK, NY 10021 USA; Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Cornell University; Scripps Research Institute			Wahlestedt, Claes/A-7039-2009					ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; AICHER SA, 1991, NEUROSCI LETT, V130, P32, DOI 10.1016/0304-3940(91)90220-N; Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; BURCH RM, 1991, J CLIN INVEST, V88, P1190, DOI 10.1172/JCI115421; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; HEILIG M, 1991, EUR J PHARMACOL, V209, P27, DOI 10.1016/0014-2999(91)90006-C; HEILIG M, 1988, EUR J PHARMACOL, V157, P205, DOI 10.1016/0014-2999(88)90384-6; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; HEILIG M, 1989, PSYCHOPHARMACOLOGY, V98, P524, DOI 10.1007/BF00441953; HEILIG M, IN PRESS NEUROPSYCHO; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MCDONALD JK, 1988, CRIT REV NEUROBIOL, V4, P97; MONTGOMERY KC, 1955, J COMP PHYSIOL PSYCH, V48, P254, DOI 10.1037/h0043788; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WAHLESTEDT C, IN PRESS ANN REV PHA; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WALKER MW, 1988, MOL PHARMACOL, V34, P779; WEST AP, 1991, MOL CELL ENDOCRINOL, V79, pR9, DOI 10.1016/0303-7207(91)90111-5; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; ZHENG HG, 1989, P NATL ACAD SCI USA, V86, P3758, DOI 10.1073/pnas.86.10.3758	31	507	535	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1993	259	5094					528	531		10.1126/science.8380941	http://dx.doi.org/10.1126/science.8380941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8380941				2022-12-24	WOS:A1993KJ07900039
J	BOLAN, CD; KRISHNAMURTI, C; TANG, DB; CARRINGTON, LR; ALVING, BM				BOLAN, CD; KRISHNAMURTI, C; TANG, DB; CARRINGTON, LR; ALVING, BM			ASSOCIATION OF PROTEIN-S DEFICIENCY WITH THROMBOSIS IN A KINDRED WITH INCREASED LEVELS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1	ANNALS OF INTERNAL MEDICINE			English	Article						PLASMINOGEN ACTIVATOR INHIBITOR-1; PROTEIN-S; THROMBOSIS; PROTEIN DEFICIENCY; HEREDITARY DISEASES	FAST-ACTING INHIBITOR; DEEP-VEIN THROMBOSIS; VENOUS THROMBOSIS; THROMBOEMBOLIC DISEASE; FIBRINOLYTIC-ACTIVITY; C4B-BINDING PROTEIN; HUMAN-PLASMA; FAMILY; RELEASE; ASSAY	Objective: A single kindred in North America with venous thrombosis was described as having defective fibrinolysis because of increased levels of plasminogen activator inhibitor-1 (PAI-1). Our study describes the discovery of protein S deficiency in this kindred and its association with venous thromboembolism. Design: A family study. Setting: Community. Participants: Twenty-eight adults (ages 21 to 71 years) from three generations of the kindred; seven had a history of venous thromboembolism. Measurements: Plasma levels of total and free protein S antigen, as well as the activities of protein S, protein C, PAI-1, and antithrombin III. Results: Six of 7 persons (86%) with a history of venous thromboembolism were deficient in total and free protein S; of 21 asymptomatic members, 9 were deficient in protein S (P = 0.08). When compared with these 9 asymptomatic family members, the 6 persons with protein S deficiency and a history of thrombosis tended to smoke (P = 0.01) and to have higher triglyceride levels (P = 0.001). Overall, the mean PAI-1 activity in the 7 persons who had thrombosis was 7.9 kAU/L (AU/mL) and was 9.3 kAU/L (AU/mL) in the 21 persons who did not have thrombosis (95% CI, -9.9 to 7.0). Conclusions: In this kindred, a deficiency of total and free or functional protein S is the cause of thrombosis. Measurement of PAI-1 activity was not useful in the evaluation of familial thrombosis. The utility of the routine measurement of PAI-1 activity in the evaluation of familial thrombosis has not been established.	WALTER REED ARMY INST RES, DEPT BIOMETR, WASHINGTON, DC 20307 USA; WALTER REED ARMY INST RES, DEPT HEMATOL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	BOLAN, CD (corresponding author), WALTER REED ARMY MED CTR, DEPT HEMATOL ONCOL, WARD 78, WASHINGTON, DC 20307 USA.							ALVING BM, 1992, THROMB HAEMOSTASIS, V67, P672; BUCOLO G, 1973, CLIN CHEM, V19, P476; CHANDLER WL, 1989, CLIN CHEM, V35, P787; CHMIELEWSKA J, 1983, THROMB RES, V31, P427, DOI 10.1016/0049-3848(83)90407-3; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; COMP PC, 1986, BLOOD, V67, P504; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; ENGEBRETSEN LF, 1986, THROMB RES, V42, P713, DOI 10.1016/0049-3848(86)90351-8; ENGESSER L, 1989, THROMB HAEMOSTASIS, V62, P673; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ENGESSER L, 1988, Fibrinolysis, V2, P55; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Jespersen J., 1983, CLIN ASPECTS FIBRINO, P273; JOHANSSON L, 1978, ACTA MED SCAND, V203, P477; JORGENSEN M, 1987, THROMB HAEMOSTASIS, V58, P872; JORGENSEN M, 1987, BRIT J HAEMATOL, V65, P175, DOI 10.1111/j.1365-2141.1987.tb02261.x; JORGENSEN M, 1982, SCAND J HAEMATOL, V29, P217; KLUFT C, 1988, Fibrinolysis, V2, P93; KRISHNAMURTI C, 1988, AM J CLIN PATHOL, V89, P747, DOI 10.1093/ajcp/89.6.747; LAUER CG, 1990, J VASC SURG, V12, P541, DOI 10.1067/mva.1990.23531; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; PARAMO JA, 1985, THROMB HAEMOSTASIS, V54, P713; PIZZO SV, 1986, ARCH INTERN MED, V146, P188, DOI 10.1001/archinte.146.1.188; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; REMINGTON RD, 1985, STATISTICS APPLICATI; SCHMIDEL DK, 1991, BLOOD, V77, P551; STEAD NW, 1983, AM J MED, V74, P33, DOI 10.1016/0002-9343(83)91115-4; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANAMSTEL HKP, 1989, BLOOD, V73, P479; WIMAN B, 1983, CLIN CHIM ACTA, V127, P279, DOI 10.1016/S0009-8981(83)80012-6; WOLF M, 1989, THROMB HAEMOSTASIS, V62, P1144; 1991, ATATXACT USER MANUAL	36	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					779	785		10.7326/0003-4819-119-8-199310150-00002	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379599				2022-12-24	WOS:A1993MB49600002
J	HORM, J; ANDERSON, K				HORM, J; ANDERSON, K			WHO IN AMERICA IS TRYING TO LOSE WEIGHT	ANNALS OF INTERNAL MEDICINE			English	Article								Objectives: To describe the characteristics and weight-loss methods of persons who are trying to lose weight; to compare the knowledges and practices regarding weight loss between those persons trying to lose weight and those not trying to lose weight; and to evaluate trends in these knowledges and practices between 1985 and 1990. Design: Large (approximately 120 000 persons per year), nationally representative random sample of the U.S. population. Setting: The 1985 and 1990 Health Promotion Disease Prevention Current Health Topics Supplements to the National Health Interview Survey. Participants: Random sample of the U.S. population. Measurements: Proportions of the NHIS sample with characteristics of interest weighted to be representative of the U.S. population. Results: Approximately 44 million persons 25 years or older were trying to lose weight in 1990; 61.8% of men and 59.6% of women were doing so by increasing their physical activity. Both proportions are significantly increased compared to the 1985 proportions of 56.9% and 56.2%, respectively. Twenty-seven percent of those persons who saw themselves as overweight were not trying to lose weight. Conclusions: More than one third of Americans see themselves as overweight, but fewer than two thirds of these persons are trying to lose weight. About 4% of self-perceived underweight persons and 11.4% of persons who think their weight was about right are also trying to lose weight. Most persons who are trying to lose weight are doing so by eating less, by increasing their physical activity, or by a combination of these methods.			HORM, J (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH INTERVIEW STAT, 6525 BELCREST RD, ROOM 850, HYATTSVILLE, MD 20782 USA.							ADAMS PF, 1991, VITAL HLTH STATIS 10, V181; BENNETT EM, 1991, AM J CLIN NUTR, V53, pS1519, DOI 10.1093/ajcn/53.6.1519S; Levy P., 1991, SAMPLING POPULATIONS; MASSEY JT, 1989, DHHS PHS891384 NAT C; MILES DS, 1991, CLIN SPORT MED, V10, P157; MILLAR WJ, 1986, J EPIDEMIOL COMMUN H, V40, P319, DOI 10.1136/jech.40.4.319; SCHOENBORN CA, 1988, VITAL HLTH STATIS 10, V163; 1989, SUDAAN PROFESSIONAL; 1991, DHHS PHS9150212 PUB; [No title captured]	10	127	127	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				672	676		10.7326/0003-4819-119-7_Part_2-199310011-00009	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363195				2022-12-24	WOS:A1993MA33000009
J	OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM				OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM			THE UREA REDUCTION RATIO AND SERUM-ALBUMIN CONCENTRATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEATH RISK; DIALYSIS; VARIABLES	Background. Among patients with end-stage renal disease who are treated with hemodialysis, solute clearance during dialysis and nutritional adequacy are determinants of mortality. We determined the effects of reductions in blood urea nitrogen concentrations during dialysis and changes in serum albumin concentrations, as an indicator of nutritional status, on mortality in a large group of patients treated with hemodialysis. Methods. We analyzed retrospectively the demographic characteristics, mortality rate, duration of hemodialysis, serum albumin concentration, and urea reduction ratio (defined as the percent reduction in blood urea nitrogen concentration during a single dialysis treatment) in 13,473 patients treated from October 1, 1990, through March 31, 1991. The risk of death was determined as a function of the urea reduction ratio and serum albumin concentration. Results. As compared with patients with urea reduction ratios of 65 to 69 percent, patients with values below 60 percent had a higher risk of death during follow-up (odds ratio, 1.28 for urea reduction ratios of 55 to 59 percent and 1.39 for ratios below 55 percent). Fifty-five percent of the patients had urea reduction ratios below 60 percent. The duration of dialysis was not predictive of mortality. The serum albumin concentration was a more powerful (21 times greater) predictor of death than the urea reduction ratio, and 60 percent of the patients had serum albumin concentrations predictive of an increased risk of death (values below 4.0 g per deciliter). The odds ratio for death was 1.48 for serum albumin concentrations of 3.5 to 3.9 g per deciliter and 3.13 for concentrations of 3.0 to 3.4 g per deciliter. Diabetic patients had lower serum albumin concentrations and urea reduction ratios than nondiabetic patients. Conclusions. Low urea reduction ratios during dialysis are associated with increased odds ratios for death. These risks are worsened by inadequate nutrition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NATL MED CARE INC,WALTHAM,MA	Harvard University; Harvard Medical School	OWEN, WF (corresponding author), BRIGHAM & WOMENS HOSP,SEELEY MUDD BLDG,250 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045656] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45656-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2, P1071; BASILE C, 1990, AM J KIDNEY DIS, V15, P40, DOI 10.1016/S0272-6386(12)80590-7; Daugirdas J T, 1989, ASAIO Trans, V35, P336, DOI 10.1097/00002480-198907000-00052; FLANIGAN MJ, 1991, AM J KIDNEY DIS, V17, P295, DOI 10.1016/S0272-6386(12)80477-X; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P156; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARTER HR, 1983, KIDNEY INT S13, V23, pS107; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HERRMANN FR, 1992, ARCH INTERN MED, V152, P125, DOI 10.1001/archinte.152.1.125; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HULL AR, 1990, AM J KIDNEY DIS, V15, P375, DOI 10.1016/S0272-6386(12)70354-2; JINDAL KK, 1987, T AM SOC ART INT ORG, V33, P286; LAIRD NM, 1983, KIDNEY INT, pS101; LINDSAY RM, 1992, KIDNEY INT, V42, pS32; LINDSAY RM, 1989, AM J KIDNEY DIS, V13, P382, DOI 10.1016/S0272-6386(89)80021-6; Lowrie E.G., 1991, CONTEMP DIAL NEPHROL, V12, P11; LOWRIE EG, 1992, KIDNEY INT, V42, pS22; LOWRIE EG, 1992, SEMIN NEPHROL, V12, P276; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 1983, KIDNEY INT S, V13, pS11; MURRAY MJ, 1988, MAYO CLIN PROC, V63, P1106, DOI 10.1016/S0025-6196(12)65505-0; PARKER TF, 1983, KIDNEY INT S13, V23, pS42; PARKER TF, 1983, KIDNEY INT S, V13, pS37; 1992, US RENAL DATA SYSTEM	25	1152	1181	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1001	1006		10.1056/NEJM199309303291404	http://dx.doi.org/10.1056/NEJM199309303291404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366899				2022-12-24	WOS:A1993LY58700004
J	ASSAF, AR; LAPANE, KL; MCKENNEY, JL; CARLETON, RA				ASSAF, AR; LAPANE, KL; MCKENNEY, JL; CARLETON, RA			POSSIBLE INFLUENCE OF THE PROSPECTIVE PAYMENT SYSTEM ON THE ASSIGNMENT OF DISCHARGE DIAGNOSES FOR CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; DRG	Background. The prospective payment system, under which diagnosis-related groups (DRGs) are used to reimburse hospitals for the care of Medicare patients, replaced the fee-for-service method of payment in Rhode Island in 1983 and in Massachusetts in 1985. Changes in financial incentives resulting from the use of the DRG system may have influenced the assignment of discharge diagnostic codes away from those with lower reimbursement toward codes with higher reimbursement. Methods. We collected data from the hospital records of patients 35 through 74 years of age who were discharged with codes 41 0 through 414 (representing various categories of coronary heart disease) of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The patients were discharged from seven hospitals in two New England communities (one in Rhode Island and one in Massachusetts) between 1980 and 1988. The rates of diagnosis of various forms of coronary heart disease were determined by studying ICD-9CM hospital discharge codes (codes 410 and 411 for acute forms of coronary heart disease and codes 412, 413, and 414 for chronic forms) and by using a computerized diagnostic algorithm designed to detect definite myocardial infarction and fatal coronary heart disease. Results. The rates of definite coronary events diagnosed by the algorithm and by the study of ICD-9-CM codes 410 through 414 were constant or increased slightly during the study period. However, the frequency of assignment of codes for the acute forms of coronary heart disease (which entail higher reimbursement) rose from 35.2 percent to 48.4 percent among discharged patients with cardiac disease after the institution of DRGs. The majority of this increase was associated with the code for unstable angina pectoris. The frequency of assignment of codes for the chronic forms of coronary heart-disease (which entail lower reimbursement) decreased reciprocally, from 64.8 percent to 51.6 percent (P<0.001). Conclusions. Our data are consistent with the hypothesis that the prospective reimbursement system has influenced the assignment of hospital discharge codes in a way that would increase payment to hospitals. However, the data do not permit us to distinguish whether hospitals began to assign more precise diagnoses with the advent of the DRG system, or whether they began to favor diagnoses of acute conditions solely for financial reasons.	MEM HOSP RHODE ISL, DEPT MED, PAWTUCKET, RI USA; BROWN UNIV, SCH MED, DEPT COMMUNITY HLTH, PROVIDENCE, RI 02912 USA; BROWN UNIV, SCH MED, DEPT MED, PROVIDENCE, RI 02912 USA	Brown University; Brown University	ASSAF, AR (corresponding author), MEM HOSP RHODE ISL, PAWTUCKET HEART HLTH PROGRAM, PAWTUCKET, RI USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023629] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23629] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assaf A R, 1987, R I Med J, V70, P541; BLACKBURN H, 1984, BEHAVIORAL HLTH HDB, P1171; Carleton R A, 1987, R I Med J, V70, P533; COHEN BB, 1987, AM J EPIDEMIOL, V126, P1; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FEINLEIB M, 1989, CIRCULATION, V79, P13; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; MAY JJ, 1985, AM J CARDIOL, V56, pC16, DOI 10.1016/S0002-9149(85)80004-7; MCKINLAY SM, 1989, INT J EPIDEMIOL, V18, P67, DOI 10.1093/ije/18.1.67; MULLIN RL, 1982, JAMA-J AM MED ASSOC, V254, P1208; MUNOZ E, 1990, ACAD MED, V65, P533, DOI 10.1097/00001888-199008000-00011; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; SYTKOWSKI P A, 1991, Comprehensive Therapy, V17, P39; 1983, FED REGISTER, V48, P39752; 1980, MASSACHUSETTS PATIEN; 1986, 31 RHOD ISL DEP HLTH; 1980, DHHS PHS801260 DEP H	18	107	108	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					931	935		10.1056/NEJM199309233291307	http://dx.doi.org/10.1056/NEJM199309233291307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361508				2022-12-24	WOS:A1993LX75100007
J	VEGA, WA; KOLODY, B; HWANG, J; NOBLE, A				VEGA, WA; KOLODY, B; HWANG, J; NOBLE, A			PREVALENCE AND MAGNITUDE OF PERINATAL SUBSTANCE EXPOSURES IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COCAINE USE; DRUG; METHAMPHETAMINE; PREGNANCY; WOMEN	Background. Perinatal substance exposure has been linked to many neonatal and obstetrical complications. There have been few population-based epidemiologic studies to identify the prevalence and demographic profiles associated with drugs, alcohol, and smoking during pregnancy. Methods. We studied a population sample selected according to a multistage probability sampling design to estimate the prevalence of perinatal substance exposures in California in 1992. Urine samples from 29,494 women presenting for delivery in 202 hospitals were coded and screened for toxins; the results of toxicology screening were later linked by code number to the subjects' demographic variables and their reported use of tobacco and prescribed drugs. Urinary toxicologic tests provide conservative estimates because they can detect only very recent substance use. Results. The weighted prevalence for perinatal substance exposure was 5.16 percent for the use of one or more drugs, 6.72 Percent for alcohol (analyzed independently), and 8.82 percent for self-reported smoking. The percentage of women testing positive for any drug, including alcohol, was 11.35 percent. Estimates for racial and ethnic groups varied widely. Black women had the highest prevalence of total drug use (14.22 percent), alcohol use (11.58 percent), cocaine use (7.79 percent), and tobacco use (20.12 percent). Most drug exposures occurred among white non-Hispanic and Hispanic women. White non-Hispanic women had the second highest prevalence rate for the use of one or more drugs (6.79 percent) and self-reported tobacco use (14.82 percent). Hispanic women had the second highest prevalence rate for alcohol (6.87 percent). Conclusions. In California in 1992, there were 67,361 estimated perinatal exposures to one or more drugs, including alcohol, and 52,346 self-reported exposures to tobacco. These findings have clinical and public health implications.	SAN DIEGO STATE UNIV, SAN DIEGO, CA 92182 USA; CALIF STATE COLL SAN BERNARDINO, SAN BERNARDINO, CA 92407 USA; WESTERN CONSORTIUM PUBL HLTH, BERKELEY, CA USA	California State University System; San Diego State University; California State University System; California State University San Bernardino	VEGA, WA (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, CTR COMMUNITY HLTH, WARREN HALL, BERKELEY, CA 94720 USA.							CHASNOFF IJ, 1989, ANN NY ACAD SCI, V562, P208, DOI 10.1111/j.1749-6632.1989.tb21019.x; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CHASNOFF IJ, 1986, J PEDIATR-US, V108, P456, DOI 10.1016/S0022-3476(86)80896-4; DIXON SD, 1989, WESTERN J MED, V150, P436; FINNEGAN LP, 1988, DRUGS ALCOHOL PREGNA, P59; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HOLLINSHEAD WH, 1990, MMWR-MORBID MORTAL W, V39, P225; KHALSA JH, 1991, SEMIN PERINATOL, V15, P265; NALTY DF, 1991, 1991 S CAROLINA PREV; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; OSTREA EM, 1992, PEDIATRICS, V89, P107; SCHYDLOWER M, 1993, PEDIATRICS, V91, P1004; VEGA WA, 1993, AM J PUBLIC HEALTH, V83, P185, DOI 10.2105/AJPH.83.2.185; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1992, CALIFORNIA VITAL STA	16	147	150	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					850	854		10.1056/NEJM199309163291207	http://dx.doi.org/10.1056/NEJM199309163291207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355744				2022-12-24	WOS:A1993LW55100007
J	HANDYSIDES, S				HANDYSIDES, S			TAKING BABIES TEMPERATURES - SCIENCE VERSUS SOCIAL TABOOS IN BATTLE OVER BABY CHECK	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIALS; SCORE CARD; INFANTS	Baby Check, a scoring system for assessing the severity of illness in babies under 6 months old, has not met with the success its developers expected. The inclusion of rectal temperature in the assessment was strongly opposed by the Royal College of Midwives, which refused to alter its view despite evidence of the safety and accuracy of rectal thermometry. British parents appear not to like rectal thermometers either. Most other medical bodies have supported Baby Check and the reason for midwives' opposition may have more to do with professional pique at not being consulted than clinical wisdom.										ASHTON RM, 1991, MIDWIVES CHRONICLE, V104, P109; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P111, DOI 10.1136/adc.66.1.111; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; SMY J, 1991, DOCTOR          0620, P24; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P115, DOI 10.1136/adc.66.1.115; THORNTON AJ, 1991, ARCH DIS CHILD, V66, P106, DOI 10.1136/adc.66.1.106; 1988, 1ST HOUS COMM SOC SE; 1991, LANCET, V337, P485	11	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1993	307	6905					673	675		10.1136/bmj.307.6905.673	http://dx.doi.org/10.1136/bmj.307.6905.673			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX470	8401058	Bronze, Green Published			2022-12-24	WOS:A1993LX47000025
J	RAUTAVA, P; HELENIUS, H; LEHTONEN, L				RAUTAVA, P; HELENIUS, H; LEHTONEN, L			PSYCHOSOCIAL PREDISPOSING FACTORS FOR INFANTILE COLIC	BRITISH MEDICAL JOURNAL			English	Article							FINNISH FAMILY COMPETENCE; CHILDBIRTH; KNOWLEDGE; DISTRESS; WOMEN	Objective-To study associations between characteristics of families during the first pregnancy and after childbirth and the development of infantile colic. Design-Randomised, stratified cluster sampling. Follow up from the first visit to a maternity health care clinic during pregnancy to three months after birth with confidential semistructured questionnaires. Setting-Maternity health care clinics in primary health care centres in Finland. Subjects-1443 nulliparous women and 1407 partners. Altogether 1333 women and 1279 men returned the questionnaires. When the infants were 3 months old 1208 women and 1115 men returned questionnaires. Main outcome measures-Marital relationship; personal and social behaviour of parents during the pregnancy and their coping with the pregnancy; mothers' physical health and events, symptoms, and experiences in relation to pregnancy; self confidence and experiences of mothers and fathers in relation to childbirth; and parents' sociodemographic and educational variables. Measure of colic when the infant was 3 months old. Results-Experience of stress and physical symptoms during the pregnancy, dissatisfaction with the sexual relationship, and negative,experiences during childbirth were associated with the development of colic in the baby. None of the sociodemographic factors was associated with colic. Conclusions-Early preventive health work during pregnancy should attempt to improve parents' tolerance of symptoms of stress and ability to cope and increase their confidence in parenting abilities.	UNIV TURKU,DEPT BIOSTAT,SF-20520 TURKU 52,FINLAND	University of Turku	RAUTAVA, P (corresponding author), UNIV TURKU,DEPT PUBL HLTH,LEMMINKAISENKATU 1,SF-20520 TURKU 52,FINLAND.			Lehtonen, Liisa/0000-0001-8925-2594				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; CAREY WB, 1972, J PEDIATR-US, V81, P823, DOI 10.1016/S0022-3476(72)80115-X; CAREY WB, 1968, CLIN PEDIATR, V7, P590, DOI 10.1177/000992286800701007; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1; FORSYTH BWC, 1989, J PEDIATR-US, V115, P521, DOI 10.1016/S0022-3476(89)80274-4; HEWSON P, 1987, CLIN PEDIATR, V26, P69, DOI 10.1177/000992288702600203; HIDE DW, 1982, ARCH DIS CHILD, V57, P559, DOI 10.1136/adc.57.7.559; HILL DJ, 1992, J PEDIATR-US, V121, P755, DOI 10.1016/S0022-3476(05)81911-0; ILLINGWORTH RS, 1985, ARCH DIS CHILD, V60, P981, DOI 10.1136/adc.60.10.981; ILLINGWORTH RS, 1954, ARCH DIS CHILD, V29, P165, DOI 10.1136/adc.29.145.165; LESTER BM, 1990, INF MENTAL HLTH J, V11, P321, DOI 10.1002/1097-0355(199024)11:4<321::AID-IMHJ2280110403>3.0.CO;2-E; MATHESON I, 1989, JAMA-J AM MED ASSOC, V261, P42, DOI 10.1001/jama.1989.03420010052018; MILLER AR, 1991, PEDIATR CLIN N AM, V38, P1407; MILLER JJ, 1989, ARCH DIS CHILD, V64, P725, DOI 10.1136/adc.64.5.725; MOORE DJ, 1988, J PEDIATR-US, V113, P979, DOI 10.1016/S0022-3476(88)80567-5; Neff FC, 1940, J AMER MED ASSOC, V114, P1745; PARADISE JL, 1966, J AMER MED ASSOC, V197, P191, DOI 10.1001/jama.1966.03110030085031; RAUTAVA P, 1989, SOC SCI MED, V29, P1105, DOI 10.1016/0277-9536(89)90023-3; RAUTAVA P, 1989, J EPIDEMIOL COMMUN H, V43, P253, DOI 10.1136/jech.43.3.253; RUBIN SP, 1984, CHILD CARE HLTH DEV, V10, P219, DOI 10.1111/j.1365-2214.1984.tb00181.x; Spock B, 1944, PSYCHOSOM MED, V6, P162, DOI 10.1097/00006842-194404000-00010; STAHLBERG MR, 1984, EUR J PEDIATR, V143, P108; THOMAS DW, 1987, AM J DIS CHILD, V141, P451, DOI 10.1001/archpedi.1987.04460040109028; THOMPSON PE, 1986, COMPREHENSIVE PEDIAT, V9, P273; WESSEL MA, 1954, PEDIATRICS, V14, P421; White PJ, 1929, AM J DIS CHILD, V38, P935; WINNICOT DW, 1991, MATURATIONAL PROCESS; 1987, STATISTICAL YB FINLA, V82	28	77	79	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					600	604		10.1136/bmj.307.6904.600	http://dx.doi.org/10.1136/bmj.307.6904.600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	8401016	Green Published, Bronze			2022-12-24	WOS:A1993LW14900017
J	CONCHA, NO; HEAD, JF; KAETZEL, MA; DEDMAN, JR; SEATON, BA				CONCHA, NO; HEAD, JF; KAETZEL, MA; DEDMAN, JR; SEATON, BA			RAT ANNEXIN-V CRYSTAL-STRUCTURE - CA2+-INDUCED CONFORMATIONAL-CHANGES	SCIENCE			English	Article							PHOSPHOLIPID-BINDING PROTEIN; MEMBRANE-BINDING; CALCIUM-BINDING; ANTICOAGULANT PROTEIN; MOLECULAR-STRUCTURE; LIPOCORTIN-I; FAMILY; REFINEMENT; LOCATION	Annexins are a family of calcium- and phospholipid-binding proteins implicated in mediating membrane-related processes such as secretion, signal transduction, and ion channel activity. The crystal structure of rat annexin V was solved to 1.9 angstrom resolution by multiple isomorphous replacement. Unlike previously solved annexin V structures, all four domains bound calcium in this structure. Calcium binding in the third domain induced a large relocation of the calcium-binding loop regions, exposing the single tryptophan residue to the solvent. These alterations in annexin V suggest a role for domain 3 in calcium-triggered interaction with phospholipid membranes.	BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118; UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267	Boston University; University System of Ohio; University of Cincinnati				Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020357] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-41740] Funding Source: Medline; NIGMS NIH HHS [R29-GM-44554] Funding Source: Medline; NINDS NIH HHS [R01-NS-20357] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BEWLEY MC, 1993, BIOCHEMISTRY-US, V32, P393; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CONCHA NO, UNPUB; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; SCHLAEPFER DD, 1987, P NATL ACAD SCI USA, V84, P6078, DOI 10.1073/pnas.84.17.6078; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SWAIRJO MA, IN PRESS ANN REV BIO; TAIT JF, 1989, J BIOL CHEM, V264, P7944; WENG XW, 1993, PROTEIN SCI, V2, P448	29	173	179	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1321	1324		10.1126/science.8362244	http://dx.doi.org/10.1126/science.8362244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8362244				2022-12-24	WOS:A1993LV65600028
J	JACENKO, O; LUVALLE, PA; OLSEN, BR				JACENKO, O; LUVALLE, PA; OLSEN, BR			SPONDYLOMETAPHYSEAL DYSPLASIA IN MICE CARRYING A DOMINANT-NEGATIVE MUTATION IN A MATRIX PROTEIN-SPECIFIC FOR CARTILAGE-TO-BONE TRANSITION	NATURE			English	Article							X COLLAGEN GENE; REGIONS; DOMAIN; VIII	THE vertebrate skeleton is formed primarily by endochondral ossification, starting during embryogenesis when cartilage anlagens develop central regions of hypertrophic cartilage which are replaced by bony trabeculae and bone marrow1,2. During this process chondrocytes express a unique matrix molecule, type X collagen3. We report here that mice carrying a mutated collagen X transgene develop skeletal deformities including compression of hypertrophic growth plate cartilage and a decrease in newly formed bone, as well as leukocyte deficiency in bone marrow, reduction in size of thymus and spleen, and lymphopenia. The defects indicate that collagen X is required for normal skeletal morphogenesis and suggest that mutations in COL10A1 are responsible for certain human chondrodysplasias, such as spondylometaphyseal dysplasias and metaphyseal chondrodysplasias4.			JACENKO, O (corresponding author), HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, 220 LONGWOOD AVE, BOSTON, MA 02115 USA.							APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; ARMAN ML, IN PRESS NATURE GENE; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Caplan AI, 1987, BONE MINERAL RES, P117; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; HAM AW, 1965, HISTOLOGY, P384; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; LUVALLE P, J CELL BIOL, V121, P1173; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V2; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V1; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749-6632.1990.tb17918.x; SUMMERS TA, 1988, J BIOL CHEM, V263, P581	20	179	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					56	61		10.1038/365056a0	http://dx.doi.org/10.1038/365056a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361538				2022-12-24	WOS:A1993LV64600053
J	XU, H; LITTMAN, DR				XU, H; LITTMAN, DR			A KINASE-INDEPENDENT FUNCTION OF LCK IN POTENTIATING ANTIGEN-SPECIFIC T-CELL ACTIVATION	CELL			English	Review							PROTEIN-TYROSINE KINASE; AMINO-TERMINAL DOMAIN; RECEPTOR ZETA-CHAIN; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; LYMPHOCYTES-T; MICE LACKING; PHYSICAL ASSOCIATION; CYTOPLASMIC DOMAINS; NEGATIVE SELECTION	The lymphocyte-specific cytoplasmic protein-tyrosine kinase p56lck (Lck) is essential for T cell development and activation. Its association with the coreceptor molecules, CD4 and CD8, is required for potentiation of antigen-specific signals through the T cell antigen receptor. To study the mechanism of action of Lck, hybrid molecules consisting of the extracellular and transmembrane domains of CD4 fused to Lck or other Src family kinases were analyzed in an antigen-specific, CD4-dependent T cell hybridoma. Surprisingly, a chimera with a deletion of the Lck kinase domain was more active than the full-length protein. In contrast, point mutations in residues required for SH2 or kinase function resulted in moderately decreased activity, while a combination of these mutations rendered the chimera largely inactive. Different domains of CD4-associated Lck therefore have distinct functions that can independently contribute to T cell activation.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	XU, H (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1991, ADV CANCER RES, V57, P103; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EMMRICH F, 1988, IMMUNOL TODAY, V9, P296, DOI 10.1016/0167-5699(88)91320-5; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, 1993, IN PRESS NATURE; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RONCHESE F, 1987, J IMMUNOL, V139, P629; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TURNER JM, 1991, ADV REG CELL GROWTH, V2, P181; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	70	222	225	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					633	643		10.1016/0092-8674(93)90511-N	http://dx.doi.org/10.1016/0092-8674(93)90511-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358792				2022-12-24	WOS:A1993LU59200007
J	BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR				BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR			THE MATERNAL GENE SKN-1 ENCODES A PROTEIN THAT IS DISTRIBUTED UNEQUALLY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; ESCHERICHIA-COLI; LOCALIZATION; LINEAGES; REVERSAL; GLP-1; GUT	The autonomous or cell-intrinsic developmental properties of early embryonic blastomeres in nematodes are thought to result from the action of maternally provided determinants. After the first cleavage of the C. elegans embryo, only the posterior blastomere, P1, has a cell-intrinsic ability to produce pharyngeal cells. The product of the maternal gene skn-1 is required for P1 to produce pharyngeal cells. We show here that the Skn-1 protein is nuclear localized and that P1 appears to accumulate markedly higher levels of Skn-1 protein than its sister, the AB blastomere. We have examined the distribution of Skn-1 protein in embryos from mothers with maternal-effect mutations in the genes mex-1, par-1, and pie-1. These results suggest that mex-1(+) and par-1(+) activities are required for the unequal distribution of the Skn-1 protein and that pie-1(+) activity may function to regulate the activity of Skn-1 protein in the descendants of the posterior blastomere P1.	FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; Ausubel F, 1989, MOL REPROD DEV, V1, P146; Boveri T., 1910, FESTSCHRIFT R HERTWI, VIII, P133; Boveri Th., 1899, Festschrift C von Kupffer, P383; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KONAPKA JB, 1984, J VIROL, V51, P223; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Stevens NM, 1909, ARCH ENTWICKLUNG ORG, V27, P622, DOI 10.1007/BF02161872; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	33	208	214	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					443	452		10.1016/0092-8674(93)80046-H	http://dx.doi.org/10.1016/0092-8674(93)80046-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348611				2022-12-24	WOS:A1993LT73900006
J	FRANCIS, CL; RYAN, TA; JONES, BD; SMITH, SJ; FALKOW, S				FRANCIS, CL; RYAN, TA; JONES, BD; SMITH, SJ; FALKOW, S			RUFFLES INDUCED BY SALMONELLA AND OTHER STIMULI DIRECT MACROPINOCYTOSIS OF BACTERIA	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS A-431; CULTURED-MAMMALIAN-CELLS; FACTOR RECEPTOR; CYTOSKELETAL CHANGES; EPITHELIAL-CELLS; TYROSINE KINASE; KB-CELLS; MEMBRANE; TYPHIMURIUM	RUFFLES are specialized plasma membrane ultrastructures of mammalian cells thought to be integral to growth, development and locomotion1-4. Induced by growth factors5-8, mitogens9 or oncogene expression10,11, ruffles are sites of filamentous actin rearrangement7,8 and are temporally associated with enhanced pinocytosis10,12. But the function of ruffles, their mechanism of induction and their role in pinocytosis are not understood. We have observed formation of structures resembling ruffles associated with the site of entry of invasive Salmonella typhimurium13. Here we report that ruffles elicited by invasive Salmonella directly mediate internalization of non-invasive bacteria in a macropinocytotic fashion, a phenomenon we term 'passive entry'. Furthermore, ruffles induced in the absence of Salmonella also facilitate passive entry. We present evidence that ruffles, common to many signalling events, comprise the macropinocytotic machinery mediating pinocytosis and are subverted by Salmonella so as to enter mammalian cells.	STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; NIH,ROCKY MT LAB,HAMILTON,MT 59840	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	FRANCIS, CL (corresponding author), STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305, USA.		Ryan, Timothy/AAO-8286-2020	Jones, Brad/0000-0002-2698-8251; Ryan, Timothy/0000-0003-2533-9548				ABERCROMBIE M., 1961, EXPTL CELL RES SUPPL, V8, P188, DOI 10.1016/0014-4827(61)90348-2; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; JACKOWSKI MM, 1990, J CELL PHYSIOL, V142, P458, DOI 10.1002/jcp.1041420304; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; LABIGNEROUSSEL AF, 1984, INFECT IMMUN, V46, P251, DOI 10.1128/IAI.46.1.251-259.1984; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MISUMI Y, 1991, AM J ANAT, V191, P419, DOI 10.1002/aja.1001910409; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; SIRAGANIAN RP, 1982, FED PROC, V41, P30; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; Trinkaus J.P., 1985, EXPL BIOL MED, V10, P130; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69	30	365	368	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					639	642		10.1038/364639a0	http://dx.doi.org/10.1038/364639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350922				2022-12-24	WOS:A1993LR77100056
J	TOKARS, JI; MARCUS, R; CULVER, DH; SCHABLE, CA; MCKIBBEN, PS; BANDEA, CI; BELL, DM				TOKARS, JI; MARCUS, R; CULVER, DH; SCHABLE, CA; MCKIBBEN, PS; BANDEA, CI; BELL, DM			SURVEILLANCE OF HIV-INFECTION AND ZIDOVUDINE USE AMONG HEALTH-CARE WORKERS AFTER OCCUPATIONAL EXPOSURE TO HIV-INFECTED BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; OCCUPATIONAL EXPOSURE; HEALTH PERSONNEL	HUMAN-IMMUNODEFICIENCY-VIRUS; SCID-HU MICE; PROPHYLACTIC ZIDOVUDINE; POSTEXPOSURE CHEMOPROPHYLAXIS; FAILURE; TYPE-1; TRANSMISSION; RESISTANCE; MUTATIONS; RISK	Objective: To study the risk for human immunodeficiency virus (HIV) infection and the patterns of use and associated toxicity of zidovudine among health care workers after an occupational exposure to HIV. Design: An ongoing, prospective surveillance project conducted by the Centers for Disease Control and Prevention. Participants: Exposed workers voluntarily reported by 312 U.S. health care facilities from August 1983 to June 1992. Results: Four of 1103 enrolled workers with percutaneous exposure to HIV-infected blood seroconverted (HIV seroconversion rate, 0.36%; upper limit of the 95% CI, 0.83%); no enrolled workers with mucous membrane (n = 75) or skin (n = 67) contact seroconverted. During October 1988 to June 1992, 31% of 848 enrolled workers used zidovudine after exposure; this proportion increased from 5% during October through December 1988 to 43% during January through June 1992. Despite using zidovudine after exposure, one worker became infected with a strain of HIV that was apparently sensitive to zidovudine. Adverse symptoms, most commonly nausea, malaise or fatigue, and headache, were reported by 75% of workers using zidovudine; 31% of workers did not complete planned courses of zidovudine because of adverse events. Conclusions: The risk for HIV seroconversion after percutaneous exposure to HIV-infected blood is 0.36%, which is similar to previous estimates. Zidovudine is used after exposure by a sizable proportion of health care workers enrolled in the project despite frequent, minor, associated symptoms. Documented failures of postexposure zidovudine prophylaxis, including in one worker enrolled in this study, indicate that if zidovudine is protective, any protection afforded is not absolute. Postexposure zidovudine, if used, requires careful consideration of possible risks and benefits.	CTR DIS CONTROL, HOSP INFECT PROGRAM, MAILSTOP A-07, ATLANTA, GA 30333 USA; CTR DIS CONTROL, NATL CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Marcus, Ruthanne/0000-0002-9094-0674				BELL DM, 1992, HOSPITAL INFECTIONS, P823; DURAND E, 1991, NEW ENGL J MED, V324, P1062; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; GIOANNINI P, 1988, EUR J EPIDEMIOL, V4, P119, DOI 10.1007/BF00152703; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1991, AM J MED, V91, pS312, DOI 10.1016/0002-9343(91)90388-E; HENDERSON DK, 1989, J INFECT DIS, V160, P321, DOI 10.1093/infdis/160.2.321; JONES PD, 1991, LANCET, V338, P884, DOI 10.1016/0140-6736(91)91535-3; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LAFON SW, 1990, 30TH INT C ANT AG CH, P167; LANGE JMA, 1990, NEW ENGL J MED, V322, P1375, DOI 10.1056/NEJM199005103221907; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LOOKE DFM, 1990, LANCET, V335, P1280, DOI 10.1016/0140-6736(90)91343-9; LOT F, 1992, B EPIDEMIOL HEBD, V26, P117; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MCCRAY E, 1986, NEW ENGL J MED, V314, P1127, DOI 10.1056/NEJM198604243141729; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; SHIH CC, 1991, J INFECT DIS, V163, P625, DOI 10.1093/infdis/163.3.625; TAIT DR, 1992, 8TH INT C AIDS AMST; TSAI CC, 1992, 32ND INT C ANT AG CH, P58; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; 1992, MMWR, V41, P823; 1992, MMWR, V41, P575; 1987, MMWR, V36, P285; 1987, MMWR, V36, pS3; 1990, MMWR, V39, P1	31	257	260	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					913	919		10.7326/0003-4819-118-12-199306150-00001	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	8387737				2022-12-24	WOS:A1993LF93700001
J	MCDERMOTT, F; GRUN, R; STRINGER, CB; HAWKESWORTH, CJ				MCDERMOTT, F; GRUN, R; STRINGER, CB; HAWKESWORTH, CJ			MASS-SPECTROMETRIC U-SERIES DATES FOR ISRAELI NEANDERTHAL EARLY-MODERN HOMINID SITES	NATURE			English	Article							BURIAL SITE; TABUN CAVE; ESR DATES; KEBARA; QAFZEH; TIME	THE nature of the relationship between Neanderthals and early modern Homo sapiens is controversial, yet it is fundamental to our understanding of early human evolution1,2. The Middle Palaeolithic sites of Israel are critical to this debate, because unlike those of western Europe and Africa they contain both Neanderthal (at Tabun3 and Kebara4 for example) and anatomically modern hominids (as at Skhul5 and Qafzeh6). Here we present new mass spectrometric Th-230/U-234 dates for dental fragments from the Middle Palaeolithic burial sites of Tabun, Qafzeh and Skhul. These data, combined with published ages from electron spin resonance (ESR), provide compelling evidence that the Tabun Neanderthals and Qafzeh early modern Homo sapiens were approximately coeval in the southern Levant some 100 +/- 5 kyr ago, but indicate that some of the Skhul material is younger. The study also shows that combined mass-spectrometric Th-230/U-234 and ESR dating is an invaluable technique for dating archaeological sites beyond the range of radiocarbon dating.	OPEN UNIV, DEPT EARTH SCI, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND; AUSTRALIA NATL UNIV, QUATERNARY DATING RES CTR, CANBERRA 2601, AUSTRALIA; NAT HIST MUSEUM, DEPT PALAEONTOL, LONDON SW7 5BD, ENGLAND	Open University - UK; Australian National University; Natural History Museum London			McDermott, Frank/F-3096-2010; Grun, Rainer/A-1437-2012	McDermott, Frank/0000-0001-7037-7936; Grun, Rainer/0000-0003-1366-3674				AITKEN MJ, 1992, PHILOS T ROY SOC B, V337, P139, DOI 10.1098/rstb.1992.0090; Bar-Yosef O., 1981, PREHISTOIRE LEVANT, P281; BARYOSEF O, 1989, HUMAN REVOLUTION, P589; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; FARRAND WR, 1979, J ARCHAEOL SCI, V6, P369, DOI 10.1016/0305-4403(79)90019-0; Garrod D.A.E., 1937, STONE AGE MOUNT CARM, VI; GRUN R, 1988, NUCL TRACKS RAD MEAS, V14, P237; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; GRUN R, 1991, J HUM EVOL, V20, P231, DOI 10.1016/0047-2484(91)90074-6; Jelinek A. J., 1990, EMERGENCE MODERN HUM, P81; Jelinek A. J., 1981, PREHISTOIRE LEVANT C, P265; JELINEK AJ, 1982, SCIENCE, V216, P1369, DOI 10.1126/science.216.4553.1369; JELINEK AJ, IN PRESS EVOLUTION D; JELINEK AJ, 1982, BAR INT SERIES, V151, P57; MASTERS PM, 1982, BRIT ARCHAEOLOGICAL, V151, P43; McCown T, 1939, STONE AGE MOUNT CARM, V2; McCown T. D., 1937, STONE AGE MOUNT CARM, V1, P91; MCKINNEY CR, 1991, THESIS SMU DALLAS; OAKLEY KP, 1975, CATALOGUE FOSSIL HOM, V3; Rae A.M., 1986, APPLIED GEOCHEMISTRY, V1, P419; RAK Y, 1990, AM J PHYS ANTHROPOL, V81, P323, DOI 10.1002/ajpa.1330810302; SCHWARCZ HP, 1989, J ARCHAEOL SCI, V16, P653, DOI 10.1016/0305-4403(89)90029-0; SCHWARCZ HP, 1988, J HUM EVOL, V17, P733, DOI 10.1016/0047-2484(88)90063-2; Stringer C. B., 1981, ASPECTS HUMAN EVOLUT, P129; STRINGER CB, 1989, NATURE, V338, P756, DOI 10.1038/338756a0; STRINGER CB, 1991, NATURE, V351, P701, DOI 10.1038/351701a0; Trinkaus E., 1984, P251; VALLADAS H, 1987, NATURE, V330, P159, DOI 10.1038/330159a0; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; Vandermeersch B., 1981, HOMMES FOSSILES QAFZ; WOLPOFF MH, 1992, NATURE, V356, P200, DOI 10.1038/356200b0	31	118	121	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1993	363	6426					252	255		10.1038/363252a0	http://dx.doi.org/10.1038/363252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	LC866	8387643				2022-12-24	WOS:A1993LC86600049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERIM METHADONE-MAINTENANCE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-24	WOS:A1993KQ85700006
J	DRESSLER, GR; WILKINSON, JE; ROTHENPIELER, UW; PATTERSON, LT; WILLIAMSSIMONS, L; WESTPHAL, H				DRESSLER, GR; WILKINSON, JE; ROTHENPIELER, UW; PATTERSON, LT; WILLIAMSSIMONS, L; WESTPHAL, H			DEREGULATION OF PAX-2 EXPRESSION IN TRANSGENIC MICE GENERATES SEVERE KIDNEY ABNORMALITIES	NATURE			English	Article							PROMOTER; GENE	THE Pax genes comprise a family of transcription factors active in specific tissues during embryonic development and are associated with at least three developmental mutations in mouse and man1,2. In the developing kidney, Pax-2 is expressed in the induced mesenchyme, in the ureter epithelium, and in early epithelial structures derived from the mesenchyme3. Pax-2 expression is repressed upon terminal differentiation of the renal tubule epithelium, but persists in the undifferentiated epithelium of human Wilms' tumours4,5. We have produced a dominant gain-of-function mutation in transgenic mice by deregulating the expression of the mouse Pax-2 gene. The data obtained with four independently derived transgenic embryos and with one transgenic line demonstrate that deregulated Pax-2 expression results in histologically abnormal and dysfunctional renal epithelium with properties similar to congenital nephrotic syndrome. Thus, repression of Pax-2 is required for normal kidney development and persistent expression of Pax-2 may restrict the differentiation potential of renal epithelial cells.	UNIV TENNESSEE,COLL VET MED,DEPT PATHOBIOL,KNOXVILLE,TN 37901	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	DRESSLER, GR (corresponding author), NICHHD,MAMMALIAN GENES & DEV LAB,BETHESDA,MD 20892, USA.							DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Hogan B., 1986, MANIPULATING MOUSE E; MAHAN JD, 1987, PEDIATRIC NEPHROLOGY; NORNES HO, 1990, DEVELOPMENT, V109, P7907; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PUESCHEL AW, 1992, MECH DEVELOP, V38, P197; Sambrook J., 1989, MOL CLONING LAB MANU; Saxen L., 1987, ORGANOGENESIS KIDNEY; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	16	258	263	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					65	67		10.1038/362065a0	http://dx.doi.org/10.1038/362065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383297				2022-12-24	WOS:A1993KP97600061
J	FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ			THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIP FRACTURE; CIGARETTE-SMOKING; OSTEOPOROSIS; RISK; MENOPAUSE; CALCIUM	Background. Estrogen therapy prevents bone loss in postmenopausal women who take it early in the postmenopausal period. The risk of fracture is highest much later in life, however. We studied whether bone mass in elderly women was affected by earlier estrogen use and how long women needed to take estrogen for it to have a beneficial effect on bone density later in life. Methods. In 1988 and 1989, we measured bone mineral density at the femur, spine, shaft of the radius, and ultradistal radius in 670 white women in the Framingham Study cohort (mean age, 76 years; range, 68 to 96). These women had been followed prospectively through menopause and had been asked repeatedly about estrogen therapy. After excluding women who began taking estrogen after a fracture, we investigated whether postmenopausal estrogen therapy affected bone density; in these analyses we adjusted for age, weight, height, cigarette smoking, physical activity, and age at menopause. Results. A total of 212 women (31.6 percent) had received estrogen therapy (mean estimated duration of treatment, 5 years). Only women who had taken estrogen for 7 to 9 years or for 10 or more years had significantly higher bone mineral density than women who had not taken estrogen (7 to 9 years of treatment, P<0.05 at sites in the femur and the spine; greater-than-or-equal-to 10 years, P<0.05 at all sites except the spine). In the women less than 75 years of age who had taken estrogen for seven or more years, the bone density was, averaging all sites, 11.2 percent greater than in women who had never received estrogen. Among women 75 years of age and older in whom the duration of therapy was comparable, bone density was only 3.2 percent higher than in women who had never taken estrogen. Conclusions. For long-term preservation of bone mineral density, women should take estrogen for at least seven years after menopause. Even this duration of therapy may have little residual effect on bone density among women 75 years of age and older, who have the highest risk of fracture.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, DEPT MED, BOSTON, MA 02118 USA; FRAMINGHAM STUDY, FRAMINGHAM, MA USA	Boston Medical Center	FELSON, DT (corresponding author), BOSTON UNIV, SCH MED, CTR ARTHRITIS, 80 E CONCORD ST, A203, BOSTON, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Zhang, Yuqing/0000-0001-7954-1149; Kiel, Douglas/0000-0001-8474-0310; Hannan, Marian/0000-0002-9586-6928	NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [R01AG09300] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARZEL US, 1988, AM J MED, V85, P847; BENGNER U, 1988, CLIN ORTHOP RELAT R, V231, P179; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; JENSEN GF, 1982, CLIN ENDOCRINOL, V16, P515, DOI 10.1111/j.1365-2265.1982.tb02769.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEY TJA, 1991, J STEROID BIOCHEM, V39, P529, DOI 10.1016/0960-0760(91)90247-3; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem-70-1-83; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PETITTI DB, 1989, CLIN ORTHOP RELAT R, P150; SERNBO I, 1988, ACTA ORTHOP SCAND, V59, P382, DOI 10.3109/17453678809149386; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	27	520	531	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1141	1146		10.1056/NEJM199310143291601	http://dx.doi.org/10.1056/NEJM199310143291601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377776				2022-12-24	WOS:A1993MA66700001
J	LIU, JP; BAKER, J; PERKINS, AS; ROBERTSON, EJ; EFSTRATIADIS, A				LIU, JP; BAKER, J; PERKINS, AS; ROBERTSON, EJ; EFSTRATIADIS, A			MICE CARRYING NULL MUTATIONS OF THE GENES ENCODING INSULIN-LIKE GROWTH FACTOR-I (IGF-1) AND TYPE-1 IGF RECEPTOR (IGF1R)	CELL			English	Article							HUMAN-FIBROBLASTS; CELLULAR-PATTERN; BINDING-PROTEIN; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; HORMONE; CELLS; PROTOONCOGENE; DETERMINANTS	Newborn mice homozygous for a targeted disruption of insulin-like growth factor gene 1 (Igf-1) exhibit a growth deficiency similar in severity to that previously observed in viable Igf-2 null mutants (60% of normal birthweight). Depending on genetic background, some of the Igf-1(-/-) dwarfs die shortly after birth, while others survive and reach adulthood. In contrast, null mutants for the Igf1r gene die invariably at birth of respiratory failure and exhibit a more severe growth deficiency (45% normal size). In addition to generalized organ hypoplasia in Igf1r(-/-) embryos, including the muscles, and developmental delays in ossification, deviations from normalcy were observed in the central nervous system and epidermis. Igf-1(-/-)/Igf1r(-/-) double mutants did not differ in phenotype from Igf1r(-/-) single mutants, while in Igf-2(-)/Igf1r(-/-) and Igf-1(-/-)/Igf-2(-) double mutants, which are phenotypically identical, the dwarfism was further exacerbated (30% normal size). The roles of the IGFs in mouse embryonic development, as revealed from the phenotypic differences between these mutants, are discussed.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA	Yale University	LIU, JP (corresponding author), COLUMBIA UNIV, DEPT GENET & DEV, NEW YORK, NY 10032 USA.							ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; [Anonymous], 1991, INSULIN LIKE GROWTH; AYERLELIEVRE C, 1991, DEVELOPMENT, V111, P105; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P131; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, PERSPECT BIOL MED, V32, P194; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; FURLANETTO RW, 1987, J CLIN ENDOCR METAB, V64, P1142, DOI 10.1210/jcem-64-6-1142; GERMAINLEE EL, 1992, BIOCHEM J, V281, P413, DOI 10.1042/bj2810413; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAN VKM, 1992, INSULIN LIKE GROWTH, P178; HILLYARD AL, 1993, MOUSE GENOME, V91, P25; Hogan B., 1986, MANIPULATING MOUSE E; ISAKSSON OGP, 1991, PEDIATR NEPHROL, V5, P451, DOI 10.1007/BF01453680; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KRANE JF, 1991, J INVEST DERMATOL, V96, P419, DOI 10.1111/1523-1747.ep12469799; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEROITH D, 1991, INSULIN LIKE GROWTH; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MOXHAM C, 1992, INSULIN LIKE GROWTH, P80; NEELY EK, 1991, ACTA PAEDIATR SCAND, P116; NISHIMOTO I, 1991, MODERN CONCEPTS INSU, P517; NISSLEY P, 1991, INSULIN LIKE GROWTH, P111; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; OEMAR BS, 1991, J BIOL CHEM, V266, P2369; OKA Y, 1985, J BIOL CHEM, V260, P9435; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEVENS LEROY C., 1958, JOUR HEREDITY, V49, P153; STRECK RD, 1992, DEV BIOL, V151, P586, DOI 10.1016/0012-1606(92)90196-N; STRECK RD, 1992, ENDOCRINOLOGY, V131, P2030, DOI 10.1210/en.131.4.2030; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	58	2391	2452	0	90	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					59	72		10.1016/S0092-8674(05)80084-4	http://dx.doi.org/10.1016/S0092-8674(05)80084-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	8402901				2022-12-24	WOS:A1993MB66700008
J	VONDEROHE, MR; CAMILLERI, M; KVOLS, LK; THOMFORDE, GM				VONDEROHE, MR; CAMILLERI, M; KVOLS, LK; THOMFORDE, GM			MOTOR DYSFUNCTION OF THE SMALL-BOWEL AND COLON IN PATIENTS WITH THE CARCINOID-SYNDROME AND DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBSTANCE-P; TRANSIT; MOTILITY; TUMORS; FLUID; POLYPEPTIDE; SOLIDS; DOG	Background and Methods. The pathophysiology of diarrhea in patients with the carcinoid syndrome is not understood. Possible causes include tumor production of neurohumoral substances, such as serotonin and substance P, which stimulate small-bowel and colonic motility, and intestinal abnormalities, such as lymphangiectasia and bacterial overgrowth. We undertook this study to determine whether carcinoid diarrhea is associated with abnormal motor function in the small intestine and colon. We measured the gastric, small-bowel, and colonic transit of radiolabeled solid residue and estimated the volume of the ascending colon in 16 patients with the carcinoid syndrome and diarrhea and 16 normal subjects. We also measured colonic tone and phasic pressure activity by intracolonic multilumen manometry and with an electronic barostat in seven patients and six normal subjects. Results. The patients with the carcinoid syndrome had elevated 24-hour urinary excretion of 5-hydroxyindoleacetic acid and elevated fasting plasma serotonin concentrations. Transit times in the small bowel and colon were two times (P<0.001) and six times (P = 0.001) faster in the patients than in the normal subjects. The volume of the ascending colon was approximately 50 percent smaller in the patients than in the normal subjects (P<0.001). The patients had normal fasting colonic tone; their mean post-prandial colonic tone was markedly increased as compared with the values in the normal subjects (mean increase, 41 percent vs. 24 percent; P = 0.03). Conclusions. Patients with the carcinoid syndrome who have diarrhea have major alterations in gut motor function that affect both the small intestine and colon.	MAYO CLIN & MAYO FDN,GASTROENTEROL RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV MED ONCOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR00585] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BADLEY AD, 1993, NUCL MED COMMUN, V14, P485; BARTHO L, 1985, NEUROSCIENCE, V16, P1, DOI 10.1016/0306-4522(85)90043-0; BULBRING E, 1958, J PHYSIOL-LONDON, V140, P381; CAMILLERI M, 1992, GASTROENTEROLOGY, V103, P36, DOI 10.1016/0016-5085(92)91092-I; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; COWLES VE, 1959, AM J PHYSIOL, V38, P2119; DANIEL EE, 1982, CAN J PHYSIOL PHARM, V60, P830, DOI 10.1139/y82-116; DEBONGNIE JC, 1978, GASTROENTEROLOGY, V74, P698; DONOWITZ M, 1975, AM J DIG DIS, V20, P1115, DOI 10.1007/BF01070754; EMSON PC, 1984, CANCER, V54, P715, DOI 10.1002/1097-0142(1984)54:4<715::AID-CNCR2820540420>3.0.CO;2-6; FELDMAN JM, 1977, AM J MED SCI, V273, P43, DOI 10.1097/00000441-197701000-00004; GREYDANUS MP, 1990, GASTROENTEROLOGY, V99, P158, DOI 10.1016/0016-5085(90)91243-Y; HAMMER J, 1992, Gastroenterology, V102, pA456; HAMMER J, 1992, J GASTROINTEST MOTIL, V4, P221; HENDRIX TR, 1957, AM J MED, V23, P886, DOI 10.1016/0002-9343(57)90298-X; KOSTERLITZ HW, 1957, J PHYSIOL-LONDON, V136, P249, DOI 10.1113/jphysiol.1957.sp005757; KOWLESSAR OD, 1959, AM J MED, V27, P673, DOI 10.1016/0002-9343(59)90051-8; LABAYLE D, 1977, GASTROEN CLIN BIOL, V1, P231; Malagelada JRCM, 1986, MANOMETRIC DIAGNOSIS; MISIEWICZ JJ, 1966, GUT, V7, P208, DOI 10.1136/gut.7.3.208; Moertel C G, 1987, J Clin Oncol, V5, P1502; OCONNOR MK, 1988, EUR J NUCL MED, V14, P562; PEARSE AGE, 1974, VIRCHOWS ARCH B, V16, P95, DOI 10.1007/BF02894068; PROANO M, 1990, AM J PHYSIOL, V258, pG856, DOI 10.1152/ajpgi.1990.258.6.G856; RAMBAUD JC, 1988, GUT, V29, P537, DOI 10.1136/gut.29.4.537; RAMBAUD JC, 1986, CLIN GASTROENTEROL, V15, P603; RICHTER G, 1986, SCAND J GASTROENTERO, V21, P193, DOI 10.3109/00365528609087452; SMITH AN, 1965, GASTROENTEROLOGY, V48, P738; SPILLER RC, 1986, GASTROENTEROLOGY, V91, P100, DOI 10.1016/0016-5085(86)90445-2; STEADMAN CJ, 1991, GASTROENTEROLOGY, V101, P373, DOI 10.1016/0016-5085(91)90014-C; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; TYCE GM, 1981, ANAL BIOCHEM, V112, P143, DOI 10.1016/0003-2697(81)90271-2; VONDEROHE M, 1992, GASTROENTEROLOGY, V103, P1378; YAKSH TL, 1988, PEPTIDES, V9, P357, DOI 10.1016/0196-9781(88)90272-0; YANG K, 1983, CANCER, V51, P1918, DOI 10.1002/1097-0142(19830515)51:10<1918::AID-CNCR2820511027>3.0.CO;2-Y	35	146	147	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1073	1078		10.1056/NEJM199310073291503	http://dx.doi.org/10.1056/NEJM199310073291503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371728				2022-12-24	WOS:A1993LZ64000003
J	DOUGLASS, JK; WILKENS, L; PANTAZELOU, E; MOSS, F				DOUGLASS, JK; WILKENS, L; PANTAZELOU, E; MOSS, F			NOISE ENHANCEMENT OF INFORMATION-TRANSFER IN CRAYFISH MECHANORECEPTORS BY STOCHASTIC RESONANCE	NATURE			English	Article							BISTABLE SYSTEMS; PHASE LOCKING; DYNAMICS; NEURONS; POPULATION	IN linear information theory, electrical engineering and neurobiology, random noise has traditionally been viewed as a detriment to information transmission. Stochastic resonance (SR) is a nonlinear, statistical dynamics whereby information flow in a multistate system is enhanced by the presence of optimized, random noise1-4. A major consequence of SR for signal reception is that it makes possible substantial improvements in the detection of weak periodic signals. Although SR has recently been demonstrated in several artificial physical systems5,6, it may also occur naturally, and an intriguing possibility is that biological systems have evolved the capability to exploit SR by optimizing endogenous sources of noise. Sensory systems are an obvious place to look for SR, as they excel at detecting weak signals in a noisy environment. Here we demonstrate SR using external noise applied to crayfish mechanoreceptor cells. Our results show that individual neurons can provide a physiological substrate for SR in sensory systems.	UNIV MISSOURI, DEPT BIOL, ST LOUIS, MO 63121 USA; UNIV MISSOURI, DEPT PHYS, ST LOUIS, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis; University of Missouri System; University of Missouri Saint Louis								BANO W, 1978, BIOL CYBERN, V31, P99; BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BULSARA A, 1993, J STAT PHYS, V70, P1, DOI 10.1007/BF01053949; Bush B.M.H., 1982, P399; CHIALVO DR, 1993, J STAT PHYS, V70, P375, DOI 10.1007/BF01053974; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DITZINGER T, 1990, BIOL CYBERN, V63, P453, DOI 10.1007/BF00199577; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GAMMAITONI L, 1989, PHYS REV LETT, V62, P349, DOI 10.1103/PhysRevLett.62.349; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GLASS L, 1979, J MATH BIOL, V7, P339, DOI 10.1007/BF00275153; GLASS L, 1980, J THEOR BIOL, V86, P455, DOI 10.1016/0022-5193(80)90345-8; JUNG P, 1989, EUROPHYS LETT, V8, P505, DOI 10.1209/0295-5075/8/6/003; KAPLAN E, 1980, NATURE, V286, P393, DOI 10.1038/286393a0; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P767, DOI 10.1085/jgp.59.6.767; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MELLON D, 1963, J EXP BIOL, V40, P137; MOORE GP, 1966, ANNU REV PHYSIOL, V28, P493, DOI 10.1146/annurev.ph.28.030166.002425; MOSS F, IN PRESS INTRO SOME; NARINS PM, 1989, J ACOUST SOC AM, V85, P1255, DOI 10.1121/1.397456; NICOLIS C, 1982, TELLUS, V34, P1, DOI 10.1111/j.2153-3490.1982.tb01786.x; ROSE JE, 1967, J NEUROPHYSIOL, V30, P769, DOI 10.1152/jn.1967.30.4.769; STEIN RB, 1965, BIOPHYS J, V5, P173, DOI 10.1016/S0006-3495(65)86709-1; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; WIESE K, 1976, J NEUROPHYSIOL, V39, P816, DOI 10.1152/jn.1976.39.4.816; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	29	1209	1234	0	100	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					337	340		10.1038/365337a0	http://dx.doi.org/10.1038/365337a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377824				2022-12-24	WOS:A1993LY49600051
J	CHAN, A; ROBERTSON, EF; HAAN, EA; KEANE, RJ; RANIERI, E; CARNEY, A				CHAN, A; ROBERTSON, EF; HAAN, EA; KEANE, RJ; RANIERI, E; CARNEY, A			PREVALENCE OF NEURAL-TUBE DEFECTS IN SOUTH-AUSTRALIA, 1966-91 - EFFECTIVENESS AND IMPACT OF PRENATAL-DIAGNOSIS	BRITISH MEDICAL JOURNAL			English	Article							ETIOLOGIC HETEROGENEITY; SPINA-BIFIDA	Objective-To determine trends in total prevalence of neural tube defects in South Australia during 1966-91, the impact of prenatal diagnosis on birth prevalence, and the effectiveness of prenatal screening for neural tube defects in 1986-91. Design-All births and terminations of pregnancy affected by neural tube defects and information on prenatal screening were ascertained from multiple sources including the South Australian perinatal and abortion statistics collections, birth defects register, and state maternal serum a fetoprotein screening programme. Setting-Southern Australia. Subjects-All 1058 births and terminations of pregnancy affected by neural tube defects in 1966-91. Main outcome measures-Total prevalence and birth prevalence of individual and all neural tube defects. The proportion of screened cases detected prenatally. Results-Total prevalence of neural tube defects during 1966-91 was 2.01/1000 births with no upward or downward trend. However, birth prevalence fell significantly (by 5.1% a year), with an 84% reduction from 2.29/1000 births in 1966 to 0.35/1000 in 1991 (relative risk=0.16, 95% confidence interval 0.07 to 0.34). The fall was 96% for anencephaly and 82% for spina bifida. 85% of defects, both open and closed, were detected before 28 weeks' gestation in women screened by serum alpha fetoprotein or mid-trimester ultrasonography, or both, in 1986-91 (99.0% for anencephaly and 75.7% for spina bifida). Conclusions-While the total prevalence of neural tube defects in South Australia remained stable, prenatal diagnosis and termination of pregnancy resulted in an 84% fall in birth prevalence during 1966-91. Screening detected over four fifths of cases in 1986-91.	ADELAIDE CHILDRENS HOSP INC,CTR MED GENET,DEPT CHEM PATHOL,SCREENING PROGRAMM,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,CTR MED GENET,DEPT MED GENET,S AUSTRALIAN BIRTH DEFECTS REGISTER,ADELAIDE,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT NEUROSURG,ADELAIDE,AUSTRALIA		CHAN, A (corresponding author), S AUSTRALIAN HLTH COMMISS,EPIDEMIOL BRANCH,PREGNANCY OUTCOME UNIT,POB 6,RUNDLE MALL,ADELAIDE,SA 5000,AUSTRALIA.							BOWER C, 1993, MED J AUSTRALIA, V158, P152, DOI 10.5694/j.1326-5377.1993.tb121690.x; BOWER C, 1984, J EPIDEMIOL COMMUN H, V38, P208, DOI 10.1136/jech.38.3.208; CREASY MR, 1976, J MED GENET, V13, P9, DOI 10.1136/jmg.13.1.9; CUCKLE H, 1987, PRENATAL DIAG, V7, P91, DOI 10.1002/pd.1970070205; CZEIZEL A, 1983, BRIT MED J, V287, P429, DOI 10.1136/bmj.287.6389.429; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Dean A. G., 1990, EPI INFO VERSION 5 W; FERGUSONSMITH MA, 1983, BRIT MED BULL, V39, P365, DOI 10.1093/oxfordjournals.bmb.a071849; GEBSKI V, 1992, STATISTICAL PACKAGE; HOLMES LB, 1976, NEW ENGL J MED, V294, P365, DOI 10.1056/NEJM197602122940704; KALLEN B, 1984, J EPIDEMIOL COMMUN H, V38, P103, DOI 10.1136/jech.38.2.103; KHOURY MJ, 1982, AM J EPIDEMIOL, V115, P538, DOI 10.1093/oxfordjournals.aje.a113335; KIRKE PN, 1984, BRIT MED J, V289, P1621, DOI 10.1136/bmj.289.6458.1621; OWENS JR, 1981, LANCET, V2, P1032; ROMIJN JA, 1983, LANCET, V1, P64; STEIN SC, 1982, PEDIATRICS, V69, P511; 1991, J EPIDEMIOL COMMUNIT, V45, P52; 1991, LANCET, V338, P131; 1992, MMWR, V41, P497; 1988, INT CLEARINGHOUSE BI	20	69	74	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1993	307	6906					703	706		10.1136/bmj.307.6906.703	http://dx.doi.org/10.1136/bmj.307.6906.703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY292	8401091	Green Published, Bronze			2022-12-24	WOS:A1993LY29200015
J	STRAND, M; PROLLA, TA; LISKAY, RM; PETES, TD				STRAND, M; PROLLA, TA; LISKAY, RM; PETES, TD			DESTABILIZATION OF TRACTS OF SIMPLE REPETITIVE DNA IN YEAST BY MUTATIONS AFFECTING DNA MISMATCH REPAIR	NATURE			English	Article							5' EXONUCLEASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SEQUENCE; MUTANTS	The genomes of all eukaryotes contain tracts of DNA in which a single base or a small number of bases is repeated. Expansions of such tracts have been associated with several human disorders including the fragile X syndrome1. In addition, simple repeats are unstable in certain forms of colorectal cancer, suggesting a defect in DNA replication or repair2-4. We show here that mutations in any three yeast genes involved in DNA mismatch repair (PMS1, MLH1 and MSH2) lead to 100- to 700-fold increases in tract instability, whereas mutations that eliminate the proof-reading function of DNA polymerases have little effect. The meiotic stability of the tracts is similar to the mitotic stability. Th results suggest that tract instability is associated with DNA polymerases slipping during replication, and that some types of colorectal cancer may reflect mutations in genes involved in DNA mismatch repair.	UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510	University of North Carolina; University of North Carolina Chapel Hill; Yale University; Yale University	STRAND, M (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KLEIN HL, 1984, MOL CELL BIOL, V4, P329, DOI 10.1128/MCB.4.2.329; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; Luria SE, 1943, GENETICS, V28, P491; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; REENAN RAG, 1992, GENETICS, V132, P963; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P818; WILLIAMSON MS, 1985, GENETICS, V110, P609	21	949	1001	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					274	276		10.1038/365274a0	http://dx.doi.org/10.1038/365274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371783				2022-12-24	WOS:A1993LX47100061
J	KIEBLER, M; KEIL, P; SCHNEIDER, H; VANDERKLEI, IJ; PFANNER, N; NEUPERT, W				KIEBLER, M; KEIL, P; SCHNEIDER, H; VANDERKLEI, IJ; PFANNER, N; NEUPERT, W			THE MITOCHONDRIAL RECEPTOR COMPLEX - A CENTRAL ROLE OF MOM22 IN MEDIATING PREPROTEIN TRANSFER FROM RECEPTORS TO THE GENERAL INSERTION PORE	CELL			English	Article							OUTER-MEMBRANE PROTEIN; ADP-ATP CARRIER; ENDOPLASMIC-RETICULUM MEMBRANE; PRECURSOR PROTEINS; DNA-POLYMERASE; POSTTRANSLATIONAL TRANSFER; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; ESCHERICHIA-COLI	The receptor complex in the mitochondrial outer membrane, which consists of at least seven different proteins, is responsible for the recognition and translocation of cytosolically synthesized preproteins. Two of its subunits, MOM19 and MOM72, function as surface receptors for preproteins. Four other subunits (MOM38, MOM30, MOM8, and MOM7) have been suggested to constitute the general insertion pore (GIP). Here we report on the structure and function of MOM22. MOM22 is anchored in the outer membrane by a single transmembrane segment. The highly negatively charged N-terminal domain is exposed to the cytosol and the C-terminal domain to the intermembrane space. MOM22 appears to be a central component of the receptor complex, required for the transfer of preproteins from the receptors to the GIP. We speculate that the negatively charged domain of MOM22 is involved in the transfer of positively charged signal sequences of preproteins.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY	University of Freiburg	KIEBLER, M (corresponding author), UNIV MUNICH, INST PHYSIOL CHEM, D-80336 MUNICH, GERMANY.		Pfanner, Nikolaus/AAV-7878-2021; van der Klei, Ida J/D-1919-2012	Kiebler, Michael/0000-0002-8850-6297; Van der Klei, Ida J./0000-0001-7165-9679				ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER K, 1992, J BIOL CHEM, V267, P5637; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; KEEGSTRA K, 1992, CELL ORGANELLES, P353; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Kyshe-Andersen J, 1984, J BIOCHEM BIOPH METH, V10, P203; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAGE MG, 1981, METHOD ENZYMOL, V73, P142; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; PFANNER N, 1987, J BIOL CHEM, V262, P7528; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFANNER N, 1990, J BIOL CHEM, V265, P16324; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZIMMERMANN R, 1980, EUR J BIOCHEM, V109, P217, DOI 10.1111/j.1432-1033.1980.tb04787.x	55	166	167	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					483	492		10.1016/0092-8674(93)80050-O	http://dx.doi.org/10.1016/0092-8674(93)80050-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348615	Green Published			2022-12-24	WOS:A1993LT73900010
J	KUPITZ, Y; ATLAS, D				KUPITZ, Y; ATLAS, D			A PUTATIVE ATP-ACTIVATED NA+ CHANNEL INVOLVED IN SPERM-INDUCED FERTILIZATION	SCIENCE			English	Article							ADENOSINE-TRIPHOSPHATE; URECHIS-CAUPO; SMOOTH-MUSCLE; MARINE WORM; SEA-URCHIN; CELLS; EGGS; POLYSPERMY; MECHANISMS; RESPONSES	Extracellular application of adenosine triphosphate (ATP) to defolliculated Xenopus laevis oocytes activated a saturating inward current with a maximal amplitude E(max) of 2.4 +/- 0.2 microamperes and an apparent Michaelis constant of 197.6 micromolar. The current was carried predominantly by sodium ions and potently inhibited by amiloride, guanosine triphosphate (GTP), and its nonhydrolyzable analogs guanosine 5'-[beta,gamma-imido]triphosphate (GppNHp) and guanosine 5'-O-(3-thiotriphosphate). Likewise, in vitro fertilization using mature eggs and Xenopus sperm was inhibited by amiloride, GTP, and GppNHp. Hence, an ATP receptor on the egg membrane may be the recipient target for ATP originating in sperm, suggesting that an ATP-induced increase in sodium permeability mediates the initial sperm to egg signal in the fertilization process.	HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EPEL D, 1990, CELL DIFFER DEV, V29, P1, DOI 10.1016/0922-3371(90)90019-S; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIEL DD, 1988, J GEN PHYSIOL, V91, P1, DOI 10.1085/jgp.91.1.1; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GOULD M, 1987, SCIENCE, V235, P1654, DOI 10.1126/science.3823908; GOULDSOMERO M, 1979, J CELL BIOL, V82, P426, DOI 10.1083/jcb.82.2.426; HAGIWARA S, 1979, ANNU REV BIOPHYS BIO, V8, P385, DOI 10.1146/annurev.bb.08.060179.002125; HUME RI, 1986, J NEUROSCI, V6, P681; JAFFE LA, 1979, J GEN PHYSIOL, V73, P469, DOI 10.1085/jgp.73.4.469; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LONGO FJ, 1986, DEV BIOL, V118, P155, DOI 10.1016/0012-1606(86)90083-7; LOTAN I, 1986, PFLUG ARCH EUR J PHY, V406, P158, DOI 10.1007/BF00586677; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; NEUHAUS R, 1991, J NEUROSCI, V11, P3984; NIEWKOOP PD, 1956, NORMAL TABLE XENOPUS, P244; SCHUEL H, 1981, DEV BIOL, V87, P249, DOI 10.1016/0012-1606(81)90148-2; SELA D, 1991, J BIOL CHEM, V266, P17990; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNEDDON P, 1982, SCIENCE, V218, P693, DOI 10.1126/science.6291151	27	39	39	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					484	486		10.1126/science.8392753	http://dx.doi.org/10.1126/science.8392753			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8392753				2022-12-24	WOS:A1993LN62300040
J	CHENG, TC; WALLACE, MC; MERLIE, JP; OLSON, EN				CHENG, TC; WALLACE, MC; MERLIE, JP; OLSON, EN			SEPARABLE REGULATORY ELEMENTS GOVERNING MYOGENIN TRANSCRIPTION IN MOUSE EMBRYOGENESIS	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; GENE-PRODUCTS; MUSCLE; EXPRESSION; PROTEINS; MYOD1; FAMILY; SOMITE; REGION; CELLS	Expression of the myogenic helix-loop-helix (HLH) protein myogenin in muscle cell precursors within somites and limb buds is among the earliest events associated with myogenic lineage determination in vertebrates. Mutations in the myogenin promoter that abolish binding sites for myogenic HLH proteins or myocyte enhancer factor-2 (MEF-2) suppressed transcription of a linked lacZ transgene in subsets of myogenic precursors in mouse embryos. These results suggest that myogenic HLH proteins and MEF-2 participate i n separable regulatory circuits leading to myogenin transcription and provide evidence for positional regulation of myogenic regulators in the embryo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)								BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG T, UNPUB; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDMONDSON DG, UNPUB; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Hogan B., 1986, MANIPULATING MOUSE E; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; OTT MO, 1991, DEVELOPMENT, V111, P1097; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THEILER K, 1989, HOUSE MOUSE; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WH, COMMUNICATION; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	33	242	242	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					215	218		10.1126/science.8392225	http://dx.doi.org/10.1126/science.8392225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8392225				2022-12-24	WOS:A1993LL59600042
J	FREY, U; HUANG, YY; KANDEL, ER				FREY, U; HUANG, YY; KANDEL, ER			EFFECTS OF CAMP SIMULATE A LATE-STAGE OF LTP IN HIPPOCAMPAL CA1 NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; DEPENDENT PROTEIN-KINASE; REGION INVITRO; DENTATE GYRUS; LATE PHASE; BLOCKS; ANISOMYCIN; RATS; MAINTENANCE; ANTAGONISTS	Hippocampal long-term potentiation (LTP) is thought to serve as an elementary mechanism for the establishment of certain forms of explicit memory in the mammalian brain. As is the case with behavioral memory, LTP in the CA1 region has stages: a short-term early potentiation lasting 1 to 3 hours, which is independent of protein synthesis, precedes a later, longer lasting stage (L-LTP), which requires protein synthesis. Inhibitors of cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) blocked L-LTP, and analogs of cAMP induced a potentiation that blocked naturally induced L-LTP. The action of the cAMP analog was blocked by inhibitors of protein synthesis. Thus, activation of PKA may be a component of the mechanism that generates L-LTP.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERI A, 1991, BRAIN RES, V546, P69, DOI 10.1016/0006-8993(91)91160-3; BAULAC M, 1986, REV NEUROL-FRANCE, V142, P895; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; ELIOT LS, 1989, P NATL ACAD SCI USA, V86, P9564, DOI 10.1073/pnas.86.23.9564; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1991, NEUROSCI LETT, V129, P111, DOI 10.1016/0304-3940(91)90732-9; FREY U, 1990, BRAIN RES, V522, P69, DOI 10.1016/0006-8993(90)91578-5; FREY U, 1989, BIOMED BIOCHIM ACTA, V48, P473; FREY U, UNPUB; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRECKSCH G, 1980, PHARMACOL BIOCHEM BE, V12, P663, DOI 10.1016/0091-3057(80)90145-8; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GROVER LM, 1992, NEUROSCIENCE, V49, P7, DOI 10.1016/0306-4522(92)90072-A; HUANG YN, UNPUB; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MATTHIES H, 1989, ANNU REV PSYCHOL, V40, P381, DOI 10.1146/annurev.ps.40.020189.002121; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTANI S, 1989, NEUROSCI LETT, V106, P175, DOI 10.1016/0304-3940(89)90222-X; REYMANN KG, 1985, BRAIN RES BULL, V15, P249, DOI 10.1016/0361-9230(85)90147-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1981, ANNU REV PHARMACOL, V21, P323, DOI 10.1146/annurev.pa.21.040181.001543; STANTON PK, 1985, BRAIN RES, V358, P343, DOI 10.1016/0006-8993(85)90981-3; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	27	978	1012	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 11	1993	260	5114					1661	1664		10.1126/science.8389057	http://dx.doi.org/10.1126/science.8389057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LG176	8389057				2022-12-24	WOS:A1993LG17600034
J	SOONG, TW; STEA, A; HODSON, CD; DUBEL, SJ; VINCENT, SR; SNUTCH, TP				SOONG, TW; STEA, A; HODSON, CD; DUBEL, SJ; VINCENT, SR; SNUTCH, TP			STRUCTURE AND FUNCTIONAL EXPRESSION OF A MEMBER OF THE LOW-VOLTAGE ACTIVATED CALCIUM-CHANNEL FAMILY	SCIENCE			English	Article							INFERIOR OLIVARY NEURONS; SKELETAL-MUSCLE; BETA-SUBUNIT; IONIC CONDUCTANCES; VERTEBRATE CELLS; SENSORY NEURONS; CA2+ CHANNELS; THRESHOLD; CURRENTS; INVITRO	Oscillatory firing patterns are an intrinsic property of some neurons and have an important function in information processing. In some cells, low voltage-activated calcium channels have been proposed to underlie a depolarizing potential that regulates bursting. The sequence of a rat brain calcium channel alpha1 subunit (rbE-II) was deduced. Although it is structurally related to high voltage-activated calcium channels, the rbE-II channel transiently activated at negative membrane potentials, required a strong hyperpolarization to deinactivate, and was highly sensitive to block by nickel. In situ hybridization showed that rbE-II messenger RNA is expressed in regions throughout the central nervous system. The electrophysiological properties of the rbE-II current are consistent with a type of low voltage-activated calcium channel that,requires membrane hyperpolarization for maximal activity, which suggests that rbE-II may be involved in the modulation of firing patterns.	UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PSYCHIAT,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia			Vincent, Steven R/D-2996-2012; Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Soong, Tuck Wah/0000-0002-0876-0325				ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BURLHIS TM, 1987, SYNAPSE, V1, P582, DOI 10.1002/syn.890010611; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; COULTER DA, 1989, NEUROSCI LETT, V98, P74, DOI 10.1016/0304-3940(89)90376-5; COULTER DA, 1989, J PHYSIOL-LONDON, V414, P587, DOI 10.1113/jphysiol.1989.sp017705; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; FRIEDMAN A, 1987, NEUROSCI LETT, V81, P117, DOI 10.1016/0304-3940(87)90350-8; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LLINAS R, 1984, BRAIN RES, V294, P127, DOI 10.1016/0006-8993(84)91316-7; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P569, DOI 10.1113/jphysiol.1981.sp013764; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SAYER RJ, 1990, NEUROSCI LETT, V120, P175, DOI 10.1016/0304-3940(90)90031-4; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WONG RKS, 1978, BRAIN RES, V159, P385, DOI 10.1016/0006-8993(78)90544-9	41	483	505	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1133	1136		10.1126/science.8388125	http://dx.doi.org/10.1126/science.8388125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	8388125				2022-12-24	WOS:A1993LC94200032
J	LOGAN, D; ABUGHAZALEH, R; BLAKEMORE, W; CURRY, S; JACKSON, T; KING, A; LEA, S; LEWIS, R; NEWMAN, J; PARRY, N; ROWLANDS, D; STUART, D; FRY, E				LOGAN, D; ABUGHAZALEH, R; BLAKEMORE, W; CURRY, S; JACKSON, T; KING, A; LEA, S; LEWIS, R; NEWMAN, J; PARRY, N; ROWLANDS, D; STUART, D; FRY, E			STRUCTURE OF A MAJOR IMMUNOGENIC SITE ON FOOT-AND-MOUTH-DISEASE VIRUS	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; ANTIGENIC VARIATION; CRYSTAL-STRUCTURE; PROTEIN; RESOLUTION; SEQUENCE; FIBRONECTIN; ANTIBODIES; REFINEMENT; LOCATION	ATTACHMENT of foot-and-mouth disease virus (FMDV) to its cellular receptor involves a long and highly antigenic loop containing the conserved sequence, Arg-Gly-Asp, a motif known to be a recognition element in many integrin-dependent cell adhesion processes1-7. In our original crystal structure of FMDV the Arg-Gly-Asp-containing loop ('the loop'), located between beta-strands G and H of capsid protein VP1, was disordered and hence essentially invisible. We previously surmised that its disorder is enhanced by a disulphide bond linking the base of the loop (Cys 134) to Cys 130 of VP2 (ref. 8). We report here the crystal structure of the virus in which this disulphide is reduced. Reduced virus retains infectivity and serological experiments suggest that some of the loop's internal structure is conserved8. But here its structure has become sufficiently ordered to allow us to describe an unambiguous conformation, which we relate to some key biological properties of the virus.	UNIV OXFORD,MOLEC BIOPHYS LAB,REX RICHARDS BLDG,OXFORD OX1 3QU,ENGLAND; AFRC,INST ANIM HLTH,WOKING GU24 0NF,ENGLAND; WELLCOME RES LABS,DEPT MOLEC SCI,BECKENHAM BR3 3BS,KENT,ENGLAND	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; GlaxoSmithKline; Wellcome Research Laboratories			Lea, Susan M/B-7678-2009; Logan, Derek T/A-1114-2011; Logan, Derek/O-2497-2019	Lea, Susan M/0000-0001-9287-8053; Logan, Derek T/0000-0002-0098-8560; Logan, Derek/0000-0002-0098-8560; Curry, Stephen/0000-0002-0552-8870; Stuart, David/0000-0002-3426-4210; lewis, richard/0000-0003-2641-8643				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ACHARYA R, 1989, VACCINES 89 MODERN A; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BAXT B, 1990, Virus Genes, V4, P73, DOI 10.1007/BF00308567; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BITTLE JL, 1982, NATURE, V298, P30, DOI 10.1038/298030a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG KH, 1992, J GEN VIROL, V73, P621, DOI 10.1099/0022-1317-73-3-621; FOX G, 1987, J MOL BIOL, V196, P591, DOI 10.1016/0022-2836(87)90035-0; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; FRY E, 1993, ACTA CRYSTALLOGR A, V49, P45, DOI 10.1107/S0108767392005737; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; HENRICK K, 1987, PROTEIN ENG, V1, P467, DOI 10.1093/protein/1.6.467; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM S, 1989, J MOL BIOL, V210, P91, DOI 10.1016/0022-2836(89)90293-3; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; PARRY N, 1990, NATURE, V347, P569, DOI 10.1038/347569a0; PFAFF E, 1982, EMBO J, V1, P869, DOI 10.1002/j.1460-2075.1982.tb01262.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; ROWLANDS DJ, 1983, NATURE, V306, P694, DOI 10.1038/306694a0; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SILIGARDI G, 1991, EUR J BIOCHEM, V199, P545, DOI 10.1111/j.1432-1033.1991.tb16153.x; STROHMAIER K, 1982, J GEN VIROL, V59, P295, DOI 10.1099/0022-1317-59-2-295; SUROVOI AY, 1989, SOV J BIOORG CHEM, V14, P572; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	36	313	364	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					566	568		10.1038/362566a0	http://dx.doi.org/10.1038/362566a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8385272				2022-12-24	WOS:A1993KW45300062
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SUMATRIPTAN APPROVED FOR MIGRAINE HEADACHE PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-24	WOS:A1993KW25000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			USER FRIENDLY REPORTING OF PROBLEMS WITH MEDICATIONS AND MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REGISTER, V26, P11768	1	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-24	WOS:A1993KW25000006
